1
00:00:06,379 --> 00:00:07,814
>> GOOD MORNING, AND
WELCOME.

2
00:00:07,814 --> 00:00:10,082
I'D LIKE TO CALL TO ORDER THE

3
00:00:10,082 --> 00:00:12,585
61ST MEETING OF THE NIH ADVISORY

4
00:00:12,585 --> 00:00:13,519
COMMITTEE ON RESEARCH ON WOMEN'S

5
00:00:13,519 --> 00:00:15,154
HEALTH.

6
00:00:15,154 --> 00:00:17,890
MY NAME IS VIVIAN OTA WANG AND

7
00:00:17,890 --> 00:00:20,726
I'M THE ORWH DEPUTY DIRECTOR AND

8
00:00:20,726 --> 00:00:21,494
EXECUTIVE SECRETARY OF THIS

9
00:00:21,494 --> 00:00:22,528
COMMITTEE.

10
00:00:22,528 --> 00:00:25,998
THIS MEETING IS OPEN TO THE

11
00:00:25,998 --> 00:00:27,834
PUBLIC BY BROADCAST ON THE NIH

12
00:00:27,834 --> 00:00:28,701
VIDEOCAST NETWORK, AND IT'S

13
00:00:28,701 --> 00:00:31,237
BEING RECORDED.

14
00:00:31,237 --> 00:00:33,406
FOR OUR ARCHIVES AND FOR FUTURE

15
00:00:33,406 --> 00:00:34,073
ON-DEMAND VIEWING FOR THE

16
00:00:34,073 --> 00:00:38,244
PUBLIC.

17
00:00:38,244 --> 00:00:41,280
IF YOU ARE A MEMBER OF THE

18
00:00:41,280 --> 00:00:42,849
PUBLIC, PER THE FEDERAL REGISTRY

19
00:00:42,849 --> 00:00:43,816
NOTICE, YOU MAY SUBMIT YOUR

20
00:00:43,816 --> 00:00:48,187
QUESTIONS IN WRITING TO ME AT

21
00:00:48,187 --> 00:00:49,055
ACRWH@NIH.GOV, AND WE WILL

22
00:00:49,055 --> 00:00:49,922
ADDRESS QUESTIONS AFTER THE

23
00:00:49,922 --> 00:00:56,729
MEETING.

24
00:00:56,729 --> 00:00:57,930
THE MEETING IS HYBRID.

25
00:00:57,930 --> 00:01:00,132
THE ADVISORY COMMITTEE AND OUR

26
00:01:00,132 --> 00:01:02,068
INVITED GUEST PRESENTERS ARE

27
00:01:02,068 --> 00:01:02,835
PARTICIPATING IN PERSON AND

28
00:01:02,835 --> 00:01:04,070
THROUGH ZOOM.

29
00:01:04,070 --> 00:01:05,905
SO NOW A MESSAGE FOR OUR MEMBERS

30
00:01:05,905 --> 00:01:10,042
WHO ARE SITTING WITH US TODAY.

31
00:01:10,042 --> 00:01:11,711
THIS IS REALLY JUST A REMINDER

32
00:01:11,711 --> 00:01:13,913
BECAUSE YOU ARE SPECIAL

33
00:01:13,913 --> 00:01:14,380
GOVERNMENT EMPLOYEES.

34
00:01:14,380 --> 00:01:16,849
AS A MEMBER OF THIS FEDERAL

35
00:01:16,849 --> 00:01:18,150
ADVISORY COMMITTEE, YOU ARE

36
00:01:18,150 --> 00:01:19,252
FEDERAL GOVERNMENT EMPLOYEES,

37
00:01:19,252 --> 00:01:20,119
WHICH MEANS YOU'RE SUBJECT TO

38
00:01:20,119 --> 00:01:22,221
THE SAME ETHICS RULES THAT APPLY

39
00:01:22,221 --> 00:01:23,956
TO GOVERNMENT EMPLOYEES.

40
00:01:23,956 --> 00:01:26,893
THESE RULES ARE DESCRIBED IN THE

41
00:01:26,893 --> 00:01:28,561
PAMPHLET TITLED STANDARDS OF

42
00:01:28,561 --> 00:01:29,629
ETHICAL CONDUCT FOR EMPLOYEES OF

43
00:01:29,629 --> 00:01:30,963
THE EXECUTIVE BRANCH.

44
00:01:30,963 --> 00:01:32,365
YOU RECEIVED A COPY OF THIS

45
00:01:32,365 --> 00:01:33,566
DOCUMENT WHEN YOU WERE APPOINTED

46
00:01:33,566 --> 00:01:34,901
AND AT EVERY MEETING, WE'D LIKE

47
00:01:34,901 --> 00:01:36,669
YOU TO REVIEW THE STEPS WE TAKE

48
00:01:36,669 --> 00:01:39,138
AND THE PROCESSES WE FOLLOW TO

49
00:01:39,138 --> 00:01:41,007
IDENTIFY AND ADDRESS ANY

50
00:01:41,007 --> 00:01:42,208
CONFLICTS BETWEEN YOUR PUBLIC

51
00:01:42,208 --> 00:01:43,209
RESPONSIBILITIES WITH US AND

52
00:01:43,209 --> 00:01:45,912
YOUR PRIVATE INTERESTS.

53
00:01:45,912 --> 00:01:48,548
AS YOU KNOW BEFORE EVERY

54
00:01:48,548 --> 00:01:50,416
MEETING, YOU PROVIDE US A GREAT

55
00:01:50,416 --> 00:01:52,285
DEAL, AND I DO KNOW IT'S A GREAT

56
00:01:52,285 --> 00:01:53,152
DEAL ABOUT YOUR INFORMATION

57
00:01:53,152 --> 00:01:54,453
ABOUT YOUR PROFESSIONAL AND

58
00:01:54,453 --> 00:01:55,688
PERSONAL FINANCIAL INTERESTS.

59
00:01:55,688 --> 00:01:57,323
WHAT WE DO IS WE USE THIS

60
00:01:57,323 --> 00:01:58,391
INFORMATION AS A FOUNDATION FOR

61
00:01:58,391 --> 00:02:00,593
ASSESSING WHETHER YOU HAVE ANY

62
00:02:00,593 --> 00:02:02,128
REAL OR POTENTIAL OR APPARENT

63
00:02:02,128 --> 00:02:04,196
CONFLICTS OF INTEREST THAT COULD

64
00:02:04,196 --> 00:02:04,897
POTENTIALLY COMPROMISE YOUR

65
00:02:04,897 --> 00:02:06,399
ABILITY TO BE OBJECTIVE IN

66
00:02:06,399 --> 00:02:07,800
GIVING US ADVICE DURING OUR

67
00:02:07,800 --> 00:02:11,637
COMMITTEE MEETING.

68
00:02:11,637 --> 00:02:15,241
IF THERE IS -- YOUR INDIVIDUAL

69
00:02:15,241 --> 00:02:16,909
SERVICES OUTWEIGHS THE POTENTIAL

70
00:02:16,909 --> 00:02:19,078
CONFLICTS OF INTEREST THAT WE

71
00:02:19,078 --> 00:02:20,379
IDENTIFIED, WE WOULD ISSUE A

72
00:02:20,379 --> 00:02:23,015
WAIVER OR RECUSE YOURSELF FOR A

73
00:02:23,015 --> 00:02:23,783
PARTICULAR PORTION OF THE

74
00:02:23,783 --> 00:02:24,250
MEETING.

75
00:02:24,250 --> 00:02:25,651
WE USUALLY WAIVE CONFLICTS OF

76
00:02:25,651 --> 00:02:26,852
INTEREST FOR GENERAL MATTERS

77
00:02:26,852 --> 00:02:28,020
BECAUSE YOUR ABILITY TO BE

78
00:02:28,020 --> 00:02:29,255
OBJECTIVE WILL NOT BE AFFECTED

79
00:02:29,255 --> 00:02:31,123
BY YOUR FINANCIAL INTERESTS.

80
00:02:31,123 --> 00:02:36,228
WE ALSO RELY A GREAT DEAL ON YOU

81
00:02:36,228 --> 00:02:39,765
AND ALSO A GREAT DEAL ON YOU.

82
00:02:39,765 --> 00:02:41,601
ALSO WE REALLY HAVE APPRECIATED

83
00:02:41,601 --> 00:02:42,868
ABOUT YOU BEING ATTENTIVE DURING

84
00:02:42,868 --> 00:02:44,337
THE MEETINGS AND THE POSSIBILITY

85
00:02:44,337 --> 00:02:46,205
THAT ISSUES COULD ARISE THAT

86
00:02:46,205 --> 00:02:48,174
COULD AFFECT OR APPEAR TO AFFECT

87
00:02:48,174 --> 00:02:51,110
YOUR FINANCIAL INTERESTS, AND IF

88
00:02:51,110 --> 00:02:52,979
THAT HAPPENS, IF YOU COULD

89
00:02:52,979 --> 00:02:53,980
RECUSE YOURSELF, THAT WOULD BE

90
00:02:53,980 --> 00:03:01,954
APPRECIATED.

91
00:03:01,954 --> 00:03:03,389
BEFORE THE INTRODUCTIONS I JUST

92
00:03:03,389 --> 00:03:05,224
WANT TO BRIEFLY REVIEW SOME OF

93
00:03:05,224 --> 00:03:06,659
OUR BEST PRACTICES THAT WE HAVE

94
00:03:06,659 --> 00:03:09,829
FOR THIS HYBRID MEETING.

95
00:03:09,829 --> 00:03:11,664
FIRST PLEASE MUTE YOUR

96
00:03:11,664 --> 00:03:13,432
MICROPHONE WHEN YOU AREN'T

97
00:03:13,432 --> 00:03:14,767
SPEAKING, AND IMPORTANTLY, WHEN

98
00:03:14,767 --> 00:03:16,502
SPEAKING, PLEASE STATE YOUR NAME

99
00:03:16,502 --> 00:03:17,803
BEFORE MAKING COMMENTS, MOTIONS

100
00:03:17,803 --> 00:03:20,006
OR RECOMMENDATIONS.

101
00:03:20,006 --> 00:03:24,577
IF YOU'RE IN PERSON, PLEASE MAKE

102
00:03:24,577 --> 00:03:25,578
SURE YOUR MICROPHONE IS ON WHEN

103
00:03:25,578 --> 00:03:27,880
SPEAKING AND PLEASE REFRAIN FROM

104
00:03:27,880 --> 00:03:28,648
DRAGGING THE MICROPHONE ACROSS

105
00:03:28,648 --> 00:03:29,281
THE TABLE.

106
00:03:29,281 --> 00:03:30,816
WE'VE HEARD IT MAKES AN

107
00:03:30,816 --> 00:03:32,585
INCREDIBLE SOUND THAT WE REALLY

108
00:03:32,585 --> 00:03:35,521
DO NOT WANT TO HEAR.

109
00:03:35,521 --> 00:03:38,157
AND FOR THOSE OF YOU WHO TEND TO

110
00:03:38,157 --> 00:03:39,291
LEAN BACK WHEN YOU'RE SPEAKING,

111
00:03:39,291 --> 00:03:40,559
WE'RE GOING TO HAVE YOU TRY TO

112
00:03:40,559 --> 00:03:42,094
LEAN INTO THE MICROPHONE SO WE

113
00:03:42,094 --> 00:03:43,496
WON'T MISS ANY WORDS THAT YOU'RE

114
00:03:43,496 --> 00:03:44,830
SAYING.

115
00:03:44,830 --> 00:03:47,900
IF YOU'RE ONLINE, PLEASE TRY TO

116
00:03:47,900 --> 00:03:50,302
USE THE HEADSET WITH A

117
00:03:50,302 --> 00:03:51,070
MICROPHONE WHEN SPEAKING.

118
00:03:51,070 --> 00:03:52,705
WE FIND THIS REALLY RESULTS IN A

119
00:03:52,705 --> 00:03:53,839
CLEAR SOUND AND PROVIDES THE

120
00:03:53,839 --> 00:03:55,274
LEAST AMOUNT OF AUDIO FEEDBACK

121
00:03:55,274 --> 00:03:59,812
FOR THE RECORDING.

122
00:03:59,812 --> 00:04:00,613
IMPORTANTLY IF YOU HAVE ANY

123
00:04:00,613 --> 00:04:01,681
QUESTIONS OR WOULD LIKE TO MAKE

124
00:04:01,681 --> 00:04:02,648
A COMMENT, PLEASE RAISE YOUR

125
00:04:02,648 --> 00:04:03,082
HAND.

126
00:04:03,082 --> 00:04:04,517
AND WHEN INDICATED, MEMBERS WILL

127
00:04:04,517 --> 00:04:06,152
VOTE BY RAISING THEIR HANDS.

128
00:04:06,152 --> 00:04:09,755
WE WILL TAKE VOTES TO ACCEPT,

129
00:04:09,755 --> 00:04:12,725
REJECT, OR ABSTAIN SEPARATELY,

130
00:04:12,725 --> 00:04:13,859
SO PLEASE RAISE YOUR HAND IN

131
00:04:13,859 --> 00:04:16,862
ACCORDANCE WITH YOUR RESPONSE.

132
00:04:16,862 --> 00:04:19,598
FOR ONLINE ATTENDEES, WE WILL

133
00:04:19,598 --> 00:04:21,701
SHARE YOUR VOTES IN THE ZOOM

134
00:04:21,701 --> 00:04:22,902
GALLERY DURING THE TIME WHEN

135
00:04:22,902 --> 00:04:28,340
WE'RE VOTING.

136
00:04:28,340 --> 00:04:31,310
SO AS I GO THROUGH THE ROSTER,

137
00:04:31,310 --> 00:04:32,278
WHEN YOU HEAR YOUR NAME, COULD

138
00:04:32,278 --> 00:04:37,216
YOU PLEASE UNMUTE YOUR MIC AND

139
00:04:37,216 --> 00:04:39,185
INTRODUCE YOURSELF BY NAME AND

140
00:04:39,185 --> 00:04:40,186
WHAT INSTITUTION YOU REPRESENT.

141
00:04:40,186 --> 00:04:41,587
I'M HOPING YOU SIGNED IN AT THE

142
00:04:41,587 --> 00:04:42,388
SHEET AT THE FRONT TABLE.

143
00:04:42,388 --> 00:04:43,789
IF NOT, PLEASE DO SO BEFORE THE

144
00:04:43,789 --> 00:04:45,858
END OF THE DAY.

145
00:04:45,858 --> 00:04:46,392
OKAY.

146
00:04:46,392 --> 00:04:47,960
SO LET'S GO WITH SOME

147
00:04:47,960 --> 00:04:58,304
INTRODUCTIONS HERE.

148
00:04:59,605 --> 00:05:00,706
FIRST I JUST WANT TO ACKNOWLEDGE

149
00:05:00,706 --> 00:05:08,047
THAT WE WANT TO THANK SOME ACRWH

150
00:05:08,047 --> 00:05:08,948
MEMBERS RETIRING IN THE COMING

151
00:05:08,948 --> 00:05:09,381
MONTHS.

152
00:05:09,381 --> 00:05:10,783
THEY'VE SERVED DILIGENTLY AS YOU

153
00:05:10,783 --> 00:05:16,188
ALL KNOW FOR THE PAST FOUR

154
00:05:16,188 --> 00:05:17,490
YEARS.

155
00:05:17,490 --> 00:05:20,426
DR. MELISSA SIMON, DR. IRENE

156
00:05:20,426 --> 00:05:23,362
ANINYE, AND DR. GARNET ANDERSON.

157
00:05:23,362 --> 00:05:25,131
SO IF WE COULD GIVE A WARM

158
00:05:25,131 --> 00:05:25,898
APPLAUSE AND THANK YOU FOR ALL

159
00:05:25,898 --> 00:05:33,305
YOUR SERVICE.

160
00:05:33,305 --> 00:05:34,740
I WOULD ALSO LIKE TO RECOGNIZE

161
00:05:34,740 --> 00:05:36,075
OUR NEW MEMBERS WHO HAVE JOINED

162
00:05:36,075 --> 00:05:38,677
US TODAY.

163
00:05:38,677 --> 00:05:42,848
DR. AYUSH GIRI AND

164
00:05:42,848 --> 00:05:45,918
DR. IGHOVWERHA OFOTOKUN.

165
00:05:45,918 --> 00:05:50,289
YOU GET APPLAUSE TOO.

166
00:05:50,289 --> 00:05:50,589
OKAY.

167
00:05:50,589 --> 00:05:54,560
NEXT SLIDE, PLEASE.

168
00:05:54,560 --> 00:05:56,962
I ALSO WANT TO RECOGNIZE SOME

169
00:05:56,962 --> 00:05:58,931
UPCOMING ACRWH MEMBERS.

170
00:05:58,931 --> 00:06:00,132
SOME OF THESE MEMBERS HAVE

171
00:06:00,132 --> 00:06:02,101
ACTUALLY JOINED US TODAY AS AD

172
00:06:02,101 --> 00:06:03,402
HOC MEMBERS.

173
00:06:03,402 --> 00:06:07,239
IT'S DR. ARTHUR ARNOLD,

174
00:06:07,239 --> 00:06:12,077
DR. LAPRINCESS BREWER AND

175
00:06:12,077 --> 00:06:14,346
DR. ROSALYN MABEN-FEASTER.

176
00:06:14,346 --> 00:06:16,649
SO YOU GET APPLAUSE AS WELL.

177
00:06:16,649 --> 00:06:19,151
AND FINALLY, WE WOULD LIKE TO

178
00:06:19,151 --> 00:06:21,120
THANK SOME OF OUR ACRWH MEMBERS

179
00:06:21,120 --> 00:06:23,856
FOR THEIR CONTINUED SERVICE.

180
00:06:23,856 --> 00:06:27,459
AND THEY INCLUDE DR. RESHMA

181
00:06:27,459 --> 00:06:29,662
JAGSI AND DR. KIMBERLY TEMPLETON

182
00:06:29,662 --> 00:06:30,663
WHO'S ACTUALLY ON THE PHONE

183
00:06:30,663 --> 00:06:31,096
TODAY WITH US.

184
00:06:31,096 --> 00:06:41,373
THANK YOU VERY MUCH.

185
00:06:41,373 --> 00:06:41,574
OKAY.

186
00:06:41,574 --> 00:06:44,109
SO I WILL SAY MY PAGES GOT OUT

187
00:06:44,109 --> 00:06:44,977
OF ORDER.

188
00:06:44,977 --> 00:06:46,178
SO I'M BACKTRACKING A LITTLE

189
00:06:46,178 --> 00:06:48,080
BIT.

190
00:06:48,080 --> 00:06:49,849
SO WHAT WE WANT TO DO NEXT IS

191
00:06:49,849 --> 00:06:51,851
REALLY GO AROUND THE ROOM AND

192
00:06:51,851 --> 00:06:53,385
EVERYONE DO THEIR INTRODUCTIONS.

193
00:06:53,385 --> 00:06:54,587
SO I'LL JUST START CALLING

194
00:06:54,587 --> 00:06:56,455
PEOPLE AND IF YOU STATE YOUR

195
00:06:56,455 --> 00:06:58,657
NAME AND YOUR AFFILIATION.

196
00:06:58,657 --> 00:07:00,860
DR. ANDERSON.

197
00:07:00,860 --> 00:07:01,927
>> GOOD MORNING.

198
00:07:01,927 --> 00:07:03,896
I'M GARNET ANDERSON.

199
00:07:03,896 --> 00:07:06,532
I REPRESENT THE FRED HUTCH SON

200
00:07:06,532 --> 00:07:07,299
CANCER RESEARCH CENTER.

201
00:07:07,299 --> 00:07:10,469
>> THANK YOU.

202
00:07:10,469 --> 00:07:11,036
DR. ANINYE.

203
00:07:11,036 --> 00:07:11,770
>> GOOD MORNING.

204
00:07:11,770 --> 00:07:14,073
I'M DR. IRENE ANINYE AND I

205
00:07:14,073 --> 00:07:15,474
REPRESENT THE SOCIETY FOR

206
00:07:15,474 --> 00:07:17,610
WOMEN'S HEALTH RESEARCH.

207
00:07:17,610 --> 00:07:18,677
>> THANK YOU.

208
00:07:18,677 --> 00:07:20,546
DR. ARNOLD.

209
00:07:20,546 --> 00:07:21,947
>> MORNING.

210
00:07:21,947 --> 00:07:22,715
I'M ART ARNOLD.

211
00:07:22,715 --> 00:07:25,017
I'M AT THE UNIVERSITY OF

212
00:07:25,017 --> 00:07:26,986
CALIFORNIA-LOS ANGELES.

213
00:07:26,986 --> 00:07:31,557
>> DR. BREWER.

214
00:07:31,557 --> 00:07:36,595
IS DR. BREWER ONLINE?

215
00:07:36,595 --> 00:07:38,931
OKAY, WE WILL CONTINUE.

216
00:07:38,931 --> 00:07:39,198
DR. GIRI.

217
00:07:39,198 --> 00:07:43,369
>> HI, I'M DR. AYUSH GIRI,

218
00:07:43,369 --> 00:07:44,203
VANDERBILT UNIVERSITY MEDICAL

219
00:07:44,203 --> 00:07:44,436
CENTER.

220
00:07:44,436 --> 00:07:48,741
>> THANK YOU.

221
00:07:48,741 --> 00:07:49,475
DR. HIGGINS.

222
00:07:49,475 --> 00:07:53,579
>.DR. JAGSI.

223
00:07:53,579 --> 00:07:56,916
>> I'M RESHMA JAGSI, EMORY

224
00:07:56,916 --> 00:07:57,650
UNIVERSITY SCHOOL OF MEDICINE.

225
00:07:57,650 --> 00:08:00,452
>> THANK YOU.

226
00:08:00,452 --> 00:08:00,719
DR. JONES?

227
00:08:00,719 --> 00:08:01,420
>> GOOD MORNING.

228
00:08:01,420 --> 00:08:04,924
MY NAME IS DR. HENDREE JONES,

229
00:08:04,924 --> 00:08:08,894
REPRESENTING UNIVERSITY OF NORTH

230
00:08:08,894 --> 00:08:10,062
CAROLINA CHAPEL HILL.

231
00:08:10,062 --> 00:08:11,196
>>

232
00:08:11,196 --> 00:08:18,370
>> GOOD MORNING, ROSALYN

233
00:08:18,370 --> 00:08:19,038
MAEBEN-FEASTER, UNIVERSITY OF

234
00:08:19,038 --> 00:08:20,139
MICHIGAN MEDICAL SCHOOL.

235
00:08:20,139 --> 00:08:21,974
>> DR. MIELENZ.

236
00:08:21,974 --> 00:08:25,277
>> GOOD MORNING, THELMA
MIELENZ

237
00:08:25,277 --> 00:08:26,011
FROM COLUMBIA UNIVERSITY.

238
00:08:26,011 --> 00:08:29,114
>> THANK YOU.

239
00:08:29,114 --> 00:08:29,381
DR. NOEL.

240
00:08:29,381 --> 00:08:31,717
>> GOOD MORNING.

241
00:08:31,717 --> 00:08:34,386
ALEXANDRA NOEL, LOUISIANA STATE

242
00:08:34,386 --> 00:08:36,255
UNIVERSITY.

243
00:08:36,255 --> 00:08:39,024
>> DR. SHARPS.

244
00:08:39,024 --> 00:08:40,426
>> GOOD MORNING.

245
00:08:40,426 --> 00:08:42,428
I'M DR. SHARPS FROM JOHNS

246
00:08:42,428 --> 00:08:42,995
HOPKINS UNIVERSITY SCHOOL OF

247
00:08:42,995 --> 00:08:43,662
NURSING.

248
00:08:43,662 --> 00:08:49,335
>> THANK YOU.

249
00:08:49,335 --> 00:08:49,601
DR. SIMON?

250
00:08:49,601 --> 00:08:55,507
>?AND DR. TEMPLETON.

251
00:08:55,507 --> 00:08:57,509
>> I'M KIM TEMPLETON FROM

252
00:08:57,509 --> 00:09:00,379
UNIVERSITY OF KANSAS IN KANSAS

253
00:09:00,379 --> 00:09:03,148
CITY.

254
00:09:03,148 --> 00:09:06,719
>> AND DR. OFOTOKUN.

255
00:09:06,719 --> 00:09:07,486
>> THANK YOU.

256
00:09:07,486 --> 00:09:09,254
GOOD MORNING.

257
00:09:09,254 --> 00:09:14,360
MY NAME IS IGHO OFOTOKUN FROM

258
00:09:14,360 --> 00:09:15,794
EMORY UNIVERSITY SCHOOL OF

259
00:09:15,794 --> 00:09:16,061
MEDICINE.

260
00:09:16,061 --> 00:09:17,129
>> I WILL GET BETTER WITH
YOUR

261
00:09:17,129 --> 00:09:17,329
NAME.

262
00:09:17,329 --> 00:09:18,864
I MAY HAVE TO REHEARSE IT A

263
00:09:18,864 --> 00:09:24,970
LITTLE BIT MORE.

264
00:09:24,970 --> 00:09:32,578
SORRY, I'M A LITTLE -- OKAY.

265
00:09:32,578 --> 00:09:34,046
NOW WE'RE UP TO OUR MINUTES.

266
00:09:34,046 --> 00:09:35,280
SO YOU WERE EACH SEPTEMBER THE

267
00:09:35,280 --> 00:09:42,421
MSEPTEMSENT THE MINTSFROM APRIL.

268
00:09:42,421 --> 00:09:44,189
PLEASE NOTE THAT ONLY FULL MEMO

269
00:09:44,189 --> 00:09:46,492
WMEMBERS OF THE ADVISORY

270
00:09:46,492 --> 00:09:46,925
COMMITTEE MAY VOTE.

271
00:09:46,925 --> 00:09:49,228
IF YOU ARE NOT A MEMBER OF ACRWH

272
00:09:49,228 --> 00:09:51,964
AS A FULL MEMBER, WE ASK THAT

273
00:09:51,964 --> 00:09:58,303
YOU REFRAIN FROM VOTING.

274
00:09:58,303 --> 00:09:59,271
SO IS THERE A MOTION ON THE

275
00:09:59,271 --> 00:10:01,607
TABLE TO ACCEPT THE APRIL 9TH,

276
00:10:01,607 --> 00:10:06,845
2024 MINUTES AS WRITTEN?

277
00:10:06,845 --> 00:10:07,713
DR. NOEL HAS SUBMITTED THE

278
00:10:07,713 --> 00:10:07,946
MOTION.

279
00:10:07,946 --> 00:10:12,317
DO I HEAR A SECOND?

280
00:10:12,317 --> 00:10:14,186
>> I'LL SECOND.

281
00:10:14,186 --> 00:10:15,587
>> DR. JONES HAS SECONDED
THE

282
00:10:15,587 --> 00:10:15,921
MOTION.

283
00:10:15,921 --> 00:10:17,656
ALL THOSE IN FAVOR OF ACCEPTING

284
00:10:17,656 --> 00:10:18,857
THE MOTION, PLEASE RAISE YOUR

285
00:10:18,857 --> 00:10:22,928
HANDS NOW.

286
00:10:22,928 --> 00:10:26,765
AND ONLINE?

287
00:10:26,765 --> 00:10:27,733
>> AYE.

288
00:10:27,733 --> 00:10:30,235
>> THANK YOU.

289
00:10:30,235 --> 00:10:32,104
FOR THOSE WHO OPPOSE THE MOTION,

290
00:10:32,104 --> 00:10:37,776
PLEASE RAISE YOUR HANDS NOW.

291
00:10:37,776 --> 00:10:38,710
AND ALL THOSE ABSTAINING FROM

292
00:10:38,710 --> 00:10:39,878
THE MOTION, PLEASE RAISE YOUR

293
00:10:39,878 --> 00:10:46,318
HANDS NOW.

294
00:10:46,318 --> 00:10:47,086
THANK YOU.

295
00:10:47,086 --> 00:10:51,690
HAVE THE VOTES BEEN RECORDED?

296
00:10:51,690 --> 00:10:52,991
THANK YOU VERY MUCH.

297
00:10:52,991 --> 00:10:55,961
SO AS YOU HEARD THE APRIL 9TH,

298
00:10:55,961 --> 00:10:58,564
2024 MEETING MINUTES HAVE BEEN

299
00:10:58,564 --> 00:10:59,665
ACCEPTED WITH 10 MEMBERS IN

300
00:10:59,665 --> 00:10:59,998
FAVOR.

301
00:10:59,998 --> 00:11:03,602
NEXT SLIDE.

302
00:11:03,602 --> 00:11:05,037
NOW I'D LIKE TO INTRODUCE THE

303
00:11:05,037 --> 00:11:07,172
CHAIR OF THE COMMITTEE AND THE

304
00:11:07,172 --> 00:11:09,374
DIRECTOR OF ORWH, DR. JANINE

305
00:11:09,374 --> 00:11:19,518
CLAYTON.

306
00:11:25,891 --> 00:11:27,159
>> GOOD MORNING, EVERYONE.

307
00:11:27,159 --> 00:11:28,427
IT GREAT TO BE WITH YOU FOR

308
00:11:28,427 --> 00:11:31,063
ANOTHER ADVISORY COMMITTEE FOR

309
00:11:31,063 --> 00:11:32,364
RESEARCH ON WOMEN'S HEALTH

310
00:11:32,364 --> 00:11:34,233
MEETING, OUR 61ST MEETING, AND

311
00:11:34,233 --> 00:11:35,434
WE'RE LOOKING FORWARD TO A

312
00:11:35,434 --> 00:11:37,169
FANTASTIC LINEUP AND AGENDA

313
00:11:37,169 --> 00:11:37,936
TODAY.

314
00:11:37,936 --> 00:11:40,038
I GET TO OPEN THESE MEETINGS BY

315
00:11:40,038 --> 00:11:42,641
SHARING WITH YOU THE INCREDIBLE

316
00:11:42,641 --> 00:11:45,177
EFFORTS THAT TEAM ORWH AND OUR

317
00:11:45,177 --> 00:11:46,912
COLLEAGUES ACROSS NIH HAVE

318
00:11:46,912 --> 00:11:49,214
ENDEAVORED TO PUT FORWARD TO

319
00:11:49,214 --> 00:11:50,849
ADVANCE THE HEALTH OF WOMEN

320
00:11:50,849 --> 00:11:52,184
THROUGH RESEARCH AND SCIENCE.

321
00:11:52,184 --> 00:11:54,253
AND I'M GOING TO COVER VERY

322
00:11:54,253 --> 00:11:56,488
BRIEFLY AN OPENING ANNOUNCEMENT.

323
00:11:56,488 --> 00:11:58,524
NIH AND ORWH UPDATES, SOME

324
00:11:58,524 --> 00:12:00,792
POLICY AND SCIENTIFIC UPDATES,

325
00:12:00,792 --> 00:12:01,527
CAREERS AND CLOSING.

326
00:12:01,527 --> 00:12:03,529
I'M GOING TO APOLOGIZE UP FRONT

327
00:12:03,529 --> 00:12:06,031
FOR NOT BEING ABLE TO INCLUDE

328
00:12:06,031 --> 00:12:07,366
EVERYTHING THAT HAS HAPPENED

329
00:12:07,366 --> 00:12:09,301
BETWEEN THE LAST MEETING IN

330
00:12:09,301 --> 00:12:11,537
APRIL AND NOW, INCREDIBLE AMOUNT

331
00:12:11,537 --> 00:12:13,172
OF WORK, WE'RE FOCUSING TODAY ON

332
00:12:13,172 --> 00:12:15,908
OUR THEME OF INNOVATION, SO I'VE

333
00:12:15,908 --> 00:12:17,342
COLLECTED THOSE ITEMS AND YOU'LL

334
00:12:17,342 --> 00:12:21,380
HEAR MORE AT THE NEXT MEETING.

335
00:12:21,380 --> 00:12:21,813
OKAY.

336
00:12:21,813 --> 00:12:23,015
IT'S REALLY EXCITING TO SHARE

337
00:12:23,015 --> 00:12:24,783
WITH YOU THAT THE NATIONAL

338
00:12:24,783 --> 00:12:27,152
LIBRARY OF MEDICINE AND ORWH

339
00:12:27,152 --> 00:12:30,455
COLLABORATED TO CREATE DISCOVER

340
00:12:30,455 --> 00:12:32,191
WHR, A CENTRALIZED RESOURCE FOR

341
00:12:32,191 --> 00:12:33,926
WOMEN'S HEALTH RESEARCH AND

342
00:12:33,926 --> 00:12:35,260
FUNDING AND INFORMATION FROM NIH

343
00:12:35,260 --> 00:12:36,228
SUPPORTING OUR EFFORTS TO CLOSE

344
00:12:36,228 --> 00:12:38,230
THE GAPS IN WOMEN'S HEALTH

345
00:12:38,230 --> 00:12:41,700
ACROSS THE LIFECOURSE.

346
00:12:41,700 --> 00:12:43,368
THE SITE LINKS DIRECTLY TO OPEN

347
00:12:43,368 --> 00:12:44,336
FUNDING OPPORTUNITIES FOR THE

348
00:12:44,336 --> 00:12:45,204
TOPICS LISTED.

349
00:12:45,204 --> 00:12:50,342
AWARDED PROJECTS, RECRUITING AND

350
00:12:50,342 --> 00:12:51,877
UPCOMING CLINICAL TRIALS, THE

351
00:12:51,877 --> 00:12:54,012
LATEST LITERATURE PUBLISHED ON

352
00:12:54,012 --> 00:12:56,248
THOSE TOPICS AND EVEN

353
00:12:56,248 --> 00:12:57,182
PATIENT-FRIENDLY SUMMARIES OF

354
00:12:57,182 --> 00:12:57,883
THOSE HEALTH TOPICS.

355
00:12:57,883 --> 00:13:00,185
SO WE STARTED IN OUR FIRST PHASE

356
00:13:00,185 --> 00:13:03,355
WITH MENOPAUSE, POLYCYSTIC OVARY

357
00:13:03,355 --> 00:13:10,028
SISYNDROME AND SER SEVERAL AUTOE

358
00:13:10,028 --> 00:13:10,295
DISEASES.

359
00:13:10,295 --> 00:13:12,764
IN THE FIRST WEEK IT HAD OVER

360
00:13:12,764 --> 00:13:16,702
3700 VIEWS.

361
00:13:16,702 --> 00:13:18,036
NATIONAL LIBRARY OF MEDICINE AND

362
00:13:18,036 --> 00:13:19,338
THANK DR. STEVE SHERRY AND OUR

363
00:13:19,338 --> 00:13:21,073
COLLEAGUES AT NLM FOR THIS BIG

364
00:13:21,073 --> 00:13:22,040
PUSH TO GET THIS INFORMATION

365
00:13:22,040 --> 00:13:24,276
AVAILABLE IN ONE PLACE TO BE

366
00:13:24,276 --> 00:13:26,111
ABLE TO ASSIST IN ADDRESSING

367
00:13:26,111 --> 00:13:28,413
GAPS AND PROVIDING ACCESS TO

368
00:13:28,413 --> 00:13:30,048
INFORMATION THAT IS VITAL TO

369
00:13:30,048 --> 00:13:36,421
MOVING THIS FIELD FORWARD.

370
00:13:36,421 --> 00:13:38,156
THE NIH DIRECTOR HAS TAKEN A

371
00:13:38,156 --> 00:13:39,458
VERY ACTIVE ROLE IN ADVANCING

372
00:13:39,458 --> 00:13:42,961
RESEARCH ON THE HEALTH OF WOMEN.

373
00:13:42,961 --> 00:13:44,162
I AM ALSO PLEASED TO SHARE WITH

374
00:13:44,162 --> 00:13:45,797
YOU THAT IN MAY, WHEN WE

375
00:13:45,797 --> 00:13:47,766
LAUNCHED THE NEW STRATEGIC PLAN,

376
00:13:47,766 --> 00:13:50,736
THE 2024 TO 2028 NIH-WIDE

377
00:13:50,736 --> 00:13:51,703
STRATEGIC PLAN FOR RESEARCH ON

378
00:13:51,703 --> 00:13:56,308
THE HEALTH OF WOMEN, DR. MONICA

379
00:13:56,308 --> 00:13:58,043
BERTAGNOLLI CREATED A VIDEO

380
00:13:58,043 --> 00:13:59,378
ENTITLED FORGING INTO THE

381
00:13:59,378 --> 00:14:00,345
FUTURE, RESEARCH ON THE HEALTH

382
00:14:00,345 --> 00:14:01,680
OF WOMEN AT NIH AND BEYOND.

383
00:14:01,680 --> 00:14:03,849
AND IN THAT VIDEO, SHE TALKED

384
00:14:03,849 --> 00:14:06,585
ABOUT HER VISION FOR WOMEN'S

385
00:14:06,585 --> 00:14:07,586
HEALTH RESEARCH.

386
00:14:07,586 --> 00:14:10,422
THAT VIDEO IS THE NUMBER ONE

387
00:14:10,422 --> 00:14:13,358
VIEWED VIDEO FOR NIH ON OUR NIH

388
00:14:13,358 --> 00:14:14,359
YOUTUBE CHANNEL.

389
00:14:14,359 --> 00:14:15,894
SO INCREDIBLE INTEREST, AND

390
00:14:15,894 --> 00:14:17,729
WE'RE SO PLEASED THAT THE NIH

391
00:14:17,729 --> 00:14:19,498
DIRECTOR HAS TAKEN SUCH AN

392
00:14:19,498 --> 00:14:21,233
ACTIVE ROLE IN TALKING ABOUT THE

393
00:14:21,233 --> 00:14:23,001
IMPORTANCE OF THIS TOPIC.

394
00:14:23,001 --> 00:14:25,203
THAT SAME WEEK, NATIONAL WOMEN'S

395
00:14:25,203 --> 00:14:26,505
HEALTH WEEK, WHICH IS ALWAYS THE

396
00:14:26,505 --> 00:14:27,806
WEEK AFTER MOTHER'S DAY IN MAY,

397
00:14:27,806 --> 00:14:30,642
WE HAD A VARIETY OF ACTIVITIES

398
00:14:30,642 --> 00:14:31,843
INCLUDING A MENOPAUSE

399
00:14:31,843 --> 00:14:32,277
ROUNDTABLE.

400
00:14:32,277 --> 00:14:33,812
THAT WAS THE VERY FIRST OF OUR

401
00:14:33,812 --> 00:14:35,714
WOMEN'S HEALTH RESEARCH

402
00:14:35,714 --> 00:14:37,115
ROUNDTABLES, AND

403
00:14:37,115 --> 00:14:38,984
DR. BERTAGNOLLI, AGAIN, PROVIDED

404
00:14:38,984 --> 00:14:40,285
REMARKS ANNOUNCING THE LAUNCH OF

405
00:14:40,285 --> 00:14:43,355
A PATHWAYS TO PREVENTION PROGRAM

406
00:14:43,355 --> 00:14:44,756
FOCUSED ON MENOPAUSE.

407
00:14:44,756 --> 00:14:47,159
WE SELECT ONE TOPIC, TWO MAXIMUM

408
00:14:47,159 --> 00:14:48,593
PER YEAR, AND WE SELECTED

409
00:14:48,593 --> 00:14:50,128
MENOPAUSE THIS YEAR.

410
00:14:50,128 --> 00:14:51,330
AND THEN ON THE RIGHT SIDE, YOU

411
00:14:51,330 --> 00:14:53,398
CAN SEE THAT SHE HAS SELECTED

412
00:14:53,398 --> 00:14:55,367
WOMEN'S HEALTH RELEVANT TOPICS

413
00:14:55,367 --> 00:14:56,568
FOR HER DIRECTOR'S BLOG.

414
00:14:56,568 --> 00:14:57,769
I'M JUST POINTING OUT TWO OF

415
00:14:57,769 --> 00:14:59,204
THEM HERE.

416
00:14:59,204 --> 00:15:00,439
SHE'S HAD SEVERAL, BEGINNING

417
00:15:00,439 --> 00:15:01,773
WITH DIAGNOSIS AND TREATMENT OF

418
00:15:01,773 --> 00:15:03,475
MENTAL HEALTH CONDITIONS DURING

419
00:15:03,475 --> 00:15:05,110
AND AFTER PREGNANCY, AND SHE

420
00:15:05,110 --> 00:15:07,279
TALKED ABOUT MATERNAL MENTAL

421
00:15:07,279 --> 00:15:08,413
HEALTH AS AN IMPORTANT CRISIS

422
00:15:08,413 --> 00:15:10,148
THAT WE NEED TO ADDRESS.

423
00:15:10,148 --> 00:15:13,985
AND THEN THE DISCOVERY OF CCN3,

424
00:15:13,985 --> 00:15:15,153
A MATERNAL BRAIN HORMONE THAT

425
00:15:15,153 --> 00:15:17,022
SHE HIGHLIGHTS ASCII TO

426
00:15:17,022 --> 00:15:18,657
STRENGTHENING BONES THAT COULD

427
00:15:18,657 --> 00:15:20,959
HELP TREAT OSTEOPOROSIS AND BONE

428
00:15:20,959 --> 00:15:21,393
FRACTURES.

429
00:15:21,393 --> 00:15:23,362
THIS HORMONE WAS FOUND IN

430
00:15:23,362 --> 00:15:26,631
LACTATING FEMALE MICE WHEN THERE

431
00:15:26,631 --> 00:15:27,733
WAS AN EXAMINATION TO UNDERSTAND

432
00:15:27,733 --> 00:15:30,035
WHY, DESPITE A DROP IN ESTROGEN

433
00:15:30,035 --> 00:15:31,236
POSTPARTUM AND INCREASED NEED

434
00:15:31,236 --> 00:15:33,105
FOR CALCIUM, LACTATING FEMALES

435
00:15:33,105 --> 00:15:36,441
DID NOT HAVE FURTHER BONE

436
00:15:36,441 --> 00:15:36,908
RESORPTION.

437
00:15:36,908 --> 00:15:39,311
SO IT WAS A WOMEN'S HEALTH

438
00:15:39,311 --> 00:15:39,978
RELEVANT RESEARCH QUESTION FROM

439
00:15:39,978 --> 00:15:41,813
THE BEGINNING, WHY DO LACTATING

440
00:15:41,813 --> 00:15:42,914
FEMALES NOT HAVE FURTHER BONE

441
00:15:42,914 --> 00:15:44,983
LOSS THAT LED TO THIS DISCOVERY,

442
00:15:44,983 --> 00:15:47,619
AND ALSO ONE OF THE SCORE

443
00:15:47,619 --> 00:15:49,688
INVESTIGATORS, NANCY LANE'S WORK

444
00:15:49,688 --> 00:15:54,059
CONTRIBUTED TO THIS EFFORT.

445
00:15:54,059 --> 00:15:54,960
DR. BERTAGNOLLI RECENTLY

446
00:15:54,960 --> 00:15:55,927
ANNOUNCED HER CARE FOR HEALTH

447
00:15:55,927 --> 00:15:56,261
INITIATIVE.

448
00:15:56,261 --> 00:15:57,796
CARE STANDS FOR COMMUNITIES

449
00:15:57,796 --> 00:16:00,132
ADVANCING RESEARCH EQUITY FOR

450
00:16:00,132 --> 00:16:01,933
HEALTH, AND IT'S DESIGNED TO

451
00:16:01,933 --> 00:16:03,235
CONDUCT RESEARCH ADDRESSING

452
00:16:03,235 --> 00:16:07,739
DIVERSE ISSUES IN A VARIETY OF

453
00:16:07,739 --> 00:16:09,374
SETTINGS AND COMMUNITIES

454
00:16:09,374 --> 00:16:10,375
GEOGRAPHICALLY DIVERSE,

455
00:16:10,375 --> 00:16:11,443
PARTICULARLY AMONG THOSE THAT

456
00:16:11,443 --> 00:16:13,845
ARE UNDERREPRESENTED IN

457
00:16:13,845 --> 00:16:14,679
BIOMEDICAL RESEARCH INCLUDING

458
00:16:14,679 --> 00:16:15,280
RURAL LOCATIONS.

459
00:16:15,280 --> 00:16:16,581
HER GOAL IS TO INTEGRATE

460
00:16:16,581 --> 00:16:20,685
RESEARCH INTO THE CLINICAL CARE

461
00:16:20,685 --> 00:16:21,486
ENVIRONMENT, AND THIS EFFORT

462
00:16:21,486 --> 00:16:22,888
DOES THAT BY TRYING TO LINK TO

463
00:16:22,888 --> 00:16:25,624
PRIMARY CARE PRACTICES, A

464
00:16:25,624 --> 00:16:27,359
COMMUNITY-BASED PRIMARY CARE

465
00:16:27,359 --> 00:16:29,461
PRACTICES, AND HOPEFULLY WITH

466
00:16:29,461 --> 00:16:30,762
THE GOAL OF REDUCING BURDEN ON

467
00:16:30,762 --> 00:16:32,497
PROVIDERS AS WELL BY USING

468
00:16:32,497 --> 00:16:33,298
INNOVATIVE DATA COLLECTION

469
00:16:33,298 --> 00:16:36,334
METHODS.

470
00:16:36,334 --> 00:16:37,669
AND EVEN IMPROVE THE EFFICIENCY

471
00:16:37,669 --> 00:16:39,304
OF CARE DELIVERY.

472
00:16:39,304 --> 00:16:40,939
$30 MILLION HAVE BEEN INVESTED

473
00:16:40,939 --> 00:16:43,542
FOR FY 24 AND GOING INTO FY 25,

474
00:16:43,542 --> 00:16:46,278
SO WE'LL CERTAINLY BE FOLLOWING

475
00:16:46,278 --> 00:16:47,379
THIS CLOSELY AND WOMEN'S HEALTH

476
00:16:47,379 --> 00:16:48,613
IS DEFINITELY A PART OF HER

477
00:16:48,613 --> 00:16:51,016
AGENDA HERE.

478
00:16:51,016 --> 00:16:52,617
I ALWAYS LIKE TO SHARE WITH YOU

479
00:16:52,617 --> 00:16:54,186
NIH LEADERSHIP UPDATES, SO YOU

480
00:16:54,186 --> 00:16:57,355
ARE AWARE OF WHO IS ON BOARD AT

481
00:16:57,355 --> 00:16:58,557
LEADERSHIP HERE.

482
00:16:58,557 --> 00:17:01,059
THE NEWEST DIRECTOR OF THE

483
00:17:01,059 --> 00:17:02,928
OFFICE OF AIDS RESEARCH AND THE

484
00:17:02,928 --> 00:17:04,996
NIH ASSOCIATE DIRECTOR FOR AIDS

485
00:17:04,996 --> 00:17:09,034
RESEARCH, DR. GERI DONENBERG HAS

486
00:17:09,034 --> 00:17:13,104
BEEN NAMED FOR THAT POSITION AND

487
00:17:13,104 --> 00:17:15,707
DR. ANNICA WAYMAN HAS BEEN NAMED

488
00:17:15,707 --> 00:17:16,808
DEPUTY DIRECTOR OF NCATS,

489
00:17:16,808 --> 00:17:19,444
BRINGING TO A TOTAL OF 12 WOMEN

490
00:17:19,444 --> 00:17:22,714
IC DEPUTY DIRECTORS OUT OF THE

491
00:17:22,714 --> 00:17:24,049
27, AND 13 WOMEN IC DIRECTORS

492
00:17:24,049 --> 00:17:25,884
OUT OF THE 27.

493
00:17:25,884 --> 00:17:27,385
DEFINITELY THE HIGHEST NUMBER WE

494
00:17:27,385 --> 00:17:30,055
HAVE HAD.

495
00:17:30,055 --> 00:17:33,325
AND I ALSO WANT TO WELCOME

496
00:17:33,325 --> 00:17:38,997
DR. LUCIA HINDORFF, SENIOR

497
00:17:38,997 --> 00:17:39,798
ADVISOR FOR SCIENTIFIC AND

498
00:17:39,798 --> 00:17:43,602
ORGANIZATIONAL STRATEGY.

499
00:17:43,602 --> 00:17:45,570
DR. HINDORFF COMES FROM THE

500
00:17:45,570 --> 00:17:47,105
NATIONAL HUMAN GENOME RESEARCH

501
00:17:47,105 --> 00:17:48,840
INSTITUTE WHERE SHE HAD SEVERAL

502
00:17:48,840 --> 00:17:50,709
POSITIONS AS A PROGRAM DIRECTOR

503
00:17:50,709 --> 00:17:52,310
AND AS A LEAD FOR THEIR TRAINING

504
00:17:52,310 --> 00:17:56,081
DIVERSITY AND EQUITY EFFORTS.

505
00:17:56,081 --> 00:17:58,049
SHE HAS OVER 100 PUBLICATIONS

506
00:17:58,049 --> 00:17:59,484
AND WE'RE REALLY EXCITE TODAY

507
00:17:59,484 --> 00:18:00,886
BRING HER ON BOARD TO HELP WITH

508
00:18:00,886 --> 00:18:03,288
SOME SENIOR ACTIVITIES,

509
00:18:03,288 --> 00:18:05,590
INCLUDING ASSISTING WITH

510
00:18:05,590 --> 00:18:06,458
OVERSIGHT OF THE WHITE HOUSE

511
00:18:06,458 --> 00:18:09,361
IMPLEMENTATION EFFORTS AT ORWH.

512
00:18:09,361 --> 00:18:10,695
FOLKS HAVE BEEN VERY INTERESTED

513
00:18:10,695 --> 00:18:12,030
IN THE WHITE HOUSE INITIATIVE ON

514
00:18:12,030 --> 00:18:14,566
WOMEN'S HEALTH RESEARCH, AND SO

515
00:18:14,566 --> 00:18:15,867
I'VE BEEN ASKED TO PROVIDE

516
00:18:15,867 --> 00:18:17,936
UPDATES ON THAT AND SPEAK AT A

517
00:18:17,936 --> 00:18:19,037
VARIETY OF COUNCILS.

518
00:18:19,037 --> 00:18:21,573
FIRST NLM, THEN THE NATIONAL

519
00:18:21,573 --> 00:18:22,874
ADVISORY COUNCIL FOR BIOMEDICAL

520
00:18:22,874 --> 00:18:26,378
IMAGING AND BIOENGINEERING, THE

521
00:18:26,378 --> 00:18:28,446
ACD, THE NIH DIRECTOR'S ADVISORY

522
00:18:28,446 --> 00:18:29,981
COMMITTEE, AND THEN MOST

523
00:18:29,981 --> 00:18:31,249
RECENTLY, THE NATIONAL ADVISORY

524
00:18:31,249 --> 00:18:34,486
COUNCIL ON AGING.

525
00:18:34,486 --> 00:18:38,423
IN THE AFTERNOON, NIA FOCUSED

526
00:18:38,423 --> 00:18:39,291
SPECIFICALLY ON WOMEN'S HEALTH.

527
00:18:39,291 --> 00:18:41,793
SO I GAVE AN UPDATE AND

528
00:18:41,793 --> 00:18:44,996
HIGHLIGHTED SOME OF THE

529
00:18:44,996 --> 00:18:46,164
IMPLEMENTATION STEPS WE'VE TAKEN

530
00:18:46,164 --> 00:18:47,799
AS WELL AS OUR INTEREST IN MID

531
00:18:47,799 --> 00:18:50,669
LIFE HEALTH AND I WAS FOLLOWED

532
00:18:50,669 --> 00:18:52,804
BY DR. HOLLY INGRAHAM, SENIOR

533
00:18:52,804 --> 00:18:56,575
AUTHOR FOR THE DISCOVERY OF THE

534
00:18:56,575 --> 00:18:57,309
CCN3 MATERNAL BRAIN HORMONE THAT

535
00:18:57,309 --> 00:18:58,009
BUILDS BONE.

536
00:18:58,009 --> 00:18:59,644
THE TITLE OF HER PRESENTATION

537
00:18:59,644 --> 00:19:01,813
WAS "UNLOCKING SECRETS OF FEMALE

538
00:19:01,813 --> 00:19:03,014
PHYSIOLOGY TO IMPROVE HUMAN

539
00:19:03,014 --> 00:19:04,449
HEALTH IN AGING."

540
00:19:04,449 --> 00:19:06,284
IF YOU GET A CHANCE TO WATCH HER

541
00:19:06,284 --> 00:19:08,820
REMARKS, SHE TALKS ABOUT HOW SHE

542
00:19:08,820 --> 00:19:10,655
FOCUSED ON FEMALE PHYSIOLOGY

543
00:19:10,655 --> 00:19:12,591
FROM THE OUTSET, DESPITE THE

544
00:19:12,591 --> 00:19:14,392
FACT THAT THERE WAS NO ONE

545
00:19:14,392 --> 00:19:15,694
REALLY ENCOURAGING HER TO DO

546
00:19:15,694 --> 00:19:17,796
THAT, AND THAT SHE WAS ACTUALLY

547
00:19:17,796 --> 00:19:19,531
CHALLENGED BY THE DYNAMIC

548
00:19:19,531 --> 00:19:22,467
CHANGES IN FEMALE HORMONES

549
00:19:22,467 --> 00:19:24,469
RATHER THAN DISSUADED BY THOSE

550
00:19:24,469 --> 00:19:25,437
DYNAMIC CYCLICAL CHANGES.

551
00:19:25,437 --> 00:19:30,575
AND AGAIN, DR. NANCY LANE IS THE

552
00:19:30,575 --> 00:19:31,343
CO-AUTHOR ON THAT PIECE.

553
00:19:31,343 --> 00:19:33,211
WE'VE ALSO BEEN BUSY ON A

554
00:19:33,211 --> 00:19:34,079
NATIONAL AND GLOBAL LEVEL.

555
00:19:34,079 --> 00:19:36,281
I WAS PARTICULARLY DELIGHTED TO

556
00:19:36,281 --> 00:19:38,583
BE RECOGNIZED AND HONORED AT THE

557
00:19:38,583 --> 00:19:40,552
2024 SOCIETY FOR WOMEN'S HEALTH

558
00:19:40,552 --> 00:19:44,155
RESEARCH EVENT.

559
00:19:44,155 --> 00:19:46,324
I REALLY APPRECIATE THAT

560
00:19:46,324 --> 00:19:46,625
RECOGNITION.

561
00:19:46,625 --> 00:19:50,495
IT WAS GREAT TO BE THERE AMONG

562
00:19:50,495 --> 00:19:52,797
MANY OTHER AWARDEES AND

563
00:19:52,797 --> 00:19:53,765
LUMINARIES.

564
00:19:53,765 --> 00:19:54,866
RECENTLY AT THE FOUNDATION FOR

565
00:19:54,866 --> 00:19:57,168
NIH, THEY FOCUSED ON WOMEN'S

566
00:19:57,168 --> 00:19:59,137
HEALTH IN THEIR ANNUAL PATIENT

567
00:19:59,137 --> 00:20:01,439
ENGAGEMENT SUMMIT.

568
00:20:01,439 --> 00:20:04,175
IT WAS AN OPPORTUNITY TO TALK TO

569
00:20:04,175 --> 00:20:04,743
ADVOCATES, PROFESSIONAL

570
00:20:04,743 --> 00:20:07,379
ORGANIZATIONS AND OTHERS,

571
00:20:07,379 --> 00:20:08,680
PRIVATE SECTOR IN THE SPACE, AND

572
00:20:08,680 --> 00:20:10,649
COME TOGETHER IN A

573
00:20:10,649 --> 00:20:12,083
PATIENT-CENTRIC WAY AND TALK

574
00:20:12,083 --> 00:20:13,518
ABOUT THE IMPORTANCE OF HEARING

575
00:20:13,518 --> 00:20:15,253
WOMEN'S VOICES AND FOR US, WHAT

576
00:20:15,253 --> 00:20:18,690
STEPS WE ARE TAKING TO MOVE

577
00:20:18,690 --> 00:20:19,858
FORWARD WITH AN NIH WOMEN'S

578
00:20:19,858 --> 00:20:22,260
HEALTH AGENDA FOR THE FUTURE.

579
00:20:22,260 --> 00:20:24,329
AT A GLOBAL LEVEL, I WAS REALLY,

580
00:20:24,329 --> 00:20:25,964
AGAIN, DELIGHTED AND HONORED TO

581
00:20:25,964 --> 00:20:28,933
BE INCLUDED AS A CHAMPION FOR

582
00:20:28,933 --> 00:20:30,902
THE GLOBAL ALLIANCE FOR WOMEN'S

583
00:20:30,902 --> 00:20:32,637
HEALTH HELD AT THE UNITED

584
00:20:32,637 --> 00:20:33,638
NATIONS GENERAL ASSEMBLY

585
00:20:33,638 --> 00:20:37,575
MEETING, AND TO SPEAK AT SWHR'S

586
00:20:37,575 --> 00:20:39,010
ECH ALLIANCE JOINT SCIENCE

587
00:20:39,010 --> 00:20:43,581
SUMMIT AS WELL.

588
00:20:43,581 --> 00:20:45,350
NOW A FEW POLICY AND SCIENTIFIC

589
00:20:45,350 --> 00:20:45,650
UPDATES.

590
00:20:45,650 --> 00:20:47,719
AS I MENTIONED TO THIS GROUP

591
00:20:47,719 --> 00:20:50,155
BEFORE, I'M HONORED TO CO-CHAIR

592
00:20:50,155 --> 00:20:54,526
ALONG WITH THE DIRECTOR OF

593
00:20:54,526 --> 00:20:59,130
NIA -- AND NIMR THE COMPASS

594
00:20:59,130 --> 00:21:00,198
INITIATIVE, COMMUNITY PARTNERS

595
00:21:00,198 --> 00:21:01,966
TO ADVANCE SCIENCE FOR SOCIETY.

596
00:21:01,966 --> 00:21:03,802
THE PURPOSE OF THE EFFORT IS TO

597
00:21:03,802 --> 00:21:06,705
ADVANCE HEALTH EQUITY, RESEARCH,

598
00:21:06,705 --> 00:21:09,074
TO CATALYZE, DEPLOY AND EVALUATE

599
00:21:09,074 --> 00:21:10,809
COMMUNITY-LED HEALTH EQUITY

600
00:21:10,809 --> 00:21:12,143
STRUCTURAL INTERVENTIONS.

601
00:21:12,143 --> 00:21:14,112
AND THESE ARE NEW -- THIS IS A

602
00:21:14,112 --> 00:21:17,615
NEW PATHWAY FOR NIH.

603
00:21:17,615 --> 00:21:18,917
THE GOAL IS TO DEVELOP

604
00:21:18,917 --> 00:21:20,418
EVENTUALLY A NEW HEALTH EQUITY

605
00:21:20,418 --> 00:21:20,852
RESEARCH MODEL.

606
00:21:20,852 --> 00:21:22,387
SO THE COMPONENTS OF COMPASS

607
00:21:22,387 --> 00:21:24,923
INCLUDE THE CHESIs OR

608
00:21:24,923 --> 00:21:26,357
COMMUNITY LED HEALTH EQUITY

609
00:21:26,357 --> 00:21:27,192
STRUCTURAL INTERVENTIONS.

610
00:21:27,192 --> 00:21:28,760
THESE FUNDS WENT DIRECTLY TO

611
00:21:28,760 --> 00:21:30,829
COMMUNITY ORGANIZATIONS TO

612
00:21:30,829 --> 00:21:32,263
DESIGN THEIR STRUCTURAL

613
00:21:32,263 --> 00:21:34,466
INTERVENTIONS FOR THEIR LOCAL

614
00:21:34,466 --> 00:21:35,100
COMMUNITIES.

615
00:21:35,100 --> 00:21:37,068
25 AWARDS WERE MADE IN 2023.

616
00:21:37,068 --> 00:21:38,603
THERE'S A COMPASS COORDINATING

617
00:21:38,603 --> 00:21:39,804
CENTER TO BRING THIS ALL

618
00:21:39,804 --> 00:21:41,539
TOGETHER AND HELP MANAGE DATA,

619
00:21:41,539 --> 00:21:43,174
THAT AWARD WAS ALSO MADE IN

620
00:21:43,174 --> 00:21:45,043
2023, AND MORE RECENTLY, THE

621
00:21:45,043 --> 00:21:48,213
HEALTH EQUITY RESEARCH HUBS WERE

622
00:21:48,213 --> 00:21:49,981
AWARDED THIS PAST YEAR AND THE

623
00:21:49,981 --> 00:21:51,816
MAP INDICATES THE LOCATIONS FOR

624
00:21:51,816 --> 00:21:53,685
EACH OF THESE COMPONENTS OF

625
00:21:53,685 --> 00:21:54,686
COMPASS DESIGNED TO WORK

626
00:21:54,686 --> 00:21:55,987
TOGETHER.

627
00:21:55,987 --> 00:21:57,188
I'M GOING TO HIGHLIGHT SOME OF

628
00:21:57,188 --> 00:21:58,823
THE TOPICS BEING ADDRESSED IN

629
00:21:58,823 --> 00:22:02,427
SOME OF THE COMMUNITY-LED

630
00:22:02,427 --> 00:22:02,994
INTERVENTIONS.

631
00:22:02,994 --> 00:22:04,195
AT UNIVERSITY OF MISSISSIPPI

632
00:22:04,195 --> 00:22:05,296
MEDICAL CENTER, THEY'RE

633
00:22:05,296 --> 00:22:06,498
ADDRESSING SOCIAL AND CULTURAL

634
00:22:06,498 --> 00:22:07,132
CONTEXT.

635
00:22:07,132 --> 00:22:08,666
AND UNIVERSITY OF MARYLAND

636
00:22:08,666 --> 00:22:10,969
BALTIMORE, COMMUNITY HEALTH

637
00:22:10,969 --> 00:22:12,070
ACCESS IN THE BUILT ENVIRONMENT

638
00:22:12,070 --> 00:22:15,573
ARE ALSO BEING ACTRESSED AND AT

639
00:22:15,573 --> 00:22:17,208
YALE, FOOD AND NUTRITION

640
00:22:17,208 --> 00:22:18,710
ENVIRONMENT ARE BEING ADDRESSED.

641
00:22:18,710 --> 00:22:20,078
IN ADDITION, OUR COLLEAGUES AT

642
00:22:20,078 --> 00:22:22,447
NYU ARE LOOKING AT NUTRITION AND

643
00:22:22,447 --> 00:22:24,415
FOOD IN SOCIAL AND CULTURAL

644
00:22:24,415 --> 00:22:25,884
CONTEXTS, AND OUR COLLEAGUES AT

645
00:22:25,884 --> 00:22:27,485
UNIVERSITY OF MICHIGAN ANN ARBOR

646
00:22:27,485 --> 00:22:30,021
ARE LOOKING AT A MULTIPLE

647
00:22:30,021 --> 00:22:31,189
DOMAINS, AS YOU CAN SEE HERE,

648
00:22:31,189 --> 00:22:32,056
INCLUDING THE BUILT ENVIRONMENT

649
00:22:32,056 --> 00:22:33,625
AND THEY'VE INCORPORATED

650
00:22:33,625 --> 00:22:34,392
ECONOMIC DEVELOPMENT.

651
00:22:34,392 --> 00:22:37,929
SO YOU CAN SEE THESE TOPICS ARE

652
00:22:37,929 --> 00:22:38,997
ALL RELATED TO STRUCTURAL

653
00:22:38,997 --> 00:22:40,331
INTERVENTIONS AND DESIGNED TO

654
00:22:40,331 --> 00:22:42,167
LOOK AT THEIR IMPACT,

655
00:22:42,167 --> 00:22:43,501
INTERVENTIONS AT THE STRUCTURAL

656
00:22:43,501 --> 00:22:44,803
LEVEL, ON A VARIETY OF HEALTH

657
00:22:44,803 --> 00:22:46,504
OUTCOMES.

658
00:22:46,504 --> 00:22:47,505
INCLUDING THOSE THAT ARE HIGHLY

659
00:22:47,505 --> 00:22:52,010
RELEVANT TO WOMEN'S HEALTH.

660
00:22:52,010 --> 00:22:53,978
SO THE ANNUAL MEETING THIS YEAR

661
00:22:53,978 --> 00:22:57,048
INCLUDED THE CHESIs

662
00:22:57,048 --> 00:22:57,882
PRESENTING, THE COMMUNITY LED

663
00:22:57,882 --> 00:22:58,583
ORGANIZATIONS.

664
00:22:58,583 --> 00:23:00,552
I WAS DELIGHTED TO GET TO MEET

665
00:23:00,552 --> 00:23:02,053
FOSTERING COMMUNITY CONNECTIONS

666
00:23:02,053 --> 00:23:03,822
THROUGH NATIVE HAWAIIAN CULTURAL

667
00:23:03,822 --> 00:23:06,124
VALUES TO STRENGTHEN YOUTH

668
00:23:06,124 --> 00:23:06,591
RESILIENCE, HEALTH AND

669
00:23:06,591 --> 00:23:07,759
WELL-BEING INVESTIGATORS.

670
00:23:07,759 --> 00:23:09,093
PICTURED HERE WITH THEIR POSTER.

671
00:23:09,093 --> 00:23:11,830
IT WAS A FANTASTIC MEETING

672
00:23:11,830 --> 00:23:12,931
AVAILABLE ONLINE WHERE YOU COULD

673
00:23:12,931 --> 00:23:14,866
HEAR DIRECTLY FROM THE

674
00:23:14,866 --> 00:23:16,534
ORGANIZATIONS WHO WERE DESIGNING

675
00:23:16,534 --> 00:23:17,502
THESE INTERVENTIONS.

676
00:23:17,502 --> 00:23:19,470
THEY WERE HIGHLY CREATIVE AND

677
00:23:19,470 --> 00:23:20,471
INNOVATIVE AND I CAN'T WAIT TO

678
00:23:20,471 --> 00:23:24,275
SEE WHAT THEY WILL DO NEXT.

679
00:23:24,275 --> 00:23:25,710
ALL OF THESE EFFORTS ARE

680
00:23:25,710 --> 00:23:27,779
COMPLETELY ALIGNED WITH OUR NEW

681
00:23:27,779 --> 00:23:28,780
NIH-WIDE STRATEGIC PLAN FOR

682
00:23:28,780 --> 00:23:30,415
RESEARCH ON THE HEALTH OF WOMEN.

683
00:23:30,415 --> 00:23:31,950
AND OUR FIVE GOALS ARE LISTED

684
00:23:31,950 --> 00:23:32,250
HERE.

685
00:23:32,250 --> 00:23:33,418
I'M GOING TO HIGHLIGHT JUST TWO

686
00:23:33,418 --> 00:23:35,553
OF THEM.

687
00:23:35,553 --> 00:23:36,855
IN ADDITION TO THE ONE AT THE

688
00:23:36,855 --> 00:23:42,760
BOTTOM, ON THE WOU BOTTOM, ADVAE

689
00:23:42,760 --> 00:23:43,428
COMMUNITY-ENGAGED SCIENCE AND

690
00:23:43,428 --> 00:23:45,163
ENHANCE THE DISSEMINATION OF

691
00:23:45,163 --> 00:23:45,930
EVIDENCE-BASED SOLUTIONS.

692
00:23:45,930 --> 00:23:47,932
COMPASS IS HIGHLY ALIGNED WITH

693
00:23:47,932 --> 00:23:48,566
THAT.

694
00:23:48,566 --> 00:23:49,100
OUR FIRST GOAL.

695
00:23:49,100 --> 00:23:50,535
WE WANT TO ADVANCE RESEARCH ON

696
00:23:50,535 --> 00:23:52,070
THE BIOLOGICAL, BEHAVIORAL,

697
00:23:52,070 --> 00:23:52,837
SOCIAL, STRUCTURAL AND

698
00:23:52,837 --> 00:23:54,572
ENVIRONMENTAL FACTORS

699
00:23:54,572 --> 00:23:55,240
INFLUENCING WOMEN'S HEALTH AND

700
00:23:55,240 --> 00:23:56,207
THEY ALL ARE FUNCTIONING

701
00:23:56,207 --> 00:23:56,708
TOGETHER.

702
00:23:56,708 --> 00:23:58,376
WE'RE LEASELY COMMITTED TO

703
00:23:58,376 --> 00:23:59,043
IMPROVING DATA SCIENCE AND

704
00:23:59,043 --> 00:24:00,178
MANAGEMENT WITH INNOVATIVE

705
00:24:00,178 --> 00:24:04,082
METHODS AND CUTTING-EDGE

706
00:24:04,082 --> 00:24:04,415
TECHNOLOGIES.

707
00:24:04,415 --> 00:24:07,285
A COUPLE OF METHODS AND

708
00:24:07,285 --> 00:24:08,152
DATA-RELATED HIGHLIGHTS FOR YOU.

709
00:24:08,152 --> 00:24:11,422
THIS GROUP IS VERY INTERESTED IN

710
00:24:11,422 --> 00:24:13,825
HOW GENERAL EDITORS AND

711
00:24:13,825 --> 00:24:14,492
PUBLISHERS PLAY A KEY GATE

712
00:24:14,492 --> 00:24:15,927
KEEPING ROLE IN WOMEN'S HEALTH

713
00:24:15,927 --> 00:24:17,262
RESEARCH AND ITS DISSEMINATION,

714
00:24:17,262 --> 00:24:18,963
AND THE SEX AND GENDER EQUITY

715
00:24:18,963 --> 00:24:21,799
AND RESEARCH OR SAGER GUIDELINES

716
00:24:21,799 --> 00:24:23,334
HAS BEEN NOW ACCESSED NEARLY A

717
00:24:23,334 --> 00:24:25,203
MILLION TIMES.

718
00:24:25,203 --> 00:24:26,671
IT'S BEEN CITED OVER 700 TIMES

719
00:24:26,671 --> 00:24:28,806
AND IS NOW WIDELY ADOPTED BY

720
00:24:28,806 --> 00:24:31,342
MANY MAJOR ACADEMIC PUBLISHERS

721
00:24:31,342 --> 00:24:33,511
BUT NOT ALL, AND THIS PAST YEAR,

722
00:24:33,511 --> 00:24:35,513
IT WAS FORMALLY ADOPTED BY THE

723
00:24:35,513 --> 00:24:36,381
WORLD HEALTH ORGANIZATION, WHICH

724
00:24:36,381 --> 00:24:38,549
THEY SEE AS A MAJOR MILESTONE.

725
00:24:38,549 --> 00:24:40,318
IT'S BEEN TRANSLATED TO SEVEN

726
00:24:40,318 --> 00:24:40,952
LANGUAGES NOW.

727
00:24:40,952 --> 00:24:43,922
IT'S NOW INCLUDED IN THE EQUATOR

728
00:24:43,922 --> 00:24:49,394
WEBSITE, AND IT'S LISTED THE

729
00:24:49,394 --> 00:24:53,865
REPORTING GUIDELINES.

730
00:24:53,865 --> 00:24:55,166
THE JOURNAL OF THE NATIONAL

731
00:24:55,166 --> 00:24:56,601
CANCER INSTITUTE HAS ALSO

732
00:24:56,601 --> 00:25:00,104
ELEVATED THEIR STANDARDS AND

733
00:25:00,104 --> 00:25:00,872
OUTLINED INCLUSIVE LANGUAGE

734
00:25:00,872 --> 00:25:01,973
GUIDELINES.

735
00:25:01,973 --> 00:25:03,808
HERE THEY'RE TALKING ABOUT

736
00:25:03,808 --> 00:25:04,575
SUMMARY CHARACTERISTICS THAT

737
00:25:04,575 --> 00:25:07,979
SHOULD BE REPORTED NOT JUST IN

738
00:25:07,979 --> 00:25:10,048
TABLE ONE OR WHERE YOU DESCRIBE

739
00:25:10,048 --> 00:25:11,683
DEMOGRAPHICS, BUT IN THE RESULTS

740
00:25:11,683 --> 00:25:14,652
SECTION OF THE MANUSCRIPT.

741
00:25:14,652 --> 00:25:16,054
THEY STATE, QUOTE, IN RESEARCH

742
00:25:16,054 --> 00:25:17,255
ARTICLES AND BRIEF

743
00:25:17,255 --> 00:25:19,257
COMMUNICATIONS, SEX OR GENDER

744
00:25:19,257 --> 00:25:21,426
AND HOW SEX OR GENDER SHOULD BE

745
00:25:21,426 --> 00:25:23,061
REPORTED AND DEFINED, AND HOW

746
00:25:23,061 --> 00:25:25,863
SEX OR GENDER WAS ASSESSED

747
00:25:25,863 --> 00:25:27,231
SHOULD BE DESCRIBED.

748
00:25:27,231 --> 00:25:28,866
WHENEVER POSSIBLE, REPORT ALL

749
00:25:28,866 --> 00:25:31,636
MAIN OUTCOMES BY SEX, OR GENDER

750
00:25:31,636 --> 00:25:33,237
IF APPROPRIATE.

751
00:25:33,237 --> 00:25:33,905
END QUOTE.

752
00:25:33,905 --> 00:25:35,440
SO WE'RE SEEING PROGRESS IN THIS

753
00:25:35,440 --> 00:25:37,175
SPACE AS WELL.

754
00:25:37,175 --> 00:25:39,143
IT WAS MY PLEASURE TO WORK WITH

755
00:25:39,143 --> 00:25:43,514
DR. SARAH TEMKIN WITH DR. KIM

756
00:25:43,514 --> 00:25:44,515
TEMPLETON ONLINE, ONE OF THE

757
00:25:44,515 --> 00:25:46,250
ADVISORY COMMITTEE MEMBERS,

758
00:25:46,250 --> 00:25:52,156
FUNDED TO LOOK AT THE INCLUSION

759
00:25:52,156 --> 00:25:54,158
OF SEX AND GENDER IN ORTHOPEDIC

760
00:25:54,158 --> 00:25:55,259
SURGERY JOURNALS.

761
00:25:55,259 --> 00:25:57,996
AND DR. TEMPLETON HAS BEEN

762
00:25:57,996 --> 00:25:59,597
PUSHING FOR THESE ADVANCES FOR

763
00:25:59,597 --> 00:26:00,932
SOME TIME, AND WE WERE DELIGHTED

764
00:26:00,932 --> 00:26:03,067
TO BE PART OF SEVERAL MEETINGS

765
00:26:03,067 --> 00:26:06,738
AND THRILLED TO BE PART OF A

766
00:26:06,738 --> 00:26:09,007
SUPPLEMENT IN THE JOURNAL OF JOF

767
00:26:09,007 --> 00:26:11,943
BONE AND JOINT SURGERY THAT SHE

768
00:26:11,943 --> 00:26:13,044
SPEARHEAD.

769
00:26:13,044 --> 00:26:14,779
THE PUBLICATION IS CITED HERE.

770
00:26:14,779 --> 00:26:16,748
ONE OF THE KEY SENTENCES FROM

771
00:26:16,748 --> 00:26:18,516
THIS PUBLICATION IS THAT

772
00:26:18,516 --> 00:26:20,351
"TRANSLATING SEX AND GENDER

773
00:26:20,351 --> 00:26:23,421
ADVANCES TO THE ENTIRE RESEARCH

774
00:26:23,421 --> 00:26:26,057
ECOSYSTEM CAN CATALYZE RIGOROUS

775
00:26:26,057 --> 00:26:27,158
BIOMEDICAL DISCOVERY THAT CAN

776
00:26:27,158 --> 00:26:28,659
IMPROVE HEALTH."

777
00:26:28,659 --> 00:26:29,994
AND, IN FACT, IT IMPROVES HEALTH

778
00:26:29,994 --> 00:26:32,930
FOR EVERYONE.

779
00:26:32,930 --> 00:26:34,232
IN ADDITION, MY PLEASURE TO WORK

780
00:26:34,232 --> 00:26:35,666
WITH THE DIRECTOR OF THE OFFICE

781
00:26:35,666 --> 00:26:37,935
OF AUTOIMMUNE DISEASE RESEARCH

782
00:26:37,935 --> 00:26:41,572
AT ORWH, DR. VICTORIA SHANMUGAM

783
00:26:41,572 --> 00:26:47,011
IN INTRODUCING TO THE PUBLIC.

784
00:26:47,011 --> 00:26:49,747
WE HIGHLIGHT OUR GOAL TO RECEIVE

785
00:26:49,747 --> 00:26:52,383
INPUT FROM THE COMMUNITY AT WRIT

786
00:26:52,383 --> 00:26:53,818
LARGE ABOUT A VARIETY OF

787
00:26:53,818 --> 00:26:54,852
OBJECTIVES.

788
00:26:54,852 --> 00:26:56,554
SHE'S LEADING AN EFFORT TO

789
00:26:56,554 --> 00:26:58,723
IDENTIFY RESEARCH AREAS FOR

790
00:26:58,723 --> 00:27:00,091
CROSS-DISCIPLINARY COLLABORATION

791
00:27:00,091 --> 00:27:01,793
HERE AT NIH, EXPLORE

792
00:27:01,793 --> 00:27:03,861
OPPORTUNITIES TO ENHANCE THESE

793
00:27:03,861 --> 00:27:06,497
COLLABORATIONS AND INNOVATION

794
00:27:06,497 --> 00:27:07,565
THROUGH INTERDISCIPLINARY

795
00:27:07,565 --> 00:27:09,700
RESEARCH APPROACHES, BRIDGING

796
00:27:09,700 --> 00:27:11,536
GAPS BETWEEN THE INSTITUTES AND

797
00:27:11,536 --> 00:27:12,637
CENTERS, AND OF COURSE WE WANT

798
00:27:12,637 --> 00:27:14,472
TO IMPROVE OUTCOMES FOR

799
00:27:14,472 --> 00:27:16,007
EVERYONE, IN PARTICULAR THOSE

800
00:27:16,007 --> 00:27:17,775
HEALTH DISPARITY POPULATIONS

801
00:27:17,775 --> 00:27:19,744
DESIGNATED BY NIH, AND

802
00:27:19,744 --> 00:27:20,678
HISTORICALLY UNDERREPRESENTED

803
00:27:20,678 --> 00:27:24,215
GROUPS.

804
00:27:24,215 --> 00:27:25,183
OUR COLLEAGUES IN NURSING

805
00:27:25,183 --> 00:27:26,717
RESEARCH HAVE ALSO BEEN

806
00:27:26,717 --> 00:27:28,786
FANTASTIC PARTNERS IN

807
00:27:28,786 --> 00:27:29,887
DISSEMINATING AND IMPLEMENTING

808
00:27:29,887 --> 00:27:33,391
THE NIH SEX AS A BIOLOGICAL

809
00:27:33,391 --> 00:27:34,592
VARIABLE AS A POLICY.

810
00:27:34,592 --> 00:27:37,795
AS A RESULT OF A CONFERENCE --

811
00:27:37,795 --> 00:27:38,629
ONE OF THE BROADER CONFERENCES

812
00:27:38,629 --> 00:27:41,165
THAT IS HELD IN NURSING

813
00:27:41,165 --> 00:27:42,366
RESEARCH, OUR COLLEAGUES

814
00:27:42,366 --> 00:27:44,869
PUBLISHED THIS PAPER ON ENSURING

815
00:27:44,869 --> 00:27:45,503
ACCOUNTABILITY FOR CONSIDERATION

816
00:27:45,503 --> 00:27:47,939
OF SEX AS A BIOLOGICAL VARIABLE

817
00:27:47,939 --> 00:27:50,141
IN NURSING OUTLOOK, WHICH

818
00:27:50,141 --> 00:27:52,009
REACHES A BROAD NUMBER OF

819
00:27:52,009 --> 00:27:52,643
NURSES.

820
00:27:52,643 --> 00:27:55,480
DESPITE CON CENSUS THAT SEX AND

821
00:27:55,480 --> 00:27:56,581
GENDER ARE DISTINCT CONSTRUCTS,

822
00:27:56,581 --> 00:27:58,349
THEIR APPLICATION IN RESEARCH

823
00:27:58,349 --> 00:27:59,984
REMAINS INCONSISTENT.

824
00:27:59,984 --> 00:28:01,419
KEY RECOMMENDATIONS INCLUDE THE

825
00:28:01,419 --> 00:28:02,753
DISSEMINATION OF RIGOROUS

826
00:28:02,753 --> 00:28:03,921
RESEARCH AND THAT INCLUDES

827
00:28:03,921 --> 00:28:06,424
ACCOUNTING FOR SABB

828
00:28:06,424 --> 00:28:07,959
APPROPRIATELY AND REFERENCING

829
00:28:07,959 --> 00:28:11,028
THE SEX AND GENDER AND EQUITY IN

830
00:28:11,028 --> 00:28:11,896
RESEARCH GUIDELINES.

831
00:28:11,896 --> 00:28:13,431
ONE SCIENCE UPDATE FROM NCI.

832
00:28:13,431 --> 00:28:15,166
IF YOU HAVEN'T SIGNED UP FOR

833
00:28:15,166 --> 00:28:16,734
NIH'S NEWS RELEASES, THIS IS A

834
00:28:16,734 --> 00:28:17,969
GREAT WAY TO GET NEWS ON THE

835
00:28:17,969 --> 00:28:22,206
FIRST DAY OF THAT NEWS BEING

836
00:28:22,206 --> 00:28:23,841
AVAILABLE, BUT NCI PERFORMED A

837
00:28:23,841 --> 00:28:25,910
LARGE-SCALE STUDY, OVER 900,000

838
00:28:25,910 --> 00:28:27,678
WOMEN FROM ABOUT NINE COHORTS,

839
00:28:27,678 --> 00:28:31,282
AND THEY UNCOVERED 56 COMMON

840
00:28:31,282 --> 00:28:33,217
GENETIC VARIANTS ASSOCIATED WITH

841
00:28:33,217 --> 00:28:34,685
MOSAIC LOSS OF CHROMOSOME X.

842
00:28:34,685 --> 00:28:36,621
MANY OF THEM WERE CLOSE TO

843
00:28:36,621 --> 00:28:37,955
AUTOIMMUNE DISEASE-RELATED

844
00:28:37,955 --> 00:28:40,358
GENES, AND CANCER-RELATED GENES.

845
00:28:40,358 --> 00:28:42,193
AND THIS IS IMPORTANT BECAUSE

846
00:28:42,193 --> 00:28:43,961
MOSAIC LOSS OF CHROMOSOME X IS

847
00:28:43,961 --> 00:28:47,265
LINKED TO ABNORMAL BLOOD CELL

848
00:28:47,265 --> 00:28:48,666
PROLIFERATION AND VARIOUS HEALTH

849
00:28:48,666 --> 00:28:50,735
ISSUES IN CREATING RISK FOR

850
00:28:50,735 --> 00:28:50,968
CANCER.

851
00:28:50,968 --> 00:28:52,170
SO THESE FINDINGS MAY LEAD TO

852
00:28:52,170 --> 00:28:54,338
BEING ABLE TO DEVELOP PREDICTIVE

853
00:28:54,338 --> 00:28:56,774
TOOLS THAT WILL DETERMINE WHICH

854
00:28:56,774 --> 00:29:01,245
CHROMOSOME IS RETAINED WITH MLOX

855
00:29:01,245 --> 00:29:02,680
AND EMPHASIZING THE NEED FOR

856
00:29:02,680 --> 00:29:04,849
FURTHER EXPLORATION OF MLO XS

857
00:29:04,849 --> 00:29:07,618
ROLE IN DISEASE RISK.

858
00:29:07,618 --> 00:29:09,820
SO GREAT TO HAVE YOU WITH US,

859
00:29:09,820 --> 00:29:12,957
YOU HAVE TO TELL DR. SHERRY NLM

860
00:29:12,957 --> 00:29:14,292
WAS PROMINENTLY FEATURED TODAY.

861
00:29:14,292 --> 00:29:15,826
I WANT TO REMIND EVERYONE ABOUT

862
00:29:15,826 --> 00:29:19,564
A REQUIREMENT AND THEN ALSO

863
00:29:19,564 --> 00:29:20,765
CONGRATULATE MY NLM COLLEAGUES

864
00:29:20,765 --> 00:29:22,833
ON MODERNIZING THE

865
00:29:22,833 --> 00:29:23,601
CLINICALTRIALS.GOV WEBSITE.

866
00:29:23,601 --> 00:29:28,306
AND SO THAT'S VERY SLEEK NOW AND

867
00:29:28,306 --> 00:29:29,407
EASIER TO USE THAN BEFORE.

868
00:29:29,407 --> 00:29:32,009
BECAUSE OF THE 21ST CENTURY

869
00:29:32,009 --> 00:29:34,745
CURES ACT, INVESTIGATORS THAT

870
00:29:34,745 --> 00:29:36,614
ARE SUPPORTED ON APPLICABLE,

871
00:29:36,614 --> 00:29:38,316
MEANING FDA-REGULATED PRODUCTS

872
00:29:38,316 --> 00:29:40,251
OR STUDIED PHASE THREE CLINICAL

873
00:29:40,251 --> 00:29:43,187
TRIALS MUST REPORT THOSE RESULTS

874
00:29:43,187 --> 00:29:44,288
DISAGGREGATED BY SEX OR GENDER,

875
00:29:44,288 --> 00:29:47,425
RACE AND ETHNICITY, INTO

876
00:29:47,425 --> 00:29:48,292
CLINICALTRIALS.GOV.

877
00:29:48,292 --> 00:29:49,093
THAT IS A REQUIREMENT FOR

878
00:29:49,093 --> 00:29:51,395
STUDIES THAT STARTED AFTER

879
00:29:51,395 --> 00:29:51,729
DECEMBER 2017.

880
00:29:51,729 --> 00:29:53,464
WE ARE LOOKING FORWARD TO THE

881
00:29:53,464 --> 00:29:54,665
OPPORTUNITY TO BE ABLE TO SEE

882
00:29:54,665 --> 00:29:57,201
FOR THE FIRST TIME DISAGGREGATED

883
00:29:57,201 --> 00:30:00,805
RESULTS BY SEX IN CT.GOV,

884
00:30:00,805 --> 00:30:02,206
CLINICALTRIALS.GOV, FOR THESE

885
00:30:02,206 --> 00:30:03,574
APPLICABLE PHASE THREE CLINICAL

886
00:30:03,574 --> 00:30:03,808
TRIALS.

887
00:30:03,808 --> 00:30:05,576
AS YOU KNOW, THOSE ARE THE LARGE

888
00:30:05,576 --> 00:30:09,880
CLINICAL TRIALS THAT CLINICIANS

889
00:30:09,880 --> 00:30:11,115
USE TO MAKE TREATMENT DECISIONS

890
00:30:11,115 --> 00:30:13,150
AND WE WANT TO BE ABLE TO USE

891
00:30:13,150 --> 00:30:15,019
AND MAKE SEX AND GENDER-AWARE

892
00:30:15,019 --> 00:30:16,554
TREATMENT DECISIONS TO BE ABLE

893
00:30:16,554 --> 00:30:17,855
TO DELIVER INDIVIDUALIZED CARE

894
00:30:17,855 --> 00:30:20,925
TO EVERYONE.

895
00:30:20,925 --> 00:30:21,726
I'LL SHIFT GEARS INTO TALKING A

896
00:30:21,726 --> 00:30:24,195
LITTLE BIT ABOUT THE WHITE HOUSE

897
00:30:24,195 --> 00:30:25,196
INITIATIVE ON WOMEN'S HEALTH

898
00:30:25,196 --> 00:30:25,630
RESEARCH.

899
00:30:25,630 --> 00:30:27,598
IT HAS TRULY BEEN TRANSFORMATIVE

900
00:30:27,598 --> 00:30:29,667
IN WOMEN'S HEALTH RESEARCH, AND

901
00:30:29,667 --> 00:30:30,901
ITS STATED PURPOSE IS TO

902
00:30:30,901 --> 00:30:32,403
FUNDAMENTALLY CHANGE THE WAY WE

903
00:30:32,403 --> 00:30:34,472
APPROACH AND FUND WOMEN'S HEALTH

904
00:30:34,472 --> 00:30:36,107
RESEARCH ACROSS THE FEDERAL

905
00:30:36,107 --> 00:30:37,108
LANDSCAPE.

906
00:30:37,108 --> 00:30:41,812
SO ON NOVEMBER 13TH LAST YEAR, I

907
00:30:41,812 --> 00:30:43,347
WAS DELIGHTED TO BE IN THE OVAL

908
00:30:43,347 --> 00:30:45,650
OFFICE ALONG WITH

909
00:30:45,650 --> 00:30:46,417
DR. BERTAGNOLLI, SECRETARY

910
00:30:46,417 --> 00:30:48,252
BECERRA AND OTHERS, WITH THE

911
00:30:48,252 --> 00:30:49,587
PRESIDENT AND THE FIRST LADY TO

912
00:30:49,587 --> 00:30:51,322
WITNESS THE SIGNING OF THIS

913
00:30:51,322 --> 00:30:53,190
PRESIDENTIAL MEMORANDUM THAT

914
00:30:53,190 --> 00:30:56,260
ESTABLISHED THIS INITIATIVE.

915
00:30:56,260 --> 00:30:57,895
A MONTH LATER, WE WERE ALL AT

916
00:30:57,895 --> 00:30:59,764
WORK, EVEN THOUGH THAT WAS A

917
00:30:59,764 --> 00:31:01,932
VERY BUSY TIME, TO RECEIVE INPUT

918
00:31:01,932 --> 00:31:04,669
FROM ALL ACROSS NIH AT BOTH

919
00:31:04,669 --> 00:31:06,103
LEADERSHIP AND PROGRAM LEVELS

920
00:31:06,103 --> 00:31:07,638
ABOUT THE WAYS THAT WE SHOULD

921
00:31:07,638 --> 00:31:09,040
ADDRESS THE 10 AREAS.

922
00:31:09,040 --> 00:31:10,808
WE WERE CHALLENGED IN THAT

923
00:31:10,808 --> 00:31:12,310
PRESIDENTIAL MEMO TO DEVELOP

924
00:31:12,310 --> 00:31:15,179
STEPS THAT WE WERE WILLING TO

925
00:31:15,179 --> 00:31:15,613
TAKE.

926
00:31:15,613 --> 00:31:16,747
ALL OF THE AGENCIES ON THE

927
00:31:16,747 --> 00:31:17,915
PRESIDENTIAL MEMO WERE CHALLENGE

928
00:31:17,915 --> 00:31:19,216
TODAY DO THAT IN A SPRINT AND

929
00:31:19,216 --> 00:31:21,752
PROVIDE THAT INFORMATION BY

930
00:31:21,752 --> 00:31:22,820
DECEMBER 28TH.

931
00:31:22,820 --> 00:31:24,789
AND SO BECAUSE OF THE HARD WORK

932
00:31:24,789 --> 00:31:26,223
ACROSS NIH, WE WERE ABLE TO HAVE

933
00:31:26,223 --> 00:31:30,061
A ROBUST NIH RESPONSE TO THAT

934
00:31:30,061 --> 00:31:30,695
PRESIDENTIAL MEMO.

935
00:31:30,695 --> 00:31:34,298
AS YOU KNOW, SEVERAL MONTHS

936
00:31:34,298 --> 00:31:34,965
LATER, PRESIDENT BIDEN FOLLOWED

937
00:31:34,965 --> 00:31:37,702
UP WITH AN EXECUTIVE ORDER

938
00:31:37,702 --> 00:31:39,003
ENTITLED ADVANCING WOMEN'S

939
00:31:39,003 --> 00:31:40,571
HEALTH RESEARCH AND INNOVATION.

940
00:31:40,571 --> 00:31:45,176
THAT WAS SIGNED ON MARCH 18TH AT

941
00:31:45,176 --> 00:31:47,345
AN EVENT THAT WAS RECOGNIZING

942
00:31:47,345 --> 00:31:48,145
WOMEN'S HEALTH AND WOMEN'S

943
00:31:48,145 --> 00:31:49,547
HISTORY AS WELL.

944
00:31:49,547 --> 00:31:56,120
AND SO THAT EXECUTIVE ORDER HAS

945
00:31:56,120 --> 00:32:00,124
MULTIPLE COMPONENTS.

946
00:32:00,124 --> 00:32:03,427
THE EO 14120 INCLUDES 11 FEDERAL

947
00:32:03,427 --> 00:32:04,328
AGENCIES AND DEPARTMENTS

948
00:32:04,328 --> 00:32:04,762
OUTLINED HERE.

949
00:32:04,762 --> 00:32:06,731
IT'S A CROSS-CUTTING PROGRAM

950
00:32:06,731 --> 00:32:08,265
DESIGNED TO ADVANCE

951
00:32:08,265 --> 00:32:09,333
INTERDISCIPLINARY WOMEN'S HEALTH

952
00:32:09,333 --> 00:32:11,102
RESEARCH ACROSS THESE AGENCIES

953
00:32:11,102 --> 00:32:11,869
TOWARDS TRANSFORMATIVE EFFORTS.

954
00:32:11,869 --> 00:32:14,138
IT'S BEEN MY PLEASURE TO WORK

955
00:32:14,138 --> 00:32:17,208
ACROSS THESE AGENCIES AND TO

956
00:32:17,208 --> 00:32:17,875
CO-CHAIR AN INTERAGENCY WORKING

957
00:32:17,875 --> 00:32:19,643
GROUP ON RESEARCH AND DATA

958
00:32:19,643 --> 00:32:20,177
STANDARDS.

959
00:32:20,177 --> 00:32:21,779
THAT'S ALIGNED WITH SEVERAL OF

960
00:32:21,779 --> 00:32:24,882
THE SECTIONS, SECTION 3 IS ABOUT

961
00:32:24,882 --> 00:32:26,517
SYSTEM-WIDEN HANSMENTS, SECTION

962
00:32:26,517 --> 00:32:29,820
4 SPEAKS TO PR PRIORITIZING FEDL

963
00:32:29,820 --> 00:32:31,021
INVESTMENTS IN WOMEN'S HEALTH

964
00:32:31,021 --> 00:32:32,890
RESEARCH ACROSS THE AGENCIES.

965
00:32:32,890 --> 00:32:33,858
I'LL TALK A LITTLE BIT ABOUT

966
00:32:33,858 --> 00:32:36,494
THESE IN MORE DETAIL.

967
00:32:36,494 --> 00:32:38,896
SECTION 5 IS SPEAKING TO

968
00:32:38,896 --> 00:32:40,197
GALVANIZING RESEARCH ON WOMEN'S

969
00:32:40,197 --> 00:32:41,399
MID LIFE HEALTH.

970
00:32:41,399 --> 00:32:45,870
A TOPIC THAT HAS NOT RECEIVED

971
00:32:45,870 --> 00:32:47,638
VERY MUCH ATTENTION IN THE PAST

972
00:32:47,638 --> 00:32:48,939
AND A VERY IMPORTANT TOPIC AS WE

973
00:32:48,939 --> 00:32:51,909
TAKE A LIFECOURSE PERSPECTIVE

974
00:32:51,909 --> 00:32:52,343
FOR WOMEN'S HEALTH.

975
00:32:52,343 --> 00:32:55,079
IN THAT REGARD, WE HAVE

976
00:32:55,079 --> 00:32:56,414
PERFORMED A LANDSCAPE ANALYSIS

977
00:32:56,414 --> 00:32:58,249
TAKING A LOOK AT

978
00:32:58,249 --> 00:32:59,083
MENOPAUSE-RELATE COMMON DATA

979
00:32:59,083 --> 00:33:00,451
ELEMENTS AND WE'RE MOVING

980
00:33:00,451 --> 00:33:01,986
FORWARD TOWARDS BEING ABLE TO

981
00:33:01,986 --> 00:33:05,322
HARMONIZE EXISTING CDEs AND

982
00:33:05,322 --> 00:33:06,223
THE IMPORTANT OPPORTUNITY TO

983
00:33:06,223 --> 00:33:07,958
CREATE NEW ONES.

984
00:33:07,958 --> 00:33:09,360
SECTION SIX ADDRESSES LOOKING AT

985
00:33:09,360 --> 00:33:10,594
THE UNMET NEEDS TO SUPPORT

986
00:33:10,594 --> 00:33:12,663
WOMEN'S HEALTH RESEARCH.

987
00:33:12,663 --> 00:33:14,064
SO ASSESSING GAPS IN FEDERAL

988
00:33:14,064 --> 00:33:15,299
FUNDING AND IDENTIFYING CHANGES

989
00:33:15,299 --> 00:33:20,004
THAT ARE NEEDED.

990
00:33:20,004 --> 00:33:21,505
ONE OF THE COMMITMENTS NIH HAS

991
00:33:21,505 --> 00:33:22,807
MADE IS A CROSS-CUTTING EFFORT

992
00:33:22,807 --> 00:33:23,941
TO TRANSFORM WOMEN'S HEALTH

993
00:33:23,941 --> 00:33:25,910
THROUGHOUT THE LIFESPAN THROUGH

994
00:33:25,910 --> 00:33:28,179
AN INTERDISCIPLINARY RESEARCH

995
00:33:28,179 --> 00:33:29,914
STRATEGY, WHERE WE'RE LOOKING

996
00:33:29,914 --> 00:33:31,582
ACROSS THE TRADITIONAL MANDATES

997
00:33:31,582 --> 00:33:32,550
OF THE 27 INSTITUTES AND

998
00:33:32,550 --> 00:33:32,883
CENTERS.

999
00:33:32,883 --> 00:33:35,619
WE KNOW THAT MANY DISEASES AND

1000
00:33:35,619 --> 00:33:36,854
CONDITIONS OVERLAP INSTITUTE AND

1001
00:33:36,854 --> 00:33:38,789
CENTER MISSIONS, AND SO WE WILL

1002
00:33:38,789 --> 00:33:42,059
BE DIRECTING $200 MILLION IN FY

1003
00:33:42,059 --> 00:33:45,796
25 TO FUND NEW INTERDISCIPLINARY

1004
00:33:45,796 --> 00:33:47,898
WOMEN'S HEALTH RESEARCH

1005
00:33:47,898 --> 00:33:49,099
PROJECTS, AND THE PARTNERSHIP

1006
00:33:49,099 --> 00:33:52,503
FOR THIS EFFORT IS BEING LED BY

1007
00:33:52,503 --> 00:33:55,005
DIRECTORS OF THE INSTITUTE ON

1008
00:33:55,005 --> 00:33:58,309
AGING, THE NIAMS, EUNICE KENNEDY

1009
00:33:58,309 --> 00:33:59,610
SHRIVER NATIONAL INSTITUTE ON

1010
00:33:59,610 --> 00:34:01,145
CHILD HEALTH AND HUMAN

1011
00:34:01,145 --> 00:34:03,414
DEVELOPMENT, NICHD, NIDA,

1012
00:34:03,414 --> 00:34:04,782
NATIONAL INSTITUTE ON DRUG

1013
00:34:04,782 --> 00:34:06,083
ABUSE, NATIONAL HEART, LUNG AND

1014
00:34:06,083 --> 00:34:08,052
BLOOD INSTITUTE AND ORWH.

1015
00:34:08,052 --> 00:34:09,787
AND OUR MULTIDIMENSIONAL

1016
00:34:09,787 --> 00:34:13,757
FRAMEWORK PICTURED HERE THAT IS

1017
00:34:13,757 --> 00:34:15,593
INCLUDED IN THE NIH-WIDE

1018
00:34:15,593 --> 00:34:16,694
STRATEGIC PLAN FOR RESEARCH ON

1019
00:34:16,694 --> 00:34:18,329
THE HEALTH OF WOMEN HIGHLIGHT

1020
00:34:18,329 --> 00:34:21,198
JUST THE IMPORTANT OPPORTUNITIES

1021
00:34:21,198 --> 00:34:24,235
TO ADDRESS INTERDISCIPLINARY

1022
00:34:24,235 --> 00:34:25,669
RESEARCH THROUGH A VARIETY OF

1023
00:34:25,669 --> 00:34:26,470
STRATEGIES ACROSS THE

1024
00:34:26,470 --> 00:34:28,439
LIFECOURSE.

1025
00:34:28,439 --> 00:34:29,507
THERE ARE INCREDIBLE

1026
00:34:29,507 --> 00:34:31,375
OPPORTUNITIES TO MOVE FORWARD,

1027
00:34:31,375 --> 00:34:33,444
LEVERAGE EQUITIES, BUILD ON

1028
00:34:33,444 --> 00:34:34,545
INVESTMENTS THAT THE INSTITUTES

1029
00:34:34,545 --> 00:34:37,515
HAVE BEEN MAKING, TAKE THAT

1030
00:34:37,515 --> 00:34:39,250
FUNDAMENTAL DISCOVERY SCIENCE

1031
00:34:39,250 --> 00:34:41,585
AND TRANSLATE IT INTO ACTIONABLE

1032
00:34:41,585 --> 00:34:44,655
BENEFIT FOR WOMEN.

1033
00:34:44,655 --> 00:34:46,190
AND WE ARE SEEKING TO ENHANCE

1034
00:34:46,190 --> 00:34:47,925
WOMEN'S HEALTH RESEARCH THROUGH

1035
00:34:47,925 --> 00:34:49,026
COLLABORATION, WHETHER IT'S

1036
00:34:49,026 --> 00:34:50,361
ALIGNING THESE EFFORTS ACROSS

1037
00:34:50,361 --> 00:34:52,763
NIH OR ALIGNING THEM ACROSS THE

1038
00:34:52,763 --> 00:34:53,397
FEDERAL GOVERNMENT.

1039
00:34:53,397 --> 00:34:56,066
WE ARE WORKING ON NEW SURVEY

1040
00:34:56,066 --> 00:34:57,902
TOOLS, ENHANCED DATA COLLECTION

1041
00:34:57,902 --> 00:34:59,570
AND TRANSPARENCY, STREAMLINING

1042
00:34:59,570 --> 00:35:00,771
EFFORTS AND MAKING THINGS EASIER

1043
00:35:00,771 --> 00:35:02,640
TO FIND, AMPLIFYING PRIORITIES.

1044
00:35:02,640 --> 00:35:04,808
THE NIH DISCOVER WHR INITIATIVE

1045
00:35:04,808 --> 00:35:08,646
IS UP WITH WAY TH ONE WAY WE'RET

1046
00:35:08,646 --> 00:35:09,647
INFORMATION EASIER TO FIND, AND

1047
00:35:09,647 --> 00:35:10,848
THIS IS JUST THE FIRST PHASE OF

1048
00:35:10,848 --> 00:35:11,682
THAT LAUNCH.

1049
00:35:11,682 --> 00:35:12,750
YOU SHOULD STAY TUNED BECAUSE WE

1050
00:35:12,750 --> 00:35:15,119
HAVE MORE PLANNED TO BE ABLE TO

1051
00:35:15,119 --> 00:35:17,621
SUPPORT RESEARCHERS,

1052
00:35:17,621 --> 00:35:18,923
PRACTITIONERS AND THE PUBLIC AS

1053
00:35:18,923 --> 00:35:20,257
THEY PRIORITIZE WOMEN'S HEALTH

1054
00:35:20,257 --> 00:35:20,691
RESEARCH.

1055
00:35:20,691 --> 00:35:22,626
AND IN FY 23 FOR THE FIRST TIME,

1056
00:35:22,626 --> 00:35:24,628
WE REPORTED OUR FUNDING FOR

1057
00:35:24,628 --> 00:35:26,297
MENOPAUSE USING THE RESEARCH

1058
00:35:26,297 --> 00:35:28,265
CONDITION AND DISEASE

1059
00:35:28,265 --> 00:35:31,302
CATEGORIZATION SYSTEM, WHICH IS

1060
00:35:31,302 --> 00:35:32,436
NIH'S PREMIER SYSTEM FOR

1061
00:35:32,436 --> 00:35:33,504
REPORTING RESEARCH SPENDING.

1062
00:35:33,504 --> 00:35:36,373
SO WE'RE ABLE TO HAVE THAT

1063
00:35:36,373 --> 00:35:37,007
INFORMATION AVAILABLE

1064
00:35:37,007 --> 00:35:40,010
TRANSPARENTLY FOR YOU.

1065
00:35:40,010 --> 00:35:41,845
WE WERE DELIGHTED TO WORK WITH

1066
00:35:41,845 --> 00:35:42,546
CDC TO DEVELOP QUESTIONS THAT

1067
00:35:42,546 --> 00:35:45,149
COULD BE INCLUDED ABOUT

1068
00:35:45,149 --> 00:35:48,986
MENOPAUSE STATUS FOR 2025 -- THE

1069
00:35:48,986 --> 00:35:49,753
2025 NATIONAL HEALTH INTERVIEW

1070
00:35:49,753 --> 00:35:50,054
SURVEY.

1071
00:35:50,054 --> 00:35:51,488
AS YOU KNOW, THAT REACHES A

1072
00:35:51,488 --> 00:35:53,157
LARGE NUMBER OF INDIVIDUALS WITH

1073
00:35:53,157 --> 00:35:54,692
A REPRESENTATIVE SAMPLE, AND

1074
00:35:54,692 --> 00:35:56,660
WILL GIVE US IMPORTANT INSIGHTS

1075
00:35:56,660 --> 00:35:58,862
AND DATA THAT CAN FUEL FUTURE

1076
00:35:58,862 --> 00:36:00,764
STUDIES.

1077
00:36:00,764 --> 00:36:03,067
I'M ALSO REALLY GRATEFUL TO

1078
00:36:03,067 --> 00:36:05,469
EVERY SINGLE INSTITUTE AND

1079
00:36:05,469 --> 00:36:06,637
CENTER.

1080
00:36:06,637 --> 00:36:08,439
ALL 27 INSTITUTES AND CENTERS,

1081
00:36:08,439 --> 00:36:10,074
ALL ELIGIBLE INSTITUTES AND

1082
00:36:10,074 --> 00:36:11,475
CENTERS THAT DO EXTRAMURAL

1083
00:36:11,475 --> 00:36:12,810
FUNDING SIGNED ON TO THIS NOTICE

1084
00:36:12,810 --> 00:36:14,645
OF SPECIAL INTEREST IN RECORD

1085
00:36:14,645 --> 00:36:16,080
TIME.

1086
00:36:16,080 --> 00:36:19,149
THIS NOSI IS LINKED TO THE

1087
00:36:19,149 --> 00:36:21,251
STANDING FUNDING, THE PARENT

1088
00:36:21,251 --> 00:36:22,219
OPPORTUNITIES THAT ARE ON THE

1089
00:36:22,219 --> 00:36:24,254
STREET ALL THE TIME.

1090
00:36:24,254 --> 00:36:26,190
THAT COVERS RESEARCH GRANTS,

1091
00:36:26,190 --> 00:36:27,358
CAREER DEVELOPMENT GRANTS,

1092
00:36:27,358 --> 00:36:28,626
FELLOWSHIPS AND SMALL BUSINESS

1093
00:36:28,626 --> 00:36:30,094
GRANTS, AND THE NUMBERS ARE

1094
00:36:30,094 --> 00:36:32,696
LISTED HERE INCLUDING

1095
00:36:32,696 --> 00:36:34,698
UNSOLICITED PROJECTS, SOLICITED

1096
00:36:34,698 --> 00:36:37,534
RESEARCH PROJECTS, Ks, Fs

1097
00:36:37,534 --> 00:36:39,169
AND THE SMALL BUSINESS

1098
00:36:39,169 --> 00:36:40,604
INNOVATION, AND SMALL BUSINESS

1099
00:36:40,604 --> 00:36:41,705
TECH TRANSFER APPLICATIONS.

1100
00:36:41,705 --> 00:36:43,440
AND YOU'RE GOING TO HEAR FROM

1101
00:36:43,440 --> 00:36:47,144
THE DIRECTOR OF THE OFFICE LATER

1102
00:36:47,144 --> 00:36:48,379
TODAY AND YOU'RE GOING TO

1103
00:36:48,379 --> 00:36:49,246
UNDERSTAND AFTER THAT

1104
00:36:49,246 --> 00:36:50,881
PRESENTATION WHAT AN INCREDIBLE

1105
00:36:50,881 --> 00:36:54,818
OPPORTUNITY THIS IS.

1106
00:36:54,818 --> 00:36:56,353
THOSE INSTITUTES AND CENTERS,

1107
00:36:56,353 --> 00:36:57,921
WHEN THEY SIGNED ON TO THAT

1108
00:36:57,921 --> 00:36:59,556
NOSI, THEY CREATED A PARAGRAPH

1109
00:36:59,556 --> 00:37:03,727
WHERE THEY ITEMIZE 175 PRIORITY

1110
00:37:03,727 --> 00:37:04,695
TOPICS RELEVANT TO WOMEN'S

1111
00:37:04,695 --> 00:37:05,796
HEALTH THAT ARE ALIGNED WITH

1112
00:37:05,796 --> 00:37:07,665
THEIR MISSION AREAS.

1113
00:37:07,665 --> 00:37:09,133
SIGNALING THEIR INTEREST IN

1114
00:37:09,133 --> 00:37:10,501
PARTICULAR TOPICS FOR THE

1115
00:37:10,501 --> 00:37:13,804
PUBLIC.

1116
00:37:13,804 --> 00:37:16,073
AND IT'S A TOTAL OF 30

1117
00:37:16,073 --> 00:37:16,640
PARTICIPATING INSTITUTES AND

1118
00:37:16,640 --> 00:37:18,409
CENTERS AND THIS IS A TOTAL OF

1119
00:37:18,409 --> 00:37:19,510
41 UNIQUE PATHS TO WOMEN'S

1120
00:37:19,510 --> 00:37:20,144
RESEARCH FUNDING.

1121
00:37:20,144 --> 00:37:21,578
WE'RE ALSO TRYING TO MAKE IT

1122
00:37:21,578 --> 00:37:22,346
EASIER TO FIND ALL OF THIS

1123
00:37:22,346 --> 00:37:24,114
INFORMATION, SO YOU CAN COME TO

1124
00:37:24,114 --> 00:37:25,649
THE ORWH WEBSITE AND GET ACCESS

1125
00:37:25,649 --> 00:37:27,184
TO ALL THE FUNDING OPPORTUNITIES

1126
00:37:27,184 --> 00:37:28,619
THAT WE'RE PARTICIPATING IN, THE

1127
00:37:28,619 --> 00:37:29,920
ONES THAT WE'RE LEADING, AND ALL

1128
00:37:29,920 --> 00:37:32,156
THE ONES THAT THE INSTITUTES AND

1129
00:37:32,156 --> 00:37:33,657
CENTERS ARE LEADING FROM ONE

1130
00:37:33,657 --> 00:37:35,726
FRONT DOOR ON OUR WEBSITE, AND

1131
00:37:35,726 --> 00:37:37,461
SO THAT WILL SPEED UP YOUR BEING

1132
00:37:37,461 --> 00:37:38,829
ABLE TO FIND THE FUNDING

1133
00:37:38,829 --> 00:37:40,097
OPPORTUNITY TO WHICH YOU WANT TO

1134
00:37:40,097 --> 00:37:40,998
APPLY, WHICH WILL GIVE YOU MORE

1135
00:37:40,998 --> 00:37:42,299
TIME TO PREPARE YOUR GRANT

1136
00:37:42,299 --> 00:37:44,535
APPLICATION.

1137
00:37:44,535 --> 00:37:45,402
INNOVATION IN WOMEN'S HEALTH

1138
00:37:45,402 --> 00:37:48,572
RESEARCH AT NIH IS OUR THEME FOR

1139
00:37:48,572 --> 00:37:49,473
TODAY.

1140
00:37:49,473 --> 00:37:50,674
WE'VE TAKEN SEVERAL STEPS TO BE

1141
00:37:50,674 --> 00:37:51,875
ABLE TO ADVANCE INNOVATION.

1142
00:37:51,875 --> 00:37:53,644
ONE OF OUR COMMITMENTS AT NIH IS

1143
00:37:53,644 --> 00:37:56,947
TO INCREASE OUR FUNDING IN TWO

1144
00:37:56,947 --> 00:37:59,016
SMALL BUSINESS INNOVATORS BY 50%

1145
00:37:59,016 --> 00:38:00,117
TO SUPPORT WOMEN'S HEALTH

1146
00:38:00,117 --> 00:38:00,884
RESEARCH.

1147
00:38:00,884 --> 00:38:03,754
AND THE FY 2025 OMNI BUS

1148
00:38:03,754 --> 00:38:08,092
SOLICITATION FOR THE SBR -- STTR

1149
00:38:08,092 --> 00:38:09,560
GRANT APPLICATIONS INCLUDES

1150
00:38:09,560 --> 00:38:10,861
SPECIFIC ARTICULATION ABOUT

1151
00:38:10,861 --> 00:38:11,829
WOMEN'S HEALTH FOR THE VERY

1152
00:38:11,829 --> 00:38:14,364
FIRST TIME.

1153
00:38:14,364 --> 00:38:17,201
THE NEXT SUBMISSION DATES ARE

1154
00:38:17,201 --> 00:38:18,335
JANUARY 5TH AND APRIL 5TH AND

1155
00:38:18,335 --> 00:38:20,404
ORWH SIGNED ON TO THIS OMNIBUS

1156
00:38:20,404 --> 00:38:21,271
FOR THE FIRST TIME.

1157
00:38:21,271 --> 00:38:22,706
YOU'LL HEAR FROM THE SMALL

1158
00:38:22,706 --> 00:38:23,807
BUSINESS EDUCATION

1159
00:38:23,807 --> 00:38:25,142
ENTREPRENEURIAL DEVELOPMENT OR

1160
00:38:25,142 --> 00:38:27,211
SEED OFFICE DIRECTOR SHORTLY,

1161
00:38:27,211 --> 00:38:30,080
AND IN ADDITION, THE NATIONAL

1162
00:38:30,080 --> 00:38:31,215
INSTITUTE OF CHILD HEALTH AND

1163
00:38:31,215 --> 00:38:32,483
HUMAN DEVELOPMENT AND THE

1164
00:38:32,483 --> 00:38:34,451
NATIONAL INSTITUTE OF BIOMEDICAL

1165
00:38:34,451 --> 00:38:36,420
IMAGING AND BIOENGINEERING, AND

1166
00:38:36,420 --> 00:38:37,788
YOU'LL HEAR FROM THAT DIRECTOR

1167
00:38:37,788 --> 00:38:40,457
SOON AS WELL, THEY PARTNERED TO

1168
00:38:40,457 --> 00:38:42,626
ISSUE A CHALLENGE TO ACCELERATE

1169
00:38:42,626 --> 00:38:45,395
THE DEVELOPMENT OF INOWE  INNOVE

1170
00:38:45,395 --> 00:38:46,597
TECHNOLOGIES TO IMPROVE THE

1171
00:38:46,597 --> 00:38:49,466
DIAGNOSIS OF ENDOMETRIOSIS.

1172
00:38:49,466 --> 00:38:51,435
AND AN IMPORTANT FEMALE-SPECIFIC

1173
00:38:51,435 --> 00:38:54,071
CONDITION THAT AFFECTS 10% OF

1174
00:38:54,071 --> 00:38:56,373
WOMEN.

1175
00:38:56,373 --> 00:38:58,242
WE NEED BETTER DIAGNOSTICS,

1176
00:38:58,242 --> 00:39:00,010
EARLIER DIAGNOSIS, AND WE NEED

1177
00:39:00,010 --> 00:39:01,311
BETTER THERAPEUTICS AND WE HAVE

1178
00:39:01,311 --> 00:39:04,948
TO LISTEN TO THE VOICES OF WOMEN

1179
00:39:04,948 --> 00:39:05,916
WHEN THEY SAY THAT SOMETHING IS

1180
00:39:05,916 --> 00:39:07,117
WRONG.

1181
00:39:07,117 --> 00:39:08,652
HERE ARE JUST A FEW OF THE

1182
00:39:08,652 --> 00:39:10,554
HIGHLIGHTS FROM THE INNOVATION

1183
00:39:10,554 --> 00:39:11,088
WEBINARS.

1184
00:39:11,088 --> 00:39:12,523
THIS EFFORT IS BEING SPEARHEADED

1185
00:39:12,523 --> 00:39:17,561
BY DR. ELIZABETH BARR IN OUR

1186
00:39:17,561 --> 00:39:20,297
OFFICE AND BLOOMER TECH IS

1187
00:39:20,297 --> 00:39:22,699
CREATING A WEARABLE ECG DEVICE

1188
00:39:22,699 --> 00:39:23,901
FOR WOMEN, THE SMART BRA.

1189
00:39:23,901 --> 00:39:28,105
THAT IS SUPPORTED BY NHLBI.

1190
00:39:28,105 --> 00:39:31,375
THEY'RE PROMOTING HEALTHY

1191
00:39:31,375 --> 00:39:32,609
LIFESTYLES AMONG LATINAS.

1192
00:39:32,609 --> 00:39:34,678
THAT IS SUPPORTED BY NCI.

1193
00:39:34,678 --> 00:39:36,113
AND YOU CAN SEE IN THE BOTTOM

1194
00:39:36,113 --> 00:39:38,816
RIGHT OF THIS SLIDE, WE HAVE HAD

1195
00:39:38,816 --> 00:39:41,251
ONE WEBINAR IN JUNE AND WE HAVE

1196
00:39:41,251 --> 00:39:45,022
TWO COMING UP, ONE IN OCTOBER,

1197
00:39:45,022 --> 00:39:45,989
OCTOBER 30TH, AND 1 IN JANUARY.

1198
00:39:45,989 --> 00:39:47,624
YOU CAN SEE THAT ALL OF THE

1199
00:39:47,624 --> 00:39:48,625
INSTITUTES AND CENTERS ARE

1200
00:39:48,625 --> 00:39:52,129
COMING ABOARD TO FEATURE THEIR

1201
00:39:52,129 --> 00:39:53,130
WORK AND THEIR INTERESTS AND

1202
00:39:53,130 --> 00:39:54,565
WE'RE DELIGHTED TO BE ABLE TO

1203
00:39:54,565 --> 00:39:57,501
STIMULATE AND CATALYZE THIS

1204
00:39:57,501 --> 00:39:57,701
WORK.

1205
00:39:57,701 --> 00:39:59,036
IN ADDITION, WE'VE CREATED A

1206
00:39:59,036 --> 00:40:00,137
NATIONAL WOMEN'S HEALTH

1207
00:40:00,137 --> 00:40:01,705
ROUNDTABLE SERIES PROMOTING

1208
00:40:01,705 --> 00:40:02,706
EDUCATION AND OUTREACH.

1209
00:40:02,706 --> 00:40:05,776
THIS EFFORT IS LED BY DR. KAREN

1210
00:40:05,776 --> 00:40:07,411
WILEY AT ORWH AND WE'RE

1211
00:40:07,411 --> 00:40:09,146
PARTNERING WITH MANY INSTITUTES

1212
00:40:09,146 --> 00:40:10,547
AND CENTERS AND OFFICES LIKE THE

1213
00:40:10,547 --> 00:40:11,582
OFFICE OF DISEASE PREVENTION ON

1214
00:40:11,582 --> 00:40:13,016
THIS ROUNDTABLE SERIES.

1215
00:40:13,016 --> 00:40:14,985
THE VERY FIRST ROUNDTABLE WAS

1216
00:40:14,985 --> 00:40:16,320
THE ONE THAT I MENTIONED THAT

1217
00:40:16,320 --> 00:40:17,721
HAPPENED IN MAY DURING NATIONAL

1218
00:40:17,721 --> 00:40:19,489
WOMEN'S HEALTH WEEK, WHERE

1219
00:40:19,489 --> 00:40:21,391
DR. BERTAGNOLLI OPENED THE GROUP

1220
00:40:21,391 --> 00:40:23,327
TALKING ABOUT THE PATHWAYS TO

1221
00:40:23,327 --> 00:40:24,728
PREVENTION PROGRAM.

1222
00:40:24,728 --> 00:40:26,530
THE SECOND WAS ON ENDOMETRIOSIS

1223
00:40:26,530 --> 00:40:28,932
WITH NICHD AS A PARTNER ENTITLED

1224
00:40:28,932 --> 00:40:30,367
BEYOND THE LESION, CHARTING NEW

1225
00:40:30,367 --> 00:40:30,701
PATHS.

1226
00:40:30,701 --> 00:40:34,204
AND THE MOST RECENT ONE WAS WITH

1227
00:40:34,204 --> 00:40:37,074
NI MH ON MATERNAL MENTAL HEALTH

1228
00:40:37,074 --> 00:40:38,342
RESEARCH, ELEVATING WOMEN'S

1229
00:40:38,342 --> 00:40:39,409
VOICES TO IMPROVE MATERNAL

1230
00:40:39,409 --> 00:40:39,810
MENTAL HEALTH.

1231
00:40:39,810 --> 00:40:42,112
I HAVE BEEN SO PLEASED TO SEE

1232
00:40:42,112 --> 00:40:45,048
THE INCREDIBLE INTEREST AND

1233
00:40:45,048 --> 00:40:46,149
APPETITE FOR THIS TYPE OF

1234
00:40:46,149 --> 00:40:50,554
INFORMATION FOR JUST THESE THREE

1235
00:40:50,554 --> 00:40:51,955
OVER 5400 PARTICIPANTS HAVE

1236
00:40:51,955 --> 00:40:53,390
ATTENDED THESE SERIES, SO WE ARE

1237
00:40:53,390 --> 00:40:54,958
CLEARLY MEETING A NEED AND WE

1238
00:40:54,958 --> 00:40:56,159
CONTINUE TO WORK WITH OUR

1239
00:40:56,159 --> 00:40:57,461
FEDERAL PARTNERS AS WELL AS OUR

1240
00:40:57,461 --> 00:40:58,996
NIH PARTNERS THROUGH THAT

1241
00:40:58,996 --> 00:41:00,964
ROUNDTABLE.

1242
00:41:00,964 --> 00:41:02,966
DURING NATIONAL WOMEN'S HEALTH

1243
00:41:02,966 --> 00:41:05,369
WEEK, WE LAUNCHED SEVERAL KEY

1244
00:41:05,369 --> 00:41:09,206
RESOURCES JUST IN THAT WEEK.

1245
00:41:09,206 --> 00:41:10,841
I WANT TO PAUSE AND THANK ORWH

1246
00:41:10,841 --> 00:41:12,175
FOR THE INCREDIBLE WORK THAT

1247
00:41:12,175 --> 00:41:13,810
THEY DID, OUR COMMUNICATIONS

1248
00:41:13,810 --> 00:41:16,480
TEAM, OUR SCIENTISTS, OUR

1249
00:41:16,480 --> 00:41:18,315
ADMINISTRATIVE STAFF BEHIND THE

1250
00:41:18,315 --> 00:41:20,183
SCENES, MAKING SURE THAT WE

1251
00:41:20,183 --> 00:41:22,052
COULD EXECUTE AND DELIVER A

1252
00:41:22,052 --> 00:41:26,890
RECORD NUMBER OF RESOURCES AND

1253
00:41:26,890 --> 00:41:27,858
PRODUCTS AND PRESENTATIONS

1254
00:41:27,858 --> 00:41:29,393
DURING THAT WEEK.

1255
00:41:29,393 --> 00:41:31,595
I THINK THEY DESERVE THAT.

1256
00:41:31,595 --> 00:41:31,895
ABSOLUTELY.

1257
00:41:31,895 --> 00:41:33,063
THANK YOU.

1258
00:41:33,063 --> 00:41:33,497
[APPLAUSE]

1259
00:41:33,497 --> 00:41:37,000
THE STRATEGIC PLAN WAS LAUNCHED.

1260
00:41:37,000 --> 00:41:39,970
THE HEALTH OF WOMEN OF

1261
00:41:39,970 --> 00:41:40,871
U3 POPULATIONS DATA BOOK WAS

1262
00:41:40,871 --> 00:41:41,305
LAUNCHED.

1263
00:41:41,305 --> 00:41:42,739
THIS IS THE FIFTH EDITION.

1264
00:41:42,739 --> 00:41:44,508
IT FOLLOWS WHEN THERE'S A CENSUS

1265
00:41:44,508 --> 00:41:46,543
UPDATE, A U.S. CENSUS UPDATE,

1266
00:41:46,543 --> 00:41:48,211
AND DELINEATES HEALTH STATUS OF

1267
00:41:48,211 --> 00:41:50,714
WOMEN FROM DIFFERENT

1268
00:41:50,714 --> 00:41:51,114
BACKGROUNDS.

1269
00:41:51,114 --> 00:41:53,483
AND WE CREATED A TOTALLY NEW

1270
00:41:53,483 --> 00:41:56,086
RESOURCE, NIH FACT SHEETS ON

1271
00:41:56,086 --> 00:41:57,087
WOMEN'S HEALTH RESEARCH.

1272
00:41:57,087 --> 00:41:58,755
THESE COVER 10 TOPICS OR SO.

1273
00:41:58,755 --> 00:42:00,290
THEY'RE TWO PAGES EACH, VERY

1274
00:42:00,290 --> 00:42:00,958
QUICK READ.

1275
00:42:00,958 --> 00:42:02,826
THEY OUTLINE THE STATE OF

1276
00:42:02,826 --> 00:42:05,662
SCIENCE, THEY TALK ABOUT GAPS.

1277
00:42:05,662 --> 00:42:07,431
VERY EASY SOURCE TO GET

1278
00:42:07,431 --> 00:42:09,066
INFORMATION ON WHAT NIH IS DOING

1279
00:42:09,066 --> 00:42:11,034
ON THOSE SPECIFIC TOPICS.

1280
00:42:11,034 --> 00:42:13,136
NIH WOMEN'S HEALTH IN FOCUS,

1281
00:42:13,136 --> 00:42:16,306
WE'RE ALWAYS EXCITED ABOUT THAT

1282
00:42:16,306 --> 00:42:16,940
QUARTERLY PUBLICATION AND THE

1283
00:42:16,940 --> 00:42:18,375
NEWS THAT WE CAN GET OUT ABOUT

1284
00:42:18,375 --> 00:42:19,376
THAT.

1285
00:42:19,376 --> 00:42:20,777
FUTURE DIRECTIONS IN MENOPAUSE

1286
00:42:20,777 --> 00:42:22,245
RESEARCH, THAT WAS THE VIDEO WE

1287
00:42:22,245 --> 00:42:25,649
LAUNCHED, AND THEN OUR ANNUAL

1288
00:42:25,649 --> 00:42:31,755
NIH VIVIAN PINN SYMPOSIUM,

1289
00:42:31,755 --> 00:42:33,757
DR. VICTORIA SHAMAGAM WAS THE

1290
00:42:33,757 --> 00:42:34,291
LEAD FOR THAT.

1291
00:42:34,291 --> 00:42:36,393
WE PUT OUT AN INCREDIBLE AMOUNT

1292
00:42:36,393 --> 00:42:37,561
OF INFORMATION HIGHLIGHTING WHAT

1293
00:42:37,561 --> 00:42:39,029
WE KNOW ABOUT THE HEALTH OF

1294
00:42:39,029 --> 00:42:40,330
WOMEN, WHAT WE DON'T KNOW ABOUT

1295
00:42:40,330 --> 00:42:42,432
THE HEALTH OF WOMEN, AND WHERE

1296
00:42:42,432 --> 00:42:43,667
WE NEED TO GO TO IMPROVE THE

1297
00:42:43,667 --> 00:42:45,635
HEALTH OF WOMEN THROUGH PUTTING

1298
00:42:45,635 --> 00:42:50,140
SCIENCE AND DATA TO WORK.

1299
00:42:50,140 --> 00:42:52,876
THE ADVISORY COMMITTEE REPORT,

1300
00:42:52,876 --> 00:42:54,177
YOUR BIENNIAL REPORT, WAS ALSO

1301
00:42:54,177 --> 00:42:58,115
FEATURED DURING THAT WEEK.

1302
00:42:58,115 --> 00:42:59,149
AGAIN REMEMBER THEIR INSTITUTE

1303
00:42:59,149 --> 00:43:00,283
AND CENTER REPORTS, EACH

1304
00:43:00,283 --> 00:43:01,651
INSTITUTE HAS A TWO OR

1305
00:43:01,651 --> 00:43:02,853
THREE-PAGE REPORT ON THEIR

1306
00:43:02,853 --> 00:43:04,921
EFFORTS, AND THERE'S INTEGRATIVE

1307
00:43:04,921 --> 00:43:08,125
CROSS-CUTTING TOPICS ALSO

1308
00:43:08,125 --> 00:43:10,660
INCLUDED.

1309
00:43:10,660 --> 00:43:13,630
THE ORWH PROGRAMS ARE SUMMARIZED

1310
00:43:13,630 --> 00:43:16,366
AND THE NEXT REPORT, THE FY

1311
00:43:16,366 --> 00:43:20,771
23-24 REPORT, IS NOW IN

1312
00:43:20,771 --> 00:43:21,571
DEVELOPMENT, SO WE LOOK FORWARD

1313
00:43:21,571 --> 00:43:23,507
TO WORKING WITH YOU ON THIS NEXT

1314
00:43:23,507 --> 00:43:23,940
BIENNIAL REPORT.

1315
00:43:23,940 --> 00:43:25,175
IF YOU WANT TO CHECK OUT THE

1316
00:43:25,175 --> 00:43:26,143
LAST ONE FOR REFERENCE, YOU CAN

1317
00:43:26,143 --> 00:43:29,546
CHECK OUT OUR WEBSITE.

1318
00:43:29,546 --> 00:43:31,314
IN 2019, I HAD A CONVERSATION

1319
00:43:31,314 --> 00:43:37,254
WITH DR. JOHN LORE JON LORSCH, E

1320
00:43:37,254 --> 00:43:39,556
TALKED ABOUT AN OPPORTUNITY TO

1321
00:43:39,556 --> 00:43:41,792
ADVANCE WOMEN'S HEALTH RESEARCH

1322
00:43:41,792 --> 00:43:43,160
IN THE IDEA STATES.

1323
00:43:43,160 --> 00:43:47,431
THESE ARE THE 23-PLUS -- 23

1324
00:43:47,431 --> 00:43:48,665
STATES PLUS PUERTO RICO THAT

1325
00:43:48,665 --> 00:43:50,100
RECEIVE THE LEAST AMOUNT OF NIH

1326
00:43:50,100 --> 00:43:53,603
FUNDING.

1327
00:43:53,603 --> 00:43:54,905
THEY'RE ALSO SETTINGS THAT HAVE

1328
00:43:54,905 --> 00:43:57,874
UNDERUNDERSERVED POPULATIONS

1329
00:43:57,874 --> 00:43:59,076
INCLUDING WHERE MATERNAL HEALTH

1330
00:43:59,076 --> 00:43:59,743
OUTCOMES ARE POOR.

1331
00:43:59,743 --> 00:44:03,146
SO WE TOGETHER CREATED THE FIRST

1332
00:44:03,146 --> 00:44:04,381
FUNDING OPPORTUNITIES ON WOMEN'S

1333
00:44:04,381 --> 00:44:08,418
HEALTH RESEARCH.

1334
00:44:08,418 --> 00:44:11,254
NOW IN FY 20, WE SUPPORTED

1335
00:44:11,254 --> 00:44:14,024
THROUGH SUPPLEMENTS 15 STATES,

1336
00:44:14,024 --> 00:44:15,659
21, 11 IDEA STATES.

1337
00:44:15,659 --> 00:44:18,528
BY FY 23, WE HAVE PROVIDED 60

1338
00:44:18,528 --> 00:44:21,031
GRANTS TOTALING OVER $16 MILLION

1339
00:44:21,031 --> 00:44:22,699
TO THE IDEA STATES TO SUPPORT

1340
00:44:22,699 --> 00:44:24,668
WOMEN'S HEALTH RESEARCH TOPICS.

1341
00:44:24,668 --> 00:44:27,003
WE DID PRIORITIZE MATERNAL

1342
00:44:27,003 --> 00:44:30,507
HEALTH RESEARCH IN THOSE INITIAL

1343
00:44:30,507 --> 00:44:32,476
ANNOUNCEMENTS, AND THIS YEAR, FY

1344
00:44:32,476 --> 00:44:36,780
24, WE JUST FINISHED, WE FUNDED

1345
00:44:36,780 --> 00:44:38,381
FIRST CENTERS OF BIOMEDICAL

1346
00:44:38,381 --> 00:44:42,052
RESEARCH EXCELLENCE OR COBREs

1347
00:44:42,052 --> 00:44:44,121
SPECIFICALLY FOCUSED ON WOMEN'S

1348
00:44:44,121 --> 00:44:44,554
HEALTH.

1349
00:44:44,554 --> 00:44:46,656
SO WE ARE THRILLED, AND THIS MAP

1350
00:44:46,656 --> 00:44:47,757
HIGHLIGHTS THE IDEA STATES THAT

1351
00:44:47,757 --> 00:44:49,626
RECEIVED FUNDING IN ANY OF THESE

1352
00:44:49,626 --> 00:44:49,960
FISCAL YEARS.

1353
00:44:49,960 --> 00:44:51,928
YOU CAN SEE THERE ARE ONLY THREE

1354
00:44:51,928 --> 00:44:53,263
THAT ARE GREY THAT HAVEN'T

1355
00:44:53,263 --> 00:44:54,464
RECEIVED FUNDING.

1356
00:44:54,464 --> 00:44:55,866
THAT DOESN'T MEAN THEY'VE

1357
00:44:55,866 --> 00:44:56,266
ACTUALLY APPLIED.

1358
00:44:56,266 --> 00:45:01,171
WE WOULD LOVE TO FILL OUT THIS

1359
00:45:01,171 --> 00:45:03,673
MAP, AND SO TO DATE, 21 IDEA

1360
00:45:03,673 --> 00:45:04,374
STATES HAVE BEEN SUPPORTED

1361
00:45:04,374 --> 00:45:07,077
THROUGH THESE AWARDS.

1362
00:45:07,077 --> 00:45:09,613
AND ON THE TOP ROW HERE, YOU CAN

1363
00:45:09,613 --> 00:45:12,249
SEE THE PIs OF THE COBREs.

1364
00:45:12,249 --> 00:45:14,451
WE LED THE SUPPORT WITH GM FOR

1365
00:45:14,451 --> 00:45:16,987
THE UNIVERSITY OF KANSAS

1366
00:45:16,987 --> 00:45:20,490
LAWRENCE COBRE, WHERE HEATHER

1367
00:45:20,490 --> 00:45:22,259
DESAIRE IS TALKING ABOUT

1368
00:45:22,259 --> 00:45:23,793
LEVERAGING BIG DATA TO IMPROVE

1369
00:45:23,793 --> 00:45:25,328
WOMEN'S HEALTH.

1370
00:45:25,328 --> 00:45:26,696
NIGMS IS LEADING THE FUNDING OF

1371
00:45:26,696 --> 00:45:30,066
THE UNIVERSITY OF IDAHO COBRE ON

1372
00:45:30,066 --> 00:45:31,401
NUTRITION AND WOMEN'S HEALTH,

1373
00:45:31,401 --> 00:45:33,036
AND TULANE RECEIVES FUNDING FROM

1374
00:45:33,036 --> 00:45:36,840
GM ON SEX-BASED PREVISION PRECIN

1375
00:45:36,840 --> 00:45:37,474
MEDICINE.

1376
00:45:37,474 --> 00:45:38,642
WE WERE PARTICULARLY EXCITED TO

1377
00:45:38,642 --> 00:45:42,045
WELCOME THE FIRST GROUP OF IDEA

1378
00:45:42,045 --> 00:45:43,380
STATES INVESTIGATORS, PEOPLE

1379
00:45:43,380 --> 00:45:44,381
THAT WERE FUNDED THROUGH THIS

1380
00:45:44,381 --> 00:45:46,950
PROGRAM IN ANY YEAR FOR OUR

1381
00:45:46,950 --> 00:45:49,186
FIRST NIH SYMPOSIUM THIS YEAR.

1382
00:45:49,186 --> 00:45:52,622
EMILY HARVILLE TALKED ABOUT

1383
00:45:52,622 --> 00:45:53,390
PREGNANCY COMPLICATIONS IN THE

1384
00:45:53,390 --> 00:45:56,359
STRONG HEART STUDY AND A

1385
00:45:56,359 --> 00:45:57,928
PARTICULARLY DIVERSE COHORT.

1386
00:45:57,928 --> 00:46:00,030
THEN KEDRA WALLACE TALKED ABOUT

1387
00:46:00,030 --> 00:46:03,333
A NEED FOR MORE THAN TELE-TEXT

1388
00:46:03,333 --> 00:46:04,568
IN POSTPARTUM HYPERTENSIVE

1389
00:46:04,568 --> 00:46:05,936
WOMEN, A CRITICAL ISSUE FOR THE

1390
00:46:05,936 --> 00:46:06,369
HEALTH OF WOMEN.

1391
00:46:06,369 --> 00:46:09,206
YOU CAN CHECK OUT THIS SYMPOSIUM

1392
00:46:09,206 --> 00:46:10,340
BOOKLET AND ABSTRACTS WITH THAT

1393
00:46:10,340 --> 00:46:15,178
QR CODE, AN WE  AND WE ARE THRIO

1394
00:46:15,178 --> 00:46:18,815
BE ABLE HAVE LAUNCHED THIS

1395
00:46:18,815 --> 00:46:20,417
EFFORT WITH MULTIPLE INSTITUTES

1396
00:46:20,417 --> 00:46:22,419
AND CENTERS THAT ALSO FUND THESE

1397
00:46:22,419 --> 00:46:23,520
RESEARCH PROGRAMS IN THE IDEA

1398
00:46:23,520 --> 00:46:24,221
STATES.

1399
00:46:24,221 --> 00:46:29,693
AS YOU KNOW, ORWH TAKES A WHOLE

1400
00:46:29,693 --> 00:46:30,994
PERSON HEALTH APPROACH TO

1401
00:46:30,994 --> 00:46:32,262
RESEARCH ON THE HEALTH OF WOMEN,

1402
00:46:32,262 --> 00:46:33,330
AND MENOPAUSE IS INCLUDED IN

1403
00:46:33,330 --> 00:46:34,864
THAT APPROACH.

1404
00:46:34,864 --> 00:46:38,068
WE HAVE REPRODUCTIVE AGING,

1405
00:46:38,068 --> 00:46:39,603
CHRONOLOGICAL AGING,

1406
00:46:39,603 --> 00:46:41,137
ORGAN-SPECIFIC AGING THAT WE NOW

1407
00:46:41,137 --> 00:46:44,407
UNDERSTAND, AND THOSE ARE ALL

1408
00:46:44,407 --> 00:46:46,009
HAPPENING AT THE SAME TIME IN

1409
00:46:46,009 --> 00:46:46,776
MID LIFE WOMEN.

1410
00:46:46,776 --> 00:46:48,411
SO IF YOU ARE SEEING A

1411
00:46:48,411 --> 00:46:50,280
48-YEAR-OLD WOMAN WHO IS

1412
00:46:50,280 --> 00:46:51,448
DEVELOPING BRAIN FOG OR SOME

1413
00:46:51,448 --> 00:46:53,149
SORT OF COGNITIVE CHANGE, YOU

1414
00:46:53,149 --> 00:46:56,753
DON'T KNOW IF IT'S NEW ONSET

1415
00:46:56,753 --> 00:46:58,188
MULTIPLE SCLEROSIS OR IF IT'S

1416
00:46:58,188 --> 00:46:59,189
RELATED TO MENOPAUSE, AND YOU

1417
00:46:59,189 --> 00:47:01,157
DON'T HAVE THAT MANY TESTS AND

1418
00:47:01,157 --> 00:47:03,360
DIAGNOSTIC STRATEGIES TO

1419
00:47:03,360 --> 00:47:04,160
DELINEATE THOSE.

1420
00:47:04,160 --> 00:47:05,929
OF COURSE YOU HAVE THE MS

1421
00:47:05,929 --> 00:47:06,563
WORKUP.

1422
00:47:06,563 --> 00:47:07,697
MUSCLE ATROPHY, YOU MAY HAVE A

1423
00:47:07,697 --> 00:47:08,932
PATIENT THAT PRESENTS WITH

1424
00:47:08,932 --> 00:47:09,399
BALANCE INSTABILITY.

1425
00:47:09,399 --> 00:47:11,101
IS THAT A NEUROLOGIC CONDITIONS,

1426
00:47:11,101 --> 00:47:13,403
IS IT NEURODEGENERATIVE, IS IT A

1427
00:47:13,403 --> 00:47:14,537
MUSCLE CONDITION, IS IT

1428
00:47:14,537 --> 00:47:15,005
MENOPAUSE?

1429
00:47:15,005 --> 00:47:15,739
BONE LOSS.

1430
00:47:15,739 --> 00:47:17,073
NEW FRACTURE.

1431
00:47:17,073 --> 00:47:18,508
UNEXPECTED.

1432
00:47:18,508 --> 00:47:20,176
OSTEOPENIA, OSTEOPOROSIS, JOINT

1433
00:47:20,176 --> 00:47:20,377
PAIN.

1434
00:47:20,377 --> 00:47:23,246
IS THAT ARTHRITIS, IS THAT

1435
00:47:23,246 --> 00:47:24,447
AUTOIMMUNE, IS THAT

1436
00:47:24,447 --> 00:47:25,682
DEGENERATIVE, IS THAT RELATED TO

1437
00:47:25,682 --> 00:47:26,783
MENOPAUSE CHANGES?

1438
00:47:26,783 --> 00:47:27,917
BUT MOST IMPORTANTLY, WHAT ARE

1439
00:47:27,917 --> 00:47:30,287
YOU GOING TO DO ABOUT IT?

1440
00:47:30,287 --> 00:47:31,388
AND CARDIOVASCULAR DISEASE, OF

1441
00:47:31,388 --> 00:47:32,188
COURSE THE LEADING CAUSE OF

1442
00:47:32,188 --> 00:47:35,458
DEATH FOR WOMEN WORLDWIDE, ARE

1443
00:47:35,458 --> 00:47:39,929
THOSE VAGUE SYMPTOMS OF

1444
00:47:39,929 --> 00:47:41,498
SHORTNESS OF BREATH AND FATIGUE

1445
00:47:41,498 --> 00:47:43,600
RELATED TO MICROVASCULAR DISEASE

1446
00:47:43,600 --> 00:47:45,869
THAT'S NOT DETECTABLE ON A

1447
00:47:45,869 --> 00:47:47,304
CORONARY ANGIOGRAM, OR IS THIS

1448
00:47:47,304 --> 00:47:50,740
JUST RELATED TO CHANGES

1449
00:47:50,740 --> 00:47:52,609
OCCURRING DURING MENOPAUSE?

1450
00:47:52,609 --> 00:47:54,177
METABOLIC DYSFUNCTION, CHANGES

1451
00:47:54,177 --> 00:47:57,781
IN ADIPOSE ACCUMULATION,

1452
00:47:57,781 --> 00:47:58,882
INCREASED INSULIN RESISTANCE.

1453
00:47:58,882 --> 00:48:02,652
HOW CAN WE SEPARATE THE MID LIFE

1454
00:48:02,652 --> 00:48:04,521
AGING, CHRONOLOGICAL AGING

1455
00:48:04,521 --> 00:48:06,456
EFFECTS FROM THE REPRODUCTIVE

1456
00:48:06,456 --> 00:48:08,458
AGING EFFECTS?

1457
00:48:08,458 --> 00:48:10,560
AND WEIGHT GAIN RELATED TO

1458
00:48:10,560 --> 00:48:12,195
FLUCTUATING HORMONES OR REDUCED

1459
00:48:12,195 --> 00:48:13,630
ENERGY EXPENDITURE IS A KEY

1460
00:48:13,630 --> 00:48:15,165
ISSUE FOR MID LIFE WOMEN.

1461
00:48:15,165 --> 00:48:16,833
MENTAL HEALTH CONCERNS RELATED

1462
00:48:16,833 --> 00:48:18,601
TO ANXIETY, ARE THOSE

1463
00:48:18,601 --> 00:48:20,570
PALPITATIONS ANXIETY, PANIC

1464
00:48:20,570 --> 00:48:22,238
ATTACKS, OR ARE THEY RELATED TO

1465
00:48:22,238 --> 00:48:22,572
MENOPAUSE?

1466
00:48:22,572 --> 00:48:24,874
HOT FLASHES, THE QUINTESSENTIAL

1467
00:48:24,874 --> 00:48:26,943
SYMPTOM OF MENOPAUSE EXPERIENCED

1468
00:48:26,943 --> 00:48:28,411
BY THE VAST MAJORITY OF WOMEN

1469
00:48:28,411 --> 00:48:29,946
WHO GO THROUGH -- WHEN THEY GO

1470
00:48:29,946 --> 00:48:33,116
THROUGH MENOPAUSE, IMPACT ON

1471
00:48:33,116 --> 00:48:35,251
SLEEP DIST DISTURBANCE, IS THERA

1472
00:48:35,251 --> 00:48:36,319
SLEEP DISORDER, DO YOU NEED TO

1473
00:48:36,319 --> 00:48:38,655
DO A WORKUP FOR SLEEP APNEA, OR

1474
00:48:38,655 --> 00:48:39,789
IS THIS RELATED TO HOT FLASHES

1475
00:48:39,789 --> 00:48:41,291
WAKING THE PERSON UP?

1476
00:48:41,291 --> 00:48:43,059
EITHER WAY, DISRUPTIVE SLEEP IS

1477
00:48:43,059 --> 00:48:44,627
AN INCREDIBLE RISK FACTOR FOR

1478
00:48:44,627 --> 00:48:45,495
POOR OUTCOMES.

1479
00:48:45,495 --> 00:48:48,465
SO WE NEED TO BE ABLE TO

1480
00:48:48,465 --> 00:48:50,333
DELINEATE WHEN A WOMAN PRESENTS

1481
00:48:50,333 --> 00:48:52,769
WITH A SYMPTOM WHETHER IT'S

1482
00:48:52,769 --> 00:48:54,070
MENOPAUSE-RELATED OR NOT, AND WE

1483
00:48:54,070 --> 00:48:55,305
NEED BETTER TOOLS TO DO THAT.

1484
00:48:55,305 --> 00:48:56,873
IN ADDITION, WE NEED TO BE ABLE

1485
00:48:56,873 --> 00:48:59,275
TO INTEGRATE ALL OF THESE

1486
00:48:59,275 --> 00:49:00,844
DOMAINS AND BODY SYSTEMS IN A

1487
00:49:00,844 --> 00:49:02,145
WAY THAT WILL ALLOW US TO TAKE

1488
00:49:02,145 --> 00:49:04,147
CARE OF THE WHOLE PERSON.

1489
00:49:04,147 --> 00:49:06,316
AND HOPEFULLY, THIS IS WHERE

1490
00:49:06,316 --> 00:49:08,651
WE'RE GOING, BEING ABLE DO THAT.

1491
00:49:08,651 --> 00:49:09,652
USING INTERDISCIPLINARY

1492
00:49:09,652 --> 00:49:11,855
APPROACHES, USING INNOVATIVE

1493
00:49:11,855 --> 00:49:13,423
STRATEGIES, USING CUTTING EDGE

1494
00:49:13,423 --> 00:49:14,958
TECHNOLOGIES, USING OUR

1495
00:49:14,958 --> 00:49:16,259
COMPUTATIONAL APPROACHES WHERE

1496
00:49:16,259 --> 00:49:17,827
WE CAN BRING IN DATA FROM A

1497
00:49:17,827 --> 00:49:20,230
VARIETY OF SOURCES, MULTIMODAL

1498
00:49:20,230 --> 00:49:21,765
DATA, AND BE ABLE TO UNDER STAND

1499
00:49:21,765 --> 00:49:23,233
USING A LIFECOURSE PERSPECTIVE

1500
00:49:23,233 --> 00:49:26,736
WHAT'S HAPPENING HERE, AND

1501
00:49:26,736 --> 00:49:28,271
INDIVIDUALIZE CARE TAILORING TO

1502
00:49:28,271 --> 00:49:29,272
THAT PARTICULAR WOMAN AND THEIR

1503
00:49:29,272 --> 00:49:31,074
NEEDS BECAUSE WE KNOW EVERY

1504
00:49:31,074 --> 00:49:32,709
WOMAN EXPERIENCES MENOPAUSE

1505
00:49:32,709 --> 00:49:33,576
DIFFERENTLY.

1506
00:49:33,576 --> 00:49:35,311
BECAUSE OF THE RCDC TERM, WE'RE

1507
00:49:35,311 --> 00:49:36,479
NOT ABLE TO REPORT THIS FUNDING

1508
00:49:36,479 --> 00:49:39,048
TO YOU FROM FY 23.

1509
00:49:39,048 --> 00:49:41,918
NIH SPENT $56 MILLION IN THIS

1510
00:49:41,918 --> 00:49:43,720
RCD CCTT GRI DESIGNATING

1511
00:49:43,720 --> 00:49:44,921
MENOPAUSE RESEARCH WITH THE VAST

1512
00:49:44,921 --> 00:49:46,623
MAJORITY BEING SUPPORTED BY THE

1513
00:49:46,623 --> 00:49:48,591
NATIONAL INSTITUTE ON AGING,

1514
00:49:48,591 --> 00:49:51,327
FOLLOWED BY NIMH, MENTAL HEALTH

1515
00:49:51,327 --> 00:49:52,862
AND HEART, LUNG AND BLOOD

1516
00:49:52,862 --> 00:49:54,864
INSTITUTE, AND NIDDK, WITH 19%

1517
00:49:54,864 --> 00:49:56,499
COMING FROM OTHER INSTITUTES

1518
00:49:56,499 --> 00:49:56,766
COMBINED.

1519
00:49:56,766 --> 00:49:58,001
THE VAST MAJORITY OF THIS

1520
00:49:58,001 --> 00:50:00,370
FUNDING IS FOCUSED AROUND

1521
00:50:00,370 --> 00:50:01,571
DEMENTIA AND COGNITIVE CHANGES,

1522
00:50:01,571 --> 00:50:04,073
AND SO THAT SHOWS THAT THERE'S

1523
00:50:04,073 --> 00:50:06,976
AN OPPORTUNITY TO ADDITIONALLY

1524
00:50:06,976 --> 00:50:08,945
INCORPORATE OTHER ASPECTS OF

1525
00:50:08,945 --> 00:50:10,280
MENOPAUSE USING THAT WHOLE

1526
00:50:10,280 --> 00:50:11,681
PERSON HEALTH APPROACH THAT I

1527
00:50:11,681 --> 00:50:14,417
MENTIONED.

1528
00:50:14,417 --> 00:50:15,785
AND OF COURSE THE NATIONAL

1529
00:50:15,785 --> 00:50:16,653
INSTITUTE ON AGING HAS HAD THE

1530
00:50:16,653 --> 00:50:18,621
STUDY OF WOMEN'S HEALTH ACROSS

1531
00:50:18,621 --> 00:50:20,523
THE NATION THAT HAS GIVEN US

1532
00:50:20,523 --> 00:50:21,624
SOME INCREDIBLE INSIGHTS.

1533
00:50:21,624 --> 00:50:22,959
I WAS ABLE TO HIGHLIGHT SOME OF

1534
00:50:22,959 --> 00:50:25,228
THOSE WHEN I SPOKE AT NIA'S

1535
00:50:25,228 --> 00:50:26,496
COUNCIL RECENTLY.

1536
00:50:26,496 --> 00:50:29,566
THIS AREA IS ONE OF PARTICULAR

1537
00:50:29,566 --> 00:50:30,867
INTEREST TO ORWH.

1538
00:50:30,867 --> 00:50:33,603
I WAS DELIGHTED TO BE -- TO JOIN

1539
00:50:33,603 --> 00:50:35,638
THE WOMEN'S CONGRESSIONAL POLICY

1540
00:50:35,638 --> 00:50:38,274
INSTITUTE PICTURED HERE ON THE

1541
00:50:38,274 --> 00:50:39,676
RIGHT FOR A CAPITOL HILL

1542
00:50:39,676 --> 00:50:41,811
BRIEFING ON MENOPAUSE AND MID

1543
00:50:41,811 --> 00:50:46,182
LIFE HEALTH.

1544
00:50:46,182 --> 00:50:47,484
ALSO GENEVIEVE SPOKE AT THE

1545
00:50:47,484 --> 00:50:49,018
MENOPAUSE ROUNDTABLE HERE LAST

1546
00:50:49,018 --> 00:50:50,887
MAY.

1547
00:50:50,887 --> 00:50:52,956
AND YOU'LL HEAR FROM THE

1548
00:50:52,956 --> 00:50:55,091
NATIONAL SCIENCE FOUNDATION,

1549
00:50:55,091 --> 00:50:56,292
SUSAN MARGULIES LATER.

1550
00:50:56,292 --> 00:50:59,195
WE JOINED NCI AND NSF ON A

1551
00:50:59,195 --> 00:51:00,830
WORKSHOP ON USING ARTIFICIAL

1552
00:51:00,830 --> 00:51:02,031
INTELLIGENCE TO BETTER

1553
00:51:02,031 --> 00:51:06,069
UNDERSTAND MENOPAUSE.

1554
00:51:06,069 --> 00:51:11,708
AND TH DR. BYRNES PRESENTED AT E

1555
00:51:11,708 --> 00:51:17,714
MENOPAUSE SOCIETY'S 2024 ANNUAL

1556
00:51:17,714 --> 00:51:19,082
MEETING, AND ORWH CREATED TWO

1557
00:51:19,082 --> 00:51:20,483
TRAVEL AWARDS FOR JUNIOR

1558
00:51:20,483 --> 00:51:24,754
INVESTIGATORS TO PRESENT.

1559
00:51:24,754 --> 00:51:25,889
JUST A SMATTERING OF OUR

1560
00:51:25,889 --> 00:51:26,122
EFFORTS.

1561
00:51:26,122 --> 00:51:28,424
WE HAVE BEEN DELIGHTED TO, WITH

1562
00:51:28,424 --> 00:51:32,629
ODP, NCI, NHLBI, THE AGING

1563
00:51:32,629 --> 00:51:33,930
INSTITUTE, CHILD HEALTH AND

1564
00:51:33,930 --> 00:51:35,265
MENTAL HEALTH, BE HELPING TO

1565
00:51:35,265 --> 00:51:37,033
PLAN THE FIRST EVER PATHWAYS TO

1566
00:51:37,033 --> 00:51:38,801
PREVENTION PROGRAM ON ADVANCING

1567
00:51:38,801 --> 00:51:41,337
MENOPAUSAL SYMPTOM MANAGEMENT.

1568
00:51:41,337 --> 00:51:44,707
AND THE FIRST STEP OF THIS

1569
00:51:44,707 --> 00:51:46,042
RIGOROUS METHODICAL APPROACH IS

1570
00:51:46,042 --> 00:51:47,176
A WORKSHOP.

1571
00:51:47,176 --> 00:51:48,845
AND THAT IS TENTATIVELY

1572
00:51:48,845 --> 00:51:50,647
SCHEDULED TO TAKE PLACE LATE IN

1573
00:51:50,647 --> 00:51:51,147
2025.

1574
00:51:51,147 --> 00:51:55,652
SO STAY TUNED FOR THAT.

1575
00:51:55,652 --> 00:51:57,287
I ALSO WANT TO APPLAUD MY

1576
00:51:57,287 --> 00:51:58,655
COLLEAGUES AT THE NATIONAL

1577
00:51:58,655 --> 00:52:00,757
INSTITUTE OF MENTAL HEALTH,

1578
00:52:00,757 --> 00:52:01,691
TAMARA LEWIS JOHNSON IS THE

1579
00:52:01,691 --> 00:52:03,793
FIRST AUTHOR AND OUR OWN MELISSA

1580
00:52:03,793 --> 00:52:05,028
SIMON, VIEDZ RECOMMITTEE MEMBER

1581
00:52:05,028 --> 00:52:08,565
IS THE LAST AUTHOR ON THIS PAPER

1582
00:52:08,565 --> 00:52:11,000
SUMMARIZING KEY FINDINGS FROM

1583
00:52:11,000 --> 00:52:11,768
MENTAL HEALTH RESEARCH DURING

1584
00:52:11,768 --> 00:52:13,570
THE MENOPAUSE TRANSITION FOR

1585
00:52:13,570 --> 00:52:15,872
RACIALLY AND ETHNICICALLY

1586
00:52:15,872 --> 00:52:17,740
MINORITIZED WOMEN LIVING IN THE

1587
00:52:17,740 --> 00:52:19,642
UNITED STATES, A SCOPING REVIEW.

1588
00:52:19,642 --> 00:52:22,078
THIS INCREDIBLE REVIEW

1589
00:52:22,078 --> 00:52:23,913
HIGHLIGHTS DATA THAT DO SHOW

1590
00:52:23,913 --> 00:52:27,083
THAT RACIAL AND ETHNICALLY

1591
00:52:27,083 --> 00:52:28,351
MINORITIZED WOMEN

1592
00:52:28,351 --> 00:52:29,218
DISPROPORTIONATELY ARE AFFECTED

1593
00:52:29,218 --> 00:52:30,320
BY MENTAL HEALTH CONDITIONS

1594
00:52:30,320 --> 00:52:33,389
DURING THE TRANSITION,

1595
00:52:33,389 --> 00:52:33,923
SPECIFICALLY DEPRESSION.

1596
00:52:33,923 --> 00:52:35,925
SOME OF THE OTHER CONDITIONS,

1597
00:52:35,925 --> 00:52:37,393
THERE WAS INSUFFICIENT DATA

1598
00:52:37,393 --> 00:52:38,494
BECAUSE MANY OF THE STUDIES DID

1599
00:52:38,494 --> 00:52:43,066
NOT HAVE SUFFICIENT NUMBERS OF

1600
00:52:43,066 --> 00:52:44,667
THESE WOMEN BUT THIS IS AN

1601
00:52:44,667 --> 00:52:45,635
INCREDIBLE SUMMARY OF A BODY OF

1602
00:52:45,635 --> 00:52:48,738
WORK THAT HELPS US TO UNDERSTAND

1603
00:52:48,738 --> 00:52:49,872
AND IDENTIFY SOME OF THE

1604
00:52:49,872 --> 00:52:53,843
DIFFERENCES THAT WERE

1605
00:52:53,843 --> 00:52:54,911
HIGHLIGHTED IN THE SWAN STUDIES

1606
00:52:54,911 --> 00:52:56,980
WHERE WE SAW DIFFERENCES IN

1607
00:52:56,980 --> 00:52:57,747
DIFFERENT GROUPS.

1608
00:52:57,747 --> 00:52:59,449
AND TRYING TO UNDERSTAND WHAT

1609
00:52:59,449 --> 00:53:01,651
ARE THE SOCIAL STRUCTURAL AND

1610
00:53:01,651 --> 00:53:03,386
OTHER FACTORS BEHIND THOSE

1611
00:53:03,386 --> 00:53:08,091
DIFFERENCES.

1612
00:53:08,091 --> 00:53:09,892
AND NIMH HAS TWO FUNDING

1613
00:53:09,892 --> 00:53:10,994
OPPORTUNITIES ON THE STREET NOW,

1614
00:53:10,994 --> 00:53:14,197
AN R01 AND R21 ON MOOD AND

1615
00:53:14,197 --> 00:53:15,298
PSYCHOSIS SYMPTOMS DURING THE

1616
00:53:15,298 --> 00:53:19,569
MENOPAUSE TRANSITION WITH

1617
00:53:19,569 --> 00:53:21,738
UPCOMING RECEIPT AND EXPIRATION

1618
00:53:21,738 --> 00:53:23,006
DATES SO PLEASE APPLY SO YOU CAN

1619
00:53:23,006 --> 00:53:23,673
TAKE ADVANTAGE OF THIS

1620
00:53:23,673 --> 00:53:24,273
OPPORTUNITY.

1621
00:53:24,273 --> 00:53:26,075
I'M JUST GOING TO HIGHLIGHT VERY

1622
00:53:26,075 --> 00:53:29,045
BRIEFLY A COUPLE OF OTHER WAYS

1623
00:53:29,045 --> 00:53:30,613
THAT NIH HAS ADDRESSED MENOPAUSE

1624
00:53:30,613 --> 00:53:32,248
RECENTLY.

1625
00:53:32,248 --> 00:53:38,154
IN THE ORWH-LED RFAs,

1626
00:53:38,154 --> 00:53:39,455
UNDERSTANDING CHRONIC

1627
00:53:39,455 --> 00:53:40,923
CONDITIONS, WE'VE CREATED WITH

1628
00:53:40,923 --> 00:53:42,358
MULTIPLE INSTITUTES AND CENTERS

1629
00:53:42,358 --> 00:53:44,093
INCLUDING NIMH, WE'RE SUPPORTING

1630
00:53:44,093 --> 00:53:46,029
THIS YEAR TWO STUDIES ON

1631
00:53:46,029 --> 00:53:47,530
REGENERATIVE BIOMATERIAL FOR

1632
00:53:47,530 --> 00:53:49,065
COMBATING THE GENITOURINARY

1633
00:53:49,065 --> 00:53:51,100
SYNDROME OF MENOPAUSE, AND ONE

1634
00:53:51,100 --> 00:53:52,969
ON CHANGES IN CARDIOMETABOLIC

1635
00:53:52,969 --> 00:53:55,038
TISSUE GENE REGULATION AND OMICS

1636
00:53:55,038 --> 00:53:58,274
PROFILES IN MENOPAUSE.

1637
00:53:58,274 --> 00:53:59,475
NIMH IS HIGHLIGHTING THREE

1638
00:53:59,475 --> 00:54:01,744
STUDIES THERE:  NEUROENDOCRINE

1639
00:54:01,744 --> 00:54:04,447
MECHANISMS UNDERLYING TRAUMA

1640
00:54:04,447 --> 00:54:05,982
MACHINE-RELATED HYPERAROUSAL IN

1641
00:54:05,982 --> 00:54:11,154
BLACK WOMEN AND THE

1642
00:54:11,154 --> 00:54:12,155
CHRONOBIOLOGICAL BASIS OF

1643
00:54:12,155 --> 00:54:14,023
DEPRESSION DURING MENOPAUSE

1644
00:54:14,023 --> 00:54:15,124
TRANSITION, AND ALSO HORMONAL

1645
00:54:15,124 --> 00:54:16,693
DRIVERS OF PERIMENOPAUSAL

1646
00:54:16,693 --> 00:54:18,027
INFLAMMATION AND MOOD SYMPTOMS.

1647
00:54:18,027 --> 00:54:19,095
THESE JUST REPRESENT A FEW OF

1648
00:54:19,095 --> 00:54:20,063
THE EFFORTS, BUT IT'S IMPORTANT

1649
00:54:20,063 --> 00:54:21,397
TO SHARE WITH YOU AND THE PUBLIC

1650
00:54:21,397 --> 00:54:24,233
THE WAYS THAT NIH IS ADDRESSING

1651
00:54:24,233 --> 00:54:25,535
THESE IMPORTANT TOPICS AS WE

1652
00:54:25,535 --> 00:54:32,809
MOVE FORWARD.

1653
00:54:32,809 --> 00:54:34,577
THAT PROGRAM AT ORWH IS LED BY

1654
00:54:34,577 --> 00:54:35,111
DR. SARAH TEMKIN.

1655
00:54:35,111 --> 00:54:36,312
WE ARE THRILLED TO BE ABLE TO

1656
00:54:36,312 --> 00:54:37,647
ALSO SHARE OUR SECOND YEAR

1657
00:54:37,647 --> 00:54:40,116
FUNDING OF OUR FIRST EVER R25, A

1658
00:54:40,116 --> 00:54:43,853
CURRICULUM DEVELOPMENT

1659
00:54:43,853 --> 00:54:46,489
MECHANISM, GALVANIZING HEALTH

1660
00:54:46,489 --> 00:54:48,891
EQUITY THROUGH NOVEL AND DIVERSE

1661
00:54:48,891 --> 00:54:50,960
EDUCATIONAL RESOURCES.

1662
00:54:50,960 --> 00:54:52,995
IN 2024, YOU CAN SEE OUR NEW

1663
00:54:52,995 --> 00:54:55,832
GRANTEES, AND WE'RE ROUNDING OUT

1664
00:54:55,832 --> 00:54:57,033
OUR EFFORT.

1665
00:54:57,033 --> 00:55:00,937
WE HAD -- NOT OUR FIRST, WE HAD

1666
00:55:00,937 --> 00:55:02,238
AN ANNUAL INVESTIGATORS MEETING

1667
00:55:02,238 --> 00:55:03,339
RECENTLY, AND THAT INCLUDED A

1668
00:55:03,339 --> 00:55:07,877
VARIETY OF TOPICS RANGING FROM

1669
00:55:07,877 --> 00:55:08,878
MENOPAUSE CARE IN WOMEN WITH

1670
00:55:08,878 --> 00:55:11,180
HIV, A VIRTUAL EDUCATION

1671
00:55:11,180 --> 00:55:15,852
PROGRAM, TO DEVELOPING A

1672
00:55:15,852 --> 00:55:16,786
SEVEN-MODULE ONLINE CURRICULUM

1673
00:55:16,786 --> 00:55:18,020
FOR NURSING STUDENTS ON

1674
00:55:18,020 --> 00:55:18,788
TRANSGENDER HEALTH, AND YOU CAN

1675
00:55:18,788 --> 00:55:21,257
SEE THE OTHER TOPICS HERE, SO

1676
00:55:21,257 --> 00:55:22,458
REALLY -- THESE WILL BE

1677
00:55:22,458 --> 00:55:23,426
AVAILABLE, THESE CURRICULA WILL

1678
00:55:23,426 --> 00:55:25,628
BE PUBLICLY AVAILABLE ONCE

1679
00:55:25,628 --> 00:55:30,533
THEY'RE COMPLETED.

1680
00:55:30,533 --> 00:55:33,369
YOU MAY RECALL WE RELEASED A

1681
00:55:33,369 --> 00:55:36,205
NOTICE OF SPECIAL INTEREST

1682
00:55:36,205 --> 00:55:37,306
EXPRESSING INTEREST IN

1683
00:55:37,306 --> 00:55:38,508
SUPPORTING RESEARCH ON IMPROVING

1684
00:55:38,508 --> 00:55:39,742
THE TOOLS FOR GENDER MEASUREMENT

1685
00:55:39,742 --> 00:55:40,510
AND ASSESSMENT.

1686
00:55:40,510 --> 00:55:41,744
WE KNOW THAT'S AN IMPORTANT

1687
00:55:41,744 --> 00:55:43,212
AREA, AND OUR PREVIOUS STRATEGIC

1688
00:55:43,212 --> 00:55:46,115
PLAN HAD A PARTICULAR GOAL

1689
00:55:46,115 --> 00:55:47,150
OBJECTIVE 2.2 ON DEVELOPING

1690
00:55:47,150 --> 00:55:48,951
RELIABLE MEASURES RELEVANT TO

1691
00:55:48,951 --> 00:55:49,952
WOMEN'S HEALTH.

1692
00:55:49,952 --> 00:55:52,054
IN FY 23, WE AWARDED EIGHT

1693
00:55:52,054 --> 00:55:53,556
AWARDS FOR RESEARCH ON

1694
00:55:53,556 --> 00:55:55,291
TERMINOLOGY AND METHODS AROUND

1695
00:55:55,291 --> 00:55:57,059
ASSESSMENT OF GENDER FOCUSING ON

1696
00:55:57,059 --> 00:55:59,996
THE TWO-STEP APPROACH, AND HERE

1697
00:55:59,996 --> 00:56:02,131
OUR FUNDERS ON THE BOTTOM, OUR

1698
00:56:02,131 --> 00:56:03,432
ICO PARTNERS, THESE GRANTEES

1699
00:56:03,432 --> 00:56:07,170
WILL BE PRESENTING AT A NOVEMBEE

1700
00:56:07,170 --> 00:56:09,672
ARE PARTICULARLY EXCITED TO SEE

1701
00:56:09,672 --> 00:56:12,742
THAT PRESENTATION AND HOPE THAT

1702
00:56:12,742 --> 00:56:13,943
THE RESULTS OF THOSE EFFORTS

1703
00:56:13,943 --> 00:56:16,045
WILL HELP INFORM RESEARCH AND

1704
00:56:16,045 --> 00:56:17,947
GENDER BEING ASCERTAINED AND

1705
00:56:17,947 --> 00:56:20,850
ASSESSED MORE REGULARLY AND MORE

1706
00:56:20,850 --> 00:56:23,319
RIGOROUSLY THROUGHOUT HEALTH

1707
00:56:23,319 --> 00:56:23,586
RESEARCH.

1708
00:56:23,586 --> 00:56:25,521
AS A RESULT OF LAST YEAR'S --

1709
00:56:25,521 --> 00:56:28,357
NO, TWO YEARS AGO, 2022 -- ALL

1710
00:56:28,357 --> 00:56:30,293
THESE YEARS RUN TOGETHER FOR

1711
00:56:30,293 --> 00:56:32,829
ME -- 2022 WORKSHOP THAT WE HAD

1712
00:56:32,829 --> 00:56:34,330
ON GENDER AND HEALTH WITH NICHD

1713
00:56:34,330 --> 00:56:39,468
AND OTHER PARTNERS, THERE WAS A

1714
00:56:39,468 --> 00:56:41,103
SPECIAL ISSUE WE COMMISSIONED IN

1715
00:56:41,103 --> 00:56:41,871
SOCIAL SCIENCE AND MEDICINE.

1716
00:56:41,871 --> 00:56:43,039
TO FEATURE THE PRESENTATIONS AND

1717
00:56:43,039 --> 00:56:46,843
THE WORK OF THOSE SPEAKERS AND

1718
00:56:46,843 --> 00:56:47,610
INVESTIGATORS.

1719
00:56:47,610 --> 00:56:50,112
INCREDIBLE AMOUNT OF -- JUST

1720
00:56:50,112 --> 00:56:51,514
INCREDIBLE SPEAKERS AND

1721
00:56:51,514 --> 00:56:52,381
KEYNOTES, AND IT'S AVAILABLE ON

1722
00:56:52,381 --> 00:56:53,649
OUR WEBSITE IF YOU'D LIKE TO

1723
00:56:53,649 --> 00:56:54,450
TAKE A LOOK.

1724
00:56:54,450 --> 00:56:58,020
BUT GENDER POWER AND HEALTH,

1725
00:56:58,020 --> 00:56:59,121
MODIFIABLE FACTORS FOR

1726
00:56:59,121 --> 00:56:59,889
INTERVENTION.

1727
00:56:59,889 --> 00:57:02,692
ELIZABETH BARR IS A CO-AUTHOR ON

1728
00:57:02,692 --> 00:57:05,728
THIS PIECE HIGHLIGHTING OUR

1729
00:57:05,728 --> 00:57:06,863
INTERESTS IN THE ENTIRE SPECIAL

1730
00:57:06,863 --> 00:57:08,164
ISSUE THAT TAKES TO THE NEXT

1731
00:57:08,164 --> 00:57:08,998
LEVEL THE WORK THAT WAS

1732
00:57:08,998 --> 00:57:10,633
PRESENTED IN THE WORKSHOP.

1733
00:57:10,633 --> 00:57:12,602
OUR E-LEARNING COURSES ATTRACT A

1734
00:57:12,602 --> 00:57:14,237
DIVERSE AUDIENCE OF LEARNERS,

1735
00:57:14,237 --> 00:57:17,139
AND WIDESPREAD PARTICIPATION

1736
00:57:17,139 --> 00:57:18,774
OVER THAT FIVE-YEAR TIME PERIOD,

1737
00:57:18,774 --> 00:57:21,611
WE'VE HAD OVER 2800 REGISTRANTS.

1738
00:57:21,611 --> 00:57:23,112
THE FAVORITE BENCH TO BEDSIDE

1739
00:57:23,112 --> 00:57:27,049
COURSE IS THE ONE ON IMMUNOLOGY.

1740
00:57:27,049 --> 00:57:28,251
I CONFESS THAT'S MY FAVORITE ONE

1741
00:57:28,251 --> 00:57:30,820
TOO, AND WE HAVE A VARIETY OF

1742
00:57:30,820 --> 00:57:31,587
SABV COURSES.

1743
00:57:31,587 --> 00:57:33,356
THAT AREA IS LED BY DR. SHARON

1744
00:57:33,356 --> 00:57:36,459
HUNTER AT ORWH, AND THAT -- IN

1745
00:57:36,459 --> 00:57:39,629
THAT MODULE, THE FAVORITE ONE IS

1746
00:57:39,629 --> 00:57:40,730
SABV AND THE HEALTH OF WOMEN AND

1747
00:57:40,730 --> 00:57:41,564
MEN.

1748
00:57:41,564 --> 00:57:42,999
80% OF THE LEARNERS

1749
00:57:42,999 --> 00:57:44,834
SELF-DESCRIBE AS FEMALE AND IN

1750
00:57:44,834 --> 00:57:46,903
TERMS OF LOCATIONS, THEY ARE

1751
00:57:46,903 --> 00:57:49,605
SCATTERED AROUND THE WORLD,

1752
00:57:49,605 --> 00:57:50,606
REACHING 69 COUNTRIES.

1753
00:57:50,606 --> 00:57:54,510
SO WE CONTINUE TO SUPPORT

1754
00:57:54,510 --> 00:57:55,077
INTERPROFESSIONAL EDUCATION

1755
00:57:55,077 --> 00:57:56,345
AROUND SEX AND GENDER TO INFORM

1756
00:57:56,345 --> 00:57:58,748
AND IMPROVE THE HEALTH OF WOMEN

1757
00:57:58,748 --> 00:58:01,717
AND PROVIDE A WIDE VARIETY OF

1758
00:58:01,717 --> 00:58:03,619
EDUCATIONAL TOOLS AT ALL LEVELS,

1759
00:58:03,619 --> 00:58:04,720
AT ALL PROFESSIONAL LEVELS

1760
00:58:04,720 --> 00:58:05,821
INCLUDING TRAIN THE TRAINER

1761
00:58:05,821 --> 00:58:07,990
MATERIALS FOR THOSE PROFESSORS

1762
00:58:07,990 --> 00:58:11,694
WHO NEED TO TEACH SABV AS PART

1763
00:58:11,694 --> 00:58:15,731
OF THEIR GRADUATE WORK.

1764
00:58:15,731 --> 00:58:17,266
A COUPLE OF UPDATES ON CAREERS.

1765
00:58:17,266 --> 00:58:18,334
I'M WRAPPING UP.

1766
00:58:18,334 --> 00:58:20,303
I SEE I'M A LITTLE CLOSE TO

1767
00:58:20,303 --> 00:58:20,736
TIME.

1768
00:58:20,736 --> 00:58:21,971
I'M GOING TO WRAP UP HERE

1769
00:58:21,971 --> 00:58:22,438
QUICKLY.

1770
00:58:22,438 --> 00:58:24,740
AS YOU KNOW, THE SCORE, THE

1771
00:58:24,740 --> 00:58:25,741
SPECIALIZED CENTERS OF RESEARCH

1772
00:58:25,741 --> 00:58:27,810
EXCELLENCE ON SEX DIFFERENCE, WE

1773
00:58:27,810 --> 00:58:29,512
ADDED A CAREER ENHANCEMENT CORE

1774
00:58:29,512 --> 00:58:31,580
IN OUR LAST ITERATION.

1775
00:58:31,580 --> 00:58:34,216
THE ANNUAL MEETING WAS HELD

1776
00:58:34,216 --> 00:58:34,984
RECENTLY.

1777
00:58:34,984 --> 00:58:36,152
DR. AGARWAL WAS OUR POINT PERSON

1778
00:58:36,152 --> 00:58:39,088
FOR THIS ONE, AND DR. VICTOR

1779
00:58:39,088 --> 00:58:46,362
DZAU AND DR. CAROLYN MAZURE

1780
00:58:46,362 --> 00:58:47,897
DELIVERED INCREDIBLE

1781
00:58:47,897 --> 00:58:49,332
PRESENTATIONS FROM THE SCORE

1782
00:58:49,332 --> 00:58:49,966
INVESTIGATORS, PEOPLE THAT

1783
00:58:49,966 --> 00:58:52,234
RECEIVED PILOT FUNDING FROM OUR

1784
00:58:52,234 --> 00:58:53,536
CAREER ENHANCEMENT CORE.

1785
00:58:53,536 --> 00:58:56,072
JUST ALWAYS AN EXCITING GROUP OF

1786
00:58:56,072 --> 00:58:57,106
SCIENCE AND WE WERE IN PERSON

1787
00:58:57,106 --> 00:58:58,307
FOR THE FIRST TIME IN FIVE

1788
00:58:58,307 --> 00:58:59,508
YEARS, SO WE WERE THRILLED TO BE

1789
00:58:59,508 --> 00:59:02,011
ABLE TO SUPPORT THAT EFFORT,

1790
00:59:02,011 --> 00:59:03,612
HEAR FROM OUR INVESTIGATORS AND

1791
00:59:03,612 --> 00:59:05,047
PEOPLE THAT WERE SUPPORTED BY

1792
00:59:05,047 --> 00:59:07,350
THE SCORE GRANTS.

1793
00:59:07,350 --> 00:59:15,191
THE NEXT DAY, WE HAD OUR BIRCWH

1794
00:59:15,191 --> 00:59:17,860
MEETING, THE SPEAKER RECOGNIZED

1795
00:59:17,860 --> 00:59:22,131
FOR THE RUTH KIRSCHSTEIN

1796
00:59:22,131 --> 00:59:23,466
MEMORIAL LECTURESHIP.

1797
00:59:23,466 --> 00:59:30,072
THIS YEAR IT WAS ABBEY BERENSON,

1798
00:59:30,072 --> 00:59:31,707
AND THEN DR. NINA SCHOR WITH WAS

1799
00:59:31,707 --> 00:59:34,210
OUR LEGACY OF LEADERSHIP

1800
00:59:34,210 --> 00:59:36,712
LECTURER AND TOOK A VERY

1801
00:59:36,712 --> 00:59:38,047
DIFFERENT TACT, INTERWOVE HER

1802
00:59:38,047 --> 00:59:39,648
SCIENCE THROUGH HER STORY.

1803
00:59:39,648 --> 00:59:45,221
AGAIN BETWEEN THESE BOOK ENDS,

1804
00:59:45,221 --> 00:59:46,322
BIRCWH SCHOLARS PRESENTED

1805
00:59:46,322 --> 00:59:48,057
AMAZING WORK THEY HAVE ADVANCED,

1806
00:59:48,057 --> 00:59:49,792
AND THE PIs AND THE

1807
00:59:49,792 --> 00:59:51,627
SCHOLARS -- THE PIs INTRODUCED

1808
00:59:51,627 --> 00:59:53,596
EACH SCHOLAR, SO IT WAS A REALLY

1809
00:59:53,596 --> 00:59:54,864
NICE WAY FOR THEM TO HEAR FROM

1810
00:59:54,864 --> 00:59:56,198
THEIR PI ABOUT WHAT THEY THINK

1811
00:59:56,198 --> 00:59:59,802
ABOUT THEM.

1812
00:59:59,802 --> 01:00:03,572
AND THEN IN AN EFFORT THAT IS

1813
01:00:03,572 --> 01:00:05,441
LED BY OUR OFFICE, WE PARTNER

1814
01:00:05,441 --> 01:00:08,477
WITH NIDDY TO AWARD ADVANCING

1815
01:00:08,477 --> 01:00:10,880
GENDER INCLUSIVE EXCELLENCE, A

1816
01:00:10,880 --> 01:00:12,381
COORDINATING CENTER TO VIRGINIA

1817
01:00:12,381 --> 01:00:12,882
COMMONWEALTH UNIVERSITY.

1818
01:00:12,882 --> 01:00:13,716
THIS COORDINATING CENTER IS

1819
01:00:13,716 --> 01:00:15,017
GOING TO DEVELOP A RESEARCH

1820
01:00:15,017 --> 01:00:16,986
STRATEGY TO ADVANCE GENDER

1821
01:00:16,986 --> 01:00:18,287
EQUITY IN ACADEMIA, AND THEY'RE

1822
01:00:18,287 --> 01:00:20,656
GOING TO MANAGE THAT PROGRAM,

1823
01:00:20,656 --> 01:00:22,391
CREATING A CENTRALIZED RESOURCE,

1824
01:00:22,391 --> 01:00:24,326
AND LESSONS LEARNED, BEST

1825
01:00:24,326 --> 01:00:27,930
PRACTICES, METRICS AND THE LIKE.

1826
01:00:27,930 --> 01:00:29,331
AND THEY WILL DEVELOP AND

1827
01:00:29,331 --> 01:00:30,533
IMPLEMENT A COMMUNICATIONS

1828
01:00:30,533 --> 01:00:31,600
DISSEMINATION AND ALSO

1829
01:00:31,600 --> 01:00:33,469
ADMINISTER AND MANAGE A PILOT

1830
01:00:33,469 --> 01:00:35,738
AND FEASIBILITY STUDIES PROGRAM

1831
01:00:35,738 --> 01:00:37,073
WHERE UNIVERSITIES AND

1832
01:00:37,073 --> 01:00:40,443
ORGANIZATIONS CAN PILOT

1833
01:00:40,443 --> 01:00:42,044
STRATEGIES RELATED TO

1834
01:00:42,044 --> 01:00:43,045
GENDER-BASED INEQUITIES.

1835
01:00:43,045 --> 01:00:44,713
IN TERMS OF UPCOMING EVENTS, I

1836
01:00:44,713 --> 01:00:51,087
WANT TO HIGHLIGHT RECENT

1837
01:00:51,087 --> 01:00:52,221
NATIONAL ACADEMIES OF SCIENCE

1838
01:00:52,221 --> 01:00:54,390
AND MEDICINE WORKSHOP WHERE

1839
01:00:54,390 --> 01:00:56,959
SHE'S CO-CHAIRING AN EFFORT OF

1840
01:00:56,959 --> 01:00:57,626
REGENERATIVE MEDICINE AND

1841
01:00:57,626 --> 01:00:58,494
WOMEN'S HEALTH.

1842
01:00:58,494 --> 01:00:59,261
FANTASTIC LINEUP.

1843
01:00:59,261 --> 01:01:00,362
I CAN'T WAIT TO WATCH THE TAPE.

1844
01:01:00,362 --> 01:01:04,066
IT WAS THE SAME TIME AS THE

1845
01:01:04,066 --> 01:01:05,167
BIRCWH MEETING SO I COULDN'T DO

1846
01:01:05,167 --> 01:01:05,468
BOTH.

1847
01:01:05,468 --> 01:01:07,269
AND THEN COMING UP ON

1848
01:01:07,269 --> 01:01:08,471
OCTOBER 30TH, WE'RE HAVING

1849
01:01:08,471 --> 01:01:12,541
ANOTHER SMALL BUSINESS WEBINAR.

1850
01:01:12,541 --> 01:01:13,976
OADR-ORWH IS HAVING THEIR FIFTH

1851
01:01:13,976 --> 01:01:15,878
SESSION ON GETTING INPUT FROM

1852
01:01:15,878 --> 01:01:18,080
THE PUBLIC AND GIVING UPDATES ON

1853
01:01:18,080 --> 01:01:21,050
NOVEMBER 8TH, AND THEN OADR-ORWH

1854
01:01:21,050 --> 01:01:22,852
SCIENCE TALKS IS FOCUSED ON THE

1855
01:01:22,852 --> 01:01:24,453
CANCER AUTOIMMUNE CONNECTION,

1856
01:01:24,453 --> 01:01:25,554
DECODING THE PARADOX.

1857
01:01:25,554 --> 01:01:27,857
I KNOW DR. SHAMAGAM WOULD LOVE

1858
01:01:27,857 --> 01:01:30,326
TO SEE YOU ALL THERE ON DECEMBE.

1859
01:01:30,326 --> 01:01:31,827
ALL OF THESE SESSIONS HAVE BEEN

1860
01:01:31,827 --> 01:01:32,795
VERY POPULAR IN THE SCIENTIFIC

1861
01:01:32,795 --> 01:01:33,462
COMMUNITY.

1862
01:01:33,462 --> 01:01:34,730
ATION I WRAP UP HERE, I JUST

1863
01:01:34,730 --> 01:01:36,098
WANT TO HIGHLIGHT OUR WOMEN'S

1864
01:01:36,098 --> 01:01:38,167
HEALTH IN FOCUS QUARTERLY

1865
01:01:38,167 --> 01:01:38,901
PUBLICATION.

1866
01:01:38,901 --> 01:01:40,069
IT JUST CAME OUT.

1867
01:01:40,069 --> 01:01:43,072
IT'S FOCUSED ON INFECTIOUS

1868
01:01:43,072 --> 01:01:43,506
DISEASE.

1869
01:01:43,506 --> 01:01:45,007
I WENT BACK ACTUALLY RECENTLY TO

1870
01:01:45,007 --> 01:01:48,811
LOOK AT THE TOPICS THAT WE'VE

1871
01:01:48,811 --> 01:01:50,112
COVERED IN THESE QUARTERLY

1872
01:01:50,112 --> 01:01:50,446
PUBLICATIONS.

1873
01:01:50,446 --> 01:01:52,548
WE HAVE COVERED A FULL RANGE OF

1874
01:01:52,548 --> 01:01:53,415
WOMEN'S HEALTH TOPICS.

1875
01:01:53,415 --> 01:01:55,251
IT'S TRULY HEAD TO TOE.

1876
01:01:55,251 --> 01:01:56,886
INSIDE AND OUT APPROACH.

1877
01:01:56,886 --> 01:01:59,488
EACH OF THESE INCLUDES A SCIENCE

1878
01:01:59,488 --> 01:02:01,123
SPOTLIGHT, AN INSTITUTIONAL

1879
01:02:01,123 --> 01:02:03,425
SPOTLIGHT, AND THIS ONE, WE IN

1880
01:02:03,425 --> 01:02:07,329
OUR SCIENCE SPOTLIGHT

1881
01:02:07,329 --> 01:02:13,536
INTERVIEWED DR. M MARAZZO.

1882
01:02:13,536 --> 01:02:15,404
THERE'S CONTENT ABOUT THE

1883
01:02:15,404 --> 01:02:17,106
INCREDIBLE AND DISTURBING

1884
01:02:17,106 --> 01:02:19,108
SITUATION WITH CONGENITAL

1885
01:02:19,108 --> 01:02:20,843
SYPHILIS AND SYPHILIS INFECTION

1886
01:02:20,843 --> 01:02:24,013
IN THIS COUNTRY, AS WELL AS SEX

1887
01:02:24,013 --> 01:02:25,314
DIFFERENCES IN INFECTION AND

1888
01:02:25,314 --> 01:02:27,049
IMMUNITY RELATED TO MICROBES.

1889
01:02:27,049 --> 01:02:28,817
SO PLEASE CHECK THIS OUT.

1890
01:02:28,817 --> 01:02:31,387
AND IF THERE'S A TOPIC YOU'RE

1891
01:02:31,387 --> 01:02:33,055
INTERESTED IN, THERE IS PROBABLY

1892
01:02:33,055 --> 01:02:37,092
A PREVIOUS INFO CUSS  IN FOCUS D

1893
01:02:37,092 --> 01:02:37,293
THAT.

1894
01:02:37,293 --> 01:02:38,928
SO WE WORK WITH THE INSTITUTES

1895
01:02:38,928 --> 01:02:40,329
AND CENTERS, WE INVITE GUEST

1896
01:02:40,329 --> 01:02:43,365
EDITORS FOR THIS FIRST QUARTER

1897
01:02:43,365 --> 01:02:44,800
EARLY PUBLICATION, AND I WANT TO

1898
01:02:44,800 --> 01:02:50,039
CALL OUT OUR COMMS TEAM AND

1899
01:02:50,039 --> 01:02:51,106
DIRECTOR FOR PUBLICIZING ALL

1900
01:02:51,106 --> 01:02:52,007
THIS INFORMATION THROUGH OUR

1901
01:02:52,007 --> 01:02:55,010
MONTHLY EMAIL, OUR IN THE SPOT

1902
01:02:55,010 --> 01:02:56,011
ARTICLES ON OUR WEBSITE AND YOU

1903
01:02:56,011 --> 01:02:57,213
CAN FOLLOW US ON SOCIAL MEDIA

1904
01:02:57,213 --> 01:02:57,780
HERE.

1905
01:02:57,780 --> 01:02:59,982
SO VIVIAN, I'M ONLY 2 MINUTES

1906
01:02:59,982 --> 01:03:01,917
OVER, BUT THAT DOESN'T GIVE ANY

1907
01:03:01,917 --> 01:03:04,019
TIME FOR DISCUSSION OR

1908
01:03:04,019 --> 01:03:04,420
QUESTIONS.

1909
01:03:04,420 --> 01:03:06,722
SHALL WE JUST TAKE ONE QUESTION

1910
01:03:06,722 --> 01:03:08,791
IF THERE'S ANYTHING BURNING, AND

1911
01:03:08,791 --> 01:03:10,526
THEN IF YOU HAVE OTHER

1912
01:03:10,526 --> 01:03:11,627
QUESTIONS, BECAUSE I DO WANT TO

1913
01:03:11,627 --> 01:03:13,963
STAY ON TIME, PLEASE WRITE THEM

1914
01:03:13,963 --> 01:03:15,531
DOWN, BECAUSE WE HAVE SEVERAL

1915
01:03:15,531 --> 01:03:17,299
DISCUSSION SLOTS DURING THE DAY,

1916
01:03:17,299 --> 01:03:19,468
AND I'LL BE HAPPY TO ENTERTAIN

1917
01:03:19,468 --> 01:03:20,236
THEM THEN.

1918
01:03:20,236 --> 01:03:21,537
THANK YOU SO MUCH FOR YOUR

1919
01:03:21,537 --> 01:03:21,971
ATTENTION.

1920
01:03:21,971 --> 01:03:26,475
ARE THERE ANY QUESTIONS FROM

1921
01:03:26,475 --> 01:03:27,676
ADVISORY MEMBERS OR VISITORS

1922
01:03:27,676 --> 01:03:28,744
THAT YOU MIGHT HAVE AT THE

1923
01:03:28,744 --> 01:03:37,319
TABLE?

1924
01:03:37,319 --> 01:03:39,655
>> THANK YOU FOR BEING
NEAR ON

1925
01:03:39,655 --> 01:03:49,765
TIME.

1926
01:03:53,869 --> 01:03:54,903
LET ME INTRODUCE YOU.

1927
01:03:54,903 --> 01:03:55,871
YOU SHOULD GO UP THERE.

1928
01:03:55,871 --> 01:03:57,072
I THINK YOU WANT TO GO UP THERE.

1929
01:03:57,072 --> 01:03:59,942
>> I THINK SO.

1930
01:03:59,942 --> 01:04:02,411
>> IT'S NOW MY PLEASURE TO

1931
01:04:02,411 --> 01:04:04,613
INTRODUCE DR. BRUCE TROMBERG.

1932
01:04:04,613 --> 01:04:06,248
DR. TROMBERG IS THE DIRECTOR OF

1933
01:04:06,248 --> 01:04:07,549
THE NATIONAL INSTITUTE OF

1934
01:04:07,549 --> 01:04:08,851
BIOMEDICAL IMAGING AND BUY

1935
01:04:08,851 --> 01:04:15,291
OWNBIOENGINEERING.

1936
01:04:15,291 --> 01:04:18,260
SOMETIMES PEOPLE SAY NIBI BI.,

1937
01:04:18,260 --> 01:04:21,630
B.I'M JUST GOING TO SAY THE FULL

1938
01:04:21,630 --> 01:04:22,064
NAME.

1939
01:04:22,064 --> 01:04:22,598
HE'LL TELL US.

1940
01:04:22,598 --> 01:04:23,999
WHERE HE OVERSEES THE RANGE OF

1941
01:04:23,999 --> 01:04:25,834
PROGRAMS THAT ADDRESS

1942
01:04:25,834 --> 01:04:27,603
DEVELOPING, TRANSLATING AND

1943
01:04:27,603 --> 01:04:28,570
COMMERCIALIZING ENGINEERING

1944
01:04:28,570 --> 01:04:29,972
PHYSICAL SCIENCES AND

1945
01:04:29,972 --> 01:04:31,607
COMPUTATIONAL TECHNOLOGIES AND

1946
01:04:31,607 --> 01:04:33,809
BIOLOGY IN MEDICINE.

1947
01:04:33,809 --> 01:04:36,512
HE LEADS NIBIB'S RAPID

1948
01:04:36,512 --> 01:04:39,014
ACCELERATION OF DIAGNOSTICS

1949
01:04:39,014 --> 01:04:39,915
TECHNOLOGY OR RADX

1950
01:04:39,915 --> 01:04:40,549
TECHNICIANTIVE WHICH WAS

1951
01:04:40,549 --> 01:04:43,052
ESTABLISHED IN 2020 TO INCREASE

1952
01:04:43,052 --> 01:04:45,354
SARS-COV-2 TESTING CAPACITY AND

1953
01:04:45,354 --> 01:04:47,423
PERFORMANCE, AND BROADEN IN 2023

1954
01:04:47,423 --> 01:04:49,291
TO INCLUDE OVER THE COUNTER

1955
01:04:49,291 --> 01:04:50,559
POINT OF CARE DIAGNOSTICS FOR

1956
01:04:50,559 --> 01:04:51,794
ADDITIONAL DISEASES AND

1957
01:04:51,794 --> 01:04:52,294
CONDITIONS.

1958
01:04:52,294 --> 01:04:55,030
AND BRUCE PLAYED A KEY ROLE IN

1959
01:04:55,030 --> 01:04:57,099
NIH BEING ABLE TO RESPOND TO THE

1960
01:04:57,099 --> 01:04:58,600
PANDEMIC AND FOR THAT, I'M

1961
01:04:58,600 --> 01:05:00,235
PERSONALLY GRATEFUL.

1962
01:05:00,235 --> 01:05:01,870
HIS LABORATORY, THE SECTION ON

1963
01:05:01,870 --> 01:05:03,839
BIOMEDICAL OPTICS, IS IN THE

1964
01:05:03,839 --> 01:05:05,174
EUNICE KENNEDY SHRIVER NATIONAL

1965
01:05:05,174 --> 01:05:06,342
INSTITUTE OF CHILD HEALTH AND

1966
01:05:06,342 --> 01:05:07,976
HUMAN DEVELOPMENT, AND HE WORKS

1967
01:05:07,976 --> 01:05:10,813
ON DEVELOPING PORTABLE BEDSIDE

1968
01:05:10,813 --> 01:05:12,648
NON-CONTACT AND WEARABLE

1969
01:05:12,648 --> 01:05:13,882
TECHNOLOGIES FOR QUANTITATIVE

1970
01:05:13,882 --> 01:05:16,385
SENSING AND IMAGING OF TISSUE

1971
01:05:16,385 --> 01:05:19,621
COMPOSITION AND METABOLISM.

1972
01:05:19,621 --> 01:05:20,789
BRUCE CAME TO US FROM THE

1973
01:05:20,789 --> 01:05:22,458
UNIVERSITY OF CALIFORNIA IRVINE,

1974
01:05:22,458 --> 01:05:26,495
HAS HAD AN OVER 300 -- NOT

1975
01:05:26,495 --> 01:05:27,963
300-YEAR.

1976
01:05:27,963 --> 01:05:28,831
30-YEAR ACADEMIC CAREER.

1977
01:05:28,831 --> 01:05:31,266
>> IT FEELS LIKE 300.

1978
01:05:31,266 --> 01:05:33,602
>>  -- DEPARTMENT OF
BIOMEDICAL

1979
01:05:33,602 --> 01:05:35,904
ENGINEERING, HAS CO-AUTHORED

1980
01:05:35,904 --> 01:05:39,742
OVER 450 PUBLICATIONS, HOLDS 25

1981
01:05:39,742 --> 01:05:41,844
PATENTS, AND IS A MEMBER OF THE

1982
01:05:41,844 --> 01:05:43,979
NATIONAL ACADEMIES OF MEDICINE

1983
01:05:43,979 --> 01:05:45,381
AND ENGINEERING.

1984
01:05:45,381 --> 01:05:47,449
IT IS MY DISTINCT PLEASURE TO

1985
01:05:47,449 --> 01:05:50,285
WELCOME DR. BRUCE TROMBERG TO

1986
01:05:50,285 --> 01:05:51,887
THE 61ST MEETING OF THE ADVISORY

1987
01:05:51,887 --> 01:05:52,788
COMMITTEE FOR RESEARCH ON

1988
01:05:52,788 --> 01:05:53,889
WOMEN'S HEALTH.

1989
01:05:53,889 --> 01:05:56,592
DR. TROMBERG.

1990
01:05:56,592 --> 01:05:57,459
>> THANK YOU, JANINE.

1991
01:05:57,459 --> 01:05:58,093
THANK YOU.

1992
01:05:58,093 --> 01:06:00,396
IT'S REALLY -- IT'S FANTASTIC TO

1993
01:06:00,396 --> 01:06:01,163
BE HERE.

1994
01:06:01,163 --> 01:06:02,898
JANINE IS SUCH AN INCREDIBLE

1995
01:06:02,898 --> 01:06:03,999
SUPPORTER OF TECHNOLOGY.

1996
01:06:03,999 --> 01:06:06,034
OF COURSE THE FORMAT OF TODAY'S

1997
01:06:06,034 --> 01:06:11,106
MEETING IS REALLY ALL AROUND

1998
01:06:11,106 --> 01:06:13,342
TECHNOLOGY I THINK THIS POSSIBLY

1999
01:06:13,342 --> 01:06:14,943
CAME FROM JANINE'S INSPIRATIONAL

2000
01:06:14,943 --> 01:06:16,378
TALK IN OUR MAY COUNCIL MEETING

2001
01:06:16,378 --> 01:06:17,780
THIS PAST YEAR.

2002
01:06:17,780 --> 01:06:21,950
OF COURSE NO GOOD DEED GOES

2003
01:06:21,950 --> 01:06:22,651
UNPUNISHED.

2004
01:06:22,651 --> 01:06:24,920
SHE IS NOW OUR KEYNOTE SPEAKER

2005
01:06:24,920 --> 01:06:26,455
FOR BIOMEDICAL ENGINEERING.

2006
01:06:26,455 --> 01:06:28,090
YOU DIDN'T PUT THAT ON YOUR

2007
01:06:28,090 --> 01:06:29,158
EVENTS.

2008
01:06:29,158 --> 01:06:30,359
OCTOBER 25TH, THE BIGGEST

2009
01:06:30,359 --> 01:06:35,597
BIOMEDICAL ENGINEERING MEETING

2010
01:06:35,597 --> 01:06:35,931
IN THE WORLD.

2011
01:06:35,931 --> 01:06:38,333
THIS IS EXACTLY THE KIND OF

2012
01:06:38,333 --> 01:06:40,102
COLLABORATION BETWEEN MEDICINE,

2013
01:06:40,102 --> 01:06:41,603
ARTICULATION OF NEEDS AND THE

2014
01:06:41,603 --> 01:06:42,204
TECHNOLOGY COMMUNITY THAT WE

2015
01:06:42,204 --> 01:06:43,472
NEED.

2016
01:06:43,472 --> 01:06:45,441
SO MY TALK IS GOING TO BE A

2017
01:06:45,441 --> 01:06:48,477
LITTLE BIT DIFFERENT AND I HAVE

2018
01:06:48,477 --> 01:06:51,647
SOME KIND OF DEMOGRAPHIC DATA ON

2019
01:06:51,647 --> 01:06:54,383
ENGINEERS AND THE ORIGIN OF

2020
01:06:54,383 --> 01:06:55,484
NIBIB, AS WELL AS SOME TECHNICAL

2021
01:06:55,484 --> 01:06:56,552
SLIDE ON WHAT SOME OF OUR

2022
01:06:56,552 --> 01:06:59,154
COMMUNITY ARE DOING.

2023
01:06:59,154 --> 01:07:01,790
BUT I HAVE MY COLLEAGUES, YOU

2024
01:07:01,790 --> 01:07:03,559
KNOW, AFTER JANINE INVITED ME TO

2025
01:07:03,559 --> 01:07:06,795
GIVE THIS TALK, WE REALLY

2026
01:07:06,795 --> 01:07:08,764
REACHED OUT AND HAD A BROAD

2027
01:07:08,764 --> 01:07:10,732
CONVERSATION WITHIN NIBIB WITH

2028
01:07:10,732 --> 01:07:14,336
OUR PROGRAM TEAM AND STAFF, AND

2029
01:07:14,336 --> 01:07:15,437
REALLY HAD A LOT OF DISCUSSION

2030
01:07:15,437 --> 01:07:16,438
ON WHAT KINDS OF TECHNOLOGIES

2031
01:07:16,438 --> 01:07:18,273
ARE WE SUPPORTING, ARE WE DOING

2032
01:07:18,273 --> 01:07:19,575
ENOUGH, WHAT'S THE EXTENT AND

2033
01:07:19,575 --> 01:07:20,876
THE SCOPE AND THE IMPACT THAT

2034
01:07:20,876 --> 01:07:23,846
WE'RE HAVING.

2035
01:07:23,846 --> 01:07:25,481
SO THIS OPPORTUNITY IS REALLY A

2036
01:07:25,481 --> 01:07:26,648
CHANCE FOR EVERYONE TO GET INTO

2037
01:07:26,648 --> 01:07:28,317
A DIALOGUE AND DISCUSSION.

2038
01:07:28,317 --> 01:07:31,353
THERE'S SO MUCH ENTHUSIASM

2039
01:07:31,353 --> 01:07:32,120
WITHIN NIBIB AND OUR COMMUNITY,

2040
01:07:32,120 --> 01:07:34,423
I THINK YOU'LL BE ABLE TO SEE

2041
01:07:34,423 --> 01:07:35,824
THAT AND FEEL IT FROM THE TALK,

2042
01:07:35,824 --> 01:07:36,925
BUT THERE'S STILL LOTS OF WORK

2043
01:07:36,925 --> 01:07:37,259
TO DO.

2044
01:07:37,259 --> 01:07:39,761
SO I REALLY THANK -- I'M VERY

2045
01:07:39,761 --> 01:07:41,630
GRATEFUL TO MY MANY COLLEAGUES,

2046
01:07:41,630 --> 01:07:43,465
PROBABLY I COULD HAVE PUT ALMOST

2047
01:07:43,465 --> 01:07:45,000
EVERYONE IN NIBIB ON THIS SLIDE.

2048
01:07:45,000 --> 01:07:48,704
BUT THESE ARE KEY PROGRAM

2049
01:07:48,704 --> 01:07:50,138
COLLABORATORS WHO ARE MANAGING

2050
01:07:50,138 --> 01:07:53,075
AND DRIVING FORWARD NEW

2051
01:07:53,075 --> 01:07:53,842
TECHNOLOGIES RELATED TO WOMEN'S

2052
01:07:53,842 --> 01:07:56,144
HEALTH.

2053
01:07:56,144 --> 01:07:57,346
SO JUST TO GIVE YOU A LITTLE BIT

2054
01:07:57,346 --> 01:08:00,182
OF BACKGROUND, JANINE SORT OF

2055
01:08:00,182 --> 01:08:02,918
MENTIONED SOME PEOPLE CALL US

2056
01:08:02,918 --> 01:08:04,553
NIBIB OR NIBIB, IT'S A VERY

2057
01:08:04,553 --> 01:08:04,953
COMPLICATED NAME.

2058
01:08:04,953 --> 01:08:06,288
LET ME GO BACK TO THE ORIGINS.

2059
01:08:06,288 --> 01:08:07,589
WE'RE ACTUALLY VERY HAPPY IF

2060
01:08:07,589 --> 01:08:09,458
ANYBODY MENTIONS US AT ALL, SO

2061
01:08:09,458 --> 01:08:12,294
WE'RE THE ENGINEERS.

2062
01:08:12,294 --> 01:08:13,695
AND PEOPLE KIND OF TAKE US FOR

2063
01:08:13,695 --> 01:08:14,463
GRANTED.

2064
01:08:14,463 --> 01:08:16,865
IF STUFF WORKS, IT'S GOOD, THE

2065
01:08:16,865 --> 01:08:18,267
ENGINEERS BUILT IT, BUT WHEN

2066
01:08:18,267 --> 01:08:19,034
IT'S BRO KERNTION WE'RE IN

2067
01:08:19,034 --> 01:08:21,537
TROUBLE.

2068
01:08:21,537 --> 01:08:22,538
 BROKEN, WE'RE IN TROUBLE.

2069
01:08:22,538 --> 01:08:23,939
SO ENGINEERING AT NIH IS KIND OF

2070
01:08:23,939 --> 01:08:26,008
A CONTROVERSIAL TOPIC.

2071
01:08:26,008 --> 01:08:27,442
HAROLD VARMUS, ONE OF THE NIH

2072
01:08:27,442 --> 01:08:30,379
DIRECTORS, IN FACT, THE ONE WHO

2073
01:08:30,379 --> 01:08:31,813
WAS AT THE HELM DURING THE

2074
01:08:31,813 --> 01:08:32,748
CREATION OF NIBIB, WHICH

2075
01:08:32,748 --> 01:08:36,051
HAPPENED IN 2000, WAS COMPLETELY

2076
01:08:36,051 --> 01:08:38,153
OPPOSED TO IT.

2077
01:08:38,153 --> 01:08:39,988
HIS PHILOSOPHY WAS THAT

2078
01:08:39,988 --> 01:08:40,956
BIOENGINEERING SHOULD BE IN ALL

2079
01:08:40,956 --> 01:08:42,157
THE INSTITUTES, AND IT DOESN'T

2080
01:08:42,157 --> 01:08:43,458
REALLY NEED ITS OWN INDEPENDENT

2081
01:08:43,458 --> 01:08:45,027
HOME.

2082
01:08:45,027 --> 01:08:46,628
BUT THE ENGINEERING AND THE

2083
01:08:46,628 --> 01:08:47,529
IMAGING COMMUNITIES REALLY GOT

2084
01:08:47,529 --> 01:08:51,900
TOGETHER AND PUT OVER ABOUT A

2085
01:08:51,900 --> 01:08:52,868
DECADE, LOTS OF PRESSURE ON

2086
01:08:52,868 --> 01:08:57,105
CONGRESS TO REALLY CONTEMPLATE

2087
01:08:57,105 --> 01:08:58,307
THAT THERE SHOULD BE A SEPARATE

2088
01:08:58,307 --> 01:08:59,541
INSTITUTE THAT REALLY CARES

2089
01:08:59,541 --> 01:09:01,276
ABOUT COMPUTATIONAL TECHNIQUES,

2090
01:09:01,276 --> 01:09:04,313
HARDWARE DEVELOPMENT, ALL OF THE

2091
01:09:04,313 --> 01:09:05,647
THINGS -- SOFT MATERIALS

2092
01:09:05,647 --> 01:09:07,482
ENGINEERING LIKE TISSUE

2093
01:09:07,482 --> 01:09:08,483
ENGINEERING, MICRO PHYSIOLOGIC

2094
01:09:08,483 --> 01:09:08,917
SYSTEMS.

2095
01:09:08,917 --> 01:09:12,287
ALL THESE THINGS THAT WERE HOPED

2096
01:09:12,287 --> 01:09:14,823
FOR, BUT NO SINGLE INSTITUTE

2097
01:09:14,823 --> 01:09:16,858
REALLY HAD, I GUESS, THE

2098
01:09:16,858 --> 01:09:18,927
RESPONSIBILITY FOR ADVANCING

2099
01:09:18,927 --> 01:09:19,728
THESE TECHNOLOGIES IN THE

2100
01:09:19,728 --> 01:09:22,230
CONTEXT OF ALL OF THE MOLECULAR

2101
01:09:22,230 --> 01:09:23,498
BIOLOGY IN MEDICINE THAT GOES ON

2102
01:09:23,498 --> 01:09:23,999
AT THE NIH.

2103
01:09:23,999 --> 01:09:26,468
SO I HAVE AN EXCERPT FROM THE

2104
01:09:26,468 --> 01:09:27,469
PUBLIC LAW, WHICH IS A LITTLE

2105
01:09:27,469 --> 01:09:28,770
BIT -- IT'S OUR CREATION STORY

2106
01:09:28,770 --> 01:09:30,405
AND I ALWAYS LIKE TO SHARE THIS.

2107
01:09:30,405 --> 01:09:32,708
THE LANGUAGE IS QUITE

2108
01:09:32,708 --> 01:09:34,676
INSPIRATIONAL AND

2109
01:09:34,676 --> 01:09:35,043
FORWARD-LOOKING.

2110
01:09:35,043 --> 01:09:36,411
KIND OF SURPRISING FOR CONGRESS,

2111
01:09:36,411 --> 01:09:38,513
BUT IT'S REALLY BEAUTIFULLY

2112
01:09:38,513 --> 01:09:40,349
ARTICULATED.

2113
01:09:40,349 --> 01:09:42,551
AND SINCE NIBIB WAS ESTABLISHED,

2114
01:09:42,551 --> 01:09:45,721
THIS NIBIB ESTABLISHMENT ACT,

2115
01:09:45,721 --> 01:09:48,423
THERE'S BEEN ENORMOUS GROWTH IN

2116
01:09:48,423 --> 01:09:49,625
BIOMEDICAL ENGINEERING ACROSS

2117
01:09:49,625 --> 01:09:50,726
THE COUNTRY AND IN FACT ALL

2118
01:09:50,726 --> 01:09:51,293
ACROSS THE WORLD.

2119
01:09:51,293 --> 01:09:52,694
YOU CAN SEE THE ARROW POINTING

2120
01:09:52,694 --> 01:09:54,029
TO THE INFLECTION POINT.

2121
01:09:54,029 --> 01:09:56,198
THERE IS A FOUNDATION CALLED THE

2122
01:09:56,198 --> 01:10:00,102
WHITTAKER FOUNDATION THAT SPENT

2123
01:10:00,102 --> 01:10:02,170
$760 MILLION OVER A 20-YEAR

2124
01:10:02,170 --> 01:10:03,372
PERIOD ON ESTABLISHING

2125
01:10:03,372 --> 01:10:04,906
BIOLOGICAL ENGINEERING

2126
01:10:04,906 --> 01:10:05,674
DEPARTMENTS ALL AROUND THE

2127
01:10:05,674 --> 01:10:06,241
COUNTRY.

2128
01:10:06,241 --> 01:10:07,442
SO AT THE TIME NIBIB WAS

2129
01:10:07,442 --> 01:10:09,011
ESTABLISHED, THERE WERE ABOUT 40

2130
01:10:09,011 --> 01:10:12,314
OR 50 WHAT WE CALL

2131
01:10:12,314 --> 01:10:12,914
ABET-CERTIFIED DEPARTMENTS IN

2132
01:10:12,914 --> 01:10:13,215
THE COUNTRY.

2133
01:10:13,215 --> 01:10:14,416
WE NOW HAVE OVER 180.

2134
01:10:14,416 --> 01:10:16,585
THERE ARE MORE THAN 200 GRADUATE

2135
01:10:16,585 --> 01:10:17,686
PROGRAMS, AND IT'S REALLY

2136
01:10:17,686 --> 01:10:19,187
CHANGED THE CULTURE AND THE

2137
01:10:19,187 --> 01:10:20,856
LANDSCAPE IN EDUCATION.

2138
01:10:20,856 --> 01:10:23,025
SO HUMAN HEALTH HAS BECOME A TOP

2139
01:10:23,025 --> 01:10:23,792
PRIORITY IN ENGINEERING.

2140
01:10:23,792 --> 01:10:25,927
SO I WAS AFFILIATED WITH THE

2141
01:10:25,927 --> 01:10:26,828
SCHOOL OF ENGINEERING IN THE

2142
01:10:26,828 --> 01:10:27,162
90s.

2143
01:10:27,162 --> 01:10:28,263
NOBODY REALLY THOUGHT ABOUT

2144
01:10:28,263 --> 01:10:29,364
HUMAN HEALTH BACK THEN.

2145
01:10:29,364 --> 01:10:31,333
IT WASN'T UNTIL THE LATE '90S,

2146
01:10:31,333 --> 01:10:33,835
WHEN WE GOT A GRANT FROM THE

2147
01:10:33,835 --> 01:10:36,338
WHITTAKER FOUNDATION, THAT

2148
01:10:36,338 --> 01:10:41,810
ALLOWED US TO START A A BIOMEDIL

2149
01:10:41,810 --> 01:10:42,344
ENGINEERING PROGRAM.

2150
01:10:42,344 --> 01:10:44,980
IT BECAME A NUMBER ONE OR TWO

2151
01:10:44,980 --> 01:10:46,381
STRATEGIC PRIORITY OF SCHOOLS OF

2152
01:10:46,381 --> 01:10:46,815
ENGINEERING.

2153
01:10:46,815 --> 01:10:49,117
WE ALSO SEE MEDICINE ENGINEERING

2154
01:10:49,117 --> 01:10:50,085
PARTNERSHIPS THROUGH SCHOOLS OF

2155
01:10:50,085 --> 01:10:50,419
MEDICINE.

2156
01:10:50,419 --> 01:10:52,487
SO THERE ARE TWO SCHOOLS OF

2157
01:10:52,487 --> 01:10:54,489
MEDICINE NOW, UNIVERSITY OF

2158
01:10:54,489 --> 01:10:56,291
ILLINOIS UR BAP NA CHAMPAGNE AND

2159
01:10:56,291 --> 01:10:58,860
TEXAS A & M UNIVERSITY.

2160
01:10:58,860 --> 01:11:01,129
THE TEXAS ONE FOUNDED BY MY

2161
01:11:01,129 --> 01:11:03,098
PREDECESSOR AND FOUNDER OF

2162
01:11:03,098 --> 01:11:13,709
NIBIB, ROB PE PETT IT GREW, THE

2163
01:11:13,909 --> 01:11:14,209
FIRST DIRECTOR.

2164
01:11:14,209 --> 01:11:15,911
STUDENTS WHO COME OUT ACTUALLY

2165
01:11:15,911 --> 01:11:17,312
GRADUATE AT LEAST IN TEXAS A

2166
01:11:17,312 --> 01:11:19,181
APPED M WITH A MASTER'S DEGREE

2167
01:11:19,181 --> 01:11:20,949
IN ENGINEERING AS WELL AS THEIR

2168
01:11:20,949 --> 01:11:21,283
M.D. DEGREES.

2169
01:11:21,283 --> 01:11:22,684
THERE ARE ALSO A NUMBER OF

2170
01:11:22,684 --> 01:11:23,985
CENTERS AND PERHAPS MANY OF YOU

2171
01:11:23,985 --> 01:11:25,087
ARE AFFILIATED WITH SOME OF

2172
01:11:25,087 --> 01:11:26,722
THOSE CENTERS FOR ENGINEERING

2173
01:11:26,722 --> 01:11:28,223
AND MEDICINE ALL AROUND THE

2174
01:11:28,223 --> 01:11:29,024
COUNTRY.

2175
01:11:29,024 --> 01:11:30,625
VIRTUALLY EVERY MAJOR RESEARCH

2176
01:11:30,625 --> 01:11:32,027
UNIVERSITY HAS THESE.

2177
01:11:32,027 --> 01:11:33,495
THEY'RE QUITE INTERDISCIPLINARY.

2178
01:11:33,495 --> 01:11:37,632
AND ALL OF THIS ACTIVITY HAS

2179
01:11:37,632 --> 01:11:39,267
HELPED DRIVE INNOVATION,

2180
01:11:39,267 --> 01:11:39,968
ENTREPRENEURSHIP, AND THERE'S

2181
01:11:39,968 --> 01:11:42,537
BEEN A REMARKABLE IMPACT IN

2182
01:11:42,537 --> 01:11:44,706
DIVERSITY, IN PARTICULAR IN THE

2183
01:11:44,706 --> 01:11:45,707
ENGAGEMENT AND PARTICIPATION OF

2184
01:11:45,707 --> 01:11:47,576
WOMEN IN SCHOOLS OF ENGINEERING

2185
01:11:47,576 --> 01:11:48,543
AND DEPARTMENTS ALL ACROSS

2186
01:11:48,543 --> 01:11:48,844
ENGINEERING.

2187
01:11:48,844 --> 01:11:50,178
AND I HAVE SOME STATISTICS THAT

2188
01:11:50,178 --> 01:11:51,279
I'LL SHOW YOU ON THAT.

2189
01:11:51,279 --> 01:11:56,718
SO WHAT DO WE DO AT NIBIB?

2190
01:11:56,718 --> 01:11:58,386
WE HAVE LESS THAN A PERCENT OF

2191
01:11:58,386 --> 01:12:00,021
THE TOTAL NIH BUDGET, BUT WE

2192
01:12:00,021 --> 01:12:02,224
FORM PARTNERSHIPS WITH VIRTUALLY

2193
01:12:02,224 --> 01:12:05,360
EVERY INSTITUTE, CENTER AND

2194
01:12:05,360 --> 01:12:06,895
OFFICE BECAUSE THERE'S THIS

2195
01:12:06,895 --> 01:12:08,663
DRIVE TO DEVELOP NEW

2196
01:12:08,663 --> 01:12:11,266
TECHNOLOGIES IN ENGINEERING THAT

2197
01:12:11,266 --> 01:12:12,734
CAN GO INTO MANY, MANY DIFFERENT

2198
01:12:12,734 --> 01:12:13,568
APPLICATION AREAS.

2199
01:12:13,568 --> 01:12:15,303
SO ENGINEERING AND IMAGING

2200
01:12:15,303 --> 01:12:16,972
TECHNOLOGIES ARE CENTRAL TO US.

2201
01:12:16,972 --> 01:12:19,674
BUT WE BUILD PARTNERSHIPS AND

2202
01:12:19,674 --> 01:12:20,575
DRIVE COLLABORATION ALL ACROSS

2203
01:12:20,575 --> 01:12:21,877
THE INSTITUTES, CENTERS AND

2204
01:12:21,877 --> 01:12:22,410
OFFICES.

2205
01:12:22,410 --> 01:12:25,480
SO IF WE BREAK DOWN HOW MUCH ALL

2206
01:12:25,480 --> 01:12:30,418
THE INSTITUTES ARE SPENDING ON

2207
01:12:30,418 --> 01:12:32,053
BIOENGINEERING, VIRTUALLY ALL OF

2208
01:12:32,053 --> 01:12:34,456
OUR RESOURCES AT NIBIB ARE SPENT

2209
01:12:34,456 --> 01:12:34,990
ON BIOENGINEERING.

2210
01:12:34,990 --> 01:12:36,424
YOU CAN SEE THE PERCENT FUNDING

2211
01:12:36,424 --> 01:12:38,193
THAT GOES TOWARDS BIOENGINEERING

2212
01:12:38,193 --> 01:12:41,229
AS A FUNCTION OF THE

2213
01:12:41,229 --> 01:12:42,531
APPROPRIATED BUDGET, SO YOU CAN

2214
01:12:42,531 --> 01:12:44,299
SEE WAY ON THE RIGHT SIDE, NCI

2215
01:12:44,299 --> 01:12:46,234
AND NIAID ARE THE BIG, BIG

2216
01:12:46,234 --> 01:12:46,701
CIRCLES.

2217
01:12:46,701 --> 01:12:48,436
THEY HAVE THE MOST MONEY PER

2218
01:12:48,436 --> 01:12:48,770
YEAR.

2219
01:12:48,770 --> 01:12:51,273
WE'RE A TINY CIRCLE IN THE UPPER

2220
01:12:51,273 --> 01:12:52,707
LEFT-HAND CORNER THAT'S

2221
01:12:52,707 --> 01:12:53,708
PROPORTIONAL TO OUR APPROPRIATED

2222
01:12:53,708 --> 01:12:56,311
BUDGET.

2223
01:12:56,311 --> 01:12:58,280
BUT THERE ARE SEVERAL

2224
01:12:58,280 --> 01:12:59,014
INSTITUTES, NATIONAL LIBRARY OF

2225
01:12:59,014 --> 01:13:03,985
MEDICINE, NIDCD, NIAMS, NEI,

2226
01:13:03,985 --> 01:13:06,288
THEY SPEND BETWEEN 20 AND 30% OF

2227
01:13:06,288 --> 01:13:08,023
THEIR BUDGETS IN TOTAL ON

2228
01:13:08,023 --> 01:13:08,790
BIOENGINEERING, WHICH IS A

2229
01:13:08,790 --> 01:13:10,425
PRETTY IMPRESSIVE NUMBER.

2230
01:13:10,425 --> 01:13:14,262
OVER A 10-YEAR PERIOD, THAT'S

2231
01:13:14,262 --> 01:13:16,364
ABOUT $60 BILLION, $55.6 BILLION

2232
01:13:16,364 --> 01:13:17,098
TOTAL THAT'S BEEN SPENT.

2233
01:13:17,098 --> 01:13:18,466
BUT IT'S INTERESTING TO LOOK AT

2234
01:13:18,466 --> 01:13:20,502
THE MOST RECENT TRENDS.

2235
01:13:20,502 --> 01:13:24,739
SO IN 2023, ALL THE INSTITUTES

2236
01:13:24,739 --> 01:13:28,844
HAVE SPENT, IN TOTAL, ABOUT 15%

2237
01:13:28,844 --> 01:13:30,445
OF THE BUDGET ON BIOENGINEERING

2238
01:13:30,445 --> 01:13:31,379
TECHNOLOGIES.

2239
01:13:31,379 --> 01:13:33,248
THAT'S OVER $7 BILLION.

2240
01:13:33,248 --> 01:13:36,051
THAT'S AN ENORMOUS INVESTMENT.

2241
01:13:36,051 --> 01:13:37,352
PEOPLE DON'T NORMALLY THINK OF

2242
01:13:37,352 --> 01:13:41,022
NIH AS A TECHNOLOGY INSTITUTE,

2243
01:13:41,022 --> 01:13:42,090
BUT THIS IS ON THE SCALE OF ALL

2244
01:13:42,090 --> 01:13:44,125
OF THE OTHER FEDERAL TECHNOLOGY

2245
01:13:44,125 --> 01:13:45,827
INSTITUTES THAT ARE INVESTING IN

2246
01:13:45,827 --> 01:13:47,062
HARD CORE TECHNOLOGIES.

2247
01:13:47,062 --> 01:13:48,663
WE ARE DOING THE SAME THING HERE

2248
01:13:48,663 --> 01:13:51,333
AT THE NIH.

2249
01:13:51,333 --> 01:13:52,834
THIS IS DOUBLING ROUGHLY EVERY

2250
01:13:52,834 --> 01:13:54,069
10 YEARS.

2251
01:13:54,069 --> 01:13:56,204
SO WE LIKE MODELING, YOU KNOW,

2252
01:13:56,204 --> 01:14:00,942
WE RECOGNIZE THAT THE NOBEL

2253
01:14:00,942 --> 01:14:03,712
PRIZE IN PHYSICS WAS FOR

2254
01:14:03,712 --> 01:14:04,446
ARTIFICIAL INTELLIGENCE TODAY.

2255
01:14:04,446 --> 01:14:07,315
SO IF WE USE SOME AI AND SOME

2256
01:14:07,315 --> 01:14:08,817
MODELING, WE WOULD PREDICT THAT

2257
01:14:08,817 --> 01:14:10,919
IN 30 YEARS, THE ENTIRE NIH

2258
01:14:10,919 --> 01:14:12,988
BUDGET WOULD BE SPENT ON

2259
01:14:12,988 --> 01:14:13,755
BIOENGINEERING BUT I DON'T KNOW

2260
01:14:13,755 --> 01:14:15,490
IF ANYONE'S GOING TO BE AROUND

2261
01:14:15,490 --> 01:14:17,025
TO SEE IF THAT'S CORRECT.

2262
01:14:17,025 --> 01:14:18,660
SO WHAT ARE WE SPENDING THE

2263
01:14:18,660 --> 01:14:19,227
MONEY ON?

2264
01:14:19,227 --> 01:14:21,663
WHAT ARE THE KEY TOPICAL AREAS?

2265
01:14:21,663 --> 01:14:28,436
SO THIS IS OUR ICONOGRAPHY

2266
01:14:28,436 --> 01:14:30,105
REPRESENTATION.

2267
01:14:30,105 --> 01:14:31,606
SO WE DO ENGINEERED BIOLOGICAL

2268
01:14:31,606 --> 01:14:32,140
SYSTEMS.

2269
01:14:32,140 --> 01:14:33,909
YOU CAN THINK OF THESE AS MICRO

2270
01:14:33,909 --> 01:14:35,377
PHYSIOLOGIC SYSTEMS, TISSUES ON

2271
01:14:35,377 --> 01:14:37,212
A CHIP, SYNTHETIC BIOLOGY.

2272
01:14:37,212 --> 01:14:38,747
YOU'VE HEARD OF ALL OF THESE

2273
01:14:38,747 --> 01:14:39,080
APPROACHES.

2274
01:14:39,080 --> 01:14:40,482
I'LL GIVE YOU A FEW EXAMPLES OF

2275
01:14:40,482 --> 01:14:42,584
THESE THROUGHOUT THE TALK.

2276
01:14:42,584 --> 01:14:44,419
WE SUPPORT -- WE ALSO CALL THAT

2277
01:14:44,419 --> 01:14:46,621
SOFT MATERIALS ENG FEARING.

2278
01:14:46,621 --> 01:14:50,091
WE SUPPORT SENSORS AND POINT OF

2279
01:14:50,091 --> 01:14:50,892
CARE DEVICES.

2280
01:14:50,892 --> 01:14:53,828
THESE INCLUDE BIOPHOTONIC,

2281
01:14:53,828 --> 01:14:54,796
BIOELECTRIC, BIOACOUSTIC TYPES

2282
01:14:54,796 --> 01:14:56,798
OF CENTERS, WEARABLE,

2283
01:14:56,798 --> 01:14:57,999
IMPLANTABLE DEVICES, THINGS THAT

2284
01:14:57,999 --> 01:14:59,734
CAN GO AT THE POINT OF CARE.

2285
01:14:59,734 --> 01:15:02,070
IF YOU THINK OF HOSPITALS, YOU

2286
01:15:02,070 --> 01:15:03,571
THINK OF BIG PHYSICS STUFF LIKE

2287
01:15:03,571 --> 01:15:05,307
YOU'LL GO INTO A GIANT MAGNET.

2288
01:15:05,307 --> 01:15:06,841
THIS IS SMALL PHYSICS THAT YOU

2289
01:15:06,841 --> 01:15:09,044
CAN BRING TO THE PATIENT AND

2290
01:15:09,044 --> 01:15:09,911
ACTUALLY PATIENTS CAN HAVE IN

2291
01:15:09,911 --> 01:15:12,414
THEIR HOMES.

2292
01:15:12,414 --> 01:15:14,849
OF COURSE WE DO SUPPORT THE BIG

2293
01:15:14,849 --> 01:15:16,151
PHYSICS TECHNOLOGIES LIKE

2294
01:15:16,151 --> 01:15:16,918
IMAGING TECHNOLOGIES.

2295
01:15:16,918 --> 01:15:18,553
SOME OF THEM ARE REALLY QUITE

2296
01:15:18,553 --> 01:15:19,087
SPECTACULAR.

2297
01:15:19,087 --> 01:15:22,190
ONE OF THEM I LIKE TO POINT OUT

2298
01:15:22,190 --> 01:15:23,825
OFTEN IS A WHOLE BODY PET

2299
01:15:23,825 --> 01:15:27,762
SCANNER THAT HAS HALF A MILLION

2300
01:15:27,762 --> 01:15:28,530
SCINTILLATORS, 50,000 DETECTORS.

2301
01:15:28,530 --> 01:15:30,332
IT ACTUALLY IS A DESIGN, IF

2302
01:15:30,332 --> 01:15:39,140
YOU'VE HEARD OF THE LARGE HEDRON

2303
01:15:39,140 --> 01:15:40,241
COLLIDER, MORE COMPACT, MORE

2304
01:15:40,241 --> 01:15:41,209
EFFICIENT AND MINIATURE AND

2305
01:15:41,209 --> 01:15:43,078
DESIGN TODAY DO ENTIRE BODY PET

2306
01:15:43,078 --> 01:15:45,480
SCAN IN SEVEN MINUTES.

2307
01:15:45,480 --> 01:15:47,549
AND EVERY SECOND, YOU CAN DO A

2308
01:15:47,549 --> 01:15:48,984
DYNAMIC CONTRAST ENHANCED

2309
01:15:48,984 --> 01:15:49,751
UPDATE.

2310
01:15:49,751 --> 01:15:51,720
SO IT'S REVOLUTIONIZING HOW

2311
01:15:51,720 --> 01:15:53,355
PEOPLE ARE LOOKING AT METABOLIC

2312
01:15:53,355 --> 01:15:54,656
AND FUNCTIONAL IMAGING.

2313
01:15:54,656 --> 01:15:56,291
WE ALSO DEVELOP THERAPEUTIC

2314
01:15:56,291 --> 01:15:56,858
SYSTEMS.

2315
01:15:56,858 --> 01:16:01,997
THESE INCLUDE ROBOTIC DEVICES,

2316
01:16:01,997 --> 01:16:03,631
ROBOTICALLY PROVIDED SURGERY,

2317
01:16:03,631 --> 01:16:04,399
EXOSKELETONS.

2318
01:16:04,399 --> 01:16:05,734
ALSO DEVICES TO DELIVER ENERGY

2319
01:16:05,734 --> 01:16:08,670
INTO THE BODY, LIKE FOCUSED

2320
01:16:08,670 --> 01:16:10,205
ULTRASOUND, BOTH LOW INTENSITY

2321
01:16:10,205 --> 01:16:11,406
AND HIGH INTENSITY.

2322
01:16:11,406 --> 01:16:13,041
HIGH INTENSITY FOCUSED

2323
01:16:13,041 --> 01:16:14,809
ULTRASOUND CAN BE USED TO

2324
01:16:14,809 --> 01:16:16,344
DELIVER ENERGY TO DO SURGERY

2325
01:16:16,344 --> 01:16:18,279
WITHOUT HAVING TO OPEN THE

2326
01:16:18,279 --> 01:16:20,181
TISSUE, OPEN THE BODY.

2327
01:16:20,181 --> 01:16:21,816
ONE VERY IMPORTANT EXAMPLE OF

2328
01:16:21,816 --> 01:16:25,086
THIS IS BRAIN SURGERY, WHICH YOU

2329
01:16:25,086 --> 01:16:26,721
CAN TREAT ESSENTIAL TREMOR WITH

2330
01:16:26,721 --> 01:16:29,224
FOCUSED ULTRASOUND TO THE BRAIN,

2331
01:16:29,224 --> 01:16:29,691
SUBMILLIMETER SPOTS TO

2332
01:16:29,691 --> 01:16:30,158
INACTIVATE.

2333
01:16:30,158 --> 01:16:33,028
YOU CAN ALSO DRIVE MOLECULAR OR

2334
01:16:33,028 --> 01:16:35,063
NANOPARTICLE PROCESSES USING

2335
01:16:35,063 --> 01:16:35,864
THAT ENERGY DELIVERY, AND SOME

2336
01:16:35,864 --> 01:16:37,932
OF THEM CAN BE DELIVERED USING

2337
01:16:37,932 --> 01:16:39,467
MINIMALLY INVASIVE AND

2338
01:16:39,467 --> 01:16:43,338
IMPLANLTABLE DEVICIMPLANTABLE DO

2339
01:16:43,338 --> 01:16:43,938
INSIDE THE BODY.

2340
01:16:43,938 --> 01:16:46,141
ALL OF THIS IS TIED TOGETHER

2341
01:16:46,141 --> 01:16:48,443
WITH COMPUTATION MODELING,

2342
01:16:48,443 --> 01:16:49,310
ARTIFICIAL INTELLIGENCE.

2343
01:16:49,310 --> 01:16:51,613
I TOOK OUT ALL OF MY A.I. SLIDES

2344
01:16:51,613 --> 01:16:54,482
BECAUSE IT'S JUST SO UBIQUITOUS.

2345
01:16:54,482 --> 01:16:57,519
EVERYTHING THAT OUR COMMUNITY IS

2346
01:16:57,519 --> 01:16:58,620
DOING, MOSTLY IN THE HARD

2347
01:16:58,620 --> 01:17:00,488
MATERIAL SPACE BUT ALSO WHAT WE

2348
01:17:00,488 --> 01:17:03,091
CALL SOFT MATERIALS, IS

2349
01:17:03,091 --> 01:17:04,526
COMPLEMENTED BY COMPUTATIONAL

2350
01:17:04,526 --> 01:17:06,594
MODELS THAT HELP US MAKE A

2351
01:17:06,594 --> 01:17:09,998
DIGITAL TWIN OF A DEVICE OR A

2352
01:17:09,998 --> 01:17:11,833
PROCESS, ALLOW US TO OPTIMIZE

2353
01:17:11,833 --> 01:17:15,003
ITS DESIGN, AND THEN ONCE WE DO

2354
01:17:15,003 --> 01:17:18,440
DEPLOY IT, IT ALLOWS US TO

2355
01:17:18,440 --> 01:17:19,307
REALLY EXTRACT UNIQUE

2356
01:17:19,307 --> 01:17:20,408
INFORMATION THAT'S NEVER BEEN

2357
01:17:20,408 --> 01:17:22,577
DERIVED BEFORE BY COMPARING HOW

2358
01:17:22,577 --> 01:17:23,812
WE GET OUR MEASUREMENTS FROM

2359
01:17:23,812 --> 01:17:27,182
THAT SYSTEM TO THE COMPUTATIONAL

2360
01:17:27,182 --> 01:17:27,615
MODEL.

2361
01:17:27,615 --> 01:17:29,384
NOW THAT'S REALLY FUNDAMENTAL TO

2362
01:17:29,384 --> 01:17:31,453
EVERYTHING WE DO, BUT IN TERMS

2363
01:17:31,453 --> 01:17:35,056
OF IMAGING TECHNOLOGIES, IT'S

2364
01:17:35,056 --> 01:17:35,623
JUST UBIQUITOUS.

2365
01:17:35,623 --> 01:17:37,158
THERE IS NO IMAGING TECHNOLOGY

2366
01:17:37,158 --> 01:17:39,027
OR THERE ARE VERY FEW THAT ARE

2367
01:17:39,027 --> 01:17:40,095
WORKING AND CERTAINLY ALL THE

2368
01:17:40,095 --> 01:17:42,197
EXAMPLES THAT I'LL SHOW YOU

2369
01:17:42,197 --> 01:17:43,198
TODAY, THE INVESTIGATORS ARE

2370
01:17:43,198 --> 01:17:44,399
USING COMPUTATIONAL APPROACHES

2371
01:17:44,399 --> 01:17:45,600
BASED ON A.I. AND MACHINE

2372
01:17:45,600 --> 01:17:46,401
LEARNING.

2373
01:17:46,401 --> 01:17:49,871
SO ALL OF THIS IS REALLY

2374
01:17:49,871 --> 01:17:51,039
CONNECTED IN A VERY SIGNIFICANT

2375
01:17:51,039 --> 01:17:53,041
WAY.

2376
01:17:53,041 --> 01:17:56,344
SO WE KIND OF ASKED THE

2377
01:17:56,344 --> 01:17:59,514
QUESTION, WHAT ABOUT THAT 15% OF

2378
01:17:59,514 --> 01:18:00,949
BIOENGINEERING THAT'S BEING DONE

2379
01:18:00,949 --> 01:18:03,017
ALL ACROSS THE NIH, WHAT

2380
01:18:03,017 --> 01:18:05,987
FRACTION OF THAT IS IN WOMEN'S

2381
01:18:05,987 --> 01:18:07,522
HEALTH?

2382
01:18:07,522 --> 01:18:09,257
AND WITH MATT HELPING OUR TEAM

2383
01:18:09,257 --> 01:18:10,692
LOOK AT THIS AND TRYING TO MAKE

2384
01:18:10,692 --> 01:18:12,127
SENSE OF ALL OF THESE DIFFERENT

2385
01:18:12,127 --> 01:18:19,234
TOPICS, WE LOOKED AT OVER 6500

2386
01:18:19,234 --> 01:18:20,568
APPLICATIONS, WARDS IN THE

2387
01:18:20,568 --> 01:18:22,770
INTERSECTION BETWEEN WOMEN'S

2388
01:18:22,770 --> 01:18:24,506
HEALTH AND BIOENGINEERING ALL

2389
01:18:24,506 --> 01:18:26,808
ACROSS THE NIH AND GROUPED THEM

2390
01:18:26,808 --> 01:18:29,644
TO NIBIB IN CATEGORIES RELEVANT

2391
01:18:29,644 --> 01:18:30,445
TO STUDY SECTIONS.

2392
01:18:30,445 --> 01:18:33,815
WHAT YOU SEE IS MAYBE NOT SO

2393
01:18:33,815 --> 01:18:35,383
SURPRISING BUT THE BIGGEST

2394
01:18:35,383 --> 01:18:36,584
REPRESENTATION IS IN IMAGING

2395
01:18:36,584 --> 01:18:37,118
TECHNOLOGIES.

2396
01:18:37,118 --> 01:18:39,954
WE ALSO HAVE VERY STRONG

2397
01:18:39,954 --> 01:18:41,723
REPRESENTATION FROM DEVICES AND

2398
01:18:41,723 --> 01:18:43,358
INSTRUMENTS, BIOENGINEERING AND

2399
01:18:43,358 --> 01:18:43,691
BIOMATERIALS.

2400
01:18:43,691 --> 01:18:45,894
SO REMEMBER THAT ICONOGRAPHY WE

2401
01:18:45,894 --> 01:18:47,428
SHOWED, THESE MAP OUT REALLY

2402
01:18:47,428 --> 01:18:48,696
WELL TO THE MAIN TOPIC AREAS OF

2403
01:18:48,696 --> 01:18:50,598
OUR FIELD.

2404
01:18:50,598 --> 01:18:52,567
BIOINFORMATICS, WHICH IS A KIND

2405
01:18:52,567 --> 01:18:54,936
OF EUPHEMISM FOR A.I. AND

2406
01:18:54,936 --> 01:18:56,504
COMPUTATION AND MACHINE LEARNING

2407
01:18:56,504 --> 01:18:57,672
APPROACHES.

2408
01:18:57,672 --> 01:18:58,640
THERAPEUTIC DEVICES AND MODELING

2409
01:18:58,640 --> 01:18:59,240
AND SIMULATION.

2410
01:18:59,240 --> 01:19:01,442
SO THIS HELPS US UNDERSTAND

2411
01:19:01,442 --> 01:19:03,178
WHERE THE NIH INVESTMENTS ARE

2412
01:19:03,178 --> 01:19:03,845
GOING.

2413
01:19:03,845 --> 01:19:06,915
AND THIS MATCHES UP REALLY WELL

2414
01:19:06,915 --> 01:19:08,783
WITH WHERE NIBIB'S INVESTMENTS

2415
01:19:08,783 --> 01:19:08,983
ARE.

2416
01:19:08,983 --> 01:19:13,154
IN FACT, PROBABLY AN

2417
01:19:13,154 --> 01:19:14,489
OVERWHELMING MAJORITY ARE IN

2418
01:19:14,489 --> 01:19:17,258
IMAGING AND IMAGING-RELATED

2419
01:19:17,258 --> 01:19:17,525
FIELDS.

2420
01:19:17,525 --> 01:19:19,294
YOU SEE THESE ARE BIG SLICES OF

2421
01:19:19,294 --> 01:19:20,595
THE PIE BUT ALSO A VERY

2422
01:19:20,595 --> 01:19:21,696
SIGNIFICANT FRACTION IN

2423
01:19:21,696 --> 01:19:23,231
BIOLOGICAL ENGINEERING,

2424
01:19:23,231 --> 01:19:23,798
BIOMEDICAL SYSTEMS.

2425
01:19:23,798 --> 01:19:26,301
THIS IS OVER A FIVE-YEAR PERIOD,

2426
01:19:26,301 --> 01:19:29,270
FY 19 THROUGH 23.

2427
01:19:29,270 --> 01:19:30,438
AND WHAT'S REALLY INTERESTING

2428
01:19:30,438 --> 01:19:32,307
HERE IS WHEN WE ASSESS THE

2429
01:19:32,307 --> 01:19:36,811
EXTENT OF OUR BUDGET COMMITMENT,

2430
01:19:36,811 --> 01:19:38,213
AND PROBABLY I DIDN'T MAKE THIS

2431
01:19:38,213 --> 01:19:39,180
POINT STRONGLY ENOUGH, ONE OF

2432
01:19:39,180 --> 01:19:41,516
THE REASONS WHY NIBIB EXISTS IS

2433
01:19:41,516 --> 01:19:43,618
TO DRIVE TECHNOLOGY DEVELOPMENT

2434
01:19:43,618 --> 01:19:45,587
WITHOUT A BIOLOGIC HYPOTHESIS.

2435
01:19:45,587 --> 01:19:50,625
SO IF YOU COME TO US AND YOU

2436
01:19:50,625 --> 01:19:53,027
STATE A REALLY DRIVING

2437
01:19:53,027 --> 01:19:53,962
HYPOTHESIS, WE'LL TYPICALLY SEND

2438
01:19:53,962 --> 01:19:55,230
YOU TO ANOTHER INSTITUTE THAT'S

2439
01:19:55,230 --> 01:19:57,732
REALLY TO ADVANCE TECHNOLOGY

2440
01:19:57,732 --> 01:19:58,032
DEVELOPMENT.

2441
01:19:58,032 --> 01:19:59,801
NEVERTHELESS, 8 TO 10% OF OUR

2442
01:19:59,801 --> 01:20:02,103
ANNUAL EXPENDITURE GOES TO

2443
01:20:02,103 --> 01:20:03,871
WOMEN'S HEALTH TECHNOLOGIES.

2444
01:20:03,871 --> 01:20:06,741
SOMETHING THAT IS CLE CLEARLY

2445
01:20:06,741 --> 01:20:07,175
CONNECTED.

2446
01:20:07,175 --> 01:20:11,212
SO IT A REALLY INTERESTING

2447
01:20:11,212 --> 01:20:12,647
STATISTIC THAT, JANINE, IF YOU

2448
01:20:12,647 --> 01:20:14,048
DIDN'T INVITE ME TO GIVE THIS

2449
01:20:14,048 --> 01:20:15,817
TALK WE NEVER REALLY WOULD HAVE

2450
01:20:15,817 --> 01:20:16,884
DUG INTO THIS.

2451
01:20:16,884 --> 01:20:18,353
AND WE HAVE MORE THAN OUR MARKET

2452
01:20:18,353 --> 01:20:20,088
SHARE IN TERMS OF WOMEN'S HEALTH

2453
01:20:20,088 --> 01:20:21,723
AND BIOENGINEERING ALL ACROSS

2454
01:20:21,723 --> 01:20:22,290
THE NIH.

2455
01:20:22,290 --> 01:20:25,893
SO THAT'S ABOUT 3.4% OF THE

2456
01:20:25,893 --> 01:20:29,197
GLOBAL NIH BIOENGINEERING IN

2457
01:20:29,197 --> 01:20:31,266
WOMEN'S HEALTH, WE'RE LESS THAN

2458
01:20:31,266 --> 01:20:33,268
1% OF THE BUDGET SO WE FEEL LIKE

2459
01:20:33,268 --> 01:20:34,435
THAT'S A VERY SIGNIFICANT SHARE

2460
01:20:34,435 --> 01:20:36,537
AND CAN BE INCREASED, AND

2461
01:20:36,537 --> 01:20:38,406
JANINE, IN YOUR TALK WHEN YOU GO

2462
01:20:38,406 --> 01:20:40,708
TO BMES, I THINK YOU'RE GOING TO

2463
01:20:40,708 --> 01:20:47,081
SATISFY A YOU'RE TO SEE SEE

2464
01:20:47,081 --> 01:20:51,819
GOGOINGTO SEE A REALLY BIG SURG.

2465
01:20:51,819 --> 01:20:53,554
SO WHAT IS AN UNDERLYING FORCE

2466
01:20:53,554 --> 01:20:54,756
NOT REALLY THAT WELL-KNOWN THAT

2467
01:20:54,756 --> 01:20:55,757
COULD BE CONTRIBUTING TO THIS

2468
01:20:55,757 --> 01:20:57,525
WOMEN'S HEALTH FOCUS THAT A LOT

2469
01:20:57,525 --> 01:21:01,896
OF OUR TECHNOLOGIES ARE

2470
01:21:01,896 --> 01:21:03,865
ATTENTIVE TO, AND IT'S THE

2471
01:21:03,865 --> 01:21:06,401
DEMOGRAPHICS OF OUR FIELD.

2472
01:21:06,401 --> 01:21:07,735
SO I REFERRED TO THE ENORMOUS

2473
01:21:07,735 --> 01:21:08,936
GROWTH OF BIOENGINEERING

2474
01:21:08,936 --> 01:21:09,237
DEPARTMENTS.

2475
01:21:09,237 --> 01:21:14,375
THE BIGGEST GROWTH DRIVER WITHIN

2476
01:21:14,375 --> 01:21:17,545
THAT EXPANSION, JUST IN TERMS OF

2477
01:21:17,545 --> 01:21:18,780
PEOPLE, ARE WOMEN ENGINEERS.

2478
01:21:18,780 --> 01:21:24,085
SO WE SEE COMPARING TWO TIME

2479
01:21:24,085 --> 01:21:25,453
POINTS, 2005 TO 2022, THE DATA

2480
01:21:25,453 --> 01:21:27,855
HERE IS THE PERCENTAGE OF

2481
01:21:27,855 --> 01:21:28,489
ENGINEERING DEGREES AWARDED TO

2482
01:21:28,489 --> 01:21:31,793
WOMEN.

2483
01:21:31,793 --> 01:21:35,096
IN 2005, 42% OF UNDERGRADS IN

2484
01:21:35,096 --> 01:21:36,764
BIOENGINEERING WERE WOMEN.

2485
01:21:36,764 --> 01:21:39,367
THIS IS THE HIGHEST PERCENTAGE

2486
01:21:39,367 --> 01:21:41,602
ACROSS ALL THE MAJOR ENGINEERING

2487
01:21:41,602 --> 01:21:43,338
DEPARTMENTS, CIVIL,

2488
01:21:43,338 --> 01:21:44,105
ENVIRONMENTAL, CHEMICAL,

2489
01:21:44,105 --> 01:21:45,440
MECHANICAL, ELECTRICAL AND

2490
01:21:45,440 --> 01:21:46,741
COMPUTER, REALLY PRETTY

2491
01:21:46,741 --> 01:21:47,942
SIGNIFICANT.

2492
01:21:47,942 --> 01:21:53,548
BUT IN 2022, THIS GREW NEARLY

2493
01:21:53,548 --> 01:21:55,416
FOUR FOLD IN TOTAL, BACHELOR'S,

2494
01:21:55,416 --> 01:21:56,284
MASTERS AND PH.D.

2495
01:21:56,284 --> 01:21:59,554
IN FACT, THE PH.D. POPULATION

2496
01:21:59,554 --> 01:22:02,457
GROWTH WAS ASTOUNDING, GOING

2497
01:22:02,457 --> 01:22:07,595
FROM 2005, NI 98 DOCTORAL, PH.Ds

2498
01:22:07,595 --> 01:22:08,696
AWARD IN THE COUNTRY.

2499
01:22:08,696 --> 01:22:11,632
IN 2022, THERE WERE 498.

2500
01:22:11,632 --> 01:22:13,501
SO THIS IS A REALLY PRETTY

2501
01:22:13,501 --> 01:22:15,269
IMPRESSIVE GROWTH THAT

2502
01:22:15,269 --> 01:22:18,439
CONSTITUTED ABOUT 44% WOMEN IN

2503
01:22:18,439 --> 01:22:22,610
PH.D. PROGRAMS AND GETTING

2504
01:22:22,610 --> 01:22:24,011
PH.D. DEGREE FS BIOMEDICAL, AND

2505
01:22:24,011 --> 01:22:26,781
OVER HALF OF UNDERGRADS ARE

2506
01:22:26,781 --> 01:22:31,486
WOMEN IN 2022, AND THIS IS MORE

2507
01:22:31,486 --> 01:22:33,554
OR LESS, ONCE THE COMMUNITY HIT

2508
01:22:33,554 --> 01:22:36,758
THAT 50% OR SO, IT'S HOVERING AT

2509
01:22:36,758 --> 01:22:39,060
50 AND IN SOME CASES EVEN GOING

2510
01:22:39,060 --> 01:22:40,061
A LITTLE BIT HIGHER.

2511
01:22:40,061 --> 01:22:44,866
SO I THINK THIS IS A VERY STABLE

2512
01:22:44,866 --> 01:22:45,533
POINT IN THE GROWTH AND

2513
01:22:45,533 --> 01:22:46,834
EVOLUTION OF BIOMEDICAL

2514
01:22:46,834 --> 01:22:47,602
ENGINEERING.

2515
01:22:47,602 --> 01:22:48,603
NOT ONLY HAS THERE BEEN AN

2516
01:22:48,603 --> 01:22:49,670
INKREAS IN THE FRACTIONAL

2517
01:22:49,670 --> 01:22:50,471
PERCENTAGE OF WOMEN IN ALL OF

2518
01:22:50,471 --> 01:22:53,875
THESE PROGRAMS, BUT IN TERMS OF

2519
01:22:53,875 --> 01:22:55,042
ABSOLUTE GROWTH IN TOTAL

2520
01:22:55,042 --> 01:22:56,844
NUMBERS, IT'S REALLY BEEN PRETTY

2521
01:22:56,844 --> 01:22:57,478
SPECTACULAR.

2522
01:22:57,478 --> 01:22:59,814
AND IF YOU COMPARE BIOMEDICAL

2523
01:22:59,814 --> 01:23:02,984
ENGINEERING, A FOUR-FOLD

2524
01:23:02,984 --> 01:23:05,286
INCREASE IN THE NUMBER OF WOMEN

2525
01:23:05,286 --> 01:23:06,487
THAT ARE IN THESE PROGRAMS, THIS

2526
01:23:06,487 --> 01:23:09,757
IS COMPARED TO OTHER

2527
01:23:09,757 --> 01:23:11,426
DEPARTMENTS, WHICH IS ONLY ABOUT

2528
01:23:11,426 --> 01:23:11,993
A 1.8 FOLD.

2529
01:23:11,993 --> 01:23:18,733
SO THE GROWTH RATE IS A FOK TORR

2530
01:23:18,733 --> 01:23:19,567
OF 2 HIGHER.

2531
01:23:19,567 --> 01:23:20,468
SO WITH ALL OF THOSE DEPARTMENTS

2532
01:23:20,468 --> 01:23:21,502
THAT ARE FORMING, THEY'RE

2533
01:23:21,502 --> 01:23:23,037
FORMING WITH AN INFLUX OF WOMEN

2534
01:23:23,037 --> 01:23:24,472
WHO ARE DRIVING AND DIVERSIFYING

2535
01:23:24,472 --> 01:23:27,708
SCHOOLS OF ENGINEERING, AND

2536
01:23:27,708 --> 01:23:29,177
THAT'S ACTUALLY INSPIRING

2537
01:23:29,177 --> 01:23:33,514
CHANGES IN OTHER DEPARTMENTS AS

2538
01:23:33,514 --> 01:23:36,951
PEOPLE SEE THE EXPANSION OF

2539
01:23:36,951 --> 01:23:38,586
OPPORTUNITIES IN HEALTH RELATED

2540
01:23:38,586 --> 01:23:39,687
AND ALTRUISTIC APPROACHES THAT

2541
01:23:39,687 --> 01:23:41,689
ARE EXPANDING ELECTRICAL

2542
01:23:41,689 --> 01:23:42,857
ENGINEERING, MECHANICAL

2543
01:23:42,857 --> 01:23:43,524
ENGINEERING AND THE OTHER

2544
01:23:43,524 --> 01:23:44,392
DEPARTMENTS AS WELL.

2545
01:23:44,392 --> 01:23:48,796
IN TERMS OF FACULTY, WE SEE

2546
01:23:48,796 --> 01:23:51,566
GOING FROM 2005 TO 2022, THERE'S

2547
01:23:51,566 --> 01:23:55,369
A 3.4 FOLD INCREASE IN WOMEN IN

2548
01:23:55,369 --> 01:23:57,472
FACULTY IN BIOENGINEERING.

2549
01:23:57,472 --> 01:23:59,106
ALL OF THE OTHER DEPARTMENTS ARE

2550
01:23:59,106 --> 01:24:02,109
A TWOFOLD 1.9X.

2551
01:24:02,109 --> 01:24:03,077
YOU CAN SEE BIOMEDICAL

2552
01:24:03,077 --> 01:24:05,146
ENGINEERING IN 2022 SNAPSHOT

2553
01:24:05,146 --> 01:24:06,481
HERE, 28% WOMEN.

2554
01:24:06,481 --> 01:24:09,016
STILL MORE TO DO TO INCREASE

2555
01:24:09,016 --> 01:24:10,651
THAT FRACTION, BUT STILL LEADING

2556
01:24:10,651 --> 01:24:15,256
AS COMPARED TO OTHER

2557
01:24:15,256 --> 01:24:16,624
DEPARTMENTS, AND IN TERMS OF OUR

2558
01:24:16,624 --> 01:24:18,392
POOL, IN TERMS OF THE SOURCE OF

2559
01:24:18,392 --> 01:24:19,927
STUDENTS, BOTH UNDERGRADUATES

2560
01:24:19,927 --> 01:24:21,796
AND PH.D. STUDENTS, THERE'S AN

2561
01:24:21,796 --> 01:24:24,665
OPPORTUNITY TO BE ABLE TO REALLY

2562
01:24:24,665 --> 01:24:28,703
ACCELERATE THAT 28%.

2563
01:24:28,703 --> 01:24:31,105
SO NOWHERE HAS THIS BEEN BETTER

2564
01:24:31,105 --> 01:24:32,440
ILLUSTRATED, THIS

2565
01:24:32,440 --> 01:24:35,510
TRANSFORMATION, IN STUDENTS AND

2566
01:24:35,510 --> 01:24:38,479
IN FACULTY THAN IN OUR DEBUT

2567
01:24:38,479 --> 01:24:40,448
CHALLENGE DESIGNED BY BIOMEDICAL

2568
01:24:40,448 --> 01:24:40,915
UNDERGRADUATE TEAMS.

2569
01:24:40,915 --> 01:24:42,216
THIS IS KIND OF THE SECRET

2570
01:24:42,216 --> 01:24:43,084
WEAPON OF OUR FIELD.

2571
01:24:43,084 --> 01:24:45,753
IN MANY WAYS, PROJECTS THAT

2572
01:24:45,753 --> 01:24:48,055
UNDERGRADUATES ARE DOING IN

2573
01:24:48,055 --> 01:24:49,257
EVERY SCHOOL OF ENGINEERING HAS

2574
01:24:49,257 --> 01:24:50,224
THESE DESIGN PROJECTS.

2575
01:24:50,224 --> 01:24:52,126
THOSE PROJECTS ARE QUITE SIMILAR

2576
01:24:52,126 --> 01:24:54,095
TO WHAT YOU MIGHT THINK OF AS A

2577
01:24:54,095 --> 01:24:56,597
PH.D. PROJECT FROM 10 YEARS AGO.

2578
01:24:56,597 --> 01:24:58,599
IT'S QUITE ASTOUNDING, WHAT

2579
01:24:58,599 --> 01:24:59,667
UNDERGRADUATE STUDENTS ARE GOING

2580
01:24:59,667 --> 01:25:01,102
TO DO -- ARE DOING, AND I'M

2581
01:25:01,102 --> 01:25:02,537
GOING TO SHOW YOU A VIDEO OF ONE

2582
01:25:02,537 --> 01:25:06,274
OF THEM IN JUST A SECOND.

2583
01:25:06,274 --> 01:25:10,311
BUT WE CURRENTLY HAVE A PURSE OF

2584
01:25:10,311 --> 01:25:11,679
$160,000, WHICH I'M PROUD TO SAY

2585
01:25:11,679 --> 01:25:14,815
IS INCREASING TO $190,000

2586
01:25:14,815 --> 01:25:16,684
THROUGH THE PARTICIPATION OF

2587
01:25:16,684 --> 01:25:17,885
ORWH IN THIS PROGRAM.

2588
01:25:17,885 --> 01:25:19,887
SO THAT'S A REALLY -- THIS IS

2589
01:25:19,887 --> 01:25:21,322
THE FIRST ANNOUNCEMENT OF THAT.

2590
01:25:21,322 --> 01:25:23,391
I THINK IT JUST MADE IT IN

2591
01:25:23,391 --> 01:25:27,562
PUBLIC DISCLOSURE, SO OUR TWO

2592
01:25:27,562 --> 01:25:32,266
NEW SPONSORS ARE ORWH AND NIA.

2593
01:25:32,266 --> 01:25:33,601
IN 2024, JUST TO GIVE YOU A

2594
01:25:33,601 --> 01:25:34,702
SENSE OF THE EXTENT OF

2595
01:25:34,702 --> 01:25:38,339
ENGAGEMENT, WE HAD OVER 350 --

2596
01:25:38,339 --> 01:25:40,074
362 STUDENTS FROM 48

2597
01:25:40,074 --> 01:25:41,309
UNIVERSITIES AND 24 STATES

2598
01:25:41,309 --> 01:25:42,076
PARTICIPATING IN THIS.

2599
01:25:42,076 --> 01:25:43,711
IT REALLY CAPTURES THE ENERGY

2600
01:25:43,711 --> 01:25:47,882
AND THE SPIRIT OF WHAT OUR

2601
01:25:47,882 --> 01:25:49,216
UNDERGRADUATE DESIGN TEAMS, OUR

2602
01:25:49,216 --> 01:25:49,984
UNDERGRADUATE PROGRAMS HAVE

2603
01:25:49,984 --> 01:25:56,524
PASSION FOR.

2604
01:25:56,524 --> 01:25:57,625
AND ONE OF THE SORT OF GREAT

2605
01:25:57,625 --> 01:26:02,330
REINS WHY ORWH CAN SUPPORT THIS

2606
01:26:02,330 --> 01:26:03,564
WITH A PRIZE IS BECAUSE WE HAVE

2607
01:26:03,564 --> 01:26:06,400
A LONG HISTORY OF IMPORTANT

2608
01:26:06,400 --> 01:26:07,501
TECHNICAL PROJECTS THAT ARE

2609
01:26:07,501 --> 01:26:10,137
DRIVEN BY UNDERGRADUATE STUDENTS

2610
01:26:10,137 --> 01:26:13,207
CONCEIVED OF AND CONTINUE TO BE

2611
01:26:13,207 --> 01:26:14,508
PUSHED BY THESE STUDENTS, MANY

2612
01:26:14,508 --> 01:26:15,743
OF THEM ARE WORKING ON

2613
01:26:15,743 --> 01:26:17,278
COMMERCIALIZATION WITH CONTINUED

2614
01:26:17,278 --> 01:26:21,983
SUPPORT FROM NIBIB AND FROM THAT

2615
01:26:21,983 --> 01:26:22,783
SEED OFFICE.

2616
01:26:22,783 --> 01:26:25,620
SO HERE AN EXAMPLE, A SNAPSHOT

2617
01:26:25,620 --> 01:26:26,821
OF SOME OF THE REALLY COOL

2618
01:26:26,821 --> 01:26:27,922
PROJECTS THAT UNDERGRADUATE

2619
01:26:27,922 --> 01:26:32,226
TEAMS HAVE BEEN DOING, FROM

2620
01:26:32,226 --> 01:26:33,761
WORKING ON A

2621
01:26:33,761 --> 01:26:37,031
SELF-CATHETERIZATION DEVICE,

2622
01:26:37,031 --> 01:26:38,933
REDESIGNING A SPECULUM, WHICH I

2623
01:26:38,933 --> 01:26:41,435
DIDN'T REALIZE UNTIL I SAW THIS

2624
01:26:41,435 --> 01:26:43,638
DEBUT AWARD THAT THE CURRENT

2625
01:26:43,638 --> 01:26:46,507
SPECULUM DESIGNS ARE EXACTLY THE

2626
01:26:46,507 --> 01:26:49,677
SAME AS 200 YEARS AGO.

2627
01:26:49,677 --> 01:26:51,412
SO THIS IS THE FIRST REDESIGN

2628
01:26:51,412 --> 01:26:52,813
FROM A MECHANICAL ENGINEERING

2629
01:26:52,813 --> 01:26:55,049
POINT OF VIEW OF A SPECULUM.

2630
01:26:55,049 --> 01:26:56,917
THIS TEAM IS WORKING ON

2631
01:26:56,917 --> 01:26:58,319
COMMERCIALIZATION OF THAT DEVICE

2632
01:26:58,319 --> 01:27:00,855
AND HAS SIGNIFICANT DI SUPPORT.

2633
01:27:00,855 --> 01:27:02,957
MANY PEOPLE HAVE BEEN DISCUSSING

2634
01:27:02,957 --> 01:27:07,128
BEING ABLE TO CAPTURE MENSTRUAL

2635
01:27:07,128 --> 01:27:08,663
EFFLUENT IN PADS THAT CAN BE

2636
01:27:08,663 --> 01:27:09,897
TAKEN FOR FURTHER ANALYSIS.

2637
01:27:09,897 --> 01:27:11,098
WELL, UNDERGRADUATE DESIGN TEAMS

2638
01:27:11,098 --> 01:27:13,534
ARE ON THIS, IN 2023, ONE OF THE

2639
01:27:13,534 --> 01:27:15,936
MAJOR AWARD WINNERS WAS IN THAT

2640
01:27:15,936 --> 01:27:17,805
AREA, AND IT'S MOVING TOWARDS A

2641
01:27:17,805 --> 01:27:19,907
PATH OF COMMERCIALIZATION.

2642
01:27:19,907 --> 01:27:22,643
SO A NUMBER OF REALLY BEAUTIFUL

2643
01:27:22,643 --> 01:27:25,379
INNOVATIVE AND MUCH NEEDED

2644
01:27:25,379 --> 01:27:26,280
TECHNOLOGIES, OUR STUDENTS ARE

2645
01:27:26,280 --> 01:27:28,249
GOING OUT, TALKING TO EXPERTS,

2646
01:27:28,249 --> 01:27:30,351
FIGURING OUT WHAT THE NEED IS,

2647
01:27:30,351 --> 01:27:32,753
AND COMING BACK WITH THE

2648
01:27:32,753 --> 01:27:34,622
CREATION OF ENTIRELY NEW

2649
01:27:34,622 --> 01:27:36,057
INVENTIONS AND DEVICES THAT ARE

2650
01:27:36,057 --> 01:27:38,592
POTENTIALLY GOING TO CHANGE THE

2651
01:27:38,592 --> 01:27:40,995
LANDSCAPE, BUT CERTAINLY

2652
01:27:40,995 --> 01:27:42,096
CHANGING THE WAY THAT THEY THINK

2653
01:27:42,096 --> 01:27:43,831
ABOUT WOMEN'S HEALTH

2654
01:27:43,831 --> 01:27:44,298
TECHNOLOGIES.

2655
01:27:44,298 --> 01:27:46,934
AS YOU KNOW, UNDERGRADUATES GET

2656
01:27:46,934 --> 01:27:48,569
THESE BEES IN THEIR BONNET, IT'S

2657
01:27:48,569 --> 01:27:50,004
KIND OF LIKE A BUG, IT GETS IN

2658
01:27:50,004 --> 01:27:51,472
THEIR HEAD, AND THEY OBSESS OVER

2659
01:27:51,472 --> 01:27:52,873
THAT FOR THE REST OF THEIR LIVES

2660
01:27:52,873 --> 01:27:54,075
AND CAREERS.

2661
01:27:54,075 --> 01:27:57,378
SO THIS IS CHANGING HOW PEOPLE

2662
01:27:57,378 --> 01:27:58,345
THINK ABOUT TECHNOLOGIES AND

2663
01:27:58,345 --> 01:28:01,982
WHERE THEY CAN GO.

2664
01:28:01,982 --> 01:28:06,387
IN 2024, WE HAD TWO IMPORTANT

2665
01:28:06,387 --> 01:28:07,621
PRIZE WINNERS IN WOMEN'S HEALTH,

2666
01:28:07,621 --> 01:28:12,293
AND IF I CAN RUN THIS VIDEO, SO

2667
01:28:12,293 --> 01:28:16,997
IT'S THE TOP ONE.

2668
01:28:16,997 --> 01:28:17,665
THAT WOULD BE GREAT.

2669
01:28:17,665 --> 01:28:21,969
I THINK YOU NEED TO HAVE --

2670
01:28:21,969 --> 01:28:23,337
GOOD.

2671
01:28:23,337 --> 01:28:28,743
BEAUTIFUL.

2672
01:28:28,743 --> 01:28:29,510
OKAY.

2673
01:28:29,510 --> 01:28:36,083
WHERE WAS IT?

2674
01:28:36,083 --> 01:28:37,785
SO THIS IS THE DESIGN TEAM

2675
01:28:37,785 --> 01:28:38,085
VIDEO.

2676
01:28:38,085 --> 01:28:40,154
>> APPROXIMATELY 140
MILLION

2677
01:28:40,154 --> 01:28:42,389
BABIES ARE BORN EVERY YEAR.

2678
01:28:42,389 --> 01:28:44,158
ABOUT 21% OF THESE BIRTHS ARE BY

2679
01:28:44,158 --> 01:28:44,792
CESAREAN DELIVERY.

2680
01:28:44,792 --> 01:28:46,127
WHEN A WOMAN IS UNDERGOING LABOR

2681
01:28:46,127 --> 01:28:47,895
THE BABY'S HEAD CAN GET STUCK

2682
01:28:47,895 --> 01:28:49,764
EXITING THE MOTHER'S PELVIS.

2683
01:28:49,764 --> 01:28:51,532
THIS COMPLICATION IS KNOWN AS AN

2684
01:28:51,532 --> 01:28:53,634
IMPACTED FETAL HEAD WHICH OCCURS

2685
01:28:53,634 --> 01:28:55,302
IN ABOUT 16% OF SECOND STAGE

2686
01:28:55,302 --> 01:28:55,603
C-SECTIONS.

2687
01:28:55,603 --> 01:28:57,438
THIS IS ESPECIALLY RISKY WHEN IT

2688
01:28:57,438 --> 01:28:59,373
OCCURS IN AN UNPLANNED EMERGENCY

2689
01:28:59,373 --> 01:29:00,274
C-SECTION.

2690
01:29:00,274 --> 01:29:04,612
THE THE PRIMARY CONCERN BECOMES

2691
01:29:04,612 --> 01:29:06,213
SAFELY REMOVING THE FETUS DURING

2692
01:29:06,213 --> 01:29:06,747
THESE PROCEDURES.

2693
01:29:06,747 --> 01:29:08,082
>> THE MOMENT AN INCISION
IS

2694
01:29:08,082 --> 01:29:09,784
MADE INTO THE UTERUS THE BABY'S

2695
01:29:09,784 --> 01:29:11,752
OXYGEN SUPPLY IS PRO ECONOMIZED.

2696
01:29:11,752 --> 01:29:12,720
THIS LEAVES THE MEDICAL TEAM

2697
01:29:12,720 --> 01:29:15,389
WITH A MATTER OF MINUTES BEFORE

2698
01:29:15,389 --> 01:29:18,993
CELL DAMAGE BEGINS AND PREVENT

2699
01:29:18,993 --> 01:29:19,760
IRREVERSIBLE BRAIN DAMAGE.

2700
01:29:19,760 --> 01:29:22,062
>> RESULTING IMPACTED
FETAL

2701
01:29:22,062 --> 01:29:24,298
HEADS REMAINS TWO CHALLENGES FOR

2702
01:29:24,298 --> 01:29:25,065
SURGEONS.

2703
01:29:25,065 --> 01:29:26,033
THE FIRST IS BEING ABLE TO GET

2704
01:29:26,033 --> 01:29:28,135
IN AND REACH THE BACK OF THE

2705
01:29:28,135 --> 01:29:29,436
BABY'S HEAD TIGHTLY IMPACTED IN

2706
01:29:29,436 --> 01:29:31,338
THE PELVIC BONE AND TISSUE AND

2707
01:29:31,338 --> 01:29:32,540
THE SECOND IS GATHERING

2708
01:29:32,540 --> 01:29:35,976
SUFFICIENT FORCE TO NOT HARM THE

2709
01:29:35,976 --> 01:29:37,111
BABY OR THE MOTHER.

2710
01:29:37,111 --> 01:29:38,646
>> THESE ARE EXACERBATED
IN LOW

2711
01:29:38,646 --> 01:29:40,414
AND MIDDLE INCOME AREAS FOR TWO

2712
01:29:40,414 --> 01:29:41,615
REASONS.

2713
01:29:41,615 --> 01:29:45,886
FIRST POOR PRENATAL CARE AND

2714
01:29:45,886 --> 01:29:46,687
SECOND LIMITED STAFFING INTO THE

2715
01:29:46,687 --> 01:29:48,222
VAST MAJORITY OF SURGERIES ARE

2716
01:29:48,222 --> 01:29:50,791
PERFORMED BY A SINGLE NOT A PAIR

2717
01:29:50,791 --> 01:29:53,194
OF PHYSICIANS.

2718
01:29:53,194 --> 01:29:55,930
FURTHER WHILE CURRENT ASSISTIVE

2719
01:29:55,930 --> 01:29:57,398
DEVICES EXIST THEY'RE EXPENSIVE

2720
01:29:57,398 --> 01:29:58,165
AND SINGLE USE.

2721
01:29:58,165 --> 01:30:00,034
THIS CREATES A LOW COST REUSABLE

2722
01:30:00,034 --> 01:30:01,569
DEVICE THAT CAN BE USED BY A

2723
01:30:01,569 --> 01:30:02,469
SINGLE PHYSICIAN.

2724
01:30:02,469 --> 01:30:03,270
>> OVER THE PAST NINE
MONTHS, WE

2725
01:30:03,270 --> 01:30:06,540
HAVE WORKED WITH U.S.-BASED

2726
01:30:06,540 --> 01:30:07,808
OB-GYN SPECIALISTS TO DEVELOP

2727
01:30:07,808 --> 01:30:09,210
THE CESAREAN DELIVERY GLOVE.

2728
01:30:09,210 --> 01:30:11,078
THE CDG HAS THREE MAIN FEATURES.

2729
01:30:11,078 --> 01:30:12,646
A HAND POCKET, A LEADING EDGE,

2730
01:30:12,646 --> 01:30:14,748
AND A SLING COMPONENT.

2731
01:30:14,748 --> 01:30:17,051
WE HAVE A HAND POCKET FOR THE

2732
01:30:17,051 --> 01:30:18,219
DOMINANT HAND FOR THE PHYSICIAN

2733
01:30:18,219 --> 01:30:21,455
WITH ONLY A 0.75 MILLIMETERS OF

2734
01:30:21,455 --> 01:30:22,756
SILICONE ON THE PALMAR SIDE

2735
01:30:22,756 --> 01:30:25,426
WHICH MAINTAINS THE TACTILE

2736
01:30:25,426 --> 01:30:27,962
SENSITIVITY DESIRED BY SURGEONS.

2737
01:30:27,962 --> 01:30:29,830
EXTENDING BEYOND THE FINGERTIPS,

2738
01:30:29,830 --> 01:30:31,232
THIS STIFFENED LEADING EDGE CAN

2739
01:30:31,232 --> 01:30:33,367
BE DIRECTED THROUGH THE

2740
01:30:33,367 --> 01:30:34,335
CONSTRICTED SPACE BETWEEN THE

2741
01:30:34,335 --> 01:30:35,803
IMPACTED HEAD AND UTERINE WALL.

2742
01:30:35,803 --> 01:30:37,137
THIS ALLOWS FOR THE DOCTOR TO

2743
01:30:37,137 --> 01:30:38,539
REACH BEHIND THE BABY'S HEAD.

2744
01:30:38,539 --> 01:30:39,974
FINALLY, THE NON-DOMINANT HAND

2745
01:30:39,974 --> 01:30:41,575
OF THE PHYSICIAN UTILIZES THE

2746
01:30:41,575 --> 01:30:42,877
SLING STRAPS TO NAVIGATE THE

2747
01:30:42,877 --> 01:30:44,712
HAMMOCK AND FACILITATES THE SAFE

2748
01:30:44,712 --> 01:30:46,180
EXTRACTION OF THE BABY.

2749
01:30:46,180 --> 01:30:47,748
>> HERE IS A SURGEON

2750
01:30:47,748 --> 01:30:48,816
DEMONSTRATING THE USE OF OUR

2751
01:30:48,816 --> 01:30:50,384
DEVICE IN A HIGH FIDELITY

2752
01:30:50,384 --> 01:30:51,018
SIMULATION.

2753
01:30:51,018 --> 01:30:52,753
YOU CAN SEE THE SURGEON AS SHE

2754
01:30:52,753 --> 01:30:53,821
INSERTS HER HAPPENED INTO THE

2755
01:30:53,821 --> 01:30:55,689
DEVICE AND THEN INSERTS THE

2756
01:30:55,689 --> 01:30:57,324
DEVICE THROUGH THE UTERINE

2757
01:30:57,324 --> 01:30:58,025
INCISION.

2758
01:30:58,025 --> 01:30:59,293
AS SHE PUSHES HER HAND DEEP IN

2759
01:30:59,293 --> 01:31:02,096
THE BODY, THE BODY CON TORTS TO

2760
01:31:02,096 --> 01:31:03,697
COVER THE BABY'S HEAD AND ALLOWS

2761
01:31:03,697 --> 01:31:04,899
THE DEVICE TO GET FURTHER THAN

2762
01:31:04,899 --> 01:31:05,666
WHERE THE HAND CAN REACH.

2763
01:31:05,666 --> 01:31:09,169
ONE THE DEVICE IS SUFFICIENTLY

2764
01:31:09,169 --> 01:31:10,938
DEEP SHE UTILIZES THE STRAPS

2765
01:31:10,938 --> 01:31:12,339
THAT CONFORM TO CRADLE THE FETAL

2766
01:31:12,339 --> 01:31:12,573
HEAD.

2767
01:31:12,573 --> 01:31:17,111
THIS ENSURES THE, TRACKS FORCES

2768
01:31:17,111 --> 01:31:18,445
ARE EVENLY DISTRIBUTED OIFER THE

2769
01:31:18,445 --> 01:31:19,280
SOFT FETAL HEAD.

2770
01:31:19,280 --> 01:31:24,919
>> APR WE OBSERVED
MULTIPLE

2771
01:31:24,919 --> 01:31:26,553
C-SECTIONS, INTRODUCED THE

2772
01:31:26,553 --> 01:31:27,755
CESAREAN DELIVERY GLOVE AND

2773
01:31:27,755 --> 01:31:28,923
GAINED VALUABLE INSIGHTS OF THE

2774
01:31:28,923 --> 01:31:29,990
EXPECTED USE ENVIRONMENT AS WELL

2775
01:31:29,990 --> 01:31:31,525
AS HIGHLY POSITIVE FEEDBACK FROM

2776
01:31:31,525 --> 01:31:32,092
LIKELY USERS.

2777
01:31:32,092 --> 01:31:34,328
>> WE WOULD LIKE TO THANK
OUR

2778
01:31:34,328 --> 01:31:36,764
TEAM, ADVISORS AND EVERYONE FOR

2779
01:31:36,764 --> 01:31:37,398
THEIR SUPPORT.

2780
01:31:37,398 --> 01:31:39,033
OUR PROGRESS TO DATE WOULD NOT

2781
01:31:39,033 --> 01:31:40,567
BE POSSIBLE WITHOUT THEM.

2782
01:31:40,567 --> 01:31:41,869
>> THANK YOU.

2783
01:31:41,869 --> 01:31:49,310
WE CAN GO BACK TO THE SLIDES.

2784
01:31:49,310 --> 01:31:51,745
SO IT'S ASTOUNDING, IF YOU'RE

2785
01:31:51,745 --> 01:31:52,746
EVER PESSIMISTIC ABOUT THE

2786
01:31:52,746 --> 01:31:54,281
WORLD, GO TO OUR WEBSITE AND

2787
01:31:54,281 --> 01:31:56,116
LOOK AT THESE VIDEOS FROM

2788
01:31:56,116 --> 01:31:58,152
UNDERGRADUATE STUDENTS WHO ARE

2789
01:31:58,152 --> 01:31:59,219
WORKING ON THESE DESIGN

2790
01:31:59,219 --> 01:32:00,120
PROJECTS.

2791
01:32:00,120 --> 01:32:01,922
NOW INCREASINGLY DESIGNED -- IN

2792
01:32:01,922 --> 01:32:03,524
THE OLD DAYS, IT WAS JUST A YEAR

2793
01:32:03,524 --> 01:32:04,725
FOR DESIGN, AND MANY

2794
01:32:04,725 --> 01:32:05,693
UNIVERSITIES ARE REALLY PUSHING

2795
01:32:05,693 --> 01:32:06,460
THAT BACK.

2796
01:32:06,460 --> 01:32:08,395
AND YOU CAN BEGIN TO PICK A

2797
01:32:08,395 --> 01:32:09,596
DESIGN PROJECT IN YOUR FRESHMAN

2798
01:32:09,596 --> 01:32:11,332
OR SOFT MORE YEAR.

2799
01:32:11,332 --> 01:32:12,533
AND STICK WITH IT THROUGH

2800
01:32:12,533 --> 01:32:13,767
MULTIPLE YEARS.

2801
01:32:13,767 --> 01:32:16,403
MANY OF THESE STUDENTS GO ON AND

2802
01:32:16,403 --> 01:32:18,038
TAKE FURTHER COMMERCIALIZATION

2803
01:32:18,038 --> 01:32:21,642
KINDS OF COURSES THAT WE AND THE

2804
01:32:21,642 --> 01:32:22,876
SEED PROGRAM SUPPORT SO WE'VE

2805
01:32:22,876 --> 01:32:23,877
HAD SEVERAL STUDENTS GO THROUGH

2806
01:32:23,877 --> 01:32:24,411
THAT.

2807
01:32:24,411 --> 01:32:27,481
AND YOU KNOW, IT'S VERY

2808
01:32:27,481 --> 01:32:29,249
INSPIRING, AND IT'S A POWERFUL

2809
01:32:29,249 --> 01:32:31,552
DRIVING FORCE BEHIND TECHNOLOGY

2810
01:32:31,552 --> 01:32:35,389
DEVELOPMENT IN OUR FIELD.

2811
01:32:35,389 --> 01:32:36,790
ANOTHER MAJOR SIGNATURE PROGRAM

2812
01:32:36,790 --> 01:32:38,292
THAT WE SUPPORT ARE POINT OF

2813
01:32:38,292 --> 01:32:39,360
CARE TECHNOLOGIES.

2814
01:32:39,360 --> 01:32:42,096
AND THIS ENTIRE U54 NETWORK

2815
01:32:42,096 --> 01:32:43,864
CALLED THE POINT OF CARE

2816
01:32:43,864 --> 01:32:46,000
TECHNOLOGIES RESEARCH NETWORK,

2817
01:32:46,000 --> 01:32:46,967
MULTIPLE UNIVERSITIES ARE

2818
01:32:46,967 --> 01:32:49,136
SUPPORTED THROUGH THIS FOR POINT

2819
01:32:49,136 --> 01:32:50,471
OF CARE TECHNOLOGIES, AND WE

2820
01:32:50,471 --> 01:32:52,806
ALSO HAVE SUPPORT FROM MULTIPLE

2821
01:32:52,806 --> 01:32:54,575
INSTITUTES AND CENTERS THAT ARE

2822
01:32:54,575 --> 01:32:57,845
CONTRIBUTING TO THE MISSION OF

2823
01:32:57,845 --> 01:32:58,612
THE NETWORK.

2824
01:32:58,612 --> 01:33:02,916
MOST NOTABLY, THE NETWORK IN

2825
01:33:02,916 --> 01:33:04,451
2020 TURNED OUT TO BE THE

2826
01:33:04,451 --> 01:33:05,119
FOUNDATIONAL STRUCTURE UPON

2827
01:33:05,119 --> 01:33:07,021
WHICH WE COULD BUILD THE RAPID

2828
01:33:07,021 --> 01:33:13,360
ACCELERATION OF DIKE NOS  DIAGNR

2829
01:33:13,360 --> 01:33:15,596
TEXT RADX PROGRAM WHERE WE WERE

2830
01:33:15,596 --> 01:33:17,364
ABLE TO TAKE ALL THE RESEARCH

2831
01:33:17,364 --> 01:33:18,966
GOING ON IN THE NETWORK AND THIS

2832
01:33:18,966 --> 01:33:20,067
URGENT AND CRITICAL TIME AND

2833
01:33:20,067 --> 01:33:21,869
SHIFT IT, WE ASKED ALL THE

2834
01:33:21,869 --> 01:33:23,604
UNIVERSITIES, THE PRINCIPAL

2835
01:33:23,604 --> 01:33:24,271
INVESTIGATORS, THE EXTERNAL

2836
01:33:24,271 --> 01:33:26,173
ADVISORY BOARD, CAN WE SUPPORT

2837
01:33:26,173 --> 01:33:27,508
THE DEVELOPMENT OF COVID-19

2838
01:33:27,508 --> 01:33:29,343
TESTING TECHNOLOGIES, WHICH WERE

2839
01:33:29,343 --> 01:33:30,944
DETERMINED AND PERCEIVED TO BE

2840
01:33:30,944 --> 01:33:35,149
REALLY INSUFFICIENT IN APRIL OF

2841
01:33:35,149 --> 01:33:35,549
2020.

2842
01:33:35,549 --> 01:33:37,084
AND THE NETWORK PIVOTED

2843
01:33:37,084 --> 01:33:37,518
ENTIRELY.

2844
01:33:37,518 --> 01:33:40,087
WE CREATED NEW STRUCTURES, AND

2845
01:33:40,087 --> 01:33:41,188
WE BUILT ALL OF THIS AROUND WHAT

2846
01:33:41,188 --> 01:33:44,024
WE CALL AN INNOVATION FUNNEL.

2847
01:33:44,024 --> 01:33:48,228
A WAY TO EASILY PROPOSE IDEAS,

2848
01:33:48,228 --> 01:33:49,530
QUICKLY EVALUATE THEM, AND MOVE

2849
01:33:49,530 --> 01:33:53,934
THEM THROUGH IN MULTIPLE STAGES

2850
01:33:53,934 --> 01:33:56,370
TO SUPPORT SO THAT ULTIMATELY

2851
01:33:56,370 --> 01:33:57,337
AND OUR GOALS WITHIN THIS

2852
01:33:57,337 --> 01:33:58,439
PROGRAM WERE NOT JUST TO DEVELOP

2853
01:33:58,439 --> 01:34:01,442
A TECHNOLOGY OR DEMONSTRATE A

2854
01:34:01,442 --> 01:34:01,842
PROTOTYPE WORKS.

2855
01:34:01,842 --> 01:34:03,644
IT WAS TO GO ALL THE WAY TO

2856
01:34:03,644 --> 01:34:04,311
MANUFACTURING.

2857
01:34:04,311 --> 01:34:06,213
WE HAD WELL OVER A THOUSAND

2858
01:34:06,213 --> 01:34:07,414
APPLICATIONS COMING INTO OUR

2859
01:34:07,414 --> 01:34:08,082
INNOVATION FUNNEL.

2860
01:34:08,082 --> 01:34:10,384
BECAUSE OF THE NATURE OF THE

2861
01:34:10,384 --> 01:34:11,452
URGENCY OF THE DEVELOPMENT OF

2862
01:34:11,452 --> 01:34:14,822
THE TECHNOLOGIES, VERY SMALL

2863
01:34:14,822 --> 01:34:15,689
FRACTION ACTUALLY MADE IT

2864
01:34:15,689 --> 01:34:18,325
THROUGH, BUT IF YOU DID ANY HOME

2865
01:34:18,325 --> 01:34:19,893
TESTING, ANY POINT-OF-CARE

2866
01:34:19,893 --> 01:34:22,062
TESTING, VIRTUALLY -- WELL, MANY

2867
01:34:22,062 --> 01:34:26,233
OF THEM CAME THROUGH THE RADX

2868
01:34:26,233 --> 01:34:28,335
PROCESS AND RESULTED IN A VERY

2869
01:34:28,335 --> 01:34:30,003
SIGNIFICANT PARADIGM SHIFT IN

2870
01:34:30,003 --> 01:34:31,305
HOW TESTING TECHNOLOGIES WERE

2871
01:34:31,305 --> 01:34:31,638
DONE.

2872
01:34:31,638 --> 01:34:33,373
ALONG THE WAY, WE STARTED WITH

2873
01:34:33,373 --> 01:34:35,642
AN INNOVATION FUNNEL, BUT WE

2874
01:34:35,642 --> 01:34:37,277
REALIZED THAT THE PROBLEM WASN'T

2875
01:34:37,277 --> 01:34:39,046
NECESSARILY TECH LOGIC, IT WAS

2876
01:34:39,046 --> 01:34:39,746
ALSO CULTURAL.

2877
01:34:39,746 --> 01:34:41,582
SO WE HAD TO CREATE OTHER TYPES

2878
01:34:41,582 --> 01:34:46,086
OF PROGRAMS, DIGITAL HEALTH

2879
01:34:46,086 --> 01:34:47,221
PLATFORM, A WAY TO TEST WHETHER

2880
01:34:47,221 --> 01:34:49,089
OVER THE COUNTER TESTS WOULD BE

2881
01:34:49,089 --> 01:34:50,157
USED BY PEOPLE AT ALL.

2882
01:34:50,157 --> 01:34:53,260
PRIOR TO THIS, PREGNANCY TESTS

2883
01:34:53,260 --> 01:34:55,796
AT 8 MILLION PER YEAR WERE THE

2884
01:34:55,796 --> 01:34:56,663
NUMBER ONE HOME TESTING

2885
01:34:56,663 --> 01:34:58,732
TECHNOLOGY.

2886
01:34:58,732 --> 01:35:00,134
IN FEBRUARY OF 2022, WE

2887
01:35:00,134 --> 01:35:01,301
DISTRIBUTED A BILLION TESTS

2888
01:35:01,301 --> 01:35:03,937
ALONE TO PEOPLE IN THEIR HOMES.

2889
01:35:03,937 --> 01:35:05,172
2 1/2 BILLION IN THAT ENTIRE

2890
01:35:05,172 --> 01:35:08,041
YEAR IN RESPONSE TO THE OMICRON

2891
01:35:08,041 --> 01:35:08,342
SURGE.

2892
01:35:08,342 --> 01:35:10,210
WE HAD TO DEVELOP A NEW WAY TO

2893
01:35:10,210 --> 01:35:12,446
ADDRESS TEST PERFORMANCE WITH

2894
01:35:12,446 --> 01:35:12,779
VARIANTS.

2895
01:35:12,779 --> 01:35:15,716
WE HAD TO WORK WITH THE FDA

2896
01:35:15,716 --> 01:35:17,751
BECAUSE AS YOU KNOW, IF IT'S NOT

2897
01:35:17,751 --> 01:35:18,719
AUTHORIZED BY THE FDA, A

2898
01:35:18,719 --> 01:35:20,087
BEAUTIFUL TECHNOLOGY WILL NEVER

2899
01:35:20,087 --> 01:35:21,455
EMERGE TO SEE THE LIGHT OF DAY.

2900
01:35:21,455 --> 01:35:23,824
SO WE CREATED SOME VERY UNIQUE

2901
01:35:23,824 --> 01:35:26,093
PATHWAYS WE CALL THE INDEPENDENT

2902
01:35:26,093 --> 01:35:27,961
TEST ASSESSMENT PROGRAM TO

2903
01:35:27,961 --> 01:35:29,029
ACCELERATE THAT AUTHORIZATION,

2904
01:35:29,029 --> 01:35:30,531
AND WE WERE ABLE TO GET TESTS

2905
01:35:30,531 --> 01:35:32,232
AUTHORIZED IN AS LITTLE AS 50 TO

2906
01:35:32,232 --> 01:35:32,833
60 DAYS.

2907
01:35:32,833 --> 01:35:35,502
WE ALSO DID TEST TO TREAT

2908
01:35:35,502 --> 01:35:37,237
PROGRAMS AT HOME IN PARTNERSHIP

2909
01:35:37,237 --> 01:35:39,373
WITH OTHER HHS AGENCIES.

2910
01:35:39,373 --> 01:35:40,674
REDESIGNED TESTS SO THEY WERE

2911
01:35:40,674 --> 01:35:42,543
MORE ACCESSIBLE AND USABLE FOR

2912
01:35:42,543 --> 01:35:45,846
PEOPLE WITH VISUAL IMPAIRMENTS

2913
01:35:45,846 --> 01:35:48,182
AND DEXTERITY IMPAIRMENTS, SO WE

2914
01:35:48,182 --> 01:35:52,085
TESTED A BUNCH OF THINGS NOORMLY

2915
01:35:52,085 --> 01:35:54,221
OUT OF OUR SWIM LANE, BUT

2916
01:35:54,221 --> 01:35:55,422
BIOENGINEERS ARE A LITTLE NUTTY

2917
01:35:55,422 --> 01:35:57,090
AND WE LIKE TO EXPAND OUR

2918
01:35:57,090 --> 01:35:58,759
TECHNOLOGY INTO AS MANY AREAS AS

2919
01:35:58,759 --> 01:35:59,026
POSSIBLE.

2920
01:35:59,026 --> 01:36:00,327
SO THIS WAS A REALLY SIGNIFICANT

2921
01:36:00,327 --> 01:36:01,094
ACHIEVEMENT.

2922
01:36:01,094 --> 01:36:02,396
BOTTOM LINE, WE INCREASED TEST

2923
01:36:02,396 --> 01:36:03,363
CAPACITY THROUGH THESE

2924
01:36:03,363 --> 01:36:05,832
INVESTMENTS BY ABOUT 8 BILLION,

2925
01:36:05,832 --> 01:36:07,501
AND REALLY HELPED DRIVE AS I

2926
01:36:07,501 --> 01:36:08,702
MENTIONED THIS PARADIGM SHIFT

2927
01:36:08,702 --> 01:36:11,338
WHERE PEOPLE NOW EXPECT TESTS TO

2928
01:36:11,338 --> 01:36:14,875
BE DONE IN THEIR HOMES, AND LOTS

2929
01:36:14,875 --> 01:36:15,842
OF OPPORTUNITY FOR GROWTH WITH

2930
01:36:15,842 --> 01:36:16,710
THAT IN THE FUTURE.

2931
01:36:16,710 --> 01:36:17,878
SO THE REASON WHY I MENTIONED

2932
01:36:17,878 --> 01:36:22,015
SOME OF THIS DETAIL ABOUT RADX

2933
01:36:22,015 --> 01:36:24,218
WITH RESPECT TO COVID TESTING IS

2934
01:36:24,218 --> 01:36:26,453
THAT WE'VE USED THIS SAME

2935
01:36:26,453 --> 01:36:28,322
PLATFORM AND SAID, HEY,

2936
01:36:28,322 --> 01:36:29,523
INFECTIOUS DISEASE IS A

2937
01:36:29,523 --> 01:36:30,724
CONTINUING NEED, SO WE'RE

2938
01:36:30,724 --> 01:36:32,426
CONTINUING TO WORK ON THAT,

2939
01:36:32,426 --> 01:36:35,062
INCLUDING WORKING WITH GENIE AND

2940
01:36:35,062 --> 01:36:38,131
HER COLLEAGUES AT NIAID.

2941
01:36:38,131 --> 01:36:39,499
SYPHILIS DIAGNOSTICS THAT CAN BE

2942
01:36:39,499 --> 01:36:40,801
USED AT HOME AND IN THE POINT OF

2943
01:36:40,801 --> 01:36:41,702
CARE.

2944
01:36:41,702 --> 01:36:42,769
MULTI-LESION PANELS, SO WE'RE

2945
01:36:42,769 --> 01:36:44,605
CONTINUING TO WORK ON THAT.

2946
01:36:44,605 --> 01:36:47,107
SUPPORTED THE FIRST MPOX

2947
01:36:47,107 --> 01:36:49,676
EMERGENCY USE AUTHORIZATIONS

2948
01:36:49,676 --> 01:36:51,378
BOTH FOR POINT OF CARE AS WELL

2949
01:36:51,378 --> 01:36:54,314
AS FOR HOME SELF-SWABBING THAT

2950
01:36:54,314 --> 01:36:56,583
CAN THEN 50 TO A LABORATORY.

2951
01:36:56,583 --> 01:36:59,152
WE RECENTLY SUPPORTED THE FIRST

2952
01:36:59,152 --> 01:37:03,857
DE NOVO FDA-APPROVED TEST FOR

2953
01:37:03,857 --> 01:37:05,559
HEP-C WHICH CAN BE USED AT POINT

2954
01:37:05,559 --> 01:37:07,227
OF CARE WITH LESS THAN AN HOUR

2955
01:37:07,227 --> 01:37:07,761
TURNAROUND TIME.

2956
01:37:07,761 --> 01:37:08,862
BUT IN TERMS OF CHRONIC DISEASE

2957
01:37:08,862 --> 01:37:10,397
AND DISEASE PREVENTION, WE'VE

2958
01:37:10,397 --> 01:37:12,532
TAKEN ON A WHOLE BUNCH OF NEW

2959
01:37:12,532 --> 01:37:12,966
INITIATIVES.

2960
01:37:12,966 --> 01:37:14,935
FIRST IN NEUROTECHNOLOGIES, BUT

2961
01:37:14,935 --> 01:37:17,004
IN SEVERAL TECHNOLOGIES THAT ARE

2962
01:37:17,004 --> 01:37:18,038
RELATED TO WOMEN'S HEALTH.

2963
01:37:18,038 --> 01:37:19,906
AND WE'VE PARTNERED WITH

2964
01:37:19,906 --> 01:37:22,075
MULTIPLE INSTITUTES AND CENTERS,

2965
01:37:22,075 --> 01:37:24,011
MOST NOTABLY IN THREE CHALLENGES

2966
01:37:24,011 --> 01:37:25,746
THAT I'LL BRIEFLY MENTION,

2967
01:37:25,746 --> 01:37:28,382
PARTNERING WITH NICHD AND ORWH,

2968
01:37:28,382 --> 01:37:31,118
AND MULTIPLE INSTITUTES.

2969
01:37:31,118 --> 01:37:33,453
SO THE FIRST IS RADX TECH FOR

2970
01:37:33,453 --> 01:37:34,221
MATERNAL HEALTH.

2971
01:37:34,221 --> 01:37:36,456
SO THIS IS NOW WINDING UP AFTER

2972
01:37:36,456 --> 01:37:38,792
A COUPLE OF YEARS OF ONGOING

2973
01:37:38,792 --> 01:37:40,994
COMPETITION AND EVALUATING OF

2974
01:37:40,994 --> 01:37:42,496
THE TECHNOLOGY PERFORMANCE.

2975
01:37:42,496 --> 01:37:44,264
THIS IS $8 MILLION IN CASH

2976
01:37:44,264 --> 01:37:46,800
AWARDS THAT ACCELERATED

2977
01:37:46,800 --> 01:37:48,235
DEVELOPMENT OF MATERNAL HEALTH

2978
01:37:48,235 --> 01:37:49,770
DIAGNOSTIC DEVICES, WEARABLES

2979
01:37:49,770 --> 01:37:52,105
AND OTHER TYPES OF REMOTE

2980
01:37:52,105 --> 01:37:56,576
SENSING, AND THE IDEA HERE IS TO

2981
01:37:56,576 --> 01:37:57,244
IMPROVE -- DEVELOP TECHNOLOGIES

2982
01:37:57,244 --> 01:37:58,612
THAT WILL IMPROVE OUTCOMES

2983
01:37:58,612 --> 01:38:00,814
DURING THE FIRST YEAR OF THE

2984
01:38:00,814 --> 01:38:01,248
POST-PARTUM PERIOD.

2985
01:38:01,248 --> 01:38:02,783
SO LESS THAN A YEAR FROM THE DAY

2986
01:38:02,783 --> 01:38:03,717
OF BIRTH OR TO THE END OF

2987
01:38:03,717 --> 01:38:04,151
PREGNANCY.

2988
01:38:04,151 --> 01:38:05,986
SO THOSE ARE THE CONSTRAINTS ON

2989
01:38:05,986 --> 01:38:07,954
THESE PRIZES.

2990
01:38:07,954 --> 01:38:10,991
AND WE STRUCTURED AGAIN WITH

2991
01:38:10,991 --> 01:38:12,492
THAT RADX INNOVATION FUNNEL

2992
01:38:12,492 --> 01:38:15,228
CONCEPT WITH MULTIPLE STAGES

2993
01:38:15,228 --> 01:38:16,530
WHERE IT WAS RELATIVELY EASY FOR

2994
01:38:16,530 --> 01:38:19,032
YOU TO PUT IN AN APPLICATION,

2995
01:38:19,032 --> 01:38:20,867
AND THEN A RIGOROUS ASSESSMENT

2996
01:38:20,867 --> 01:38:23,303
OF VIABILITY, DEEP DIVES,

2997
01:38:23,303 --> 01:38:25,872
WORKING CLOSELY WITH THE TEAMS,

2998
01:38:25,872 --> 01:38:28,041
AWARDS AT MULTIPLE STAGES.

2999
01:38:28,041 --> 01:38:29,910
IN THE TECHNOLOGY ASSESSMENT

3000
01:38:29,910 --> 01:38:34,348
PHASE, FINALISTS WERE GIVEN OVER

3001
01:38:34,348 --> 01:38:36,850
A HALF A MILLION EACH, AND WE

3002
01:38:36,850 --> 01:38:38,552
JUST NOW COMPLETED -- I CAN'T

3003
01:38:38,552 --> 01:38:39,753
ANNOUNCE THE RESULTS BUT WE JUST

3004
01:38:39,753 --> 01:38:42,956
NOW COMPLETED THE FINAL

3005
01:38:42,956 --> 01:38:44,624
EVALUATION PHASE AND WE'LL BE

3006
01:38:44,624 --> 01:38:46,927
ANNOUNCING THE GRAND PRIZES AND

3007
01:38:46,927 --> 01:38:48,695
RUNNERS UP PRETTY SOON.

3008
01:38:48,695 --> 01:38:50,530
HOPEFULLY THESE WERE TRANSITION

3009
01:38:50,530 --> 01:38:52,032
TO NIH NETWORKS FOR FURTHER

3010
01:38:52,032 --> 01:38:53,667
CLINICAL STUDIES.

3011
01:38:53,667 --> 01:38:55,135
HERE ARE THE TECHNOLOGIES, THE

3012
01:38:55,135 --> 01:38:56,903
10 THAT MADE TO THAT FINAL

3013
01:38:56,903 --> 01:38:57,904
STAGE.

3014
01:38:57,904 --> 01:38:59,973
THESE WENT INTO OUR VALIDATION

3015
01:38:59,973 --> 01:39:03,043
CORE AT EMORY GEORGIA TECH WITH

3016
01:39:03,043 --> 01:39:04,845
MULTIPLE CLINICAL PROTOCOLS

3017
01:39:04,845 --> 01:39:06,580
DESIGNED TO EVALUATE THEIR

3018
01:39:06,580 --> 01:39:08,248
PERFORMANCE IN KIND OF A ROUND

3019
01:39:08,248 --> 01:39:09,449
ROBIN FASHION SO EVERY ONE OF

3020
01:39:09,449 --> 01:39:11,685
THEM, WE WERE ABLE TO RECRUIT A

3021
01:39:11,685 --> 01:39:15,188
SUFFICIENT NUMBER OF WOMEN AND

3022
01:39:15,188 --> 01:39:16,723
BRING THESE TECHNOLOGIES

3023
01:39:16,723 --> 01:39:18,325
SOMETIMES INTO THEIR HOMES, INTO

3024
01:39:18,325 --> 01:39:22,262
THE POINT OF CARE, AND DO

3025
01:39:22,262 --> 01:39:23,363
RIGOROUS EVALUATION OF THE

3026
01:39:23,363 --> 01:39:23,663
PERFORMANCE.

3027
01:39:23,663 --> 01:39:25,198
WE JUST RECENTLY EVALUATED ALL

3028
01:39:25,198 --> 01:39:26,133
OF THAT STUFF AND MADE

3029
01:39:26,133 --> 01:39:27,768
RECOMMENDATIONS TO THE IMPROVE

3030
01:39:27,768 --> 01:39:29,770
COMMITTEE, WHO WILL ULTIMATELY

3031
01:39:29,770 --> 01:39:31,004
FINALIZE WHAT SOME OF THOSE

3032
01:39:31,004 --> 01:39:31,671
RECOMMENDATIONS ARE.

3033
01:39:31,671 --> 01:39:33,774
BUT YOU CAN SEE THESE

3034
01:39:33,774 --> 01:39:34,941
TECHNOLOGIES REPRESENT A KIND OF

3035
01:39:34,941 --> 01:39:37,077
BROAD RANGE OF NEEDS.

3036
01:39:37,077 --> 01:39:38,645
FROM DIGITAL HEALTH PLATFORMS

3037
01:39:38,645 --> 01:39:41,815
THAT CAN HELP FACILITATE

3038
01:39:41,815 --> 01:39:45,318
ASSESSMENT OF POSTPARTUM

3039
01:39:45,318 --> 01:39:46,586
DEPRESSION TO A SIMPLE

3040
01:39:46,586 --> 01:39:48,088
DIAGNOSTIC THAT CAN BE USED AT

3041
01:39:48,088 --> 01:39:51,491
HOME TO ASSESS UTIs, AND

3042
01:39:51,491 --> 01:39:53,627
SEVERAL THAT ARE DESIGNED FOR

3043
01:39:53,627 --> 01:39:54,628
CARDIOVASCULAR MONITORING THAT

3044
01:39:54,628 --> 01:39:56,496
ARE WEARABLE DEVICES THAT CAN BE

3045
01:39:56,496 --> 01:39:58,732
POTENTIALLY USED AT HOME THAT

3046
01:39:58,732 --> 01:40:00,700
CAN EVALUATE BLOOD PRESSURE,

3047
01:40:00,700 --> 01:40:04,304
EVALUATE HEMORRHAGE, AND OTHER

3048
01:40:04,304 --> 01:40:09,209
HUMAN DYNAMIC PROPERTIES SO

3049
01:40:09,209 --> 01:40:09,943
EVENTUALLY PREECLAMPSIA CAN BE

3050
01:40:09,943 --> 01:40:11,812
OVAL WAITED AND A VARIETY OF

3051
01:40:11,812 --> 01:40:14,114
DIFFERENT EARLY INTERVENTIONS

3052
01:40:14,114 --> 01:40:15,649
CAN BE DEPLOYED ALL WITH MHEALTH

3053
01:40:15,649 --> 01:40:16,917
TYPES OF APPROACHES TO GIVE

3054
01:40:16,917 --> 01:40:19,319
RAPID AND DYNAMIC FEEDBACK

3055
01:40:19,319 --> 01:40:19,953
TO CLINICIANS.

3056
01:40:19,953 --> 01:40:23,657
ONE OF THESE WHICH MATT HAS ALSO

3057
01:40:23,657 --> 01:40:25,659
BEEN INVOLVED IN IS LOOKING AT

3058
01:40:25,659 --> 01:40:27,694
ANEMIA, USING A DIGITAL HEALTH

3059
01:40:27,694 --> 01:40:28,795
PLATFORM, A SMARTPHONE THAT

3060
01:40:28,795 --> 01:40:30,330
REALLY JUST TAKES A PICTURE OF

3061
01:40:30,330 --> 01:40:32,466
YOUR FINGERNAILS AND THROUGH

3062
01:40:32,466 --> 01:40:34,568
THAT INFORMATION CONTENT AND

3063
01:40:34,568 --> 01:40:37,070
ALGORITHMS THAT ARE DESIGNED TO

3064
01:40:37,070 --> 01:40:38,071
EXTRACT THAT INFORMATION CAN

3065
01:40:38,071 --> 01:40:40,140
MEASURE WHAT YOUR HEMOGLOBIN

3066
01:40:40,140 --> 01:40:41,975
LEVELS ARE DYNAMICALLY OVER TIME

3067
01:40:41,975 --> 01:40:43,743
WITHOUT ANY KIND OF BLOOD DRAW

3068
01:40:43,743 --> 01:40:45,579
THAT'S ASSOCIATED WITH THAT.

3069
01:40:45,579 --> 01:40:47,981
SO OUR NEXT CHALLENGE WAS IN

3070
01:40:47,981 --> 01:40:51,518
FETAL MONITORING.

3071
01:40:51,518 --> 01:40:53,220
WE'RE NOW SUPPORTING SIX

3072
01:40:53,220 --> 01:40:54,254
DIFFERENT TECHNOLOGIES IN THIS

3073
01:40:54,254 --> 01:40:54,855
AREA.

3074
01:40:54,855 --> 01:40:56,189
I WON'T GO INTO DETAILS ON THESE

3075
01:40:56,189 --> 01:40:57,624
BUT THEY'RE KIND OF A COLLECTION

3076
01:40:57,624 --> 01:41:00,327
OF BIOPHOTONIC, BIOELECTRONIC

3077
01:41:00,327 --> 01:41:01,962
AND BIOACOUSTIC DEVICES.

3078
01:41:01,962 --> 01:41:04,364
THE MINIATURIZATION OF THESE

3079
01:41:04,364 --> 01:41:07,400
TECHNOLOGIES INTO SIMPLE

3080
01:41:07,400 --> 01:41:08,502
WEARABLES WITH THE CAPABILITY TO

3081
01:41:08,502 --> 01:41:09,803
TRANSMIT THAT INFORMATION TO

3082
01:41:09,803 --> 01:41:12,772
APPS OR TO MHEALTH APPROACHES

3083
01:41:12,772 --> 01:41:14,474
WHERE ALGORITHMS CAN EXTRACT THE

3084
01:41:14,474 --> 01:41:18,078
DATA AND OPTIMIZE CONTRAST AND

3085
01:41:18,078 --> 01:41:18,845
INFORMATION CONTENT THAT COULD

3086
01:41:18,845 --> 01:41:20,680
BE FED TO PROVIDERS.

3087
01:41:20,680 --> 01:41:25,352
ALSO AT UCSF, A NEXT GEN

3088
01:41:25,352 --> 01:41:26,753
ULTRASOUND APPROACH THAT USES A

3089
01:41:26,753 --> 01:41:28,488
DEEP LEARNING MODEL FOR

3090
01:41:28,488 --> 01:41:29,689
ULTRASOUND DETECTION OF

3091
01:41:29,689 --> 01:41:30,557
CONGENITAL HEART DISEASE.

3092
01:41:30,557 --> 01:41:31,224
THIS ONE IS A LITTLE BIT

3093
01:41:31,224 --> 01:41:33,360
DIFFERENT IN THAT IT'S A

3094
01:41:33,360 --> 01:41:34,561
PROVIDER-BASED TECHNOLOGY WHERE

3095
01:41:34,561 --> 01:41:35,662
WOMEN WOULD HAVE TO GO AND GET

3096
01:41:35,662 --> 01:41:37,864
THAT ULTRASOUND, BUT IT REALLY

3097
01:41:37,864 --> 01:41:39,466
ADVANCES COMPUTATIONAL

3098
01:41:39,466 --> 01:41:41,201
APPROACHES AND EXTRACTING

3099
01:41:41,201 --> 01:41:42,068
INFORMATION CONTENT.

3100
01:41:42,068 --> 01:41:43,937
AND OUR MOST CURRENT ONE,

3101
01:41:43,937 --> 01:41:47,307
DEADLINE IS OCTOBER 11TH.

3102
01:41:47,307 --> 01:41:49,809
NICHD AGAIN IS DRIVING AND

3103
01:41:49,809 --> 01:41:50,577
SUPPORTING THIS.

3104
01:41:50,577 --> 01:41:55,081
THIS IS THE ACT ENDO CHALLENGE,

3105
01:41:55,081 --> 01:41:58,285
$3 MILLION IN PRIZES TO EXCEL

3106
01:41:58,285 --> 01:42:00,687
ACCELERATE THE DEVELOPMENT OF

3107
01:42:00,687 --> 01:42:01,688
NONINVASIVE TECHNOLOGIES TO

3108
01:42:01,688 --> 01:42:02,756
IMPROVE DIAGNOSIS OF

3109
01:42:02,756 --> 01:42:03,590
ENDOMETRIOSIS.

3110
01:42:03,590 --> 01:42:06,560
AN URGENTLY NEEDED PROBLEM.

3111
01:42:06,560 --> 01:42:07,994
IT'S NOT AN ENORMOUS AMOUNT OF

3112
01:42:07,994 --> 01:42:09,129
MONEY WE HAVE.

3113
01:42:09,129 --> 01:42:10,130
I BELIEVE OVER 60 APPLICANTS

3114
01:42:10,130 --> 01:42:11,765
THAT HAVE STARTED TO FILL OUT

3115
01:42:11,765 --> 01:42:13,300
THIS APPLICATION PROCESS, SO

3116
01:42:13,300 --> 01:42:15,769
WE'RE QUITE HOPEFUL, AND WE'VE

3117
01:42:15,769 --> 01:42:17,737
HAD GREAT RESPONSE FROM OUR

3118
01:42:17,737 --> 01:42:18,705
COMMUNITY THAT SUGGESTS THAT

3119
01:42:18,705 --> 01:42:20,674
WE'RE GOING TO GET LOTS OF GREAT

3120
01:42:20,674 --> 01:42:21,775
APPLICATIONS IN, AND THIS IS

3121
01:42:21,775 --> 01:42:23,476
GOING TO BE AT LEAST THE FIRST

3122
01:42:23,476 --> 01:42:25,712
STEP IN WHAT CAN BE SUBSEQUENT

3123
01:42:25,712 --> 01:42:27,714
FUNDING THAT COULD DRAMATICALLY

3124
01:42:27,714 --> 01:42:30,016
EXPAND AND ADVANCE THIS FIELD.

3125
01:42:30,016 --> 01:42:32,786
SO LET ME KIND OF RUN THROUGH,

3126
01:42:32,786 --> 01:42:34,454
AND THIS IS A BIT OF EYE CANDY.

3127
01:42:34,454 --> 01:42:36,556
I WANT TO GIVE YOU A SNAPSHOT OF

3128
01:42:36,556 --> 01:42:37,657
SOME OF THE TECHNOLOGIES THAT

3129
01:42:37,657 --> 01:42:41,995
ARE BEING DEVELOPED BY SUPPORTED

3130
01:42:41,995 --> 01:42:42,529
INVESTIGATORS.

3131
01:42:42,529 --> 01:42:44,164
I WON'T SPEND A LOT OF TIME ON

3132
01:42:44,164 --> 01:42:45,599
EACH ONE, BUT GIVES YOU A SENSE

3133
01:42:45,599 --> 01:42:47,434
FOR THE SCOPE OF ACTIVITIES AND

3134
01:42:47,434 --> 01:42:49,169
THE AMBITION OF OUR

3135
01:42:49,169 --> 01:42:50,036
INVESTIGATORS ACROSS OUR

3136
01:42:50,036 --> 01:42:50,370
COMMUNITY.

3137
01:42:50,370 --> 01:42:55,175
SO I'LL FOCUS IN FIRST ON SOME

3138
01:42:55,175 --> 01:42:56,810
ENGINEERED BIOLOGICAL SYSTEMS OR

3139
01:42:56,810 --> 01:43:00,313
WHAT WE CALL SOFT MATERIALS

3140
01:43:00,313 --> 01:43:02,349
ENGINEERING.

3141
01:43:02,349 --> 01:43:04,751
ONE INTERESTING PROBLEM THAT

3142
01:43:04,751 --> 01:43:06,720
ARIELLA IS WORKING ON IS THE

3143
01:43:06,720 --> 01:43:08,788
ENCAPSULATION OF OVARIAN TISSUE.

3144
01:43:08,788 --> 01:43:10,724
SO OVARIAN INSUFFICIENCY IS A

3145
01:43:10,724 --> 01:43:12,692
PROBLEM THAT CAN BE FACED BY

3146
01:43:12,692 --> 01:43:14,628
WOMEN, FOR EXAMPLE, WHO'VE GONE

3147
01:43:14,628 --> 01:43:15,829
THROUGH CANCER THERAPIES AT A

3148
01:43:15,829 --> 01:43:17,230
YOUNG AGE.

3149
01:43:17,230 --> 01:43:19,332
ADEALLY, ONE WOULD LIKE TO HAVE

3150
01:43:19,332 --> 01:43:21,801
AN OVARIAN TISSUE ALLOGRAFT AND

3151
01:43:21,801 --> 01:43:25,739
DO AN IMPLANTATION THAT COULD

3152
01:43:25,739 --> 01:43:27,040
HELP THEN ACCELERATE OR

3153
01:43:27,040 --> 01:43:31,411
COMPENSATE FOR THAT

3154
01:43:31,411 --> 01:43:32,012
INSUFFICIENCY, AND ONE OF THE

3155
01:43:32,012 --> 01:43:33,847
BIG CHALLENGES, OF COURSE, IS

3156
01:43:33,847 --> 01:43:36,016
IMMUNE REJECTION.

3157
01:43:36,016 --> 01:43:37,417
SO AIR YES LA HAS BEEN WORKING

3158
01:43:37,417 --> 01:43:44,991
ON A WAY TO TAKE THAT TISSUE AND

3159
01:43:44,991 --> 01:43:47,093
FORM MULTIPLE ENCANCELLATION

3160
01:43:47,093 --> 01:43:49,796
ZONES USING CROSSLINKING

3161
01:43:49,796 --> 01:43:51,164
APPROACHES TO PROTECT IT SO THAT

3162
01:43:51,164 --> 01:43:52,699
IT'S NOT ATTACKED BY THE IMMUNE

3163
01:43:52,699 --> 01:43:54,000
SYSTEM AND IT FULLY FUNCTIONAL.

3164
01:43:54,000 --> 01:43:56,936
SO THIS IS A DUAL GEL, AND THE

3165
01:43:56,936 --> 01:43:59,105
OVARIAN TISSUE, WHICH WOULD BE

3166
01:43:59,105 --> 01:44:01,508
AN ALLOGRAFT IS ENCAPSULATED IN

3167
01:44:01,508 --> 01:44:02,575
THE CORE OF THE GEL AND THEN

3168
01:44:02,575 --> 01:44:03,677
THERE'S A SHELL BUILT AROUND

3169
01:44:03,677 --> 01:44:03,977
THAT.

3170
01:44:03,977 --> 01:44:05,912
SO SHE'S HAD LOTS OF SUCCESS IN

3171
01:44:05,912 --> 01:44:07,681
BUILDING THE STRUCTURE AND

3172
01:44:07,681 --> 01:44:09,315
SHOWING THAT IT'S EFFECTIVE,

3173
01:44:09,315 --> 01:44:11,851
IT'S HORMONALLY EFFECTIVE, COULD

3174
01:44:11,851 --> 01:44:14,421
POTENTIALLY BE A REPLACEMENT FOR

3175
01:44:14,421 --> 01:44:15,955
AN ALTERNATIVE TO HORMONE

3176
01:44:15,955 --> 01:44:17,157
REPLACEMENT THERAPIES WHICH ARE

3177
01:44:17,157 --> 01:44:19,125
ONLY USING TWO PARTICULAR

3178
01:44:19,125 --> 01:44:20,293
AGENTS, SO THIS IS A MORE

3179
01:44:20,293 --> 01:44:21,828
COMPLEX AND REALISTIC TISSUE

3180
01:44:21,828 --> 01:44:25,231
THAT COULD BE FULLY FUNCTIONAL

3181
01:44:25,231 --> 01:44:27,267
AND COULD ALSO BE BANKED AND

3182
01:44:27,267 --> 01:44:29,135
CRYOPRESERVED THAT WOULD BE DONE

3183
01:44:29,135 --> 01:44:32,539
IN AN ALLOGRAFT SETTING.

3184
01:44:32,539 --> 01:44:35,975
THERE'S THIS REALLY SIGNIFICANT

3185
01:44:35,975 --> 01:44:40,714
NEED FOR CREATING SOLUTIONS FOR

3186
01:44:40,714 --> 01:44:42,982
URINARY INCONTINENCE, STRESS

3187
01:44:42,982 --> 01:44:43,883
INCONTINENCE, AND ONE OF THE

3188
01:44:43,883 --> 01:44:46,853
NEEDS IS TO BE ABLE TO DI

3189
01:44:46,853 --> 01:44:50,290
DYNAMICALLY MODULATE WHAT SLING

3190
01:44:50,290 --> 01:44:52,125
DESIGN SO THEY REALLY ARE BETTER

3191
01:44:52,125 --> 01:44:53,993
AT FUNCTIONING BOTH WHEN YOU

3192
01:44:53,993 --> 01:44:57,263
NEED THEM TO BE OPENED AND ALSO

3193
01:44:57,263 --> 01:44:59,232
WHEN THE SLING ITSELF IS SHUT,

3194
01:44:59,232 --> 01:45:00,834
IT NEEDS TO PREVENT LEAKAGE.

3195
01:45:00,834 --> 01:45:06,439
SO THIS IS A VERY CLEVER LIQUID

3196
01:45:06,439 --> 01:45:07,640
CRYSTAL ELASTOMER DEVICE THAT

3197
01:45:07,640 --> 01:45:09,576
CAN BE 3D PRINTED AND PUT ON ANY

3198
01:45:09,576 --> 01:45:11,111
KIND OF MATERIAL.

3199
01:45:11,111 --> 01:45:12,912
IT RESPONDS TO HEAT, SO IT CAN

3200
01:45:12,912 --> 01:45:14,447
BE ACTIVATED WITH HEAT, AND THIS

3201
01:45:14,447 --> 01:45:19,486
WORK IS BEING DONE BY TAYLOR

3202
01:45:19,486 --> 01:45:25,158
WARE, TEXAS A & M.

3203
01:45:25,158 --> 01:45:27,460
SO WE'RE ALL FOLLOWING CAR T

3204
01:45:27,460 --> 01:45:30,830
THERAPY AND EXCITED ABOUT IT FOR

3205
01:45:30,830 --> 01:45:32,499
HEMATOLOGIC MALIGNANCIES, BUT

3206
01:45:32,499 --> 01:45:33,967
THERE ARE REALLY SIGNIFICANT

3207
01:45:33,967 --> 01:45:35,068
LIMITATIONS IN CAR-T-CELL

3208
01:45:35,068 --> 01:45:37,036
THERAPY IN SOLID TUMORS LIKE IN

3209
01:45:37,036 --> 01:45:40,974
BREAST CANCER, AND THERE ARE

3210
01:45:40,974 --> 01:45:44,043
VERY SIGNIFICANT OFF-TARGET

3211
01:45:44,043 --> 01:45:45,879
EFFECTS AND ANTIGEN EXHAUSTION,

3212
01:45:45,879 --> 01:45:47,814
SO CAR-T CELLS ARE REALLY NOT

3213
01:45:47,814 --> 01:45:48,915
WORKING IN THESE KINDS OF

3214
01:45:48,915 --> 01:45:52,952
TUMORS.

3215
01:45:52,952 --> 01:45:56,689
SO TAL DANINO, COLUMBIA, HAS

3216
01:45:56,689 --> 01:45:59,192
BEEN DEVELOPING A

3217
01:45:59,192 --> 01:46:00,593
PROBIOTIC-GUIDED CAR-T-CELL

3218
01:46:00,593 --> 01:46:04,164
THERAPY FOR BREAST CANCER.

3219
01:46:04,164 --> 01:46:07,267
SO HIS INNOVATION IS ENGINEERING

3220
01:46:07,267 --> 01:46:09,102
BACTERIA, SO ENGINEERING E. COLI

3221
01:46:09,102 --> 01:46:13,106
TO SELECTIVELY COLONIZE TUMORS

3222
01:46:13,106 --> 01:46:14,440
AND RELEASE PAY LOADS WITH

3223
01:46:14,440 --> 01:46:16,843
ANTIGENS THAT WOULD ENHANCE

3224
01:46:16,843 --> 01:46:18,144
CAR-T-CELL TARGETING.

3225
01:46:18,144 --> 01:46:20,980
SO IT DOESN'T RELY ON THE

3226
01:46:20,980 --> 01:46:21,848
INTRINSIC ANTIGEN PRESENTATION

3227
01:46:21,848 --> 01:46:22,816
OF THE TUMOR.

3228
01:46:22,816 --> 01:46:25,652
IT RELIES ON AN ENGINEERED

3229
01:46:25,652 --> 01:46:27,720
BACTERIUM WHICH IS A SYNTHETIC

3230
01:46:27,720 --> 01:46:29,155
BIOLOGY APPROACH TO BE DELIVERED

3231
01:46:29,155 --> 01:46:30,924
AND THEN COLONIZED IN THE

3232
01:46:30,924 --> 01:46:33,593
MICROBIOME OF THE TUMOR THAT'S

3233
01:46:33,593 --> 01:46:35,461
EXPRESSED AND THEN THE

3234
01:46:35,461 --> 01:46:37,764
CAR-T-CELL CAN BE TRAINED OR

3235
01:46:37,764 --> 01:46:47,340
OTHER CAR-CELL CON JEW GGUGATESE

3236
01:46:47,340 --> 01:46:49,509
GONE IN TO TRAIN THE TUMOR AND

3237
01:46:49,509 --> 01:46:54,147
HE'S SHOWED -- IT CAPTURES STATE

3238
01:46:54,147 --> 01:46:57,283
OF THE ART IN SYNTHETIC

3239
01:46:57,283 --> 01:46:58,351
BIOENGINEERING OF BACTERIA TO

3240
01:46:58,351 --> 01:46:59,619
DRIVE THIS.

3241
01:46:59,619 --> 01:47:01,821
AND ANOTHER EXAMPLE IN SOFT

3242
01:47:01,821 --> 01:47:03,456
MATERIALS IS THE WORK OF LINDA

3243
01:47:03,456 --> 01:47:05,325
GRIFFITH, WHO'S PROFESSOR OF

3244
01:47:05,325 --> 01:47:07,727
BIOENGINEERING AT MIT, WHOSE

3245
01:47:07,727 --> 01:47:08,795
PIONEERED THE DEVELOPMENT OF A

3246
01:47:08,795 --> 01:47:11,431
NUMBER OF MICRO PHYSIOLOGIC

3247
01:47:11,431 --> 01:47:12,966
SYSTEMS, BUT SHE'S REALLY

3248
01:47:12,966 --> 01:47:16,135
FOCUSED HER ENERGY NOW ON AN

3249
01:47:16,135 --> 01:47:18,771
ORGANOID CO-CULTURE MODEL OF THE

3250
01:47:18,771 --> 01:47:19,405
HUMAN ENDOMETRIUM.

3251
01:47:19,405 --> 01:47:21,407
IT'S A FULLY SYNTHETIC

3252
01:47:21,407 --> 01:47:23,476
EXTRACELLULAR MATRIX, SO THE

3253
01:47:23,476 --> 01:47:25,712
EXTRACELLULAR MATRIX MATRIGEL

3254
01:47:25,712 --> 01:47:26,880
HAS BEEN OFTEN USED IN THESE

3255
01:47:26,880 --> 01:47:27,847
KINDS OF CO-CULTURES.

3256
01:47:27,847 --> 01:47:30,149
THAT'S NOT VERY REPRODUCIBLE,

3257
01:47:30,149 --> 01:47:30,617
IT'S HIGHLY VARIABLE.

3258
01:47:30,617 --> 01:47:33,186
IF YOU'RE GOING TO DRIVE

3259
01:47:33,186 --> 01:47:34,187
DISCOVERY, YOU HAVE TO

3260
01:47:34,187 --> 01:47:36,155
STANDARDIZE THESE APPROACHES IN

3261
01:47:36,155 --> 01:47:37,257
SOFT MATERIALS ENGINEERING JUST

3262
01:47:37,257 --> 01:47:39,325
LIKE WE DO IN THE DEVELOPMENT OF

3263
01:47:39,325 --> 01:47:41,060
OTHER TYPES OF HARDWARE.

3264
01:47:41,060 --> 01:47:42,695
SO THE HARDWARE THAT YOU CAN BUY

3265
01:47:42,695 --> 01:47:45,531
OFF THE SHELF REALLY WORKS IN A

3266
01:47:45,531 --> 01:47:46,933
VERY STANDARDIZED WAY.

3267
01:47:46,933 --> 01:47:49,035
THE ENGINEERED BIOLOGY WORKS IN

3268
01:47:49,035 --> 01:47:54,374
SOME PEOPL PEOPLE'S LA PEOPLE'SY

3269
01:47:54,374 --> 01:47:55,141
WELL.

3270
01:47:55,141 --> 01:47:56,643
SO LINDA HAS TAKEN ON THIS

3271
01:47:56,643 --> 01:47:57,977
REALLY HUGE CHALLENGE OF

3272
01:47:57,977 --> 01:47:59,512
ENGINEERING AND APPROACH THAT

3273
01:47:59,512 --> 01:48:02,215
MIMICS THE FULL ENDOMETRIAL

3274
01:48:02,215 --> 01:48:05,952
GROWTH AND SA CYCLE PROCESS THAT

3275
01:48:05,952 --> 01:48:07,387
CAN BE DISTRIBUTED TO MULTIPLE

3276
01:48:07,387 --> 01:48:08,488
INVESTIGATORS AND WORK EXACTLY

3277
01:48:08,488 --> 01:48:11,724
THE SAME, SO THAT COULD

3278
01:48:11,724 --> 01:48:12,191
PARALLELIZE DISCOVERY.

3279
01:48:12,191 --> 01:48:15,795
SO VERY BRIEFLY, THE CO-CULTURE

3280
01:48:15,795 --> 01:48:17,430
IS AN ENDOMETRIAL CELLS AS WELL

3281
01:48:17,430 --> 01:48:17,964
AS STROMAL CELLS.

3282
01:48:17,964 --> 01:48:22,235
YOU CAN SEE WITH 3D OBSTETRICAL

3283
01:48:22,235 --> 01:48:24,337
IMAGING THAT YOU CAN INTERROGATE

3284
01:48:24,337 --> 01:48:26,406
THESE STRUCTURES REALLY QUITE

3285
01:48:26,406 --> 01:48:29,676
BEAUTIFULLY, AND THEY ARE

3286
01:48:29,676 --> 01:48:33,179
RESPONSIVE TO PROLIFERATIVE

3287
01:48:33,179 --> 01:48:35,315
PHASES, MENSES, AS YOU CAN SEE

3288
01:48:35,315 --> 01:48:36,783
ON THE LEFT LOWER PANEL, THEY

3289
01:48:36,783 --> 01:48:38,985
FORM POLARIZED STRUCTURES JUST

3290
01:48:38,985 --> 01:48:40,687
LIKE WE SEE IN GLANDULAR

3291
01:48:40,687 --> 01:48:41,587
STRUCTURES IN ENDOMETRIOSIS, SO

3292
01:48:41,587 --> 01:48:44,190
THIS IS A BIOMIMIC THAT HAS

3293
01:48:44,190 --> 01:48:47,593
REALLY BEAUTIFUL FEATURES OF

3294
01:48:47,593 --> 01:48:49,329
ENDOMETRIAL PHYSIOLOGY, AND IT'S

3295
01:48:49,329 --> 01:48:51,731
A VERY STABLE PLATFORM THAT CAN

3296
01:48:51,731 --> 01:48:53,499
BE USED BY INVESTIGATORS TO

3297
01:48:53,499 --> 01:48:55,134
UNDERSTAND THIS -- TO UNDERSTAND

3298
01:48:55,134 --> 01:48:56,869
ENDOMETRIOSIS AND PROLIFERATION

3299
01:48:56,869 --> 01:48:59,172
EXTREMELY WELL.

3300
01:48:59,172 --> 01:49:01,708
SO I'LL GO INTO SOME BIOMEDICAL

3301
01:49:01,708 --> 01:49:02,241
IMAGING EXAMPLES.

3302
01:49:02,241 --> 01:49:04,644
THERE IS AN ENORMOUS -- IF YOU

3303
01:49:04,644 --> 01:49:06,512
REMEMBER THAT PIE CHART,

3304
01:49:06,512 --> 01:49:08,681
ENORMOUS AMOUNT OF ACTIVITY IN

3305
01:49:08,681 --> 01:49:10,783
BIOMEDICAL IMAGING THAT'S GOING

3306
01:49:10,783 --> 01:49:11,651
ACROSS OUR FIELD AND OUR

3307
01:49:11,651 --> 01:49:12,218
COMMUNITY.

3308
01:49:12,218 --> 01:49:14,153
I JUST HAVE A FEW SNAPSHOTS OF

3309
01:49:14,153 --> 01:49:14,587
THESE.

3310
01:49:14,587 --> 01:49:17,090
I THINK WE HAVE AN ENTIRE

3311
01:49:17,090 --> 01:49:19,025
SYMPOSIUM FOR MULTIPLE DAYS AND

3312
01:49:19,025 --> 01:49:20,593
ALL THE STUFF ON IMAGING.

3313
01:49:20,593 --> 01:49:22,095
ONE OF THE THINGS THAT REALLY

3314
01:49:22,095 --> 01:49:25,798
JUMPED OUT AT ME IS WORK IN

3315
01:49:25,798 --> 01:49:27,367
DOPPLER ULTRASOUND BREAST

3316
01:49:27,367 --> 01:49:27,667
IMAGING.

3317
01:49:27,667 --> 01:49:30,136
THIS IS BEING LED BY A GROUP AT

3318
01:49:30,136 --> 01:49:30,536
THE MAYO CLINIC.

3319
01:49:30,536 --> 01:49:32,238
WHAT THEY'RE DOING IS TAKING A

3320
01:49:32,238 --> 01:49:36,075
NORMAL ULTRASOUND, BUT COMBINING

3321
01:49:36,075 --> 01:49:39,245
NORMAL ULTRASOUND SCANNING WITH

3322
01:49:39,245 --> 01:49:40,613
HIGH SPEED 600 FRAMES PER

3323
01:49:40,613 --> 01:49:43,282
SECRETARY PO DELL-BASED DOPPLER

3324
01:49:43,282 --> 01:49:43,916
ULTRASOUND RECONSTRUCTION.

3325
01:49:43,916 --> 01:49:46,419
SO IN THE UPPER PANEL, YOU SEE

3326
01:49:46,419 --> 01:49:49,155
MALIGNANT BREAST TUMORS AND

3327
01:49:49,155 --> 01:49:50,823
BENIGN TUMORS, AND YOU SEE THE

3328
01:49:50,823 --> 01:49:51,791
DOPPLER SIGNATURE.

3329
01:49:51,791 --> 01:49:53,092
IF YOU'VE EVER DONE ULTRASOUND

3330
01:49:53,092 --> 01:49:56,029
OR SEEN ULTRASOUNDS WITH

3331
01:49:56,029 --> 01:49:57,463
DOPPLER, YOU'RE NOT NECESSARILY

3332
01:49:57,463 --> 01:49:59,298
TERRIBLY IMPRESSED WITH THE

3333
01:49:59,298 --> 01:50:00,500
STRUCTURE OF THE MICRO

3334
01:50:00,500 --> 01:50:00,800
VASCULATURE.

3335
01:50:00,800 --> 01:50:02,368
IT REALLY DOESN'T SHOW IT USING

3336
01:50:02,368 --> 01:50:03,136
COMMERCIAL SOFTWARE.

3337
01:50:03,136 --> 01:50:05,972
SO WHAT THEY'VE DONE IS TAKEN

3338
01:50:05,972 --> 01:50:07,607
MODEL-BASED APPROACHES FOR

3339
01:50:07,607 --> 01:50:09,308
RECONSTRUCTING THE INFORMATION.

3340
01:50:09,308 --> 01:50:11,944
THEY'VE BEEN ABLE TO PULL OUT

3341
01:50:11,944 --> 01:50:12,512
MICROVASCULAR STRUCTURES.

3342
01:50:12,512 --> 01:50:17,650
YOU CAN SEE IN THE SECOND COLUMN

3343
01:50:17,650 --> 01:50:21,254
AND ABLE TO USE FEATURES OF THAT

3344
01:50:21,254 --> 01:50:22,655
STRUCTURE LIKE THE FRACK TALL

3345
01:50:22,655 --> 01:50:23,856
DIMENSIONALITY TO IT, THE

3346
01:50:23,856 --> 01:50:25,324
BRANCHING FEATURES, AND YOU CAN

3347
01:50:25,324 --> 01:50:27,727
SEE ALL OF THESE NEW BIOMARKERS

3348
01:50:27,727 --> 01:50:30,496
IN THE THIRD ROW GOING ACROSS.

3349
01:50:30,496 --> 01:50:32,765
AND HAVE SHOWN IN A MORE THAN

3350
01:50:32,765 --> 01:50:34,967
500 PATIENT STUDY THAT THESE NEW

3351
01:50:34,967 --> 01:50:37,570
BIOMARKERS DRAMATICALLY ENHANCE

3352
01:50:37,570 --> 01:50:40,306
PERFORMANCE, SO ALMOST 94%

3353
01:50:40,306 --> 01:50:41,941
SENSITIVITY TO BREAST CANCER OF

3354
01:50:41,941 --> 01:50:45,311
ALL TUMOR SIZES AND ABOUT 89%

3355
01:50:45,311 --> 01:50:46,179
SPECIFICITY.

3356
01:50:46,179 --> 01:50:47,280
THEY'VE DEMONSTRATED THIS IN

3357
01:50:47,280 --> 01:50:48,481
KIDNEY, LIVER AND THYROID.

3358
01:50:48,481 --> 01:50:53,519
IN ADDITION TO BREAST CANCER.

3359
01:50:53,519 --> 01:50:54,821
SO AN INTERESTING AND PROMPTING

3360
01:50:54,821 --> 01:50:55,488
TECHNOLOGY DEVELOP M.

3361
01:50:55,488 --> 01:50:56,789
THERE ARE ALTERNATIVE APPROACHES

3362
01:50:56,789 --> 01:50:57,857
THAT ARE BEING DEVELOPED IN

3363
01:50:57,857 --> 01:51:01,194
BREAST IMAGING.

3364
01:51:01,194 --> 01:51:05,598
MANY OF US HAVE HEARD OF

3365
01:51:05,598 --> 01:51:06,966
PHOTOACOUSTIC COMPUTED

3366
01:51:06,966 --> 01:51:07,266
TOMOGRAPHY.

3367
01:51:07,266 --> 01:51:08,734
THIS INVOSMS USING A LASER WITH

3368
01:51:08,734 --> 01:51:10,069
A SHORT PULSE THAT DEPOSITS

3369
01:51:10,069 --> 01:51:11,270
ENERGY INTO THE TISSUE.

3370
01:51:11,270 --> 01:51:14,540
THE ENERGY IS ABSORBED BY BLOOD

3371
01:51:14,540 --> 01:51:15,842
VESSELS.

3372
01:51:15,842 --> 01:51:16,943
THE BLOOD VESSELS IN THE

3373
01:51:16,943 --> 01:51:18,478
DISSIPATION OF THAT ENERGY

3374
01:51:18,478 --> 01:51:21,114
GENERATE HEAT AND ALSO THEY

3375
01:51:21,114 --> 01:51:23,182
GENERATE MECHANICAL WAVES THAT

3376
01:51:23,182 --> 01:51:26,552
ARE PROPAGATING IN AT THE SPEED

3377
01:51:26,552 --> 01:51:29,922
OF SOUND FROM THE SOURCE BACK TO

3378
01:51:29,922 --> 01:51:31,157
THE SURFACE OF THE TISSUE.

3379
01:51:31,157 --> 01:51:32,325
THOSE MECHANICAL WAVES ARE WHAT

3380
01:51:32,325 --> 01:51:33,860
WE CALL BROADBAND ULTRASOUND, SO

3381
01:51:33,860 --> 01:51:36,596
YOU CAN USE AN ULTRASOUND

3382
01:51:36,596 --> 01:51:37,930
TRANSDUCER LITERALLY TO LISTEN

3383
01:51:37,930 --> 01:51:40,466
TO THE LIGHT THAT IS DEPOSITED

3384
01:51:40,466 --> 01:51:42,268
INSIDE THE TISSUE.

3385
01:51:42,268 --> 01:51:44,370
AND IF WE USE DIFFERENT

3386
01:51:44,370 --> 01:51:46,472
WAVELENGTHS OF LIGHT, WE CAN SEE

3387
01:51:46,472 --> 01:51:49,175
THE CONTRIBUTIONS DIFFERENTIALLY

3388
01:51:49,175 --> 01:51:52,478
OF OXYHEMOGLOBIN AND

3389
01:51:52,478 --> 01:51:53,779
DEOXYHEMOGLOBIN, IF YOU HAVE AN

3390
01:51:53,779 --> 01:51:54,981
AREA OF DENSE VASCULARITY AND

3391
01:51:54,981 --> 01:51:59,785
THIS IS WORK BEING LED BY MARK

3392
01:51:59,785 --> 01:52:04,490
AT ONE OF OUR TECHNOLOGY -- I

3393
01:52:04,490 --> 01:52:06,559
WOULD LIKE TO SAY THAT THESE ARE

3394
01:52:06,559 --> 01:52:11,264
FROM REAL PISHTS, BUT THEY

3395
01:52:11,264 --> 01:52:12,565
ILLUSTRATE -- I WANT TO GET

3396
01:52:12,565 --> 01:52:13,232
THESE THOUGH SPIN AROUND A

3397
01:52:13,232 --> 01:52:14,967
LITTLE BIT, THEY ILLUSTRATE THE

3398
01:52:14,967 --> 01:52:17,403
POTENTIAL TO SEPARATE THE

3399
01:52:17,403 --> 01:52:18,938
ARTERIAL SIDE FROM THE VENOUS

3400
01:52:18,938 --> 01:52:23,009
SIDE, AND QUANTIFY TISSUE

3401
01:52:23,009 --> 01:52:24,076
HEMOGLOBIN OXYGEN SATURATION IN

3402
01:52:24,076 --> 01:52:25,411
THE VESSELS AND IN THE TUMORS,

3403
01:52:25,411 --> 01:52:27,046
WHICH IS A NEW CONTRAST

3404
01:52:27,046 --> 01:52:30,016
MECHANISM THAT CAN BE USED TO

3405
01:52:30,016 --> 01:52:31,350
SEPARATE MALIGNANT FROM BENIGN

3406
01:52:31,350 --> 01:52:35,922
TUMORS.

3407
01:52:35,922 --> 01:52:38,124
IN GENITOURINARY SYMPTOMS OF

3408
01:52:38,124 --> 01:52:39,659
MENOPAUSE, THERE'S REALLY AN

3409
01:52:39,659 --> 01:52:42,728
INTERESTING PROJECT THAT IS LED

3410
01:52:42,728 --> 01:52:45,231
BY CHEN AND LANE AT U.C. IRVINE

3411
01:52:45,231 --> 01:52:46,966
WHERE THEY'VE DEVELOPED AN

3412
01:52:46,966 --> 01:52:49,268
INTRAVAGINAL OPTICAL COHERENCE

3413
01:52:49,268 --> 01:52:49,802
TOMOGRAPHY PROBE.

3414
01:52:49,802 --> 01:52:54,473
IF YOU HAVEN'T HEARD OF OPTICAL

3415
01:52:54,473 --> 01:52:55,107
COHERENCE TOMORROWGRAPHY IN THE

3416
01:52:55,107 --> 01:52:56,242
CONTEXT OF GENITOURINARY

3417
01:52:56,242 --> 01:52:57,476
SYNDROME, YOU'RE PROBABLY NOT

3418
01:52:57,476 --> 01:52:57,677
ALONE.

3419
01:52:57,677 --> 01:53:01,380
IT WAS DEVELOPED ORIGINALLY IN

3420
01:53:01,380 --> 01:53:03,583
OPHTHALMOLOGY, AND WE HAD LASKER

3421
01:53:03,583 --> 01:53:06,285
PRIZE WINNERS LAST YEAR, FEUJ

3422
01:53:06,285 --> 01:53:10,323
KNOWFORTHAT TECHNOLOGY.

3423
01:53:10,323 --> 01:53:12,091
IN OPHTHALMOLOGY, IT BEEN

3424
01:53:12,091 --> 01:53:12,959
TRANSFORMATIONAL IN THAT FIELD,

3425
01:53:12,959 --> 01:53:16,095
BUT IT BEING EXTENDED USING

3426
01:53:16,095 --> 01:53:17,263
FIBEROPTIC APPROACHES AND STATE

3427
01:53:17,263 --> 01:53:19,298
OF THE ART MICRO MECHANICAL

3428
01:53:19,298 --> 01:53:20,800
MACHINE SYSTEMS, SCANNERS, LOTS

3429
01:53:20,800 --> 01:53:23,002
OF REALLY COOL TECHNOLOGY ARE

3430
01:53:23,002 --> 01:53:25,504
GOING INTO THIS.

3431
01:53:25,504 --> 01:53:26,706
THIS GROUP HAS ADOPTED THAT

3432
01:53:26,706 --> 01:53:28,975
BEAUTIFUL TECHNOLOGY AND HAVE

3433
01:53:28,975 --> 01:53:30,843
DEVELOPED AN INTRAVAGINAL

3434
01:53:30,843 --> 01:53:33,479
IMAGING DEVICE THAT MEASURES THE

3435
01:53:33,479 --> 01:53:35,081
VAGINAL EPITHELIAL THICKNESS,

3436
01:53:35,081 --> 01:53:37,650
BLOOD VESSEL DENSITY, COLLAGEN

3437
01:53:37,650 --> 01:53:39,685
CONTENT AND ELASTICITY, AND HERE

3438
01:53:39,685 --> 01:53:43,189
I SHOW A SERIES OF IMAGES OF THE

3439
01:53:43,189 --> 01:53:43,823
VASCULAR STRUCTURE.

3440
01:53:43,823 --> 01:53:48,094
NOW AGAIN, THIS IS LABEL-FREE

3441
01:53:48,094 --> 01:53:49,629
AND THE INFORMATION ON THE

3442
01:53:49,629 --> 01:53:50,930
VASCULATURE COMES FROM

3443
01:53:50,930 --> 01:53:53,666
SCATTERING OF MOVING

3444
01:53:53,666 --> 01:53:55,635
ERYTHROCYTES, WHICH SHIFT THE

3445
01:53:55,635 --> 01:53:57,370
LIGHT SIGNAL SLIGHTLY IN

3446
01:53:57,370 --> 01:53:58,337
FREQUENCY, THAT'S CALLED THE

3447
01:53:58,337 --> 01:53:59,105
DOPPLER SHIFT.

3448
01:53:59,105 --> 01:54:03,142
SO THEY'RE ABLE TO TAKE THAT

3449
01:54:03,142 --> 01:54:04,343
INFORMATION, CALCULATE EXACTLY

3450
01:54:04,343 --> 01:54:06,545
WHERE THE MICRO VASCULATURE IS,

3451
01:54:06,545 --> 01:54:08,848
AND HERE YOU SEE BEFORE LASER

3452
01:54:08,848 --> 01:54:11,917
AND AFTER LASER TREATMENTS THAT

3453
01:54:11,917 --> 01:54:16,389
ARE SEPARATED BY FOUR WEEKS.

3454
01:54:16,389 --> 01:54:20,092
OOA VERY SIGNIFICANT INCREASE IN

3455
01:54:20,092 --> 01:54:20,559
EPITHELIAL THICKNESS.

3456
01:54:20,559 --> 01:54:24,697
I JUST WANT TO SHOW YOU WHAT A

3457
01:54:24,697 --> 01:54:25,998
TYPICAL PULL-BACK LOOKS LIKE.

3458
01:54:25,998 --> 01:54:27,566
SO THIS IS THE AMOUNT OF TIME

3459
01:54:27,566 --> 01:54:30,303
THAT IT TAKES TO GET ALL OF THAT

3460
01:54:30,303 --> 01:54:30,836
INFORMATION.

3461
01:54:30,836 --> 01:54:34,440
YOU SEE THIS IS A

3462
01:54:34,440 --> 01:54:36,108
CIRCUMFERENTIAL PULL-BACK VIEW.

3463
01:54:36,108 --> 01:54:38,744
THE DEPTH OF INTERROGATION IS

3464
01:54:38,744 --> 01:54:39,478
ABOUT 2 MILLIMETERS.

3465
01:54:39,478 --> 01:54:42,548
SO AS YOU PULL BACK, YOU GET

3466
01:54:42,548 --> 01:54:44,083
THAT FULL 2-MILLIMETER

3467
01:54:44,083 --> 01:54:46,152
THICKNESS, YOU GET THE FULL

3468
01:54:46,152 --> 01:54:46,819
INFORMATION CONTENT FROM THE

3469
01:54:46,819 --> 01:54:51,190
SURFACE AND ALL OF THAT DEPTH.

3470
01:54:51,190 --> 01:54:52,958
AND THEN THROUGH COMPUTATIONAL

3471
01:54:52,958 --> 01:54:54,126
APPROACHES CAN RENDER THAT

3472
01:54:54,126 --> 01:54:54,427
INFORMATION.

3473
01:54:54,427 --> 01:54:56,228
SO PRETTY SPECTACULAR

3474
01:54:56,228 --> 01:54:59,165
INFORMATION CONTENT AND

3475
01:54:59,165 --> 01:54:59,832
EXQUISITELY SENSITIVE CHANGES.

3476
01:54:59,832 --> 01:55:01,467
YOU CAN IMAGINE A VARIETY OF

3477
01:55:01,467 --> 01:55:05,838
DIFFERENT APPLICATIONS OF THAT.

3478
01:55:05,838 --> 01:55:08,074
LARINA AT THE UNIVERSITY OF

3479
01:55:08,074 --> 01:55:12,645
HOUSTON IS USING OCT IN MOUSE --

3480
01:55:12,645 --> 01:55:15,815
TO DRIVE OUR UNDERSTANDING OF

3481
01:55:15,815 --> 01:55:16,349
FERTILIZATION.

3482
01:55:16,349 --> 01:55:17,583
WHAT WE SEE HERE I DON'T

3483
01:55:17,583 --> 01:55:20,753
NECESSARILY NEED TO EXPLAIN IN

3484
01:55:20,753 --> 01:55:23,389
VIVO IMAGING OF OVULATION,

3485
01:55:23,389 --> 01:55:25,925
IMAGING CILIA, LOOKING AT THE

3486
01:55:25,925 --> 01:55:28,861
FREQUENCY OF BEADING OF THE

3487
01:55:28,861 --> 01:55:31,697
CILIA IN THE FALLOPIAN TUBES.

3488
01:55:31,697 --> 01:55:32,798
PRETTY SPECTACULAR, FIRST TIME

3489
01:55:32,798 --> 01:55:34,433
EVER AND THIS IS REALLY DRIVING

3490
01:55:34,433 --> 01:55:37,136
SOME UNDERSTANDINGS IN

3491
01:55:37,136 --> 01:55:38,671
TECHNOLOGY, AND IT'S BEING

3492
01:55:38,671 --> 01:55:40,005
TRANSLATED INTO THE CLINICAL

3493
01:55:40,005 --> 01:55:42,508
SETTING, WORKING WITH JENNIFER

3494
01:55:42,508 --> 01:55:44,143
BARTON IN THE DESIGN OF AN ENDO

3495
01:55:44,143 --> 01:55:46,645
SCOPE THAT CAN BE PUT THROUGH

3496
01:55:46,645 --> 01:55:50,616
THE CERVICAL OS AND UP INTO A

3497
01:55:50,616 --> 01:55:51,784
FALLOPIAN TUBE SO THE DIAMETER

3498
01:55:51,784 --> 01:55:53,786
IS LESS THAN A MILLIMETER.

3499
01:55:53,786 --> 01:55:55,955
IT PACKS IN AN ENORMOUS AMOUNT

3500
01:55:55,955 --> 01:56:04,830
OF CAPABILITY WITH FLUORESCENCE,

3501
01:56:04,830 --> 01:56:07,666
REFLECTANCE AND OPTICAL

3502
01:56:07,666 --> 01:56:08,100
TOMOGRAPHY.

3503
01:56:08,100 --> 01:56:11,737
WHAT YOU SEE, AS YOU INSERT THE

3504
01:56:11,737 --> 01:56:12,605
ENDOSCOPE, THE WHITE LIGHT

3505
01:56:12,605 --> 01:56:15,207
REFLECTING AND THEN RECONSTRUCT

3506
01:56:15,207 --> 01:56:17,543
INFORMATION ON THE STRUCTURE

3507
01:56:17,543 --> 01:56:19,512
WITHIN THE FALLOPIAN TUBE.

3508
01:56:19,512 --> 01:56:22,081
ON THE LOWER RIGHT, YOU CAN SEE

3509
01:56:22,081 --> 01:56:28,154
ONE FROM A NORMAL FLOAP WAN FALE

3510
01:56:28,154 --> 01:56:29,789
AND ONE WITH A PATIENT WITH

3511
01:56:29,789 --> 01:56:30,556
ENDOMETRIOSIS.

3512
01:56:30,556 --> 01:56:34,927
THEY'RE COLOR-CODED, AN ENTIRELY

3513
01:56:34,927 --> 01:56:36,896
NEW BIOMARKER DIAGNOSTIC THAT

3514
01:56:36,896 --> 01:56:39,298
REALLY HASN'T BEEN USED/SEEN

3515
01:56:39,298 --> 01:56:40,833
BEFORE AND THAT THEY'RE NOW

3516
01:56:40,833 --> 01:56:41,400
CHARACTERIZING FOR THE FIRST

3517
01:56:41,400 --> 01:56:41,700
TIME.

3518
01:56:41,700 --> 01:56:43,669
I'LL TRY TO JUST WRAP EVERYTHING

3519
01:56:43,669 --> 01:56:49,475
UP WITH THESE LAST TECHNOLOGY

3520
01:56:49,475 --> 01:56:52,645
EXAMPLES.

3521
01:56:52,645 --> 01:56:59,785
NIMMI RAMANUJAM AT DUKE, THE

3522
01:56:59,785 --> 01:57:01,287
CALLASCOPE ON RIGHT IS A

3523
01:57:01,287 --> 01:57:02,955
SELF-INSERTION SPECULUM-FREE

3524
01:57:02,955 --> 01:57:03,189
DEVICE.

3525
01:57:03,189 --> 01:57:06,759
YOU CAN SEE IT IN REALTIME BEING

3526
01:57:06,759 --> 01:57:08,828
INSERTED BY A PATIENT, AND THE

3527
01:57:08,828 --> 01:57:11,697
IMAGE ULTIMATELY THAT'S FORMED

3528
01:57:11,697 --> 01:57:15,301
IS REALLY THE SAME QUALITY AS A

3529
01:57:15,301 --> 01:57:19,905
VERY EXPENSIVE SCOPE THAT CAN

3530
01:57:19,905 --> 01:57:21,307
CAUSE 10, 15 OR 20 TIMES MORE,

3531
01:57:21,307 --> 01:57:22,074
DEPENDING ON WHATEVER EXAMPLE

3532
01:57:22,074 --> 01:57:22,842
THAT YOU GET.

3533
01:57:22,842 --> 01:57:26,011
AND THIS IS COMBINED WITH A

3534
01:57:26,011 --> 01:57:27,746
POCKET SCOPE THAT'S USED IN A

3535
01:57:27,746 --> 01:57:29,949
MORE TRADITIONAL SETTING WITH A

3536
01:57:29,949 --> 01:57:31,817
SPECULUM THAT HAS EVEN HIGHER

3537
01:57:31,817 --> 01:57:33,419
RESOLUTION CAPABILITY AND IS

3538
01:57:33,419 --> 01:57:37,590
QOIT POWERFUL  QUITE POWERFUL WU

3539
01:57:37,590 --> 01:57:39,492
COMBINE WITH ACETYL WHITENING.

3540
01:57:39,492 --> 01:57:42,695
THIS IS COMBINED WITH MULTIPLE

3541
01:57:42,695 --> 01:57:43,963
RESEARCH SITE ALL ACROSS THE

3542
01:57:43,963 --> 01:57:44,630
WORLD.

3543
01:57:44,630 --> 01:57:47,132
SHE'S ESTABLISHED THE CALLA

3544
01:57:47,132 --> 01:57:48,801
HEALTH FOUNDATION IN ORDER TO

3545
01:57:48,801 --> 01:57:51,303
DELIVER AND EXPAND ACCESS TO

3546
01:57:51,303 --> 01:57:54,406
THIS TECHNOLOGIES, INEXPENSE

3547
01:57:54,406 --> 01:57:56,775
SIEVE TECHNOLOGY.

3548
01:57:56,775 --> 01:58:01,280
SHE'S COORDINATING TO DEVELOP AN

3549
01:58:01,280 --> 01:58:02,815
IMAGING PROBE THAT WORKS IN

3550
01:58:02,815 --> 01:58:07,186
COMPATIBILITY WITH THE POCKET

3551
01:58:07,186 --> 01:58:09,054
SCOPE ITSELF, SO CAN YOU GO TO

3552
01:58:09,054 --> 01:58:10,723
SPECIFIC AREAS, GET VERY HIGH

3553
01:58:10,723 --> 01:58:12,358
RESOLUTION OF CELLULAR

3554
01:58:12,358 --> 01:58:15,427
PROCESSES, AND THEN MOVE THAT

3555
01:58:15,427 --> 01:58:18,163
ACROSS THE CERVIX TO BUILD UP

3556
01:58:18,163 --> 01:58:23,402
INFORMATION CONTENT ON CERVICAL

3557
01:58:23,402 --> 01:58:25,704
INTEREPITHELIAL APLASIAS AND

3558
01:58:25,704 --> 01:58:26,805
ULTIMATELY COME TO A DIAGNOSE ON

3559
01:58:26,805 --> 01:58:28,440
THE SPOT.

3560
01:58:28,440 --> 01:58:29,542
THE PERFORMANCE OVERALL OF THIS

3561
01:58:29,542 --> 01:58:31,944
DEVICE ACTUALLY EXCEEDS

3562
01:58:31,944 --> 01:58:32,878
HISTORICAL CLINICAL PERFORMANCE.

3563
01:58:32,878 --> 01:58:34,246
I CAN TALK ABOUT IT BUT LET ME

3564
01:58:34,246 --> 01:58:36,348
JUST SHOW YOU THIS VIDEO OF THE

3565
01:58:36,348 --> 01:58:37,316
PROBE IN ACTION.

3566
01:58:37,316 --> 01:58:39,518
YOU CAN SEE THESE WHITE SPOTS,

3567
01:58:39,518 --> 01:58:44,690
THOSE ARE ACTUALLY CELLULAR

3568
01:58:44,690 --> 01:58:46,859
STRUCTURES, THE WHITE IS REFLECK

3569
01:58:46,859 --> 01:58:48,494
TANTS FROM ACETYL WHITENING

3570
01:58:48,494 --> 01:58:50,262
COMING FROM THE NUCLEUS OF THOSE

3571
01:58:50,262 --> 01:58:51,230
CELLS, SO EVERY ONE OF THOSE

3572
01:58:51,230 --> 01:58:54,099
DOTS IS FROM A SINGLE CELL FROM

3573
01:58:54,099 --> 01:58:55,067
THE NUCLEUS.

3574
01:58:55,067 --> 01:58:57,269
THE BRAITNESS AND THE DENSITY IS

3575
01:58:57,269 --> 01:58:59,471
THE REFLECTION OF THE DISEASE

3576
01:58:59,471 --> 01:59:02,308
PROCESS THAT'S OCCURRING.

3577
01:59:02,308 --> 01:59:05,377
ON THE REALTIME CALCULATION

3578
01:59:05,377 --> 01:59:06,912
USING A TYPE OF NEURAL NETWORK

3579
01:59:06,912 --> 01:59:08,013
APPROACH THAT SCORES THE REGION

3580
01:59:08,013 --> 01:59:10,849
WHERE YOU ARE, AND ACCOUNTS FOR

3581
01:59:10,849 --> 01:59:12,651
ALL OF THE NUMBERS OF CELLS IN

3582
01:59:12,651 --> 01:59:16,021
THE FIELD OF VIEW TET.

3583
01:59:16,021 --> 01:59:17,222
THAT'S THE MTN SCORE.

3584
01:59:17,222 --> 01:59:18,457
SO YOU KIND OF GET THE IDEA,

3585
01:59:18,457 --> 01:59:19,325
THIS IS MULTI-SCALE.

3586
01:59:19,325 --> 01:59:21,627
YOU GET THE MACROSCOPIC IMAGING

3587
01:59:21,627 --> 01:59:25,030
FROM THE POCKET COLPOSCOPE WHICH

3588
01:59:25,030 --> 01:59:26,899
IS EXTREMELY INEXPENSIVE AND

3589
01:59:26,899 --> 01:59:28,867
ACCESSIBLE, AND YOU GET THE HIGH

3590
01:59:28,867 --> 01:59:31,070
RESOLUTION INFORMATION FROM THIS

3591
01:59:31,070 --> 01:59:35,774
PROBE THAT CAN BE MOVED AROUND

3592
01:59:35,774 --> 01:59:38,277
AND COME UP WITH A SCORE THAT'S

3593
01:59:38,277 --> 01:59:39,144
HIGHLY PREDICTIVE.

3594
01:59:39,144 --> 01:59:41,981
THE LAST THING I'D LIKE TO

3595
01:59:41,981 --> 01:59:46,051
SUPPORT, WE SUPPORT A

3596
01:59:46,051 --> 01:59:47,353
BIOTECHNOLOGY CENTER, AND THERE

3597
01:59:47,353 --> 01:59:48,887
ARE ABOUT A THOUSAND VIRTUAL

3598
01:59:48,887 --> 01:59:51,290
PATIENT MODELS FOR FEMALES, FOR

3599
01:59:51,290 --> 01:59:52,691
WOMEN THAT INCLUDE DETAILED

3600
01:59:52,691 --> 01:59:54,360
STRUCTURES OF BREAST AND BONE TO

3601
01:59:54,360 --> 01:59:56,795
OPTIMIZE IMAGING TECHNOLOGIES.

3602
01:59:56,795 --> 01:59:59,465
THEY DEVELOP SOME PHANTOMS AND

3603
01:59:59,465 --> 02:00:03,002
AN APPROACH TO ASSESS THE IMPACT

3604
02:00:03,002 --> 02:00:06,839
OF RADIATION IN SPACE TRAVEL,

3605
02:00:06,839 --> 02:00:08,374
AND WERE ABLE TO PUT THESE

3606
02:00:08,374 --> 02:00:11,977
MODELS ON THE ARTEMUS MISSION

3607
02:00:11,977 --> 02:00:20,386
THAT FLU ARO FLEW AROUND THE MO.

3608
02:00:20,386 --> 02:00:22,655
WE THINK A LOT ABOUT DIGITAL

3609
02:00:22,655 --> 02:00:24,823
TWINS, SO WE CAN DO THESE WITH

3610
02:00:24,823 --> 02:00:26,025
THESE MODELS WITHOUT HAVING TO

3611
02:00:26,025 --> 02:00:28,560
GO INTO VERY EXPENSIVE

3612
02:00:28,560 --> 02:00:29,428
HUMAN-BASED CLINICAL TRIALS.

3613
02:00:29,428 --> 02:00:31,296
CLEARLY GOING INTO SPACE AND

3614
02:00:31,296 --> 02:00:34,133
ASSESSING HOW A FEMALE AS NOT

3615
02:00:34,133 --> 02:00:36,368
WOULD BE EXPOSED TO RADIATION IS

3616
02:00:36,368 --> 02:00:37,970
ONE THAT'S NOT REALLY EASY OR

3617
02:00:37,970 --> 02:00:39,304
THAT COMMON TO DO, BUT THERE'S

3618
02:00:39,304 --> 02:00:42,908
SOME VERY COMMON ONES LIKE DOES

3619
02:00:42,908 --> 02:00:45,744
DIGITAL MEMOGRAPHY WORK AS WELL

3620
02:00:45,744 --> 02:00:49,581
AS WHAT WE MIGHT WANT TO DO WITH

3621
02:00:49,581 --> 02:00:50,549
ANOTHER TECHNOLOGY?

3622
02:00:50,549 --> 02:00:52,418
CAN WE EVALUATE AND COMPARE

3623
02:00:52,418 --> 02:00:53,285
DIGITAL MAMMOGRAPHY AS COMPARED

3624
02:00:53,285 --> 02:00:55,254
TO NEWER EMERGING TECHNOLOGIES?

3625
02:00:55,254 --> 02:00:57,356
AND THESE THINGS CAN ALL BE

3626
02:00:57,356 --> 02:01:00,092
EVALUATED IN THESE TYPES OF

3627
02:01:00,092 --> 02:01:01,727
VIRTUAL STUDIES.

3628
02:01:01,727 --> 02:01:03,929
SO LET ME TRY TO WRAP EVERYTHING

3629
02:01:03,929 --> 02:01:04,697
UP.

3630
02:01:04,697 --> 02:01:10,936
LOTS OF INVESTMENT ACROSS THE

3631
02:01:10,936 --> 02:01:12,371
NIH IN BIOENGINEERING

3632
02:01:12,371 --> 02:01:12,905
TECHNOLOGIES.

3633
02:01:12,905 --> 02:01:14,440
OUR WORKFORCE HAS BEEN A KEY

3634
02:01:14,440 --> 02:01:16,075
DRIVER, I THINK, IN WOMEN'S

3635
02:01:16,075 --> 02:01:18,043
HEALTH TECHNOLOGIES IN

3636
02:01:18,043 --> 02:01:18,477
BIOENGINEERING.

3637
02:01:18,477 --> 02:01:19,778
THERE'S BEEN AN ENORMOUS

3638
02:01:19,778 --> 02:01:20,913
INCREASE OVER THE LAST SEVERAL

3639
02:01:20,913 --> 02:01:21,113
YEARS.

3640
02:01:21,113 --> 02:01:24,850
IN TERMS OF WOMEN'S HEALTH, WE

3641
02:01:24,850 --> 02:01:26,151
SEE THESE PURPOSE-DRIVEN

3642
02:01:26,151 --> 02:01:27,352
ENGINEERING TECHNOLOGIES COMING

3643
02:01:27,352 --> 02:01:30,222
TO AN INSTITUTE THAT SAYS COME

3644
02:01:30,222 --> 02:01:31,523
TO US WITH YOUR IDEAS WITHOUT A

3645
02:01:31,523 --> 02:01:33,158
PURPOSE.

3646
02:01:33,158 --> 02:01:34,593
SO THERE'S A VERY INTERESTING

3647
02:01:34,593 --> 02:01:35,461
DRIVING FORCE BEHIND THAT.

3648
02:01:35,461 --> 02:01:37,229
WE SEE ENORMOUS CONTRIBUTIONS

3649
02:01:37,229 --> 02:01:40,099
FROM THE UNDERGRADUATE DESIGN

3650
02:01:40,099 --> 02:01:40,833
APPROACHES.

3651
02:01:40,833 --> 02:01:41,834
INNOVATION, ENTREPRENEURSHIP,

3652
02:01:41,834 --> 02:01:48,307
THE GROWTH OF THE FEMTECH

3653
02:01:48,307 --> 02:01:49,374
CENTER.

3654
02:01:49,374 --> 02:01:50,476
I SORT OF POSE THE QUESTION, IS

3655
02:01:50,476 --> 02:01:53,979
ALL OF THIS EXPANSION IN OUR

3656
02:01:53,979 --> 02:01:54,947
COMMUNITY, UNDERGRADS AND

3657
02:01:54,947 --> 02:01:56,148
GRADUATE LEVEL AND FACULTY

3658
02:01:56,148 --> 02:01:57,683
LEVEL, IS THAT A KEY DRIVER FOR

3659
02:01:57,683 --> 02:01:59,218
THE GROWTH OF THESE WOMEN'S

3660
02:01:59,218 --> 02:02:00,419
HEALTH TECHNOLOGIES?

3661
02:02:00,419 --> 02:02:03,489
I IMAGINE IF YOU DOLL THE

3662
02:02:03,489 --> 02:02:04,556
THOUGHT EXPERIMENT AND TAKE ALL

3663
02:02:04,556 --> 02:02:06,358
THOSE FOLKS AWAY I THINK THE

3664
02:02:06,358 --> 02:02:07,326
EASY ANSWER IS YES.

3665
02:02:07,326 --> 02:02:08,861
BUT TO UNDERSTAND IT A LITTLE

3666
02:02:08,861 --> 02:02:10,395
MORE DEEPLY AND ENCOURAGE IT

3667
02:02:10,395 --> 02:02:11,930
FURTHER, WE HAVE A NUMBER OF

3668
02:02:11,930 --> 02:02:12,297
CHALLENGES.

3669
02:02:12,297 --> 02:02:14,466
WE NEED TO CONTINUE TO INCREASE

3670
02:02:14,466 --> 02:02:15,968
THE NUMBER OF WOMEN IN

3671
02:02:15,968 --> 02:02:17,069
BIOMEDICAL ENGINEERING SO THE

3672
02:02:17,069 --> 02:02:21,340
FACULTY NUMBERS ROW FLECT THE

3673
02:02:21,340 --> 02:02:24,309
PH.D. NUMBERS, THE PH.D. NUMBERS

3674
02:02:24,309 --> 02:02:25,277
REPRESENT THE STUDENTS.

3675
02:02:25,277 --> 02:02:27,479
THE VALIDATION OF MANY OF THESE

3676
02:02:27,479 --> 02:02:28,647
TECHNOLOGIES, WE KNOW CULTURALLY

3677
02:02:28,647 --> 02:02:30,549
IT CAN TAKE A WHILE FOR THESE

3678
02:02:30,549 --> 02:02:33,051
ADVANCES TO MOVE, AND OVERALL,

3679
02:02:33,051 --> 02:02:34,486
WE NEED TO BE INNOVATIVE IN THE

3680
02:02:34,486 --> 02:02:35,387
OPPORTUNITIES THAT WE CREATE.

3681
02:02:35,387 --> 02:02:38,757
SO WE TALKED ABOUT THE RADX

3682
02:02:38,757 --> 02:02:39,525
PROGRAM.

3683
02:02:39,525 --> 02:02:40,626
THESE ARE ALTERNATIVE PATHWAYS

3684
02:02:40,626 --> 02:02:42,394
TO HELP STIMULATE INNOVATION,

3685
02:02:42,394 --> 02:02:43,695
COMMERCIALIZATION, AND

3686
02:02:43,695 --> 02:02:46,365
PARTICIPATION, EASIER

3687
02:02:46,365 --> 02:02:46,999
PARTICIPATION IN THE DEVELOPMENT

3688
02:02:46,999 --> 02:02:47,900
OF THESE TECHNOLOGIES FOR

3689
02:02:47,900 --> 02:02:48,333
WOMEN'S HEALTH.

3690
02:02:48,333 --> 02:02:58,744
SO WITH THAT, I WILL WRAP IT UP.

3691
02:02:58,744 --> 02:03:01,914
>> THANK YOU SO MUCH,
BRUCE.

3692
02:03:01,914 --> 02:03:03,115
I'M NOT SURE WHAT TO SAY.

3693
02:03:03,115 --> 02:03:06,418
THAT WAS AN INCREDIBLY

3694
02:03:06,418 --> 02:03:10,789
COMPREHENSIVE PICTURE OF

3695
02:03:10,789 --> 02:03:12,658
OPPORTUNITIES, OF ADVANCES, OF

3696
02:03:12,658 --> 02:03:14,526
PROMISE, AND ALL THE INCREDIBLE

3697
02:03:14,526 --> 02:03:17,029
WORK THAT NIBIB IS LEADING IN

3698
02:03:17,029 --> 02:03:17,863
THIS SPACE COLLABORATIVELY

3699
02:03:17,863 --> 02:03:22,301
ACROSS NIH.

3700
02:03:22,301 --> 02:03:23,735
WE ARE A LITTLE OVER, SO LET ME

3701
02:03:23,735 --> 02:03:30,008
ASK IF THERE ARE ANY COMPELLING

3702
02:03:30,008 --> 02:03:30,642
QUESTIONS.

3703
02:03:30,642 --> 02:03:31,410
DR. ANDERSON HAS A QUESTION, I

3704
02:03:31,410 --> 02:03:31,743
CAN TELL.

3705
02:03:31,743 --> 02:03:32,277
>> THANK YOU.

3706
02:03:32,277 --> 02:03:33,712
IT WAS REALLY EXCITING TO SEE

3707
02:03:33,712 --> 02:03:37,883
ALL OF THIS AND THE PROGRESS IN

3708
02:03:37,883 --> 02:03:38,851
HAVING WOMEN IN THE FIELD AND

3709
02:03:38,851 --> 02:03:40,152
PUSHING THIS IS JUST REALLY

3710
02:03:40,152 --> 02:03:40,652
REWARDING.

3711
02:03:40,652 --> 02:03:41,954
I HAVE ONE SIMPLE QUESTION.

3712
02:03:41,954 --> 02:03:45,023
WHAT FRACTION OF THE BIOMEDICAL

3713
02:03:45,023 --> 02:03:45,791
ENGINEERING DEPARTMENTS ARE LED

3714
02:03:45,791 --> 02:03:48,427
BY WOMEN?

3715
02:03:48,427 --> 02:03:49,428
>> OH, GOSH.

3716
02:03:49,428 --> 02:03:53,365
YOU KNOW, THAT'S A QUESTION YOU

3717
02:03:53,365 --> 02:03:54,766
COULD ASK PERHAPS SUSAN

3718
02:03:54,766 --> 02:03:56,301
MARGULIES, WHO'S COMING LATER,

3719
02:03:56,301 --> 02:03:59,805
AND WHO, IN FACT, HAS LED TWO

3720
02:03:59,805 --> 02:04:00,339
BIOENGINEERING DEPARTMENTS

3721
02:04:00,339 --> 02:04:02,207
HERSELF AND IS VERY IN TUNE WITH

3722
02:04:02,207 --> 02:04:04,209
THAT, AND NOW LEADS THE NATIONAL

3723
02:04:04,209 --> 02:04:07,179
SCIENCE FOUNDATION'S ENGINEERING

3724
02:04:07,179 --> 02:04:08,347
DIRECTORATE.

3725
02:04:08,347 --> 02:04:10,215
BUT SEVERAL OF THEM ARE ON NIGH

3726
02:04:10,215 --> 02:04:13,986
NATON MYNATIONAL ADVISORY COUNC.

3727
02:04:13,986 --> 02:04:15,220
I THINK IT'S -- I DON'T WANT TO

3728
02:04:15,220 --> 02:04:18,156
GIVE YOU A HARD NUMBER, BUT IT'S

3729
02:04:18,156 --> 02:04:20,025
SIGNIFICANT, I THINK.

3730
02:04:20,025 --> 02:04:21,693
>> I ASK BECAUSE, YOU
KNOW, IN

3731
02:04:21,693 --> 02:04:25,130
THE MEDICAL FIELD, WE HAVE

3732
02:04:25,130 --> 02:04:27,032
SOMEWHAT OF A FALLOFF OF WOMEN

3733
02:04:27,032 --> 02:04:28,567
HE HIGHER LEVELS OF LEADERSHIP,

3734
02:04:28,567 --> 02:04:29,902
SO I'M JUST WONDERING WHETHER

3735
02:04:29,902 --> 02:04:31,003
YOU MIGHT BE A LITTLE BEHIND IN

3736
02:04:31,003 --> 02:04:32,304
THAT BECAUSE YOUR WOMEN ARE JUST

3737
02:04:32,304 --> 02:04:33,705
COMING INTO THAT, BUT SOMETHING

3738
02:04:33,705 --> 02:04:34,873
TO PAY ATTENTION TO.

3739
02:04:34,873 --> 02:04:36,508
>> WELL, AND YOU KNOW,
ANOTHER

3740
02:04:36,508 --> 02:04:38,810
THING, AND EVEN KIND OF AT

3741
02:04:38,810 --> 02:04:44,049
ANOTHER LEVEL, WE SEE MANY

3742
02:04:44,049 --> 02:04:45,250
WOMEN, BIOMEDICAL ENGINEERS,

3743
02:04:45,250 --> 02:04:47,019
TAKING LEADERSHIP POSITIONS AT

3744
02:04:47,019 --> 02:04:49,655
THE DEAN LEVEL IN SCHOOLS OF

3745
02:04:49,655 --> 02:04:49,955
ENGINEERING.

3746
02:04:49,955 --> 02:04:52,925
AND SO LONG TIME COLLEAGUE OF

3747
02:04:52,925 --> 02:04:56,094
MINE, NANCY, THE DEAN OF THE

3748
02:04:56,094 --> 02:04:59,731
UNIVERSITY OF WASHINGTON, -- SO

3749
02:04:59,731 --> 02:05:01,800
NOT JUST BIOENGINEERING, THEY

3750
02:05:01,800 --> 02:05:03,368
ARE NOW LEADING BROADER EFFORTS

3751
02:05:03,368 --> 02:05:05,404
IN ENGINEERING.

3752
02:05:05,404 --> 02:05:07,139
THREE OF THE PAST PRESIDENTS OF

3753
02:05:07,139 --> 02:05:08,106
THE AMERICAN INSTITUTE OF

3754
02:05:08,106 --> 02:05:09,174
MEDICAL AND BIOLOGICAL

3755
02:05:09,174 --> 02:05:11,576
ENGINEERING ARE WOMEN.

3756
02:05:11,576 --> 02:05:14,746
SO WE'RE SEEING CERTAINLY

3757
02:05:14,746 --> 02:05:16,281
GROWTH -- BUT THIS IS ALL

3758
02:05:16,281 --> 02:05:16,548
ANECDOTAL.

3759
02:05:16,548 --> 02:05:18,350
>> DR. TEMPLETON, DO YOU
HAVE A

3760
02:05:18,350 --> 02:05:19,017
QUESTION ONLINE?

3761
02:05:19,017 --> 02:05:19,718
>> YEAH, YOU THAT VERY
MUCH.

3762
02:05:19,718 --> 02:05:22,788
IT WAS AN AMAZING PRESENTATION.

3763
02:05:22,788 --> 02:05:24,423
REALLY, I'M OVERWHELMED WITH THE

3764
02:05:24,423 --> 02:05:25,557
AMOUNT OF WORK THAT YOU'RE

3765
02:05:25,557 --> 02:05:25,757
DOING.

3766
02:05:25,757 --> 02:05:26,091
>> THANK YOU.

3767
02:05:26,091 --> 02:05:27,626
>> BUT A QUESTION ABOUT
THE

3768
02:05:27,626 --> 02:05:28,493
UNDERGRADUATES THAT ARE DOING

3769
02:05:28,493 --> 02:05:29,828
TEASE PROJECTS, WHICH ARE

3770
02:05:29,828 --> 02:05:31,029
AMAZING.

3771
02:05:31,029 --> 02:05:33,665
IS THERE AN EDUCATION PROGRAM OR

3772
02:05:33,665 --> 02:05:35,200
MODULE OR SOME SORT OF OUTREACH

3773
02:05:35,200 --> 02:05:36,868
TO THESE STUDENTS AHEAD OF TIME

3774
02:05:36,868 --> 02:05:39,371
TO TALK ABOUT THE EXPANSE OF

3775
02:05:39,371 --> 02:05:41,573
WOMEN'S HEALTH SO THEY CAN SEE

3776
02:05:41,573 --> 02:05:42,874
ALL OF THE BREADTH OF CONDITIONS

3777
02:05:42,874 --> 02:05:44,309
THAT COULD BE INCLUDED?

3778
02:05:44,309 --> 02:05:46,511
BEYOND THE TRADITIONAL VIEWS OF

3779
02:05:46,511 --> 02:05:49,348
WOMEN'S HEALTH INTO THINGS SUCH

3780
02:05:49,348 --> 02:05:53,618
AS OSTEOPOROSIS, PULLS,

3781
02:05:53,618 --> 02:05:54,519
FRACTURES, OSTEOARTHRITIS,

3782
02:05:54,519 --> 02:05:55,954
CHRONIC PAIN, ARE THEY LEARNING

3783
02:05:55,954 --> 02:05:56,555
ABOUT WOMEN'S HEALTH AND THEN

3784
02:05:56,555 --> 02:05:57,589
COMING UP WITH PROJECTS OR HOW

3785
02:05:57,589 --> 02:05:58,590
IS THAT HAPPENING?

3786
02:05:58,590 --> 02:06:00,993
>> NO, THAT'S GREAT
QUESTION,

3787
02:06:00,993 --> 02:06:01,994
AND I THINK THAT'S THE MISSION

3788
02:06:01,994 --> 02:06:04,629
THAT JANINE AND I ARE ON, WITH

3789
02:06:04,629 --> 02:06:08,033
THIS KIND OF EFFORT TO REALLY

3790
02:06:08,033 --> 02:06:10,002
KIND OF BRIDGE OUR COMMUNITIES

3791
02:06:10,002 --> 02:06:11,670
IN A SYSTEMATIC AND THOUGHTFUL

3792
02:06:11,670 --> 02:06:11,937
WAY.

3793
02:06:11,937 --> 02:06:13,505
SO IT'S A TERRIFIC SUGGESTION TO

3794
02:06:13,505 --> 02:06:14,639
INTEGRATE THAT IN EDUCATION.

3795
02:06:14,639 --> 02:06:17,609
ONE OF THE THINGS THAT'S -- IF

3796
02:06:17,609 --> 02:06:19,678
YOU'RE A BIOMEDICAL ENGINEERING

3797
02:06:19,678 --> 02:06:23,415
DEPARTMENT AND YOU DON'T HAVE A

3798
02:06:23,415 --> 02:06:24,383
BIODESIGN PROGRAM WITH

3799
02:06:24,383 --> 02:06:25,283
SIGNIFICANT INSTRUCTION ON HOW

3800
02:06:25,283 --> 02:06:28,120
YOU DEVELOP DEVICES, HOW YOU

3801
02:06:28,120 --> 02:06:30,655
MOVE THEM THROUGH THE

3802
02:06:30,655 --> 02:06:31,990
AUTHORIZATION PROCESS, AND HOW

3803
02:06:31,990 --> 02:06:33,959
YOU SECURE AND RAISE FUNDING FOR

3804
02:06:33,959 --> 02:06:36,561
YOUR IDEAS AND CONTINUED GROWTH.

3805
02:06:36,561 --> 02:06:38,663
AT THE UNDERGRADUATE LEVEL, THEN

3806
02:06:38,663 --> 02:06:41,566
YOU'RE NOT GOING TO GET STUDENTS

3807
02:06:41,566 --> 02:06:41,867
WHO COME.

3808
02:06:41,867 --> 02:06:45,470
SO I THINK THAT WOULD BE A VERY

3809
02:06:45,470 --> 02:06:47,272
ATTRACTIVE PIECE THAT SHOULD BE

3810
02:06:47,272 --> 02:06:48,473
INTEGRATED INTO THE ENGINEERING

3811
02:06:48,473 --> 02:06:50,675
CURRICULUM, AND I'LL HAVE MORE

3812
02:06:50,675 --> 02:06:52,611
OF A DISCUSSION WITH THAT IN OUR

3813
02:06:52,611 --> 02:06:53,645
TRAINING DIVISION AND SORT OF

3814
02:06:53,645 --> 02:06:56,181
IMAGINE HOW WE COULD DO THAT.

3815
02:06:56,181 --> 02:06:57,783
>> THAT'S GREAT BECAUSE
THAT

3816
02:06:57,783 --> 02:06:58,984
MIGHT ATTRACT EVEN MORE WOMEN TO

3817
02:06:58,984 --> 02:07:00,552
THE FIELD IF THEY COULD SEE THE

3818
02:07:00,552 --> 02:07:01,887
LINK BETWEEN EVERYTHING THAT

3819
02:07:01,887 --> 02:07:02,421
COMPRISES WOMEN'S HEALTH.

3820
02:07:02,421 --> 02:07:02,854
THANK YOU.

3821
02:07:02,854 --> 02:07:03,955
>> YEAH, THANK YOU.

3822
02:07:03,955 --> 02:07:05,757
AND I SHOULD ALSO EMPHASIZE HOW

3823
02:07:05,757 --> 02:07:07,726
THESE DESIGN PROJECTS ARE

3824
02:07:07,726 --> 02:07:10,429
SELECTED, LIKE THE STUDENTS

3825
02:07:10,429 --> 02:07:12,731
THEMSELVES ARE -- THEY ARE

3826
02:07:12,731 --> 02:07:15,600
THINKING THROUGH THE IDEAS AND

3827
02:07:15,600 --> 02:07:16,802
SYSTEMATICALLY GOING AROUND AND

3828
02:07:16,802 --> 02:07:18,437
INTERVIEWS PEOPLE THROUGH A VERY

3829
02:07:18,437 --> 02:07:19,671
SYSTEMATIC PROCESS TO UNDERSTAND

3830
02:07:19,671 --> 02:07:21,106
THE NEED AND ENGAGING.

3831
02:07:21,106 --> 02:07:22,841
SO THERE ARE MULTIPLE WAYS THAT

3832
02:07:22,841 --> 02:07:25,710
THESE THINGS DO COME ABOUT.

3833
02:07:25,710 --> 02:07:27,813
>> THANKS, KIM.

3834
02:07:27,813 --> 02:07:28,080
DR. NOEL?

3835
02:07:28,080 --> 02:07:30,549
>> HI, ALEXANDRA NOEL.

3836
02:07:30,549 --> 02:07:31,416
VERY NICE PRESENTATION.

3837
02:07:31,416 --> 02:07:35,921
YOU MENTIONED ABOUT THE

3838
02:07:35,921 --> 02:07:36,588
POSTPARTUM WEARABLE OR SENSORS

3839
02:07:36,588 --> 02:07:37,789
THAT ARE AVAILABLE FOR WOMEN AND

3840
02:07:37,789 --> 02:07:39,424
YOU TALKED ALSO A LOT ABOUT

3841
02:07:39,424 --> 02:07:42,394
FETAL MONITORING IN TERMS OF

3842
02:07:42,394 --> 02:07:43,061
BIOLOGICAL OUTCOMES.

3843
02:07:43,061 --> 02:07:46,031
I WAS WONDERING IF THERE ARE ANY

3844
02:07:46,031 --> 02:07:47,265
PROJECTS THAT ARE ALSO LOOKING

3845
02:07:47,265 --> 02:07:49,868
AT WEARABLE SENSORS FOR PREGNANT

3846
02:07:49,868 --> 02:07:52,604
WOMEN TO LOOK AT EXPOSURE

3847
02:07:52,604 --> 02:07:54,473
ASSESSMENT, FOR EXAMPLE, WITH

3848
02:07:54,473 --> 02:07:55,941
AIR POLLUTION BECAUSE THAT HAS A

3849
02:07:55,941 --> 02:07:57,242
GREAT -- WE KNOW THAT THAT CAN

3850
02:07:57,242 --> 02:07:59,010
AFFECT THE GENE ENVIRONMENT

3851
02:07:59,010 --> 02:08:00,879
INTERACTION AND THAT COULD ALSO

3852
02:08:00,879 --> 02:08:02,747
AFFECT THE OFFSPRING OR THE

3853
02:08:02,747 --> 02:08:04,049
NEONATE, SO JUST WONDERING.

3854
02:08:04,049 --> 02:08:06,918
>> NO, I FEEL LIKE AT SOME
POINT

3855
02:08:06,918 --> 02:08:09,387
IN THE FUTURE, THE EXPOSOME IS

3856
02:08:09,387 --> 02:08:11,456
GOING TO BE PART OF OUR

3857
02:08:11,456 --> 02:08:13,859
ELECTRONIC HEALTH RECORD.

3858
02:08:13,859 --> 02:08:15,193
HOW ARE WE GOING TO GET THERE?

3859
02:08:15,193 --> 02:08:16,828
I THINK THE ONLY THING I KNOW

3860
02:08:16,828 --> 02:08:18,263
FOR SURE IS WE'VE GOT TO ENGAGE

3861
02:08:18,263 --> 02:08:20,232
THE ENGINEERING COMMUNITY AND

3862
02:08:20,232 --> 02:08:24,402
THE DIRECTOR OF NIEHS, RICK

3863
02:08:24,402 --> 02:08:26,037
WOYCHIK, HAS GIVEN A QUITE

3864
02:08:26,037 --> 02:08:27,939
INSPIRATIONAL TALK AT NIBIB

3865
02:08:27,939 --> 02:08:29,241
EXACTLY ALONG THOSE LINES

3866
02:08:29,241 --> 02:08:31,776
SAYING, OKAY, YOU GUYS, SH WE'VE

3867
02:08:31,776 --> 02:08:34,880
GOT TO COME UP WITH SYSTEMATIC

3868
02:08:34,880 --> 02:08:36,081
AND POTENTIALLY WEARABLE

3869
02:08:36,081 --> 02:08:38,283
APPROACHES TO GET MEASURABLE

3870
02:08:38,283 --> 02:08:40,051
FEATURES AT THE EXPOSOME THAT WE

3871
02:08:40,051 --> 02:08:41,486
CAN INTEGRATE INTO THE HEALTH

3872
02:08:41,486 --> 02:08:46,491
RECORD OF INDIVIDUALS AND --

3873
02:08:46,491 --> 02:08:47,159
OUTCOMES RELATED TO THOSE

3874
02:08:47,159 --> 02:08:47,592
THINGS.

3875
02:08:47,592 --> 02:08:49,694
WHAT DO WE NEED TO INTEGRATE?

3876
02:08:49,694 --> 02:08:53,965
IT'S MORE COMPLICATED THAN THE

3877
02:08:53,965 --> 02:08:55,534
APPLE WATCH, I THINK WE CAN SAY

3878
02:08:55,534 --> 02:08:57,302
THAT, BUT IT'S NOT AS

3879
02:08:57,302 --> 02:08:57,936
COMPLICATED AS SOME OF THOSE

3880
02:08:57,936 --> 02:08:59,271
THINGS THAT I SHOWED YOU TODAY.

3881
02:08:59,271 --> 02:09:00,672
SO THIS IS GOING TO REQUIRE

3882
02:09:00,672 --> 02:09:01,273
COMMUNITY EFFORT.

3883
02:09:01,273 --> 02:09:02,140
PHYSICIANS WORKING WITH

3884
02:09:02,140 --> 02:09:04,309
ENGINEERS TO SAY, THESE ARE

3885
02:09:04,309 --> 02:09:06,411
IMPORTANT THINGS TO MEASURE.

3886
02:09:06,411 --> 02:09:07,512
WE NEED TO UNDERSTAND, BECAUSE

3887
02:09:07,512 --> 02:09:10,048
WE CAN MEASURE ANYTHING.

3888
02:09:10,048 --> 02:09:11,116
AND SO REALLY TEASING THAT OUT

3889
02:09:11,116 --> 02:09:13,251
AND GETTING THE ENVIRONMENTAL

3890
02:09:13,251 --> 02:09:14,886
SCIENCE COMMUNITY, ENVIRONMENTAL

3891
02:09:14,886 --> 02:09:16,087
HEALTH COMMUNITY TO FOCUS IN,

3892
02:09:16,087 --> 02:09:17,389
BECAUSE THE EXPOSOME IS

3893
02:09:17,389 --> 02:09:19,191
EVERYTHING, AND IT CAN BE QUITE

3894
02:09:19,191 --> 02:09:19,824
OVERWHELMING.

3895
02:09:19,824 --> 02:09:22,460
BUT I AM CONFIDENT THAT AT SOME

3896
02:09:22,460 --> 02:09:23,461
POINT IN THE FUTURE, IT'S GOING

3897
02:09:23,461 --> 02:09:25,797
TO BE PART OF OUR EHR THAT'S

3898
02:09:25,797 --> 02:09:26,998
GOING TO BE CRITICALLY

3899
02:09:26,998 --> 02:09:30,936
IMPORTANT.

3900
02:09:30,936 --> 02:09:32,604
>> THANK YOU FOR THIS
AMAZING

3901
02:09:32,604 --> 02:09:32,938
PRESENTATION.

3902
02:09:32,938 --> 02:09:34,239
BECAUSE TIME IS SHORT, I WON'T

3903
02:09:34,239 --> 02:09:35,607
ANSWER ANY OF THOSE COMMENTS BUT

3904
02:09:35,607 --> 02:09:37,075
I'LL FOLLOW UP WITH YOU BECAUSE

3905
02:09:37,075 --> 02:09:38,276
THERE ARE SEVERAL CONNECTION

3906
02:09:38,276 --> 02:09:38,476
POINT.

3907
02:09:38,476 --> 02:09:40,478
>> I'LL BE HANGING AROUND,
SO IF

3908
02:09:40,478 --> 02:09:42,781
FOLKS HAVE SOME QUESTIONS, I'M

3909
02:09:42,781 --> 02:09:43,481
HAPPY TO TALK.

3910
02:09:43,481 --> 02:09:45,450
>> THANK YOU SO MUCH,

3911
02:09:45,450 --> 02:09:45,784
DR. TROMBERG.

3912
02:09:45,784 --> 02:09:47,419
WE APPRECIATE YOUR PRESENTATION.

3913
02:09:47,419 --> 02:09:50,155
[APPLAUSE]

3914
02:09:50,155 --> 02:09:51,690
IT'S NOW MY PLEASURE TO

3915
02:09:51,690 --> 02:09:53,024
INTRODUCE OUR NEXT SPEAKER,

3916
02:09:53,024 --> 02:09:54,292
DR. MATT MCMAHON, WHO'S THE

3917
02:09:54,292 --> 02:09:56,094
DIRECTOR FOR THE NIH SMALL

3918
02:09:56,094 --> 02:09:57,762
BUSINESS EDUCATION AND

3919
02:09:57,762 --> 02:10:00,232
ENTREPRENEURIAL DEVELOPMENT OR

3920
02:10:00,232 --> 02:10:01,833
SEED OFFICE.

3921
02:10:01,833 --> 02:10:03,034
HE LEADS THE SEED OFFICE IN

3922
02:10:03,034 --> 02:10:06,104
HELPING TO TRANSFORM CUTTING

3923
02:10:06,104 --> 02:10:07,205
EDGE TECHNOLOGIES INTO PRODUCTS

3924
02:10:07,205 --> 02:10:08,173
TO IMPROVE HEALTH AND SAVE

3925
02:10:08,173 --> 02:10:09,074
LIVES.

3926
02:10:09,074 --> 02:10:13,144
HE HAS A DIVERSE BACKGROUND IN

3927
02:10:13,144 --> 02:10:14,379
ACADEMIA OF SMALL BUSINESSES,

3928
02:10:14,379 --> 02:10:16,781
CONGRESSIONAL POLICY, AND NIH

3929
02:10:16,781 --> 02:10:18,083
PROGRAM MANAGEMENT, AND HE

3930
02:10:18,083 --> 02:10:21,786
PREVIOUSLY SERVED AS THE FIRST

3931
02:10:21,786 --> 02:10:24,356
DIRECTOR OF NHLBI'S OFFICE OF

3932
02:10:24,356 --> 02:10:27,325
TRANSLATIONAL ALLIANCES AND

3933
02:10:27,325 --> 02:10:28,760
COORDINATION, AND HE CREATED THE

3934
02:10:28,760 --> 02:10:29,761
NEI OFFICE OF TRANSLATIONAL

3935
02:10:29,761 --> 02:10:30,061
RESEARCH.

3936
02:10:30,061 --> 02:10:32,831
SO PLEASE HELP ME WELCOME

3937
02:10:32,831 --> 02:10:35,900
DR. MATT MCMAHON.

3938
02:10:35,900 --> 02:10:38,203
>> WELL, THANK YOU VERY
MUCH FOR

3939
02:10:38,203 --> 02:10:38,837
INVITING ME.

3940
02:10:38,837 --> 02:10:40,272
IT'S REALLY A GREAT OPPORTUNITY

3941
02:10:40,272 --> 02:10:43,908
TO BE HERE AND TALK TO THIS

3942
02:10:43,908 --> 02:10:46,544
ADVISORY COUNCIL, AND TO BUILD

3943
02:10:46,544 --> 02:10:49,047
SOME MORE BRIDGES BETWEEN THE

3944
02:10:49,047 --> 02:10:51,383
COMMUNITIES THAT WE REPRESENT,

3945
02:10:51,383 --> 02:10:53,385
BECAUSE WE HAVE MANY OVERLAPPING

3946
02:10:53,385 --> 02:10:54,152
GOALS.

3947
02:10:54,152 --> 02:10:56,888
ONE OF THE THINGS THAT I LIKE TO

3948
02:10:56,888 --> 02:11:00,525
POINT OUT IS THAT MANY PEOPLE

3949
02:11:00,525 --> 02:11:02,294
UNDERSTAND NIH AS BEING THE

3950
02:11:02,294 --> 02:11:04,362
FOUNDATION OF BASIC BIOMEDICAL

3951
02:11:04,362 --> 02:11:06,331
RESEARCH IN THE UNITED STATES.

3952
02:11:06,331 --> 02:11:07,899
BUT IT'S ALSO IMPORTANT TO NOTE

3953
02:11:07,899 --> 02:11:10,402
THAT THE MISSION OF THE NIH IS

3954
02:11:10,402 --> 02:11:12,804
NOT JUST TO SEEK FUNDAMENTAL

3955
02:11:12,804 --> 02:11:14,105
KNOWLEDGE ABOUT THE NATURE AND

3956
02:11:14,105 --> 02:11:16,207
BEHAVIOR OF LIVING SYSTEMS, BUT

3957
02:11:16,207 --> 02:11:19,511
ALSO TO APPLY THAT KNOWLEDGE TO

3958
02:11:19,511 --> 02:11:21,346
ENHANCE HEALTH, LENGTHEN LIFE

3959
02:11:21,346 --> 02:11:23,048
AND REDUCE ILLNESS AND

3960
02:11:23,048 --> 02:11:23,882
DISABILITY.

3961
02:11:23,882 --> 02:11:28,920
SO THAT APPLICATION OF THE BASIC

3962
02:11:28,920 --> 02:11:30,455
BIOLOGICAL KNOWLEDGE THAT WE

3963
02:11:30,455 --> 02:11:32,891
GENERATE THROUGH ALL OF THE

3964
02:11:32,891 --> 02:11:34,859
RESEARCH THAT WE FUND ACROSS THE

3965
02:11:34,859 --> 02:11:36,494
COUNTRY IS A CRITICAL PART OF

3966
02:11:36,494 --> 02:11:38,496
WHAT WE'RE TRYING TO DO.

3967
02:11:38,496 --> 02:11:40,131
THE SEED OFFICE IS A RELATIVELY

3968
02:11:40,131 --> 02:11:42,467
NEW PLAYER ON THE SCENE.

3969
02:11:42,467 --> 02:11:47,806
THE SEED OFFICE WAS FOUNDED AT

3970
02:11:47,806 --> 02:11:49,107
NIH AROUND 2019, AND THE REASON

3971
02:11:49,107 --> 02:11:53,845
THAT THE SEED OFFICE WAS FOUNDED

3972
02:11:53,845 --> 02:11:55,714
IS BECAUSE ALL ACROSS THE

3973
02:11:55,714 --> 02:11:58,116
DIFFERENT INSTITUTES AND CENTERS

3974
02:11:58,116 --> 02:12:00,452
AT NIH, THERE WAS AN INKREASING

3975
02:12:00,452 --> 02:12:02,320
UNDERSTANDING OF THE NEED TO

3976
02:12:02,320 --> 02:12:03,955
HELP INVESTIGATORS UNDERSTAND

3977
02:12:03,955 --> 02:12:06,057
ALL THE STEPS THEY WOULD NEED TO

3978
02:12:06,057 --> 02:12:09,027
TAKE TO BRIDGE THE GAP BETWEEN

3979
02:12:09,027 --> 02:12:11,863
BASIC SCIENTIFIC DISCOVERIES IN

3980
02:12:11,863 --> 02:12:14,332
THAT APPLICATION OF THOSE

3981
02:12:14,332 --> 02:12:17,135
DISCOVERIES TO IMPROVE LOU MAN

3982
02:12:17,135 --> 02:12:17,736
HEALTH.

3983
02:12:17,736 --> 02:12:20,071
SO THERE WERE A NUMBER OF MODELS

3984
02:12:20,071 --> 02:12:21,539
THAT WERE GENERATED AT THE

3985
02:12:21,539 --> 02:12:23,074
DIFFERENT INSTITUTES AND CENTERS

3986
02:12:23,074 --> 02:12:24,442
THAT LED TO THE FORMATION OF THE

3987
02:12:24,442 --> 02:12:27,178
SEED OFFICE, BUT WHAT THE SEED

3988
02:12:27,178 --> 02:12:32,350
OFFICE ESSENTIALLY IS, IS A

3989
02:12:32,350 --> 02:12:33,451
IN-HOUSE COMMERCIALIZATION

3990
02:12:33,451 --> 02:12:36,087
ASSISTANCE UNIT, AN IN-HOUSE

3991
02:12:36,087 --> 02:12:37,055
PRODUCT DEVELOPMENT ASSISTANCE

3992
02:12:37,055 --> 02:12:38,590
SERVICE.

3993
02:12:38,590 --> 02:12:42,360
SO WITHIN OUR OFFICE, WE HAVE A

3994
02:12:42,360 --> 02:12:43,895
TEAM OF ENTREPRENEURS AND

3995
02:12:43,895 --> 02:12:45,964
RESIDENTS WHO HAVE DEEP

3996
02:12:45,964 --> 02:12:47,399
EXPERIENCE IN THE BUSINESS AND

3997
02:12:47,399 --> 02:12:49,167
COMMERCIAL SECTOR.

3998
02:12:49,167 --> 02:12:50,168
MANY OF THEM HAVE STARTED THEIR

3999
02:12:50,168 --> 02:12:51,236
OWN BUSINESSES.

4000
02:12:51,236 --> 02:12:53,104
MANY OF THEM HAVE WORKED IN

4001
02:12:53,104 --> 02:12:54,539
INDUSTRY, AND THEY UNDERSTAND

4002
02:12:54,539 --> 02:12:56,708
HOW TO WORK AT THAT INTERFACE OF

4003
02:12:56,708 --> 02:12:58,943
SCIENCE AND TECHNOLOGY AND

4004
02:12:58,943 --> 02:13:02,647
PRODUCT DEVELOPMENT.

4005
02:13:02,647 --> 02:13:04,449
WE HAVE ALMOST TENANT PRE NEWERS

4006
02:13:04,449 --> 02:13:06,751
AND RESIDENTS NOW.

4007
02:13:06,751 --> 02:13:08,186
OVER OVER HALF OF THEM ARE

4008
02:13:08,186 --> 02:13:08,820
WOMEN.

4009
02:13:08,820 --> 02:13:13,658
SOME HAVE DEEP EXPERIENCE IN THE

4010
02:13:13,658 --> 02:13:14,559
FEMTECH DEVELOPMENT SPACE.

4011
02:13:14,559 --> 02:13:16,094
WE ALSO HAVE AN IN-HOUSE

4012
02:13:16,094 --> 02:13:17,195
REGULATORY TEAM THAT HELPS

4013
02:13:17,195 --> 02:13:19,364
PEOPLE UNDERSTAND THE BARRIERS

4014
02:13:19,364 --> 02:13:21,933
TO FDA APPROVAL AND MARKETING

4015
02:13:21,933 --> 02:13:22,267
APPROVAL.

4016
02:13:22,267 --> 02:13:25,537
AND WE ALSO HAVE A TEAM THAT

4017
02:13:25,537 --> 02:13:26,738
HELPS UNDERSTAND -- HELPS

4018
02:13:26,738 --> 02:13:29,407
INVESTIGATORS PLAN AND

4019
02:13:29,407 --> 02:13:31,276
UNDERSTAND THE CHALLENGES OF THE

4020
02:13:31,276 --> 02:13:32,677
BUSINESS PROCESSES THAT ARE

4021
02:13:32,677 --> 02:13:35,980
NECESSARY TO GET YOUR PRODUCT

4022
02:13:35,980 --> 02:13:37,415
PAID FOR IN THE COMPETITIVE

4023
02:13:37,415 --> 02:13:37,982
HEALTHCARE MARKETPLACE.

4024
02:13:37,982 --> 02:13:40,285
THAT'S REALLY A CRITICAL PART OF

4025
02:13:40,285 --> 02:13:42,987
GETTING THESE TECHNOLOGIES INTO

4026
02:13:42,987 --> 02:13:45,123
THE HANDS OF CLINICIANS, AND

4027
02:13:45,123 --> 02:13:48,626
FAMILY MEMBERS THAT NEED TO USE

4028
02:13:48,626 --> 02:13:49,961
THEM, IS HOW ARE THOSE DEVICES

4029
02:13:49,961 --> 02:13:51,229
AND THOSE TREATMENTS GOING TO BE

4030
02:13:51,229 --> 02:13:51,496
PAID FOR.

4031
02:13:51,496 --> 02:13:54,899
SO OUR TEAM, YOU CAN THINK OF

4032
02:13:54,899 --> 02:13:57,368
OUR TEAM AS A KIND OF ASSISTANCE

4033
02:13:57,368 --> 02:13:58,736
SERVICE THAT CAN WORK ACROSS ALL

4034
02:13:58,736 --> 02:14:01,706
THE DIFFERENT DOMAINS THAT NIH

4035
02:14:01,706 --> 02:14:04,776
WORKS IN TO HELP PEOPLE MAKE

4036
02:14:04,776 --> 02:14:06,311
THAT TRANSFORMATION BETWEEN

4037
02:14:06,311 --> 02:14:06,811
SCIENTIFIC DISCOVERY AND

4038
02:14:06,811 --> 02:14:12,250
BUSINESS DEVELOPMENT.

4039
02:14:12,250 --> 02:14:13,418
SO WHAT I WANT TO TALK ABOUT

4040
02:14:13,418 --> 02:14:14,219
TODAY IS REALLY THAT

4041
02:14:14,219 --> 02:14:15,353
INTERSECTION OF WHAT SEED DOES,

4042
02:14:15,353 --> 02:14:23,027
WHAT OUR OFFICE DOES, AND THE

4043
02:14:23,027 --> 02:14:27,732
PART OF THE NIH OFFICE OF

4044
02:14:27,732 --> 02:14:29,000
RESEARCH ON WOMEN'S HEALTH AND

4045
02:14:29,000 --> 02:14:30,702
THAT PLAN THAT DR. CLAYTON

4046
02:14:30,702 --> 02:14:32,003
TALKED ABOUT TO REALLY TAKE

4047
02:14:32,003 --> 02:14:33,304
THOSE ADVANCES AND THAT

4048
02:14:33,304 --> 02:14:34,672
KNOWLEDGE THAT'S BEING GENERATED

4049
02:14:34,672 --> 02:14:36,007
AND APPLY THAT TO THE WOMEN'S

4050
02:14:36,007 --> 02:14:38,943
HEALTH CHALLENGES THAT EXIST IN

4051
02:14:38,943 --> 02:14:43,214
THE HEALTHCARE MARKETPLACE.

4052
02:14:43,214 --> 02:14:45,550
SO AN INTEGRAL PART OF THAT THAT

4053
02:14:45,550 --> 02:14:46,518
DR. TROMBERG TALKED ABOUT QUITE

4054
02:14:46,518 --> 02:14:50,455
A BIT WAS THE INTERSECTION WITH

4055
02:14:50,455 --> 02:14:53,157
THE BIOMEDICAL WORKFORCE AND THE

4056
02:14:53,157 --> 02:14:55,226
ROLE THAT INCREASING DIET VERSE

4057
02:14:55,226 --> 02:14:59,597
IT OF THE BIOMEDICAL WORKFORCE

4058
02:14:59,597 --> 02:15:01,032
PLAYS IN ACHIEVING THOSE GOALS.

4059
02:15:01,032 --> 02:15:02,033
SO I'LL TALK A LITTLE BIT ABOUT

4060
02:15:02,033 --> 02:15:07,305
THAT ALSO.

4061
02:15:07,305 --> 02:15:08,940
SO LET ME SET THINGS UP A LITTLE

4062
02:15:08,940 --> 02:15:10,808
BIT BY TALKING ABOUT THE

4063
02:15:10,808 --> 02:15:11,676
INVESTMENT ENVIRONMENT AND THE

4064
02:15:11,676 --> 02:15:13,945
PRODUCT DEVELOPMENT ENVIRONMENT

4065
02:15:13,945 --> 02:15:16,714
IN THE WOMEN'S HEALTH SECTOR,

4066
02:15:16,714 --> 02:15:20,084
BECAUSE I THINK THAT WE'RE IN A

4067
02:15:20,084 --> 02:15:23,221
REALTIMEREAL TIME OF OPPORTUNITD

4068
02:15:23,221 --> 02:15:25,323
THERE ARE CHALLENGES, MANY

4069
02:15:25,323 --> 02:15:28,526
CHALLENGES, BUT STARTING ABOUT

4070
02:15:28,526 --> 02:15:33,765
PROBABLY EVEN BEFORE 2020 THERE

4071
02:15:33,765 --> 02:15:35,400
WAS STARTING TO BE AN INCREASING

4072
02:15:35,400 --> 02:15:36,968
APPRECIATION FOR THE UNMET --

4073
02:15:36,968 --> 02:15:39,270
NOT ONLY THE UNMET MEDICAL

4074
02:15:39,270 --> 02:15:41,539
NEEDS, BUT THE MARKET

4075
02:15:41,539 --> 02:15:42,807
OPPORTUNITIES THAT EXISTED IN

4076
02:15:42,807 --> 02:15:46,010
THE WOMEN'S HEALTH SECTOR.

4077
02:15:46,010 --> 02:15:49,047
SO THERE'S NOT ONLY A LARGE

4078
02:15:49,047 --> 02:15:51,583
MARKET OPPORTUNITY, BUT AT THAT

4079
02:15:51,583 --> 02:15:57,855
TIME THE -- CONDUCIVE REGULATORY

4080
02:15:57,855 --> 02:15:59,490
ENVIRONMENT, THERE WERE ALSO

4081
02:15:59,490 --> 02:16:01,793
INVESTMENT FIRMS, VENTURE

4082
02:16:01,793 --> 02:16:02,994
CAPITAL FIRMS AND ANGEL

4083
02:16:02,994 --> 02:16:03,962
INVESTORS WHO WERE VERY

4084
02:16:03,962 --> 02:16:10,101
INTERESTED IN, WOULDING IN THI S

4085
02:16:10,101 --> 02:16:10,835
SECTOR BUT AT THE SAME TIME

4086
02:16:10,835 --> 02:16:13,705
THERE WAS AN INCREASE IN FUNDING

4087
02:16:13,705 --> 02:16:15,139
GOING INTO PREVENTIVE MEDICINE

4088
02:16:15,139 --> 02:16:18,576
AND HOLISTIC HEALTH, AND AN

4089
02:16:18,576 --> 02:16:20,979
INCREASING APPRECIATION OF THE

4090
02:16:20,979 --> 02:16:24,482
ROLE OF HEALTH I.T. AND AI AND

4091
02:16:24,482 --> 02:16:26,184
MACHINE LEARNING ADVANCES, AND

4092
02:16:26,184 --> 02:16:29,020
ALL THESE THINGS WERE WORKING

4093
02:16:29,020 --> 02:16:31,356
TOGETHER TO INKREAS THE INCREASE

4094
02:16:31,356 --> 02:16:32,624
OPPORTUNITY FOR THESE EARLY

4095
02:16:32,624 --> 02:16:33,958
STAGE PROJECTS TO ACTUALLY TURN

4096
02:16:33,958 --> 02:16:35,059
INTO USEFUL PRODUCTS AND

4097
02:16:35,059 --> 02:16:38,663
SERVICES.

4098
02:16:38,663 --> 02:16:40,465
SILICON VALLEY BANK IN 2023

4099
02:16:40,465 --> 02:16:43,735
RELEASED A REPORT THAT MADE SOME

4100
02:16:43,735 --> 02:16:45,169
PREDICTIONS ABOUT WOMEN'S HEALTH

4101
02:16:45,169 --> 02:16:48,206
INNOVATION, AND I THINK THEY'RE

4102
02:16:48,206 --> 02:16:49,674
VERY IMPORTANT TO JUST REVIEW

4103
02:16:49,674 --> 02:16:52,644
THEM BECAUSE ONE OF THE THINGS

4104
02:16:52,644 --> 02:16:54,612
THAT WE'RE SEEING IN NOT ONLY

4105
02:16:54,612 --> 02:16:58,816
OUR PORTFOLIO BUT BROADLY IN THE

4106
02:16:58,816 --> 02:16:59,884
INNOVATION SPACE IS THAT THERE'S

4107
02:16:59,884 --> 02:17:02,286
A GROWTH IN NON-REPRODUCTIVE

4108
02:17:02,286 --> 02:17:05,089
FOCUS AREAS, AND YOU'VE HEARD A

4109
02:17:05,089 --> 02:17:06,290
LITTLE BIT ABOUT THAT ALREADY

4110
02:17:06,290 --> 02:17:08,059
TODAY.

4111
02:17:08,059 --> 02:17:10,361
THIS IS MORE INTEREST IN

4112
02:17:10,361 --> 02:17:12,997
PHYSICAL AND MENTAL WELL-BEING

4113
02:17:12,997 --> 02:17:15,099
IN WOMEN'S HEALTH, AND ALSO MORE

4114
02:17:15,099 --> 02:17:16,434
INTEREST IN CARE ACROSS THE

4115
02:17:16,434 --> 02:17:19,804
WHOLE LIFETIME.

4116
02:17:19,804 --> 02:17:22,106
SO THAT COULD BE INCREASES IN

4117
02:17:22,106 --> 02:17:32,917
ATITIATTENTION TO -- OR MENOPAUD

4118
02:17:33,384 --> 02:17:34,318
WOMEN'S HEL LATER IN LIFE.

4119
02:17:34,318 --> 02:17:36,220
SO THESE ARE A FEW OF THE THINGS

4120
02:17:36,220 --> 02:17:37,889
THAT WERE BEING BROUGHT TO THE

4121
02:17:37,889 --> 02:17:39,490
FOREFRONT IN THE INVESTMENT

4122
02:17:39,490 --> 02:17:40,358
WORLD.

4123
02:17:40,358 --> 02:17:46,898
ALSO THERE WERE MANY MORE --

4124
02:17:46,898 --> 02:17:49,200
MUCH MORE ACTION IN THE CLINICAL

4125
02:17:49,200 --> 02:17:50,968
SPACE, INCREASES IN CLINICAL

4126
02:17:50,968 --> 02:17:52,470
RESEARCH, INCREASES IN

4127
02:17:52,470 --> 02:17:53,538
DIAGNOSTIC AND DEVICE

4128
02:17:53,538 --> 02:17:54,939
DEVELOPMENT AND THERAPEUTICS

4129
02:17:54,939 --> 02:17:56,808
THAT WERE FOCUSED ON WOMEN'S

4130
02:17:56,808 --> 02:17:57,775
HEALTH.

4131
02:17:57,775 --> 02:18:00,878
AND ALSO THE VENTURE CAPITAL

4132
02:18:00,878 --> 02:18:02,413
COMMUNITY WAS PUMPING MORE MONEY

4133
02:18:02,413 --> 02:18:04,882
INTO WOMEN'S HEALTH-RELATED

4134
02:18:04,882 --> 02:18:05,750
PROJECTS, AND WE'RE STARTING TO

4135
02:18:05,750 --> 02:18:09,020
SEE A LITTLE BIT OF A

4136
02:18:09,020 --> 02:18:10,021
TRANSFORMATION IN THAT FUNDING.

4137
02:18:10,021 --> 02:18:14,759
SO IT'S PART OF THE NORMAL

4138
02:18:14,759 --> 02:18:16,961
LIFECYCLE OF THE INVESTMENT

4139
02:18:16,961 --> 02:18:22,400
WORLD WHERE IN EMERGING STAGES

4140
02:18:22,400 --> 02:18:24,335
OF AN AREA, THERE'S MUCH MORE

4141
02:18:24,335 --> 02:18:26,237
FUNDING IN THE VENTURE STAGE OF

4142
02:18:26,237 --> 02:18:28,039
THE PROJECTS AND AS THE FIELD

4143
02:18:28,039 --> 02:18:30,074
STARTS TO MATURE, THE VENTURE

4144
02:18:30,074 --> 02:18:32,243
CAPITAL INVESTORS START TO SHIFT

4145
02:18:32,243 --> 02:18:34,312
THEIR FOCUS TO LATER STAGE

4146
02:18:34,312 --> 02:18:35,179
RESEARCH PROJECTS.

4147
02:18:35,179 --> 02:18:36,380
AND I THINK IT'S A TESTAMENT TO

4148
02:18:36,380 --> 02:18:37,815
THE INTEREST IN WOMEN'S HEALTH

4149
02:18:37,815 --> 02:18:40,885
THAT THE VENTURE COMMUNITY IS

4150
02:18:40,885 --> 02:18:43,755
STARTING TO SHIFT THOSE

4151
02:18:43,755 --> 02:18:45,389
INVESTMENTS TO LATER STAGE

4152
02:18:45,389 --> 02:18:48,226
PROJECTS AS THE FIELD STARTS TO

4153
02:18:48,226 --> 02:18:49,327
MATURE AND BECOME MORE WELL

4154
02:18:49,327 --> 02:18:49,761
ESTABLISHED.

4155
02:18:49,761 --> 02:18:52,330
SO I THINK THAT'S REALLY LAYING

4156
02:18:52,330 --> 02:18:54,065
OUT A FIELD OF OPPORTUNITY IN

4157
02:18:54,065 --> 02:18:57,034
WOMEN'S HEALTH.

4158
02:18:57,034 --> 02:18:58,603
THE WORLD ECONOMIC FORUM

4159
02:18:58,603 --> 02:19:00,505
RELEASED THIS REPORT IN JANUARY

4160
02:19:00,505 --> 02:19:01,372
WHERE THEY WERE TALKING ABOUT

4161
02:19:01,372 --> 02:19:05,176
CLOSING THE WOMEN'S HEALTH GAP,

4162
02:19:05,176 --> 02:19:07,879
AND THIS, I THINK, ILLUSTRATES

4163
02:19:07,879 --> 02:19:09,614
THE DUAL NATURE OF THE SITUATION

4164
02:19:09,614 --> 02:19:10,715
THAT WE'RE IN.

4165
02:19:10,715 --> 02:19:14,552
ON THE ONE HAND, THERE IS A

4166
02:19:14,552 --> 02:19:15,686
TREMENDOUS GAP IN WOMEN'S

4167
02:19:15,686 --> 02:19:18,523
HEALTH, BUT AT THE SAME TIME,

4168
02:19:18,523 --> 02:19:22,260
THAT PRESENTS A MARKET

4169
02:19:22,260 --> 02:19:23,761
OPPORTUNITY THAT MARKET FORCES

4170
02:19:23,761 --> 02:19:25,363
CAN COME IN AND ADDRESS.

4171
02:19:25,363 --> 02:19:26,664
SO ALTHOUGH WOMEN LIVE LONGER

4172
02:19:26,664 --> 02:19:30,701
THAN MEN, THEY SPEND 25% MORE OF

4173
02:19:30,701 --> 02:19:32,003
THEIR TIME IN POOR HEALTH THAN

4174
02:19:32,003 --> 02:19:35,006
MEN, AND THAT OPPORTUNITY REALLY

4175
02:19:35,006 --> 02:19:40,144
CREATES A CHALLENGE FOR THE

4176
02:19:40,144 --> 02:19:41,679
INNOVATION COMMUNITY TO GO

4177
02:19:41,679 --> 02:19:43,414
AFTER.

4178
02:19:43,414 --> 02:19:44,582
THE ROOT CAUSES OF THIS GAP IN

4179
02:19:44,582 --> 02:19:45,817
THIS REPORT THAT WERE IDENTIFIED

4180
02:19:45,817 --> 02:19:47,552
WERE SCIENCE, DATA, CARE

4181
02:19:47,552 --> 02:19:50,655
DELIVERY, AND INVESTMENT.

4182
02:19:50,655 --> 02:19:52,957
AND AS I MENTIONED BEFORE, THERE

4183
02:19:52,957 --> 02:19:56,828
THERETHERE'S SO MUCH ACTIVITY IE

4184
02:19:56,828 --> 02:19:57,829
INVESTMENT SPACE, IN THE WOMEN'S

4185
02:19:57,829 --> 02:19:59,463
HEALTH SPACE, AND AS

4186
02:19:59,463 --> 02:20:01,866
DR. TROMBERG MENTIONED,

4187
02:20:01,866 --> 02:20:03,334
INCREASING -- AND DR. CLAYTON,

4188
02:20:03,334 --> 02:20:05,169
INCREASING INVESTMENTS AND

4189
02:20:05,169 --> 02:20:06,504
ATTENTION TO THESE OTHER AREAS

4190
02:20:06,504 --> 02:20:10,374
OF BASIC SCIENTIFIC RESEARCH AND

4191
02:20:10,374 --> 02:20:11,909
DATA AND CARE DELIVERY THAT ARE

4192
02:20:11,909 --> 02:20:16,514
ALL GOING TO CONTRIBUTE TO

4193
02:20:16,514 --> 02:20:17,915
INCREASES IN PRODUCT DEVELOPMENT

4194
02:20:17,915 --> 02:20:19,283
AND INNOVATION IN THIS SPACE.

4195
02:20:19,283 --> 02:20:26,624
ON THE INVESTMENT SIDE, YOU CAN

4196
02:20:26,624 --> 02:20:28,993
SEE HERE THERE'S A TR TREMENDOUS

4197
02:20:28,993 --> 02:20:30,261
AMOUNT OF CAPITAL THAT HAS BEEN

4198
02:20:30,261 --> 02:20:31,362
DEVOTED TO WOMEN'S HEALTH

4199
02:20:31,362 --> 02:20:33,431
PRODUCTS AND WOMEN'S HEALTH

4200
02:20:33,431 --> 02:20:37,101
SERVICES, AND AN INCREASING

4201
02:20:37,101 --> 02:20:38,970
ATTENTION TO THOSE AREAS IN THE

4202
02:20:38,970 --> 02:20:39,403
INVESTMENT WORLD.

4203
02:20:39,403 --> 02:20:40,972
SO I THINK THAT'S REALLY

4204
02:20:40,972 --> 02:20:42,206
CHANGING THE LANDSCAPE FROM A

4205
02:20:42,206 --> 02:20:43,808
DECADE AGO, WHERE A DECADE AGO,

4206
02:20:43,808 --> 02:20:45,910
THERE WAS A GREAT UNMET MEDICAL

4207
02:20:45,910 --> 02:20:48,179
NEED, BUT THERE WAS NOT A MARKET

4208
02:20:48,179 --> 02:20:49,480
OPPORTUNITY, THERE WASN'T AN

4209
02:20:49,480 --> 02:20:50,882
OPPORTUNITY FOR THOSE PRODUCTS

4210
02:20:50,882 --> 02:20:52,750
TO BE DEVELOPED ALL THE WAY TO

4211
02:20:52,750 --> 02:20:57,755
THE HEALTHCARE MARKETPLACE,

4212
02:20:57,755 --> 02:20:59,924
WHEREAS NOW, WE GO TO INVESTMENT

4213
02:20:59,924 --> 02:21:00,791
MEETINGS AND ATTEND INVESTMENT

4214
02:21:00,791 --> 02:21:02,493
MEETINGS ALL THE TIME, AND IT'S

4215
02:21:02,493 --> 02:21:05,763
NOT UNCOMMON NOW TO SEE PITCH

4216
02:21:05,763 --> 02:21:06,764
COMPETITIONS THAT ARE FOCUSED

4217
02:21:06,764 --> 02:21:08,432
JUST ON WOMEN'S HEALTH PRODUCTS

4218
02:21:08,432 --> 02:21:12,069
AND SERVICES, AND THAT'S BECAUSE

4219
02:21:12,069 --> 02:21:14,238
THERE'S A GREAT DESIRE IN THE

4220
02:21:14,238 --> 02:21:17,308
INVESTMENT WORLD TO ATTACK THESE

4221
02:21:17,308 --> 02:21:17,742
ISSUES.

4222
02:21:17,742 --> 02:21:20,244
SO THAT'S JUST A BRIEF PICTURE

4223
02:21:20,244 --> 02:21:22,613
OF THE INVESTMENT AND PRODUCT

4224
02:21:22,613 --> 02:21:23,214
DEVELOPMENT LANDSCAPE AROUND

4225
02:21:23,214 --> 02:21:24,715
WOMEN'S HEALTH, AND I THINK IT'S

4226
02:21:24,715 --> 02:21:27,618
A GREAT WAY TO KIND OF LAY THE

4227
02:21:27,618 --> 02:21:28,920
FOUNDATION FOR WHERE NIH FITS

4228
02:21:28,920 --> 02:21:31,789
INTO THE PICTURE.

4229
02:21:31,789 --> 02:21:35,559
SO AT THE TOP OF THE SLIDE, YOU

4230
02:21:35,559 --> 02:21:37,628
CAN SEE THAT -- AND MANY OF YOU

4231
02:21:37,628 --> 02:21:39,196
DON'T NEED TO BE REMINDED THAT

4232
02:21:39,196 --> 02:21:43,734
IT'S A LONG ROAD BETWEEN BASIC

4233
02:21:43,734 --> 02:21:44,702
RESEARCH DISCOVERIES AND YOUR

4234
02:21:44,702 --> 02:21:47,538
ABILITY OR YOUR FAMILY MEMBERS'

4235
02:21:47,538 --> 02:21:50,942
ABILITY TO RECEIVE A PRODUCT OR

4236
02:21:50,942 --> 02:21:52,209
SERVICE IN THE DOCTOR'S OFFICE.

4237
02:21:52,209 --> 02:21:54,178
THAT'S PART OF THE REASON WHY I

4238
02:21:54,178 --> 02:21:55,079
GOT INTO THE LINE OF WORK THAT

4239
02:21:55,079 --> 02:22:00,117
I'M IN, IS THAT I WAS CONSTANTLY

4240
02:22:00,117 --> 02:22:01,218
FRUSTRATED BETWEEN -- BY SEEING

4241
02:22:01,218 --> 02:22:04,288
THESE AWESOME SCIENTIFIC

4242
02:22:04,288 --> 02:22:05,723
ADVANCES AND SEEING THOSE

4243
02:22:05,723 --> 02:22:08,159
SCIENTIFIC ADVANCES FAIL AS THEY

4244
02:22:08,159 --> 02:22:10,695
CROSS THE SPECTRUM FROM BASIC

4245
02:22:10,695 --> 02:22:12,129
RESEARCH THROUGH PROOF OF

4246
02:22:12,129 --> 02:22:15,066
CONCEPT, RESEARCH AND

4247
02:22:15,066 --> 02:22:16,233
DEVELOPMENT, THEIR

4248
02:22:16,233 --> 02:22:17,301
TRANSFORMATION INTO ACTUAL

4249
02:22:17,301 --> 02:22:19,303
HEALTHCARE PRODUCTS AND

4250
02:22:19,303 --> 02:22:20,604
SERVICES, AND THEN NOT ONLY

4251
02:22:20,604 --> 02:22:22,907
THAT, THEIR DISSEMINATION AND

4252
02:22:22,907 --> 02:22:23,741
IMPLEMENTATION AND THEIR ABILITY

4253
02:22:23,741 --> 02:22:27,011
IN THE HEALTHCARE MARKETPLACE.

4254
02:22:27,011 --> 02:22:30,748
AND NOT ONLY IS THAT CHALLENGE

4255
02:22:30,748 --> 02:22:32,049
THERE FOR ALL TYPES OF PRODUCT

4256
02:22:32,049 --> 02:22:33,517
AND SERVICES, BUT THE TREMENDOUS

4257
02:22:33,517 --> 02:22:37,288
HEALTH DISPARITIES THAT WE SEE

4258
02:22:37,288 --> 02:22:38,856
IN THE UNITED STATES ARE ALSO A

4259
02:22:38,856 --> 02:22:41,359
PART OF THAT PROBLEM.

4260
02:22:41,359 --> 02:22:45,162
SO THE PRODUCTS AND SERVICES

4261
02:22:45,162 --> 02:22:47,365
THAT ARE NECESSARY TO REACH

4262
02:22:47,365 --> 02:22:48,899
COMMUNITIES THAT ARE IN GREATEST

4263
02:22:48,899 --> 02:22:50,167
NEED ARE OFTENTIMES THE ONES

4264
02:22:50,167 --> 02:22:51,736
THAT ARE MOST CHALLENGING TO

4265
02:22:51,736 --> 02:22:55,940
BRING TO THE COMMERCIAL

4266
02:22:55,940 --> 02:22:56,240
MARKETPLACE.

4267
02:22:56,240 --> 02:22:57,141
SO WHAT I'M GOING TO TALK A

4268
02:22:57,141 --> 02:22:58,576
LITTLE BIT ABOUT TODAY IS A FEW

4269
02:22:58,576 --> 02:23:01,512
OF NIH'S PROGRAMS THAT HELP AT

4270
02:23:01,512 --> 02:23:03,647
DIFFERENT STAGES OF THIS PRODUCT

4271
02:23:03,647 --> 02:23:07,585
DEVELOPMENT LIFECYCLE, AND HOW

4272
02:23:07,585 --> 02:23:09,553
WOMEN'S HEALTH AND A FOCUS ON

4273
02:23:09,553 --> 02:23:12,123
WOMEN'S HEALTH IS REALLY BEING

4274
02:23:12,123 --> 02:23:17,795
FACILITATED BY THESE PROGRAMS.

4275
02:23:17,795 --> 02:23:18,896
YOU CAN SEE HERE I'M GOING TO

4276
02:23:18,896 --> 02:23:19,764
TALK ABOUT TWO DIFFERENT

4277
02:23:19,764 --> 02:23:20,164
PROGRAMS.

4278
02:23:20,164 --> 02:23:21,132
ONE IS THE REACH PROGRAM WHICH

4279
02:23:21,132 --> 02:23:22,867
IS SITTING IN THE ACADEMIC SPACE

4280
02:23:22,867 --> 02:23:24,769
AT THE EARLIEST STAGE OF PRODUCT

4281
02:23:24,769 --> 02:23:26,637
DEVELOPMENT, AND THEN THE NEXT

4282
02:23:26,637 --> 02:23:28,639
ONE IS THE SMALL BUSINESS

4283
02:23:28,639 --> 02:23:30,708
PROGRAM, WHICH IS REFERRED TO AS

4284
02:23:30,708 --> 02:23:32,777
AMERICA'S SEED FUND, WHICH FUNDS

4285
02:23:32,777 --> 02:23:34,211
SMALL BUSINESSES ALL ACROSS THE

4286
02:23:34,211 --> 02:23:37,882
UNITED STATES TO EARLY STAGE

4287
02:23:37,882 --> 02:23:38,449
PRODUCT DEVELOPMENT.

4288
02:23:38,449 --> 02:23:41,652
SO THE REACH PROGRAM, OR

4289
02:23:41,652 --> 02:23:42,853
RESEARCH EVALUATION AND

4290
02:23:42,853 --> 02:23:45,022
COMMERCIALIZATION HUBS, IS A

4291
02:23:45,022 --> 02:23:47,224
PROGRAM THAT HELPS ACADEMIC

4292
02:23:47,224 --> 02:23:48,659
INVESTIGATORS CONVERT THEIR

4293
02:23:48,659 --> 02:23:50,461
SCIENCE PROJECTS INTO PRODUCT

4294
02:23:50,461 --> 02:23:52,096
DEVELOPMENT PROJECTS WITHIN THE

4295
02:23:52,096 --> 02:23:53,831
ACADEMIC SPACE.

4296
02:23:53,831 --> 02:23:57,034
AND MANY ACADEMIC RESEARCHERS

4297
02:23:57,034 --> 02:23:59,603
STRUGGLE WITH THIS ISSUE BECAUSE

4298
02:23:59,603 --> 02:24:04,208
THERE'S A GREAT GAP BETWEEN THE

4299
02:24:04,208 --> 02:24:07,578
SKILLS AND THE PROCESSES AND THE

4300
02:24:07,578 --> 02:24:09,080
LANGUAGE AND THE TERMINOLOGY

4301
02:24:09,080 --> 02:24:10,481
THAT'S NECESSARY TO BE

4302
02:24:10,481 --> 02:24:12,349
SUCCESSFUL IN THE ACADEMIC

4303
02:24:12,349 --> 02:24:15,753
WORLD, AND THOSE SAME SKILLS AND

4304
02:24:15,753 --> 02:24:17,221
LANGUAGE AND TERMINOLOGY THAT

4305
02:24:17,221 --> 02:24:19,156
ARE NECESSARY TO BE SUCCESSFUL

4306
02:24:19,156 --> 02:24:20,391
IN THE BUSINESS AND

4307
02:24:20,391 --> 02:24:24,028
ENTREPRENEURIAL WORLD.

4308
02:24:24,028 --> 02:24:25,796
SO WHAT THE REACH PROGRAM TRIES

4309
02:24:25,796 --> 02:24:27,998
TO DO IS ALLOW ACADEMIC

4310
02:24:27,998 --> 02:24:29,200
INVESTIGATORS TO STRENGTHEN

4311
02:24:29,200 --> 02:24:32,002
THOSE PROJECTS AND MAKE THEM AS

4312
02:24:32,002 --> 02:24:32,870
ATTRACTIVE AS POSSIBLE FOR

4313
02:24:32,870 --> 02:24:36,507
COMMERCIAL DEVELOPMENT AND TO

4314
02:24:36,507 --> 02:24:38,576
CONVERT THEM INTO PRODUCT

4315
02:24:38,576 --> 02:24:39,376
DEVELOPMENT PROJECTS.

4316
02:24:39,376 --> 02:24:43,981
SO THE FIRST THING THEY DO IS,

4317
02:24:43,981 --> 02:24:45,516
THESE HUBS PROVIDE FUNDING FOR

4318
02:24:45,516 --> 02:24:47,151
PRODUCT VALIDATION PROJECTS.

4319
02:24:47,151 --> 02:24:49,086
SO THAT IS ONE OF THE GREATEST

4320
02:24:49,086 --> 02:24:52,690
NEEDS THAT PEOPLE HAVE, BECAUSE

4321
02:24:52,690 --> 02:24:54,225
ONCE YOU TRANSITION TO EARLY

4322
02:24:54,225 --> 02:24:55,993
STAGE PRODUCT DEVELOPMENT, THOSE

4323
02:24:55,993 --> 02:25:00,965
PROJECTS ARE OFTENTIMES NOT

4324
02:25:00,965 --> 02:25:01,499
DISCOVERY-BASED SCIENTIFIC

4325
02:25:01,499 --> 02:25:02,933
PROJECTS THAT ARE EASILY FUNDED

4326
02:25:02,933 --> 02:25:05,603
BY R01 RESEARCH AWARDS, SO

4327
02:25:05,603 --> 02:25:06,704
INVESTIGATORS FIND THEMSELVES

4328
02:25:06,704 --> 02:25:08,572
WITH NO FUNDING TO DO THOSE

4329
02:25:08,572 --> 02:25:10,541
EARLY STAGES OF PRODUCT

4330
02:25:10,541 --> 02:25:11,342
VALIDATION.

4331
02:25:11,342 --> 02:25:17,982
SO THESE HUBS PROVIDE UP TO

4332
02:25:17,982 --> 02:25:20,084
$100,000 FOR PRODUCT VALIDATION

4333
02:25:20,084 --> 02:25:21,886
PROJECTS.

4334
02:25:21,886 --> 02:25:23,687
BUT THEY ALSO HELP INVESTIGATORS

4335
02:25:23,687 --> 02:25:25,856
MANAGE THOSE PROJECTS NOT LIKE A

4336
02:25:25,856 --> 02:25:29,360
BASIC RESEARCH GRANT, BUT BY AN

4337
02:25:29,360 --> 02:25:30,961
INDUSTRY-STYLE MILESTONE-BASED

4338
02:25:30,961 --> 02:25:32,830
PROJECT MANAGEMENT APPROACH.

4339
02:25:32,830 --> 02:25:34,465
THAT WILL REALLY TAKE THEM

4340
02:25:34,465 --> 02:25:38,502
THROUGH THE STEPS NECESSARY TO

4341
02:25:38,502 --> 02:25:40,004
MOVE THAT PROJECT TOWARD PRODUCT

4342
02:25:40,004 --> 02:25:42,940
DEVELOPMENT.

4343
02:25:42,940 --> 02:25:44,241
AND THE WAY THAT WE DO THAT IS

4344
02:25:44,241 --> 02:25:45,476
THROUGH PROVIDING

4345
02:25:45,476 --> 02:25:46,610
ENTREPRENEURIAL TRAINING AND

4346
02:25:46,610 --> 02:25:47,611
MENTORING, AND ALSO BY PROVIDING

4347
02:25:47,611 --> 02:25:50,881
THOSE PROJECTS WITH PERSONALIZED

4348
02:25:50,881 --> 02:25:52,650
FEEDBACK FROM OUR GOVERNMENT

4349
02:25:52,650 --> 02:25:54,885
PARTNERS LIKE THE FDA, THE

4350
02:25:54,885 --> 02:25:56,086
CENTER FOR MEDICAID AND MEDICARE

4351
02:25:56,086 --> 02:25:57,188
SERVICES, THE PATENT AND

4352
02:25:57,188 --> 02:26:02,493
TRADEMARK OFFICE, AND OTHER

4353
02:26:02,493 --> 02:26:03,360
INDUSTRY VETERANS WHO HAVE

4354
02:26:03,360 --> 02:26:04,361
REALLY HAD EXPERIENCE MOVING

4355
02:26:04,361 --> 02:26:07,798
THROUGH THIS DPROW PRODUCT DEVET

4356
02:26:07,798 --> 02:26:14,271
PATHWAY.

4357
02:26:14,271 --> 02:26:16,073
THIS PROGRAM WAS AUTHORIZED BY

4358
02:26:16,073 --> 02:26:17,641
CONGRESS IN 2011.

4359
02:26:17,641 --> 02:26:19,476
WE STARTED WITH THREE CENTERS

4360
02:26:19,476 --> 02:26:20,778
FUNDED BY THE NATIONAL HEART,

4361
02:26:20,778 --> 02:26:22,079
LUNG AND BLOOD INSTITUTE, BUT WE

4362
02:26:22,079 --> 02:26:23,681
FOLLOWED THAT IN 2015 BY FUNDING

4363
02:26:23,681 --> 02:26:26,417
THREE CENTERS THAT WERE COVERING

4364
02:26:26,417 --> 02:26:30,154
THE ENTIRE NIH MISSION SPACE.

4365
02:26:30,154 --> 02:26:32,823
AND FIVE MORE IN 2019.

4366
02:26:32,823 --> 02:26:34,892
NOW, THESE CENTERS AND THESE

4367
02:26:34,892 --> 02:26:37,528
PRINCIPLES THAT ARE LAID OUT

4368
02:26:37,528 --> 02:26:39,163
HERE ARE ACTUALLY VERY SIMILAR,

4369
02:26:39,163 --> 02:26:41,198
IF NOT IDENTICAL, TO THE

4370
02:26:41,198 --> 02:26:43,167
PRINCIPLES OF THE POINT OF CARE

4371
02:26:43,167 --> 02:26:46,003
TECHNOLOGY RESEARCH NETWORK THAT

4372
02:26:46,003 --> 02:26:46,971
DR. TROMBERG TALKED ABOUT.

4373
02:26:46,971 --> 02:26:49,573
SO THESE PRINCIPLES OF HOW TO

4374
02:26:49,573 --> 02:26:52,109
HELP AN INVESTIGATOR NOT --

4375
02:26:52,109 --> 02:26:54,345
INVESTIGATORS KNOW HOW TO VAL

4376
02:26:54,345 --> 02:26:55,112
VALIDATE THE TECHNOLOGY AND

4377
02:26:55,112 --> 02:26:56,413
VALIDATE THE SCIENCE.

4378
02:26:56,413 --> 02:26:58,148
THAT'S THE BREAD AND BUTTER OF

4379
02:26:58,148 --> 02:26:59,483
WHAT ACADEMIC INVESTIGATORS DO.

4380
02:26:59,483 --> 02:27:03,187
BUT THE BASICS OF WHAT THIS

4381
02:27:03,187 --> 02:27:04,922
REACH NETWORK DOES ALSO ALLOWS

4382
02:27:04,922 --> 02:27:07,358
INVESTIGATORS TO VALIDATE THE

4383
02:27:07,358 --> 02:27:10,794
BUSINESS AND COMMERCIAL AND

4384
02:27:10,794 --> 02:27:12,196
HEALTHCARE POTENTIAL OF THOSE

4385
02:27:12,196 --> 02:27:13,964
TECHNOLOGIES IN PARALLEL WITH

4386
02:27:13,964 --> 02:27:15,766
WORKING ON THE TECHNOLOGY

4387
02:27:15,766 --> 02:27:16,267
DEVELOPMENT.

4388
02:27:16,267 --> 02:27:17,901
AND THAT'S REALLY CRITICAL TO

4389
02:27:17,901 --> 02:27:19,970
MAKING SURE THAT THESE

4390
02:27:19,970 --> 02:27:22,840
TECHNOLOGIES DON'T DROP OUT AS

4391
02:27:22,840 --> 02:27:25,609
THEY PROCEED IN DEVELOPMENT.

4392
02:27:25,609 --> 02:27:30,014
IN 2023, WE FUNDED FIVE NEW HUBS

4393
02:27:30,014 --> 02:27:32,916
ACROSS 12 STATES AND MORE THAN

4394
02:27:32,916 --> 02:27:33,884
75 INSTITUTIONS, AND WHAT WE

4395
02:27:33,884 --> 02:27:35,519
REALLY TRIED TO DO IN THIS

4396
02:27:35,519 --> 02:27:39,356
LATEST ROUND OF REACH HUBS WAS

4397
02:27:39,356 --> 02:27:43,027
SPREAD THIS KNOWLEDGE IN THIS MO

4398
02:27:43,027 --> 02:27:43,994
MODEL TO PART OF THE COUNTRY

4399
02:27:43,994 --> 02:27:44,995
WHERE IT'S NOT COMMON.

4400
02:27:44,995 --> 02:27:47,164
EVERYBODY KNOWS THAT IF YOU GO

4401
02:27:47,164 --> 02:27:53,070
TO BOSTON OR SAN FRANCISCO, OR

4402
02:27:53,070 --> 02:27:54,038
NEW YORK CITY, THERE'S A CULTURE

4403
02:27:54,038 --> 02:27:57,408
OF INNOVATION AND OF PRODUCT

4404
02:27:57,408 --> 02:27:59,476
DEVELOPMENT, AND A REAL

4405
02:27:59,476 --> 02:28:00,744
INTERSECTION OF THE BUSINESS

4406
02:28:00,744 --> 02:28:02,880
WORLD AND THE ACADEMIC AND

4407
02:28:02,880 --> 02:28:03,747
ACADEMIC MEDICAL CENTER

4408
02:28:03,747 --> 02:28:04,448
ENVIRONMENT.

4409
02:28:04,448 --> 02:28:07,184
BUT WHAT WE'RE TRYING TO DO IS

4410
02:28:07,184 --> 02:28:08,619
TAKE THESE PRINCIPLES AND THESE

4411
02:28:08,619 --> 02:28:10,154
PROCESSES THAT WE'VE PROVED OUT

4412
02:28:10,154 --> 02:28:16,460
IN THESE OTHER HUBS AND MOVE

4413
02:28:16,460 --> 02:28:17,428
THEM TO PART OF THE COUNTRY

4414
02:28:17,428 --> 02:28:18,495
WHERE THEY'RE NOT COMMON, WHERE

4415
02:28:18,495 --> 02:28:20,297
THERE'S NOT A CONDUCIVE

4416
02:28:20,297 --> 02:28:22,700
INVESTMENT ENVIRONMENT, OR

4417
02:28:22,700 --> 02:28:24,735
BUSINESS ENVIRONMENT FOR BIOTECH

4418
02:28:24,735 --> 02:28:26,270
AND BIOMEDICAL AND LIFE SCIENCE

4419
02:28:26,270 --> 02:28:29,773
DEVELOPMENT.

4420
02:28:29,773 --> 02:28:31,208
SO YOU CAN SEE HERE THE FIVE

4421
02:28:31,208 --> 02:28:32,142
HUBS WE FUNDED RECENTLY.

4422
02:28:32,142 --> 02:28:33,777
MANY OF YOU IN THE ROOM ARE

4423
02:28:33,777 --> 02:28:34,878
PROBABLY AT INSTITUTIONS THAT

4424
02:28:34,878 --> 02:28:36,914
ARE SUPPORTED BY ONE OF THESE

4425
02:28:36,914 --> 02:28:38,582
REACH HUBS, AND I WOULD

4426
02:28:38,582 --> 02:28:41,051
ENCOURAGE YOU TO TAKE A LOOK AT

4427
02:28:41,051 --> 02:28:46,056
THE WEBSITE FOR THE PROGRAM AND

4428
02:28:46,056 --> 02:28:47,057
SEE HOW INVESTIGATORS AT YOUR

4429
02:28:47,057 --> 02:28:49,326
INSTITUTION MIGHT BE ABLE TO GET

4430
02:28:49,326 --> 02:28:49,793
INVOLVED.

4431
02:28:49,793 --> 02:28:52,429
ONE OF THE OTHER FOCUSES OF THIS

4432
02:28:52,429 --> 02:28:56,100
ROUND OF THE REACH HUBS WAS ON

4433
02:28:56,100 --> 02:28:58,302
THIS CHALLENGE TO DIVERSIFY THE

4434
02:28:58,302 --> 02:29:00,604
BIOMEDICAL WORKFORCE.

4435
02:29:00,604 --> 02:29:02,272
SO WE TRIED TO COVER AS MANY OF

4436
02:29:02,272 --> 02:29:03,173
THE IDEA STATES AS WE COULD

4437
02:29:03,173 --> 02:29:05,709
COVER WITH THESE HUBS, BUT ALSO

4438
02:29:05,709 --> 02:29:08,045
MANY OF THESE INSTITUTIONS AND

4439
02:29:08,045 --> 02:29:10,280
THE TYPES OF INSTITUTIONS THAT

4440
02:29:10,280 --> 02:29:12,349
ARE PART OF THESE HUBS ARE NOT

4441
02:29:12,349 --> 02:29:14,318
THE TRADITIONAL R1 RESEARCH

4442
02:29:14,318 --> 02:29:14,952
UNIVERSITIES.

4443
02:29:14,952 --> 02:29:19,189
THERE'S AN INCREASING NUMBER IN

4444
02:29:19,189 --> 02:29:20,491
THIS NETWORK OF HISTORICALLY

4445
02:29:20,491 --> 02:29:21,825
BLACK COLLEGES AND UNIVERSITIES,

4446
02:29:21,825 --> 02:29:25,062
OF TRIBAL COLLEGES AND

4447
02:29:25,062 --> 02:29:25,929
UNIVERSITIES, OF OTHER TYPES OF

4448
02:29:25,929 --> 02:29:28,098
MINORITY SERRING INSTITUTIONS,

4449
02:29:28,098 --> 02:29:31,935
BUT ALSO LOOKING BACK TO

4450
02:29:31,935 --> 02:29:34,304
TECHNICAL COLLEGES AND

4451
02:29:34,304 --> 02:29:35,105
UNIVERSITIES, TWO-YEAR COLLEGES

4452
02:29:35,105 --> 02:29:37,574
AND REALLY TRYING TO HELP PEOPLE

4453
02:29:37,574 --> 02:29:40,811
TO UNDERSTAND THIS MINDSET OF

4454
02:29:40,811 --> 02:29:43,213
SITTING -- OF SMOOTHING OUT THAT

4455
02:29:43,213 --> 02:29:46,583
TRANSITION BETWEEN SCIENCE AND

4456
02:29:46,583 --> 02:29:48,085
HEALTHCARE PRODUCTS, AND

4457
02:29:48,085 --> 02:29:49,319
INCREASING THAT PROCESS LITERACY

4458
02:29:49,319 --> 02:29:51,622
OF WHAT IT WILL TAKE TO BE

4459
02:29:51,622 --> 02:29:52,823
SUCCESSFUL AT ALL DIFFERENT

4460
02:29:52,823 --> 02:29:55,092
STAGES AND ALL DIFFERENT PLACES

4461
02:29:55,092 --> 02:29:58,162
ACROSS THE UNITED STATES.

4462
02:29:58,162 --> 02:30:01,331
SO THIS NETWORK IS NOT JUST

4463
02:30:01,331 --> 02:30:03,066
ABOUT SUPPORTING RESEARCH

4464
02:30:03,066 --> 02:30:05,135
PROJECTS, TECHNOLOGY DEVELOPMENT

4465
02:30:05,135 --> 02:30:06,236
PROJECTS, BUT IT'S ABOUT

4466
02:30:06,236 --> 02:30:06,637
EDUCATING PEOPLE.

4467
02:30:06,637 --> 02:30:12,142
AND IN THESE INITIAL ROUNDS OF

4468
02:30:12,142 --> 02:30:13,377
THE REACH PROGRAM, WE'VE

4469
02:30:13,377 --> 02:30:14,945
EDUCATED OVER 2600 INVESTIGATORS

4470
02:30:14,945 --> 02:30:17,681
THROUGH THE VARIOUS EDUCATIONAL

4471
02:30:17,681 --> 02:30:18,649
OPPORTUNITIES THAT THESE REACH

4472
02:30:18,649 --> 02:30:22,152
HUBS HAVE MADE AVAILABLE.

4473
02:30:22,152 --> 02:30:23,554
SO IT'S REALLY AN AMAZING WAY TO

4474
02:30:23,554 --> 02:30:25,522
SPREAD THIS METHODOLOGY AND

4475
02:30:25,522 --> 02:30:27,491
SPREAD THIS MINDSET INTO THE

4476
02:30:27,491 --> 02:30:31,161
ACADEMIC COMMUNITY.

4477
02:30:31,161 --> 02:30:34,231
THE PROJECTS THAT HAVE BEEN

4478
02:30:34,231 --> 02:30:35,432
SUPPORTED, THERE'S ABOUT 250 OF

4479
02:30:35,432 --> 02:30:37,034
THEM, BUT I'LL GIVE YOU A LITTLE

4480
02:30:37,034 --> 02:30:38,001
SAMPLE OF SOME OF THE ONES THAT

4481
02:30:38,001 --> 02:30:40,204
HAVE BEEN SUPPORTED THAT ARE

4482
02:30:40,204 --> 02:30:41,371
RELATED TO WOMEN'S HEALTH,

4483
02:30:41,371 --> 02:30:43,140
BECAUSE REMEMBER, THESE HUBS ARE

4484
02:30:43,140 --> 02:30:44,641
SUPPORTING TECHNOLOGY

4485
02:30:44,641 --> 02:30:46,410
DEVELOPMENT ACROSS THE ENTIRE

4486
02:30:46,410 --> 02:30:49,046
NIH MISSION SPACE.

4487
02:30:49,046 --> 02:30:53,050
SO JUST SOME EXAMPLES HERE, SO

4488
02:30:53,050 --> 02:30:55,219
MANY WOMEN ABANDON BREASTFEEDING

4489
02:30:55,219 --> 02:30:56,720
BEFORE THE INFANT TURNS SIX

4490
02:30:56,720 --> 02:31:00,123
MONTHS OLD.

4491
02:31:00,123 --> 02:31:01,558
OBVIOUSLY A WEARABLE LACTATION

4492
02:31:01,558 --> 02:31:03,193
DEVICE AND CHALLENGES IN THAT

4493
02:31:03,193 --> 02:31:05,829
AREA -- ANYONE WHO IS A PARENT

4494
02:31:05,829 --> 02:31:07,764
WILL UNDERSTAND THAT THIS IS AN

4495
02:31:07,764 --> 02:31:09,166
ONGOING CHALLENGE THAT HAS NOT

4496
02:31:09,166 --> 02:31:13,537
REALLY BEEN PROPERLY ADDRESSED.

4497
02:31:13,537 --> 02:31:14,471
ALSO ONE IN THREE INFANTS WITH

4498
02:31:14,471 --> 02:31:16,807
FEEDING PROBLEMS EXHIBIT MILK

4499
02:31:16,807 --> 02:31:18,208
REFUSAL WHEN THEY TRANSITION

4500
02:31:18,208 --> 02:31:20,944
FROM BREAST MILK TO BOTTLE

4501
02:31:20,944 --> 02:31:24,081
FEEDING, AND WE HAD A GREAT

4502
02:31:24,081 --> 02:31:26,817
PROJECT TO DEVELOP A CONTINGENT

4503
02:31:26,817 --> 02:31:28,685
MUSIC BABY BOTTLE TO ASSIST IN

4504
02:31:28,685 --> 02:31:32,155
THAT TRANSITION.

4505
02:31:32,155 --> 02:31:33,257
SO ONE OF THE THINGS THAT I JUST

4506
02:31:33,257 --> 02:31:34,791
WANT TO MENTION, THOUGH, AS I GO

4507
02:31:34,791 --> 02:31:36,660
THROUGH THESE PROJECTS IS THAT

4508
02:31:36,660 --> 02:31:39,563
IT NOT JUST THE TECHNOLOGY

4509
02:31:39,563 --> 02:31:40,097
DEVELOPMENT.

4510
02:31:40,097 --> 02:31:41,532
WHAT THESE INVESTIGATORS ARE

4511
02:31:41,532 --> 02:31:43,734
LEARNING THROUGH THE PROGRAM IS

4512
02:31:43,734 --> 02:31:47,104
ALSO WHAT ARE THE MARKET FORCES

4513
02:31:47,104 --> 02:31:48,539
THAT WILL REALLY BE NECESSARY

4514
02:31:48,539 --> 02:31:51,008
FOR YOU TO ADDRESS IN ORDER TO

4515
02:31:51,008 --> 02:31:53,076
MAKE THESE PRODUCTS AVAILABLE IN

4516
02:31:53,076 --> 02:31:55,779
THE MARKETPLACE.

4517
02:31:55,779 --> 02:31:57,848
SO EVERYBODY HEARS ABOUT SOME

4518
02:31:57,848 --> 02:32:00,684
KIND OF NEW FLASHY TECHNOLOGY OR

4519
02:32:00,684 --> 02:32:02,886
THEY READ A PRESS RELEASE ABOUT

4520
02:32:02,886 --> 02:32:05,389
SOME SCIENTIFIC DISCOVERY, AND

4521
02:32:05,389 --> 02:32:07,891
THEN MANY TIMES LATER ON, YOU

4522
02:32:07,891 --> 02:32:14,398
ASK YOURSELF, WHY STHAT NOT IS T

4523
02:32:14,398 --> 02:32:16,934
AVAILABLE FOR ME?

4524
02:32:16,934 --> 02:32:17,901
THERE ARE ALL THESE OTHER

4525
02:32:17,901 --> 02:32:19,303
FACTORS THAT NEED TO BE TAKEN

4526
02:32:19,303 --> 02:32:19,970
INTO ACCOUNT.

4527
02:32:19,970 --> 02:32:26,176
A GOOD EXAMPLE OF THIS IS

4528
02:32:26,176 --> 02:32:28,579
THIS -- DIRECT PCR HAS REALLY

4529
02:32:28,579 --> 02:32:30,113
REVOLUTIONIZED THE CLINICAL PCR

4530
02:32:30,113 --> 02:32:31,315
ENVIRONMENT, BUT BRIDGING THAT

4531
02:32:31,315 --> 02:32:33,050
GAP BETWEEN CLINICAL PCR TESTING

4532
02:32:33,050 --> 02:32:36,086
AND FORENSIC TESTING HAS BEEN A

4533
02:32:36,086 --> 02:32:39,690
REAL CHALLENGE, BECAUSE THERE'S

4534
02:32:39,690 --> 02:32:42,326
NO WAY TO COLLECT THE SAMPLES IN

4535
02:32:42,326 --> 02:32:45,062
A WAY THAT FACILITATE THEIR USE

4536
02:32:45,062 --> 02:32:46,430
IN THAT KIND OF CONTROLLED

4537
02:32:46,430 --> 02:32:48,198
TESTING ENVIRONMENT.

4538
02:32:48,198 --> 02:32:50,500
SO THAT PROJECT WAS LOOKING TO

4539
02:32:50,500 --> 02:32:52,669
DEVELOP A FORENSIC DNA SAMPLE

4540
02:32:52,669 --> 02:32:56,607
CHECK SCOLLECTION TOOL THAT COUP

4541
02:32:56,607 --> 02:32:58,575
ADDRESS THE TREMENDOUS BACKLOG

4542
02:32:58,575 --> 02:33:00,077
IN SEXUAL ASSAULT KITS THAT WE

4543
02:33:00,077 --> 02:33:00,944
SEE ACROSS THE COUNTRY.

4544
02:33:00,944 --> 02:33:06,516
YOU HEARD ABOUT SOME NONINVASIVE

4545
02:33:06,516 --> 02:33:07,818
DIAGNOSTICS FOR ENDOMETRIOSIS.

4546
02:33:07,818 --> 02:33:09,586
WE'RE GOING TO SEND THIS TEAM TO

4547
02:33:09,586 --> 02:33:11,088
NIBIB AND I HOPE THAT THEY WILL

4548
02:33:11,088 --> 02:33:15,092
WIN BRUCE'S PRIZE COMPETITION,

4549
02:33:15,092 --> 02:33:17,861
BECAUSE THEY ARE WORKING ON A

4550
02:33:17,861 --> 02:33:21,365
NONINVASIVE DIAGNOSTIC FOR

4551
02:33:21,365 --> 02:33:23,000
ENDOMETRIOSIS THAT USES

4552
02:33:23,000 --> 02:33:24,968
MENSTRUAL EFFLUENT, AND THE

4553
02:33:24,968 --> 02:33:28,205
CHANGES IN THE MENSTRUAL

4554
02:33:28,205 --> 02:33:30,140
EFFLUENT AS AN EARLY DIAGNOSTIC

4555
02:33:30,140 --> 02:33:30,607
FOR ENDOMETRIOSIS.

4556
02:33:30,607 --> 02:33:32,976
SO THEY WILL COME TO YOUR PRIZE

4557
02:33:32,976 --> 02:33:34,177
COMPETITION, BRUCE, AND

4558
02:33:34,177 --> 02:33:36,613
HOPEFULLY THEY WILL WIN AND WHAT

4559
02:33:36,613 --> 02:33:41,952
A TREMENDOUS OPPORTUNITY.

4560
02:33:41,952 --> 02:33:43,687
DRUGS FOR GENITOURINARY SYNDROME

4561
02:33:43,687 --> 02:33:47,824
OF MENOPAUSE, THIS PROJECT IS

4562
02:33:47,824 --> 02:33:49,893
LOOKING TO DEVELOP A RAPIDLY

4563
02:33:49,893 --> 02:33:52,295
ACTING LOCAL TREATMENT INSTEAD

4564
02:33:52,295 --> 02:33:56,433
OF SYSTEMIC ESTROGEN, AND TRYING

4565
02:33:56,433 --> 02:33:59,069
TO UNDERSTAND THE DYNAMICS OF

4566
02:33:59,069 --> 02:34:02,873
THE DEVELOPMENT OF THIS PRODUCT

4567
02:34:02,873 --> 02:34:04,841
AS A LOCAL TOPICAL TREATMENT AS

4568
02:34:04,841 --> 02:34:07,010
OPPOSED TO SYSTEMIC CAUSE.

4569
02:34:07,010 --> 02:34:11,481
AND ANOTHER ONE THAT'S REALLY

4570
02:34:11,481 --> 02:34:14,985
INTERESTING AS A CASE STUDY IS

4571
02:34:14,985 --> 02:34:18,021
THIS VULVOVAGINAL ANTIFUNGAL

4572
02:34:18,021 --> 02:34:18,789
AGENT.

4573
02:34:18,789 --> 02:34:22,059
THAT PRODUCT HAD ALREADY BEEN

4574
02:34:22,059 --> 02:34:24,561
INVESTIGATED FOR USE IN HIV.

4575
02:34:24,561 --> 02:34:27,831
SO THERE WAS SOME TOXICITY DATA

4576
02:34:27,831 --> 02:34:29,800
THAT WAS AVAILABLE AND HAD BEEN

4577
02:34:29,800 --> 02:34:35,038
USED IN FDA FILING FOR THAT

4578
02:34:35,038 --> 02:34:37,240
AGENT FOR A RECTAL APPLICATION

4579
02:34:37,240 --> 02:34:38,008
FOR HIV.

4580
02:34:38,008 --> 02:34:40,911
SO THAT TOXICITY DATA THAT WAS

4581
02:34:40,911 --> 02:34:43,113
SUFFICIENT QUALITY FOR FDA

4582
02:34:43,113 --> 02:34:45,716
ALREADY EXISTED.

4583
02:34:45,716 --> 02:34:47,984
SO THIS THROUGH THE ASSISTANCE

4584
02:34:47,984 --> 02:34:50,287
OF THE REACH HUB, THOSE

4585
02:34:50,287 --> 02:34:53,690
INVESTIGATORS REALIZED THAT THE

4586
02:34:53,690 --> 02:34:54,791
PATH TO COMMERCIALIZATION WOULD

4587
02:34:54,791 --> 02:34:57,728
BE FASTER TO DEVELOP THEIR

4588
02:34:57,728 --> 02:34:59,663
PRODUCT AS A RECTAL ANTIFUNGAL

4589
02:34:59,663 --> 02:35:04,267
EVEN THOUGH THERE ARE MORE

4590
02:35:04,267 --> 02:35:06,670
PATIENTS WITH VAGINAL THAN

4591
02:35:06,670 --> 02:35:08,739
RECTAL FUNGAL INFECTIONS BECAUSE

4592
02:35:08,739 --> 02:35:09,639
OF THIS REGULATORY ADVANTAGE

4593
02:35:09,639 --> 02:35:10,907
THEY HAD FROM THIS PREVIOUS

4594
02:35:10,907 --> 02:35:11,675
DATA.

4595
02:35:11,675 --> 02:35:15,412
SO THAT'S JUST AN EXAMPLE OF HOW

4596
02:35:15,412 --> 02:35:17,647
THIS TYPE OF COMMERCIAL AND

4597
02:35:17,647 --> 02:35:21,585
BUSINESS EXPERTISE CAN HELP AN

4598
02:35:21,585 --> 02:35:22,686
INVESTIGATOR CHART THIS PATH TO

4599
02:35:22,686 --> 02:35:25,622
THE FASTEST WAY TO COMMERCIAL

4600
02:35:25,622 --> 02:35:26,823
AVAILABILITY AND TO HEALTHCARE

4601
02:35:26,823 --> 02:35:31,294
AVAILABILITY OF THEIR PRODUCTS.

4602
02:35:31,294 --> 02:35:32,496
AND ALSO IT PROBABLY GOES

4603
02:35:32,496 --> 02:35:33,497
WITHOUT SAYING THAT A LARGE

4604
02:35:33,497 --> 02:35:35,198
PERCENTAGE OF THE PRODUCTS AND

4605
02:35:35,198 --> 02:35:37,067
THE TECHNOLOGY DEVELOPMENT

4606
02:35:37,067 --> 02:35:38,935
PROJECTS THAT ARE RELATED TO

4607
02:35:38,935 --> 02:35:43,607
WOMEN'S HEALTH ARE IN THE CANCER

4608
02:35:43,607 --> 02:35:45,142
FIELD, IN BREAST CANCER, IN

4609
02:35:45,142 --> 02:35:46,777
OVARIAN CANCER, AND WE SEE THAT

4610
02:35:46,777 --> 02:35:49,079
IN OUR PORTFOLIO, IN THIS

4611
02:35:49,079 --> 02:35:51,581
PROGRAM ALSO.

4612
02:35:51,581 --> 02:35:53,750
SO IN THE ACADEMIC SPACE, WE

4613
02:35:53,750 --> 02:35:56,820
HAVE THE REACH HUBS IN THIS

4614
02:35:56,820 --> 02:35:58,889
MODEL THAT HELPS INVESTIGATORS

4615
02:35:58,889 --> 02:36:00,123
STRENGTHEN THEIR PROJECTS, BUT

4616
02:36:00,123 --> 02:36:02,392
THE BIGGEST WAY THAT NIH

4617
02:36:02,392 --> 02:36:03,693
SUPPORTS EARLY STAGE PRODUCT

4618
02:36:03,693 --> 02:36:05,562
DEVELOPMENT IS THROUGH OUR SMALL

4619
02:36:05,562 --> 02:36:07,063
BUSINESS PROGRAM.

4620
02:36:07,063 --> 02:36:09,366
AND AS DR. CLAYTON MENTIONED,

4621
02:36:09,366 --> 02:36:15,138
THE SBIR AND STTR PROGRAMS ARE A

4622
02:36:15,138 --> 02:36:15,806
CONGRESSIONALLY MANDATED PROGRAM

4623
02:36:15,806 --> 02:36:20,110
AND THEY ARE PROVIDING

4624
02:36:20,110 --> 02:36:22,112
$1.4 BILLION PER YEAR TO

4625
02:36:22,112 --> 02:36:22,679
AMERICAN SMALL BUSINESSES TO

4626
02:36:22,679 --> 02:36:24,514
DEVELOP PRODUCTS IN THE LIFE

4627
02:36:24,514 --> 02:36:26,550
SCIENCES.

4628
02:36:26,550 --> 02:36:27,117
THAT'S $1.4 BILLION A YEAR.

4629
02:36:27,117 --> 02:36:31,822
IT'S ACTUALLY 4% OF NIH'S

4630
02:36:31,822 --> 02:36:32,789
EXTRAMURAL RESEARCH BUDGET

4631
02:36:32,789 --> 02:36:34,224
ACROSS THE ENTIRE NIH.

4632
02:36:34,224 --> 02:36:36,593
IT'S A CONGRESSIONALLY MANDATED

4633
02:36:36,593 --> 02:36:37,594
PROGRAM.

4634
02:36:37,594 --> 02:36:39,796
AND THE IDEA IS TO HELP

4635
02:36:39,796 --> 02:36:42,532
TRANSITION THOSE TECHNOLOGIES

4636
02:36:42,532 --> 02:36:46,436
FROM THE ACADEMIC WORLD OR FOR

4637
02:36:46,436 --> 02:36:47,204
SCIENTIFIC DISCOVERY INTO EARLY

4638
02:36:47,204 --> 02:36:48,638
STAGE PRODUCT DEVELOPMENT AT

4639
02:36:48,638 --> 02:36:51,041
U.S. SMALL BUSINESSES.

4640
02:36:51,041 --> 02:36:53,343
AND THERE'S A NOTICE OF SPECIAL

4641
02:36:53,343 --> 02:36:55,278
INTEREST THAT ACTUALLY

4642
02:36:55,278 --> 02:36:57,013
ENCOURAGES INVESTIGATORS WHO ARE

4643
02:36:57,013 --> 02:36:58,682
WORKING ON WOMEN'S HEALTH

4644
02:36:58,682 --> 02:37:01,284
RESEARCH TO UTILIZE THE SMALL

4645
02:37:01,284 --> 02:37:02,252
BUSINESS PROGRAM AS A WAY TO

4646
02:37:02,252 --> 02:37:03,687
DEVELOP THEIR PRODUCT AND

4647
02:37:03,687 --> 02:37:05,655
SERVICES.

4648
02:37:05,655 --> 02:37:08,291
SO THE SMALL BUSINESS PORTFOLIO,

4649
02:37:08,291 --> 02:37:10,894
WE'RE SUPPORTING ABOUT 1400

4650
02:37:10,894 --> 02:37:12,395
SMALL BUSINESSES EVERY YEAR.

4651
02:37:12,395 --> 02:37:14,264
AND YOU CAN SEE HERE THE

4652
02:37:14,264 --> 02:37:15,465
BREAKDOWN OF THE TYPES OF

4653
02:37:15,465 --> 02:37:17,934
PROJECTS THAT ARE SUPPORTED

4654
02:37:17,934 --> 02:37:20,704
ACROSS THE DIFFERENT TYPES OF

4655
02:37:20,704 --> 02:37:22,372
PROJECTS.

4656
02:37:22,372 --> 02:37:24,341
SO THERE'S A LARGE NUMBER OF

4657
02:37:24,341 --> 02:37:28,378
PROJECTS IN RESEARCH TOOLS AND

4658
02:37:28,378 --> 02:37:29,446
DIAGNOSTICS, BUT WE REALLY SPAN

4659
02:37:29,446 --> 02:37:32,282
THE ENTIRE PRODUCT DEVELOPMENT

4660
02:37:32,282 --> 02:37:32,949
SPECTRUM, AND ONE OF THE THINGS

4661
02:37:32,949 --> 02:37:35,719
I WANT TO NOTE IS THAT THE

4662
02:37:35,719 --> 02:37:37,754
HEALTH INFORMATION TECHNOLOGIES,

4663
02:37:37,754 --> 02:37:39,789
ALTHOUGH NOW IS ONLY ABOUT 10%

4664
02:37:39,789 --> 02:37:44,094
OF OUR PORTFOLIO, WE'RE SEEING

4665
02:37:44,094 --> 02:37:47,898
THAT GROW AS MORE INTEREST IN

4666
02:37:47,898 --> 02:37:49,633
THAT AREA PERVADES ACROSS THE

4667
02:37:49,633 --> 02:37:55,071
DIFFERENT SECTORS OF HEALTHCARE.

4668
02:37:55,071 --> 02:37:58,241
BUT ALSO I WANT TO MAKE A POINT

4669
02:37:58,241 --> 02:38:02,312
HERE IN THE MAP TO THE LEFT THAT

4670
02:38:02,312 --> 02:38:03,880
WE ARE FUNDING SMALL BUSINESSES

4671
02:38:03,880 --> 02:38:04,915
ALL ACROSS THE UNITED STATES AND

4672
02:38:04,915 --> 02:38:10,820
ALL PARTS OF THE COUNTRY, AND

4673
02:38:10,820 --> 02:38:11,788
THIS $1.4 BILLION A YEAR IS

4674
02:38:11,788 --> 02:38:13,990
ACTUALLY THE LARGEST SOURCE OF

4675
02:38:13,990 --> 02:38:15,725
EARLY STAGE PRODUCT DEVELOPMENT

4676
02:38:15,725 --> 02:38:17,794
FUNDING IN THE COUNTRY.

4677
02:38:17,794 --> 02:38:21,398
SO YOU MIGHT HEAR ABOUT VENTURE

4678
02:38:21,398 --> 02:38:22,732
CAPITOLLISTS AND THE VENTURE

4679
02:38:22,732 --> 02:38:24,367
CAPITAL FOLKS AND THEY THINK

4680
02:38:24,367 --> 02:38:26,202
THEY CORNER THE MARKET ON

4681
02:38:26,202 --> 02:38:28,705
DECIDING AND SUPPORTING EARLY

4682
02:38:28,705 --> 02:38:30,240
STAGE PRODUCT DEVELOPMENT BUT

4683
02:38:30,240 --> 02:38:32,876
ACTUALLY NIH IS THE LARGEST

4684
02:38:32,876 --> 02:38:34,511
SUPPORTER OF EARLY STAGE PRODUCT

4685
02:38:34,511 --> 02:38:35,578
DEVELOPMENT IN THE COUNTRY, AND

4686
02:38:35,578 --> 02:38:37,180
THAT'S THROUGH THE SMALL

4687
02:38:37,180 --> 02:38:40,617
BUSINESS PROGRAM.

4688
02:38:40,617 --> 02:38:42,585
SO THREE TIMES A YEAR EVERY

4689
02:38:42,585 --> 02:38:45,322
YEAR, JANUARY 5TH, APRIL 5TH,

4690
02:38:45,322 --> 02:38:46,723
SEPTEMBER 5TH, THERE'S A RECEIPT

4691
02:38:46,723 --> 02:38:50,994
DATE FOR SMALL BUSINESS PROGRAM

4692
02:38:50,994 --> 02:38:52,295
APPLICATIONS AND WE HOPE THAT

4693
02:38:52,295 --> 02:38:53,430
SMALL BUSINESSES ALL AROUND THE

4694
02:38:53,430 --> 02:38:54,364
COUNTRY WILL COME AND CONTINUE

4695
02:38:54,364 --> 02:38:56,132
TO USE IT AS A MAJOR WAY TO

4696
02:38:56,132 --> 02:39:01,805
SUPPORT THEIR PROGRAMS.

4697
02:39:01,805 --> 02:39:03,106
THE OTHER THING IS, IT'S NOT

4698
02:39:03,106 --> 02:39:03,773
JUST THE FUNDING YOU RECEIVE

4699
02:39:03,773 --> 02:39:04,541
THROUGH THE SMALL BUSINESS

4700
02:39:04,541 --> 02:39:04,774
PROGRAM.

4701
02:39:04,774 --> 02:39:09,879
IN ADDITION TO THE FUNDING, YOU

4702
02:39:09,879 --> 02:39:12,716
GAIN ACCESS TO ALL THE

4703
02:39:12,716 --> 02:39:13,516
COMMERCIALIZATION SERVICES OUR

4704
02:39:13,516 --> 02:39:15,018
OFFICE PROVIDES AND OTHER

4705
02:39:15,018 --> 02:39:19,055
ADDITIONAL PROGRAMS THAT PROVIDE

4706
02:39:19,055 --> 02:39:19,656
COMMERCIALIZATION SUPPORT FOR

4707
02:39:19,656 --> 02:39:19,990
YOUR PROJECT.

4708
02:39:19,990 --> 02:39:22,225
SO YOU NOT ONLY GET FUNDING FOR

4709
02:39:22,225 --> 02:39:24,828
TECHNOLOGY DEVELOPMENT, BUT YOU

4710
02:39:24,828 --> 02:39:27,130
ALSO GET SUPPORT FOR BUSINESS

4711
02:39:27,130 --> 02:39:28,765
DEVELOPMENT, FOR INTELLECTUAL

4712
02:39:28,765 --> 02:39:30,967
PROPERTY, FOR MARKET ANALYSIS,

4713
02:39:30,967 --> 02:39:34,004
FOR REGULATORY PLANNING, FOR

4714
02:39:34,004 --> 02:39:35,405
INSURANCE PAYMENT OR

4715
02:39:35,405 --> 02:39:37,173
REIMBURSEMENT, AND ALL OF THOSE

4716
02:39:37,173 --> 02:39:39,175
COMPONENTS WORK TOGETHER TO HELP

4717
02:39:39,175 --> 02:39:41,044
PEOPLE BECOME MORE SUCCESSFUL AS

4718
02:39:41,044 --> 02:39:43,279
THEY MAKE IT INTO THE HEALTHCARE

4719
02:39:43,279 --> 02:39:45,682
MARKETPLACE.

4720
02:39:45,682 --> 02:39:48,852
SO WHAT'S THE FOOTPRINT OF THE

4721
02:39:48,852 --> 02:39:50,153
PROGRAM FOR IN THE WOMEN'S

4722
02:39:50,153 --> 02:39:51,254
HEALTH SPACE?

4723
02:39:51,254 --> 02:39:54,424
WE'RE FUNDING AT LEAST 200 SMALL

4724
02:39:54,424 --> 02:39:56,159
BUSINESSES, WORK ON WOMEN'S

4725
02:39:56,159 --> 02:39:59,229
HEALTH APPLICATIONS EVERY YEAR.

4726
02:39:59,229 --> 02:40:01,197
AND LIKE DR. TROMBERG TALKED

4727
02:40:01,197 --> 02:40:04,234
ABOUT, THIS WORD CLOUD IS BASED

4728
02:40:04,234 --> 02:40:06,636
ON THE TYPES OF PROJECTS, THE

4729
02:40:06,636 --> 02:40:09,372
TYPES OF WOMEN'S HEALTH PROJECTS

4730
02:40:09,372 --> 02:40:11,775
AND THE NIH STUDY SECTIONS THAT

4731
02:40:11,775 --> 02:40:14,944
REVIEWED THEM, AND YOU CAN SEE

4732
02:40:14,944 --> 02:40:16,446
HERE THAT THE WOMEN'S HEALTH

4733
02:40:16,446 --> 02:40:18,982
PROJECTS THAT ARE FUNDED BY THE

4734
02:40:18,982 --> 02:40:22,452
NIH SMALL BUSINESS PROGRAM ARE

4735
02:40:22,452 --> 02:40:23,420
REALLY SCATTERED ACROSS ALL OF

4736
02:40:23,420 --> 02:40:25,088
THE DIFFERENT AREAS THAT NIH

4737
02:40:25,088 --> 02:40:26,823
SUPPORTS.

4738
02:40:26,823 --> 02:40:31,094
FROM ENVIRONMENTAL HEALTH TO

4739
02:40:31,094 --> 02:40:33,396
OPHTHALMOLOGY TO DENTAL AND

4740
02:40:33,396 --> 02:40:37,100
CRANIOFACIAL RESEARCH, TO CANCER

4741
02:40:37,100 --> 02:40:38,735
WITH THE LARGEST FOOTPRINT BEING

4742
02:40:38,735 --> 02:40:40,703
IN CANCER, BUT YOU CAN SEE HERE

4743
02:40:40,703 --> 02:40:43,440
THAT THOSE PROJECTS ARE REALLY

4744
02:40:43,440 --> 02:40:45,942
RUNNING THE GAMUT ACROSS ALL OF

4745
02:40:45,942 --> 02:40:50,346
THE DIFFERENT AREAS THAT NIH

4746
02:40:50,346 --> 02:40:52,182
SUPPORTS.

4747
02:40:52,182 --> 02:40:53,316
SO THAT'S A REALLY IMPORTANT

4748
02:40:53,316 --> 02:40:54,784
POINT TO BE MADE BECAUSE AS WE

4749
02:40:54,784 --> 02:40:57,954
INCROSE OUR ATTENTION TO WOMEN'S

4750
02:40:57,954 --> 02:41:00,590
HEALTH, THOSE ADVANCES AND THOSE

4751
02:41:00,590 --> 02:41:02,759
PROJECTS CAN BE COMING THROUGH

4752
02:41:02,759 --> 02:41:04,160
MANY OF THE DIFFERENT INSTITUTES

4753
02:41:04,160 --> 02:41:06,262
AND CENTERS, NOT JUST BIOMEDICAL

4754
02:41:06,262 --> 02:41:07,564
IMAGING AND BIOENGINEERING OR

4755
02:41:07,564 --> 02:41:09,532
THE CANCER INSTITUTE, BUT

4756
02:41:09,532 --> 02:41:11,167
THROUGH ALL OF THOSE INSTITUTES

4757
02:41:11,167 --> 02:41:13,403
AND CENTERS THAT ARE WORKING IN

4758
02:41:13,403 --> 02:41:14,471
COLLABORATION WITH THE OFFICE OF

4759
02:41:14,471 --> 02:41:16,639
RESEARCH IN WOMEN'S HEALTH TO

4760
02:41:16,639 --> 02:41:17,841
ACHIEVE THE GOALS THAT WE'RE

4761
02:41:17,841 --> 02:41:19,576
TRYING TO ACHIEVE IN WOMEN'S

4762
02:41:19,576 --> 02:41:25,381
HEALTH.

4763
02:41:25,381 --> 02:41:26,583
SO I WANT TO RUN THROUGH SOME

4764
02:41:26,583 --> 02:41:28,418
EXAMPLES OF THESE PROJECTS IN

4765
02:41:28,418 --> 02:41:32,889
THE SMALL BUSINESS SPACE.

4766
02:41:32,889 --> 02:41:33,790
ONE OF THE PROJECT FROM A

4767
02:41:33,790 --> 02:41:37,060
COMPANY CALLED RIVANNA IS A

4768
02:41:37,060 --> 02:41:43,633
HANDHELD ULTRASOUND DEVICE FOR

4769
02:41:43,633 --> 02:41:46,469
EPIDURAL PLACEMENT.

4770
02:41:46,469 --> 02:41:48,138
THEY STILL AFFECT THOUSANDS OF

4771
02:41:48,138 --> 02:41:49,105
WOMEN EACH YEAR, AND I WAS

4772
02:41:49,105 --> 02:41:50,974
THINKING ABOUT THIS PROJECT THE

4773
02:41:50,974 --> 02:41:52,809
OTHER DAY BECAUSE MY MOTHER HAD

4774
02:41:52,809 --> 02:41:59,582
AN EPIDURAL INJECTION FOR A

4775
02:41:59,582 --> 02:42:01,117
STENOSIS AND SHE HAD TO GO TO AN

4776
02:42:01,117 --> 02:42:01,985
OUTPATIENT SURGERY CENTER AND

4777
02:42:01,985 --> 02:42:04,154
HAVE THAT DONE UNDER X-RAY

4778
02:42:04,154 --> 02:42:04,821
GUIDANCE, BUT WOULDN'T IT BE

4779
02:42:04,821 --> 02:42:06,022
GREAT IF THERE WAS A DEVICE THAT

4780
02:42:06,022 --> 02:42:08,324
COULD BE USED IN THE DOCTOR'S

4781
02:42:08,324 --> 02:42:10,293
OFFICE TO HELP THEM GUIDE

4782
02:42:10,293 --> 02:42:11,794
EPIDURAL PLACEMENT AND THAT'S

4783
02:42:11,794 --> 02:42:13,863
THE PRODUCT THAT RIVANNA IS

4784
02:42:13,863 --> 02:42:15,064
WORKING TO DEVELOP.

4785
02:42:15,064 --> 02:42:19,002
AND HOPEFULLY IN THE NEXT FEW

4786
02:42:19,002 --> 02:42:20,637
YEARS, THAT DEVICE WILL BE

4787
02:42:20,637 --> 02:42:29,679
AVAILABLE FOR COMMERCIAL USE.

4788
02:42:29,679 --> 02:42:33,750
DAREBIO IS A COMPANY WORKING ON

4789
02:42:33,750 --> 02:42:34,651
NON-HORMONAL BIRTH CONTROL

4790
02:42:34,651 --> 02:42:35,084
DEVICES.

4791
02:42:35,084 --> 02:42:38,888
THE FOUNDER OF THIS COMPANY, SHE

4792
02:42:38,888 --> 02:42:40,757
CO-FUNDED THIS COMPANY AFTER

4793
02:42:40,757 --> 02:42:43,059
LEAVING A WOMEN'S HEALTH

4794
02:42:43,059 --> 02:42:43,393
NON-PROFIT.

4795
02:42:43,393 --> 02:42:45,228
AND THE REASON SHE LEFT THIS

4796
02:42:45,228 --> 02:42:47,730
WOMEN'S HEALTH NON-PROFIT IS

4797
02:42:47,730 --> 02:42:49,399
BECAUSE SHE KEPT SEEING ALL

4798
02:42:49,399 --> 02:42:50,700
THESE WOMEN'S HEALTHCARE

4799
02:42:50,700 --> 02:42:52,435
PRODUCTS THAT DIDN'T HAVE A

4800
02:42:52,435 --> 02:42:54,103
PATHWAY TO COMMERCIALIZATION,

4801
02:42:54,103 --> 02:42:56,372
AND SHE THOUGHT, WELL, I CAN DO

4802
02:42:56,372 --> 02:42:57,907
SOMETHING ABOUT THAT IN THE

4803
02:42:57,907 --> 02:43:00,210
BUSINESS ENVIRONMENT MYSELF.

4804
02:43:00,210 --> 02:43:01,611
AND SO DARE IS NOT ONLY WORKING

4805
02:43:01,611 --> 02:43:04,013
ON THIS PRODUCT, BUT THEY HAVE

4806
02:43:04,013 --> 02:43:06,649
ANOTHER -- MANY OTHER NIH AWARDS

4807
02:43:06,649 --> 02:43:08,818
WORKING ON PRETERM BIRTH

4808
02:43:08,818 --> 02:43:10,553
PRODUCTS AND OTHER TYPES OF

4809
02:43:10,553 --> 02:43:15,158
CONTRACEPTIVE DEVICES.

4810
02:43:15,158 --> 02:43:19,095
NEAR OWECRINE BIOSCIENCE,

4811
02:43:19,095 --> 02:43:20,296
THEY'VE HAD DECADES OF SUPPORT.

4812
02:43:20,296 --> 02:43:21,598
THEY'RE A GREAT EXAMPLE OF HOW

4813
02:43:21,598 --> 02:43:25,501
SUSTAINED INVESTMENTS IN BASIC

4814
02:43:25,501 --> 02:43:26,936
SCIENCE AND SUPPORTING

4815
02:43:26,936 --> 02:43:28,037
TECHNOLOGY ALL THE WAY FROM

4816
02:43:28,037 --> 02:43:29,138
BASIC SCIENCE THROUGH EARLY

4817
02:43:29,138 --> 02:43:32,942
PRODUCT DEVELOPMENT IS REALLY

4818
02:43:32,942 --> 02:43:36,546
NECESSARY TO CRACK SOME OF THESE

4819
02:43:36,546 --> 02:43:37,780
PROBLEMS OPEN AND COME WITH

4820
02:43:37,780 --> 02:43:39,415
SOLUTIONS.

4821
02:43:39,415 --> 02:43:42,352
SO NEUROCRINE HAS HAD DECADES OF

4822
02:43:42,352 --> 02:43:45,622
SUPPORT WORKING ON THE BASIC

4823
02:43:45,622 --> 02:43:47,357
MECHANISMS RELATED TO

4824
02:43:47,357 --> 02:43:49,759
ENDOMETRIOSIS, AND THEY'VE USED

4825
02:43:49,759 --> 02:43:51,761
THAT UNDERLYING KNOWLEDGE TO

4826
02:43:51,761 --> 02:43:57,000
DEVELOP A FAST-ACTING TREATMENT

4827
02:43:57,000 --> 02:44:01,237
FOR ENDOMETRIOSIS.

4828
02:44:01,237 --> 02:44:03,673
SO IT'S JUST AN EXAMPLE OF HOW

4829
02:44:03,673 --> 02:44:06,843
IT'S NOT JUST THE TECHNOLOGY

4830
02:44:06,843 --> 02:44:08,044
DEVELOPMENT OR THE BUSINESS

4831
02:44:08,044 --> 02:44:09,445
DEVELOPMENT, BUT IT'S THE

4832
02:44:09,445 --> 02:44:10,847
INTERSECTION OF THE TWO THAT

4833
02:44:10,847 --> 02:44:11,981
ENABLES THESE COMPANIES TO BE

4834
02:44:11,981 --> 02:44:15,451
SUCCESSFUL.

4835
02:44:15,451 --> 02:44:17,320
BIOPSY SCIENCES, THAT'S A

4836
02:44:17,320 --> 02:44:21,057
COMPANY THAT FORMED WHEN TWO

4837
02:44:21,057 --> 02:44:22,358
SOCCER DADS GOT TO CHATTING WITH

4838
02:44:22,358 --> 02:44:23,893
EACH OTHER AT THE SOCCER FIELD,

4839
02:44:23,893 --> 02:44:26,195
ONE WAS AN ENGINEER, AND ONE WAS

4840
02:44:26,195 --> 02:44:31,100
A RADIOLOGIST, AND THEY GOT

4841
02:44:31,100 --> 02:44:32,402
TALKING ABOUT CHALLENGES IN

4842
02:44:32,402 --> 02:44:33,703
BREAST CANCER DIAGNOSTICS, AND

4843
02:44:33,703 --> 02:44:35,805
THEY FORMED A COMPANY CALLED

4844
02:44:35,805 --> 02:44:37,774
BIOPSY SCIENCES.

4845
02:44:37,774 --> 02:44:43,246
AND THIS PROJECT WAS ONE, WHEN

4846
02:44:43,246 --> 02:44:47,750
THEY TAKE A BIOPSY AND TEST THAT

4847
02:44:47,750 --> 02:44:49,152
BIOPSY, LATER ON WHEN THEY HAVE

4848
02:44:49,152 --> 02:44:50,687
TO GO BACK TO DO SURGERY, IT'S

4849
02:44:50,687 --> 02:44:53,222
VERY DIFFICULT TO KNOW THE EXACT

4850
02:44:53,222 --> 02:44:54,757
LOCATION OF WHERE THAT BIOPSY

4851
02:44:54,757 --> 02:44:56,159
WAS TAKEN.

4852
02:44:56,159 --> 02:44:57,460
SO OFTENTIMES A CLINICIAN WILL

4853
02:44:57,460 --> 02:44:59,329
HAVE TO PLACE A NEEDLE TO TRY

4854
02:44:59,329 --> 02:45:02,498
AND LOCATE WHERE THAT BIOPSY WAS

4855
02:45:02,498 --> 02:45:03,933
DONE, BUT WHAT THEY DID IS THEY

4856
02:45:03,933 --> 02:45:05,568
DEVELOPED A HYDROGEL MARKER THAT

4857
02:45:05,568 --> 02:45:06,969
THEY COULD INJECT AT THE TIME

4858
02:45:06,969 --> 02:45:09,706
THEY TAKE THE BIOPSY, WHICH IS

4859
02:45:09,706 --> 02:45:11,808
VISIBLE WITH ULTRASOUND AND

4860
02:45:11,808 --> 02:45:13,776
LASTS FOR LESS THAN A YEAR BUT

4861
02:45:13,776 --> 02:45:16,412
IS RESORBABLE THAT ALLOWS THE

4862
02:45:16,412 --> 02:45:19,248
CLINICIANS TO VERY EASILY LOCATE

4863
02:45:19,248 --> 02:45:20,316
THE PRECISE LOCATION WHERE THE

4864
02:45:20,316 --> 02:45:23,720
BIOPSY WAS TAKEN.

4865
02:45:23,720 --> 02:45:24,821
SO THAT IS A PRODUCT THAT'S

4866
02:45:24,821 --> 02:45:25,922
UNDER DEVELOPMENT WITH NIH

4867
02:45:25,922 --> 02:45:28,057
FUNDING.

4868
02:45:28,057 --> 02:45:32,095
AND NUGENEREX WAS A COMPANY THAT

4869
02:45:32,095 --> 02:45:34,464
WAS SPUN OUT OF UMASS IN THE

4870
02:45:34,464 --> 02:45:37,166
90s BASED ON A DISCOVERY THAT

4871
02:45:37,166 --> 02:45:38,601
SMALL BITS OF A TUMOR OR VIRUS

4872
02:45:38,601 --> 02:45:40,470
COULD BE USED TO STIMULATE THE

4873
02:45:40,470 --> 02:45:42,004
IMMUNE SYSTEM TO ATTACK CANCER

4874
02:45:42,004 --> 02:45:43,206
CELLS.

4875
02:45:43,206 --> 02:45:47,043
SO OVER THE YEARS, THAT BASIC

4876
02:45:47,043 --> 02:45:50,079
DISCOVERY WAS USED TO FORM -- TO

4877
02:45:50,079 --> 02:45:51,948
TEST A NUMBER OF PRODUCTS BUT

4878
02:45:51,948 --> 02:45:54,350
MOST RECENTLY, A TREATMENT FOR

4879
02:45:54,350 --> 02:45:55,451
AN AGGRESSIVE FORM OF BREAST

4880
02:45:55,451 --> 02:45:56,552
CANCER.

4881
02:45:56,552 --> 02:45:59,188
SO THIS IS JUST A SAMPLING OF

4882
02:45:59,188 --> 02:46:00,757
SOME OF THOSE PRODUCTS THAT ARE

4883
02:46:00,757 --> 02:46:02,291
COMING OUT OF THE SMALL BUSINESS

4884
02:46:02,291 --> 02:46:05,395
PROGRAM THAT ARE RELATED TO

4885
02:46:05,395 --> 02:46:05,828
WOMEN'S HEALTH.

4886
02:46:05,828 --> 02:46:08,698
IT'S IMPORTANT TO NOTE THAT MANY

4887
02:46:08,698 --> 02:46:11,200
OF THESE PROJECTS, THE VERY

4888
02:46:11,200 --> 02:46:12,869
FIRST INVESTMENT THAT THESE

4889
02:46:12,869 --> 02:46:14,270
COMPANIES RECEIVED TO DO THEIR

4890
02:46:14,270 --> 02:46:16,806
PRODUCT DEVELOPMENT IS FROM THE

4891
02:46:16,806 --> 02:46:18,541
NIH SMALL BUSINESS PROGRAM.

4892
02:46:18,541 --> 02:46:20,076
AND WITHOUT THAT FUNDING AND

4893
02:46:20,076 --> 02:46:22,612
WITHOUT THAT $1.4 BILLION OF

4894
02:46:22,612 --> 02:46:24,347
SUSTAINED FUNDING OVER TIME,

4895
02:46:24,347 --> 02:46:26,182
MANY OF THESE PROJECTS WOULD

4896
02:46:26,182 --> 02:46:28,384
HAVE NEVER MADE THAT TRANSITION

4897
02:46:28,384 --> 02:46:31,988
FROM AN IDEA OR A DISCOVERY INTO

4898
02:46:31,988 --> 02:46:34,857
PRODUCT DEVELOPMENT.

4899
02:46:34,857 --> 02:46:36,592
SO THAT'S WHY AT NIH, WE'RE

4900
02:46:36,592 --> 02:46:39,862
TRYING TO REALLY MAXIMIZE THE

4901
02:46:39,862 --> 02:46:41,531
BENEFIT OF THAT PROGRAM AND THE

4902
02:46:41,531 --> 02:46:43,800
DOLLARS THAT ARE AVAILABLE AND

4903
02:46:43,800 --> 02:46:44,801
SURROUND THOSE PROJECTS WITH ALL

4904
02:46:44,801 --> 02:46:47,203
THE RESOURCES THAT WE CAN

4905
02:46:47,203 --> 02:46:49,605
MARSHAL TO HELP THEM BE

4906
02:46:49,605 --> 02:46:51,140
SUCCESSFUL AS THEY MOVE FORWARD

4907
02:46:51,140 --> 02:46:52,475
IN THOSE EARLY STAGES.

4908
02:46:52,475 --> 02:46:56,412
WE REALIZE THAT THE MONEY THAT

4909
02:46:56,412 --> 02:46:57,547
WE'RE PROVIDING WHICH FOR ANY

4910
02:46:57,547 --> 02:46:59,115
ONE OF THESE SMALL BUSINESSES

4911
02:46:59,115 --> 02:47:02,852
COULD BE IN TOTAL UP TO 5 OR

4912
02:47:02,852 --> 02:47:04,487
$7 MILLION, THAT MIGHT BE -- IT

4913
02:47:04,487 --> 02:47:06,556
MIGHT BE A DROP IN THE BUCKET

4914
02:47:06,556 --> 02:47:09,225
FOR WHAT IT COULD TAKE TO GET AN

4915
02:47:09,225 --> 02:47:10,526
ACTUAL SAFE THERAPEUTIC ALL THE

4916
02:47:10,526 --> 02:47:13,796
WAY TO THE HEALTHCARE

4917
02:47:13,796 --> 02:47:14,464
MARKETPLACE, BUT IT'S REALLY

4918
02:47:14,464 --> 02:47:16,432
CRITICAL IN THOSE EARLY STAGES,

4919
02:47:16,432 --> 02:47:18,601
AND THE OTHER ADVANTAGE OF THIS

4920
02:47:18,601 --> 02:47:20,269
FUNDING IS THE MONEY THAT THEY

4921
02:47:20,269 --> 02:47:21,771
GET FROM THE NIH SMALL BUSINESS

4922
02:47:21,771 --> 02:47:24,307
PROGRAM IS FREE MONEY, IN THE

4923
02:47:24,307 --> 02:47:25,508
SENSE THAT THEY DON'T HAVE TO

4924
02:47:25,508 --> 02:47:27,710
GIVE UP A PIECE OF THEIR COMPANY

4925
02:47:27,710 --> 02:47:29,779
TO GET ACCESS TO THIS MONEY,

4926
02:47:29,779 --> 02:47:31,614
LIKE THEY DO WITH VENTURE

4927
02:47:31,614 --> 02:47:32,849
CAPITALISTS WHO ARE SPENDING

4928
02:47:32,849 --> 02:47:35,151
OTHER PEOPLE'S MONEY OR ANGEL

4929
02:47:35,151 --> 02:47:36,686
INVESTORS WHO ARE SPENDING THEIR

4930
02:47:36,686 --> 02:47:38,955
OWN MONEY, THEY'RE ABLE TO DO

4931
02:47:38,955 --> 02:47:41,390
THIS TECHNOLOGY DEVELOPMENT AND

4932
02:47:41,390 --> 02:47:43,025
MOVE THESE PROJECTS FORWARD WITH

4933
02:47:43,025 --> 02:47:44,360
THIS FUNDING THAT COMES FROM THE

4934
02:47:44,360 --> 02:47:47,096
FEDERAL GOVERNMENT.

4935
02:47:47,096 --> 02:47:49,198
SO THE OTHER THING I WANTED

4936
02:47:49,198 --> 02:47:52,034
TO -- OH, AND YOU CAN SEE ALL OF

4937
02:47:52,034 --> 02:47:54,537
THESE EXAMPLES THAT I'VE SHOWN

4938
02:47:54,537 --> 02:47:58,608
HERE, THERE ARE ONE PAGE SUCCESS

4939
02:47:58,608 --> 02:47:59,976
STORIES THAT ARE ON OUR SUCCESS

4940
02:47:59,976 --> 02:48:01,244
STORY WEBSITE THAT DESCRIBE IN

4941
02:48:01,244 --> 02:48:04,247
MORE DETAIL THE PATHWAY THAT

4942
02:48:04,247 --> 02:48:05,882
THESE COMPANIES HAVE TAKEN TO

4943
02:48:05,882 --> 02:48:07,283
DEVELOP THEIR PRODUCTS.

4944
02:48:07,283 --> 02:48:11,888
AND WE MAKE THESE ONE-PAGE

4945
02:48:11,888 --> 02:48:15,057
SUCCESS STORIES, THEY'RE

4946
02:48:15,057 --> 02:48:15,958
AVAILABLE, THEY'RE GEARED TOWARD

4947
02:48:15,958 --> 02:48:18,027
A GENERAL AUDIENCE FOR A FEW

4948
02:48:18,027 --> 02:48:21,898
REASONS, BUT ONE REASON IS

4949
02:48:21,898 --> 02:48:22,732
BECAUSE WE FIND THESE STORIES

4950
02:48:22,732 --> 02:48:24,267
ARE REALLY INSPIRATIONAL.

4951
02:48:24,267 --> 02:48:27,770
SO PEOPLE MIGHT THINK, OKAY,

4952
02:48:27,770 --> 02:48:29,839
WELL, MAYBE NIH DOESN'T REALLY

4953
02:48:29,839 --> 02:48:30,840
SUPPORT WOMEN'S HEALTHCARE,

4954
02:48:30,840 --> 02:48:33,242
PRODUCT DEVELOPMENT.

4955
02:48:33,242 --> 02:48:34,644
IT'S A GREAT WAY FOR PEOPLE TO

4956
02:48:34,644 --> 02:48:38,381
BE ABLE TO LEARN AND BE INSPIRED

4957
02:48:38,381 --> 02:48:40,449
BY OTHER PEOPLE'S SUCCESS, AND

4958
02:48:40,449 --> 02:48:43,419
BY OTHER PEOPLE'S EXPERIENCES.

4959
02:48:43,419 --> 02:48:45,855
SO WE HAVE A NUMBER OF

4960
02:48:45,855 --> 02:48:48,257
WOMEN-OWNED SMALL BUSINESSES

4961
02:48:48,257 --> 02:48:49,859
THAT ARE HIGHLIGHTED ON THIS

4962
02:48:49,859 --> 02:48:51,761
WEBSITE.

4963
02:48:51,761 --> 02:48:53,062
THERE'S ALMOST 100 SUCCESS

4964
02:48:53,062 --> 02:48:54,397
STORIES THERE NOW.

4965
02:48:54,397 --> 02:48:56,399
SO I WOULD ENCOURAGE YOU TO GO

4966
02:48:56,399 --> 02:48:58,534
AND CHECK OUT THE WEBSITE FOR

4967
02:48:58,534 --> 02:49:01,504
MORE INFORMATION.

4968
02:49:01,504 --> 02:49:02,805
NOW ANOTHER THING THAT I

4969
02:49:02,805 --> 02:49:05,775
MENTIONED WAS THIS INTERSECTION

4970
02:49:05,775 --> 02:49:09,912
WITH BIOMEDICAL WORKFORCE

4971
02:49:09,912 --> 02:49:11,213
DEVELOPMENT, AND IN THE SMALL

4972
02:49:11,213 --> 02:49:14,083
BUSINESS SPACE, WE ARE REALLY

4973
02:49:14,083 --> 02:49:16,152
COMMITTED TO TRAINING AND

4974
02:49:16,152 --> 02:49:19,755
SUPPORTING WOMEN INNOVATORS AND

4975
02:49:19,755 --> 02:49:20,623
WOMEN ENTREPRENEURS.

4976
02:49:20,623 --> 02:49:25,127
AND YOU KNOW, IT'S REALLY A

4977
02:49:25,127 --> 02:49:27,663
PRETTY SIMPLE IDEA WHICH IS THAT

4978
02:49:27,663 --> 02:49:29,398
PEOPLE ARE INTERESTED IN WORKING

4979
02:49:29,398 --> 02:49:30,700
ON THE ISSUES THAT AFFECT THEM

4980
02:49:30,700 --> 02:49:33,402
AND AFFECT THEIR COMMUNITIES AND

4981
02:49:33,402 --> 02:49:34,437
AFFECT THE PEOPLE THAT THEY'RE

4982
02:49:34,437 --> 02:49:37,073
CLOSE TO.

4983
02:49:37,073 --> 02:49:39,241
AND THAT'S WHAT DIVERSITY IN THE

4984
02:49:39,241 --> 02:49:42,979
BIOMEDICAL WORKFORCE IS ALL

4985
02:49:42,979 --> 02:49:44,213
ABOUT, IS BEING MORE INCLUSIVE

4986
02:49:44,213 --> 02:49:45,915
IN THE PEOPLE WHO WE'RE TRAINING

4987
02:49:45,915 --> 02:49:47,650
AND THE PEOPLE WE'RE SUPPORTING

4988
02:49:47,650 --> 02:49:49,018
SO THAT THOSE PEOPLE CAN ADDRESS

4989
02:49:49,018 --> 02:49:50,186
THE ISSUES THAT ARE IMPORTANT TO

4990
02:49:50,186 --> 02:49:53,155
THEM AND THAT THEY CARE ABOUT,

4991
02:49:53,155 --> 02:49:55,358
AND THAT'S IMPORTANT IN WOMEN'S

4992
02:49:55,358 --> 02:49:56,225
HEALTH ALSO.

4993
02:49:56,225 --> 02:50:02,665
IT TURNS OUT THAT 76% OF THE

4994
02:50:02,665 --> 02:50:03,332
VC-BACKED WOMEN'S HEALTH

4995
02:50:03,332 --> 02:50:05,601
COMPANIES HAVE AT LEAST ONE

4996
02:50:05,601 --> 02:50:08,037
FEMALE CO-FOUNDER.

4997
02:50:08,037 --> 02:50:11,207
SO THAT IS DIRECTLY RELATED TO

4998
02:50:11,207 --> 02:50:14,110
THE STATEMENT THAT I JUST MADE.

4999
02:50:14,110 --> 02:50:16,912
SO THAT'S EVIDENCE THAT

5000
02:50:16,912 --> 02:50:18,914
SUPPORTING WOMEN'S -- WOMEN

5001
02:50:18,914 --> 02:50:21,617
INNOVATORS AND SUPPORTING WOMEN

5002
02:50:21,617 --> 02:50:23,285
FOUNDERS IS REALLY ONE OF THE

5003
02:50:23,285 --> 02:50:25,554
BEST THINGS THAT WE CAN DO TO

5004
02:50:25,554 --> 02:50:26,689
INCREASE ATTENTION TO WOMEN'S

5005
02:50:26,689 --> 02:50:30,393
HEALTH PROJECTS.

5006
02:50:30,393 --> 02:50:31,027
SO THREE PROJECTS HERE.

5007
02:50:31,027 --> 02:50:33,129
THE FIRST ONE, DR. CLAYTON

5008
02:50:33,129 --> 02:50:36,966
MENTIONED.

5009
02:50:36,966 --> 02:50:40,903
THIS ONE, ANNA CONSUELO MATIANA

5010
02:50:40,903 --> 02:50:41,871
STARTED HER COMPANY BECAUSE SHE

5011
02:50:41,871 --> 02:50:45,908
NOTICED A LACK OF CULTURALLY

5012
02:50:45,908 --> 02:50:50,346
AWARE COMMUNE KEATION COMMUNICAS

5013
02:50:50,346 --> 02:50:51,847
AND OTHER PEOPLE OF COLOR, AND

5014
02:50:51,847 --> 02:50:53,516
ON THE BASIS OF THAT, SHE

5015
02:50:53,516 --> 02:50:56,485
DEVELOPED THESE PHOTO NOVELLAS

5016
02:50:56,485 --> 02:50:57,687
FOR DIFFERENT HEALTHCARE

5017
02:50:57,687 --> 02:50:58,888
CONDITIONS, AND SHE'S LEVERAGED

5018
02:50:58,888 --> 02:51:01,057
NIH FUNDING TO MOVE THIS PROJECT

5019
02:51:01,057 --> 02:51:01,290
FORWARD.

5020
02:51:01,290 --> 02:51:04,894
AND THIS IS ANOTHER ONE WHERE

5021
02:51:04,894 --> 02:51:05,528
ONE OF THE OTHER ADVANTAGES OF

5022
02:51:05,528 --> 02:51:08,631
NIH FUNDING IS THAT IT ALLOWS

5023
02:51:08,631 --> 02:51:12,134
YOU TO KIND OF MOVE A PROJECT

5024
02:51:12,134 --> 02:51:17,807
FORWARD THAT MIGHT NOT HAVE A

5025
02:51:17,807 --> 02:51:20,443
VERY STRONG INVESTMENT

5026
02:51:20,443 --> 02:51:20,776
HYPOTHESIS.

5027
02:51:20,776 --> 02:51:22,545
SO THESE ARE PROJECTS THAT HAVE

5028
02:51:22,545 --> 02:51:24,613
GREAT HEALTHCARE POTENTIAL, BUT

5029
02:51:24,613 --> 02:51:26,716
THEY MIGHT NOT HAVE THE SAME

5030
02:51:26,716 --> 02:51:28,017
MARKET POTENTIAL THAT OTHER

5031
02:51:28,017 --> 02:51:30,953
PROJECTS HAVE, SO UTILIZING NIH

5032
02:51:30,953 --> 02:51:33,055
FUNDING TO PUSH THEM FORWARD IS

5033
02:51:33,055 --> 02:51:36,125
ONE WAY TO REALLY INCREASE OUR

5034
02:51:36,125 --> 02:51:38,427
ABILITY TO BRING THEM INTO THE

5035
02:51:38,427 --> 02:51:39,195
MARKETPLACE.

5036
02:51:39,195 --> 02:51:43,799
THE NEXT PROJECT, RACHEL

5037
02:51:43,799 --> 02:51:45,201
DRILINGER, SHE WAS A BIOMEDICAL

5038
02:51:45,201 --> 02:51:46,669
ENGINEER FOR LIKE 20 YEARS, 20

5039
02:51:46,669 --> 02:51:47,603
YEARS OF ENGINEERING EXPERIENCE,

5040
02:51:47,603 --> 02:51:52,675
BUT SHE USED SBIR FUNDING TO

5041
02:51:52,675 --> 02:51:53,976
SPIN OUT AND START HER OWN

5042
02:51:53,976 --> 02:51:54,877
COMPANY, WHICH WAS A GREAT

5043
02:51:54,877 --> 02:51:56,712
CHALLENGE TO HER, NOT ONLY AS A

5044
02:51:56,712 --> 02:51:59,815
WOMAN ENGINEER BUT AS A NAVAJO

5045
02:51:59,815 --> 02:52:04,820
WOMAN ALSO, SO HER COMPANY,

5046
02:52:04,820 --> 02:52:07,123
NEURAMEDICA HAS BEEN DEVELOP AGO

5047
02:52:07,123 --> 02:52:08,224
BIOABSORBABLE CLIP THAT ENHANCES

5048
02:52:08,224 --> 02:52:09,425
PATIENT CARE DURING SPINAL

5049
02:52:09,425 --> 02:52:13,562
SURGERY.

5050
02:52:13,562 --> 02:52:15,331
IT'S ON ITS WAY TO

5051
02:52:15,331 --> 02:52:16,398
COMMERCIALIZATION.

5052
02:52:16,398 --> 02:52:18,400
SHE AS NOT ONLY SUCCESSFUL AS A

5053
02:52:18,400 --> 02:52:20,369
WOMEN BUSINESS OWNER BUT ALSO

5054
02:52:20,369 --> 02:52:24,640
BROUGHT IN NUMBER OF NAVAJO

5055
02:52:24,640 --> 02:52:25,241
INTERNS INTO HER COMPANY.

5056
02:52:25,241 --> 02:52:26,942
AND THEN THE FINAL EXAMPLE IS

5057
02:52:26,942 --> 02:52:29,044
CATHY ROLAND, SHE STRUCK OUT OF

5058
02:52:29,044 --> 02:52:30,780
THE UNIVERSITY OF UNIVERSITY OF

5059
02:52:30,780 --> 02:52:32,214
COLORADO BOULDER, TO START A

5060
02:52:32,214 --> 02:52:33,749
COMPANY TO MAKE VIRUS

5061
02:52:33,749 --> 02:52:34,950
MEASUREMENTS FASTER AND MORE

5062
02:52:34,950 --> 02:52:37,119
ACCURATE.

5063
02:52:37,119 --> 02:52:38,788
AND NOT ONLY HAS THAT PROJECT

5064
02:52:38,788 --> 02:52:44,927
BEEN SUCCESSFUL, BUT INDEVR IS A

5065
02:52:44,927 --> 02:52:45,795
WOMAN-OWNED COMPANY AND ITS

5066
02:52:45,795 --> 02:52:47,463
LEADERSHIP, INCIDENTALLY, IS

5067
02:52:47,463 --> 02:52:47,997
ALSO ALL WOMEN.

5068
02:52:47,997 --> 02:52:49,365
THIS IS REALLY IMPORTANT TO US

5069
02:52:49,365 --> 02:52:50,499
BECAUSE THE SMALL BUSINESS

5070
02:52:50,499 --> 02:52:52,935
PROGRAM ACTUALLY HAS A

5071
02:52:52,935 --> 02:52:53,836
CONGRESSIONAL MANDATE TO

5072
02:52:53,836 --> 02:52:55,805
INCREASE THE NUMBER OF WOMEN

5073
02:52:55,805 --> 02:52:57,873
OWNED SMALL BUSINESSES, AND OVER

5074
02:52:57,873 --> 02:52:59,842
THE LAST FEW DECADES, IT'S

5075
02:52:59,842 --> 02:53:02,678
REALLY BEEN A CHALLENGE, WE'VE

5076
02:53:02,678 --> 02:53:06,448
BEEN STUCK AT AROUND 10 TO 15%

5077
02:53:06,448 --> 02:53:09,051
OF THE NUMBER OF SMALL

5078
02:53:09,051 --> 02:53:10,586
BUSINESSES WE FUND THAT ARE

5079
02:53:10,586 --> 02:53:12,788
WOMEN-OWNED, AND ALTHOUGH THAT

5080
02:53:12,788 --> 02:53:14,423
NUMBER CLOSELY TRACKS THE NUMBER

5081
02:53:14,423 --> 02:53:17,259
OF WOMEN-OWNED SMALL BUSINESSES

5082
02:53:17,259 --> 02:53:19,695
IN THE BUSINESS ENVIRONMENT IN

5083
02:53:19,695 --> 02:53:22,031
THE LIFE SCIENCE ENVIRONMENT, WE

5084
02:53:22,031 --> 02:53:23,432
ARE COMMITTED TO DOING BETTER

5085
02:53:23,432 --> 02:53:24,066
THAN THAT.

5086
02:53:24,066 --> 02:53:28,337
SO A NUMBER OF OUR PROGRAMS IN

5087
02:53:28,337 --> 02:53:29,338
COLLABORATION NOT JUST WITH THE

5088
02:53:29,338 --> 02:53:30,873
OFFICE OF RESEARCH OF WOMEN'S

5089
02:53:30,873 --> 02:53:35,244
HEALTH BUT WITH THE NIH

5090
02:53:35,244 --> 02:53:36,245
INITIATIVE ARE GEARED TO

5091
02:53:36,245 --> 02:53:37,780
INCREASING THE NUMBER OF

5092
02:53:37,780 --> 02:53:38,647
WOMEN-OWNED SMALL BUSINESSES AND

5093
02:53:38,647 --> 02:53:40,182
WOMEN ENTREPRENEURS THAT WE

5094
02:53:40,182 --> 02:53:40,516
FUND.

5095
02:53:40,516 --> 02:53:42,284
SO THAT'S A BRIEF OVERVIEW OF

5096
02:53:42,284 --> 02:53:46,222
THE SEED OFFICE AND HOW WE CAN

5097
02:53:46,222 --> 02:53:48,824
HELP MEET THE GOALS OF

5098
02:53:48,824 --> 02:53:51,160
INCREASING WOMEN'S HEALTH

5099
02:53:51,160 --> 02:53:51,427
RESEARCH.

5100
02:53:51,427 --> 02:53:52,394
I'D ENCOURAGE YOU TO CHECK OUT

5101
02:53:52,394 --> 02:53:52,928
OUR WEBSITE.

5102
02:53:52,928 --> 02:53:55,998
YOU CAN GET ON OUR LISTSERV.

5103
02:53:55,998 --> 02:53:58,267
WE HAVE AN NIH ENTREPRENEURSHIP

5104
02:53:58,267 --> 02:53:59,935
NEWS WHICH IS A NEWSLETTER THAT

5105
02:53:59,935 --> 02:54:03,239
COMES OUT ABOUT EVERY TWO WEEKS.

5106
02:54:03,239 --> 02:54:04,874
AND I'M JUST SO EXCITING TO BE

5107
02:54:04,874 --> 02:54:06,141
WORKING IN PARTNERSHIP WITH THE

5108
02:54:06,141 --> 02:54:09,044
OFFICE OF RESEARCH ON WOMEN'S

5109
02:54:09,044 --> 02:54:12,181
HEALTH, AND I WOULD BE HAPPY TO

5110
02:54:12,181 --> 02:54:13,649
HELP ANYBODY OUT WHO THINKS THEY

5111
02:54:13,649 --> 02:54:14,850
COULD BENEFIT FROM OUR SERVICES.

5112
02:54:14,850 --> 02:54:15,951
SO THANK YOU VERY MUCH.

5113
02:54:15,951 --> 02:54:22,725
[APPLAUSE]

5114
02:54:22,725 --> 02:54:24,226
>> THAT WAS AN INCREDIBLE

5115
02:54:24,226 --> 02:54:24,927
PRESENTATION AS WELL.

5116
02:54:24,927 --> 02:54:26,328
WE COULDN'T HAVE PLANNED IT ANY

5117
02:54:26,328 --> 02:54:28,530
BETTER FOR THE AREA OF SYNERGY.

5118
02:54:28,530 --> 02:54:29,098
THANK YOU SO MUCH.

5119
02:54:29,098 --> 02:54:31,834
THE FLOOR IS OPEN FOR QUESTIONS.

5120
02:54:31,834 --> 02:54:35,771
AND COMMENTS.

5121
02:54:35,771 --> 02:54:37,740
>> EXCELLENT TALK.

5122
02:54:37,740 --> 02:54:38,741
I THINK THE QUESTION I HAVE

5123
02:54:38,741 --> 02:54:41,911
WOULD BE RELEVANT TO YOU AND

5124
02:54:41,911 --> 02:54:43,312
POSSIBLY TO DR. TROMBERG AS

5125
02:54:43,312 --> 02:54:44,546
WELL.

5126
02:54:44,546 --> 02:54:46,415
SO WHAT ARE THE PROCESSES THAT

5127
02:54:46,415 --> 02:54:49,251
ARE SET IN PLACE, YOU KNOW, FOR

5128
02:54:49,251 --> 02:54:51,120
A PRODUCT DEVELOPMENT STAGE OR

5129
02:54:51,120 --> 02:54:55,057
VALIDATION WHERE INCORPORATION

5130
02:54:55,057 --> 02:54:57,826
OF INDIVIDUALS OF MINORITY ARE

5131
02:54:57,826 --> 02:54:59,228
EITHER REQUIRED AND/OR

5132
02:54:59,228 --> 02:54:59,895
ENCOURAGED, BECAUSE IN THE PAST,

5133
02:54:59,895 --> 02:55:01,330
THERE HAVE BEEN PRODUCTS THAT

5134
02:55:01,330 --> 02:55:03,532
HAVE BEEN DEVELOPED, DEVELOPED

5135
02:55:03,532 --> 02:55:05,167
THAT HAVE CATERED TO ONLY

5136
02:55:05,167 --> 02:55:07,236
INDIVIDUALS OF EUROPEAN

5137
02:55:07,236 --> 02:55:08,804
ANCESTRY, BUT ARE THERE

5138
02:55:08,804 --> 02:55:10,439
PROCESSES MORE SORT OF PROACTIVE

5139
02:55:10,439 --> 02:55:13,842
PROCESSES IN PLACE WHERE THAT

5140
02:55:13,842 --> 02:55:17,479
TYPE OF CONSIDERATION IS GETTING

5141
02:55:17,479 --> 02:55:17,746
DEVELOPED?

5142
02:55:17,746 --> 02:55:19,581
AND THEN ESPECIALLY FOR PRODUCTS

5143
02:55:19,581 --> 02:55:20,816
THAT INVOLVE A.I., MACHINE

5144
02:55:20,816 --> 02:55:24,787
LEARNING TECHNOLOGIES.

5145
02:55:24,787 --> 02:55:26,422
>> WELL, I CAN -- THERE
ARE A

5146
02:55:26,422 --> 02:55:30,159
FEW TRAINING PROGRAMS THAT WE

5147
02:55:30,159 --> 02:55:30,592
HAVE.

5148
02:55:30,592 --> 02:55:32,094
THE MOST RECENT ONE WE'VE JUST

5149
02:55:32,094 --> 02:55:33,662
STARTED, WE RAN ONE COHORT

5150
02:55:33,662 --> 02:55:37,499
CALLED THE NIH CAPSTONE PROGRAM,

5151
02:55:37,499 --> 02:55:38,534
ENTREPRENEURSHIP CAPSTONE

5152
02:55:38,534 --> 02:55:40,169
PROGRAM, AND THAT WAS A PROGRAM

5153
02:55:40,169 --> 02:55:42,438
THAT WAS DEVELOPED AND RUN IN

5154
02:55:42,438 --> 02:55:45,607
COLLABORATION WITH THE EE JUST

5155
02:55:45,607 --> 02:55:47,309
LIFE SCIENCES COMMUNITY, AN

5156
02:55:47,309 --> 02:55:48,711
OFFSHOOT OF THE UNITED NEGRO

5157
02:55:48,711 --> 02:55:49,611
COLLEGE FUND, AND THAT PROGRAM

5158
02:55:49,611 --> 02:55:53,549
IS REALLY A KIND OF A COMBINED

5159
02:55:53,549 --> 02:55:55,084
MENTORING AND PRODUCT

5160
02:55:55,084 --> 02:55:55,651
DEVELOPMENT PROGRAM.

5161
02:55:55,651 --> 02:55:58,253
SO THAT IS REALLY FOCUSED ON

5162
02:55:58,253 --> 02:56:01,256
BRINGING PEOPLE FROM

5163
02:56:01,256 --> 02:56:02,024
UNDERREPRESENTED BACKGROUNDS

5164
02:56:02,024 --> 02:56:02,992
INTO THE PRODUCT DEVELOPMENT

5165
02:56:02,992 --> 02:56:04,093
SPACE.

5166
02:56:04,093 --> 02:56:05,394
I THINK YOUR QUESTION, THOUGH,

5167
02:56:05,394 --> 02:56:08,397
IS MORE ABOUT ADDRESSING THE

5168
02:56:08,397 --> 02:56:11,667
UNIQUE CHALLENGES OF BRINGING

5169
02:56:11,667 --> 02:56:14,203
PRODUCTS TO MARKET THAT ARE

5170
02:56:14,203 --> 02:56:15,938
ADDRESSING HEALTH DISPARITIES,

5171
02:56:15,938 --> 02:56:17,439
AND THAT, I THINK, IS A PROBLEM

5172
02:56:17,439 --> 02:56:19,375
THAT'S A LITTLE BIT HARDER TO GO

5173
02:56:19,375 --> 02:56:19,808
AFTER.

5174
02:56:19,808 --> 02:56:21,343
I THINK IT'S MULTIFACETED.

5175
02:56:21,343 --> 02:56:23,579
IT PARTLY DEALS WITH THE

5176
02:56:23,579 --> 02:56:25,114
APPETITE OF THE INVESTMENT

5177
02:56:25,114 --> 02:56:29,918
COMMUNITY, AND WE SEE THAT IN

5178
02:56:29,918 --> 02:56:31,020
OUR SPACE QUITE A BIT.

5179
02:56:31,020 --> 02:56:32,755
WE HAVE RELATIONSHIPS WITH A

5180
02:56:32,755 --> 02:56:35,290
NUMBER OF ORGANIZATIONS.

5181
02:56:35,290 --> 02:56:36,592
ONE OF THOSE ORGANIZATIONS IS

5182
02:56:36,592 --> 02:56:43,198
CALLED MED TECH COLOR, WHICH IS

5183
02:56:43,198 --> 02:56:44,500
A JOINT INDUSTRY AND PRIVATE

5184
02:56:44,500 --> 02:56:45,167
SECTOR AND GOVERNMENT

5185
02:56:45,167 --> 02:56:46,035
ORGANIZATION THAT'S LOOKING TO

5186
02:56:46,035 --> 02:56:49,171
INCREASE THE NUMBER OF BLACK AND

5187
02:56:49,171 --> 02:56:50,572
BROWN INNOVATORS IN THE MEDICAL

5188
02:56:50,572 --> 02:56:51,640
DEVICE SPACE.

5189
02:56:51,640 --> 02:56:52,975
THAT ORGANIZATION HAS BEEN VERY

5190
02:56:52,975 --> 02:56:54,443
ACTIVE IN ADDRESSING SOME OF

5191
02:56:54,443 --> 02:56:57,379
THESE CHALLENGES.

5192
02:56:57,379 --> 02:57:01,917
ALSO WOMEN IN BIO AND ALSO THE

5193
02:57:01,917 --> 02:57:04,053
ASSOCIATION FOR WOMEN IN

5194
02:57:04,053 --> 02:57:05,788
SCIENCE, AWIS, WE HAVE

5195
02:57:05,788 --> 02:57:06,588
RELATIONSHIPS WITH THESE

5196
02:57:06,588 --> 02:57:07,222
ORGANIZATIONS AND WE WORK

5197
02:57:07,222 --> 02:57:08,223
TOGETHER WITH THEM TO ADDRESS

5198
02:57:08,223 --> 02:57:11,894
SOME OF THOSE CHALLENGES.

5199
02:57:11,894 --> 02:57:12,961
>> MAYBE I COULD KIND OF
ADD A

5200
02:57:12,961 --> 02:57:15,697
LITTLE BIT TO THAT OR BUILD ON

5201
02:57:15,697 --> 02:57:16,999
THESE POINTS FROM MATT.

5202
02:57:16,999 --> 02:57:19,334
IT'S A LITTLE BIT OF A CHICKEN

5203
02:57:19,334 --> 02:57:20,869
AND AN EGG PROBLEM.

5204
02:57:20,869 --> 02:57:24,907
SO FEM TECH, IT NOW KIND OF

5205
02:57:24,907 --> 02:57:26,475
COMMONLY ACCEPTED TO BE

5206
02:57:26,475 --> 02:57:28,444
SOMETHING, AN ENTITY THAT

5207
02:57:28,444 --> 02:57:31,180
MARKETS CAN BE DRIVEN TOWARDS

5208
02:57:31,180 --> 02:57:34,049
FEMTECH CAN BE SUCCESSFUL, BUT I

5209
02:57:34,049 --> 02:57:35,551
THINK MAYBE, I DON'T KNOW, MATT,

5210
02:57:35,551 --> 02:57:37,853
FIVE YEARS AGO, SIX YEARS AGO,

5211
02:57:37,853 --> 02:57:41,490
IT WAS ALMOST TRANSPARENT, AND

5212
02:57:41,490 --> 02:57:43,826
SO THAT'S A REALLY BIG DRIVER

5213
02:57:43,826 --> 02:57:46,095
THAT'S LIKE A BIG SHIP THAT'S

5214
02:57:46,095 --> 02:57:48,764
GENERATED INTEREST IN MARKETS.

5215
02:57:48,764 --> 02:57:50,466
SO THE EVOLUTION OF TECHNOLOGY,

5216
02:57:50,466 --> 02:57:52,534
YOU KNOW, EVERYBODY WANTS AN APP

5217
02:57:52,534 --> 02:57:56,071
TO BECOME THE NEXT GOOGLE, BUT

5218
02:57:56,071 --> 02:57:59,007
IT'S NOT NECESSARILY A BAD THING

5219
02:57:59,007 --> 02:58:01,510
TO CREATE SMALLER SCALE PRODUCTS

5220
02:58:01,510 --> 02:58:03,412
THAT HAVE SMALLER MARKETS THAT

5221
02:58:03,412 --> 02:58:05,347
ARE SUSTAINABLE IN REGIONS THAT

5222
02:58:05,347 --> 02:58:07,015
PERHAPS HAVEN'T HAD THAT

5223
02:58:07,015 --> 02:58:07,683
INNOVATION BEFORE.

5224
02:58:07,683 --> 02:58:09,985
AND THEN CREATE A NETWORK OF

5225
02:58:09,985 --> 02:58:12,921
SMALL SCALE INNOVATION IN

5226
02:58:12,921 --> 02:58:14,923
REGIONS WHERE IF THE PRODUCT

5227
02:58:14,923 --> 02:58:17,226
GOES UNDER, THE WHOLE TEAM TOANT

5228
02:58:17,226 --> 02:58:21,096
HAVE TO LEADOESN'T HAVE TO LEAVE

5229
02:58:21,096 --> 02:58:22,197
TO BOSTON OR THE BAY AREA.

5230
02:58:22,197 --> 02:58:23,966
SO THAT'S A BIG AREA OF GROWTH,

5231
02:58:23,966 --> 02:58:28,103
I THINK, IN PARTICULAR WITH

5232
02:58:28,103 --> 02:58:29,004
PRODUCTS THAT HAVEN'T GOTTEN THE

5233
02:58:29,004 --> 02:58:29,872
ATTENTION BECAUSE, YOU KNOW,

5234
02:58:29,872 --> 02:58:30,973
FROM A MARKET POINT OF VIEW,

5235
02:58:30,973 --> 02:58:32,307
IT'S A SMALLER NICHE.

5236
02:58:32,307 --> 02:58:33,842
SO I THINK THAT'S A BIG

5237
02:58:33,842 --> 02:58:35,477
STRATEGY, AND THAT'S RIGHT

5238
02:58:35,477 --> 02:58:38,013
BEHIND THE DEVELOPMENT OF MATT'S

5239
02:58:38,013 --> 02:58:39,548
PROGRAMS, WHERE THERE'S A

5240
02:58:39,548 --> 02:58:41,550
DISTRIBUTION OF CENTERS OF

5241
02:58:41,550 --> 02:58:42,518
EXCELLENCE ALL AROUND THE

5242
02:58:42,518 --> 02:58:44,386
COUNTRY AND IN KIND OF

5243
02:58:44,386 --> 02:58:48,991
UNDERPOPULATED REGIONS.

5244
02:58:48,991 --> 02:58:51,093
AND ANOTHER AREA WE MIGHT TALK

5245
02:58:51,093 --> 02:58:54,263
OFFLINE ABOUT THIS IS WITH A.I.

5246
02:58:54,263 --> 02:58:54,830
TODAY'S ANNOUNCEMENT OF THE

5247
02:58:54,830 --> 02:58:57,366
NOBEL PRIZE, LIKE, HOW DO WE

5248
02:58:57,366 --> 02:59:00,402
ENSURE THAT A.I. IS REALLY

5249
02:59:00,402 --> 02:59:01,670
WORKING FOR EVERYONE?

5250
02:59:01,670 --> 02:59:03,639
THOSE OF US IN THE ENGINEERING

5251
02:59:03,639 --> 02:59:07,342
COMMUNITY OBSESS OVER THIS.

5252
02:59:07,342 --> 02:59:09,178
AND I THINK WE'LL GO OFFLINE TO

5253
02:59:09,178 --> 02:59:10,012
TALK ABOUT IT, BUT I WOULD LIKE

5254
02:59:10,012 --> 02:59:14,716
PEOPLE TO BE AWARE OF MIDRC.ORG,

5255
02:59:14,716 --> 02:59:16,185
THE MEDICAL IMAGING DATA

5256
02:59:16,185 --> 02:59:18,253
RESOURCE CENTER THAT WE SUPPORT,

5257
02:59:18,253 --> 02:59:21,557
THAT HAS EXTENSIVE TOOLS TO

5258
02:59:21,557 --> 02:59:25,260
ADDRESS BIAS IN DATA, THE

5259
02:59:25,260 --> 02:59:27,930
DEVELOPMENT OF EXPLAINABLE AND

5260
02:59:27,930 --> 02:59:31,767
ETHICAL ALGORITHMS, THE

5261
02:59:31,767 --> 02:59:32,467
TRACEABILITY.

5262
02:59:32,467 --> 02:59:33,869
SO IT'S IN A WAY WHERE YOU CAN

5263
02:59:33,869 --> 02:59:35,737
ACTUALLY USE THOSE TOOLS IN YOUR

5264
02:59:35,737 --> 02:59:37,539
DATA, AND UNDERSTAND WHAT ARE

5265
02:59:37,539 --> 02:59:38,640
SOME OF THE KEY DRIVERS.

5266
02:59:38,640 --> 02:59:40,275
SO LIKE IT CAN BE VERY

5267
02:59:40,275 --> 02:59:41,610
TECHNICAL, BUT IT'S ALSO AT A

5268
02:59:41,610 --> 02:59:43,745
VERY HIGH LEVEL VERY

5269
02:59:43,745 --> 02:59:45,247
UNDERSTANDABLE, COMPARES YOUR

5270
02:59:45,247 --> 02:59:48,116
DATA TOOLS TO EVALUATE THE

5271
02:59:48,116 --> 02:59:49,751
ORIGIN OF YOUR DATA TO THE

5272
02:59:49,751 --> 02:59:51,186
POPULATION CENSUS, SO A LOT OF

5273
02:59:51,186 --> 02:59:53,055
GREAT TOOLS THERE, AND GREAT

5274
02:59:53,055 --> 02:59:54,923
QUESTIONS, YOU KNOW, THERE ARE

5275
02:59:54,923 --> 02:59:55,457
BIG CHALLENGES.

5276
02:59:55,457 --> 02:59:56,925
I CAN SAY THE ENGINEERING

5277
02:59:56,925 --> 02:59:58,794
COMMUNITY IS UP TO IT BUT MAYBE

5278
02:59:58,794 --> 03:00:00,562
THERE AREN'T ENOUGH OF US.

5279
03:00:00,562 --> 03:00:01,630
BECAUSE THEY'RE ALL GETTING

5280
03:00:01,630 --> 03:00:03,098
HIRED BECAUSE MATT IS CREATING

5281
03:00:03,098 --> 03:00:05,534
ALL THESE BUSINESSES.

5282
03:00:05,534 --> 03:00:09,571
>> I'M GOING TO GO TO IGHO
AND

5283
03:00:09,571 --> 03:00:09,905
THEN STEVE.

5284
03:00:09,905 --> 03:00:10,772
>> THANK YOU SO MUCH.

5285
03:00:10,772 --> 03:00:14,409
THIS IS REALLY AMAZING,

5286
03:00:14,409 --> 03:00:15,143
FASCINATING, THE WORK THAT IS

5287
03:00:15,143 --> 03:00:17,179
BEING DONE IN THIS SPACE.

5288
03:00:17,179 --> 03:00:26,488
I JUST -- THE WORKFORCE

5289
03:00:26,488 --> 03:00:27,256
DEVELOPMENT, BECAUSE PEOPLE TEND

5290
03:00:27,256 --> 03:00:29,658
TO REALLY WORK ON THOSE THINGS

5291
03:00:29,658 --> 03:00:31,693
THAT ARE OF INTEREST TO THEIR

5292
03:00:31,693 --> 03:00:37,132
COMMUNITY.

5293
03:00:37,132 --> 03:00:39,301
I'M REALLY INTERESTED IN THE

5294
03:00:39,301 --> 03:00:40,302
SPECIFIC STEPS THAT HAVE BEEN

5295
03:00:40,302 --> 03:00:46,775
TAKEN BY NIBIB TO ATTRACT

5296
03:00:46,775 --> 03:00:48,644
DIVERSITY INTO THE PROGRAM,

5297
03:00:48,644 --> 03:00:51,046
BRING IN MORE WOMEN, BRING IN

5298
03:00:51,046 --> 03:00:52,614
MORE UNDERREPRESENTED MINORITY,

5299
03:00:52,614 --> 03:00:54,483
BECAUSE ONE WAY TO REALLY BRIDGE

5300
03:00:54,483 --> 03:00:56,385
THE GAP IS TO BRING PEOPLE WHO

5301
03:00:56,385 --> 03:00:58,053
ARE REALLY INTERESTED IN WORKING

5302
03:00:58,053 --> 03:01:01,757
IN THIS SPACE.

5303
03:01:01,757 --> 03:01:04,126
>> I CAN JUST ADDRESS THAT
FROM

5304
03:01:04,126 --> 03:01:06,561
THE PERSPECTIVE OF THE REACH

5305
03:01:06,561 --> 03:01:08,630
PROGRAM, WHEN WE RELEASE THIS

5306
03:01:08,630 --> 03:01:10,098
NOTICE OF FUNDING OPPORTUNITY

5307
03:01:10,098 --> 03:01:14,036
THAT FUNDED THE MOST CURRENT SET

5308
03:01:14,036 --> 03:01:17,072
OF FIVE HUBS, WE CHANGE THAT

5309
03:01:17,072 --> 03:01:18,640
FUNDING OPPORTUNITY FROM THE

5310
03:01:18,640 --> 03:01:23,245
PREVIOUS ONE TO HAVE AN EMPHASIS

5311
03:01:23,245 --> 03:01:24,346
ON INCREASING DIVERSITY IN THE

5312
03:01:24,346 --> 03:01:25,547
REACH PROGRAM.

5313
03:01:25,547 --> 03:01:31,019
SO THAT WAS BROADLY DEFINED AS

5314
03:01:31,019 --> 03:01:31,653
GEOGRAPHICAL DIVERSITY, RACIAL

5315
03:01:31,653 --> 03:01:34,323
AND ETHNIC DIVERSITY, DIVERSITY

5316
03:01:34,323 --> 03:01:36,325
OF THE STAGE OF CAREER

5317
03:01:36,325 --> 03:01:39,828
DEVELOPMENT OF THE

5318
03:01:39,828 --> 03:01:40,262
INVESTIGATORS.

5319
03:01:40,262 --> 03:01:42,097
AND WE WORK THAT INTO THE NOTICE

5320
03:01:42,097 --> 03:01:42,664
OF FUNDING OPPORTUNITY AND I

5321
03:01:42,664 --> 03:01:44,466
THINK YOU CAN SEE THAT IN THE

5322
03:01:44,466 --> 03:01:46,868
NEW HUBS THAT WE FUNDED IN BOTH

5323
03:01:46,868 --> 03:01:49,404
THE PARTNER INSTITUTIONS AND

5324
03:01:49,404 --> 03:01:51,373
HOPEFULLY AS WE MOVE FORWARD IN

5325
03:01:51,373 --> 03:01:52,841
THE PROGRAM, THAT WILL BE

5326
03:01:52,841 --> 03:01:54,376
REFLECTED IN THE TECHNOLOGY

5327
03:01:54,376 --> 03:01:55,477
DEVELOPMENT PROJECTS THAT THEY

5328
03:01:55,477 --> 03:01:56,878
FUND.

5329
03:01:56,878 --> 03:01:58,680
EVERY ONE OF THESE HUBS HAS AN

5330
03:01:58,680 --> 03:02:02,818
EXTERNAL ADVISORY BOARD THAT IS

5331
03:02:02,818 --> 03:02:06,621
TRYING TO CREATE LIKE A LOCAL

5332
03:02:06,621 --> 03:02:08,323
ENVIRONMENT, A LOCAL PRODUCT

5333
03:02:08,323 --> 03:02:10,192
DEVELOPMENT ECOSYSTEM THAT

5334
03:02:10,192 --> 03:02:13,562
COMBINES THE INDUSTRY AND THE

5335
03:02:13,562 --> 03:02:15,964
ACADEMIC WORLD AND THEIR

5336
03:02:15,964 --> 03:02:19,368
REGIONAL LOCATION.

5337
03:02:19,368 --> 03:02:21,370
TO COMBINE PATIENT ADVOCACY AND

5338
03:02:21,370 --> 03:02:23,338
PATIENT REPRESENTATIVES.

5339
03:02:23,338 --> 03:02:24,673
THAT'S ANOTHER GREAT WAY TO

5340
03:02:24,673 --> 03:02:26,108
ENSURE THOSE NEEDS ARE BEING

5341
03:02:26,108 --> 03:02:30,278
ADDRESSED IN THOSE COMMUNITIES.

5342
03:02:30,278 --> 03:02:33,448
>> IF I CAN ADD A LITTLE
BIT TO

5343
03:02:33,448 --> 03:02:33,782
THAT.

5344
03:02:33,782 --> 03:02:36,218
SO WE HAVE A NUMBER OF

5345
03:02:36,218 --> 03:02:37,219
DIVERSITY-FOCUSED FUNDING

5346
03:02:37,219 --> 03:02:40,722
OPPORTUNITIES LIKE A DIVERSITY

5347
03:02:40,722 --> 03:02:42,491
R01, DIVERSITY SUPPLEMENTS.

5348
03:02:42,491 --> 03:02:45,594
THESE ARE VERY ACTIVE AND VERY

5349
03:02:45,594 --> 03:02:47,229
SUCCESSFUL AND WELL SUBSCRIBED

5350
03:02:47,229 --> 03:02:48,063
PROGRAMS.

5351
03:02:48,063 --> 03:02:51,199
WE CREATED AN ENTIRE CENTER

5352
03:02:51,199 --> 03:02:52,868
WITHIN NIBIB, THE BIOMEDICAL

5353
03:02:52,868 --> 03:02:54,603
ENGINEERING AND TECHNOLOGY

5354
03:02:54,603 --> 03:03:01,543
ACCELERATION CENTER THAT

5355
03:03:01,543 --> 03:03:02,744
DR. PLATT IS LEADING AND HE CAN

5356
03:03:02,744 --> 03:03:04,613
SPEAK TO SEVERAL REALLY HIGHLY

5357
03:03:04,613 --> 03:03:06,581
IMPACTFUL PROGRAMS THAT HE'S

5358
03:03:06,581 --> 03:03:08,583
LAUNCHED WITHIN THE BETA CENTER

5359
03:03:08,583 --> 03:03:11,219
THAT ARE KIND OF BUILDING

5360
03:03:11,219 --> 03:03:12,387
BRIDGES TO THE INTRAMURAL

5361
03:03:12,387 --> 03:03:14,723
PROGRAM AND THE EXTRAMURAL

5362
03:03:14,723 --> 03:03:16,591
PROGRAM, BECAUSE THIS IS A --

5363
03:03:16,591 --> 03:03:18,894
IT'S A CHALLENGE ACROSS KIND OF

5364
03:03:18,894 --> 03:03:19,561
ALL SECTORS OF THE NIH.

5365
03:03:19,561 --> 03:03:21,029
SO WE HAVE A NUMBER OF

5366
03:03:21,029 --> 03:03:21,329
MECHANISMS.

5367
03:03:21,329 --> 03:03:24,866
A LOT OF ENTHUSIASTIC PEOPLE AND

5368
03:03:24,866 --> 03:03:29,805
GREAT LEADERSHIP, SO THOSE ARE

5369
03:03:29,805 --> 03:03:30,439
SOME CONCRETE APPROACHES AND I

5370
03:03:30,439 --> 03:03:31,673
CAN SHOW YOU A FEW MORE OF THESE

5371
03:03:31,673 --> 03:03:32,774
IF YOU'D LIKE TO SEE THEM.

5372
03:03:32,774 --> 03:03:34,576
OUR WEBSITE HAS A PRETTY GOOD

5373
03:03:34,576 --> 03:03:38,947
LISTING OF ALL THESE FUNDING

5374
03:03:38,947 --> 03:03:42,250
OPPORTUNITIES.

5375
03:03:42,250 --> 03:03:43,552
ONE SURPRISING THING, THE ENGS

5376
03:03:43,552 --> 03:03:45,153
PANICS OF WOMEN IN

5377
03:03:45,153 --> 03:03:46,121
BIOENGINEERING, NOBODY PLANNED

5378
03:03:46,121 --> 03:03:46,455
THAT.

5379
03:03:46,455 --> 03:03:51,026
YOU KNOW, THERE WASN'T LIKE AN

5380
03:03:51,026 --> 03:03:55,997
NIH SAYING -- THIS IS FEEDING

5381
03:03:55,997 --> 03:04:00,101
INTO I GUESS A NEED IN SOCIETY

5382
03:04:00,101 --> 03:04:02,571
THAT COMBINES KIND OF THE

5383
03:04:02,571 --> 03:04:04,105
ABILITY TO SORT OF INTEGRATE

5384
03:04:04,105 --> 03:04:07,742
YOUR PASSION FOR SCIENCE, MATH,

5385
03:04:07,742 --> 03:04:11,780
TECHNOLOGY, MEDICINE, BIOLOGY,

5386
03:04:11,780 --> 03:04:12,347
AND ALTRUISTIC GOOD.

5387
03:04:12,347 --> 03:04:14,349
SO THAT DIDN'T EXIST BEFORE

5388
03:04:14,349 --> 03:04:15,217
WITHIN SCHOOLS OF ENGINEERING.

5389
03:04:15,217 --> 03:04:17,419
SO IT'S A REALLY INTERESTING

5390
03:04:17,419 --> 03:04:18,253
CULTURAL PHENOMENON.

5391
03:04:18,253 --> 03:04:20,522
I'M A BIOENGINEER, NOT A SOCIAL

5392
03:04:20,522 --> 03:04:21,623
SCIENTIST, BUT YOU KNOW, IT'S

5393
03:04:21,623 --> 03:04:25,927
JUST FASCINATING, AND THOSE 6100

5394
03:04:25,927 --> 03:04:29,531
OR OVER 6,000 WOMEN GRADS IN

5395
03:04:29,531 --> 03:04:31,833
2022, THEY HAVE TO GET HIRED.

5396
03:04:31,833 --> 03:04:34,002
AND I THINK A LOT OF THEM ARE

5397
03:04:34,002 --> 03:04:36,471
GOING BOTH INTO INDUSTRY AND

5398
03:04:36,471 --> 03:04:39,207
STARTING THEIR OWN INNOVATION

5399
03:04:39,207 --> 03:04:40,408
AND ENTREPRENEURIAL CAREER

5400
03:04:40,408 --> 03:04:42,611
JOURNEYS.

5401
03:04:42,611 --> 03:04:43,578
>> THANK YOU.

5402
03:04:43,578 --> 03:04:44,513
AS YOU CAN TELL, EVEN THOUGH I

5403
03:04:44,513 --> 03:04:46,481
AM THE TIME MASTER, I COULDN'T

5404
03:04:46,481 --> 03:04:48,116
HELP MYSELF, I COULDN'T STOP YOU

5405
03:04:48,116 --> 03:04:49,918
ALL.

5406
03:04:49,918 --> 03:04:51,553
SO FIRST OF ALL, JUST THANK YOU

5407
03:04:51,553 --> 03:04:53,855
FOR REALLY NOT ONLY THE GREAT

5408
03:04:53,855 --> 03:04:55,957
PRESENTATIONS BUT REALLY THE

5409
03:04:55,957 --> 03:04:56,358
GREAT DISCUSSIONS.

5410
03:04:56,358 --> 03:04:59,127
I THINK THAT WHAT AN EXCITING

5411
03:04:59,127 --> 03:05:01,129
TIME FOR WOMEN'S HEALTH

5412
03:05:01,129 --> 03:05:01,463
RESEARCH.

5413
03:05:01,463 --> 03:05:03,098
SO THANK YOU FOR REALLY SPURRING

5414
03:05:03,098 --> 03:05:05,667
THAT DISCUSSION ON.

5415
03:05:05,667 --> 03:05:09,371
ALSO, I WANTED TO -- WE'RE GOING

5416
03:05:09,371 --> 03:05:10,472
TO DO A PICTURE AND I WANT TO

5417
03:05:10,472 --> 03:05:11,840
GIVE YOU SOME TIME TO AT LEAST

5418
03:05:11,840 --> 03:05:13,475
GET SOME FOOD AND COME BACK.

5419
03:05:13,475 --> 03:05:16,545
SO I'M GOING TO SLIP THE AGENDA

5420
03:05:16,545 --> 03:05:17,379
BY 15 MINUTES.

5421
03:05:17,379 --> 03:05:18,547
SO AT LEAST YOU CAN GET SOME

5422
03:05:18,547 --> 03:05:20,415
FOOD AND SOME NUTRITION AND

5423
03:05:20,415 --> 03:05:21,850
HYDRATION.

5424
03:05:21,850 --> 03:05:23,618
AND PLEASE FEEL FREE TO COME

5425
03:05:23,618 --> 03:05:24,519
BACK AND EAT WHILE WE'RE DOING

5426
03:05:24,519 --> 03:05:25,720
THE NEXT PRESENTATIONS.

5427
03:05:25,720 --> 03:05:27,155
BECAUSE I DID PROMISE YOU AND I

5428
03:05:27,155 --> 03:05:29,724
KNOW SOME OF YOU MAY ACTUALLY

5429
03:05:29,724 --> 03:05:30,926
HAVE YOUR TRAVEL ARRANGEMENTS

5430
03:05:30,926 --> 03:05:33,428
BASED ON OUR STOP TIME AT 4:10.

5431
03:05:33,428 --> 03:05:35,497
SO I'M GOING TO EAT INTO HER

5432
03:05:35,497 --> 03:05:39,367
TIME INSTEAD, AND SHE WILL SORT

5433
03:05:39,367 --> 03:05:40,035
OF FOCUS IT.

5434
03:05:40,035 --> 03:05:41,136
AND OF COURSE THESE ARE GOING TO

5435
03:05:41,136 --> 03:05:42,637
BE CONTINUE CONVERSATIONS.

5436
03:05:42,637 --> 03:05:43,605
SO IF WE COULD HAVE THE MEMBERS

5437
03:05:43,605 --> 03:05:45,140
GO TO THE FRONT OF THE ROOM FOR

5438
03:05:45,140 --> 03:05:47,242
THE PICTURE, AND THE BACK OF THE

5439
03:05:47,242 --> 03:05:48,810
ROOM, GO FIND SOME FOOD, AND

5440
03:05:48,810 --> 03:05:50,206
WE'LL SEE YOU AT 12:45.

5441
03:05:52,629 --> 03:05:54,431
>> HERE WE GO.

5442
03:05:54,431 --> 03:05:55,498
FIRST OF ALL, THANK YOU FOR YOUR

5443
03:05:55,498 --> 03:05:58,568
TIME AND WELCOME BACK.

5444
03:05:58,568 --> 03:06:01,137
I'D NOW LIKE TO CALL THE MEETING

5445
03:06:01,137 --> 03:06:04,441
TO ORDER AND INVITE DR. MANU

5446
03:06:04,441 --> 03:06:06,309
PLATT TO THE PODIUM, WHO WILL

5447
03:06:06,309 --> 03:06:08,845
MODERATE A PANEL ON TECHNOLOGY,

5448
03:06:08,845 --> 03:06:10,246
ENGINEERING AND INNOVATION IN

5449
03:06:10,246 --> 03:06:14,217
WOMEN'S HEALTH RESEARCH.

5450
03:06:14,217 --> 03:06:16,085
SO LET ME TALK ABOUT DR. PLATT

5451
03:06:16,085 --> 03:06:24,727
IN FRONT OF HIM.

5452
03:06:24,727 --> 03:06:25,728
DR. PLATT IS DIRECTOR OF THE

5453
03:06:25,728 --> 03:06:26,729
BETA CENTER AND ASSOCIATE

5454
03:06:26,729 --> 03:06:28,064
DIRECTOR OF SCIENTIFIC

5455
03:06:28,064 --> 03:06:30,233
DIVERSITY, EQUITY AND INCLUSION

5456
03:06:30,233 --> 03:06:31,534
FOR THE NATIONAL INSTITUTE OF

5457
03:06:31,534 --> 03:06:33,770
BIOMEDICAL IMAGING AND

5458
03:06:33,770 --> 03:06:34,437
BIOENGINEERING.

5459
03:06:34,437 --> 03:06:35,872
DR. MANU PLATT RECEIVED HIS B.S.

5460
03:06:35,872 --> 03:06:39,809
IN BIOLOGY FROM MOREHOUSE

5461
03:06:39,809 --> 03:06:42,479
COLLEGE AND PH.D. IN BIOMEDICAL

5462
03:06:42,479 --> 03:06:44,013
ENGINEERING.

5463
03:06:44,013 --> 03:06:46,649
AFTER A POSTDOC AT MASSACHUSETTS

5464
03:06:46,649 --> 03:06:47,450
INSTITUTE OF TECHNOLOGY, HE

5465
03:06:47,450 --> 03:06:49,519
RETURNED TO THE GEORGIA TECH

5466
03:06:49,519 --> 03:06:51,054
EMORY DEPARTMENT OF BIOMEDICAL

5467
03:06:51,054 --> 03:06:52,255
ENGINEERING, WHERE HE ADVANCED

5468
03:06:52,255 --> 03:06:53,623
TO FULL PROFESSOR.

5469
03:06:53,623 --> 03:06:56,025
HIS RESEARCH PROGRAM FOCUSES ON

5470
03:06:56,025 --> 03:06:57,227
PROTEOLYTIC MECHANISMS OF

5471
03:06:57,227 --> 03:06:58,394
DISEASE, TRANSLATIONAL

5472
03:06:58,394 --> 03:06:59,796
APPROACHES TO REDUCE STROKES IN

5473
03:06:59,796 --> 03:07:02,298
PEOPLE AFFECTED BY SICKLE CELL

5474
03:07:02,298 --> 03:07:05,802
DISEASE, AND HARNESSING NETWORKS

5475
03:07:05,802 --> 03:07:08,471
AND SYSTEMS BIOLOGY TOOLS TO

5476
03:07:08,471 --> 03:07:09,672
PREDICT DISEASE PROGRESSION.

5477
03:07:09,672 --> 03:07:11,975
HE'S ALSO INTEGRATED WITH

5478
03:07:11,975 --> 03:07:13,776
RESEARCH -- INTEGRATED WITH HIS

5479
03:07:13,776 --> 03:07:15,178
RESEARCH IMPORTANTLY ARE

5480
03:07:15,178 --> 03:07:16,613
MENTORING GOALS, CHANGING THE

5481
03:07:16,613 --> 03:07:18,481
LOOK OF THE NEXT GENERATION OF

5482
03:07:18,481 --> 03:07:20,817
SCIENTISTS AND ENGINEERS THROUGH

5483
03:07:20,817 --> 03:07:22,118
SUCCESSFUL DIVERSITY PROGRAMS

5484
03:07:22,118 --> 03:07:23,887
HE'S INITIATED.

5485
03:07:23,887 --> 03:07:26,456
IN 2003, DR. PLATT BECAME THE

5486
03:07:26,456 --> 03:07:27,557
INAUGURAL DIRECTOR OF THE BETA

5487
03:07:27,557 --> 03:07:30,260
CENTER THAT I JUST MENTIONED

5488
03:07:30,260 --> 03:07:32,929
THAT HE'S ALSO A FELLOW OF THE

5489
03:07:32,929 --> 03:07:38,301
AIMBE AND THE MBMES, THERE WE

5490
03:07:38,301 --> 03:07:42,505
GO, AND RECEIVED THE ROUTE 100

5491
03:07:42,505 --> 03:07:44,541
IN 2019 AND AAAS MENTOR AWARD IN

5492
03:07:44,541 --> 03:07:45,375
2021.

5493
03:07:45,375 --> 03:07:46,409
WELCOME, DR. PLATT.

5494
03:07:46,409 --> 03:07:47,310
>> THANK YOU VERY MUCH.

5495
03:07:47,310 --> 03:07:51,080
THANK YOU I'M REALLY EXCITED TO

5496
03:07:51,080 --> 03:07:52,949
BE HERE TO MODERATE THIS SESSION

5497
03:07:52,949 --> 03:07:54,551
ESPECIALLY COMING AFTER SOME

5498
03:07:54,551 --> 03:07:55,184
GREAT BIOMEDICAL ENGINEERING

5499
03:07:55,184 --> 03:07:55,618
DISCUSSIONS.

5500
03:07:55,618 --> 03:07:58,354
I'M PLEASED TO INTRODUCE OUR

5501
03:07:58,354 --> 03:08:07,931
PANELISTS, DR. KIM, DR. OYEN AND

5502
03:08:07,931 --> 03:08:08,565
MS. TARIYAL.

5503
03:08:08,565 --> 03:08:11,634
DR. KIM RECEIVED A BS IN

5504
03:08:11,634 --> 03:08:12,402
MICROBIOLOGY FROM THE UNIVERSITY

5505
03:08:12,402 --> 03:08:16,506
OF TORONTO AND A PH.D. IN QUEBEC

5506
03:08:16,506 --> 03:08:17,140
CITY.

5507
03:08:17,140 --> 03:08:18,875
SHE COMPLETED POSTDOCTORAL

5508
03:08:18,875 --> 03:08:19,876
TRAINING AT THE UNIVERSITY OF

5509
03:08:19,876 --> 03:08:20,910
ILLINOIS AT CHICAGO AND

5510
03:08:20,910 --> 03:08:22,312
ESTABLISHED AN INDEPENDENT

5511
03:08:22,312 --> 03:08:24,414
RESEARCH LABORATORY AT

5512
03:08:24,414 --> 03:08:25,281
NORTHWESTERN UNIVERSITY.

5513
03:08:25,281 --> 03:08:27,483
HER LABORATORY IS FOCUSED ON

5514
03:08:27,483 --> 03:08:30,453
UNDERSTANDING THE PLEIOTROPIC

5515
03:08:30,453 --> 03:08:33,456
INTERACTION OF HORMONES --

5516
03:08:33,456 --> 03:08:34,724
INCLUDING ENDOMETRIAL CANCER,

5517
03:08:34,724 --> 03:08:35,858
UTERINE FIBROIDS AND

5518
03:08:35,858 --> 03:08:37,160
ENDOMETRIOSIS.

5519
03:08:37,160 --> 03:08:38,728
THE LAB DEVELOPS APPROPRIATE IN

5520
03:08:38,728 --> 03:08:40,330
VITRO AND IN VIVO MODELS THAT

5521
03:08:40,330 --> 03:08:42,031
BEST REPRESENT THE PHYSIOLOGY OF

5522
03:08:42,031 --> 03:08:43,900
REPRODUCTIVE TISSUES.

5523
03:08:43,900 --> 03:08:46,569
INCLUDING 3D ORGAN CULTURES ON

5524
03:08:46,569 --> 03:08:48,004
MICRO FLEW TICK PLATFORMS,

5525
03:08:48,004 --> 03:08:50,506
PATIENT DERIVED XENOGRAFTED

5526
03:08:50,506 --> 03:08:51,908
TUMORS, PLEUR OWE POTENT STEM

5527
03:08:51,908 --> 03:08:54,043
CELLS OR IPSCs FOR DISEASE

5528
03:08:54,043 --> 03:08:55,144
MODELING.

5529
03:08:55,144 --> 03:08:56,679
THE ULTIMATE GOAL IS TO PROVIDE

5530
03:08:56,679 --> 03:08:58,047
POTENTIAL NEW DRUG TARGETS AS

5531
03:08:58,047 --> 03:08:59,115
WELL AS BETTER DRUG SCREENING

5532
03:08:59,115 --> 03:09:00,216
APPROACHES FOR THESE UTERINE

5533
03:09:00,216 --> 03:09:02,085
DISEASES.

5534
03:09:02,085 --> 03:09:04,721
DR. KIM IS A MEMBER OF THE

5535
03:09:04,721 --> 03:09:05,855
ROBERT LU RI. E COMPREHENSIVE

5536
03:09:05,855 --> 03:09:08,024
CANCER CENTER AND IS INVOLVED IN

5537
03:09:08,024 --> 03:09:09,626
EDUCATION PROGRAMS OF

5538
03:09:09,626 --> 03:09:10,593
NORTHWESTERN UNIVERSITY GRADUATE

5539
03:09:10,593 --> 03:09:11,461
SCHOOL.

5540
03:09:11,461 --> 03:09:14,631
OUR SECOND SPEAKER IS DR. OYEN,

5541
03:09:14,631 --> 03:09:16,065
WAYNE STATE UNIVERSITY IN

5542
03:09:16,065 --> 03:09:16,599
DETROIT, MICHIGAN.

5543
03:09:16,599 --> 03:09:17,800
SHE HAS A BACKGROUND IN

5544
03:09:17,800 --> 03:09:18,968
MATERIALS SCIENCE, MECHANICAL

5545
03:09:18,968 --> 03:09:21,904
ENGINEERING AND MEDICAL PHYSICS,

5546
03:09:21,904 --> 03:09:23,940
AND SHE HAS RESEARCHED AND

5547
03:09:23,940 --> 03:09:25,441
ADVOCATED FOR ENGINEERING

5548
03:09:25,441 --> 03:09:26,609
METHODOLOGIES WITHIN MATERNAL

5549
03:09:26,609 --> 03:09:27,477
HEALTH AND WOMEN'S HEALTH FOR

5550
03:09:27,477 --> 03:09:32,382
MORE THAN 2 25 YEARS TO IMPROVE

5551
03:09:32,382 --> 03:09:34,017
MATERNAL FETAL OUTCOMES

5552
03:09:34,017 --> 03:09:35,952
INCLUDING PREVENTION,

5553
03:09:35,952 --> 03:09:36,919
DIAGNOSTICS, AND INTERVENTIONS

5554
03:09:36,919 --> 03:09:39,322
RELEVANT TO PRETERM BIRTH.

5555
03:09:39,322 --> 03:09:41,290
CURRENT RESEARCH PROJECTS FOCUS

5556
03:09:41,290 --> 03:09:43,426
ON MULTI-SCALE CHARACTERIZATION,

5557
03:09:43,426 --> 03:09:46,496
PLACENTA FUNCTION, BIOMIMETIC

5558
03:09:46,496 --> 03:09:48,231
MATERIALS OF THE UTERUS AND

5559
03:09:48,231 --> 03:09:49,098
DIGITAL REPRESENTATIONS OF

5560
03:09:49,098 --> 03:09:49,499
PREGNANCY.

5561
03:09:49,499 --> 03:09:51,000
SHE ALSO HAS THE ADDED BONUS OF

5562
03:09:51,000 --> 03:09:52,201
MAKING ME THINK ABOUT THE

5563
03:09:52,201 --> 03:09:55,004
PLACENTA AND VASCULAR FLOW.

5564
03:09:55,004 --> 03:09:56,773
OUR FINAL PANELIST AND SPEAKER

5565
03:09:56,773 --> 03:09:58,841
IS MS. TARIYAL, THE CHIEF

5566
03:09:58,841 --> 03:10:00,943
EXECUTIVE OFFICER AND CO-FOUNDER

5567
03:10:00,943 --> 03:10:02,578
OF NEXGEN JANE.

5568
03:10:02,578 --> 03:10:05,448
SHE RECEIVED HER B.S. DEGREE

5569
03:10:05,448 --> 03:10:12,388
FROM GEORGIA TECH, SHOUT OUT.

5570
03:10:12,388 --> 03:10:15,124
AT NEXGEN JANE, SHE'S DRIVEN THE

5571
03:10:15,124 --> 03:10:17,927
DEVELOPMENT OF A NOVEL DATA

5572
03:10:17,927 --> 03:10:19,128
PLATFORM CHARACTERIZING UTERINE

5573
03:10:19,128 --> 03:10:19,996
BIOLOGY AT A MOLECULAR LEVEL.

5574
03:10:19,996 --> 03:10:22,665
IN THIS EFFORT SHE HAS RAISED

5575
03:10:22,665 --> 03:10:23,566
CAPITAL, ESTABLISHED AN I.P.

5576
03:10:23,566 --> 03:10:24,734
POSITION AND DEVELOPED A TEAM TO

5577
03:10:24,734 --> 03:10:26,836
CREATE BOTH MO VEL HARDWARE AND

5578
03:10:26,836 --> 03:10:28,337
SOFTWARE TO CHANGE HOW WOMEN

5579
03:10:28,337 --> 03:10:31,374
ACCESS CARE.

5580
03:10:31,374 --> 03:10:33,543
BEFORE THAT, SHE WORKED AT THE

5581
03:10:33,543 --> 03:10:36,312
BROAD INSTITUTE AND AT

5582
03:10:36,312 --> 03:10:36,713
BRISTOL-MYERS KIB.

5583
03:10:36,713 --> 03:10:40,783
SOSQUIBB.I'D LIKE TO CALL DR. KE

5584
03:10:40,783 --> 03:10:42,919
PODIUM AND WE DO ASK THAT ALL

5585
03:10:42,919 --> 03:10:44,320
AUDIENCE PARTICIPANT QUESTIONS

5586
03:10:44,320 --> 03:10:45,955
UNTIL WE GET TO THE PANEL AFTER

5587
03:10:45,955 --> 03:10:46,322
THE TALKS.

5588
03:10:46,322 --> 03:10:56,666
THANK YOU VERY MUCH.

5589
03:10:57,433 --> 03:11:00,803
>> NIRS OF

5590
03:11:00,803 --> 03:11:03,740
>> FULL DISCLOSURE, I'M
NOT AN

5591
03:11:03,740 --> 03:11:04,941
ENGINEER, I'M GOING TO TELL YOU

5592
03:11:04,941 --> 03:11:06,075
HOW WE INCORPORATE SOME

5593
03:11:06,075 --> 03:11:07,076
ENGINEERING TECHNOLOGIES INTO

5594
03:11:07,076 --> 03:11:11,214
OUR WORK.

5595
03:11:11,214 --> 03:11:14,283
SO AS MANU DESCRIBED, QUICKLY I

5596
03:11:14,283 --> 03:11:15,985
JUST WANTED TO INTRODUCE MYSELF.

5597
03:11:15,985 --> 03:11:17,153
THE RESEARCH THAT WE DO IN THE

5598
03:11:17,153 --> 03:11:20,289
LAB, WE ARE VERY INTERESTED IN

5599
03:11:20,289 --> 03:11:21,691
UNDERSTANDING ENDOMETRIOSIS,

5600
03:11:21,691 --> 03:11:23,559
ENDOMETRIAL CANCER, UTERINE

5601
03:11:23,559 --> 03:11:25,094
FIBROIDS, HOW THEY DEVELOP, HOW

5602
03:11:25,094 --> 03:11:27,430
THEY GROW SO THAT WE CAN FIND

5603
03:11:27,430 --> 03:11:28,765
NOVEL TARGETS, ULTIMATELY FOR

5604
03:11:28,765 --> 03:11:29,866
THERAPY.

5605
03:11:29,866 --> 03:11:32,835
AND WE ARE LOOKING AT IT IN THE

5606
03:11:32,835 --> 03:11:34,337
LENS OF WHAT DRIVES DISEASES,

5607
03:11:34,337 --> 03:11:35,938
WHAT ARE THE MASTER REGULATORS.

5608
03:11:35,938 --> 03:11:38,207
WE LOOK AT SEX HORMONES, THEN WE

5609
03:11:38,207 --> 03:11:39,275
LOOK AT RISK FACTORS FOR EACH OF

5610
03:11:39,275 --> 03:11:41,878
THE DISEASES SUCH AS OBESITY,

5611
03:11:41,878 --> 03:11:48,751
GENETICS, RACE, ET CETERA.

5612
03:11:48,751 --> 03:11:49,952
WE'RE ALSO VERY INTERESTED IN

5613
03:11:49,952 --> 03:11:50,820
MODELING THE DISEASES

5614
03:11:50,820 --> 03:11:51,587
APPROPRIATELY IN THE LAB WHICH

5615
03:11:51,587 --> 03:11:52,121
I'LL GET INTO.

5616
03:11:52,121 --> 03:11:54,056
SO I WANT TO START OFF BY SAYING

5617
03:11:54,056 --> 03:11:55,691
THAT MEDICINE IS FAILING WOMEN'S

5618
03:11:55,691 --> 03:11:57,326
HEALTH AT THE CURRENT TIME.

5619
03:11:57,326 --> 03:11:59,428
WE STILL SUFFER FROM A LOT OF

5620
03:11:59,428 --> 03:12:03,499
THE DISEASES AND CONDITIONS.

5621
03:12:03,499 --> 03:12:05,368
THERE ARE NO EFFECTIVE MEDICINES

5622
03:12:05,368 --> 03:12:06,636
OR TREATMENTS FOR THEM, EVEN

5623
03:12:06,636 --> 03:12:07,637
THOUGH THEY'VE BEEN AROUND SINCE

5624
03:12:07,637 --> 03:12:09,272
THE BEGINNING OF WOMEN.

5625
03:12:09,272 --> 03:12:11,674
AND SO I FEEL THAT WE NEED TO

5626
03:12:11,674 --> 03:12:14,143
UNDERSTAND THE BIOLOGY AND THE

5627
03:12:14,143 --> 03:12:15,778
SCIENCE BETTER, AND IN ORDER FOR

5628
03:12:15,778 --> 03:12:18,981
US TO DO THAT IN 2024, IS TO USE

5629
03:12:18,981 --> 03:12:20,550
THE TECHNOLOGIES THAT ARE BEING

5630
03:12:20,550 --> 03:12:23,386
USED IN OTHER FIELDS AND REALLY

5631
03:12:23,386 --> 03:12:27,890
HONE THEM IN ON WOMEN'S HEALTH.

5632
03:12:27,890 --> 03:12:29,592
AND SO CONVENTIONALLY, WHEN

5633
03:12:29,592 --> 03:12:31,994
WE'RE TRYING TO MIMIC WOMEN'S

5634
03:12:31,994 --> 03:12:36,532
HEALTH IN THE LAB, WE USE CELL

5635
03:12:36,532 --> 03:12:38,501
CULTURE TECHNIQUES, WE TAKE

5636
03:12:38,501 --> 03:12:40,837
CELLS OUT OF THE WOMEN'S BODY

5637
03:12:40,837 --> 03:12:43,005
AND THEN STUDY THEM IN THE LAB,

5638
03:12:43,005 --> 03:12:45,474
BUT THERE'S A PROBLEM WITH THAT.

5639
03:12:45,474 --> 03:12:49,612
WHEN WE'RE TALKING ABOUT WOMEN'S

5640
03:12:49,612 --> 03:12:51,147
HEALTH, WE CAN'T JUST STUDY ONE

5641
03:12:51,147 --> 03:12:54,383
CELL TYPE AT A TIME IN A MONO

5642
03:12:54,383 --> 03:12:55,685
LAYER, BECAUSE BODIES ARE MADE

5643
03:12:55,685 --> 03:12:57,887
UP OF CELLS THAT LIVE TOGETHER

5644
03:12:57,887 --> 03:13:00,957
AND WORK TOGETHER IN ORDER TO

5645
03:13:00,957 --> 03:13:01,390
FUNCTION.

5646
03:13:01,390 --> 03:13:02,992
SO SO FAR, CONVENTIONALLY WE'VE

5647
03:13:02,992 --> 03:13:04,827
BEEN USING ONE CELL TYPE MONO

5648
03:13:04,827 --> 03:13:08,831
LAYERS IN PLASTIC, WE HAVE

5649
03:13:08,831 --> 03:13:10,566
EVOLVED TO ORGANOIDS NOW,

5650
03:13:10,566 --> 03:13:12,201
THREE-DIMENSIONAL STRUCTURES

5651
03:13:12,201 --> 03:13:14,136
THAT MIMIC THE ARCHITECTURAL AS

5652
03:13:14,136 --> 03:13:16,072
WELL AS THE FUNCTION OF THE

5653
03:13:16,072 --> 03:13:16,639
ORGAN.

5654
03:13:16,639 --> 03:13:17,707
BUT ULTIMATELY AT THE END OF THE

5655
03:13:17,707 --> 03:13:19,709
DAY, WHAT WE WANT IS AN

5656
03:13:19,709 --> 03:13:21,177
INTERACTION BETWEEN MULTIPLE

5657
03:13:21,177 --> 03:13:24,580
CELL TYPES IN THE BODY.

5658
03:13:24,580 --> 03:13:27,750
AND SO I CAN SAY THIS ABOUT

5659
03:13:27,750 --> 03:13:28,718
REPRODUCTIVE BIOLOGY IN GENERAL,

5660
03:13:28,718 --> 03:13:29,886
BUT IN ORDER FOR US TO

5661
03:13:29,886 --> 03:13:30,987
UNDERSTAND THE BIOLOGY, THERE

5662
03:13:30,987 --> 03:13:33,055
ARE VARIOUS MODEL SYSTEMS THAT

5663
03:13:33,055 --> 03:13:37,593
WE HAVE USED IN THE PAST, AND IN

5664
03:13:37,593 --> 03:13:38,828
ORDER TO UNDERSTAND THE DISEASES

5665
03:13:38,828 --> 03:13:40,429
OF, FOR EXAMPLE, THE

5666
03:13:40,429 --> 03:13:41,764
ENDOMETRIUM, WE NEED TO

5667
03:13:41,764 --> 03:13:43,599
UNDERSTAND NORMAL PHYSIOLOGY AS

5668
03:13:43,599 --> 03:13:44,100
WELL.

5669
03:13:44,100 --> 03:13:47,069
SO THIS IS JUST AN EXAMPLE OF MY

5670
03:13:47,069 --> 03:13:49,438
JOURNEY OF USING THE COW UTERUS

5671
03:13:49,438 --> 03:13:53,042
AS A MODEL DURING MY PH.D.

5672
03:13:53,042 --> 03:13:56,379
I EVOLVED TO PRIMATE UTERUS

5673
03:13:56,379 --> 03:13:58,014
DURING MY POSTDOC AND NOW

5674
03:13:58,014 --> 03:14:00,750
EXCLUSIVELY I STUDY HUMANS.

5675
03:14:00,750 --> 03:14:04,954
AND SO WE KNOW THATTER SINGLE

5676
03:14:04,954 --> 03:14:05,821
MODEL SYSTEM IS VALUABLE IN THE

5677
03:14:05,821 --> 03:14:09,225
CONTEXT THAT THEY'RE USED IN.

5678
03:14:09,225 --> 03:14:11,460
BUT NOT EVERY MODEL OR ANY MODEL

5679
03:14:11,460 --> 03:14:13,863
IS THE PERFECT MODEL FOR THE

5680
03:14:13,863 --> 03:14:18,701
WOMEN, WOMEN'S CONDITION.

5681
03:14:18,701 --> 03:14:20,102
SO IT'S VERY IMPORTANT TO

5682
03:14:20,102 --> 03:14:21,003
INTERPRET THE DATA THAT IS

5683
03:14:21,003 --> 03:14:23,339
COMING OUT OF OUR MODEL SYSTEMS

5684
03:14:23,339 --> 03:14:24,440
IN THE APPROPRIATE MANNER.

5685
03:14:24,440 --> 03:14:27,276
SO IN VIVO MODELS ALL THE WAY

5686
03:14:27,276 --> 03:14:32,148
FROM WORMS TO PRIMATES TO WOMEN,

5687
03:14:32,148 --> 03:14:33,983
THEN IN VITRO LIKE I WAS

5688
03:14:33,983 --> 03:14:35,484
MENTIONING, CELL CULTURE TISSUES

5689
03:14:35,484 --> 03:14:38,120
IN 2D, IN 3D, INTERACTIONS

5690
03:14:38,120 --> 03:14:39,288
BETWEEN TWO CELL TYPES, AND I

5691
03:14:39,288 --> 03:14:40,957
WILL TALK TO YOU A LITTLE BIT

5692
03:14:40,957 --> 03:14:42,224
ABOUT THE MULTI-TISSUE

5693
03:14:42,224 --> 03:14:47,363
INTERACTIONS THAT WE CAN NOW

5694
03:14:47,363 --> 03:14:47,697
STUDY.

5695
03:14:47,697 --> 03:14:49,932
WHY IS MODELING THE FEMALE

5696
03:14:49,932 --> 03:14:50,599
REPRODUCTIVE SYSTEM SO IMPORTANT

5697
03:14:50,599 --> 03:14:51,233
AND SO DIFFICULT?

5698
03:14:51,233 --> 03:14:52,802
WELL, THERE ARE LIMITATIONS OF

5699
03:14:52,802 --> 03:14:54,904
THE KINDS OF RESEARCH THAT WE

5700
03:14:54,904 --> 03:14:57,406
CAN DO IN WOMEN, ESPECIALLY IN

5701
03:14:57,406 --> 03:14:59,608
WOMEN THAT ARE OF FERTILE AGE

5702
03:14:59,608 --> 03:15:02,979
AND PREGNANT.

5703
03:15:02,979 --> 03:15:05,448
SO THERE ARE ETHICAL CONCERNS.

5704
03:15:05,448 --> 03:15:06,983
SPECIES DIFFERENCES DO EXIST AND

5705
03:15:06,983 --> 03:15:08,084
HORMONES ARE COMPLICATED.

5706
03:15:08,084 --> 03:15:10,786
ESTROGEN AND PROGESTERONE AND

5707
03:15:10,786 --> 03:15:11,821
TESTOSTERONE, THEY DO COMPLICATE

5708
03:15:11,821 --> 03:15:16,459
THE DATA.

5709
03:15:16,459 --> 03:15:17,426
SEX DIFFERENCES WE KIND OF

5710
03:15:17,426 --> 03:15:18,594
MENTIONED THAT EARLIER ON, THERE

5711
03:15:18,594 --> 03:15:19,929
ARE SEX DIFFERENCES IN DRUG

5712
03:15:19,929 --> 03:15:21,664
RESPONSES, SO 8 OUT OF THE 10

5713
03:15:21,664 --> 03:15:23,165
DRUGS THAT ARE PULLED FROM THE

5714
03:15:23,165 --> 03:15:24,033
MARKET BECAUSE OF BAD SIDE

5715
03:15:24,033 --> 03:15:26,302
EFFECTS IN WOMEN.

5716
03:15:26,302 --> 03:15:29,572
SO PRE-CLINICAL AND CLINICAL

5717
03:15:29,572 --> 03:15:34,577
RESEARCH MUST HAVE BOTH MALE AND

5718
03:15:34,577 --> 03:15:35,911
FEMALES, AND IN THE PAST IT HAS

5719
03:15:35,911 --> 03:15:38,214
MORE SO IN MALES, WHICH IS WHY

5720
03:15:38,214 --> 03:15:39,882
WE DON'T HAVE THE DATA.

5721
03:15:39,882 --> 03:15:41,550
SO HERE'S SOME CHALLENGES OF

5722
03:15:41,550 --> 03:15:42,618
STUDYING REPRODUCTIVE DISEASES.

5723
03:15:42,618 --> 03:15:44,553
AS WE MENTIONED, THE HUMAN

5724
03:15:44,553 --> 03:15:50,259
REPRODUCTIVE TRACT IS UNIQUE.

5725
03:15:50,259 --> 03:15:52,094
THERE ARE NO GREAT PHYSIOLOGICAL

5726
03:15:52,094 --> 03:15:53,329
MODELS THAT DEPICT THE HUMAN

5727
03:15:53,329 --> 03:15:54,030
CONDITION.

5728
03:15:54,030 --> 03:15:55,564
HORMONES ARE COMPLEX.

5729
03:15:55,564 --> 03:15:59,502
THE CURRENT IN VITRO MODELS ARE

5730
03:15:59,502 --> 03:16:00,036
SIMPLE.

5731
03:16:00,036 --> 03:16:01,637
AND WHEN WE DO TAKE TISSUES FROM

5732
03:16:01,637 --> 03:16:06,675
WOMEN, THE AMOUNT OF TISSUES WE

5733
03:16:06,675 --> 03:16:08,811
GET IS VERY, VERY SMALL.

5734
03:16:08,811 --> 03:16:10,112
SO I WANT TO INTRODUCE YOU TO

5735
03:16:10,112 --> 03:16:10,646
TISSUE CHIPS.

5736
03:16:10,646 --> 03:16:11,947
THIS ALL STARTED ABOUT 10 YEARS

5737
03:16:11,947 --> 03:16:12,381
AGO.

5738
03:16:12,381 --> 03:16:14,650
IT WAS A COLLABORATION BETWEEN

5739
03:16:14,650 --> 03:16:16,619
DARPA AND NCATS, WHERE

5740
03:16:16,619 --> 03:16:19,255
ULTIMATELY AT THE END OF THE

5741
03:16:19,255 --> 03:16:20,756
DAY, THE GOAL WAS TO MAKE A

5742
03:16:20,756 --> 03:16:23,125
HUMAN ON A CHIP SO THAT THE DRUG

5743
03:16:23,125 --> 03:16:26,195
SCREENING PROCESS WOULD BE MORE

5744
03:16:26,195 --> 03:16:27,296
EFFECTIVE IN BETWEEN

5745
03:16:27,296 --> 03:16:29,265
PRE-CLINICAL MOUSE MODELS TO

5746
03:16:29,265 --> 03:16:33,903
CLINICAL TRIALS.

5747
03:16:33,903 --> 03:16:35,871
THIS WAS OPEN TO ALL FIELDS AND

5748
03:16:35,871 --> 03:16:38,741
WE INSISTED THAT WE NEEDED A

5749
03:16:38,741 --> 03:16:40,176
FEMALE REPRODUCTIVE TRACT

5750
03:16:40,176 --> 03:16:41,410
REPRESENTED IN THIS TISSUE CHIP.

5751
03:16:41,410 --> 03:16:43,379
SO THIS IS WHAT WE DID.

5752
03:16:43,379 --> 03:16:44,747
DR. TERESA WOODRUFF IS THE ONE

5753
03:16:44,747 --> 03:16:48,684
THAT REALLY SPEARHEADED THIS

5754
03:16:48,684 --> 03:16:48,918
MISSION.

5755
03:16:48,918 --> 03:16:51,887
WE COLLABORATED WITH THE VERY,

5756
03:16:51,887 --> 03:16:53,923
VERY SMART ENGINEERS AT DRAPER

5757
03:16:53,923 --> 03:16:58,360
LABS WHO MADE A MICRO FLUIDIC

5758
03:16:58,360 --> 03:17:01,464
PLATFORM.

5759
03:17:01,464 --> 03:17:05,334
, WHICH IS VERY SIMILAR TO A

5760
03:17:05,334 --> 03:17:07,002
TISSUE CULTURE PLATE SO THE FORM

5761
03:17:07,002 --> 03:17:09,205
FACTOR IS VERY FAMILIAR.

5762
03:17:09,205 --> 03:17:11,707
AND IN THIS FLUIDIC PLATFORM,

5763
03:17:11,707 --> 03:17:14,043
WHAT YOU SEE ARE LITTLE CHAMBERS

5764
03:17:14,043 --> 03:17:17,146
THAT ARE ULTIMATELY CONNECTED

5765
03:17:17,146 --> 03:17:19,181
WITH CHANNELS WHERE THE FLUID

5766
03:17:19,181 --> 03:17:23,786
CAN BE SHARED BETWEEN EACH OF

5767
03:17:23,786 --> 03:17:24,453
THE MOLECULES THAT YOU PUT IN.

5768
03:17:24,453 --> 03:17:27,957
SO OUR GOAL WAS TO CREATE AN

5769
03:17:27,957 --> 03:17:30,626
OVARY, AN ENDOMETRIUM MIMIC, THE

5770
03:17:30,626 --> 03:17:32,394
FALLOPIAN TUBE, AND THE

5771
03:17:32,394 --> 03:17:37,466
ECTOCERVIX AND PLACE IT INTO

5772
03:17:37,466 --> 03:17:40,102
THIS EVATAR SYSTEM WE CALLED IT,

5773
03:17:40,102 --> 03:17:41,303
SO THEY COULD ALL TALK TO EACH

5774
03:17:41,303 --> 03:17:41,637
OTHER.

5775
03:17:41,637 --> 03:17:44,707
THE REALLY, REALLY NEAT THING

5776
03:17:44,707 --> 03:17:45,841
THAT TERESA WOODRUFF DID WAS

5777
03:17:45,841 --> 03:17:49,345
THAT SHE WAS ABLE TO TAKE MOUSE

5778
03:17:49,345 --> 03:17:55,484
OVARIES, ADD IN GONADOTROPES TO

5779
03:17:55,484 --> 03:17:57,186
MIMIC THE HUMAN MENSTRUAL CYCLE,

5780
03:17:57,186 --> 03:17:59,822
WHEREAS A MOUSE ESTRUS CYCLE IS

5781
03:17:59,822 --> 03:18:00,756
FOUR DAYS, SHE WAS ABLE TO MAKE

5782
03:18:00,756 --> 03:18:04,360
THIS OVARY BEHAVE LIKE A HUMAN

5783
03:18:04,360 --> 03:18:05,728
OVARY IN THE SENSE THAT OVER THE

5784
03:18:05,728 --> 03:18:06,729
COURSE OF 28 DAYS, THAT OVARY

5785
03:18:06,729 --> 03:18:09,131
MADE ESTROGEN AND PROGESTERONE

5786
03:18:09,131 --> 03:18:11,167
SIMILAR TO THE HUMAN OVARY.

5787
03:18:11,167 --> 03:18:15,804
AND WITH THAT, THIS IS JUST A

5788
03:18:15,804 --> 03:18:19,975
PICTURE OF WHAT WE OBSERVED, IF

5789
03:18:19,975 --> 03:18:22,845
YOU CAN SEE RIGHT HERE, YOU CAN

5790
03:18:22,845 --> 03:18:33,022
SEE FOLLICLES OFF LATING  OVULA8

5791
03:18:33,022 --> 03:18:34,190
DAYS.

5792
03:18:34,190 --> 03:18:34,957
OVULATING FOLLICLES.

5793
03:18:34,957 --> 03:18:36,358
SO TO SUMMARIZE WHAT WE

5794
03:18:36,358 --> 03:18:37,560
DISCOVERED BY DOING THIS, FIRST

5795
03:18:37,560 --> 03:18:39,195
OF ALL, IT WAS POSSIBLE.

5796
03:18:39,195 --> 03:18:41,263
SECOND, ALL OF THE DIFFERENT

5797
03:18:41,263 --> 03:18:43,098
TISSUES THAT WERE REPRESENTED IN

5798
03:18:43,098 --> 03:18:46,368
THIS MICRO FLUIDIC SYSTEM, THEY

5799
03:18:46,368 --> 03:18:48,003
WERE FAMILIAR WITH EACH OTHER

5800
03:18:48,003 --> 03:18:51,840
AND THE SECRETED PRODUCTS OF THE

5801
03:18:51,840 --> 03:18:54,009
CULTURES AND SO THEY DID BETTER

5802
03:18:54,009 --> 03:18:56,946
AND THEY RESPONDED TO HORMONES

5803
03:18:56,946 --> 03:18:57,279
BETTER.

5804
03:18:57,279 --> 03:18:58,714
SO THE OTHER THING WAS BECAUSE

5805
03:18:58,714 --> 03:19:01,450
MEDIA IS CONTINUALLY FED IN AND

5806
03:19:01,450 --> 03:19:03,319
TAKEN OUT, TISSUES WERE ABLE TO

5807
03:19:03,319 --> 03:19:05,154
LAST LONGER AND MORE VIABLE.

5808
03:19:05,154 --> 03:19:09,658
HERE AGAIN, YOU SEE THE HORMONE

5809
03:19:09,658 --> 03:19:11,293
PATTERN SIMILAR TO A HUMAN

5810
03:19:11,293 --> 03:19:13,696
HORMONE SECRETION PATTERN.

5811
03:19:13,696 --> 03:19:16,365
SO WE LEARNED A LOT BY USING

5812
03:19:16,365 --> 03:19:20,035
THIS METHOD IN TERMS OF HAVING

5813
03:19:20,035 --> 03:19:26,242
TISSUES INTERACT WITH EACH

5814
03:19:26,242 --> 03:19:26,442
OTHER.

5815
03:19:26,442 --> 03:19:27,276
WE FOUND A LOT OF NEW BIOLOGY

5816
03:19:27,276 --> 03:19:28,844
WITH THIS AND WE FOUND THAT

5817
03:19:28,844 --> 03:19:29,478
ULTIMATELY AT THE END OF THE

5818
03:19:29,478 --> 03:19:31,146
DAY, TISSUES DO LIKE BEING WITH

5819
03:19:31,146 --> 03:19:32,815
EACH OTHER BECAUSE OF THE

5820
03:19:32,815 --> 03:19:36,085
SECRETED PRODUCTS THAT THEY SEE.

5821
03:19:36,085 --> 03:19:38,721
NOW, THIS WAS EVATAR, THIS WAS A

5822
03:19:38,721 --> 03:19:39,989
MICROFLUIDIC PLATFORM ENGINEERED

5823
03:19:39,989 --> 03:19:45,127
BY VERY, VERY SMART ENGINEERS IT

5824
03:19:45,127 --> 03:19:47,162
WAS VERY, VERY EXPENSIVE AND

5825
03:19:47,162 --> 03:19:48,497
VERY DIFFICULT TO USE BY

5826
03:19:48,497 --> 03:19:49,465
MOLECULAR BIOLOGISTS, SO THE

5827
03:19:49,465 --> 03:19:53,602
NEXT PHASE WAS TO BUILD

5828
03:19:53,602 --> 03:19:54,670
SOMETHING COMPARABLE THAT WAS

5829
03:19:54,670 --> 03:19:56,005
CHEAPER AND EASIER TO USE.

5830
03:19:56,005 --> 03:19:56,972
BASICALLY WE WANTED SOMEONE TO

5831
03:19:56,972 --> 03:20:00,009
TAKE IT OUT OF THE BOX, PLUG IT

5832
03:20:00,009 --> 03:20:04,847
IN AND USE IT.

5833
03:20:04,847 --> 03:20:07,383
SO THAT IS WHEN WE DEVELOPED

5834
03:20:07,383 --> 03:20:12,855
LATTICE, WORKING WITH A DEVICE

5835
03:20:12,855 --> 03:20:13,088
COMPANY.

5836
03:20:13,088 --> 03:20:15,057
AND WHAT IT IS IS, IT'S VERY

5837
03:20:15,057 --> 03:20:19,094
SIMILAR TO EVATAR WHERE IT A

5838
03:20:19,094 --> 03:20:21,730
FAMILIAR PLATE THAT HAS

5839
03:20:21,730 --> 03:20:23,132
MULTI-WELLS, HERE WE HAVE EIGHT

5840
03:20:23,132 --> 03:20:23,332
WELLS.

5841
03:20:23,332 --> 03:20:28,170
CAN YOU PUT WH.EACH OF THESE WEE

5842
03:20:28,170 --> 03:20:29,438
CONNECTED TO THROUGH CHANNELS

5843
03:20:29,438 --> 03:20:31,340
WHERE THE MEDIA IS PROPELLED

5844
03:20:31,340 --> 03:20:33,475
THROUGH, AND SO THEY'RE SEEING

5845
03:20:33,475 --> 03:20:35,077
EACH OTHER'S SECRETED PRODUCTS.

5846
03:20:35,077 --> 03:20:37,246
AND YOU CAN -- WE CAN

5847
03:20:37,246 --> 03:20:39,581
ORCHESTRATE WHERE THE FLOW GOES

5848
03:20:39,581 --> 03:20:40,883
BY A COMPUTER.

5849
03:20:40,883 --> 03:20:44,887
IT'S VERY CUSTOMIZED.

5850
03:20:44,887 --> 03:20:46,889
SO WE CAN STUDY THE INTERACTIONS

5851
03:20:46,889 --> 03:20:49,558
BETWEEN TWO DIFFERENT OR THREE

5852
03:20:49,558 --> 03:20:52,094
OR FOUR, WHAT HAVE YOU.

5853
03:20:52,094 --> 03:20:54,963
SO THE TECHNOLOGY IS EXTREMELY

5854
03:20:54,963 --> 03:20:55,898
SIMPLE.

5855
03:20:55,898 --> 03:20:57,266
IT'S BASICALLY THIS VALVE SYSTEM

5856
03:20:57,266 --> 03:21:01,270
THAT BRINGS UP FLUID AND THEN

5857
03:21:01,270 --> 03:21:02,571
DEPOSITS TO THE NEXT WELL.

5858
03:21:02,571 --> 03:21:04,773
AND WE CAN DO THIS 40 MICRO

5859
03:21:04,773 --> 03:21:07,509
LITERS EVERY HOUR.

5860
03:21:07,509 --> 03:21:11,080
SO AGAIN, VERY SIMPLE SYSTEM,

5861
03:21:11,080 --> 03:21:12,715
AND PRETTY EASY TO USE.

5862
03:21:12,715 --> 03:21:17,186
NOW WE WANTED TO MODEL A

5863
03:21:17,186 --> 03:21:18,687
REPRODUCTIVE DISEASE THAT

5864
03:21:18,687 --> 03:21:20,656
REQUIRED MULTIORGANS SUCH AS

5865
03:21:20,656 --> 03:21:23,258
PCOS, POLYCYSTIC OVARIAN

5866
03:21:23,258 --> 03:21:24,493
SYNDROME IS A SYNDROME THAT

5867
03:21:24,493 --> 03:21:27,329
IMPACTS MANY WOMEN, BUT THERE

5868
03:21:27,329 --> 03:21:29,398
ARE MANY DIFFERENT ORGAN SYSTEMS

5869
03:21:29,398 --> 03:21:31,400
INVOLVED, AND IT'S STILL NOT

5870
03:21:31,400 --> 03:21:34,570
CLEAR WHAT CAUSES PCOS, WHETHER

5871
03:21:34,570 --> 03:21:38,273
IT IS A HYPERANDROGENIC OVARY,

5872
03:21:38,273 --> 03:21:40,042
LOTS OF TESTOSTERONE BEING

5873
03:21:40,042 --> 03:21:41,009
PRODUCED, OR IF IT'S PRODUCTION

5874
03:21:41,009 --> 03:21:43,545
OF A LOT OF INSULIN, THAT IS NOT

5875
03:21:43,545 --> 03:21:44,046
KNOWN YET.

5876
03:21:44,046 --> 03:21:45,481
SO WITH THIS KIND OF SYSTEM, YOU

5877
03:21:45,481 --> 03:21:48,217
CAN IMAGINE HOW YOU CAN

5878
03:21:48,217 --> 03:21:50,119
MANIPULATE WHAT TISSUES ARE

5879
03:21:50,119 --> 03:21:52,888
REPRESENTED, AND YOU CAN SEE

5880
03:21:52,888 --> 03:21:56,592
WHICH O ORGAN THAT IS

5881
03:21:56,592 --> 03:21:57,493
DYSFUNCTIONAL DRIVES THE

5882
03:21:57,493 --> 03:21:57,726
DISEASE.

5883
03:21:57,726 --> 03:21:58,560
SO FOR EXAMPLE, WE HAVE BEEN

5884
03:21:58,560 --> 03:22:00,529
ABLE TO MAKE A HYPERANDROGENIC

5885
03:22:00,529 --> 03:22:02,030
OVARY SIMILAR TO THE SYSTEM

5886
03:22:02,030 --> 03:22:03,465
WHERE WE INCREASE THE LEVEL OF

5887
03:22:03,465 --> 03:22:06,301
LH LIKE WE FIND IN WOMEN WITH

5888
03:22:06,301 --> 03:22:10,973
PCOS, AND THEN LEVELS OF

5889
03:22:10,973 --> 03:22:11,940
TESTOSTERONE INCREASE IN SUCH A

5890
03:22:11,940 --> 03:22:12,274
SYSTEM.

5891
03:22:12,274 --> 03:22:13,609
THEN WE SEE WHAT HAPPENS

5892
03:22:13,609 --> 03:22:19,815
DOWNSTREAM.

5893
03:22:19,815 --> 03:22:24,186
SO I'VE INTRODUCED TO YOU

5894
03:22:24,186 --> 03:22:25,387
MICROFLUIDICS OF THE FEMALE

5895
03:22:25,387 --> 03:22:26,588
REPRODUCTIVE TRACT, AND HERE WE

5896
03:22:26,588 --> 03:22:31,593
HAVE A NEW TOOL TO START IS

5897
03:22:31,593 --> 03:22:32,828
ASKING NEW QUESTIONS AND GETTING

5898
03:22:32,828 --> 03:22:35,230
NEW ANSWERS, AND THEN THIS IS A

5899
03:22:35,230 --> 03:22:39,001
VERY NICE PLATFORM WHERE WE CAN

5900
03:22:39,001 --> 03:22:40,202
ACTUALLY INCREASE THE

5901
03:22:40,202 --> 03:22:46,875
COMPLEXITY, BUT THEN CONTROL THE

5902
03:22:46,875 --> 03:22:48,076
PARAMETERS SO IT IS VERY

5903
03:22:48,076 --> 03:22:49,411
CONTROLLED AND NEW SCIENTIFIC

5904
03:22:49,411 --> 03:22:51,246
QUESTIONS CAN BE ASKED.

5905
03:22:51,246 --> 03:22:52,314
SO ONE OF THE THINGS THAT WE CAN

5906
03:22:52,314 --> 03:22:56,285
DO WITH THIS PLATFORM IS

5907
03:22:56,285 --> 03:22:56,985
ULTIMATELY DRUG TESTING.

5908
03:22:56,985 --> 03:22:59,087
IF WE HAD MULTIPLE DIFFERENT

5909
03:22:59,087 --> 03:23:01,690
CELL TYPES REPRESENTED, WE CAN

5910
03:23:01,690 --> 03:23:03,625
SEEK POTENTIAL SIDE EFFECTS OF

5911
03:23:03,625 --> 03:23:08,030
THE DRUGS BEING TESTED.

5912
03:23:08,030 --> 03:23:11,433
A COLLABORATIVE OF OURS AT

5913
03:23:11,433 --> 03:23:13,769
RUTGERS IS LOOKING AT PFAS AND

5914
03:23:13,769 --> 03:23:14,903
ENVIRONMENTAL TOXINS AND THE

5915
03:23:14,903 --> 03:23:16,738
IMPACT ON OVARIAN FOLLICLE

5916
03:23:16,738 --> 03:23:17,840
DEVELOPMENT AND MATURATION, AND

5917
03:23:17,840 --> 03:23:20,142
IT'S BEEN VERY, VERY SUCCESSFUL

5918
03:23:20,142 --> 03:23:21,443
AND HE'S ALSO DONE IT IN THE

5919
03:23:21,443 --> 03:23:28,217
LATTICE PLATFORM.

5920
03:23:28,217 --> 03:23:29,885
SO TRANSLATION TO HUMAN HEALTH,

5921
03:23:29,885 --> 03:23:33,789
IT IS OBVIOUS WHETHER WE STUDY

5922
03:23:33,789 --> 03:23:34,890
THE BASIC SCIENCES AND GET

5923
03:23:34,890 --> 03:23:36,225
INFORMATION FROM THAT, WE CAN

5924
03:23:36,225 --> 03:23:38,260
ULTIMATELY USE THAT TO FIND NEW

5925
03:23:38,260 --> 03:23:39,628
COMPOUNDS, FIND NEW TARGETS, ET

5926
03:23:39,628 --> 03:23:40,162
CETERA.

5927
03:23:40,162 --> 03:23:41,630
BUT IT'S ALSO IMPORTANT TO TEST

5928
03:23:41,630 --> 03:23:44,566
ALL OF THESE NEW DRUGS IN THE

5929
03:23:44,566 --> 03:23:48,971
CONTEXT OF SEX HORMONES.

5930
03:23:48,971 --> 03:23:53,408
WHANS WHEN THERE'SWHAT HAPPENS T

5931
03:23:53,408 --> 03:23:55,477
OF ESTROGEN, TESTOSTERONE, ET

5932
03:23:55,477 --> 03:23:56,044
CETERA.

5933
03:23:56,044 --> 03:23:57,479
THIS ALLOWS YOU TO ARE MORE

5934
03:23:57,479 --> 03:23:58,313
COMPLEX IN A PHYSIOLOGICAL

5935
03:23:58,313 --> 03:24:00,015
MANNER AND IT DOES MIMIC THE

5936
03:24:00,015 --> 03:24:01,783
HUMAN BODY BETTER FOR DRUG

5937
03:24:01,783 --> 03:24:02,017
TESTING.

5938
03:24:02,017 --> 03:24:04,086
SO I WAS ALSO ASKED WHAT

5939
03:24:04,086 --> 03:24:05,854
CHALLENGES WE FACE IN OUR

5940
03:24:05,854 --> 03:24:10,759
RESEARCH.

5941
03:24:10,759 --> 03:24:11,927
IN TERMS OF THE RESEARCH, WE

5942
03:24:11,927 --> 03:24:13,795
WORK WITH HUMAN TISSUES.

5943
03:24:13,795 --> 03:24:14,997
GETTING HUMAN TISSUES IS NOT

5944
03:24:14,997 --> 03:24:16,164
ALWAYS EASY.

5945
03:24:16,164 --> 03:24:17,799
WE GET THEM FROM THE O.R. WHEN

5946
03:24:17,799 --> 03:24:19,902
PATIENTS CONSENT TO DONATE THEIR

5947
03:24:19,902 --> 03:24:20,769
TISSUES THAT'S OTHERWISE GOING

5948
03:24:20,769 --> 03:24:21,837
TO BE DISCARDED.

5949
03:24:21,837 --> 03:24:23,906
SO SOMETIMES WE GET VERY LITTLE,

5950
03:24:23,906 --> 03:24:25,874
SOMETIMES WE DON'T GET ANY.

5951
03:24:25,874 --> 03:24:28,510
AND THEN TRYING TO SYNCHRONIZE

5952
03:24:28,510 --> 03:24:30,479
GETTING DIFFERENT HUMAN TISSUES,

5953
03:24:30,479 --> 03:24:32,981
DIFFERENT SURGERY SCHEDULES, IS

5954
03:24:32,981 --> 03:24:33,749
A CHALLENGE.

5955
03:24:33,749 --> 03:24:38,320
WE WOULD NEED SOME REALLY NICE

5956
03:24:38,320 --> 03:24:39,521
FREEZING PROTOCOLS SO WE CAN GET

5957
03:24:39,521 --> 03:24:41,490
ALL THE TISSUE TYPES WE WANT AND

5958
03:24:41,490 --> 03:24:42,991
PUT THEM TOGETHER IN THE

5959
03:24:42,991 --> 03:24:43,959
MICROFLUIDIC PLATFORM.

5960
03:24:43,959 --> 03:24:45,827
SCALABILITY IS ALSO A PROBLEM

5961
03:24:45,827 --> 03:24:48,463
RIGHT NOW BECAUSE OF THE TISSUE

5962
03:24:48,463 --> 03:24:49,865
AVAILABILITY, AND THEN REALTIME

5963
03:24:49,865 --> 03:24:51,400
MONITORING OF HEALTHY CULTURES,

5964
03:24:51,400 --> 03:24:53,135
WE CAN DO THIS BY EYE WITH A

5965
03:24:53,135 --> 03:24:55,637
MICROSCOPE BUT OTHER THAN THAT,

5966
03:24:55,637 --> 03:24:57,773
WE DO NEED BETTER BIOSENSORS, ET

5967
03:24:57,773 --> 03:25:00,709
CETERA.

5968
03:25:00,709 --> 03:25:05,047
WHAT HAVE BEEN THE CH CHALLENGEN

5969
03:25:05,047 --> 03:25:05,514
COMMERCIALIZATION?

5970
03:25:05,514 --> 03:25:07,215
WE DO WANT PEOPLE TO USE

5971
03:25:07,215 --> 03:25:10,152
LATTICE, AND I'VE EVEN GONE

5972
03:25:10,152 --> 03:25:13,989
THROUGH PITCH PRACTICES WITH

5973
03:25:13,989 --> 03:25:16,058
NORTHWESTERN FOLKS, AND ALWAYS

5974
03:25:16,058 --> 03:25:17,926
THE QUESTION THAT I'M ASKED IS,

5975
03:25:17,926 --> 03:25:19,461
WHAT MARKET ARE YOU TRYING TO

5976
03:25:19,461 --> 03:25:20,996
TARGET?

5977
03:25:20,996 --> 03:25:22,831
BECAUSE LATTICE IS A PLATFORM

5978
03:25:22,831 --> 03:25:23,899
AND IT'S AGNOSTIC.

5979
03:25:23,899 --> 03:25:26,935
WE CAN USE TO STUDY FEMALE

5980
03:25:26,935 --> 03:25:27,536
REPRODUCTIVE HEALTH OR WE CAN

5981
03:25:27,536 --> 03:25:31,206
USE TO STUDY BRAIN HEALTH OR I

5982
03:25:31,206 --> 03:25:34,610
EVEN PROPOSED A GRANT TO STUDY

5983
03:25:34,610 --> 03:25:37,245
MENOPAUSE IN DIFFERENT TISSUE

5984
03:25:37,245 --> 03:25:38,647
TYPES THAT ARE INVOLVED IN

5985
03:25:38,647 --> 03:25:38,914
MENOPAUSE.

5986
03:25:38,914 --> 03:25:40,949
SO THAT IS A QUESTION I'M ALWAYS

5987
03:25:40,949 --> 03:25:42,584
FACED, WHAT MARKET ARE YOU

5988
03:25:42,584 --> 03:25:45,520
TRYING TO TARGET.

5989
03:25:45,520 --> 03:25:46,922
ALSO USABILITY, IT HAS TO BE

5990
03:25:46,922 --> 03:25:48,857
SIMPLE, IT CANNOT BREAK DOWN, IT

5991
03:25:48,857 --> 03:25:51,927
HAS TO BE CHEAP ENOUGH, AND THEN

5992
03:25:51,927 --> 03:25:53,028
FINDING THE COMMERCIAL PARTNERS

5993
03:25:53,028 --> 03:25:55,631
AS WELL AND THEN FUNDERS.

5994
03:25:55,631 --> 03:25:58,300
SO I WAS VERY GLAD TO HEAR THE

5995
03:25:58,300 --> 03:26:00,335
TWO PREVIOUS SPEAKERS ABOUT SEED

5996
03:26:00,335 --> 03:26:05,440
AND SBIR, ET CETERA.

5997
03:26:05,440 --> 03:26:06,742
SO THIS IS A GREAT BIG MARKET

5998
03:26:06,742 --> 03:26:08,844
THAT WE STILL HAVE TO PLUG INTO.

5999
03:26:08,844 --> 03:26:10,812
MENOPAUSE IS A HUGE MARKET,

6000
03:26:10,812 --> 03:26:13,315
$17 BILLION, AND YOU CAN SEE ALL

6001
03:26:13,315 --> 03:26:14,282
THE NUMBERS.

6002
03:26:14,282 --> 03:26:17,452
THERE IS THE NEED, ESPECIALLY IN

6003
03:26:17,452 --> 03:26:18,086
WOMEN'S HEALTH AND DISEASES,

6004
03:26:18,086 --> 03:26:20,722
THERE NEEDS TO BE BETTER DRUGS,

6005
03:26:20,722 --> 03:26:22,157
BETTER TREATMENT, SURGERY CANNOT

6006
03:26:22,157 --> 03:26:24,760
BE THE ONLY OPTION.

6007
03:26:24,760 --> 03:26:26,094
AND I SEE YOU STANDING UP.

6008
03:26:26,094 --> 03:26:26,928
I'M DONE.

6009
03:26:26,928 --> 03:26:27,796
THANK YOU.

6010
03:26:27,796 --> 03:26:28,964
THIS TAKES A VILLAGE.

6011
03:26:28,964 --> 03:26:31,867
THANK YOU TO MY PREVIOUS MEMBERS

6012
03:26:31,867 --> 03:26:33,935
AS WELL AS MY CURRENT MEMBER OF

6013
03:26:33,935 --> 03:26:36,805
MY LAB, OTHER COLLABORATORS

6014
03:26:36,805 --> 03:26:40,609
INCLUDING TERESA WOODRUFF,

6015
03:26:40,609 --> 03:26:44,880
MARGRIT URBANEK, CHRISTINA

6016
03:26:44,880 --> 03:26:46,615
BOOTS, OTHER COLLABORATORS AS

6017
03:26:46,615 --> 03:26:48,016
WELL AT DRAPER LABS AND OF

6018
03:26:48,016 --> 03:26:50,385
COURSE ALL THE FUNDING AGENCIES.

6019
03:26:50,385 --> 03:26:52,554
THANK YOU.

6020
03:26:52,554 --> 03:27:02,731
[APPLAUSE]

6021
03:27:05,300 --> 03:27:07,302
>> OKAY, SO FORTUNATELY I
KNEW

6022
03:27:07,302 --> 03:27:08,470
JULIE WAS GOING TO TALK BEFORE

6023
03:27:08,470 --> 03:27:10,539
ME SO I'M GOING TO PURPOSEFULLY

6024
03:27:10,539 --> 03:27:12,374
SCWIP OVER TALKING MUCH ABOUT

6025
03:27:12,374 --> 03:27:15,243
MICRO FLUIDICS AND FOCUS A

6026
03:27:15,243 --> 03:27:17,312
LITTLE BIT MORE ON DIGITAL TWINS

6027
03:27:17,312 --> 03:27:18,714
AND COMPUTATIONAL MODELS FOR

6028
03:27:18,714 --> 03:27:19,481
STUDYING PREGNANCY.

6029
03:27:19,481 --> 03:27:21,316
SO I'D LIKE TO INTRODUCE A

6030
03:27:21,316 --> 03:27:22,517
LITTLE BIT OF MY BACKGROUND

6031
03:27:22,517 --> 03:27:23,618
BECAUSE IT'S KIND OF A WEIRD

6032
03:27:23,618 --> 03:27:27,889
THING TO SAY WHERE AN ENGINEER

6033
03:27:27,889 --> 03:27:28,857
GOT INTO BEING A PREGNANCY

6034
03:27:28,857 --> 03:27:29,191
RESEARCHER.

6035
03:27:29,191 --> 03:27:31,493
I STARTED OUT IN ORTHOPEDIC

6036
03:27:31,493 --> 03:27:33,128
SCIENCE, SO I STARTED OUT IN

6037
03:27:33,128 --> 03:27:35,197
ARTHRITIS RESEARCH, I DID A LOT

6038
03:27:35,197 --> 03:27:36,832
LOT WITH BONE AND CARTILAGE.

6039
03:27:36,832 --> 03:27:37,966
THAT'S A FIELD WHERE ENGINEERING

6040
03:27:37,966 --> 03:27:39,434
HAS HAD A FOOTHOLD FOR MORE THAN

6041
03:27:39,434 --> 03:27:40,001
50 YEARS.

6042
03:27:40,001 --> 03:27:43,538
SO IF YOU GO AND LOOK AT THE

6043
03:27:43,538 --> 03:27:45,841
ROSTER OF MOST ORTHOPEDICS

6044
03:27:45,841 --> 03:27:46,408
DEPARTMENTS, CLINICAL

6045
03:27:46,408 --> 03:27:47,476
DEPARTMENTS IN THE UNITED

6046
03:27:47,476 --> 03:27:50,846
STATES, YOU WILL FIND

6047
03:27:50,846 --> 03:27:52,147
ENGINEERING PROFESSORS WITHIN

6048
03:27:52,147 --> 03:27:53,014
THEIR FACULTY BECAUSE THERE IS

6049
03:27:53,014 --> 03:27:53,882
AN ACKNOWLEDGMENT THAT

6050
03:27:53,882 --> 03:27:56,184
MECHANICAL LOADING IS IMPORTANT

6051
03:27:56,184 --> 03:27:57,319
IN ORTHOPEDIC INJURIES AND OR

6052
03:27:57,319 --> 03:28:00,222
THE PEE ORTHOPEDIC REPAIRS.

6053
03:28:00,222 --> 03:28:03,525
MY GOAL IS TO MAKE THAT HAPPEN

6054
03:28:03,525 --> 03:28:04,693
IN OB-GYN BECAUSE THERE ARE

6055
03:28:04,693 --> 03:28:06,561
PROBLEMS HERE THAT ALSO HAVE

6056
03:28:06,561 --> 03:28:07,095
MECHANICAL COMPONENTS.

6057
03:28:07,095 --> 03:28:08,396
AND IN FACT, THAT'S WHAT

6058
03:28:08,396 --> 03:28:08,864
HAPPENED TO ME.

6059
03:28:08,864 --> 03:28:10,932
I WAS A GRADUATE STUDENT WORKING

6060
03:28:10,932 --> 03:28:12,667
IN THE LAB ON A CARTILAGE

6061
03:28:12,667 --> 03:28:14,736
PROJECT, AND I TOOK A COLD CALL

6062
03:28:14,736 --> 03:28:17,472
FROM AN OBSTETRICIAN WHO WAS

6063
03:28:17,472 --> 03:28:18,907
INTERESTED IN PREMATURE RUPTURE

6064
03:28:18,907 --> 03:28:20,542
OF THE FETAL MEMBRANES IN

6065
03:28:20,542 --> 03:28:21,409
PRETERM BIRTH.

6066
03:28:21,409 --> 03:28:23,478
AND HE SAID, I THINK THIS IS A

6067
03:28:23,478 --> 03:28:24,012
MECHANICAL PROBLEM.

6068
03:28:24,012 --> 03:28:26,214
DO YOU HAVE AN ABILITY TO

6069
03:28:26,214 --> 03:28:27,082
MEASURE FORCES?

6070
03:28:27,082 --> 03:28:29,451
AND I SAID YES, YES, I DO.

6071
03:28:29,451 --> 03:28:31,887
AND SO BY THE TIME I FINISHED MY

6072
03:28:31,887 --> 03:28:33,855
PH.D., I WAS ACTUALLY WORKING

6073
03:28:33,855 --> 03:28:38,193
FULL TIME IN OB-GYN IN A PROJECT

6074
03:28:38,193 --> 03:28:40,061
LOOKING AT PRETERM RUPTURE OF

6075
03:28:40,061 --> 03:28:44,199
FETAL MEMBRANES AND FIRI FINISHY

6076
03:28:44,199 --> 03:28:45,167
PH.D. ON THE SIDE.

6077
03:28:45,167 --> 03:28:47,135
SO THAT'S HOW I GOT HERE.

6078
03:28:47,135 --> 03:28:48,770
BUT ONCE I DISCOVERED THERE WERE

6079
03:28:48,770 --> 03:28:49,638
ALL THESE OPPORTUNITIES IN

6080
03:28:49,638 --> 03:28:50,639
WOMEN'S HEALTH THAT HAD

6081
03:28:50,639 --> 03:28:51,406
ENGINEERING COMPONENTS THAT HAD

6082
03:28:51,406 --> 03:28:53,008
NOT BEEN STUDIED, I ESSENTIALLY

6083
03:28:53,008 --> 03:28:54,342
STOPPED DOING ORTHOPEDICS

6084
03:28:54,342 --> 03:28:56,211
RESEARCH OVER TIME AND SPENT ALL

6085
03:28:56,211 --> 03:28:58,380
OF MY TIME NOW FOCUSED ON

6086
03:28:58,380 --> 03:28:59,781
PREGNANCY AND OTHER ASPECTS OF

6087
03:28:59,781 --> 03:29:02,083
WOMEN'S HEALTH.

6088
03:29:02,083 --> 03:29:03,385
SO FOR EXAMPLE, THIS IS A FIGURE

6089
03:29:03,385 --> 03:29:05,787
FROM A PAPER ABOUT PRETERM

6090
03:29:05,787 --> 03:29:07,122
BIRTH, PRETERM BIRTH IS ABOUT

6091
03:29:07,122 --> 03:29:10,292
10% OF ALL BIRTHS, SO AGAIN, A

6092
03:29:10,292 --> 03:29:10,625
HUGE PROBLEM.

6093
03:29:10,625 --> 03:29:14,329
AND WHAT I HAVE HIGHLIGHTED IN

6094
03:29:14,329 --> 03:29:15,831
RED HERE ARE THE DIFFERENT AREAS

6095
03:29:15,831 --> 03:29:16,965
OF PRETERM BIRTH THAT CLEARLY

6096
03:29:16,965 --> 03:29:18,934
HAVE A MECHANICAL COMPONENT.

6097
03:29:18,934 --> 03:29:20,135
SO YOU'VE GOT THINGS ON THE

6098
03:29:20,135 --> 03:29:22,504
MATERNAL SIDE, MATERNAL TRAUMA,

6099
03:29:22,504 --> 03:29:25,006
PREECLAMPSIA, AN ELEVATED

6100
03:29:25,006 --> 03:29:25,874
PRESSURE.

6101
03:29:25,874 --> 03:29:30,579
YOU HAVE THINGS ON THE FETAL

6102
03:29:30,579 --> 03:29:31,479
SIDE.

6103
03:29:31,479 --> 03:29:33,481
PLACENTAL SIDE, PLACENTAL

6104
03:29:33,481 --> 03:29:34,382
ABRUPTION WHEN YOU GET

6105
03:29:34,382 --> 03:29:35,383
DETACHMENT OF THE PLACENTA FROM

6106
03:29:35,383 --> 03:29:37,018
THE UTERUS, AND THEN THINGS TO

6107
03:29:37,018 --> 03:29:38,587
DO WITH BIRTH INCLUDING

6108
03:29:38,587 --> 03:29:40,088
PREMATURE RUPTURE AND CERVICAL

6109
03:29:40,088 --> 03:29:40,856
SHORTENING AND CERVICAL

6110
03:29:40,856 --> 03:29:42,591
DILATION.

6111
03:29:42,591 --> 03:29:44,192
SO AS THE PREVIOUS SPEAKER WAS

6112
03:29:44,192 --> 03:29:46,061
SAYING, THE TRADITIONAL ROUTE TO

6113
03:29:46,061 --> 03:29:48,463
GET THINGS APPROVED THROUGH THE

6114
03:29:48,463 --> 03:29:51,633
FDA WAS REALLY FOCUSED ON ANIMAL

6115
03:29:51,633 --> 03:29:53,501
RESEARCH, BUT ANIMAL RESEARCH IS

6116
03:29:53,501 --> 03:29:55,003
NOT ALWAYS GREAT.

6117
03:29:55,003 --> 03:29:58,206
MY PRIMARY AREA OF INTEREST

6118
03:29:58,206 --> 03:29:59,674
THESE DAYS IS THE PLACENTA AND

6119
03:29:59,674 --> 03:30:01,576
THERE ARE NO GOOD ANIMAL MODELS

6120
03:30:01,576 --> 03:30:04,179
FOR THE HUMAN PLACENTA.

6121
03:30:04,179 --> 03:30:05,480
STRUCTURALLY, IT IS DIFFERENT,

6122
03:30:05,480 --> 03:30:07,148
IT IS DIFFERENT PARTICULARLY ON

6123
03:30:07,148 --> 03:30:08,984
A MICROSCOPIC STRUCTURE, EVEN

6124
03:30:08,984 --> 03:30:11,119
THOUGH THE MOUSE PLACENTA AND

6125
03:30:11,119 --> 03:30:12,153
THE HUMAN PLACENTA ARE THE SAME

6126
03:30:12,153 --> 03:30:12,587
SHAPE.

6127
03:30:12,587 --> 03:30:14,656
THEY DON'T HAVE THE SAME TISSUE

6128
03:30:14,656 --> 03:30:15,757
LAYERS.

6129
03:30:15,757 --> 03:30:16,725
HUMAN PLACENTA IS MUCH MORE

6130
03:30:16,725 --> 03:30:17,259
INVASIVE.

6131
03:30:17,259 --> 03:30:18,159
BUT OF COURSE BEING SOMEONE

6132
03:30:18,159 --> 03:30:19,694
WHO'S INTERESTED IN

6133
03:30:19,694 --> 03:30:23,632
BIOMECHANICS, I ALSO LOOK AT

6134
03:30:23,632 --> 03:30:26,134
QUADRA PEDAL ANIMALS HAVING

6135
03:30:26,134 --> 03:30:27,869
LITTERS AND SEE THAT THE

6136
03:30:27,869 --> 03:30:29,037
MECHANICS OF PREGNANCY ARE VERY

6137
03:30:29,037 --> 03:30:30,405
DIFFERENT IN THAT CASE COMPARED

6138
03:30:30,405 --> 03:30:31,373
TO IN HUMANS.

6139
03:30:31,373 --> 03:30:34,075
SO I ALSO EXCLUSIVELY STUDY

6140
03:30:34,075 --> 03:30:35,076
HUMAN TISSUES.

6141
03:30:35,076 --> 03:30:37,312
AND THESE DAYS, WITH THE FDA

6142
03:30:37,312 --> 03:30:40,782
MODERNIZATION ACT THAT HAPPEN IN

6143
03:30:40,782 --> 03:30:44,719
A BIZARRE BIPARTISAN ACT OF

6144
03:30:44,719 --> 03:30:46,254
CONGRESS IN 2022, NON-CLINICAL

6145
03:30:46,254 --> 03:30:47,656
TESTS ARE NOW AN IMPORTANT PART

6146
03:30:47,656 --> 03:30:49,724
OF THE OVERALL MECHANISM TO

6147
03:30:49,724 --> 03:30:51,159
GETTING NEW DRUGS AND DEVICES

6148
03:30:51,159 --> 03:30:51,559
APPROVED.

6149
03:30:51,559 --> 03:30:55,397
AND THAT INCLUDES THINGS LIKE

6150
03:30:55,397 --> 03:30:56,197
MICROPHYSIOLOGICAL SYSTEMS AND

6151
03:30:56,197 --> 03:30:57,832
ORGANS ON CHIPS, BUT IT ALSO

6152
03:30:57,832 --> 03:31:01,002
INCLUDES COMPUTATIONAL MODELS.

6153
03:31:01,002 --> 03:31:02,871
AND SO I'M NOT GOING TO GO INTO

6154
03:31:02,871 --> 03:31:05,040
MUCH AS I SAID ABOUT

6155
03:31:05,040 --> 03:31:06,007
MICROPHYSIOLOGICAL SYSTEMS OR

6156
03:31:06,007 --> 03:31:07,976
TISSUE ENGINEERING, JUST TO SAY

6157
03:31:07,976 --> 03:31:10,812
THAT WE, TOO, HAVE DELVED IN

6158
03:31:10,812 --> 03:31:12,347
THIS AREA FOCUSED ON MATCHING

6159
03:31:12,347 --> 03:31:13,648
MECHANICAL PROPERTIES, BUT WE'RE

6160
03:31:13,648 --> 03:31:16,818
ALSO VERY INTERESTED IN USING

6161
03:31:16,818 --> 03:31:19,354
COMPUTATIONAL MODELS TO LOOK AT

6162
03:31:19,354 --> 03:31:21,289
PREGNANCY, AND ALSO INCREASINGLY

6163
03:31:21,289 --> 03:31:22,958
USING BIG DATA, LOOKING AT

6164
03:31:22,958 --> 03:31:25,193
MACHINE LEARNING, IMAGE

6165
03:31:25,193 --> 03:31:26,594
PROCESSING, TO DO WITH PREGNANCY

6166
03:31:26,594 --> 03:31:27,929
AND OTHER ASPECTS OF WOMEN'S

6167
03:31:27,929 --> 03:31:28,163
HEALTH.

6168
03:31:28,163 --> 03:31:30,198
SO I'M GOING TO FOCUS THE REST

6169
03:31:30,198 --> 03:31:34,035
OF MY PRESENTATION ON INSILICO

6170
03:31:34,035 --> 03:31:34,469
APPROACHES.

6171
03:31:34,469 --> 03:31:36,471
SO WHAT WE'RE DOING RIGHT NOW IS

6172
03:31:36,471 --> 03:31:39,941
REALLY FOCUSED ON TRYING TO MAKE

6173
03:31:39,941 --> 03:31:43,778
COMPUTATIONAL MODELS ENTER THE

6174
03:31:43,778 --> 03:31:45,213
TRADITIONAL CLINICAL PATHWAY FOR

6175
03:31:45,213 --> 03:31:46,948
LOOKING AT HUMAN PREGNANCY.

6176
03:31:46,948 --> 03:31:48,583
SO WHAT DID WE DO IN HUMAN

6177
03:31:48,583 --> 03:31:49,918
PREGNANCY ALL THE TIME?

6178
03:31:49,918 --> 03:31:51,987
WE DO ULTRASOUNDS.

6179
03:31:51,987 --> 03:31:53,088
SO WITH THOSE ULTRASOUNDS, WE

6180
03:31:53,088 --> 03:31:55,056
CAN GET A LOT OF CLINICAL DATA

6181
03:31:55,056 --> 03:31:57,993
THAT'S VERY RELEVANT THAT CAN BE

6182
03:31:57,993 --> 03:32:00,195
USED TO BUILD A COMPUTATIONAL

6183
03:32:00,195 --> 03:32:01,596
MODEL, AND THAT COMPUTATIONAL

6184
03:32:01,596 --> 03:32:03,798
MODEL CAN THEN BE USED FOR

6185
03:32:03,798 --> 03:32:05,333
CLINICAL DECISION-MAKING.

6186
03:32:05,333 --> 03:32:09,938
AND YOU CAN DO THIS AT A

6187
03:32:09,938 --> 03:32:11,539
MACROSCOPIC SCALE, IF YOU'RE

6188
03:32:11,539 --> 03:32:12,173
DOING RESEARCH LIKE WE ARE, YOU

6189
03:32:12,173 --> 03:32:14,075
CAN ALSO DO THIS AT A

6190
03:32:14,075 --> 03:32:14,476
MICROSCOPIC SCALE.

6191
03:32:14,476 --> 03:32:16,478
SO WE DO THIS WITH RESEARCH

6192
03:32:16,478 --> 03:32:17,979
IMAGES, JUST AS MUCH AS WE DO IT

6193
03:32:17,979 --> 03:32:19,848
WITH CLINICAL IMAGES.

6194
03:32:19,848 --> 03:32:22,384
THE RESEARCH IMAGES ARE THERE

6195
03:32:22,384 --> 03:32:24,219
FOR, AT A SMALLER SCALE, SO

6196
03:32:24,219 --> 03:32:25,653
THESE PICTURES ON THE TOP ROW

6197
03:32:25,653 --> 03:32:28,156
ARE LOOKING AT BLOOD FLOW AND

6198
03:32:28,156 --> 03:32:32,927
OXYGEN T DI FAWTION IN THE DIFFE

6199
03:32:32,927 --> 03:32:34,763
PLACENTA, WHEREAS THE BOTTOM IS

6200
03:32:34,763 --> 03:32:36,164
MACROSCOPIC BASED ON ULTRASOUND,

6201
03:32:36,164 --> 03:32:37,499
BUT THE WORKFLOW IS THE SAME IN

6202
03:32:37,499 --> 03:32:38,700
BOTH OF THESE CASES.

6203
03:32:38,700 --> 03:32:39,567
IT'S TAKING PICTURE OF

6204
03:32:39,567 --> 03:32:41,069
SOMETHING, USING TO BUILD

6205
03:32:41,069 --> 03:32:43,505
COMPUTATIONAL MODELS, AND THOSE

6206
03:32:43,505 --> 03:32:45,040
COMPUTATIONAL MODELS ARE

6207
03:32:45,040 --> 03:32:45,874
PATIENT-SPECIFIC AND WE'RE

6208
03:32:45,874 --> 03:32:47,375
TRYING TO MAKE THEM AS REALTIME

6209
03:32:47,375 --> 03:32:48,943
AS POSSIBLE.

6210
03:32:48,943 --> 03:32:50,712
SO THEY CAN BE USED FOR

6211
03:32:50,712 --> 03:32:53,882
DIAGNOSTIC PURPOSES.

6212
03:32:53,882 --> 03:32:55,850
SO AS I SAID, WE SPEND A LOT OF

6213
03:32:55,850 --> 03:32:56,718
TIME WORKING ON PLACENTAL

6214
03:32:56,718 --> 03:32:57,385
TRANSPORT.

6215
03:32:57,385 --> 03:32:59,120
WE'VE BEEN BUILDING DIGITAL

6216
03:32:59,120 --> 03:33:01,656
TWINS OF THE PLACENTA AND I LIKE

6217
03:33:01,656 --> 03:33:02,857
TO POINT OUT THAT A DIGITAL TWIN

6218
03:33:02,857 --> 03:33:07,028
IS A VERY SPECIFIC TYPE OF

6219
03:33:07,028 --> 03:33:07,996
COMPUTATIONAL MODEL.

6220
03:33:07,996 --> 03:33:09,631
THIS IS WHERE YOU CAN TAKE

6221
03:33:09,631 --> 03:33:10,832
INFORMATION FLOW GOING BACK AND

6222
03:33:10,832 --> 03:33:12,167
FORTH BETWEEN THE PATIENT AND

6223
03:33:12,167 --> 03:33:13,034
THE MODEL.

6224
03:33:13,034 --> 03:33:15,403
SO THIS IS PARTICULARLY

6225
03:33:15,403 --> 03:33:16,838
INTERESTING IN PREGNANCY, WHERE

6226
03:33:16,838 --> 03:33:18,807
YOU MATE DO REPEATED ULTRASOUNDS

6227
03:33:18,807 --> 03:33:22,210
ON A PERSON THROUGHOUT THE

6228
03:33:22,210 --> 03:33:23,078
PREGNANCY SUCH THAT YOU'RE

6229
03:33:23,078 --> 03:33:24,279
GETTING NEW INFORMATION THAT YOU

6230
03:33:24,279 --> 03:33:25,713
CAN FEEDBACK INTO THE MODEL, YOU

6231
03:33:25,713 --> 03:33:27,682
CAN RUN SCENARIOS AND THEN YOU

6232
03:33:27,682 --> 03:33:31,252
CAN USE THAT INFORMATION FROM

6233
03:33:31,252 --> 03:33:35,123
THOSE MODELING SCENARIOS TO

6234
03:33:35,123 --> 03:33:35,657
EFFECT PATIENT CARE.

6235
03:33:35,657 --> 03:33:36,858
SO I'M NOT GOING TO TALK ANY

6236
03:33:36,858 --> 03:33:38,326
MORE ABOUT THE PLACENTAL

6237
03:33:38,326 --> 03:33:38,726
TRANSPORT MODELS.

6238
03:33:38,726 --> 03:33:44,766
AIM GOINGI'M GOING TO FOCUS ON E

6239
03:33:44,766 --> 03:33:46,501
TRYING TO DO TO LOOK AT

6240
03:33:46,501 --> 03:33:47,368
C-SECTION SCARS.

6241
03:33:47,368 --> 03:33:49,137
SO C-SECTIONS ARE RISING ACROSS

6242
03:33:49,137 --> 03:33:50,004
THE WORLD, PARTICULARLY IN

6243
03:33:50,004 --> 03:33:51,206
DEVELOPED COUNTRIES, THEY'VE

6244
03:33:51,206 --> 03:33:53,274
BEEN VERY HIGH FOR A LONG TIME,

6245
03:33:53,274 --> 03:33:55,477
WELL OVER 30%, BUT THEY'RE GOING

6246
03:33:55,477 --> 03:33:57,545
UP IN DEVELOPING COUNTRIES AS

6247
03:33:57,545 --> 03:33:58,313
WELL.

6248
03:33:58,313 --> 03:33:59,514
SOME ANALYSIS HAS SHOWN THAT

6249
03:33:59,514 --> 03:34:01,816
ABOVE A C-SECTION RATE OF ABOUT

6250
03:34:01,816 --> 03:34:04,752
19%, YOU DO NOT GET ANY FURTHER

6251
03:34:04,752 --> 03:34:06,821
IMPROVEMENT IN MATERNAL

6252
03:34:06,821 --> 03:34:09,591
MORTALITY OR FETAL MORTALITY.

6253
03:34:09,591 --> 03:34:12,327
SO 19% LOOKS LIKE THIS.

6254
03:34:12,327 --> 03:34:13,862
THIS IS A MAP OF THE WORLD.

6255
03:34:13,862 --> 03:34:15,830
YELLOW IS 19%.

6256
03:34:15,830 --> 03:34:20,335
SO ANYWHERE THAT'S GREEN IS A

6257
03:34:20,335 --> 03:34:22,504
RATE OF C-SECTIONS BELOW 19%.

6258
03:34:22,504 --> 03:34:24,372
YOU COULD PROBABLY ARGUE THAT IN

6259
03:34:24,372 --> 03:34:25,473
MANY OF THOSE PLACES, THERE IS

6260
03:34:25,473 --> 03:34:26,875
AN OPPORTUNITY FOR DECREASING

6261
03:34:26,875 --> 03:34:29,377
MATERNAL MORTALITY BY DOING MORE

6262
03:34:29,377 --> 03:34:31,813
WITH C-SECTIONS, BUT IN OTHER

6263
03:34:31,813 --> 03:34:32,914
PLACES THAT ARE BRIGHT RED ON

6264
03:34:32,914 --> 03:34:36,384
THIS MAP, WHICH INDICATES OVER

6265
03:34:36,384 --> 03:34:40,421
50% OF BIRTHS ARE BY  C-SECTION,

6266
03:34:40,421 --> 03:34:42,423
THOSE ARE NOT IMPROVING MATERNAL

6267
03:34:42,423 --> 03:34:42,657
HEALTH.

6268
03:34:42,657 --> 03:34:44,425
AND THE PROBLEM IS THAT WHEN YOU

6269
03:34:44,425 --> 03:34:45,960
DO A C-SECTION, YOU ARE LEFT

6270
03:34:45,960 --> 03:34:47,929
WITH A SCAR, AND WHEN YOU ARE

6271
03:34:47,929 --> 03:34:50,231
LEFT WITH A SCAR, THERE IS RISK

6272
03:34:50,231 --> 03:34:52,700
OF BAD THINGS HAPPENING

6273
03:34:52,700 --> 03:34:53,601
SUBSEQUENTLY, ESPECIALLY BUT NOT

6274
03:34:53,601 --> 03:34:57,906
ONLY IN A LATER PREGNANCY.

6275
03:34:57,906 --> 03:35:00,608
SO YOU CAN HAVE AN ECTOPIC

6276
03:35:00,608 --> 03:35:01,309
C-SECTION SCAR PREGNANCY WHERE

6277
03:35:01,309 --> 03:35:03,444
IT IMPLANTS IN THE SCAR AND IS A

6278
03:35:03,444 --> 03:35:03,912
NON-VIABLE PREGNANCY.

6279
03:35:03,912 --> 03:35:05,980
CAN YOU HAVE PLACENTA ACCRETA,

6280
03:35:05,980 --> 03:35:08,650
WHICH IS WHEN THE PLACENTA IS

6281
03:35:08,650 --> 03:35:11,986
TOO INVASIVE AND YOU SEE

6282
03:35:11,986 --> 03:35:12,754
PROBLEMS AND COULD HAVE A CASE

6283
03:35:12,754 --> 03:35:15,156
WHERE YOU NEED TO DO A

6284
03:35:15,156 --> 03:35:16,124
HYSTERECTOMY AT DELIVERY, AND

6285
03:35:16,124 --> 03:35:17,458
YOU CAN HAVE UTERINE RUPTURE

6286
03:35:17,458 --> 03:35:18,893
FROM THE SCAR.

6287
03:35:18,893 --> 03:35:20,328
AND PART OF THE PROBLEM WITH A

6288
03:35:20,328 --> 03:35:21,629
SCAR IS THAT YOU OFTEN SEE IN

6289
03:35:21,629 --> 03:35:24,832
THE PICTURE ON THE RIGHT THERE A

6290
03:35:24,832 --> 03:35:26,334
DEFECT, WHERE YOU DON'T HAVE

6291
03:35:26,334 --> 03:35:28,603
FULL THICKNESS HEALING, AND FROM

6292
03:35:28,603 --> 03:35:29,837
AN ENGINEERING PERSPECTIVE, THAT

6293
03:35:29,837 --> 03:35:32,140
LOOKS LIKE A STRESS

6294
03:35:32,140 --> 03:35:33,775
CONCENTRATION, AND SO AN

6295
03:35:33,775 --> 03:35:34,909
INCREASED RISK OF FUTURE

6296
03:35:34,909 --> 03:35:37,946
RUPTURE.

6297
03:35:37,946 --> 03:35:39,147
SO WHAT WE'VE BEEN DOING WITH

6298
03:35:39,147 --> 03:35:41,549
OUR COLLABORATORS UP AT

6299
03:35:41,549 --> 03:35:42,951
COLUMBIA, THEY HAVE BEEN TAKING

6300
03:35:42,951 --> 03:35:45,153
GEOMETRICAL INFORMATION ABOUT

6301
03:35:45,153 --> 03:35:46,921
UTERUSES IN PREGNANT WOMEN, AND

6302
03:35:46,921 --> 03:35:48,790
THEY HAVE MADE THIS ALL OPEN

6303
03:35:48,790 --> 03:35:51,192
SOURCE.

6304
03:35:51,192 --> 03:35:54,362
SO ANYONE WHO WANTS TO BUILD A

6305
03:35:54,362 --> 03:35:56,097
COMPUTATIONAL MODEL OF THE

6306
03:35:56,097 --> 03:35:57,732
UTERUS CAN DOWNLOAD THIS

6307
03:35:57,732 --> 03:35:59,267
BEAUTIFUL DATASET THAT HAS ALL

6308
03:35:59,267 --> 03:36:00,602
THESE JE MET CAL PARAMETERS

6309
03:36:00,602 --> 03:36:02,337
THROUGHOUT THE ENTIRE PREGNANCY.

6310
03:36:02,337 --> 03:36:04,405
WE THEN TAKE THOSE GEOMETRICAL

6311
03:36:04,405 --> 03:36:07,609
PARAMETERS, TURN THEM INTO A

6312
03:36:07,609 --> 03:36:11,212
3-DIMENSDIMENSIONAL MODEL AND RN

6313
03:36:11,212 --> 03:36:13,081
SIMULATIONS BASED ON THAT.

6314
03:36:13,081 --> 03:36:15,583
SO WE STARTED OUT THIS PROJECT

6315
03:36:15,583 --> 03:36:18,786
WITH JUST SORT OF A HISTORICAL

6316
03:36:18,786 --> 03:36:19,754
FACT THAT THERE WAS A TIME WHEN

6317
03:36:19,754 --> 03:36:22,290
A LOT OF C-SECTION SCARS WENT UP

6318
03:36:22,290 --> 03:36:23,057
AND DOWN INSTEAD OF TRANSVERSE,

6319
03:36:23,057 --> 03:36:24,726
AND THE RISK OF RUPTURE OF THE

6320
03:36:24,726 --> 03:36:26,961
UTERUS WAS ACTUALLY GREATER.

6321
03:36:26,961 --> 03:36:28,396
SO WE THOUGHT, WELL, WE SHOULD

6322
03:36:28,396 --> 03:36:29,597
BE ABLE TO SHOW THAT THE

6323
03:36:29,597 --> 03:36:31,466
STRESSES ARE HIGHER IN THAT CASE

6324
03:36:31,466 --> 03:36:33,101
CASE, AND SURE ENOUGH, WE RUN

6325
03:36:33,101 --> 03:36:33,968
THE SIMULATIONS AND WE GET THAT

6326
03:36:33,968 --> 03:36:38,473
SORT OF PROOF OF CONCEPT.

6327
03:36:38,473 --> 03:36:39,874
SO THAT ENCOURAGES US TO

6328
03:36:39,874 --> 03:36:41,276
CONTINUE LOOKING AT THIS, AND IN

6329
03:36:41,276 --> 03:36:44,812
FACT, WHAT WE THEN DID WAS

6330
03:36:44,812 --> 03:36:46,014
MEASURE SOME OF THESE DEFECTS

6331
03:36:46,014 --> 03:36:47,882
AND ACTUALLY MODEL THE DEA FECT.

6332
03:36:47,882 --> 03:36:52,220
DEFECT.THE GRAPH ON THE RIGHT IS

6333
03:36:52,220 --> 03:36:53,021
SHOWING THE STRESS GOING ACROSS

6334
03:36:53,021 --> 03:36:54,889
THE SCAR FROM THE EDGE TO THE

6335
03:36:54,889 --> 03:36:57,959
CENTER, AND SO THE BLACK LINE

6336
03:36:57,959 --> 03:36:59,827
THAT JUST KIND OF GOES DOWNWARDS

6337
03:36:59,827 --> 03:37:01,162
IS WITH NO DEFECT.

6338
03:37:01,162 --> 03:37:03,131
THE RED LINE IS WITH A DEFECT.

6339
03:37:03,131 --> 03:37:05,733
SO IF YOU HAVE A C-SECTION SCAR

6340
03:37:05,733 --> 03:37:07,935
DEFECT, YOU CAN ACTUALLY HAVE

6341
03:37:07,935 --> 03:37:10,905
ABOUT A FACTOR OF 2 GREATER

6342
03:37:10,905 --> 03:37:12,774
STRESSES IN THAT DEFECTED

6343
03:37:12,774 --> 03:37:14,075
REGION, WHICH MEANS THAT'S A

6344
03:37:14,075 --> 03:37:18,780
PERSON WHO'S AT GREATER RISK OF

6345
03:37:18,780 --> 03:37:22,517
NOT JUST A UTE L UTERINE RUPTURT

6346
03:37:22,517 --> 03:37:24,152
IT TURNS OUT POSSIBLY PRETERM

6347
03:37:24,152 --> 03:37:24,585
BIRTH AS WELL.

6348
03:37:24,585 --> 03:37:26,454
SO BY LOOKING AT THIS IN

6349
03:37:26,454 --> 03:37:28,656
INDIVIDUAL PATIENTS, WE CAN DO

6350
03:37:28,656 --> 03:37:30,591
SOMETHING THAT'S CLINICALLY

6351
03:37:30,591 --> 03:37:33,094
RELEVANT IN TERMS OF PREDICTING

6352
03:37:33,094 --> 03:37:34,162
LONG TERM RISK.

6353
03:37:34,162 --> 03:37:36,464
SO IN FACT, WHAT WE'RE DOING NOW

6354
03:37:36,464 --> 03:37:38,766
IS WE'RE WORKING WITH THE GROUP

6355
03:37:38,766 --> 03:37:40,835
AT UNIVERSITY COLLEGE LONDON, SO

6356
03:37:40,835 --> 03:37:41,703
I SPENT A GREAT DEAL OF MY

6357
03:37:41,703 --> 03:37:43,905
CAREER OVER IN THE UK AT

6358
03:37:43,905 --> 03:37:46,207
CAMBRIDGE, SO I HAVE A LOT OF

6359
03:37:46,207 --> 03:37:47,075
COLLABORATORS STILL OVER THERE.

6360
03:37:47,075 --> 03:37:49,610
THEY HAVE BEEN DOING AN ENTIRE

6361
03:37:49,610 --> 03:37:51,012
PROGRAM OF JUST MEASURING

6362
03:37:51,012 --> 03:37:54,649
C-SECTION SCARS AND SCAR

6363
03:37:54,649 --> 03:37:54,882
DEFECTS.

6364
03:37:54,882 --> 03:37:56,284
SO THEY HAVE BEEN COLLECTING A

6365
03:37:56,284 --> 03:37:57,885
LOT OF THIS ANATOMICAL DATA

6366
03:37:57,885 --> 03:38:00,455
ABOUT THE NATURE OF THESE SCARS,

6367
03:38:00,455 --> 03:38:03,091
AND ABOUT HOW THESE SCAR DEFECTS

6368
03:38:03,091 --> 03:38:06,227
ARE PRESENT IN SOME OF THEIR

6369
03:38:06,227 --> 03:38:07,562
PATIENTS, AND THEN THEY COLLECT

6370
03:38:07,562 --> 03:38:09,397
INFORMATION ON CLINICAL OUTCOMES

6371
03:38:09,397 --> 03:38:12,467
INCLUDING PRETERM BIRTH AND ANY

6372
03:38:12,467 --> 03:38:13,234
OTHER COMPLICATIONS THAT THEY

6373
03:38:13,234 --> 03:38:14,569
SEE IN THE PREGNANCY.

6374
03:38:14,569 --> 03:38:15,970
AND SO AT THE MOMENT, WHERE WE

6375
03:38:15,970 --> 03:38:17,538
ARE WITH THIS PROJECT, THIS IS

6376
03:38:17,538 --> 03:38:20,508
ONLY ABOUT A YEAR OLD PROJECT,

6377
03:38:20,508 --> 03:38:22,043
AND SO RIGHT NOW THEY'RE FEEDING

6378
03:38:22,043 --> 03:38:23,644
US ALL OF THE INFORMATION ABOUT

6379
03:38:23,644 --> 03:38:25,413
THESE C-SECTION SCARS SO IT

6380
03:38:25,413 --> 03:38:27,382
BASICALLY IN THE FORM OF A

6381
03:38:27,382 --> 03:38:29,584
RETROSPECTIVE STUDY WHERE WE CAN

6382
03:38:29,584 --> 03:38:32,520
THEN SAY TRY TO CLASSIFY THE

6383
03:38:32,520 --> 03:38:34,722
RISK IN THESE PATIENTS FOR WHICH

6384
03:38:34,722 --> 03:38:37,291
THEY HAVE THE CLINICAL DATA AND

6385
03:38:37,291 --> 03:38:39,093
CAN COMPARE THAT AGAINST WHAT

6386
03:38:39,093 --> 03:38:41,963
WE'VE BEEN GETTING.

6387
03:38:41,963 --> 03:38:43,831
SO WITH THE MEASUREMENTS THAT WE

6388
03:38:43,831 --> 03:38:46,033
HAVE, IN FACT, WE CAN TRACK HOW

6389
03:38:46,033 --> 03:38:47,869
THAT C-SECTION SCAR LOOKS

6390
03:38:47,869 --> 03:38:49,637
THROUGHOUT THE PREGNANCY,

6391
03:38:49,637 --> 03:38:51,272
BECAUSE THIS BASELINE DATASET

6392
03:38:51,272 --> 03:38:53,374
FROM OUR COLLABORATORS AT

6393
03:38:53,374 --> 03:38:55,877
COLUMBIA, YOU CAN SEE THESE

6394
03:38:55,877 --> 03:38:56,411
INDIVIDUAL PARAMETERS AS A

6395
03:38:56,411 --> 03:38:58,980
FUNCTION OF GESTATIONAL AGE.

6396
03:38:58,980 --> 03:39:00,281
FIRST OF ALL, THE STANDARD

6397
03:39:00,281 --> 03:39:01,916
DEVIATIONS ARE QUITE SMALL, SO A

6398
03:39:01,916 --> 03:39:03,785
UTERUS KIND OF IS THE SAME SIZE

6399
03:39:03,785 --> 03:39:06,220
AND SHAPE AS IT GETS BIGGER

6400
03:39:06,220 --> 03:39:07,955
DURING PREGNANCY ACROSS A LARGE

6401
03:39:07,955 --> 03:39:10,158
POPULATION OF PEOPLE, AND THESE

6402
03:39:10,158 --> 03:39:12,660
NUMBERS SEEM TO VARY RELATIVELY

6403
03:39:12,660 --> 03:39:14,328
SMOOTHLY SUCH THAT WE CAN

6404
03:39:14,328 --> 03:39:17,298
BASICALLY MAP OUT AN AVERAGE

6405
03:39:17,298 --> 03:39:19,834
SECOND TRIMESTER PLACENTA AT

6406
03:39:19,834 --> 03:39:21,102
THIS MANY WEEKS GESTATION VERSUS

6407
03:39:21,102 --> 03:39:23,070
LOOK AT A THIRD TRIMESTER ONE AT

6408
03:39:23,070 --> 03:39:25,473
THIS MANY WEEKS GESTATION,

6409
03:39:25,473 --> 03:39:26,140
KNOWING WHAT WE KNOW ABOUT THE

6410
03:39:26,140 --> 03:39:27,809
C-SECTION AND THE C-SECTION SCAR

6411
03:39:27,809 --> 03:39:31,112
AND SCAR DEA FECT.

6412
03:39:31,112 --> 03:39:31,345
 DEFECT.

6413
03:39:31,345 --> 03:39:32,647
WE CAN PUT THOSE INTO OUR MODEL

6414
03:39:32,647 --> 03:39:36,684
FOR NIECE PATIENT-SPECIF THESE C

6415
03:39:36,684 --> 03:39:37,018
SIMULATIONS.

6416
03:39:37,018 --> 03:39:38,786
SO WE ARE VERY INTERESTED IN HOW

6417
03:39:38,786 --> 03:39:40,755
THIS KIND OF INTERDISCIPLINARY

6418
03:39:40,755 --> 03:39:45,026
LAB RANGE OF MCOLLABORATION COUT

6419
03:39:45,026 --> 03:39:46,127
OB-GYN BECAUSE THIS HAS BEEN BIG

6420
03:39:46,127 --> 03:39:49,197
IN OTHER FIELDS, AS I SAID, I

6421
03:39:49,197 --> 03:39:50,631
CAME FROM AN ORTHOPEDICS

6422
03:39:50,631 --> 03:39:51,799
BACKGROUND BUT THERE'S ALSO BEEN

6423
03:39:51,799 --> 03:39:53,601
A LONG HISTORY OF BIOENGINEERING

6424
03:39:53,601 --> 03:39:55,002
COLLABORATION IN CANCER

6425
03:39:55,002 --> 03:39:58,873
RESEARCH, IN CARDIOVASCULAR

6426
03:39:58,873 --> 03:39:59,373
RESEARCH, NEUROSCIENCE.

6427
03:39:59,373 --> 03:40:01,909
I COULD GO ON AND ON.

6428
03:40:01,909 --> 03:40:06,280
BUT OB-GYN HAS HISTORICALLY NOT

6429
03:40:06,280 --> 03:40:08,182
HAD THIS MUCH OF A COLLABORATION

6430
03:40:08,182 --> 03:40:08,950
WITH ENGINEERING AND WE BELIEVE

6431
03:40:08,950 --> 03:40:10,685
THERE ARE A LOT OF OPPORTUNITIES

6432
03:40:10,685 --> 03:40:12,019
HERE, BOTH IN VITRO AND IN

6433
03:40:12,019 --> 03:40:12,587
SILICO.

6434
03:40:12,587 --> 03:40:16,390
WE NEED TRAINING DATASETS FOR

6435
03:40:16,390 --> 03:40:19,227
MACHINE LEARNING.

6436
03:40:19,227 --> 03:40:21,362
SO MIDRC WAS MENTIONED EARLIER

6437
03:40:21,362 --> 03:40:23,397
BY THE NIBIB DIRECTOR.

6438
03:40:23,397 --> 03:40:26,801
THERE ARE NOT OBSTETRICAL OR

6439
03:40:26,801 --> 03:40:27,869
GYNECOLOGICAL ULTRASOUNDS IN

6440
03:40:27,869 --> 03:40:28,202
THAT DATASET.

6441
03:40:28,202 --> 03:40:30,004
THERE IS NO CLINICALLY AVAILABLE

6442
03:40:30,004 --> 03:40:33,407
OR ENGINEERING AVAILABLE DATASET

6443
03:40:33,407 --> 03:40:37,345
OF TRAINING IMAGES BECAUSE

6444
03:40:37,345 --> 03:40:39,213
OB-GYN ULTRASOUND IMAGING IS

6445
03:40:39,213 --> 03:40:40,615
DIVORCED FROM THE REST OF

6446
03:40:40,615 --> 03:40:40,948
RADIOLOGY.

6447
03:40:40,948 --> 03:40:43,150
IT'S DONE IN OB-GYN CLINICS.

6448
03:40:43,150 --> 03:40:44,218
SO THIS IS A RESOURCE THAT IN

6449
03:40:44,218 --> 03:40:45,453
ORDER TO GET WOMEN'S HEALTH UP

6450
03:40:45,453 --> 03:40:47,788
TO SPEED WITH THE REST OF

6451
03:40:47,788 --> 03:40:49,857
MEDICINE, WITH THE EXPANSION IN

6452
03:40:49,857 --> 03:40:51,726
A.I. AND MACHINE LEARNING, WE

6453
03:40:51,726 --> 03:40:53,895
NEED THESE SORTS OF OPEN SOURCE

6454
03:40:53,895 --> 03:40:54,996
TRAINING DATASET THAT ARE

6455
03:40:54,996 --> 03:40:58,733
AVAILABLE TO THE RESEARCH

6456
03:40:58,733 --> 03:40:59,166
COMMUNITY.

6457
03:40:59,166 --> 03:41:01,235
WE ALSO NEED A MECHANISM TO

6458
03:41:01,235 --> 03:41:03,871
HARNESS ETHICALLY THE BIG DATA

6459
03:41:03,871 --> 03:41:04,772
NATURAL EXPERIMENTS THAT ARE

6460
03:41:04,772 --> 03:41:06,274
HAPPENING IN WOMEN'S HEALTH.

6461
03:41:06,274 --> 03:41:08,476
MILLIONS OF WOMEN ARE PREGNANT

6462
03:41:08,476 --> 03:41:09,477
EVERY YEAR.

6463
03:41:09,477 --> 03:41:10,778
THERE'S A LOT OF DATA OUT THERE.

6464
03:41:10,778 --> 03:41:12,213
IF YOU'RE IN SCANDINAVIA, YOU

6465
03:41:12,213 --> 03:41:16,484
MIGHT HAVE ACCESS TO THE ENTIRE

6466
03:41:16,484 --> 03:41:17,785
COUNTRY'S DATABASE OF ELECTRONIC

6467
03:41:17,785 --> 03:41:18,152
HEALTH RECORDS.

6468
03:41:18,152 --> 03:41:19,053
WE DON'T HAVE ANYTHING LIKE THAT

6469
03:41:19,053 --> 03:41:19,453
HERE.

6470
03:41:19,453 --> 03:41:20,721
WE NEED TO FIGURE OUT HOW TO

6471
03:41:20,721 --> 03:41:22,657
COME UP WITH THAT SORT OF DATA,

6472
03:41:22,657 --> 03:41:25,927
SO WE CAN USE MACHINE LEARNING

6473
03:41:25,927 --> 03:41:27,795
AND BIOSTATISTICAL METHODS.

6474
03:41:27,795 --> 03:41:30,665
WE NEED GOOD HUMAN CELL SOURCES

6475
03:41:30,665 --> 03:41:32,967
AND CONSISTENT TISSUE SCAFFOLDS

6476
03:41:32,967 --> 03:41:34,168
FOR IN VITRO STUDIES.

6477
03:41:34,168 --> 03:41:35,703
I WON'T BELABOR THAT POINT SINCE

6478
03:41:35,703 --> 03:41:36,904
IT'S BEEN MADE ALREADY.

6479
03:41:36,904 --> 03:41:39,140
AND FINALLY, THE LAST POINT THAT

6480
03:41:39,140 --> 03:41:43,277
I WANT TO MAKE BEFORE I FINISH

6481
03:41:43,277 --> 03:41:45,012
IS THAT WE STILL NEED MORE

6482
03:41:45,012 --> 03:41:45,780
MECHANISTIC UNDERSTANDING.

6483
03:41:45,780 --> 03:41:47,882
IT SEEMS AS THOUGH THERE'S BUN A

6484
03:41:47,882 --> 03:41:50,051
LOT OF PUSH RECENTLY, INCLUDING

6485
03:41:50,051 --> 03:41:52,687
THE RADX PROGRAM, FOR GETTING

6486
03:41:52,687 --> 03:41:53,254
PATIENT-CENTERED DEVICES OUT

6487
03:41:53,254 --> 03:41:55,756
THERE AND DOING DIAGNOSTICS AND

6488
03:41:55,756 --> 03:41:56,958
END-STAGE THINGS, BUT WE DON'T

6489
03:41:56,958 --> 03:41:58,826
HAVE THE UNDERLYING

6490
03:41:58,826 --> 03:42:00,061
UNDERSTANDING OF MECHANISM IN A

6491
03:42:00,061 --> 03:42:03,331
LOT OF THESE CASES.

6492
03:42:03,331 --> 03:42:05,199
OTHERWISE THE PRETERM BIRTH RATE

6493
03:42:05,199 --> 03:42:06,934
WOULD HAVE BEEN STATIONARY AT

6494
03:42:06,934 --> 03:42:09,036
10% FOR SO MANY DECADES.

6495
03:42:09,036 --> 03:42:12,306
AND SO WE NEED TO BE ABLE TO USE

6496
03:42:12,306 --> 03:42:13,307
ENGINEERING METHODS AND OTHER

6497
03:42:13,307 --> 03:42:16,243
METHODS TO OH FOCUS OP GETTING

6498
03:42:16,243 --> 03:42:18,579
THE UNDERLYING UNDERSTANDING NOT

6499
03:42:18,579 --> 03:42:20,748
JUST THE NEW DEVICES TO TREAT

6500
03:42:20,748 --> 03:42:22,717
DISEASES OR TO DIAGNOSE DISEASES

6501
03:42:22,717 --> 03:42:24,051
THAT WE DON'T REALLY UNDERSTAND

6502
03:42:24,051 --> 03:42:27,388
WHAT THEY'RE DOING.

6503
03:42:27,388 --> 03:42:28,522
SO WITH THAT, I'LL THANK YOU

6504
03:42:28,522 --> 03:42:29,457
VERY MUCH.

6505
03:42:29,457 --> 03:42:31,525
JUST AS AN AMUSING POINT, I

6506
03:42:31,525 --> 03:42:34,195
SHOULD RUN OUT THAT I RUN AN

6507
03:42:34,195 --> 03:42:36,697
ALMOST ENTIRELY FEMALE-RUN

6508
03:42:36,697 --> 03:42:37,098
ENGINEERING GROUP.

6509
03:42:37,098 --> 03:42:38,366
WOMEN FLOCK TO THIS SORT OF

6510
03:42:38,366 --> 03:42:39,900
RESEARCH, AND I TAUGHT THE

6511
03:42:39,900 --> 03:42:43,004
FIRST-EVER COURSE THIS PAST

6512
03:42:43,004 --> 03:42:44,405
SPRING ON ENGINEERING IN WOMEN'S

6513
03:42:44,405 --> 03:42:46,841
HEALTH COVERING REPRODUCTIVE AND

6514
03:42:46,841 --> 03:42:47,608
NON-REPRODUCTIVE DISEASES AND

6515
03:42:47,608 --> 03:42:49,610
HAD ALMOST 50 ENGINEERING

6516
03:42:49,610 --> 03:42:50,911
STUDENTS, ALMOST ALL FEMALE.

6517
03:42:50,911 --> 03:42:52,546
SO WITH THAT, I WILL STOP AND

6518
03:42:52,546 --> 03:42:53,681
HAND IT OVER.

6519
03:42:53,681 --> 03:42:54,348
THANK YOU.

6520
03:42:54,348 --> 03:43:04,525
[APPLAUSE]

6521
03:43:09,096 --> 03:43:09,764
>> THANK YOU SO MUCH FOR
THE

6522
03:43:09,764 --> 03:43:10,765
OPPORTUNITY TO SPEAK TO ALL OF

6523
03:43:10,765 --> 03:43:11,198
YOU.

6524
03:43:11,198 --> 03:43:14,168
I LOVE GOING AFTER JULIAN

6525
03:43:14,168 --> 03:43:15,569
MICHELLE BECAUSE IT GIVES ME A

6526
03:43:15,569 --> 03:43:16,470
LOT OF HOPE.

6527
03:43:16,470 --> 03:43:17,772
IT GETS ME EXCITED ABOUT

6528
03:43:17,772 --> 03:43:19,674
RESEARCH HAPPENING IN WOMEN'S

6529
03:43:19,674 --> 03:43:20,241
HEALTH AND THAT'S NECESSARY

6530
03:43:20,241 --> 03:43:21,642
BECAUSE WHEN WE STARTED TOWN

6531
03:43:21,642 --> 03:43:23,477
THIS PATH OF LOOKING AT

6532
03:43:23,477 --> 03:43:25,813
MENSTRUATION AS A NOVEL SAMPLE

6533
03:43:25,813 --> 03:43:30,184
TYPE FOR MOLECULAR PROFILING IN

6534
03:43:30,184 --> 03:43:31,585
2013, THE LANDSCAPE WAS VERY

6535
03:43:31,585 --> 03:43:31,852
DIFFERENT.

6536
03:43:31,852 --> 03:43:34,689
I WILL TELL YOU THAT I WENT TO

6537
03:43:34,689 --> 03:43:36,557
MEETINGS WHERE MALE INVESTORS

6538
03:43:36,557 --> 03:43:37,858
WOULD NOT MAKE EYE CONTACT WITH

6539
03:43:37,858 --> 03:43:39,493
ME AND THEY WOULD ACTUALLY LOOK

6540
03:43:39,493 --> 03:43:40,928
TO MY MALE CO-FOUNDER TO TALK

6541
03:43:40,928 --> 03:43:42,697
ABOUT THE LIVED EXPERIENCE OF

6542
03:43:42,697 --> 03:43:43,597
MENSTRUATION, WHICH I THOUGHT

6543
03:43:43,597 --> 03:43:47,535
WAS VERY AMUSING.

6544
03:43:47,535 --> 03:43:48,969
BECAUSE HE WAS ILL-EQUIPPED TO

6545
03:43:48,969 --> 03:43:51,806
ANSWER THOSE QUESTIONS.

6546
03:43:51,806 --> 03:43:53,007
AS WELL AS THEY WOULDN'T SAY THE

6547
03:43:53,007 --> 03:43:55,009
WORD MENSTRUATION, THEY ACTUALLY

6548
03:43:55,009 --> 03:43:57,311
USED EUPHEMISMS SUCH AS "THAT

6549
03:43:57,311 --> 03:44:00,815
TIME OF A MONTH" THAT A WOMAN

6550
03:44:00,815 --> 03:44:02,049
DOES WHATEVER IT IS THAT SHE

6551
03:44:02,049 --> 03:44:03,584
DOES, WHICH MADE ME QUESTION IF

6552
03:44:03,584 --> 03:44:05,419
THEY ACTUALLY KNEW WHAT A WOMAN

6553
03:44:05,419 --> 03:44:07,354
DOES AT THAT TIME OF THE MONTH.

6554
03:44:07,354 --> 03:44:08,856
WE ADVANCED BEYOND THAT.

6555
03:44:08,856 --> 03:44:10,291
THE NEXT CHALLENGE WE FACED WAS

6556
03:44:10,291 --> 03:44:11,592
WHEN WE TRANSITIONED OUR WORK

6557
03:44:11,592 --> 03:44:12,460
SPECIFICALLY TO LOOK AT

6558
03:44:12,460 --> 03:44:18,733
ENDOMETRIOSIS IN 2016, A LOT OF

6559
03:44:18,733 --> 03:44:19,266
PEOPLE COULDN'T PRONOUNCE

6560
03:44:19,266 --> 03:44:21,802
ENDOMETRIOSIS SO WE JUST KEEP

6561
03:44:21,802 --> 03:44:23,504
TACKLING THESE CHALLENGES AND

6562
03:44:23,504 --> 03:44:24,805
THE LANDSCAPE KEEPS GETTING

6563
03:44:24,805 --> 03:44:26,474
BETTER AND BETTER SO IT'S VERY

6564
03:44:26,474 --> 03:44:27,108
EXCITING.  I WANT TO SHARE WITH

6565
03:44:27,108 --> 03:44:28,209
YOU THIS DIAGNOSTIC PLATFORM

6566
03:44:28,209 --> 03:44:30,111
WE'VE BEEN BUILDING FOR THE PAST

6567
03:44:30,111 --> 03:44:32,513
DECADE, AND SOME OF THE SORT OF

6568
03:44:32,513 --> 03:44:34,715
CORE HYPOTHESES WE'VE BUILT IT

6569
03:44:34,715 --> 03:44:36,050
ON THE DATA WE'VE GENERATED AND

6570
03:44:36,050 --> 03:44:37,251
MOST IMPORTANTLY THE CHALLENGES

6571
03:44:37,251 --> 03:44:37,918
WE HAVE FACED AND CONTINUE TO

6572
03:44:37,918 --> 03:44:40,020
FACE AND HOPE TO HAVE

6573
03:44:40,020 --> 03:44:42,089
INTERDISCIPLINARY APPROACHES TO

6574
03:44:42,089 --> 03:44:43,090
TACKLE.

6575
03:44:43,090 --> 03:44:45,059
SO I'LL START WITH THIS SLIDE

6576
03:44:45,059 --> 03:44:46,594
BECAUSE THE CORE THESIS OF OUR

6577
03:44:46,594 --> 03:44:47,695
COMPANY REALLY IS THAT THE

6578
03:44:47,695 --> 03:44:50,030
UTERUS IS AN EXQUISITELY

6579
03:44:50,030 --> 03:44:51,899
SENSITIVE AND RESPONSIVE ORGAN

6580
03:44:51,899 --> 03:44:53,300
THAT ESSENTIALLY TAKES ALL OF

6581
03:44:53,300 --> 03:44:56,637
ITS MARCHING ORDERS FROM A

6582
03:44:56,637 --> 03:44:58,038
BEAUTIFULLY COORDINATED HORMONAL

6583
03:44:58,038 --> 03:44:58,372
CASCADE.

6584
03:44:58,372 --> 03:45:00,341
WHEN TO GROW, WHEN TO SHED, WHEN

6585
03:45:00,341 --> 03:45:01,475
TO BECOME PLACENTA.

6586
03:45:01,475 --> 03:45:02,777
SO ANYTHING -- ANY HORMONAL

6587
03:45:02,777 --> 03:45:04,979
CHANGE, NO MATTER HOW SUBTLE

6588
03:45:04,979 --> 03:45:06,180
HAPPENS, IT SHOULD SHOW UP IN

6589
03:45:06,180 --> 03:45:08,716
THE UTERINE LINING THAT'S SHED

6590
03:45:08,716 --> 03:45:10,251
EVERY SINGLE MONTH IF YOU ARE

6591
03:45:10,251 --> 03:45:17,158
ACTUALLY PROFILING IT A AT A VEY

6592
03:45:17,158 --> 03:45:17,725
GRANULAR LEVEL.

6593
03:45:17,725 --> 03:45:20,795
THTHE GREAT THING ABOUT IT IS IF

6594
03:45:20,795 --> 03:45:21,896
YOU BELIEVE THESE MOLECULAR

6595
03:45:21,896 --> 03:45:23,330
CHANGES ARE DETECTABLE, EVEN IF

6596
03:45:23,330 --> 03:45:24,532
THEY'RE VERY SMALL, YOU CAN

6597
03:45:24,532 --> 03:45:26,467
ACCESS THEM THROUGH MENSTRUAL

6598
03:45:26,467 --> 03:45:27,935
BLOOD BECAUSE THERE IS THIS VERY

6599
03:45:27,935 --> 03:45:29,370
REGULAR NATURAL BIOPSY THAT IS

6600
03:45:29,370 --> 03:45:31,906
PRODUCED EVERY SINGLE MONTH FOR

6601
03:45:31,906 --> 03:45:34,208
DECADES IN FEMALE-BORN BODIES.

6602
03:45:34,208 --> 03:45:36,544
SO IF YOU CAN SIMPLIFY AND

6603
03:45:36,544 --> 03:45:39,513
CREATE AN ELEGANT WAY TO COLLECT

6604
03:45:39,513 --> 03:45:40,514
IT AND THEN STANDARDIZE HOW DO

6605
03:45:40,514 --> 03:45:42,683
YOU ACTUALLY GENERATE THESE AND

6606
03:45:42,683 --> 03:45:44,018
CHARACTERIZE THESE UTERINE

6607
03:45:44,018 --> 03:45:45,186
PROFILES, YOU MIGHT BE ABLE TO

6608
03:45:45,186 --> 03:45:46,453
DO SOMETHING PROFOUND.

6609
03:45:46,453 --> 03:45:48,522
AND THEN AGAIN, THE CONTEXT IS,

6610
03:45:48,522 --> 03:45:51,125
IS THAT IF THERE ARE SHIFTS IN

6611
03:45:51,125 --> 03:45:51,826
HORMONE PROFILE, WHETHER IT IS

6612
03:45:51,826 --> 03:45:54,328
YOU'RE LOOKING AT AN

6613
03:45:54,328 --> 03:45:54,929
ESTROGEN-DOMINANT DISEASE LIKE

6614
03:45:54,929 --> 03:45:57,331
ENDOMETRIOSIS OR YOU'RE LOOKING

6615
03:45:57,331 --> 03:45:59,266
AT PCOS, THAT YOU SHOULD NOTICE

6616
03:45:59,266 --> 03:46:02,436
A DIFFERENT UTERINE RESPONSE.

6617
03:46:02,436 --> 03:46:04,538
ALL OF THIS IS SORT OF BASED ON

6618
03:46:04,538 --> 03:46:07,508
WHAT I CALL ALARMINGLY MUNDANE

6619
03:46:07,508 --> 03:46:09,443
PROCESSES, WHICH IS HOW DO YOU

6620
03:46:09,443 --> 03:46:10,511
STANDARDIZE ALL OF THIS?

6621
03:46:10,511 --> 03:46:12,346
HOW DO YOU STANDARDIZE SAMPLE

6622
03:46:12,346 --> 03:46:13,347
COLLECTION?

6623
03:46:13,347 --> 03:46:14,748
WHAT TAMPON DO YOU USE?

6624
03:46:14,748 --> 03:46:17,318
AND YOU SAW PEOPLE USING PADS,

6625
03:46:17,318 --> 03:46:19,720
PEOPLE HAVE USED MENSTRUAL CUPS.

6626
03:46:19,720 --> 03:46:22,256
WHAT PLATFORMS ARE YOU ACTUALLY

6627
03:46:22,256 --> 03:46:23,023
RUNNING ON THE SAMPLES THAT YOU

6628
03:46:23,023 --> 03:46:23,424
COLLECT?

6629
03:46:23,424 --> 03:46:24,692
ARE YOU DOING SEQUENCING, ARE

6630
03:46:24,692 --> 03:46:26,760
YOU DOING PROTEOMICS?

6631
03:46:26,760 --> 03:46:27,328
WHAT ARE YOU LOOKING AT?

6632
03:46:27,328 --> 03:46:28,762
AND THEN HOW ARE YOU THINKING

6633
03:46:28,762 --> 03:46:31,966
ABOUT THE DATA ANALYTIC AND

6634
03:46:31,966 --> 03:46:32,833
BIOINFORMATIC PIPELINES?

6635
03:46:32,833 --> 03:46:34,235
I WILL GET INTO ALL OF THOSE

6636
03:46:34,235 --> 03:46:36,770
THINGS BUT, YOU KNOW, THE

6637
03:46:36,770 --> 03:46:38,138
NEAR-TERM GOAL FOR US THAT WE

6638
03:46:38,138 --> 03:46:39,440
REALLY HAVE SPENT A LOT OF TIME

6639
03:46:39,440 --> 03:46:42,376
LOOKING AT IS, CAN YOU ACTUALLY

6640
03:46:42,376 --> 03:46:44,945
FIND A PREDICTION BLI ALTERED

6641
03:46:44,945 --> 03:46:45,479
UTERINE RESPONSE TO

6642
03:46:45,479 --> 03:46:45,913
ENDOMETRIOSIS?

6643
03:46:45,913 --> 03:46:47,648
SO THIS WAS WORK THAT WE STARTED

6644
03:46:47,648 --> 03:46:49,283
IN 2016 WHEN WE COLLECTED OUR

6645
03:46:49,283 --> 03:46:50,451
FIRST TAMPONS FROM INDIVIDUALS

6646
03:46:50,451 --> 03:46:51,218
WHO HAD ENDOMETRIOSIS AND

6647
03:46:51,218 --> 03:46:52,753
COMPARED THEM TO HEALTHY

6648
03:46:52,753 --> 03:46:53,254
CONTROLS.

6649
03:46:53,254 --> 03:46:55,789
WE USED THAT DATA TO GET OUR

6650
03:46:55,789 --> 03:46:59,894
FIRST NIH SBIR OF $1.8 MILLION

6651
03:46:59,894 --> 03:47:02,863
THAT REALLY FUELED A LOT OF OUR

6652
03:47:02,863 --> 03:47:04,298
VALIDATION STUDIES, SO THEN WE

6653
03:47:04,298 --> 03:47:07,801
TOOK THE INITIAL SIGNAL WE

6654
03:47:07,801 --> 03:47:09,770
FOUND, WE VALIDATED IT IN AN

6655
03:47:09,770 --> 03:47:10,838
INDEPENDENT DATASET AND NOW

6656
03:47:10,838 --> 03:47:12,539
WE'RE LOOKING AT HOW WELL THIS

6657
03:47:12,539 --> 03:47:15,042
CLASSIFIER WORKS IN INFERTILITY

6658
03:47:15,042 --> 03:47:16,677
POPULATIONS SPECIFICALLY.

6659
03:47:16,677 --> 03:47:19,813
I WANT TO MENTION AS YOU GUYS

6660
03:47:19,813 --> 03:47:21,482
KNOW, A LOT OF CLINICIANS AND

6661
03:47:21,482 --> 03:47:22,650
SCIENTISTS IN THE ROOM ARE VERY

6662
03:47:22,650 --> 03:47:24,118
FAMILIAR WITH THIS CONDITION.

6663
03:47:24,118 --> 03:47:25,319
IT'S EXTREMELY COMPLEX.

6664
03:47:25,319 --> 03:47:27,221
IT HAS A LOT OF COMORBIDITIES.

6665
03:47:27,221 --> 03:47:28,522
PEOPLE WHO HAVE ENDOMETRIOSIS

6666
03:47:28,522 --> 03:47:30,491
OFTEN HAVE INFERTILITY, THEY

6667
03:47:30,491 --> 03:47:32,159
ALSO OFTEN HAVE AUTOIMMUNE

6668
03:47:32,159 --> 03:47:34,561
CONDITIONS, IBS, ET CETERA, SO

6669
03:47:34,561 --> 03:47:37,231
PATIENTS WILL COME TO CLINICIANS

6670
03:47:37,231 --> 03:47:39,533
WITH A VERY GENERIC SET OF

6671
03:47:39,533 --> 03:47:39,967
SYMPTOMS.

6672
03:47:39,967 --> 03:47:41,702
AND SO A LOT OF THE DIAGNOSIS,

6673
03:47:41,702 --> 03:47:43,671
IF IT DRIVEN BY PATIENTS

6674
03:47:43,671 --> 03:47:46,240
RECOGNIZING THEIR SYMPTOMS, IT'S

6675
03:47:46,240 --> 03:47:47,675
SORT OF INHERENTLY SUBJECTIVE.

6676
03:47:47,675 --> 03:47:49,777
IS MY BLEEDING, IS MY MENSTRUAL

6677
03:47:49,777 --> 03:47:50,411
BLEEDING ACTUALLY HEAVY?

6678
03:47:50,411 --> 03:47:50,878
I DON'T KNOW.

6679
03:47:50,878 --> 03:47:52,179
IS THERE SOME SORT OF STANDARD

6680
03:47:52,179 --> 03:47:54,381
THAT'S BEEN RELEASED SOMEWHERE?

6681
03:47:54,381 --> 03:47:57,584
IS MY BLEEDING -- IS THIS PAIN

6682
03:47:57,584 --> 03:47:58,986
THAT I'M EXPERIENCING

6683
03:47:58,986 --> 03:48:00,321
CYCLICICALLY, IS THIS REALLY

6684
03:48:00,321 --> 03:48:01,455
EXTREME OR IS THIS JUST WHAT

6685
03:48:01,455 --> 03:48:02,523
EVERYONE EXPERIENCES ON A

6686
03:48:02,523 --> 03:48:03,190
MONTHLY BASIS?

6687
03:48:03,190 --> 03:48:05,492
SO THERE'S JUST SO MUCH INHERENT

6688
03:48:05,492 --> 03:48:06,827
SUBJECTIVITY IN THE PATIENT

6689
03:48:06,827 --> 03:48:08,896
EXPERIENCE, THAT ADDS TO THE

6690
03:48:08,896 --> 03:48:09,997
CONFUSION AND DIAGNOSIS.

6691
03:48:09,997 --> 03:48:11,532
FIRST LINE OF DEFENSE,

6692
03:48:11,532 --> 03:48:13,334
ESPECIALLY IF YOU ARE A

6693
03:48:13,334 --> 03:48:15,602
TEENAGER, AND YOU'RE GOING TO A

6694
03:48:15,602 --> 03:48:17,471
PEDIATRICIAN OR A GP, IS NOT

6695
03:48:17,471 --> 03:48:20,240
GOING TO BE SOMEONE WHO HAS THE

6696
03:48:20,240 --> 03:48:21,108
TOOL SET TO ACTUALLY MAKE THE

6697
03:48:21,108 --> 03:48:22,443
DIAGNOSIS IMMEDIATELY, RIGHT?

6698
03:48:22,443 --> 03:48:26,914
THIS TAKES A SPECIAL -- WHO

6699
03:48:26,914 --> 03:48:28,582
KNOWS HOW TO RECOGNIZE THE

6700
03:48:28,582 --> 03:48:30,117
SYMPTOMS, SO THERE'S A LOT OF

6701
03:48:30,117 --> 03:48:32,319
AMBIGUITY IN THAT CLINICAL

6702
03:48:32,319 --> 03:48:32,920
INTERPRETATION, DEPENDING ON

6703
03:48:32,920 --> 03:48:34,955
WHAT TYPE OF DOCTOR THAT YOU

6704
03:48:34,955 --> 03:48:35,322
ENCOUNTER FIRST.

6705
03:48:35,322 --> 03:48:36,390
AND PART OF WHAT'S INTERESTING

6706
03:48:36,390 --> 03:48:39,026
ABOUT THIS CONDITION IS THAT SO

6707
03:48:39,026 --> 03:48:42,229
MUCH OF THE FOUNDATIONAL

6708
03:48:42,229 --> 03:48:43,864
UNDERSTANDING IS BASED ON

6709
03:48:43,864 --> 03:48:44,631
ANATOMICAL FEATURES.

6710
03:48:44,631 --> 03:48:53,207
IS THERE AN ENDOMETRIOMA, WHEN

6711
03:48:53,207 --> 03:48:55,709
REALLY IT SHOULD BE DRIVEN BY

6712
03:48:55,709 --> 03:48:56,310
MOLECULAR CLASSIFICATION WHICH

6713
03:48:56,310 --> 03:48:58,245
WOULD THEN DRIVE BETTER DRUG

6714
03:48:58,245 --> 03:48:59,346
DEVELOPMENT.

6715
03:48:59,346 --> 03:49:00,981
AGAIN, WORTH HIGHLIGHTING THAT

6716
03:49:00,981 --> 03:49:02,249
BASICALLY THE ONLY DRUG MODALITY

6717
03:49:02,249 --> 03:49:06,253
WE HAVE FOR ENDOMETRIOSIS IS

6718
03:49:06,253 --> 03:49:08,255
PROGESTIN AND GNRH ANALOGS.

6719
03:49:08,255 --> 03:49:10,457
THE THESIS BEING IT'S AN

6720
03:49:10,457 --> 03:49:11,892
ESTROGEN-DOMINANT DISEASE, LET'S

6721
03:49:11,892 --> 03:49:13,394
JUST STOP ESTROGEN AND SEE IF

6722
03:49:13,394 --> 03:49:14,762
THIS ACTUALLY MAKES AN IMPACT ON

6723
03:49:14,762 --> 03:49:15,396
THE DISEASE.

6724
03:49:15,396 --> 03:49:17,731
AND WE NEED BETTER, LESS BLUNT

6725
03:49:17,731 --> 03:49:19,600
INSTRUMENTS TO ACTUALLY BE ABLE

6726
03:49:19,600 --> 03:49:20,501
TO TACKLE THIS.

6727
03:49:20,501 --> 03:49:24,638
SO I'M GOING TO -- THE BIG

6728
03:49:24,638 --> 03:49:25,839
CHALLENGE THAT'S BEEN MENTIONED

6729
03:49:25,839 --> 03:49:27,207
A COUPLE OF TIMES, I SAW IT IN

6730
03:49:27,207 --> 03:49:28,075
JULIE'S PRESENTATION AS WELL,

6731
03:49:28,075 --> 03:49:29,843
WHICH WAS THE CHALLENGE THAT

6732
03:49:29,843 --> 03:49:31,712
EVERYONE FACES WHEN STUDYING

6733
03:49:31,712 --> 03:49:32,913
FEMALE-BORN BODIES IS WE HAVE

6734
03:49:32,913 --> 03:49:34,815
THE HORMONE CYCLE AND IT MAKES

6735
03:49:34,815 --> 03:49:35,816
EXPERIMENTS EXTREMELY NOISY.

6736
03:49:35,816 --> 03:49:37,251
SO ONE OF THE THINGS THAT WE

6737
03:49:37,251 --> 03:49:39,553
LIKE TO POINT OUT IS THAT WHAT

6738
03:49:39,553 --> 03:49:40,788
MENSTRUATION DOES IS IF YOU'RE

6739
03:49:40,788 --> 03:49:42,423
ACTUALLY LOOKING AT A REDUCED

6740
03:49:42,423 --> 03:49:45,325
WINDOW, SO DAYS 1 THROUGH 3 OF

6741
03:49:45,325 --> 03:49:45,926
MENSTRUATION, FOR EXAMPLE, ALL

6742
03:49:45,926 --> 03:49:48,162
OF YOUR PATIENT POPULATION IS

6743
03:49:48,162 --> 03:49:48,929
ACTUALLY AT THE SAME PLACE IN

6744
03:49:48,929 --> 03:49:49,930
THEIR MENSTRUAL CYCLE.

6745
03:49:49,930 --> 03:49:52,933
SO YOU ARE PASSIVELY

6746
03:49:52,933 --> 03:49:55,002
BIOLOGICALLY ALIGNING EVERYONE

6747
03:49:55,002 --> 03:49:56,870
AND YOU'RE REDUCING ONE OF THE

6748
03:49:56,870 --> 03:49:59,873
MOST CONSIDERABLE FACTORS OF

6749
03:49:59,873 --> 03:50:01,708
NOISE ACROSS WOMEN'S HEALTH.

6750
03:50:01,708 --> 03:50:03,343
ANOTHER ISSUE, AGAIN AS I

6751
03:50:03,343 --> 03:50:05,212
MENTIONED, WHAT FORM FACTOR DO

6752
03:50:05,212 --> 03:50:06,146
YOU CHOOSE?

6753
03:50:06,146 --> 03:50:07,214
WE'VE BEEN ASKED WHY DID YOU

6754
03:50:07,214 --> 03:50:08,415
CHOOSE A TAMPON?

6755
03:50:08,415 --> 03:50:11,652
YOU SORT OF HAVE TO PICK ONE AND

6756
03:50:11,652 --> 03:50:12,853
BRING THAT PRODUCT HOME.

6757
03:50:12,853 --> 03:50:13,720
NUMBER TWO, WE WANTED FOR

6758
03:50:13,720 --> 03:50:15,689
SOMETHING THAT STAYED IN THE

6759
03:50:15,689 --> 03:50:18,258
BODY AS LONG AS POSSIBLE, ALMOST

6760
03:50:18,258 --> 03:50:22,296
ACTING LIKE A LITTLE INCUBATOR,

6761
03:50:22,296 --> 03:50:24,698
VERSUS ONCE IT OUTSIDE, THE

6762
03:50:24,698 --> 03:50:25,732
DEGRADATION IS WORSE.

6763
03:50:25,732 --> 03:50:27,267
ONCE WE PICKED A TAMPON, YOU MAY

6764
03:50:27,267 --> 03:50:29,002
OR MAY NOT BE AWARE THAT TAMPONS

6765
03:50:29,002 --> 03:50:30,571
HAVE A LOT OF ADDITIVES.

6766
03:50:30,571 --> 03:50:32,673
IT CAN HAVE BLEACHES, SCENTS

6767
03:50:32,673 --> 03:50:34,308
THAT INTERFERE WITH DOWNSTREAM

6768
03:50:34,308 --> 03:50:36,310
CHEMISTRY, SO WE HAD TO PICK THE

6769
03:50:36,310 --> 03:50:37,644
TAMPON THAT HAD MINIMIZED ALL OF

6770
03:50:37,644 --> 03:50:39,079
THOSE VARIABLES, AND THEN WE HAD

6771
03:50:39,079 --> 03:50:41,381
TO BUILD A SYSTEM THAT COULD

6772
03:50:41,381 --> 03:50:42,816
ELIMINATE COACHING, AND THAT WAS

6773
03:50:42,816 --> 03:50:44,051
REALLY IMPORTANT FOR US BECAUSE

6774
03:50:44,051 --> 03:50:47,788
WE REALLY FEEL LIKE TRYING TO

6775
03:50:47,788 --> 03:50:48,689
COLLECT SAMPLES AT HOME

6776
03:50:48,689 --> 03:50:50,190
DECREASES ACTIVATION AND ENERGY

6777
03:50:50,190 --> 03:50:51,391
AND GETS PEOPLE TO PARTICIPATE

6778
03:50:51,391 --> 03:50:54,061
IN THEIR HEALTHCARE IN A MUCH

6779
03:50:54,061 --> 03:50:54,628
MORE MEANINGFUL LEVEL.

6780
03:50:54,628 --> 03:50:55,996
SO WHAT YOU'RE LOOKING AT IS ONE

6781
03:50:55,996 --> 03:50:58,765
OF OUR NEXTGEN JANE KITS THAT

6782
03:50:58,765 --> 03:51:00,033
HAS BEEN IN OUR CLINICAL STUDIES

6783
03:51:00,033 --> 03:51:02,536
FOR YEARS, AND IS ABLE TO

6784
03:51:02,536 --> 03:51:04,605
PRESERVE HIGH FIDELITY DNA AND

6785
03:51:04,605 --> 03:51:06,874
RNA SUCH THAT IT IS USED IN THE

6786
03:51:06,874 --> 03:51:09,476
PRIVACY OF A WOMAN'S HOME, IT IS

6787
03:51:09,476 --> 03:51:13,380
SNAIL MAILED, USPS, NO COLD

6788
03:51:13,380 --> 03:51:14,548
CHAIN, SO NO DRY ICE, NO WET

6789
03:51:14,548 --> 03:51:15,015
ICE.

6790
03:51:15,015 --> 03:51:16,750
IT HAS UP TO TWO WEEKS TO ARRIVE

6791
03:51:16,750 --> 03:51:18,385
AT OUR LABS IN OAKLAND.

6792
03:51:18,385 --> 03:51:20,654
WE HAVE TESTED IT AS FAR AWAY AS

6793
03:51:20,654 --> 03:51:22,890
ALASKA AND HAWAII, SO OUR

6794
03:51:22,890 --> 03:51:24,191
CLINICAL STUDIES ARE NATIONAL.

6795
03:51:24,191 --> 03:51:27,060
AND HAS REALLY GREAT ABILITY TO

6796
03:51:27,060 --> 03:51:29,796
GIVE US HIGH FIDELITY DNA AND

6797
03:51:29,796 --> 03:51:30,097
RNA.

6798
03:51:30,097 --> 03:51:33,333
AND SO THIS HAS POWERED ALL OF

6799
03:51:33,333 --> 03:51:35,002
OUR STUDIES FOR I WOULD SAY THE

6800
03:51:35,002 --> 03:51:36,336
LAST FIVE YEARS, WE'VE LANDED ON

6801
03:51:36,336 --> 03:51:38,305
THIS FORM FACTOR.

6802
03:51:38,305 --> 03:51:42,209
THERE ARE CHAL THE CHALLENGES TE

6803
03:51:42,209 --> 03:51:43,510
FACED IN THE BEGINNING.

6804
03:51:43,510 --> 03:51:44,945
WHEN WE WERE LOOKING AT THE

6805
03:51:44,945 --> 03:51:46,780
SAMPLE TYPE, IT IS CLOTTED, IT

6806
03:51:46,780 --> 03:51:58,058
IS HETEROJ HETEROGENEOUS IT I M.

6807
03:51:58,058 --> 03:51:59,459
AND THEN WE HAD TO ACCOUNT FOR

6808
03:51:59,459 --> 03:52:01,228
THINGS LIKE VARYING LEVELS OF

6809
03:52:01,228 --> 03:52:02,296
DEGRADATION.

6810
03:52:02,296 --> 03:52:03,630
PEOPLE WORE THESE TAMPONS FOR

6811
03:52:03,630 --> 03:52:04,865
DIFFERENT TIMES.

6812
03:52:04,865 --> 03:52:05,532
NO MATTER WHAT YOU SAY IN THE

6813
03:52:05,532 --> 03:52:06,166
INSTRUCTIONS FOR USE.

6814
03:52:06,166 --> 03:52:07,834
SO HOW DO YOU ACCOUNT FOR THAT

6815
03:52:07,834 --> 03:52:09,836
DOWNSTREAM.

6816
03:52:09,836 --> 03:52:12,573
ANOTHER PROBLEM WAS DIFFERING

6817
03:52:12,573 --> 03:52:13,574
TISSUE COMPOSITION.

6818
03:52:13,574 --> 03:52:16,076
SO AS YOU CAN ASK SOMEBODY, TELL

6819
03:52:16,076 --> 03:52:17,778
US WHAT DAY YOU WORE THIS

6820
03:52:17,778 --> 03:52:19,713
TAMPON, AND CAN YOU GIVE US SOME

6821
03:52:19,713 --> 03:52:21,248
SORT OF SENSE WHETHER IT'S HEAVY

6822
03:52:21,248 --> 03:52:24,384
FLOW DAY, LIGHT FLOW DAY, MEDIUM

6823
03:52:24,384 --> 03:52:24,651
FLOW DAY?

6824
03:52:24,651 --> 03:52:26,687
THAT'S REALLY IMPORTANT BECAUSE

6825
03:52:26,687 --> 03:52:27,888
TISSUE DIFFERENTIATION IS PROB

6826
03:52:27,888 --> 03:52:34,328
BY GPROBABLY GOING TO BE ONE OFE

6827
03:52:34,328 --> 03:52:36,296
BIGGEST VARYING DRIVERS -- I

6828
03:52:36,296 --> 03:52:38,498
SHOW YOU THIS GRAPH BECAUSE IT

6829
03:52:38,498 --> 03:52:39,132
REALLY GIVES YOU A GREAT EXAMPLE

6830
03:52:39,132 --> 03:52:40,267
OF HOW IMPORTANT IT IS TO

6831
03:52:40,267 --> 03:52:41,802
NORMALIZE THIS DATASET.

6832
03:52:41,802 --> 03:52:43,904
ON THE LEFT-HAND SIDE, THE RED

6833
03:52:43,904 --> 03:52:47,307
AND YELLOW DOTS, YOU'RE SEEING

6834
03:52:47,307 --> 03:52:48,642
SUBJECTIVELY LABELED PLOT OF

6835
03:52:48,642 --> 03:52:50,978
PEOPLE TELLING US, I THINK THIS

6836
03:52:50,978 --> 03:52:52,179
IS MY HEAVY FLOW DAY, I THINK

6837
03:52:52,179 --> 03:52:54,047
THIS IS MY LIGHT, MEDIUM FLOW

6838
03:52:54,047 --> 03:52:55,349
DAY, WHAT YOU SHOULD IMMEDIATELY

6839
03:52:55,349 --> 03:52:56,917
JUST SEE IS NOISE.

6840
03:52:56,917 --> 03:52:57,217
IT'S CHAOS.

6841
03:52:57,217 --> 03:52:57,751
THERE'S NO PATTERN THERE.

6842
03:52:57,751 --> 03:53:01,822
PEOPLE ARE NOT RELIABLY CALLING

6843
03:53:01,822 --> 03:53:03,223
WHAT DAY THEY'RE ON.

6844
03:53:03,223 --> 03:53:03,790
ON THE RIGHT-HAND SIDE, WE

6845
03:53:03,790 --> 03:53:05,259
DEVELOPED A MOLECULAR LABELING

6846
03:53:05,259 --> 03:53:06,994
SYSTEM, WE SAMPLED PEOPLE EVERY

6847
03:53:06,994 --> 03:53:09,029
SINGLE DAY OF THEIR MENSTRUAL

6848
03:53:09,029 --> 03:53:11,198
CYCLE AND WE SAID THIS IS

6849
03:53:11,198 --> 03:53:13,333
HEAVIEST FLOW DAY, THIS IS

6850
03:53:13,333 --> 03:53:13,834
ABSOLUTELY NO BLEEDING.

6851
03:53:13,834 --> 03:53:15,969
IF YOU USED THAT ACTUALLY

6852
03:53:15,969 --> 03:53:17,604
DATA-DRIVEN APPROACH TO

6853
03:53:17,604 --> 03:53:18,972
MOLECULARLY LABEL THESE SAMPLES,

6854
03:53:18,972 --> 03:53:21,141
BOOM, YOU GET THIS IMMEDIATE

6855
03:53:21,141 --> 03:53:22,009
PATTERN.

6856
03:53:22,009 --> 03:53:23,877
SO IT REALLY WAS YEARS OF

6857
03:53:23,877 --> 03:53:25,579
DEVELOPING THESE NORMALIZATION

6858
03:53:25,579 --> 03:53:27,414
STRATEGIES THAT TOOK A LONG

6859
03:53:27,414 --> 03:53:28,649
TIME, BUT GOT YOU TO A PLACE

6860
03:53:28,649 --> 03:53:30,050
THAT WHEN YOU'RE COMPARING

6861
03:53:30,050 --> 03:53:31,285
SAMPLES FROM INDIVIDUALS, YOU

6862
03:53:31,285 --> 03:53:33,053
KNOW WHAT YOU'RE LOOKING AT IS A

6863
03:53:33,053 --> 03:53:34,488
DIFFERENCE THAT COULD BE

6864
03:53:34,488 --> 03:53:36,156
ATTRIBUTABLE TO BIOLOGICAL

6865
03:53:36,156 --> 03:53:39,126
PHENOMENON AND NOT AN ARTIFACT.

6866
03:53:39,126 --> 03:53:40,093
ALL RIGHT, OTHER CHALLENGES.

6867
03:53:40,093 --> 03:53:41,228
THERE ARE CHALLENGES DEFINING

6868
03:53:41,228 --> 03:53:44,631
WHAT A CASE IS.

6869
03:53:44,631 --> 03:53:45,932
THE LAPAROSCOPY IS REFERRED TO

6870
03:53:45,932 --> 03:53:47,134
AS A GOLD STANDARD.

6871
03:53:47,134 --> 03:53:49,102
I ONCE HEARD SOMEONE VERY

6872
03:53:49,102 --> 03:53:50,804
BRILLIANTLY REFER TO IT AS A

6873
03:53:50,804 --> 03:53:53,974
BRONZE STANDARD, WHICH IS --

6874
03:53:53,974 --> 03:53:54,941
SOME SURGEONS WILL GO IN AND

6875
03:53:54,941 --> 03:53:57,244
THEY WON'T TAKE A BIOPSY FOR THE

6876
03:53:57,244 --> 03:53:57,844
PATH LAB.

6877
03:53:57,844 --> 03:54:00,047
IS THAT AN ENDOMETRIOSIS CALL?

6878
03:54:00,047 --> 03:54:02,516
SOMEONE WILL, YOU KNOW, GET 20

6879
03:54:02,516 --> 03:54:04,251
BIOPSIES AND ONE IS CALLED

6880
03:54:04,251 --> 03:54:04,518
POSITIVE.

6881
03:54:04,518 --> 03:54:05,919
DO YOU WANT TO CALL THAT AN

6882
03:54:05,919 --> 03:54:07,020
ENDOMETRIOSIS PATIENT?

6883
03:54:07,020 --> 03:54:09,423
SOMEONE WILL GO IN AND THEY HAD

6884
03:54:09,423 --> 03:54:11,325
ENDOMETRIOSIS THREE YEARS AGO,

6885
03:54:11,325 --> 03:54:12,659
THEY HAD MOST OF THE TISSUE

6886
03:54:12,659 --> 03:54:13,960
REMOVED AND THEY COME TO YOU AND

6887
03:54:13,960 --> 03:54:15,262
THEY'RE LIKE, I HAVE

6888
03:54:15,262 --> 03:54:15,595
ENDOMETRIOSIS.

6889
03:54:15,595 --> 03:54:16,997
HOW DO YOU CLASSIFY THEM?

6890
03:54:16,997 --> 03:54:17,731
DO THEY STILL HAVE

6891
03:54:17,731 --> 03:54:20,233
ENDOMETRIOSIS?

6892
03:54:20,233 --> 03:54:23,070
AND SO THERE'S A LOT OF

6893
03:54:23,070 --> 03:54:25,105
CHALLENGES REALLY HONING IN AND

6894
03:54:25,105 --> 03:54:27,040
BEING VERY PRECISE ABOUT WHAT A

6895
03:54:27,040 --> 03:54:27,941
CASE IS.

6896
03:54:27,941 --> 03:54:29,242
SAME CHALLENGES IN DEFINING WHAT

6897
03:54:29,242 --> 03:54:31,178
A CONTROL IS.

6898
03:54:31,178 --> 03:54:34,581
WURNTION THERE'S A SCARCITY OF

6899
03:54:34,581 --> 03:54:38,852
TRUE ENDO NEGATIVE CONTROLS.

6900
03:54:38,852 --> 03:54:39,920
THERE ARE OTHER CHALLENGES.

6901
03:54:39,920 --> 03:54:41,521
EVEN PEOPLE WHO ARE

6902
03:54:41,521 --> 03:54:42,255
ENDO-NEGATIVE, THEY COME IN AND

6903
03:54:42,255 --> 03:54:43,924
THEY SAY I HAD A LAP THREE YEARS

6904
03:54:43,924 --> 03:54:45,125
AGO WHEN WE'VE ACTUALLY HAD

6905
03:54:45,125 --> 03:54:47,694
PEOPLE IN OUR TRIALS WHO HAD

6906
03:54:47,694 --> 03:54:52,232
LAPS TWO YEARS AGO, E

6907
03:54:52,232 --> 03:54:52,999
ENDO-NEGATIVE, STILL HAD

6908
03:54:52,999 --> 03:54:54,067
SYMPTOMS, THEY WENT TO A

6909
03:54:54,067 --> 03:54:55,736
DIFFERENT SURGEON, THEY'RE

6910
03:54:55,736 --> 03:54:56,169
ENDO-POSITIVE.

6911
03:54:56,169 --> 03:54:59,606
SO THERE'S A LOT OF

6912
03:54:59,606 --> 03:55:00,374
SUBJECTIVITY, SURGEON SKILLSET.

6913
03:55:00,374 --> 03:55:02,342
THERE'S A LOT OF NOISE IN THE

6914
03:55:02,342 --> 03:55:03,810
SYSTEM THAT CAN MAKE DEFINING

6915
03:55:03,810 --> 03:55:06,046
WHAT A CONTROL IS CHALLENGING.

6916
03:55:06,046 --> 03:55:09,383
THERE ARE CHALLENGES IN -- ONE

6917
03:55:09,383 --> 03:55:11,251
IS DIAGNOSTIC REIMBURSEMENT, SO

6918
03:55:11,251 --> 03:55:13,487
WE HEARD A LOT BL INVESTING IN

6919
03:55:13,487 --> 03:55:15,355
THE SPACE AND INVESTMENT FOR

6920
03:55:15,355 --> 03:55:17,090
DIAGNOSTICS IN GENERAL IS

6921
03:55:17,090 --> 03:55:19,025
CHALLENGING BECAUSE IT'S NOT AS

6922
03:55:19,025 --> 03:55:21,962
LUCRATIVE FROM AN ROI

6923
03:55:21,962 --> 03:55:22,863
PERSPECTIVE DOLLAR FOR DOLLAR

6924
03:55:22,863 --> 03:55:24,531
THAT YOU PUT INTO A DRUG, YOU'RE

6925
03:55:24,531 --> 03:55:26,166
GOING TO GET A HIGHER RETURN

6926
03:55:26,166 --> 03:55:27,167
INTO DEVELOPMENT OF DIAGNOSTIC.

6927
03:55:27,167 --> 03:55:28,468
THE OTHER THING IS THAT WE ARE

6928
03:55:28,468 --> 03:55:31,571
IN A COMMERCIAL REIMBURSEMENT

6929
03:55:31,571 --> 03:55:34,207
SYSTEM FOR WOMEN WHO ARE OF

6930
03:55:34,207 --> 03:55:35,075
REPRODUCTIVE AGE THROUGH THE

6931
03:55:35,075 --> 03:55:36,276
RUBRIC THAT INSURANCE COMPANIES

6932
03:55:36,276 --> 03:55:38,745
USE TO SAY CAN YOU SAVE ME MONEY

6933
03:55:38,745 --> 03:55:40,247
WITH THIS DIAGNOSTIC IN 12

6934
03:55:40,247 --> 03:55:41,715
MONTHS, WHICH IS ABOUT ON

6935
03:55:41,715 --> 03:55:43,216
AVERAGE HOW LONG I WILL HOLD ON

6936
03:55:43,216 --> 03:55:43,850
TO THIS PATIENT.

6937
03:55:43,850 --> 03:55:46,953
SO THIS IS PRIVATE PAYERS.

6938
03:55:46,953 --> 03:55:49,456
SO IF YOU ARE DIAGNOSING SOMEONE

6939
03:55:49,456 --> 03:55:51,057
WITH ENDOMETRIOSIS

6940
03:55:51,057 --> 03:55:52,359
NON-INVASIVELY, YOU'VE MADE THAT

6941
03:55:52,359 --> 03:55:53,660
PROCESS VERY EASY, YOU ARE

6942
03:55:53,660 --> 03:55:55,562
LIKELY INCREASING THE COST OF

6943
03:55:55,562 --> 03:55:56,563
THAT HUMAN BEING WHILE THEY ARE

6944
03:55:56,563 --> 03:55:58,532
BEING COVERED BY THAT COMMERCIAL

6945
03:55:58,532 --> 03:56:00,167
PAYER.

6946
03:56:00,167 --> 03:56:01,468
SO INCENTIVES AREN'T QUITE THERE

6947
03:56:01,468 --> 03:56:03,103
TO ACTUALLY MAKE THIS SOMETHING

6948
03:56:03,103 --> 03:56:04,971
THAT INSURANCE COMPANIES WANT TO

6949
03:56:04,971 --> 03:56:05,439
REIMBURSE.

6950
03:56:05,439 --> 03:56:08,475
BUT WE KEEP GOING BECAUSE THE

6951
03:56:08,475 --> 03:56:09,743
RESEARCH ON ENDOMETRIOSIS IS

6952
03:56:09,743 --> 03:56:09,943
CLEAR.

6953
03:56:09,943 --> 03:56:11,478
HIGHER RATES OF INFERTILITY,

6954
03:56:11,478 --> 03:56:14,481
HIGHER RATES OF OVARIAN CANCER,

6955
03:56:14,481 --> 03:56:15,248
PREECLAMPSIA, PRETERM LABOR.

6956
03:56:15,248 --> 03:56:17,317
AND THIS IS A BIG FOOTPRINT.

6957
03:56:17,317 --> 03:56:20,787
10% OF ALL FEMALE-BORN BODIES

6958
03:56:20,787 --> 03:56:21,321
AFFECTED BY THIS DISEASE.

6959
03:56:21,321 --> 03:56:22,756
SO ALL OF THOSE CHALLENGES

6960
03:56:22,756 --> 03:56:25,058
BECOME WORTH TACKLING.

6961
03:56:25,058 --> 03:56:26,626
I'LL JUST POINT OUT A COUPLE

6962
03:56:26,626 --> 03:56:26,960
OTHER THINGS.

6963
03:56:26,960 --> 03:56:28,795
WE'RE OBVIOUSLY WORKING ON A

6964
03:56:28,795 --> 03:56:31,097
NONINVASIVE DIAGNOSTIC, BUT IT

6965
03:56:31,097 --> 03:56:34,234
COULD BE, IF IT WORKS, AN

6966
03:56:34,234 --> 03:56:35,302
EVALUATIVE PLATFORM, SO YOU

6967
03:56:35,302 --> 03:56:37,471
COULD IMAGINE NOW IN CLINICAL

6968
03:56:37,471 --> 03:56:39,105
TRIALS, YOU TAKE A TAMPON-BASED

6969
03:56:39,105 --> 03:56:40,640
TEST, DETERMINE WHETHER YOU HAVE

6970
03:56:40,640 --> 03:56:41,942
THE DISEASE, YOU ADMINISTER A

6971
03:56:41,942 --> 03:56:46,279
SMALL MOLECULE, YOU TAKE A TAM

6972
03:56:46,279 --> 03:56:47,180
TAMPON-BASED TEST SIX MONTHS

6973
03:56:47,180 --> 03:56:48,815
LATER, REALLY SIMPLIFYING HOW

6974
03:56:48,815 --> 03:56:49,749
YOU DO CLINICAL RESEARCH.

6975
03:56:49,749 --> 03:56:51,051
THE OTHER OPPORTUNITY IS

6976
03:56:51,051 --> 03:56:51,618
PRE-CLINICAL IMPACT.

6977
03:56:51,618 --> 03:56:54,020
WE'VE ACTUALLY TAKEN MENSTRUAL

6978
03:56:54,020 --> 03:56:56,923
BLOOD COLLECTED IN CUPS, WHICH

6979
03:56:56,923 --> 03:56:59,659
HAS LIVE CELLS, AN WE HAVE

6980
03:56:59,659 --> 03:57:00,961
INTRODUCED DIFFERENT

6981
03:57:00,961 --> 03:57:02,596
CONCENTRATIONS OF DRUGS AT

6982
03:57:02,596 --> 03:57:04,631
DIFFERENT TIME POINT AND DONE

6983
03:57:04,631 --> 03:57:05,765
SEQUENCING ON BOTH THE VEHICLE,

6984
03:57:05,765 --> 03:57:07,467
NO DRUG, AND ALL THESE

6985
03:57:07,467 --> 03:57:08,502
EXPERIMENTAL CONDITIONS TO BE

6986
03:57:08,502 --> 03:57:13,340
ABLE TO STEAP WH ESTABLISH WHATS

6987
03:57:13,340 --> 03:57:14,541
CHANGING AND WHAT IT'S DONE TO

6988
03:57:14,541 --> 03:57:17,143
HELP DRUG DEVELOPERS UNDERSTAND

6989
03:57:17,143 --> 03:57:17,911
MECHANISM OF ACTION.

6990
03:57:17,911 --> 03:57:19,112
SO THERE ARE JUST MANY

6991
03:57:19,112 --> 03:57:21,414
INTERESTING THINGS YOU CAN DO

6992
03:57:21,414 --> 03:57:22,682
WITH THIS SAMPLE TYPE AND I

6993
03:57:22,682 --> 03:57:24,084
THINK A LOT OF PEOPLE ARE

6994
03:57:24,084 --> 03:57:26,486
BEGINNING TO RECOGNIZE THAT

6995
03:57:26,486 --> 03:57:28,221
EVERY TIME SOMEONE HAS MENTIONED

6996
03:57:28,221 --> 03:57:32,592
A MENSTRUAL E EFFLUENCE EFFORT

6997
03:57:32,592 --> 03:57:34,895
HERE BEFORE, JULIE ELBOWED ME

6998
03:57:34,895 --> 03:57:37,264
AND HE SAID WAS THAT YOU, AND

6999
03:57:37,264 --> 03:57:38,465
THE SPACE IS HOT NOW WHICH WE

7000
03:57:38,465 --> 03:57:38,999
LOVE.

7001
03:57:38,999 --> 03:57:41,701
I JUST -- THE NUMBER ONE THANK

7002
03:57:41,701 --> 03:57:43,770
YOU I WANT TO GIVE IS TO OUR

7003
03:57:43,770 --> 03:57:44,437
CLINICAL TRIAL PARTICIPANTS.

7004
03:57:44,437 --> 03:57:46,072
THEY HAVE GIVEN US OVER 2,000

7005
03:57:46,072 --> 03:57:47,541
TAMPONS AND NONE OF THIS WOULD

7006
03:57:47,541 --> 03:57:48,875
BE POSSIBLE WITHOUT THEM.

7007
03:57:48,875 --> 03:57:57,751
THANK YOU.

7008
03:57:57,751 --> 03:57:59,152
>> I'D LIKE TO INVITE EACH
OF

7009
03:57:59,152 --> 03:58:01,054
OUR SPEAKERS UP TO JOIN ME ON

7010
03:58:01,054 --> 03:58:01,321
THE PANEL.

7011
03:58:01,321 --> 03:58:02,389
WE'LL HAVE A BRIEF MODERATED

7012
03:58:02,389 --> 03:58:03,723
DISCUSSION AND I WILL, OF

7013
03:58:03,723 --> 03:58:06,159
COURSE, LEAVE ROOM FOR OUR

7014
03:58:06,159 --> 03:58:16,703
COUNCILMEMBERS TO QUERY AS WELL.

7015
03:58:17,203 --> 03:58:19,406
>> THAT WAS FANTASTIC
OBVIOUSLY.

7016
03:58:19,406 --> 03:58:23,109
YOWE DID A GREAT JOB CHOOSING OR

7017
03:58:23,109 --> 03:58:23,476
PANELISTS.

7018
03:58:23,476 --> 03:58:24,744
AND WE ALSO COVERED SEVERAL

7019
03:58:24,744 --> 03:58:26,112
DIFFERENT AREAS AND BASES BUT

7020
03:58:26,112 --> 03:58:29,282
ONE THING I REALLY WANT TO HIT I

7021
03:58:29,282 --> 03:58:31,685
THINK EACH OF YOU TOUCHED ON IN

7022
03:58:31,685 --> 03:58:33,486
DIFFERENT WAYS AND I THINK IT'S

7023
03:58:33,486 --> 03:58:35,922
A CONCERN OF THE PUBLIC, DATA.

7024
03:58:35,922 --> 03:58:37,691
THE MANAGING IT, YOU COLLECTED

7025
03:58:37,691 --> 03:58:39,292
LARGE AMOUNTS OF VERY PERSONAL

7026
03:58:39,292 --> 03:58:40,493
SPECIFIC DATA, WE THINK ABOUT

7027
03:58:40,493 --> 03:58:41,595
SAFETY, WE THINK ABOUT

7028
03:58:41,595 --> 03:58:42,596
CONVINCING PATIENTS TO PROVIDE

7029
03:58:42,596 --> 03:58:44,197
THE DATA AND WE THINK ABOUT

7030
03:58:44,197 --> 03:58:47,000
USING DATA AND DATA OF YOUR

7031
03:58:47,000 --> 03:58:48,134
COMMERCIAL ENTITY IS ALSO A

7032
03:58:48,134 --> 03:58:48,835
COMMODITY.

7033
03:58:48,835 --> 03:58:50,503
JUST CURIOUS HOW YOU ALL THINK

7034
03:58:50,503 --> 03:58:51,805
ABOUT DATA IN THE ASPECTS OF

7035
03:58:51,805 --> 03:58:55,108
YOUR WORK AND WHAT WE NEED TO BE

7036
03:58:55,108 --> 03:59:01,581
THINKING ABOUT.

7037
03:59:01,581 --> 03:59:03,183
>> YOU'VE MENTIONED ALL
THE DATA

7038
03:59:03,183 --> 03:59:03,717
WE COLLECTED.

7039
03:59:03,717 --> 03:59:07,454
WE HAVE A VERY EXPLICIT APPROACH

7040
03:59:07,454 --> 03:59:11,625
OF PERMISSING THE DATA, THIS IS

7041
03:59:11,625 --> 03:59:12,993
A 30-MINUTE CALL, WALKING THEM

7042
03:59:12,993 --> 03:59:14,027
THROUGH CONSENT, EXPLAINING ALL

7043
03:59:14,027 --> 03:59:15,795
OF THE RESEARCH PRIORITIES THAT

7044
03:59:15,795 --> 03:59:16,796
WE'RE PRESUMING AND MAKING SURE

7045
03:59:16,796 --> 03:59:19,532
THEY UNDERSTAND THAT, AND SO

7046
03:59:19,532 --> 03:59:21,668
EVERY SAMPLE THAT IS IN OUR

7047
03:59:21,668 --> 03:59:25,605
DATABASE AND OUR BIOBANK IS

7048
03:59:25,605 --> 03:59:26,406
EXPLICITLY CONSENTED TO BE USED

7049
03:59:26,406 --> 03:59:28,642
FOR THAT RESEARCH.

7050
03:59:28,642 --> 03:59:30,510
WE ALSO GO THROUGH THE EFFORT OF

7051
03:59:30,510 --> 03:59:31,945
DE-IDENTIFYING IT SO WE GIVE

7052
03:59:31,945 --> 03:59:38,084
THEM ALL ALPHANUMERIC IDs AND

7053
03:59:38,084 --> 03:59:39,252
AFTER A CERTAIN AMOUNT OF TIME,

7054
03:59:39,252 --> 03:59:40,320
WE'RE OBLIGATED TO KEEP THE

7055
03:59:40,320 --> 03:59:41,821
CONNECTION, THE LINK BETWEEN

7056
03:59:41,821 --> 03:59:44,124
THEIR IDENTITY AND THEIR

7057
03:59:44,124 --> 03:59:45,525
ALPHANUMERIC CODE FOR ABOUT FIVE

7058
03:59:45,525 --> 03:59:45,725
YEARS.

7059
03:59:45,725 --> 03:59:49,095
AFTER THAT, WE DESTROY IT AND

7060
03:59:49,095 --> 03:59:50,196
THERE'S NO WAY FOR US TO EVEN

7061
03:59:50,196 --> 03:59:51,097
LINK BACK TO WHO IT IS.

7062
03:59:51,097 --> 03:59:52,499
SO WE TRY TO BE BOTH UP FRONT

7063
03:59:52,499 --> 03:59:54,234
ABOUT WHAT WE'RE GOING TO DO AND

7064
03:59:54,234 --> 03:59:56,202
GET PERMISSION TO USE THE DATA

7065
03:59:56,202 --> 03:59:57,203
EXACTLY HOW WE'RE GOING TO USE

7066
03:59:57,203 --> 03:59:59,572
IT AND THEN WE ARE VERY THOROUGH

7067
03:59:59,572 --> 04:00:01,641
ABOUT MAKING SURE WE'RE

7068
04:00:01,641 --> 04:00:02,609
DE-LINKING IT FROM WHO THE

7069
04:00:02,609 --> 04:00:07,013
PERSON ACTUALLY IS.

7070
04:00:07,013 --> 04:00:08,948
>> I THINK FROM A RESEARCH

7071
04:00:08,948 --> 04:00:09,716
PERSPECTIVE, THERE'S NO QUESTION

7072
04:00:09,716 --> 04:00:11,151
THAT DATA IS THING THAT WE'RE

7073
04:00:11,151 --> 04:00:13,787
MISSING THE MOST IN WOMEN'S

7074
04:00:13,787 --> 04:00:14,020
HEALTH.

7075
04:00:14,020 --> 04:00:16,156
I RAN A WORKSHOP THIS SUMMER ON

7076
04:00:16,156 --> 04:00:17,824
ENGINEERING AND WOMEN'S HEALTH

7077
04:00:17,824 --> 04:00:19,059
AND SOME OF THE PEOPLE IN THE

7078
04:00:19,059 --> 04:00:19,859
ROOM WERE THERE.

7079
04:00:19,859 --> 04:00:22,462
I DID AN ANALYSIS, JUST A

7080
04:00:22,462 --> 04:00:23,329
TEXT-BASED ANALYSIS OF ALL OF

7081
04:00:23,329 --> 04:00:25,131
THE NOTES FROM THAT ENTIRE

7082
04:00:25,131 --> 04:00:26,366
MEETING, AND THE SINGLE MOST

7083
04:00:26,366 --> 04:00:28,334
COMMONLY UTTERED WORD IN THOSE

7084
04:00:28,334 --> 04:00:31,037
NOTES WAS "DATA," BECAUSE ALL OF

7085
04:00:31,037 --> 04:00:32,672
US WHO ARE RESEARCHERS IN THIS

7086
04:00:32,672 --> 04:00:35,241
FIELD REALLY ARE LACKING DATA,

7087
04:00:35,241 --> 04:00:36,376
AND I GAVE THE EXAMPLE ALREADY

7088
04:00:36,376 --> 04:00:38,712
OF MIDRC AND HOW YOU HAVE -- IF

7089
04:00:38,712 --> 04:00:40,513
YOU WANT TO TRAIN AN A.I. MODEL

7090
04:00:40,513 --> 04:00:42,348
ON THOUSANDS OF COVID LUNGS, YOU

7091
04:00:42,348 --> 04:00:44,084
CAN VERY EASILY DO THAT.

7092
04:00:44,084 --> 04:00:45,285
IF YOU WANT TO DO SOMETHING LIKE

7093
04:00:45,285 --> 04:00:47,120
THIS IN WOMEN'S HEALTH, YOU HAVE

7094
04:00:47,120 --> 04:00:49,956
TO COLLECT THE DATA

7095
04:00:49,956 --> 04:00:50,290
PROSPECTIVELY.

7096
04:00:50,290 --> 04:00:54,961
NOW THE GOOD THING FROM MY

7097
04:00:54,961 --> 04:00:55,562
PERSPECTIVE IN THE YEARS I'VE

7098
04:00:55,562 --> 04:00:57,163
BEEN DOING THIS IS, I HAVE FOUND

7099
04:00:57,163 --> 04:00:59,332
MOST PREGNANT WOMEN TO BE

7100
04:00:59,332 --> 04:01:02,936
EXTREMELY GENEROUS WITH THEIR

7101
04:01:02,936 --> 04:01:04,871
GIVING CONSENT TO PARTICIPATE IN

7102
04:01:04,871 --> 04:01:06,306
THE RESEARCH FOR US TO KEEP THE

7103
04:01:06,306 --> 04:01:06,740
IMAGES.

7104
04:01:06,740 --> 04:01:08,775
WE DON'T DO ANYTHING WITH

7105
04:01:08,775 --> 04:01:09,442
GENETICS, AND I THINK THAT DOES

7106
04:01:09,442 --> 04:01:11,311
HELP US A LITTLE BIT BECAUSE

7107
04:01:11,311 --> 04:01:13,613
WE'RE MOSTLY COLLECTING IMAGING

7108
04:01:13,613 --> 04:01:16,883
DATA AND CHART KIND OF DATA AND

7109
04:01:16,883 --> 04:01:18,384
ALSO DE-IDENTIFYING EVERYTHING,

7110
04:01:18,384 --> 04:01:20,153
AND WE TREAT THAT DATA LIKE GOLD

7111
04:01:20,153 --> 04:01:21,988
AND WE USE IT OVER AND OVER AND

7112
04:01:21,988 --> 04:01:23,189
OVER AGAIN AND THAT'S PART OF

7113
04:01:23,189 --> 04:01:24,624
OUR INITIAL CONSENT PROCESS

7114
04:01:24,624 --> 04:01:27,026
BECAUSE THIS DATA IS SO

7115
04:01:27,026 --> 04:01:27,660
PRECIOUS, THERE'S SO LITTLE OF

7116
04:01:27,660 --> 04:01:28,962
IT AND WE NEED SO MUCH MORE OF

7117
04:01:28,962 --> 04:01:32,932
IT.

7118
04:01:32,932 --> 04:01:34,467
>> OKAY, GREAT.

7119
04:01:34,467 --> 04:01:36,402
THANK YOU FOR THAT.

7120
04:01:36,402 --> 04:01:38,705
AND JULIE, I DO WANT TO TURN TO

7121
04:01:38,705 --> 04:01:40,573
IT BECAUSE YOU SAID YOU WEREN'T

7122
04:01:40,573 --> 04:01:44,077
AN ENGINEER, THEN YOU WENT TO

7123
04:01:44,077 --> 04:01:45,578
EVATAR, YOU WANTED TO MAKE IT

7124
04:01:45,578 --> 04:01:47,113
FASTER, BETTER, CHEAPER, THAT'S

7125
04:01:47,113 --> 04:01:48,815
WHAT THEY DO TO GET TO LATTICE,

7126
04:01:48,815 --> 04:01:52,085
TO THE LATTICE MODEL.

7127
04:01:52,085 --> 04:01:54,053
BUT ALSO PCOS, HOW THAT HASN'T

7128
04:01:54,053 --> 04:01:56,122
COME UP A LOT AND HOW THAT

7129
04:01:56,122 --> 04:01:58,291
INFLUENCES MANY OF THESE OTHER

7130
04:01:58,291 --> 04:01:59,826
DISEASES THAT THE OTHER TWO

7131
04:01:59,826 --> 04:02:01,027
RESEARCHERS WERE DISCUSSING.

7132
04:02:01,027 --> 04:02:01,895
SO WHEN I HEAR ABOUT ALL THIS, I

7133
04:02:01,895 --> 04:02:03,129
HAVE FRIENDS WITH MULTIPLE

7134
04:02:03,129 --> 04:02:05,031
CROSSOVER ISSUES, AND I REALLY

7135
04:02:05,031 --> 04:02:05,832
BEGIN TO THINK ABOUT THIS AS

7136
04:02:05,832 --> 04:02:08,334
THIS N OF 1 ISSUE, RIGHT?

7137
04:02:08,334 --> 04:02:10,103
IT'S NOT -- WE COLLECT DATA TO

7138
04:02:10,103 --> 04:02:11,271
TRY TO DO AVERAGES, THAT DOESN'T

7139
04:02:11,271 --> 04:02:12,705
WORK FOR ALL WOMEN AS WE'VE BEEN

7140
04:02:12,705 --> 04:02:13,473
HEARING ABOUT.

7141
04:02:13,473 --> 04:02:14,674
I'M CURIOUS HOW YOU THINK ABOUT

7142
04:02:14,674 --> 04:02:16,943
AN N OF 1, HOW YOUR TOOLS MIGHT

7143
04:02:16,943 --> 04:02:20,113
HELP INFORM A PATIENT AND A

7144
04:02:20,113 --> 04:02:22,282
CLINICIAN, HOW TO DEAL WITH ME

7145
04:02:22,282 --> 04:02:24,818
VERSUS THE BROADER POPULATION.

7146
04:02:24,818 --> 04:02:27,086
>> THAT'S A GREAT
QUESTION.

7147
04:02:27,086 --> 04:02:28,521
I TALKED A LITTLE BIT ABOUT THIS

7148
04:02:28,521 --> 04:02:30,723
IN ANOTHER TALK, BUT I THINK THE

7149
04:02:30,723 --> 04:02:35,829
WAY TO STUDY THOSE DISEASES IS

7150
04:02:35,829 --> 04:02:37,030
TO LOOK AT THE GENETICS.

7151
04:02:37,030 --> 04:02:38,665
PCOS DOES HAVE A GENETIC

7152
04:02:38,665 --> 04:02:39,532
COMPONENT.

7153
04:02:39,532 --> 04:02:46,306
BUT IF WE WERE ABLE TO GET AND

7154
04:02:46,306 --> 04:02:49,342
INDUCE PLAWR EE POTENT STEM

7155
04:02:49,342 --> 04:02:52,412
CELLS IN A PATIENT WITH PCOS

7156
04:02:52,412 --> 04:02:53,279
AND -- CELLS INTERESTED IN

7157
04:02:53,279 --> 04:02:54,781
WORKING TOGETHER, THAT WOULD BE

7158
04:02:54,781 --> 04:02:55,381
MORE OF A PERSONALIZED PLATE

7159
04:02:55,381 --> 04:02:58,985
WHERE YOU CAN TRY DRUGS, ET

7160
04:02:58,985 --> 04:02:59,886
CETERA, AND ULTIMATELY AT THE

7161
04:02:59,886 --> 04:03:01,387
END OF THE DAY, THAT'S WHAT WE

7162
04:03:01,387 --> 04:03:02,121
WANT.

7163
04:03:02,121 --> 04:03:03,957
WE WANT TO STUDY EACH PATIENT

7164
04:03:03,957 --> 04:03:05,291
AND THEIR CONDITIONS AND THEIR

7165
04:03:05,291 --> 04:03:08,328
GENETICS ALL IN ONE, AND SEE

7166
04:03:08,328 --> 04:03:11,497
WHAT IS THE OVARY DOING OR

7167
04:03:11,497 --> 04:03:12,899
GRANULOIS A CELLS DOING WHRA IS

7168
04:03:12,899 --> 04:03:17,103
THE LIVER DOING, WHAT IS THE

7169
04:03:17,103 --> 04:03:18,071
PANCREAS DOING.

7170
04:03:18,071 --> 04:03:19,672
SO I THINK THAT IS THE WAY TO GO

7171
04:03:19,672 --> 04:03:21,507
WHEN WE TALKED ABOUT A LOT OF

7172
04:03:21,507 --> 04:03:23,076
THE NOISE WE TALKED ABOUT,

7173
04:03:23,076 --> 04:03:24,510
HETEROGENEITY, TO BE ABLE TO

7174
04:03:24,510 --> 04:03:26,813
LOOK AT IT IN A PERMIZED MATTER.

7175
04:03:26,813 --> 04:03:29,482
>> AND WHAT MEDICAL
EDUCATION DO

7176
04:03:29,482 --> 04:03:30,917
YOU THINK NEEDS TO BE DEVELOPED

7177
04:03:30,917 --> 04:03:34,687
FOR THE CLINICIANS TO BUY INTO

7178
04:03:34,687 --> 04:03:36,389
THE DATA OR THE N OF 1 YOU

7179
04:03:36,389 --> 04:03:38,391
PREDICTED IN YOUR MODELS? 

7180
04:03:38,391 --> 04:03:40,059
EDUCATION FOR THE CLINICIAN, TO

7181
04:03:40,059 --> 04:03:41,594
COME IN AND SAY I WOULD BELIEVE

7182
04:03:41,594 --> 04:03:45,565
THIS DATA AND APPLY TO MY

7183
04:03:45,565 --> 04:03:45,798
PATIENT.

7184
04:03:45,798 --> 04:03:48,167
>> YES, WE WOULD HAVE TO
PROVIDE

7185
04:03:48,167 --> 04:03:53,206
THEM CONVINCING DATA, NOT AN N

7186
04:03:53,206 --> 04:03:55,942
OF 1, BUT LET'S SAY A VILLAGE OF

7187
04:03:55,942 --> 04:03:57,343
PEOPLE AND LINK THAT INTO A

7188
04:03:57,343 --> 04:03:58,211
CERTAIN PHENOTYPE, FOR EXAMPLE.

7189
04:03:58,211 --> 04:04:00,313
SO AGAIN, DATA COLLECTION,

7190
04:04:00,313 --> 04:04:01,981
CONVINCING CLINICIANS THAT THIS

7191
04:04:01,981 --> 04:04:03,583
IS THE WAY TO GO, LOOK AT THE

7192
04:04:03,583 --> 04:04:04,550
DIFFERENT PATIENTS THAT WE HAVE

7193
04:04:04,550 --> 04:04:08,821
ON THIS PLATE, LOOK HOW

7194
04:04:08,821 --> 04:04:10,089
DIFFERENTLY THEY'RE RESPONDING

7195
04:04:10,089 --> 04:04:10,657
TO DIFFERENT MEDICATIONS AND

7196
04:04:10,657 --> 04:04:15,028
PROVIDE THEM WITH SUFFICIENT

7197
04:04:15,028 --> 04:04:16,562
DATA.

7198
04:04:16,562 --> 04:04:19,699
>> BACK TO YOU, MICHELLE.

7199
04:04:19,699 --> 04:04:20,466
THE DIGITAL TWINS, A DIFFERENT

7200
04:04:20,466 --> 04:04:22,101
TAKE ON THE N OF 1 MODEL, BUT

7201
04:04:22,101 --> 04:04:24,103
ALSO WHEN I LISTENED TO THE

7202
04:04:24,103 --> 04:04:24,804
THREE OF YOU SPEAK, SURGERIES

7203
04:04:24,804 --> 04:04:26,906
DIDN'T COME UP MUCH, MAYBE IT'S

7204
04:04:26,906 --> 04:04:28,841
A GOOD THING, MAYBE IT'S NOT.

7205
04:04:28,841 --> 04:04:29,809
I WONDER, MICHELLE, IN SOME OF

7206
04:04:29,809 --> 04:04:31,878
YOUR MODELS WHERE YOU TALKED

7207
04:04:31,878 --> 04:04:33,146
ABOUT CESAREAN SECTIONS, THAT

7208
04:04:33,146 --> 04:04:33,880
WAS CHANGED.

7209
04:04:33,880 --> 04:04:35,915
NOW AS YOU DO THESE NEW MODELS,

7210
04:04:35,915 --> 04:04:37,550
ARE THEY TO INFORM SURGICAL

7211
04:04:37,550 --> 04:04:39,552
ADVICE, TREATMENTS, THERAPIES OR

7212
04:04:39,552 --> 04:04:40,720
WHAT WOULD THE CLINICIAN BE

7213
04:04:40,720 --> 04:04:44,657
ASKED TO DO ON THE OTHER SIDE OF

7214
04:04:44,657 --> 04:04:46,392
RECEIVING YOUR ANALYSIS AND

7215
04:04:46,392 --> 04:04:46,993
AGAIN, HOW WOULD YOU TAKE THAT

7216
04:04:46,993 --> 04:04:47,827
ON THAT WALK WITH YOU AS YOU'VE

7217
04:04:47,827 --> 04:04:48,728
BEEN DEVELOPING THESE DIFFERENT

7218
04:04:48,728 --> 04:04:51,064
PRAK CYSTS SO THEN THEY'RE READY

7219
04:04:51,064 --> 04:04:51,998
TO DO THIS AND BELIEVE?

7220
04:04:51,998 --> 04:04:54,467
>> SO I MEAN, THE REASON
WE'RE

7221
04:04:54,467 --> 04:04:56,602
DOING SOME OF THIS MODELING BOTH

7222
04:04:56,602 --> 04:04:57,236
IN THE CONTEXT OF THE PLACENTA

7223
04:04:57,236 --> 04:05:02,308
AND THEN THE CONTEXT OF THE

7224
04:05:02,308 --> 04:05:04,544
C-SECTION IS TO INFORM WHETHER

7225
04:05:04,544 --> 04:05:07,113
OR NOT PEOPLE NEED C-SECTIONS

7226
04:05:07,113 --> 04:05:07,680
AND WHETHER OR NOT THEY NEED

7227
04:05:07,680 --> 04:05:07,981
THEM EARLY.

7228
04:05:07,981 --> 04:05:09,849
SO WITH PLACENTA MALFUNCTION,

7229
04:05:09,849 --> 04:05:11,851
YOU OFTEN HAVE A HIGH RATE OF

7230
04:05:11,851 --> 04:05:12,485
STILLBIRTH, SO THEY WILL GO IN

7231
04:05:12,485 --> 04:05:14,887
AND DO A PROPHYLACTIC C-SECTION

7232
04:05:14,887 --> 04:05:16,990
BUT THAT THEN LEADS TO AN

7233
04:05:16,990 --> 04:05:18,291
INDUCED PRETERM BIRTH.

7234
04:05:18,291 --> 04:05:20,159
OR WITH SOMEONE WHO'S HAD A

7235
04:05:20,159 --> 04:05:21,794
PREVIOUS C-SECTION IN AMERICA,

7236
04:05:21,794 --> 04:05:24,430
THEY WILL SCHEDULE ANOTHER

7237
04:05:24,430 --> 04:05:25,264
C-SECTION ALMOST BY DEFAULT.

7238
04:05:25,264 --> 04:05:27,700
THE RATE OF VAGINAL BIRTH AFTER

7239
04:05:27,700 --> 04:05:30,970
CESAREAN SECTION PREVIOUSLY IS

7240
04:05:30,970 --> 04:05:33,139
WELL OVER 50% IN PLACES LIKE

7241
04:05:33,139 --> 04:05:34,240
SCANDINAVIA -- I'M NORWEGIAN SO

7242
04:05:34,240 --> 04:05:35,975
I CAN KEEP REFERRING TO

7243
04:05:35,975 --> 04:05:39,145
SCANDINAVIA.

7244
04:05:39,145 --> 04:05:42,849
BUT SO IN OTHER PLAWS PLACES, M,

7245
04:05:42,849 --> 04:05:45,218
MANY WOMEN HAVE A SUCCESSFUL

7246
04:05:45,218 --> 04:05:46,619
VAGINAL BIRTH AFTER C-SECTION,

7247
04:05:46,619 --> 04:05:48,421
IN THE UNITED STATES, ANOTHER

7248
04:05:48,421 --> 04:05:51,324
C-SECTION IS ALMOST ROUTINELY

7249
04:05:51,324 --> 04:05:51,591
SCHEDULED.

7250
04:05:51,591 --> 04:05:53,993
SO THAT'S ANOTHER PERVASIVE

7251
04:05:53,993 --> 04:05:55,728
PROCEDURE THAT HAS MAJOR

7252
04:05:55,728 --> 04:05:56,829
ABDOMINAL COMPLICATIONS FOR A

7253
04:05:56,829 --> 04:05:58,798
WOMAN WHO'S TRYING TO HOLD A

7254
04:05:58,798 --> 04:06:03,269
NEWBORN BABY WITH A

7255
04:06:03,269 --> 04:06:04,370
10-CENTIMETER GASH ACROSS HER

7256
04:06:04,370 --> 04:06:05,671
FRONT.

7257
04:06:05,671 --> 04:06:07,840
SO THE IDEA IS TO TRY TO REDUCE

7258
04:06:07,840 --> 04:06:08,941
THE C-SECTION RATE AND

7259
04:06:08,941 --> 04:06:10,576
PARTICULARLY IN THE CAUSE OF

7260
04:06:10,576 --> 04:06:11,911
POSSIBLE STILLBIRTH, TO REDUCE

7261
04:06:11,911 --> 04:06:13,646
THE EARLY C-SECTION RATE.

7262
04:06:13,646 --> 04:06:16,149
IF WE CAN USE OUR DIGITAL TWINS

7263
04:06:16,149 --> 04:06:17,784
TO SAY WE CAN DETECT THAT THE

7264
04:06:17,784 --> 04:06:18,885
PLACENTA IS FUNCTIONING, YOU

7265
04:06:18,885 --> 04:06:20,520
DON'T NEED TO DO A C-SECTION

7266
04:06:20,520 --> 04:06:22,255
EARLY, YOU DON'T NEED TO INDUCE

7267
04:06:22,255 --> 04:06:24,123
A PRETERM BIRTH, THAT WOULD BE

7268
04:06:24,123 --> 04:06:24,457
GREAT.

7269
04:06:24,457 --> 04:06:28,461
IF WE COULD DE-RISK A VBAC AND

7270
04:06:28,461 --> 04:06:31,764
ALLOW WOMEN TO CHOOSE TO HAVE A

7271
04:06:31,764 --> 04:06:33,499
VAGINAL BIRTH OR AT LEAST AN

7272
04:06:33,499 --> 04:06:34,834
ATTEMPT AT A TRIAL OF LABOR

7273
04:06:34,834 --> 04:06:37,303
BEFORE JUST ASSUMING A

7274
04:06:37,303 --> 04:06:38,604
C-SECTION, THESE ARE BOTH THINGS

7275
04:06:38,604 --> 04:06:39,739
THAT WOULD IMPROVE WOMEN'S LIVES

7276
04:06:39,739 --> 04:06:42,208
BY REDUCING THE C-SECTION RATE.

7277
04:06:42,208 --> 04:06:44,110
AND SO WE ARE HOPING TO GET

7278
04:06:44,110 --> 04:06:46,612
THESE INTO CLINICAL PRACTICE

7279
04:06:46,612 --> 04:06:48,281
WITH PROSPECTIVE TRIALS IN THE

7280
04:06:48,281 --> 04:06:50,883
VERY NEAR FUTURE.

7281
04:06:50,883 --> 04:06:52,618
>> OKAY, WOW, THAT'S
GREAT.

7282
04:06:52,618 --> 04:06:53,820
THIS WILL BE MY LAST QUESTION

7283
04:06:53,820 --> 04:06:56,456
BEFORE I OPEN UP TO THE COUNCIL.

7284
04:06:56,456 --> 04:06:57,056
I WANT TO LEAVE YOU ALL SOME

7285
04:06:57,056 --> 04:07:01,027
TIME AND I THINK THIS IS MAYBE

7286
04:07:01,027 --> 04:07:04,530
FOR MS. TARIYAL AND KIM.

7287
04:07:04,530 --> 04:07:07,266
YOU'VE LISTED SOME OF THE

7288
04:07:07,266 --> 04:07:07,600
CHALLENGES.

7289
04:07:07,600 --> 04:07:09,202
I'M GOING TO ASK THE WORST

7290
04:07:09,202 --> 04:07:10,336
QUESTION THAT I COULD PROBABLY

7291
04:07:10,336 --> 04:07:12,405
ASK IN THIS FORUM.

7292
04:07:12,405 --> 04:07:14,040
IF YOU SAID IT APPLIED TO MEN IN

7293
04:07:14,040 --> 04:07:17,443
SOME ASPECT, WOULD THAT MAKE THE

7294
04:07:17,443 --> 04:07:21,914
COMMERCIALIZATION EAZIER?

7295
04:07:21,914 --> 04:07:22,882
COMMERCIALIZATION EASIER?

7296
04:07:22,882 --> 04:07:25,451
IT DOESN'T HAVE TO BE FOR

7297
04:07:25,451 --> 04:07:27,019
WOMEN'S REPRODUCTIVE HEALTH.

7298
04:07:27,019 --> 04:07:27,687
I'M CURIOUS IF THAT'S A GOOD

7299
04:07:27,687 --> 04:07:28,888
APPROACH AND HOW HAVE YOU

7300
04:07:28,888 --> 04:07:33,926
RECEIVED THOSE MESSAGES IF THEY

7301
04:07:33,926 --> 04:07:34,627
WERE CORRECT?

7302
04:07:34,627 --> 04:07:36,095
>> WHEN WE WERE FIRST
MAKING

7303
04:07:36,095 --> 04:07:38,498
EVATAR, WE ALSO HAD A MALE

7304
04:07:38,498 --> 04:07:39,832
VERSION, AND TERESA CALLED IT

7305
04:07:39,832 --> 04:07:41,901
THE DUDE CUBE.

7306
04:07:41,901 --> 04:07:42,869
[LAUGHTER]

7307
04:07:42,869 --> 04:07:45,271
AND PEOPLE WERE REALLY

7308
04:07:45,271 --> 04:07:45,838
INTERESTED IN THAT.

7309
04:07:45,838 --> 04:07:48,374
I DON'T KNOW IF IT WERE MEN OR

7310
04:07:48,374 --> 04:07:49,542
WOMEN, BUT WHAT ABOUT -- A LOT

7311
04:07:49,542 --> 04:07:52,612
OF TIMES WHEN WE PRESENTED

7312
04:07:52,612 --> 04:07:54,013
EVATAR, ULTIMATELY THE QUESTION

7313
04:07:54,013 --> 04:07:55,314
IS, DO YOU HAVE A MALE VERSION?

7314
04:07:55,314 --> 04:07:57,517
DO YOU HAVE A MALE VERSION?

7315
04:07:57,517 --> 04:07:59,385
SO I THINK -- I DON'T KNOW THE

7316
04:07:59,385 --> 04:08:02,455
ANSWER TO YOUR QUESTION.

7317
04:08:02,455 --> 04:08:03,856
BUT THE FACT THAT WE ARE ALL --

7318
04:08:03,856 --> 04:08:06,025
THIS IS THE CENTER OF WOMEN'S

7319
04:08:06,025 --> 04:08:08,060
HEALTH RESEARCH, I'M SO HAPPY

7320
04:08:08,060 --> 04:08:08,427
ABOUT THAT.

7321
04:08:08,427 --> 04:08:11,497
WE NEED TO PUSH THIS AGENDA

7322
04:08:11,497 --> 04:08:13,799
FORWARD.

7323
04:08:13,799 --> 04:08:16,402
>> I AM IN THE UNIQUE
POSITION,

7324
04:08:16,402 --> 04:08:20,006
MY PRODUCT CAN'T BE USED -- YOU

7325
04:08:20,006 --> 04:08:24,377
KNOW, FOR BETTER OR FOR WORSE.

7326
04:08:24,377 --> 04:08:26,546
WOULD IT IMPROVE INVESTING?

7327
04:08:26,546 --> 04:08:26,746
MAYBE.

7328
04:08:26,746 --> 04:08:29,649
YOU KNOW, I THINK THAT THE

7329
04:08:29,649 --> 04:08:30,850
BIGGEST PROBLEM IS JUST THAT THE

7330
04:08:30,850 --> 04:08:32,919
PEOPLE THAT UNDERSTAND THE

7331
04:08:32,919 --> 04:08:34,353
CHALLENGES OF MENSTRUAL

7332
04:08:34,353 --> 04:08:36,956
DISORDERS AND THE LONG-TERM

7333
04:08:36,956 --> 04:08:38,858
IMPACT, AND IT'S VERY CLASSIC,

7334
04:08:38,858 --> 04:08:40,560
IF YOU HAVE LIVED EXPERIENCE,

7335
04:08:40,560 --> 04:08:44,063
YOUR MORE EMPATHETIC T TO IT AND

7336
04:08:44,063 --> 04:08:46,365
YOU WANT TO FIND SOLUTIONS AND

7337
04:08:46,365 --> 04:08:48,134
YOU KNOW WHAT IT MEALS LIKE TO

7338
04:08:48,134 --> 04:08:48,768
GO THROUGH THIS, SO THAT

7339
04:08:48,768 --> 04:08:50,503
PROBABLY WAS A BIG MISS TO SAY

7340
04:08:50,503 --> 04:08:52,471
MOST INVESTORS DON'T HAVE THAT

7341
04:08:52,471 --> 04:08:53,539
LIVED EXPERIENCE SO YOU HAVE

7342
04:08:53,539 --> 04:08:54,674
TROUBLE BRIDGING THAT EMPATHY

7343
04:08:54,674 --> 04:08:57,743
GAP, SO I DON'T KNOW THAT -- I

7344
04:08:57,743 --> 04:08:59,912
WAS BEING FACETIOUS, I DON'T

7345
04:08:59,912 --> 04:09:00,580
KNOW THAT I NEEDED TO ACTUALLY

7346
04:09:00,580 --> 04:09:01,781
WORK FOR MEN, BUT IT WOULD HAVE

7347
04:09:01,781 --> 04:09:03,216
BEEN NICE IF THERE WERE MORE

7348
04:09:03,216 --> 04:09:05,618
WOMEN WHO HAD BIGGER

7349
04:09:05,618 --> 04:09:11,424
CHECK-WRITING POWER.

7350
04:09:11,424 --> 04:09:12,892
>> I'LL OPEN UP TO
QUESTIONS

7351
04:09:12,892 --> 04:09:13,593
FROM THE COUNCIL.

7352
04:09:13,593 --> 04:09:18,331
OR I'M HAPPY TO KEEP GOING.

7353
04:09:18,331 --> 04:09:19,966
>> THANK YOU FOR THE GREAT

7354
04:09:19,966 --> 04:09:21,667
PRESENTATION, AND SO YOU SHOWED

7355
04:09:21,667 --> 04:09:23,336
INNOVATIVE RESEARCH APPROACH

7356
04:09:23,336 --> 04:09:25,338
REGARDING MAINLY APPLICATION FOR

7357
04:09:25,338 --> 04:09:27,740
EITHER C-SECTION AND

7358
04:09:27,740 --> 04:09:28,074
ENDOMETRIOSIS.

7359
04:09:28,074 --> 04:09:30,209
SO I WAS WONDERING IF YOU GUYS

7360
04:09:30,209 --> 04:09:31,577
THINK THAT THESE METHODS COULD

7361
04:09:31,577 --> 04:09:34,080
ALSO APPLY IN THE CONTEXT OF

7362
04:09:34,080 --> 04:09:36,716
FIBROIDS, BECAUSE WE DO KNOW

7363
04:09:36,716 --> 04:09:38,684
THAT WHEN SOMEBODY HAS A

7364
04:09:38,684 --> 04:09:39,418
MYOMECTOMY, THERE'S GOING TO BE

7365
04:09:39,418 --> 04:09:41,087
SCAR TISSUE AND THEN IF THERE'S

7366
04:09:41,087 --> 04:09:42,288
A SUBSEQUENT PREGNANCY, THEY'RE

7367
04:09:42,288 --> 04:09:44,490
GOING TO GO TOWARDS A C-SECTION

7368
04:09:44,490 --> 04:09:45,558
BY PREVENTIVE MEASURE.

7369
04:09:45,558 --> 04:09:48,327
AND ALSO, IF ESTABLISHING A

7370
04:09:48,327 --> 04:09:50,096
TRANSCRIPTOMIC PROFILE WITH THE

7371
04:09:50,096 --> 04:09:51,030
MENSTRUAL BLOOD COULD ACTUALLY

7372
04:09:51,030 --> 04:09:52,231
HELP IN THE TREATMENT OF

7373
04:09:52,231 --> 04:09:54,533
FIBROSIS.

7374
04:09:54,533 --> 04:09:55,968
OR FIBROIDS.

7375
04:09:55,968 --> 04:09:56,202
THANKS.

7376
04:09:56,202 --> 04:09:57,570
>> I LOVE THAT QUESTION.

7377
04:09:57,570 --> 04:09:58,904
THANK YOU SO MUCH FOR ASKING IT.

7378
04:09:58,904 --> 04:10:03,376
WE'RE DEEPLY INTERESTED IN

7379
04:10:03,376 --> 04:10:08,848
FIBROIDS, BIG STRUCTURAL CHANGES

7380
04:10:08,848 --> 04:10:09,949
IN ENDOMETRIUM, ENDOMETRIAL

7381
04:10:09,949 --> 04:10:10,316
CANCER.

7382
04:10:10,316 --> 04:10:13,919
ARE WE TRYING TO BE VERY CAREFUL

7383
04:10:13,919 --> 04:10:15,688
ABOUT HOW MUCH WE TAKE ON ALL AT

7384
04:10:15,688 --> 04:10:17,490
ONCE, BUT I WILL TELL YOU THAT

7385
04:10:17,490 --> 04:10:19,692
BECAUSE WOMEN HAVE SO MANY

7386
04:10:19,692 --> 04:10:21,294
COMORBIDITIES, YOU ALMOST CAN'T

7387
04:10:21,294 --> 04:10:22,862
AVOID IT.

7388
04:10:22,862 --> 04:10:24,397
WE ARE RUNNING AN ENDOMETRIOSIS

7389
04:10:24,397 --> 04:10:27,133
TRIAL AND WE HAVE PEOPLE WITH

7390
04:10:27,133 --> 04:10:29,902
FIBROIDS, WITH ADNO, SO WE ARE

7391
04:10:29,902 --> 04:10:31,270
BUILDING THAT DATABASE TO SAY AT

7392
04:10:31,270 --> 04:10:32,305
SOME POINT, YOU'LL HAVE A BIG

7393
04:10:32,305 --> 04:10:34,173
ENOUGH N THAT YOU CAN ACTUALLY

7394
04:10:34,173 --> 04:10:35,207
USE THE SAME TRAINING SET TO

7395
04:10:35,207 --> 04:10:37,176
LOOK AT FIBROIDS, EVEN THOUGH IT

7396
04:10:37,176 --> 04:10:39,712
WAS COLLECTED FOR ENDOMETRIOSIS.

7397
04:10:39,712 --> 04:10:42,315
>> CAN I ASK A FOLLOW-UP
THERE?

7398
04:10:42,315 --> 04:10:43,516
HAVE YOU HAD ANY PATIENT THAT

7399
04:10:43,516 --> 04:10:45,484
BASED ON YOUR PROFILING YOU TOLD

7400
04:10:45,484 --> 04:10:46,786
THEM OF A CONDITION THAT THEY

7401
04:10:46,786 --> 04:10:47,653
WERE NOT AWARE THAT THEY HAD?

7402
04:10:47,653 --> 04:10:49,755
>> WE'RE NOT ALLOWED TO DO
THAT

7403
04:10:49,755 --> 04:10:51,390
BY OUR IRB.

7404
04:10:51,390 --> 04:10:52,358
>> OKAY, WOW.

7405
04:10:52,358 --> 04:10:53,459
OTHER QUESTIONS FROM THE

7406
04:10:53,459 --> 04:10:53,826
COUNCILMEMBERS?

7407
04:10:53,826 --> 04:10:56,862
YES, PLEASE.

7408
04:10:56,862 --> 04:10:58,664
>> THANK YOU ALL SO MUCH
FOR ALL

7409
04:10:58,664 --> 04:11:00,533
OF THOSE TALKS AS AN OB-GYN, I

7410
04:11:00,533 --> 04:11:02,268
FELT REALLY INVIGORATED TO SEE

7411
04:11:02,268 --> 04:11:04,437
WHAT WORK WAS BEING DONE, BUT

7412
04:11:04,437 --> 04:11:05,738
NOW SELFISHLY I WANT TO KNOW HOW

7413
04:11:05,738 --> 04:11:07,506
I CAN USE IT RIGHT NOW.

7414
04:11:07,506 --> 04:11:09,909
AND I GUESS MY BROAD QUESTION

7415
04:11:09,909 --> 04:11:12,311
IS, TO ME, I SEE THIS AS THE

7416
04:11:12,311 --> 04:11:14,080
FUTURE OF LIKE WHAT PRECISION

7417
04:11:14,080 --> 04:11:15,748
MEDICINE LOOKS LIKE FOR

7418
04:11:15,748 --> 04:11:17,783
PATIENTS, SO I OFTEN FIND MYSELF

7419
04:11:17,783 --> 04:11:19,018
COUNSELING PEOPLE, WELL, YOU

7420
04:11:19,018 --> 04:11:21,120
HAVE PCOS BUT IT'S A SPECTRUM,

7421
04:11:21,120 --> 04:11:23,255
SO YOU MAY BE X AND INSERT, YOU

7422
04:11:23,255 --> 04:11:24,457
KNOW, A VARIETY OF THINGS THAT

7423
04:11:24,457 --> 04:11:26,992
VARY.

7424
04:11:26,992 --> 04:11:27,760
HOW FAR AWAY DO YOU THINK WE ARE

7425
04:11:27,760 --> 04:11:29,495
FOR ME BEING ABLE TO SAY, LIKE,

7426
04:11:29,495 --> 04:11:31,597
YOU HAVE THIS TYPE, SO WE'RE

7427
04:11:31,597 --> 04:11:33,566
GOING TO DO X TO MAKE SURE

7428
04:11:33,566 --> 04:11:38,604
YOU'RE BEST TREATED.

7429
04:11:38,604 --> 04:11:43,042
>> TO ME, I'LL ANSWER FOR

7430
04:11:43,042 --> 04:11:43,476
ENDOMETRIOSIS FIRST.

7431
04:11:43,476 --> 04:11:45,611
I THINK THAT THE GOAL WOULD BE,

7432
04:11:45,611 --> 04:11:46,779
AND IT IS ACTUALLY REALLY PART

7433
04:11:46,779 --> 04:11:49,682
OF OUR VISION TO DO THIS FOR

7434
04:11:49,682 --> 04:11:50,850
EVERY REPRODUCTIVE DISORDER TO

7435
04:11:50,850 --> 04:11:52,485
BE ABLE TO MOLECULARLY CLASSIFY

7436
04:11:52,485 --> 04:11:54,186
IT SO YOU CAN MAKE THE DI TINGS

7437
04:11:54,186 --> 04:11:54,720
THAT YOU'RE TALKING ABOUT.

7438
04:11:54,720 --> 04:11:56,756
FOR ENDOMETRIOSIS, PART OF OUR

7439
04:11:56,756 --> 04:11:58,924
MANDATE IS NOT JUST YOU HAVE

7440
04:11:58,924 --> 04:12:00,493
ENDOMETRIOSIS, BUT A THIRD OF

7441
04:12:00,493 --> 04:12:01,927
WOMEN DON'T RESPOND TO HORMONE

7442
04:12:01,927 --> 04:12:02,561
THERAPY.

7443
04:12:02,561 --> 04:12:03,963
SO YOU SHOULD KNOW THAT

7444
04:12:03,963 --> 04:12:05,631
BEFOREHAND SO YOU'RE NOT

7445
04:12:05,631 --> 04:12:06,799
UNNECESSARILY GOING ON HORMONE

7446
04:12:06,799 --> 04:12:08,901
THERAPY AND JUST NOT RESPONDING.

7447
04:12:08,901 --> 04:12:11,203
OR, THERE ARE MANY DRUGS NOW

7448
04:12:11,203 --> 04:12:12,938
BEING DEVELOPED FOR

7449
04:12:12,938 --> 04:12:14,707
ENDOMETRIOSIS THAT ARE TARGETING

7450
04:12:14,707 --> 04:12:17,109
A PARTICULAR PATHWAY, WE'RE

7451
04:12:17,109 --> 04:12:18,010
ACTUALLY WORKING WITH A COUPLE

7452
04:12:18,010 --> 04:12:21,480
OF ENDEAVORS TO EXPLORE IF LET'S

7453
04:12:21,480 --> 04:12:22,915
JUST SAY A PARTICULAR

7454
04:12:22,915 --> 04:12:24,784
INFLAMMATORY PATHWAY IS

7455
04:12:24,784 --> 04:12:25,751
ACTIVATED IN ENDOMETRIOSIS

7456
04:12:25,751 --> 04:12:26,419
POPULATION SUCH THAT THE

7457
04:12:26,419 --> 04:12:27,887
MOLECULE THAT EXISTS TO TARGET

7458
04:12:27,887 --> 04:12:29,288
THAT PATHWAY COULD BE USEFUL.

7459
04:12:29,288 --> 04:12:30,823
AND IN THAT -- THAT'S PROBABLY

7460
04:12:30,823 --> 04:12:32,324
WHAT'S MOST EXCITING TO US, AS

7461
04:12:32,324 --> 04:12:38,931
WE MOVE AWAY FROM JUST -- IF YOU

7462
04:12:38,931 --> 04:12:41,066
WERE ACTIVATED IN X PATHWAY FOR

7463
04:12:41,066 --> 04:12:42,101
ENDOMETRIOSIS, NOW YOU HAVE AN

7464
04:12:42,101 --> 04:12:42,968
ENTIRE DIFFERENT WAR CHEST OF

7465
04:12:42,968 --> 04:12:44,403
DRUGS THAT YOU CAN ACTUALLY

7466
04:12:44,403 --> 04:12:44,837
ACCESS.

7467
04:12:44,837 --> 04:12:48,007
AND FOR THAT, I WOULD SAY IT WEE

7468
04:12:48,007 --> 04:12:49,508
PROBABLY T MINUS FIVE YEARS

7469
04:12:49,508 --> 04:12:50,609
AWAY.

7470
04:12:50,609 --> 04:12:53,446
>> I WOULD PROBABLY SECOND
FIVE

7471
04:12:53,446 --> 04:12:54,647
YEARS AS BEING A REASONABLE TIME

7472
04:12:54,647 --> 04:12:55,648
FRAME FOR STARTING TO SEE SOME

7473
04:12:55,648 --> 04:12:58,250
OF THESE THINGS.

7474
04:12:58,250 --> 04:13:00,619
I THINK PART OF THE CHALLENGE IS

7475
04:13:00,619 --> 04:13:01,987
THAT FROM A RESEARCH

7476
04:13:01,987 --> 04:13:02,855
PERSPECTIVE, A LOT OF WHAT WE'RE

7477
04:13:02,855 --> 04:13:04,290
DOING IS RELATIVELY

7478
04:13:04,290 --> 04:13:04,857
STRAIGHTFORWARD AND THAT THE

7479
04:13:04,857 --> 04:13:06,358
TECHNOLOGY ALREADY EXISTS.

7480
04:13:06,358 --> 04:13:07,760
SO WE DON'T ALWAYS HAVE TO

7481
04:13:07,760 --> 04:13:09,929
DEVELOP ALL NEW TECHNOLOGIES.

7482
04:13:09,929 --> 04:13:11,697
THERE'S CERTAINLY SOME NEW

7483
04:13:11,697 --> 04:13:13,833
TECHNOLOGIES WE HAVE TO DEVELOP,

7484
04:13:13,833 --> 04:13:14,767
BUT THERE'S A LOT OF THINGS

7485
04:13:14,767 --> 04:13:16,302
WHERE IF WE JUST APPLIED THE

7486
04:13:16,302 --> 04:13:17,603
TECHNOLOGIES THAT EXIST ALREADY

7487
04:13:17,603 --> 04:13:18,938
IN OTHER AREAS OF MEDICINE TO

7488
04:13:18,938 --> 04:13:21,040
WOMEN'S HEALTH, WE COULD DO

7489
04:13:21,040 --> 04:13:24,743
THINGS RELATIVELY QUICKLY.

7490
04:13:24,743 --> 04:13:26,145
THE CHALLENGE IN THAT AS A

7491
04:13:26,145 --> 04:13:28,247
RESEARCHER IS THAT IT VERY HARD

7492
04:13:28,247 --> 04:13:30,983
TO GET FUNDING TO DO THINGS THAT

7493
04:13:30,983 --> 04:13:31,884
LOOK SIMPLE AND STRAIGHTFORWARD

7494
04:13:31,884 --> 04:13:32,618
BECAUSE THEY'RE NOT AT THE

7495
04:13:32,618 --> 04:13:34,687
CUTTING EDGE OF DOING NOVEL

7496
04:13:34,687 --> 04:13:35,888
THINGS, AND THE PROBLEM WITH

7497
04:13:35,888 --> 04:13:37,223
WOMEN'S HEALTH IS THAT BECAUSE

7498
04:13:37,223 --> 04:13:38,958
THERE'S SO MANY BLACK HOLES IN

7499
04:13:38,958 --> 04:13:42,895
OUR KNOWLEDGE, THIS INTRODUCES

7500
04:13:42,895 --> 04:13:45,498
AN INTERESTING CHALLENGE.

7501
04:13:45,498 --> 04:13:47,032
SO THAT'S KIND OF WHY I TAKE

7502
04:13:47,032 --> 04:13:48,033
EVERY OPPORTUNITY LIKE THIS TO

7503
04:13:48,033 --> 04:13:49,802
BE ABLE TO TALK TO PEOPLE ABOUT

7504
04:13:49,802 --> 04:13:52,972
WHAT WE DO AND HOW IT DIFFERENT

7505
04:13:52,972 --> 04:13:54,273
THAN WHAT'S ALREADY OUT THERE

7506
04:13:54,273 --> 04:13:54,940
AND WHERE THERE ARE

7507
04:13:54,940 --> 04:13:56,342
OPPORTUNITIES FOR INNOVATION,

7508
04:13:56,342 --> 04:13:58,944
USING ENGINEERING IN WOMEN'S

7509
04:13:58,944 --> 04:13:59,745
HEALTH, BECAUSE I THINK THERE

7510
04:13:59,745 --> 04:14:01,380
JUST NEEDS TO BE SORT OF GETTING

7511
04:14:01,380 --> 04:14:02,715
EVERYBODY ON BOARD TO THE IDEA

7512
04:14:02,715 --> 04:14:04,216
THAT THIS IS SOMETHING THAT

7513
04:14:04,216 --> 04:14:06,652
COULD HAPPEN WITH EXISTING

7514
04:14:06,652 --> 04:14:10,022
TECHNOLOGY IF WE COULD JUST PUT

7515
04:14:10,022 --> 04:14:11,790
MECHANISMS IN PLACE TO FUND THE

7516
04:14:11,790 --> 04:14:14,627
STUDIES THAT NEED TO BE DONE TO

7517
04:14:14,627 --> 04:14:15,528
DEMONSTRATE THE THINGS THAT

7518
04:14:15,528 --> 04:14:17,062
ALREADY EXIST WOULD BENEFIT

7519
04:14:17,062 --> 04:14:21,333
HUMAN HEALTH IN THIS WAY.

7520
04:14:21,333 --> 04:14:22,968
>> I JUST WANT TO ADD ALSO
THAT

7521
04:14:22,968 --> 04:14:25,137
WE HAVE SO MUCH DATA OUT THERE.

7522
04:14:25,137 --> 04:14:26,272
THERE'S JUST SO MUCH.

7523
04:14:26,272 --> 04:14:27,339
YOU JUST DO WHOLE GENOME

7524
04:14:27,339 --> 04:14:28,874
SEQUENCING IN ONE PATIENT,

7525
04:14:28,874 --> 04:14:31,076
THERE'S SO MUCH INFORMATION OUT

7526
04:14:31,076 --> 04:14:34,480
THERE, AND IT'S JUST A MATTER OF

7527
04:14:34,480 --> 04:14:38,183
TRYING TO USE THAT DATA AND LOOK

7528
04:14:38,183 --> 04:14:39,818
AT IT IN DIFFERENT AND VERY

7529
04:14:39,818 --> 04:14:41,387
CREATIVE WAYS SO THAT YOU CAN

7530
04:14:41,387 --> 04:14:42,588
GET NEW INFORMATION OUT OF THAT.

7531
04:14:42,588 --> 04:14:45,424
I FEEL LIKE WE HAVE THE DATA, WE

7532
04:14:45,424 --> 04:14:47,226
JUST NEED TO MINE THROUGH IT,

7533
04:14:47,226 --> 04:14:49,028
AND IT'S GOING TO TAKE A LOT OF

7534
04:14:49,028 --> 04:14:50,996
PEOPLE IN DIFFERENT FIELDS TO

7535
04:14:50,996 --> 04:14:51,997
COME TOGETHER TO MAKE SENSE OF

7536
04:14:51,997 --> 04:14:57,136
IT ALL.

7537
04:14:57,136 --> 04:15:01,273
>> YES.

7538
04:15:01,273 --> 04:15:06,645
>> IGHO FROM EMORY.

7539
04:15:06,645 --> 04:15:08,080
REALLY FASCINATING TO SEE ALL

7540
04:15:08,080 --> 04:15:09,615
THESE WONDERFUL ADVANCES.

7541
04:15:09,615 --> 04:15:10,482
JUST WONDERING IF YOU'RE

7542
04:15:10,482 --> 04:15:14,320
THINKING AHEAD OF DISSEMINATION

7543
04:15:14,320 --> 04:15:15,688
IMPLEMENTATION.

7544
04:15:15,688 --> 04:15:16,322
WHEN ALL OF THIS BECOMES -- FIVE

7545
04:15:16,322 --> 04:15:17,723
YEARS FROM NOW, YOUR TECHNOLOGY

7546
04:15:17,723 --> 04:15:23,529
IS READY TO BE ROLLED OUT.

7547
04:15:23,529 --> 04:15:24,930
SOME OF THE -- IMPLEMENTATION.

7548
04:15:24,930 --> 04:15:25,931
I DON'T KNOW IF YOU'VE BEEN

7549
04:15:25,931 --> 04:15:31,837
THINKING ABOUT THAT.

7550
04:15:31,837 --> 04:15:35,007
>> ANYONE?

7551
04:15:35,007 --> 04:15:36,742
>> FOR US WHEN WE THINK
ABOUT

7552
04:15:36,742 --> 04:15:38,077
THE PRODUCT GOING TO MARKET, I

7553
04:15:38,077 --> 04:15:40,446
THINK THE BIGGEST CHALLENGE THAT

7554
04:15:40,446 --> 04:15:43,015
WE CONSIDER IS THAT THE CURRENT

7555
04:15:43,015 --> 04:15:44,550
GOLD STANDARD DIAGNOSTIC IS

7556
04:15:44,550 --> 04:15:45,217
SURGERY.

7557
04:15:45,217 --> 04:15:49,355
AND YOU'RE NOT PROVIDING

7558
04:15:49,355 --> 04:15:51,757
SOMETHING THAT'S SIMILAR, YOU'RE

7559
04:15:51,757 --> 04:15:52,758
PROVIDING SOMETHING COMPLETELY

7560
04:15:52,758 --> 04:15:57,229
NOVEL, WHICH IS A FIRST GENOMIC

7561
04:15:57,229 --> 04:15:59,198
WAY TO LOOK AT MENSTRUAL BLOOD,

7562
04:15:59,198 --> 04:16:00,633
JUST ADDING LAYERS OF NOVELTY,

7563
04:16:00,633 --> 04:16:01,300
RIGHT?

7564
04:16:01,300 --> 04:16:07,373
M, SOMETHING THAT A SURGEONWOULO

7565
04:16:07,373 --> 04:16:08,273
DESCRIBEMENT SO I THINK FOR US

7566
04:16:08,273 --> 04:16:12,311
WHEN WE THINK ABOUT

7567
04:16:12,311 --> 04:16:13,278
DISSEMINATION, THE EDUCATION

7568
04:16:13,278 --> 04:16:14,279
PIECE, WHO ARE YOU TRYING TO

7569
04:16:14,279 --> 04:16:15,481
EDUCATE WITH THIS?

7570
04:16:15,481 --> 04:16:17,349
IS IT SURGEONS?

7571
04:16:17,349 --> 04:16:18,217
USUALLY -- I'VE BEEN TOLD BY

7572
04:16:18,217 --> 04:16:19,184
ALMOST EVERY SURGEON BY THE TIME

7573
04:16:19,184 --> 04:16:20,619
THEY GET TO MY OFFICE, I DON'T

7574
04:16:20,619 --> 04:16:22,454
NEED ANY HELP IN DIAGNOSING,

7575
04:16:22,454 --> 04:16:23,889
WHETHER OR NOT THEY HAVE

7576
04:16:23,889 --> 04:16:24,556
ENDOMETRIOSIS.

7577
04:16:24,556 --> 04:16:25,524
SO DOES THAT MEAN THAT IT GOES

7578
04:16:25,524 --> 04:16:28,727
TO THE GYN?

7579
04:16:28,727 --> 04:16:30,429
AND THEN THE LATEST RESEARCH

7580
04:16:30,429 --> 04:16:31,063
SHOWS THAT THIS REALLY IS A

7581
04:16:31,063 --> 04:16:32,665
CONDITION THAT STARTS AT

7582
04:16:32,665 --> 04:16:33,098
MENARCHE.

7583
04:16:33,098 --> 04:16:34,767
SO IS IT PEDIATRICIANS THAT

7584
04:16:34,767 --> 04:16:36,301
REALLY NEED TO BE TRAINED ON IT,

7585
04:16:36,301 --> 04:16:37,936
SO WE NEED TO THINK ABOUT

7586
04:16:37,936 --> 04:16:38,804
DISSEMINATION, WE THINK WHO

7587
04:16:38,804 --> 04:16:41,907
NEEDS TO BE TRAINED ON THIS AND

7588
04:16:41,907 --> 04:16:43,342
IN WHAT WAYS.

7589
04:16:43,342 --> 04:16:47,579
>> WE'VE PK VE BECOME VERY
INTED

7590
04:16:47,579 --> 04:16:48,180
IN ULTRASOUND FOR EVERYTHING

7591
04:16:48,180 --> 04:16:49,081
THAT WE'RE DOING BECAUSE OF THE

7592
04:16:49,081 --> 04:16:51,984
FACT THAT IT CAN BE DISSEMINATED

7593
04:16:51,984 --> 04:16:53,652
ESPECIALLY IN MATERNAL

7594
04:16:53,652 --> 04:16:55,287
HEALTHCARE DESERTS HERE IN THE

7595
04:16:55,287 --> 04:16:56,655
UNITED STATES AND ESPECIALLY IN

7596
04:16:56,655 --> 04:16:58,290
LOW AND MIDDLE INCOME COUNTRIES.

7597
04:16:58,290 --> 04:17:00,092
BECAUSE I CAN NOW BUY, AND I

7598
04:17:00,092 --> 04:17:01,393
HAVE, AN ULTRASOUND PROBE THAT

7599
04:17:01,393 --> 04:17:03,162
IS THE SIZE OF YOUR CELL PHONE

7600
04:17:03,162 --> 04:17:04,596
AND THAT TALKS TO MY CELL PHONE

7601
04:17:04,596 --> 04:17:06,865
OR MY iPAD, AND, THEREFORE, I

7602
04:17:06,865 --> 04:17:09,968
DON'T NEED A FANCY CLINIC-BASED

7603
04:17:09,968 --> 04:17:10,502
ULTRASOUND CART.

7604
04:17:10,502 --> 04:17:12,705
I CAN USE THIS PROBE AND THE

7605
04:17:12,705 --> 04:17:13,639
ADVANTAGE OF THE PROBE IS NOT

7606
04:17:13,639 --> 04:17:16,108
ONLY THAT IT'S PORTABLE, BUT

7607
04:17:16,108 --> 04:17:18,944
BECAUSE IT'S NOT FROM ONE OF THE

7608
04:17:18,944 --> 04:17:20,012
GIANTS IN MEDICAL IMAGING WHO

7609
04:17:20,012 --> 04:17:22,314
ARE USED TO THEIR REVENUE

7610
04:17:22,314 --> 04:17:23,849
STREAMS, I CAN GET THE RAW DATA.

7611
04:17:23,849 --> 04:17:25,718
AND SO NOT ONLY CAN I GET THE

7612
04:17:25,718 --> 04:17:27,519
IMAGES FOR BUILDING MY

7613
04:17:27,519 --> 04:17:28,821
COMPUTATIONAL MODEL, I CAN ALSO

7614
04:17:28,821 --> 04:17:31,790
GET RAW DATA OUT OF THEM AND GET

7615
04:17:31,790 --> 04:17:32,524
ADDITIONAL INFORMATION THAT I

7616
04:17:32,524 --> 04:17:34,293
DON'T HAVE ACCESS TO IN A

7617
04:17:34,293 --> 04:17:35,961
COMMERCIAL ULTRASOUND.

7618
04:17:35,961 --> 04:17:38,130
AND SO THE GOLD STANDARD FOR

7619
04:17:38,130 --> 04:17:40,632
BUILDING COMPUTATIONAL MODELS IN

7620
04:17:40,632 --> 04:17:41,333
THREE DIMENSIONS WOULD BE MRI,

7621
04:17:41,333 --> 04:17:42,835
BUT THAT'S NEVER GOING TO BE

7622
04:17:42,835 --> 04:17:44,603
CLINICALLY SCALABLE, AND THAT'S

7623
04:17:44,603 --> 04:17:46,905
EXACTLY WHY WE'RE FOCUSING

7624
04:17:46,905 --> 04:17:47,673
EVERYTHING ON ULTRASOUND.

7625
04:17:47,673 --> 04:17:48,874
AND I DIDN'T MENTION IT, WHICH

7626
04:17:48,874 --> 04:17:50,509
IS QUITE SURPRISING SINCE IT'S

7627
04:17:50,509 --> 04:17:51,910
USUALLY SOMETHING I SPEND A LOT

7628
04:17:51,910 --> 04:17:53,712
OF TIME TALKING ABOUT, BUT WE

7629
04:17:53,712 --> 04:17:55,247
USE ALL OPEN SOURCE SOFTWARE FOR

7630
04:17:55,247 --> 04:17:57,449
OUR MODELING AS WELL, AND SO WE

7631
04:17:57,449 --> 04:18:00,085
ARE NOT USING COMMERCIAL

7632
04:18:00,085 --> 04:18:02,154
PROPRIETARY MODELING SOFTWARE,

7633
04:18:02,154 --> 04:18:05,591
WE ARE, IN FACT, USING FEBIO,

7634
04:18:05,591 --> 04:18:07,326
WHICH CAME OUT OF NIH AND IS

7635
04:18:07,326 --> 04:18:07,760
OPEN SOURCE.

7636
04:18:07,760 --> 04:18:09,027
SO ALL OF THE WORK THAT WE'RE

7637
04:18:09,027 --> 04:18:11,063
DOING IS BASED ON PLATFORMS THAT

7638
04:18:11,063 --> 04:18:16,201
ARE LOW COST FOR WIDE SCALE

7639
04:18:16,201 --> 04:18:18,370
DISSEMINATION INTO NOT JUST

7640
04:18:18,370 --> 04:18:21,006
WEALTHY AREAS WITH VERY HIGH

7641
04:18:21,006 --> 04:18:22,441
QUALITY MEDICAL CARE.

7642
04:18:22,441 --> 04:18:23,308
ESPECIALLY IN THE U.S. RIGHT

7643
04:18:23,308 --> 04:18:26,278
NOW, WHERE THE HEALTHCARE

7644
04:18:26,278 --> 04:18:28,347
DESERTS FOR MATERNAL CARE ARE

7645
04:18:28,347 --> 04:18:28,714
GETTING WORSE.

7646
04:18:28,714 --> 04:18:33,285
>> AS FOR OUR DEVICE, I
WOULD

7647
04:18:33,285 --> 04:18:35,554
LOVE EVERYONE THAT WORKS WITH

7648
04:18:35,554 --> 04:18:36,922
CELL CULTURE TO USE IT.

7649
04:18:36,922 --> 04:18:39,758
SO IT WOULD BE AN ALTERNATIVE TO

7650
04:18:39,758 --> 04:18:40,526
CELL CULTURES.

7651
04:18:40,526 --> 04:18:43,796
BUT BEYOND THAT, LIKE I SAID,

7652
04:18:43,796 --> 04:18:45,697
WHAT IS THE MARKET?

7653
04:18:45,697 --> 04:18:46,331
BEYOND RESEARCH?

7654
04:18:46,331 --> 04:18:48,100
WE CAN TRANSLATE THAT INTO

7655
04:18:48,100 --> 04:18:52,471
ANYTHING THAT REQUIRES FRESH

7656
04:18:52,471 --> 04:18:53,939
MEDIA BEING DELIVERED, OLD MEDIA

7657
04:18:53,939 --> 04:18:55,541
TAKEN OUT TO INCREASE LONGEVITY,

7658
04:18:55,541 --> 04:18:57,876
WE THOUGHT POTENTIALLY IVF TO

7659
04:18:57,876 --> 04:19:01,914
INCREASE THE NUMBER THAT ARE

7660
04:19:01,914 --> 04:19:03,749
MORE VIABLE GIVING THE WOMAN A

7661
04:19:03,749 --> 04:19:05,551
GREATER CHANCE OF A PREGNANCY.

7662
04:19:05,551 --> 04:19:07,286
EVEN IN THE INDUSTRY,

7663
04:19:07,286 --> 04:19:10,255
AGRICULTURAL INDUSTRY, IN VITRO

7664
04:19:10,255 --> 04:19:11,557
FERTILIZATION IS USED FOR THE

7665
04:19:11,557 --> 04:19:13,225
DAIRY AND -- I MEAN, THERE'S

7666
04:19:13,225 --> 04:19:15,294
JUST SO MANY NEEDS OUT THERE,

7667
04:19:15,294 --> 04:19:16,495
BUT ULTIMATELY, I WOULD LOVE TO

7668
04:19:16,495 --> 04:19:21,800
SEE THE DEVICE BENEFIT PATIENT

7669
04:19:21,800 --> 04:19:23,435
CONDITIONS AND TO TEST THE MOST

7670
04:19:23,435 --> 04:19:26,572
EFFECTIVE TREATMENTS IN THE

7671
04:19:26,572 --> 04:19:27,673
PLATFORM BEFORE IT ACTUALLY GOES

7672
04:19:27,673 --> 04:19:30,309
INTO THE PATIENT.

7673
04:19:30,309 --> 04:19:30,809
>> THIS HAS BEEN GREAT.

7674
04:19:30,809 --> 04:19:32,211
WE ARE OUT OF TIME, BUT I DO

7675
04:19:32,211 --> 04:19:33,512
ALSO WANT TO MAKE ONE MORE PLUG

7676
04:19:33,512 --> 04:19:34,046
HERE.

7677
04:19:34,046 --> 04:19:35,514
I THINK -- I WAS A PROFESSOR IN

7678
04:19:35,514 --> 04:19:37,583
THE LARGEST BIOMEDICAL

7679
04:19:37,583 --> 04:19:38,350
ENGINEERING DEPARTMENT IN THE

7680
04:19:38,350 --> 04:19:38,784
COUNTRY.

7681
04:19:38,784 --> 04:19:39,985
THE WOMEN STUDENTS ARE READY,

7682
04:19:39,985 --> 04:19:42,621
THEY ARE INVOLVED, THIS IS A

7683
04:19:42,621 --> 04:19:44,056
GREAT ATTRACTIVE TOOL FOR OUR

7684
04:19:44,056 --> 04:19:45,490
COMMUNITY TO BRING PEOPLE IN AND

7685
04:19:45,490 --> 04:19:46,358
TO ASK THESE QUESTIONS EARLY ON

7686
04:19:46,358 --> 04:19:47,593
AND TO BEGIN TO THINK ABOUT THIS

7687
04:19:47,593 --> 04:19:49,561
IN THE EARLY STAGES OF LEARNING.

7688
04:19:49,561 --> 04:19:50,629
SO THANK YOU ALL FOR BRINGING

7689
04:19:50,629 --> 04:19:51,630
TECHNOLOGY TO WOMEN'S HEALTH AND

7690
04:19:51,630 --> 04:19:54,299
THANK YOU ALL FOR THIS TIME.

7691
04:19:54,299 --> 04:20:00,839
[APPLAUSE]

7692
04:20:00,839 --> 04:20:01,473
>> THANK YOU, DR. PLATT,
AND

7693
04:20:01,473 --> 04:20:02,841
THANK YOU, PANELISTS.

7694
04:20:02,841 --> 04:20:03,709
REALLY TERRIFIC PRESENTATIONS

7695
04:20:03,709 --> 04:20:06,678
AND DISCUSSION.

7696
04:20:06,678 --> 04:20:08,547
I'D LIKE TO NOW INVITE

7697
04:20:08,547 --> 04:20:09,748
DR. CLAYTON TO INTRODUCE OUR

7698
04:20:09,748 --> 04:20:14,887
NEXT SPEAKER.

7699
04:20:14,887 --> 04:20:17,890
>> IT'S MY PLEASURE TO
INTRODUCE

7700
04:20:17,890 --> 04:20:19,625
DR. SUSAN MARGULIES.

7701
04:20:19,625 --> 04:20:21,693
SHE LEADS THE DIRECTORATE FOR

7702
04:20:21,693 --> 04:20:22,461
ENGINEERING AND AS YOU KNOW,

7703
04:20:22,461 --> 04:20:23,896
THEY HAVE A MISSION TO TRANSFORM

7704
04:20:23,896 --> 04:20:24,763
OUR WORLD FOR A BETTER TOMORROW

7705
04:20:24,763 --> 04:20:29,268
BY DRIVING DISCOVERY, INSPIRING

7706
04:20:29,268 --> 04:20:30,135
INNOVATION, ENRICHING EDUCATION

7707
04:20:30,135 --> 04:20:33,338
AND ACCELERATING ACCESS.

7708
04:20:33,338 --> 04:20:35,407
THE NSF'S ENGINEERING

7709
04:20:35,407 --> 04:20:37,342
DIRECTORATE PROVIDES OVER 40% OF

7710
04:20:37,342 --> 04:20:39,144
THE FEDERAL FUNDING FOR

7711
04:20:39,144 --> 04:20:40,779
FUNDAMENTAL RESEARCH IN

7712
04:20:40,779 --> 04:20:42,581
ENGINEERING AT ACADEMIC

7713
04:20:42,581 --> 04:20:42,915
INSTITUTIONS.

7714
04:20:42,915 --> 04:20:44,616
AND WE'RE THRILLED TO HAVE HER

7715
04:20:44,616 --> 04:20:45,284
HERE TODAY.

7716
04:20:45,284 --> 04:20:47,920
SHE JOINED NSF AS ASSISTANT

7717
04:20:47,920 --> 04:20:50,222
DIRECTOR IN AUGUST OF 2021,

7718
04:20:50,222 --> 04:20:53,525
AFTER LEADING THE DEPARTMENT OF

7719
04:20:53,525 --> 04:20:57,462
BIOMEDICAL ENGINEERING AT

7720
04:20:57,462 --> 04:20:58,096
GEORGIA INSTITUTE OF TECHNOLOGY

7721
04:20:58,096 --> 04:21:00,432
AND EMORY UNIVERSITY.

7722
04:21:00,432 --> 04:21:02,067
DR. MARGULIES, I DISCUSSED THIS

7723
04:21:02,067 --> 04:21:03,502
WITH YOU WHEN WE FIRST MET

7724
04:21:03,502 --> 04:21:05,904
FAIRLY RECENTLY, IS

7725
04:21:05,904 --> 04:21:06,772
INTERNATIONALLY RECOGNIZED FOR

7726
04:21:06,772 --> 04:21:09,741
PIONEERING STUDIES TO IDENTIFY

7727
04:21:09,741 --> 04:21:10,309
MECHANISMS UNDERLYING BRAIN

7728
04:21:10,309 --> 04:21:11,510
INJURIES IN CHILDREN AND

7729
04:21:11,510 --> 04:21:13,145
ADOLESCENTS, AND LUNG INJURIES

7730
04:21:13,145 --> 04:21:15,681
ASSOCIATED WITH MECHANICAL

7731
04:21:15,681 --> 04:21:18,951
VENTILATION, LEADING TO IMPROVED

7732
04:21:18,951 --> 04:21:20,285
INJURY PREVENTION DIAGNOSIS AND

7733
04:21:20,285 --> 04:21:22,587
TREATMENTS.

7734
04:21:22,587 --> 04:21:25,223
HER TRANSDISCIPLINARY SCHOLARLY

7735
04:21:25,223 --> 04:21:26,758
IMPACT HAS BEEN RECOGNIZED BY

7736
04:21:26,758 --> 04:21:29,161
HER ELECTION AS A FELLOW IN THE

7737
04:21:29,161 --> 04:21:30,929
AMERICAN SOCIETY SOCIETY OF MECL

7738
04:21:30,929 --> 04:21:32,464
ENGINEER, THE BIOMEDICAL

7739
04:21:32,464 --> 04:21:34,366
ENGINEERING SOCIETY, AND THE

7740
04:21:34,366 --> 04:21:35,834
AMERICAN INSTITUTE FOR MEDICAL

7741
04:21:35,834 --> 04:21:40,339
AND BIOLOGICAL ENGINEERING.

7742
04:21:40,339 --> 04:21:43,608
SHE IS A MEMBER OF THE NATIONAL

7743
04:21:43,608 --> 04:21:46,311
ACADEMY OF ENG FEARING, NATIONAL

7744
04:21:46,311 --> 04:21:47,279
ACADEMY OF MEDICINE AND THE

7745
04:21:47,279 --> 04:21:48,146
AMERICAN ACADEMY OF ARTS AND

7746
04:21:48,146 --> 04:21:48,647
SCIENCES.

7747
04:21:48,647 --> 04:21:50,248
IT'S MY PLEASURE TO INTRODUCE

7748
04:21:50,248 --> 04:21:50,716
DR. SUSAN MARGULIES.

7749
04:21:50,716 --> 04:21:56,655
>> THANK YOU.

7750
04:21:56,655 --> 04:21:59,257
>> ABOUT HALF OF -- UNLIKE
NSF

7751
04:21:59,257 --> 04:22:01,059
WHERE THE DIRECTORS OF THE

7752
04:22:01,059 --> 04:22:02,594
INSTITUTES AND CENTERS ARE

7753
04:22:02,594 --> 04:22:03,695
PERMANENT FEDS, AT NSF, ABOUT

7754
04:22:03,695 --> 04:22:07,566
HALF OF US WHO LEAD DIRECTORATES

7755
04:22:07,566 --> 04:22:08,433
ARE ROTATORS.

7756
04:22:08,433 --> 04:22:10,268
SO I'M ON A FOUR-YEAR TERM.

7757
04:22:10,268 --> 04:22:12,471
I STILL HAVE MY EMORY AND

7758
04:22:12,471 --> 04:22:13,205
GEORGIA TECH PAYCHECKS.

7759
04:22:13,205 --> 04:22:14,840
I'M NO LONGER CHAIR OF THE

7760
04:22:14,840 --> 04:22:17,042
DEPARTMENT THAT MANU IS PART OF,

7761
04:22:17,042 --> 04:22:21,413
BUT I STILL RUN A LAB AND I HAVE

7762
04:22:21,413 --> 04:22:22,614
THE OPPORTUNITY AND TAKE TO GO

7763
04:22:22,614 --> 04:22:24,483
BACK TO ATLANTA ONCE A MONTH TO

7764
04:22:24,483 --> 04:22:25,450
DO EXPERIMENTS.

7765
04:22:25,450 --> 04:22:27,452
SO IT'S KIND OF AN ECLECTIC

7766
04:22:27,452 --> 04:22:29,855
OPPORTUNITY, BUT IT'S ALSO AN

7767
04:22:29,855 --> 04:22:31,289
OPPORTUNITY TO SERVE THE NATION

7768
04:22:31,289 --> 04:22:34,526
BY BRINGING ACTIVE RESEARCH

7769
04:22:34,526 --> 04:22:38,063
MINDSET TO THE NATIONAL SCIENCE

7770
04:22:38,063 --> 04:22:38,463
FOUNDATION.

7771
04:22:38,463 --> 04:22:40,766
MOST OF MY RESEARCH OVER THE

7772
04:22:40,766 --> 04:22:45,470
COURSE OF MY DECADES-LONG CAREER

7773
04:22:45,470 --> 04:22:46,338
THAT BE NIH.

7774
04:22:46,338 --> 04:22:47,439
SO ONE OF THE THINGS THAT I

7775
04:22:47,439 --> 04:22:49,441
BRING TO THE ENGINEERING

7776
04:22:49,441 --> 04:22:51,243
DIRECTORATE, AND I AM THE FIRST

7777
04:22:51,243 --> 04:22:52,077
BIOENGINEER TO LEAD THE

7778
04:22:52,077 --> 04:22:54,246
ENGINEERING DIRECTORATE, IS TO

7779
04:22:54,246 --> 04:22:55,981
ADDRESS FUNDING DEZ ERTS.

7780
04:22:55,981 --> 04:22:57,749
YOU WERE TALKING ABOUT A FUNDING

7781
04:22:57,749 --> 04:22:59,184
DESERT RELATED TO WOMEN'S HEALTH

7782
04:22:59,184 --> 04:23:01,486
THAT IS BROADER THAN ONE AGENCY.

7783
04:23:01,486 --> 04:23:03,588
BUT I WANT TO ALSO TALK ABOUT

7784
04:23:03,588 --> 04:23:05,791
IPT AGENCY COLLABORATION AND THE

7785
04:23:05,791 --> 04:23:09,261
FUNDING DEZ ERTS THAT OCCUR.

7786
04:23:09,261 --> 04:23:10,929
SO AT THE NATIONAL SCIENCE

7787
04:23:10,929 --> 04:23:11,663
FOUNDATION, WE FUND ALL

7788
04:23:11,663 --> 04:23:14,299
ENGINEERING, ALL SCIENCE, AND A

7789
04:23:14,299 --> 04:23:18,070
FUNDAMENTAL LEVEL WITH EARLY

7790
04:23:18,070 --> 04:23:19,404
TRANSLATION.

7791
04:23:19,404 --> 04:23:20,138
AS YOU'LL SEE FROM MY FIRST

7792
04:23:20,138 --> 04:23:21,273
SLIDE, HEALTH IS IN THE NAME OF

7793
04:23:21,273 --> 04:23:25,077
OUR AGENCY'S MISSION.

7794
04:23:25,077 --> 04:23:27,279
TO REALLY BE A BIOENGINEER AND

7795
04:23:27,279 --> 04:23:28,947
BIOMEDICAL ENGINEER AND IDENTIFY

7796
04:23:28,947 --> 04:23:31,016
FOR OUR P.I. POPULATIONS, WHEN

7797
04:23:31,016 --> 04:23:33,618
DO THEY GO TO NSF, WHEN DO THEY

7798
04:23:33,618 --> 04:23:35,720
GO TO NIH, FOR THAT IMPORTANT

7799
04:23:35,720 --> 04:23:37,389
FUNDING.

7800
04:23:37,389 --> 04:23:38,924
AND I'M PLEASED TO SHARE WITH

7801
04:23:38,924 --> 04:23:41,326
YOU THE OPPORTUNITY TO DECREASE

7802
04:23:41,326 --> 04:23:42,627
THOSE FUNDING DESERTS AND

7803
04:23:42,627 --> 04:23:43,395
COLLABORATE ACROSS AGENCIES.

7804
04:23:43,395 --> 04:23:45,197
SO I WOULD SAY THE PURPOSE OF MY

7805
04:23:45,197 --> 04:23:49,568
TALK IS TO ASK YOU TO HELP US

7806
04:23:49,568 --> 04:23:51,002
THINK ABOUT REDUCING THOSE

7807
04:23:51,002 --> 04:23:53,405
FUNDING DESERTS AND FIND THOSE

7808
04:23:53,405 --> 04:23:55,707
OPPORTUNITIES FOR SYNERGY TO

7809
04:23:55,707 --> 04:23:57,742
REALLY CATALYZE RESEARCH AT THE

7810
04:23:57,742 --> 04:24:00,078
INTERFACE THAT SERVES THE NEEDS

7811
04:24:00,078 --> 04:24:02,814
OF BOTH NIH AND NSF.

7812
04:24:02,814 --> 04:24:06,218
AND I WOULD SAY I'M DOING THIS

7813
04:24:06,218 --> 04:24:07,419
IN ALL ENGINEERING.

7814
04:24:07,419 --> 04:24:08,086
DEPARTMENT OF TRANSPORTATION HAS

7815
04:24:08,086 --> 04:24:10,755
NEVER REALLY HAD RELATIONSHIPS

7816
04:24:10,755 --> 04:24:11,423
WITH THE NATIONAL SCIENCE

7817
04:24:11,423 --> 04:24:14,593
FOUNDATION, BUT ALSO DOD, AND AS

7818
04:24:14,593 --> 04:24:16,862
WELL THE DEPARTMENT OF COMMERCE

7819
04:24:16,862 --> 04:24:19,397
AND THE DEPARTMENT OF ENERGY.

7820
04:24:19,397 --> 04:24:21,299
BIG PARTNERS FOR US TO REALLY

7821
04:24:21,299 --> 04:24:23,368
IDENTIFY THOSE FUNDING DESERTS

7822
04:24:23,368 --> 04:24:24,936
AND TO ACCELERATE THE

7823
04:24:24,936 --> 04:24:27,339
TRANSLATION FROM FUNDAMENTAL

7824
04:24:27,339 --> 04:24:28,673
RESEARCH TO AN APPLICATION

7825
04:24:28,673 --> 04:24:31,042
THAT'S IN THE HANDS OF THOSE IN

7826
04:24:31,042 --> 04:24:31,943
OUR COUNTRY AND IMPROVE THE

7827
04:24:31,943 --> 04:24:36,114
QUALITY OF THE LIVES FOR ALL.

7828
04:24:36,114 --> 04:24:37,949
IN ADDITION, THE ENGINEERING

7829
04:24:37,949 --> 04:24:39,751
DIRECTORATE WAS FORMED AT A

7830
04:24:39,751 --> 04:24:41,419
TIME, 1981, NOT UNLIKE TODAY,

7831
04:24:41,419 --> 04:24:43,922
WHEN THE U.S. DID NOT HAVE

7832
04:24:43,922 --> 04:24:47,993
INDUSTRIAL PROMINENCE GLOBALLY

7833
04:24:47,993 --> 04:24:48,360
AS WE ONCE DID.

7834
04:24:48,360 --> 04:24:49,928
SO THE ENGINEERING DIRECTORATE

7835
04:24:49,928 --> 04:24:53,131
WAS LAUNCHED THAT TIME TO

7836
04:24:53,131 --> 04:24:55,767
IDENTIFY CLOSE SYNERGIES WITH

7837
04:24:55,767 --> 04:24:56,034
INDUSTRY.

7838
04:24:56,034 --> 04:24:57,869
BOTH IN TERMS OF AREAS RESEARCH

7839
04:24:57,869 --> 04:25:01,173
THAT WERE SO IMPORTANT, BUT ALSO

7840
04:25:01,173 --> 04:25:03,241
THE ENGINEERING WORKFORCE.

7841
04:25:03,241 --> 04:25:04,876
SO THE OTHER PLACE THAT WE

7842
04:25:04,876 --> 04:25:06,978
COLLABORATE BETWEEN OUR AGENCIES

7843
04:25:06,978 --> 04:25:09,314
ARE THE OPPORTUNITY TO TRAIN AND

7844
04:25:09,314 --> 04:25:11,449
I CREASE NOT ONLY THE

7845
04:25:11,449 --> 04:25:12,017
EDUCATIONAL PATHWAYS BUT THE

7846
04:25:12,017 --> 04:25:14,653
WORKFORCE DEVELOPMENT PATHWAYS

7847
04:25:14,653 --> 04:25:17,455
FOR BIOENGINEERS AND BAY OWE

7848
04:25:17,455 --> 04:25:17,856
MEDICAL ENGINEERS.

7849
04:25:17,856 --> 04:25:19,357
I DO ALL ENGINEERING IN YOU MY

7850
04:25:19,357 --> 04:25:21,126
ROLE RIGHT NOW, BUT FOR TODAY,

7851
04:25:21,126 --> 04:25:22,961
THAT'S AN IMPORTANT ONE AS WELL.

7852
04:25:22,961 --> 04:25:25,430
WE HAVE A COLLABORATION IN

7853
04:25:25,430 --> 04:25:27,499
PLACE, I DECIDED AT THE VERY

7854
04:25:27,499 --> 04:25:30,702
BEGINNING OF MY TERM TO BROADEN

7855
04:25:30,702 --> 04:25:32,204
AND ENRICH OUR ADVISORY

7856
04:25:32,204 --> 04:25:34,005
COMMITTEE FOR THE ENGINEERING

7857
04:25:34,005 --> 04:25:36,741
DIRECTORATE BY ADDING BRUCE

7858
04:25:36,741 --> 04:25:38,243
TROMBERG TO OUR ADVISORY

7859
04:25:38,243 --> 04:25:38,510
COMMITTEE.

7860
04:25:38,510 --> 04:25:43,014
HE GOT AN INSIDE LOOK OF HOW NSF

7861
04:25:43,014 --> 04:25:45,183
WORKS, WHICH IS DIFFERENT THAN

7862
04:25:45,183 --> 04:25:48,053
HOW NIH WORKS.

7863
04:25:48,053 --> 04:25:49,921
AND OPPORTUNITIES THAT ARE NOT

7864
04:25:49,921 --> 04:25:52,090
JUST A PULL FROM NSF TO NIH IN

7865
04:25:52,090 --> 04:25:56,828
THIS CASE, NIBIB, BUT A PULL

7866
04:25:56,828 --> 04:25:58,363
FROM NIB TO NSF.

7867
04:25:58,363 --> 04:25:59,464
THROUGH THAT I'M GOING TO

7868
04:25:59,464 --> 04:26:01,166
HIGHLIGHT A FEW PARTNERSHIPS AT

7869
04:26:01,166 --> 04:26:01,399
THE END.

7870
04:26:01,399 --> 04:26:02,100
I KNOW YOU'RE GOING TO HAVE MORE

7871
04:26:02,100 --> 04:26:03,535
IDEAS OF OTHER WAYS THAT WE

7872
04:26:03,535 --> 04:26:06,371
COULD BE PARTNERING.

7873
04:26:06,371 --> 04:26:08,473
INCLUDING USING SOME OF THE

7874
04:26:08,473 --> 04:26:09,674
INNOVATIVE MECHANISMS THAT WE'VE

7875
04:26:09,674 --> 04:26:11,543
DEVELOPED NOW IN THREE YEARS TO

7876
04:26:11,543 --> 04:26:14,446
FUND BETWEEN OUR AGENCIES,

7877
04:26:14,446 --> 04:26:17,682
YOU'LL THINK OF OTHER ICs

7878
04:26:17,682 --> 04:26:19,551
WITHIN NIH WHO WE SHOULD BE

7879
04:26:19,551 --> 04:26:20,752
APPROACHING TO USE THESE VERY

7880
04:26:20,752 --> 04:26:22,187
SAME MECHANISMS.

7881
04:26:22,187 --> 04:26:23,855
OKAY.

7882
04:26:23,855 --> 04:26:26,391
I PROMISED YOU THAT THE NSF

7883
04:26:26,391 --> 04:26:28,727
MISSION STATEMENT INCLUDES

7884
04:26:28,727 --> 04:26:32,430
HEALTH AND I DUG IN DEEP.

7885
04:26:32,430 --> 04:26:34,065
SO THE AREA OF HEALTH THAT WE DO

7886
04:26:34,065 --> 04:26:36,234
OVERLAP WITH IS REALLY ANYTHING

7887
04:26:36,234 --> 04:26:38,370
THAT HAS TO DO WITH

7888
04:26:38,370 --> 04:26:39,471
DISEASE-AGNOSTIC, SO MAKING SURE

7889
04:26:39,471 --> 04:26:41,106
PROOF OF CONCEPT, THE ANIMAL

7890
04:26:41,106 --> 04:26:42,774
MODELS, YOU HAVE HUMAN STUDIES,

7891
04:26:42,774 --> 04:26:44,843
ALL TYPES OF AREAS WHERE WE

7892
04:26:44,843 --> 04:26:45,910
INTERACT, BUT IF YOU START

7893
04:26:45,910 --> 04:26:48,246
GETTING DOWN INTO A PARTICULAR

7894
04:26:48,246 --> 04:26:51,316
DISEASE THAT THIS IS GOOD FOR,

7895
04:26:51,316 --> 04:26:52,517
THEN IT MUST BE NIH.

7896
04:26:52,517 --> 04:26:55,353
AND THAT IS TO KEEP OUR AGENCY

7897
04:26:55,353 --> 04:26:56,488
DISTINCT.

7898
04:26:56,488 --> 04:26:57,589
BUT THERE'S A HUGE OVERLAP OF

7899
04:26:57,589 --> 04:26:58,890
SPACE WHERE OUR AGENCIES

7900
04:26:58,890 --> 04:27:00,692
COLLABORATE.

7901
04:27:00,692 --> 04:27:02,627
AND THE OPPORTUNITY TO CREATE

7902
04:27:02,627 --> 04:27:04,596
THAT COLLABORATION THAT IS ALSO

7903
04:27:04,596 --> 04:27:05,930
A BATON PASSING WHERE THE BATON

7904
04:27:05,930 --> 04:27:07,899
IS NOT DROPPED BETWEEN AGENCIES

7905
04:27:07,899 --> 04:27:09,467
IS SO IMPORTANT AND I'LL SHARE

7906
04:27:09,467 --> 04:27:11,036
ONE OF THOSE WITH YOU.

7907
04:27:11,036 --> 04:27:13,204
SO AT THE NATIONAL SCIENCE

7908
04:27:13,204 --> 04:27:15,774
FOUNDATION, WE REALLY FUND

7909
04:27:15,774 --> 04:27:17,075
CURIOSITY-DRIVEN AND

7910
04:27:17,075 --> 04:27:18,843
DISCOVERY-BASED EXPLORATIONS.

7911
04:27:18,843 --> 04:27:20,912
SO WHEN THE EQUIVALENT SECTION

7912
04:27:20,912 --> 04:27:23,548
OF SIGNIFICANCE AND INNOVATION

7913
04:27:23,548 --> 04:27:26,418
IN AN NSF GRANT, IT'S OKAY TO

7914
04:27:26,418 --> 04:27:28,720
SAY, WE NEED THIS, WE DON'T

7915
04:27:28,720 --> 04:27:29,587
UNDERSTAND HOW IT WORKS.

7916
04:27:29,587 --> 04:27:31,356
NOW IN THE ENGINEERING

7917
04:27:31,356 --> 04:27:32,791
DIRECTORATE, ALMOST EVERYTHING

7918
04:27:32,791 --> 04:27:36,761
THAT WE FUND HAS A USE-INSPIRED,

7919
04:27:36,761 --> 04:27:41,666
SOLUTION-FOCUSED INNOVATION

7920
04:27:41,666 --> 04:27:43,034
ASPECT TO IT, BUT THERE'S SOME

7921
04:27:43,034 --> 04:27:44,536
FIELDS THAT ARE REALLY

7922
04:27:44,536 --> 04:27:45,670
FUNDAMENTAL DISCOVERY-BASED, AND

7923
04:27:45,670 --> 04:27:48,173
MORE AND MORE, OUR AGENCY IS

7924
04:27:48,173 --> 04:27:49,607
REALLY FOCUSING ON THE POTENTIAL

7925
04:27:49,607 --> 04:27:51,576
USE OF SOME OF THE DISCOVERIES.

7926
04:27:51,576 --> 04:27:53,378
MAYBE NOT IN THE LIFETIME OF THE

7927
04:27:53,378 --> 04:27:54,779
INVESTIGATOR, OR THE DURATION OF

7928
04:27:54,779 --> 04:27:58,516
THAT GRANT, BUT TELL US HOW IT

7929
04:27:58,516 --> 04:27:59,884
MIGHT TRANSLATE, AND KREA ATE

7930
04:27:59,884 --> 04:28:00,618
THOSE OPPORTUNITIES AND AVENUES

7931
04:28:00,618 --> 04:28:03,455
TO HASTEN THAT TRANSLATION.

7932
04:28:03,455 --> 04:28:05,557
OUR MAJOR PRIORITIES ARE THE

7933
04:28:05,557 --> 04:28:07,759
HORIZONTALS THAT WE'VE HAD IN

7934
04:28:07,759 --> 04:28:10,161
OUR BUDGET FOR A WHILE.

7935
04:28:10,161 --> 04:28:13,264
A RESILIENT PLANET HAS DEFINITE

7936
04:28:13,264 --> 04:28:14,599
HEALTH EFFECTS, AND I'M TALKING

7937
04:28:14,599 --> 04:28:16,868
TO ENVIRONMENTAL HEALTH AND

7938
04:28:16,868 --> 04:28:20,205
SCIENCE TO REALLY EXAMINE HOW WE

7939
04:28:20,205 --> 04:28:22,607
CAN COLLABORATE THERE, BUT

7940
04:28:22,607 --> 04:28:23,675
RESILIENT PLANET IS SO MANY

7941
04:28:23,675 --> 04:28:24,342
DIFFERENT THINGS.

7942
04:28:24,342 --> 04:28:26,344
IT ALSO INVOLVES CLEAN ENERGY

7943
04:28:26,344 --> 04:28:27,879
APPROACHES, CLEAN ENERGY

7944
04:28:27,879 --> 04:28:29,114
TECHNOLOGY, WHICH ALSO HAS A

7945
04:28:29,114 --> 04:28:30,515
PUBLIC HEALTH INTERACTION.

7946
04:28:30,515 --> 04:28:34,486
BUT ADVANCING EMERGING

7947
04:28:34,486 --> 04:28:36,554
INDUSTRIES FOR NATIONAL AND

7948
04:28:36,554 --> 04:28:39,357
ECONOMIC SECURITY, BIOTECH IS

7949
04:28:39,357 --> 04:28:40,825
ONE OF THE -- BUT

7950
04:28:40,825 --> 04:28:41,993
BIOMANUFACTURING SITS IN THERE,

7951
04:28:41,993 --> 04:28:43,828
WE CAN ALSO TALK ABOUT A.I.,

7952
04:28:43,828 --> 04:28:46,431
WIRELESS, THESE ALL HAVE

7953
04:28:46,431 --> 04:28:48,533
DEVICE -- HAVE APPLICATIONS IN

7954
04:28:48,533 --> 04:28:49,000
HEALTH AS WELL.

7955
04:28:49,000 --> 04:28:52,370
THE OTHER EMERGING INDUSTRIES

7956
04:28:52,370 --> 04:28:55,440
ARE -- I SHOULD NOTE --

7957
04:28:55,440 --> 04:28:55,907
SEMICONDUCTORS, MICRO

7958
04:28:55,907 --> 04:28:56,441
ELECTRONICS AND QUANTUM.

7959
04:28:56,441 --> 04:28:58,643
ALL OF THIS WILL INTERSECTS WITH

7960
04:28:58,643 --> 04:28:59,644
NIH'S MISSION.

7961
04:28:59,644 --> 04:29:00,412
CREATING OPPORTUNITIES

7962
04:29:00,412 --> 04:29:01,846
EVERYWHERE, SERVING PARTS OF THE

7963
04:29:01,846 --> 04:29:02,981
NATION WE DON'T CURRENTLY SERVE,

7964
04:29:02,981 --> 04:29:04,883
AND STRENGTHENING RESEARCH

7965
04:29:04,883 --> 04:29:06,551
INFRASTRUCTURE AND ACCESS TO

7966
04:29:06,551 --> 04:29:09,754
THAT RESEARCH INFRASTRUCTURE.

7967
04:29:09,754 --> 04:29:10,422
OUR VALUES ARE THE VERTICALS AND

7968
04:29:10,422 --> 04:29:11,623
THEY'RE PART OF OUR FIVE-YEAR

7969
04:29:11,623 --> 04:29:13,591
PLAN THAT WE HAVE RIGHT NOW

7970
04:29:13,591 --> 04:29:15,160
ABOUT A STRENGTHENING THAT

7971
04:29:15,160 --> 04:29:19,631
DISCOVERY BASIS FOR NSF,

7972
04:29:19,631 --> 04:29:20,832
INSPIRING THOSE TO HAVE CAREER

7973
04:29:20,832 --> 04:29:22,634
PATHS IN STEM AND ADVANCING

7974
04:29:22,634 --> 04:29:24,469
TECHNOLOGY AND INNOVATION.

7975
04:29:24,469 --> 04:29:27,472
SO NSF BY THE NUMBERS, WE'RE A

7976
04:29:27,472 --> 04:29:27,906
$9 BILLION AGENCY.

7977
04:29:27,906 --> 04:29:29,407
THAT'S SMALL COMPARED TO NIH.

7978
04:29:29,407 --> 04:29:32,377
FLAWCIAL BUT UNLIKE NIH, WE HAVE

7979
04:29:32,377 --> 04:29:34,813
NO INTRAMURAL LABS, SO THAT

7980
04:29:34,813 --> 04:29:36,915
MEANS MOST OF OUR TAXPAYER

7981
04:29:36,915 --> 04:29:38,983
DOLLARS IS GOING OUT THE DOOR.

7982
04:29:38,983 --> 04:29:40,618
93% OF OUR DOLLARS GO OUT THE

7983
04:29:40,618 --> 04:29:42,287
DOOR IN FUNDING RESEARCH AND

7984
04:29:42,287 --> 04:29:44,923
EDUCATION-RELATED ACTIVITIES.

7985
04:29:44,923 --> 04:29:49,427
SO IN THE ENGINEERING

7986
04:29:49,427 --> 04:29:51,863
DIRECTORATE, OVER 320 DIFFERENT

7987
04:29:51,863 --> 04:29:54,265
INSTITUTIONS, AND THERE ARE ONLY

7988
04:29:54,265 --> 04:29:55,133
ABOUT 340 ENGINEERING

7989
04:29:55,133 --> 04:29:56,468
INSTITUTIONS.

7990
04:29:56,468 --> 04:29:57,135
WE DO FUND OUTSIDE OF

7991
04:29:57,135 --> 04:29:57,569
ENGINEERING.

7992
04:29:57,569 --> 04:29:59,003
YOU DON'T HAVE TO BE AN ENGINEER

7993
04:29:59,003 --> 04:30:01,739
TO GET ENGINEERING DIRECTORATE

7994
04:30:01,739 --> 04:30:01,973
FUNDING.

7995
04:30:01,973 --> 04:30:03,608
WHITE HOUSE PRIORITIES FOR 2025,

7996
04:30:03,608 --> 04:30:07,045
WHICH WERE PUBLISHED IN AUGUST

7997
04:30:07,045 --> 04:30:09,447
OF 2024, INTERESTINGLY WHEN YOU

7998
04:30:09,447 --> 04:30:11,316
HAVE AN ADMINISTRATION

7999
04:30:11,316 --> 04:30:12,617
TRANSITION, WE ARE STILL WAITING

8000
04:30:12,617 --> 04:30:14,452
FOR OUR WHITE HOUSE PRIORITIES

8001
04:30:14,452 --> 04:30:15,119
BECAUSE THERE WILL BE NEW PEOPLE

8002
04:30:15,119 --> 04:30:15,954
IN THE WHITE HOUSE COMING SOON.

8003
04:30:15,954 --> 04:30:17,555
SO IF YOU TAKE A LOOK AT THESE

8004
04:30:17,555 --> 04:30:20,425
WHITE HOUSE PRIORITIES, I WILL

8005
04:30:20,425 --> 04:30:24,329
TELL YOU THAT NSF EN ENGINEERING

8006
04:30:24,329 --> 04:30:24,963
DIRECT TEMPERATURE IS INVOLVED

8007
04:30:24,963 --> 04:30:26,297
IN ALL OF THEM.

8008
04:30:26,297 --> 04:30:27,799
THE PRIORITIES AND GOALS FOR THE

8009
04:30:27,799 --> 04:30:28,700
ENGINEERING DIRECTORATE ARE

8010
04:30:28,700 --> 04:30:30,368
REALLY TO TRANSFORM OUR WORLD

8011
04:30:30,368 --> 04:30:32,036
FOR A BETTER TOMORROW.

8012
04:30:32,036 --> 04:30:33,438
SO REALLY TO HIGHLIGHT THAT WE

8013
04:30:33,438 --> 04:30:35,974
NOT ONLY DO RESEARCH AND DRIVE

8014
04:30:35,974 --> 04:30:37,442
DISCOVERY, WE INSPIRE A LOT OF

8015
04:30:37,442 --> 04:30:39,611
CREATIVITY AND INNOVATION,

8016
04:30:39,611 --> 04:30:41,112
ENRICHING EDUCATION AND

8017
04:30:41,112 --> 04:30:42,146
ACCELERATING ACCESS.

8018
04:30:42,146 --> 04:30:44,015
SO ONE OF THE GOALS IN MY TERM

8019
04:30:44,015 --> 04:30:47,852
IS REALLY TO PROPEL OUR

8020
04:30:47,852 --> 04:30:49,220
LEADERSHIP IN ENGINEERING

8021
04:30:49,220 --> 04:30:50,889
INNOVATION IN AREAS OF SOCIETAL

8022
04:30:50,889 --> 04:30:51,923
IMPACT.

8023
04:30:51,923 --> 04:30:54,125
WOMEN'S HEALTH IS RIGHT IN THAT

8024
04:30:54,125 --> 04:30:57,428
SWEET SPOT, TO REALLY EXPAND

8025
04:30:57,428 --> 04:30:58,663
OPPORTUNITIES FOR PEOPLE TO

8026
04:30:58,663 --> 04:30:59,731
BENEFIT FROM THE RESEARCH THAT

8027
04:30:59,731 --> 04:31:02,100
WE FUND AS WELL AS THE EDUCATION

8028
04:31:02,100 --> 04:31:02,967
AND INNOVATION, BUT ALSO TO

8029
04:31:02,967 --> 04:31:03,768
PARTICIPATE IN.

8030
04:31:03,768 --> 04:31:10,108
AND THEN TO CATALYZE, PERSONAL

8031
04:31:10,108 --> 04:31:10,742
PARTNERSHIPS.

8032
04:31:10,742 --> 04:31:12,410
HOW MANY PERSONAL PARTNERSHIPS

8033
04:31:12,410 --> 04:31:13,745
HAVE WE KREA ATED IN THE TIME

8034
04:31:13,745 --> 04:31:16,681
I'VE BEEN THE ASSISTANT

8035
04:31:16,681 --> 04:31:18,850
DIRECTOR, WE'RE ABOUT 80

8036
04:31:18,850 --> 04:31:20,018
PURPOSEFUL PARTNERSHIPS.

8037
04:31:20,018 --> 04:31:21,219
SO THE OPPORTUNITY TO

8038
04:31:21,219 --> 04:31:23,288
COLLABORATE WITH THE NATIONAL

8039
04:31:23,288 --> 04:31:25,390
SCIENCE FOUNDATION BETWEEN NSF

8040
04:31:25,390 --> 04:31:27,825
AND NIH IS TRULY ONE OF THOSE,

8041
04:31:27,825 --> 04:31:29,127
AND A SWEET SPOT FOR THE WAY

8042
04:31:29,127 --> 04:31:32,096
THAT WE'VE BEEN ABLE TO

8043
04:31:32,096 --> 04:31:32,697
TRANSFORM.

8044
04:31:32,697 --> 04:31:35,833
THEY'RE ALSO WITH INDUSTRY, WITH

8045
04:31:35,833 --> 04:31:36,501
PHILANTHROPES, WITH OTHER

8046
04:31:36,501 --> 04:31:37,802
COUNTRIES AND OTHER AGENCIES

8047
04:31:37,802 --> 04:31:38,903
BEYOND NSF.

8048
04:31:38,903 --> 04:31:40,038
SO OUR AREAS OF FOCUS ARE THE

8049
04:31:40,038 --> 04:31:41,039
HORIZONTALS THAT YOU SEE HERE.

8050
04:31:41,039 --> 04:31:44,676
ALL OF THEM HAVE HEALTH

8051
04:31:44,676 --> 04:31:45,977
IMPLICATIONS, AND OUR VERTICALS

8052
04:31:45,977 --> 04:31:47,946
TRULY ARE OUR VALUES IN THE

8053
04:31:47,946 --> 04:31:50,181
ENGINEERING DIRECTORATE.

8054
04:31:50,181 --> 04:31:50,848
EQUITY, JUSTICE AND ACCESS IS

8055
04:31:50,848 --> 04:31:51,816
SOMETHING WE HAVEN'T REALLY

8056
04:31:51,816 --> 04:31:54,218
TALKED ABOUT HERE, BUT IS

8057
04:31:54,218 --> 04:31:56,654
CERTAIN RI A RIVER THAT RUNS

8058
04:31:56,654 --> 04:31:57,255
THROUGH, THE COMMENTS PEOPLE

8059
04:31:57,255 --> 04:31:59,624
HAVE BEEN MAKING, BUT WE ALWAYS

8060
04:31:59,624 --> 04:32:01,593
THINK ABOUT SUSTAINABLE AND

8061
04:32:01,593 --> 04:32:02,794
RESILIENT SOLUTIONS.

8062
04:32:02,794 --> 04:32:04,262
THESE ARE AREAS THAT IN THE

8063
04:32:04,262 --> 04:32:06,698
DIVISIONS ACROSS THE

8064
04:32:06,698 --> 04:32:09,200
ENGINEERING -- WE CO-FUND IN

8065
04:32:09,200 --> 04:32:10,201
THESE AREAS.

8066
04:32:10,201 --> 04:32:11,436
SO I LEAK TO LOOK BACKWARDS ON

8067
04:32:11,436 --> 04:32:12,971
INVESTMENTS TO TALK ABOUT HOW

8068
04:32:12,971 --> 04:32:14,272
HAVE INVESTMENTS IN THE

8069
04:32:14,272 --> 04:32:16,207
ENGINEERING DIRECTORATE AND EVEN

8070
04:32:16,207 --> 04:32:17,308
BEFORE THE ENGINEERING

8071
04:32:17,308 --> 04:32:18,476
DIRECTORATE ENGINEERING RESEARCH

8072
04:32:18,476 --> 04:32:22,046
FUNDED BY NSF LED TO IMPACT IN

8073
04:32:22,046 --> 04:32:25,216
MEDICINE.

8074
04:32:25,216 --> 04:32:27,285
SO THESE AREAS, WHETHER WE TALK

8075
04:32:27,285 --> 04:32:30,355
ABOUT MRNA VACCINES, DIRECTED

8076
04:32:30,355 --> 04:32:32,790
EVOLUTION, TISSUE ENGINEERING,

8077
04:32:32,790 --> 04:32:35,727
MRI, DIGITAL TWIN MODELING,

8078
04:32:35,727 --> 04:32:36,594
LASIK, ARTIFICIAL NEURAL

8079
04:32:36,594 --> 04:32:38,396
NETWORKS THAT ACTUALLY JUST WON

8080
04:32:38,396 --> 04:32:39,397
THE NOBEL PRIZE TODAY, THESE ARE

8081
04:32:39,397 --> 04:32:45,103
AREAS WHERE NSF INVESTMENT IN

8082
04:32:45,103 --> 04:32:46,771
ENGINEERING HAS BEEN

8083
04:32:46,771 --> 04:32:47,071
SIGNIFICANT.

8084
04:32:47,071 --> 04:32:48,172
OFTEN AT THAT EARLY STAGE,

8085
04:32:48,172 --> 04:32:50,375
WORKING OUT THE CHALLENGES WITH

8086
04:32:50,375 --> 04:32:52,510
TRANSITION FOR LATER FUNDING.

8087
04:32:52,510 --> 04:32:53,578
IN BIOTECHNOLOGY ACROSS THE TOP,

8088
04:32:53,578 --> 04:32:55,546
YOU CAN SEE INVESTMENTS THAT

8089
04:32:55,546 --> 04:32:57,415
HAVE BEEN MADE ACROSS THE

8090
04:32:57,415 --> 04:32:58,916
DECADES, AND CURRENT IMPACTS

8091
04:32:58,916 --> 04:33:01,853
THAT ARE STILL BENEFITS TODAY.

8092
04:33:01,853 --> 04:33:03,821
NOT THE EARLY ONES, BUT THE

8093
04:33:03,821 --> 04:33:04,355
CURRENT ONES.

8094
04:33:04,355 --> 04:33:07,225
AND I HELP YOU RECOGNIZE THAT

8095
04:33:07,225 --> 04:33:08,226
THAT IMPORTANCE OF TAKING RISK

8096
04:33:08,226 --> 04:33:10,395
AND INVESTING IN HIGH RISK

8097
04:33:10,395 --> 04:33:12,397
POTENTIALLY HIGH REWARD RESEARCH

8098
04:33:12,397 --> 04:33:15,566
IS SOMETHING THAT'S HARD TO DO.

8099
04:33:15,566 --> 04:33:18,269
PANELS OF REVIEWERS WANT TO SAY

8100
04:33:18,269 --> 04:33:19,370
IS THIS THE NEXT STEP?

8101
04:33:19,370 --> 04:33:21,839
WHAT HAVE YOU DONE TO DE-RISK

8102
04:33:21,839 --> 04:33:24,175
THAT FOR US TO BE ABLE TO SAY,

8103
04:33:24,175 --> 04:33:25,276
YES, THIS ONE IS GOING TO BE A

8104
04:33:25,276 --> 04:33:26,577
GREAT INVESTMENT WITH AN

8105
04:33:26,577 --> 04:33:27,679
EXCELLENT RETURN ON THE

8106
04:33:27,679 --> 04:33:29,113
INVESTMENT OF ALL OF YOUR

8107
04:33:29,113 --> 04:33:34,719
TAXPAYER DOLLARS THAT WE STEWARD

8108
04:33:34,719 --> 04:33:36,020
FOR BENEFIT BUT WE ALSO HAVE TO

8109
04:33:36,020 --> 04:33:37,989
TAKE RISK BECAUSE WE HAVE TO

8110
04:33:37,989 --> 04:33:39,357
UNDERSTAND THE IMPORTANCE THAT

8111
04:33:39,357 --> 04:33:40,425
CUTTING EDGE RESEARCH THAT IS

8112
04:33:40,425 --> 04:33:42,193
AGNOSTIC IN MY CASE FOR TODAY TO

8113
04:33:42,193 --> 04:33:43,494
THE DISEASE THAT IT MAY TOUCH ON

8114
04:33:43,494 --> 04:33:45,496
AND MAY IMPROVE, THAT CUTTING

8115
04:33:45,496 --> 04:33:46,931
EDGE RESEARCH IS TRULY

8116
04:33:46,931 --> 04:33:48,132
IMPORTANT, AND WE KEEP REAPING

8117
04:33:48,132 --> 04:33:49,233
THOSE BENEFITS.

8118
04:33:49,233 --> 04:33:51,469
THE IDEA TO BE ABLE TO GO BACK

8119
04:33:51,469 --> 04:33:54,639
AND THEN FUND NEW APPLICATIONS

8120
04:33:54,639 --> 04:33:56,374
OF OLDER INNOVATIONS IS ANOTHER

8121
04:33:56,374 --> 04:33:58,943
THING THAT WE MUST ACTUALLY GIVE

8122
04:33:58,943 --> 04:34:02,013
TIME TO, AND NOT ALL INNOVATION

8123
04:34:02,013 --> 04:34:03,748
STARTS AT THE FIRST SQUARE.

8124
04:34:03,748 --> 04:34:05,616
SOME INNOVATION ACTUALLY IS

8125
04:34:05,616 --> 04:34:06,217
THINKING DIFFERENTLY ABOUT

8126
04:34:06,217 --> 04:34:08,419
SOMETHING THAT WE HAVE ALREADY.

8127
04:34:08,419 --> 04:34:09,721
AND A NEW INNOVATION.

8128
04:34:09,721 --> 04:34:11,989
SO IF WE LOOK FORWARD TO

8129
04:34:11,989 --> 04:34:13,624
ENGINEERING RESEARCH HORIZONS

8130
04:34:13,624 --> 04:34:15,026
WITH THE EXECUTIVE ORDER ON

8131
04:34:15,026 --> 04:34:20,565
WOMEN'S HEALTH, AND THE MANDATED

8132
04:34:20,565 --> 04:34:21,432
AREAS, THESE ACTIONS ARE

8133
04:34:21,432 --> 04:34:22,867
PRIORITY FOR THE NATIONAL

8134
04:34:22,867 --> 04:34:23,601
SCIENCE FOUNDATION, AND WE'RE

8135
04:34:23,601 --> 04:34:25,503
PART OF THE TEAM THAT REPORTS ON

8136
04:34:25,503 --> 04:34:30,241
A REGULAR BASIS ABOUT WHAT WE'RE

8137
04:34:30,241 --> 04:34:32,076
DOING AND WE'RE QUITE COMMITTED.

8138
04:34:32,076 --> 04:34:34,112
THE ENDING UNEQUAL TREATMENT

8139
04:34:34,112 --> 04:34:35,313
REPORT, I SEE THAT CONSENSUS

8140
04:34:35,313 --> 04:34:36,848
REPORT THAT WE'RE GOING TO BE

8141
04:34:36,848 --> 04:34:39,517
TALKING ABOUT THAT NEXT.

8142
04:34:39,517 --> 04:34:40,384
SO IT'S SO IMPORTANT TO BE ABLE

8143
04:34:40,384 --> 04:34:44,422
TO DEMOCRATIZE ACCESS AND

8144
04:34:44,422 --> 04:34:45,423
TREATMENT.

8145
04:34:45,423 --> 04:34:48,860
THE NSF INVESTMENT IN WOMEN'S

8146
04:34:48,860 --> 04:34:49,627
HEALTH IS MODEST.

8147
04:34:49,627 --> 04:34:53,765
I THINK IT SHOULD BE MORE.

8148
04:34:53,765 --> 04:34:56,968
AND I LOOK FORWARD TODAY TO LOOK

8149
04:34:56,968 --> 04:34:57,635
FOR AN OPPORTUNITY TO HOW WE CAN

8150
04:34:57,635 --> 04:34:58,202
INCREASE IT.

8151
04:34:58,202 --> 04:35:00,404
WOMEN'S HEALTH IS NOT A DISEASE.

8152
04:35:00,404 --> 04:35:02,740
WOMEN'S HEALTH IS

8153
04:35:02,740 --> 04:35:03,841
DISEASE-AGNOSTIC.

8154
04:35:03,841 --> 04:35:05,376
SO NSF CAN BE FUNDING THIS.

8155
04:35:05,376 --> 04:35:08,346
AND IT WAS WITH A GREAT

8156
04:35:08,346 --> 04:35:08,946
EAGERNESS THAT WE HAD SEVERAL

8157
04:35:08,946 --> 04:35:09,781
THINGS THAT WE'RE GOING TO

8158
04:35:09,781 --> 04:35:11,749
HIGHLIGHT THAT ARE A RESULT OF

8159
04:35:11,749 --> 04:35:15,586
THAT EXECUTIVE ORDER.

8160
04:35:15,586 --> 04:35:19,991
OUR ENG 'NOTHERRING VISIONING

8161
04:35:19,991 --> 04:35:21,659
ALLIANCE THAT WAS STOOD UP TO

8162
04:35:21,659 --> 04:35:23,494
IDENTIFY THE FRONTIERS WHERE

8163
04:35:23,494 --> 04:35:25,630
ENGINEERING CAN LEAD, WHILE THE

8164
04:35:25,630 --> 04:35:27,064
ENGINEERING DIRECTORATE OF NSF

8165
04:35:27,064 --> 04:35:28,800
IS ONE OF THE TARGETS, ALL

8166
04:35:28,800 --> 04:35:31,769
ENGINEERING, THIS COULD BE FOR

8167
04:35:31,769 --> 04:35:33,471
DEPARTMENT OF ENGINEERING,

8168
04:35:33,471 --> 04:35:34,872
DEPARTMENT OF ENERGY, JUST

8169
04:35:34,872 --> 04:35:36,507
ENGINEERING, WHERE SHOULD WE BE

8170
04:35:36,507 --> 04:35:37,375
LEADING?

8171
04:35:37,375 --> 04:35:39,877
AND THEY IDENTIFY AND CATALYZE

8172
04:35:39,877 --> 04:35:41,746
AND BRING TOGETHER INDUSTRY,

8173
04:35:41,746 --> 04:35:44,782
INVESTORS, ACADEMIA, AS WELL AS

8174
04:35:44,782 --> 04:35:47,318
OTHER AGENCIES TO THINK ABOUT

8175
04:35:47,318 --> 04:35:50,288
PRIORITIES FOR THE NATION.

8176
04:35:50,288 --> 04:35:51,289
DON'T THINK ABOUT THE NEXT FIVE

8177
04:35:51,289 --> 04:35:51,589
YEARS.

8178
04:35:51,589 --> 04:35:54,225
WE'VE ACTUALLY PLANNED OUR

8179
04:35:54,225 --> 04:35:56,160
BUDGETS, WE'VE SUBMITTED BUDGETS

8180
04:35:56,160 --> 04:35:56,694
FOR 2026.

8181
04:35:56,694 --> 04:35:57,795
DON'T TELL US WHAT WE SHOULD BE

8182
04:35:57,795 --> 04:36:00,097
DOING IN FIVE YEARS, WE NEED TO

8183
04:36:00,097 --> 04:36:02,133
KNOW WHAT TO BE DOING IN 20

8184
04:36:02,133 --> 04:36:02,800
YEARS.

8185
04:36:02,800 --> 04:36:05,102
WE NEED TO KNOW HOW TO PLAN TO

8186
04:36:05,102 --> 04:36:06,170
GET THERE AND WE HAVE THOSE

8187
04:36:06,170 --> 04:36:10,208
VOICES AT THE TABLE.

8188
04:36:10,208 --> 04:36:11,709
IN JUNE THERE WAS A VISIONING

8189
04:36:11,709 --> 04:36:14,145
EVENT, TRANSFORMING WOMEN'S

8190
04:36:14,145 --> 04:36:16,280
HEALTH, WELL ATTENDED, I

8191
04:36:16,280 --> 04:36:16,681
ATTENDED AS WELL.

8192
04:36:16,681 --> 04:36:20,852
THE SCOPE WAS GOING BEYOND THE

8193
04:36:20,852 --> 04:36:21,752
REPRODUCTIVE -- PRENAY IT WILL

8194
04:36:21,752 --> 04:36:23,754
TO PUBERTY REPRODUCTIVE YEARS,

8195
04:36:23,754 --> 04:36:25,590
AND THEN REPRODUCTIVE YEARS NOT

8196
04:36:25,590 --> 04:36:27,024
RELATED TO PREGNANCY

8197
04:36:27,024 --> 04:36:29,026
IMPORTANTLY, AND THEN PRE,

8198
04:36:29,026 --> 04:36:30,261
PERIAND POST-MENOPAUSAL, REALLY

8199
04:36:30,261 --> 04:36:31,462
THINKING ABOUT TECHNOLOGY.

8200
04:36:31,462 --> 04:36:34,932
SO THIS IS ENGINEERING FORWARD.

8201
04:36:34,932 --> 04:36:37,068
THAT CONFERENCE WAS IN JUNE, THE

8202
04:36:37,068 --> 04:36:38,269
REPORT, MICHELLE TELLS ME, WAS

8203
04:36:38,269 --> 04:36:40,304
SUBMITTED TORE REVIEW AND

8204
04:36:40,304 --> 04:36:41,706
EVALUATION THE SAME NASEM

8205
04:36:41,706 --> 04:36:44,242
REPORTS GO OUT FOR REVIEW, THESE

8206
04:36:44,242 --> 04:36:46,210
DO AS WELL, AND THAT REPORT

8207
04:36:46,210 --> 04:36:47,678
EXPECT THAT IT WILL BE RELEASED

8208
04:36:47,678 --> 04:36:48,112
THIS FALL.

8209
04:36:48,112 --> 04:36:48,980
MICHELLE HOPES IT WILL BE

8210
04:36:48,980 --> 04:36:49,881
RELEASED IN TWO WEEKS.

8211
04:36:49,881 --> 04:36:50,848
I'M NOT SURE.

8212
04:36:50,848 --> 04:36:52,884
IN ADDITION, SO THAT WAS JUNE,

8213
04:36:52,884 --> 04:36:59,891
IN AUGUST, WE FUNDED ELEVATEHER,

8214
04:36:59,891 --> 04:37:00,625
ENGINEERING SOLUTIONS FOR

8215
04:37:00,625 --> 04:37:01,726
WOMEN'S HEALTH.

8216
04:37:01,726 --> 04:37:02,493
YOU CAN SEE THE TOPICS HERE

8217
04:37:02,493 --> 04:37:05,429
COMPLEMENT THE ONES OF THE ONE

8218
04:37:05,429 --> 04:37:06,530
WE HAD -- THE CONFERENCE

8219
04:37:06,530 --> 04:37:06,964
EARLIER.

8220
04:37:06,964 --> 04:37:08,666
WE EXPECT THAT WHAT COMES FROM

8221
04:37:08,666 --> 04:37:10,835
THIS REPORT ARE SUGGESTIONS FOR

8222
04:37:10,835 --> 04:37:12,470
WHERE WE SHOULD HAVE CALLS FOR

8223
04:37:12,470 --> 04:37:15,339
PROPOSALS.

8224
04:37:15,339 --> 04:37:17,341
SO I WANT TO COMMENT ALSO ABOUT

8225
04:37:17,341 --> 04:37:18,442
EARLIER IN SEPTEMBER, USING A.I.

8226
04:37:18,442 --> 04:37:19,644
TO BETTER UNDERSTAND MENOPAUSE.

8227
04:37:19,644 --> 04:37:23,381
THAT WAS ACTUALLY ANOTHER THAT

8228
04:37:23,381 --> 04:37:25,383
WE OFTEN BEGIN WITH HAVING A

8229
04:37:25,383 --> 04:37:26,684
CONFERENCE TO STIMULATE

8230
04:37:26,684 --> 04:37:28,986
COMMUNITIES TO COME TOGETHER,

8231
04:37:28,986 --> 04:37:32,290
THAT'S THAT PAIR FINDING BUT

8232
04:37:32,290 --> 04:37:34,425
THEN IT STIMULATES US, THE NSF,

8233
04:37:34,425 --> 04:37:36,494
TO UNDERSTAND WHERE WE NEED TO

8234
04:37:36,494 --> 04:37:37,695
FIND AND FUND THOSE

8235
04:37:37,695 --> 04:37:40,431
OPPORTUNITIES.

8236
04:37:40,431 --> 04:37:44,302
WE SUBMITTED -- WE PUBLISHED AN

8237
04:37:44,302 --> 04:37:45,703
NSF FUNDING OPPORTUNITY CALLED A

8238
04:37:45,703 --> 04:37:50,274
DEAR COLLEAGUE LEDDER OR DCL.

8239
04:37:50,274 --> 04:37:51,442
HIGHLIGHTING THAT NSF FUNDS IN

8240
04:37:51,442 --> 04:37:52,109
THIS AREA.

8241
04:37:52,109 --> 04:37:53,644
AND WE HAVE HAD PROPOSALS, THIS

8242
04:37:53,644 --> 04:37:55,880
CAME OUT IN THE SPRING, AND IT'S

8243
04:37:55,880 --> 04:37:58,849
HIGHLIGHTED THE AREAS IN WHICH

8244
04:37:58,849 --> 04:38:00,952
THOSE WHO SLY OR CONFUSED ABOUT

8245
04:38:00,952 --> 04:38:02,286
WHAT NSF MIGHT FUND IN THE AREA

8246
04:38:02,286 --> 04:38:03,921
OF WOMEN'S HEALTH REALLY BE

8247
04:38:03,921 --> 04:38:05,356
SPECIFIC, AND YOU CAN SEE THEM

8248
04:38:05,356 --> 04:38:07,591
LISTED HERE.

8249
04:38:07,591 --> 04:38:08,826
THESE ARE AREAS THAT ARE

8250
04:38:08,826 --> 04:38:10,361
SOMETIMES NOT FUNDED AT NIH.

8251
04:38:10,361 --> 04:38:14,899
ESPECIALLY THE DEVELOPMENT OF

8252
04:38:14,899 --> 04:38:15,666
MODELS NOT OFTEN FUNDED AT NIH.

8253
04:38:15,666 --> 04:38:17,301
YOU CAN USE THE MODEL FOR

8254
04:38:17,301 --> 04:38:19,403
SOMETHING, BUT AT NSF, WE FUND

8255
04:38:19,403 --> 04:38:20,071
THE DEVELOPMENT OF THOSE MODELS

8256
04:38:20,071 --> 04:38:21,505
BUT YOU CAN SEE MANY OTHER

8257
04:38:21,505 --> 04:38:22,807
THINGS THAT YOU MIGHT HAVE

8258
04:38:22,807 --> 04:38:24,275
THOUGHT, OH, WOW, I DIDN'T EVEN

8259
04:38:24,275 --> 04:38:26,310
KNOW THAT THE NATIONAL SCIENCE

8260
04:38:26,310 --> 04:38:27,678
FOUNDATION FUNDS THESE TYPES OF

8261
04:38:27,678 --> 04:38:29,213
AREAS OF RESEARCH IN WOMEN'S

8262
04:38:29,213 --> 04:38:32,984
HEALTH.

8263
04:38:32,984 --> 04:38:33,718
THE CORE ENGINEERING PROGRAMS

8264
04:38:33,718 --> 04:38:35,920
THAT ARE PARTICIPATING ARE SHOWN

8265
04:38:35,920 --> 04:38:38,055
HEE AND I JUST HIGHLIGHTED ONE

8266
04:38:38,055 --> 04:38:38,522
AWARD, A CAREER AWARD.

8267
04:38:38,522 --> 04:38:40,691
THIS IS AN EARLY STAGE

8268
04:38:40,691 --> 04:38:43,961
INVESTIGATOR AWARD IN BIOME CAN

8269
04:38:43,961 --> 04:38:46,297
NEXT AND MECHANOBIOLOGY OF

8270
04:38:46,297 --> 04:38:48,265
UTERINE GROWTH AND REMODELING.

8271
04:38:48,265 --> 04:38:50,868
SO THOSE ARE FUNDING ALREADY AT

8272
04:38:50,868 --> 04:38:52,203
THE NATIONAL SCIENCE FOUNDATION.

8273
04:38:52,203 --> 04:38:54,372
WE HAVE LARGE INVESTMENTS, OUR

8274
04:38:54,372 --> 04:38:56,040
ENGINEERING RESOURCE CENTERS.

8275
04:38:56,040 --> 04:38:58,409
YOU CAN SEE THOSE TOUCHING ON

8276
04:38:58,409 --> 04:38:59,810
THE AREAS THAT COULD GO IN THE

8277
04:38:59,810 --> 04:39:01,245
DIRECTION OF WOMEN'S HEALTH BUT

8278
04:39:01,245 --> 04:39:04,315
ARE NOT LIMITED, AND I WANT TO

8279
04:39:04,315 --> 04:39:05,683
HIGHLIGHT ONE MECHANISM THAT WAS

8280
04:39:05,683 --> 04:39:10,588
OF GREAT INTEREST TO NIBIB, THE

8281
04:39:10,588 --> 04:39:11,522
INDUSTRY UNIVERSITY COOPERATIVE

8282
04:39:11,522 --> 04:39:12,023
RESEARCH CENTERS.

8283
04:39:12,023 --> 04:39:13,924
THIS IS WHERE THERE'S A MODEST

8284
04:39:13,924 --> 04:39:15,326
INVESTMENT BY THE NSF, THEED ARE

8285
04:39:15,326 --> 04:39:16,427
LED THROUGH THE ENGINEERING

8286
04:39:16,427 --> 04:39:18,262
DIRECTORATE BUT NOT LIMITED TO

8287
04:39:18,262 --> 04:39:18,562
ENGINEERING.

8288
04:39:18,562 --> 04:39:22,733
AND YOU CAN SEE THESE TOPICS.

8289
04:39:22,733 --> 04:39:24,502
NOW IMAGINE EACH P.I. MUST BRING

8290
04:39:24,502 --> 04:39:28,372
IN MEMBERS WHO ARE PAYING

8291
04:39:28,372 --> 04:39:29,907
MEMBER, 50 TO $75,000 A YEAR TO

8292
04:39:29,907 --> 04:39:32,376
SIT AT THE TABLE OF

8293
04:39:32,376 --> 04:39:32,943
PREDECISIONAL RESEARCH AND

8294
04:39:32,943 --> 04:39:34,912
INFLUENCE THE P.I.'S PROPOSALS

8295
04:39:34,912 --> 04:39:36,547
THAT THEY'RE PUTTING IN FOR THIS

8296
04:39:36,547 --> 04:39:41,085
AWARD, WHICH IS COMBINED NSF AND

8297
04:39:41,085 --> 04:39:42,720
MEMBER FUNDING, TO FUND.

8298
04:39:42,720 --> 04:39:44,121
NOW, NIH COULD BE AT THE TABLE

8299
04:39:44,121 --> 04:39:45,856
AS A MEMBER AS WELL, AND THEY

8300
04:39:45,856 --> 04:39:48,592
CAN INFLUENCE THE DIRECTION THAT

8301
04:39:48,592 --> 04:39:50,661
THESE IUCRCs ARE TAKING IN

8302
04:39:50,661 --> 04:39:51,929
THEIR PILOT.

8303
04:39:51,929 --> 04:39:55,132
WHAT ENDS UP HAPPENING IS THOSE

8304
04:39:55,132 --> 04:39:58,502
MEMBERS AT THE TABLE, INDUSTRY,

8305
04:39:58,502 --> 04:40:00,438
OTHER -- INFLUENCE THOSE PILOTS

8306
04:40:00,438 --> 04:40:02,173
AND THEN LEAD TO FOLLOW-ON

8307
04:40:02,173 --> 04:40:06,911
FUNDING DIRECTLY TO P.I. OR THAT

8308
04:40:06,911 --> 04:40:08,379
OTHER AGENCY WHERE THEY SAY WE

8309
04:40:08,379 --> 04:40:09,346
INVITE YOU TO, PLEASE, COME, WE

8310
04:40:09,346 --> 04:40:11,749
HAVE FUNDING OPPORTUNITIES, AND

8311
04:40:11,749 --> 04:40:13,451
DE-RISKING IT FOR THOSE FUNDING

8312
04:40:13,451 --> 04:40:13,717
AGENCIES.

8313
04:40:13,717 --> 04:40:15,019
I WANT TO HIGHLIGHT ALSO THE

8314
04:40:15,019 --> 04:40:16,287
PROGRAM WE'VE HAD FOR A NUMBER

8315
04:40:16,287 --> 04:40:18,189
OF YEARS WITH A NUMB WE ARE OF

8316
04:40:18,189 --> 04:40:19,723
DIFFERENT ICs AT NIH IN SMART

8317
04:40:19,723 --> 04:40:21,092
HEALTH AND BIOMEDICAL RESEARCH

8318
04:40:21,092 --> 04:40:26,664
IN THE AREA OF ARTIFICIAL

8319
04:40:26,664 --> 04:40:27,298
INTELLIGENCE AND WHEN YOU TAKE A

8320
04:40:27,298 --> 04:40:28,432
LOOK AT WHAT THAT IS, I JUST

8321
04:40:28,432 --> 04:40:31,402
WANT TO HIGHLIGHT THIS ONE AWARD

8322
04:40:31,402 --> 04:40:34,505
THAT WE MADE IN PERSONALIZED

8323
04:40:34,505 --> 04:40:38,676
WATCH BASED FALL DETECTION, SO

8324
04:40:38,676 --> 04:40:39,743
CLEARLY IN THE AREA OF WOMEN'S

8325
04:40:39,743 --> 04:40:40,911
HEALTH, SOMEONE WITH

8326
04:40:40,911 --> 04:40:41,645
OSTEOPOROSIS, WHEN I WAS TOLD

8327
04:40:41,645 --> 04:40:43,314
THAT I HAVE A 30% CHANCE OF

8328
04:40:43,314 --> 04:40:45,015
FRACTURE WITH A FALL, I

8329
04:40:45,015 --> 04:40:45,983
IMMEDIATELY CHANGED MY BEHAVIOR,

8330
04:40:45,983 --> 04:40:48,519
I NEVER WALK AND LOOK AT MY

8331
04:40:48,519 --> 04:40:49,086
PHONE AT THE SAME TIME, BUT

8332
04:40:49,086 --> 04:40:51,655
WOULDN'T IT BE GREAT TO BE ABLE

8333
04:40:51,655 --> 04:40:52,623
TO HAVE SOME TECHNOLOGY THAT

8334
04:40:52,623 --> 04:40:54,492
REALLY COULD, IN REALTIME,

8335
04:40:54,492 --> 04:40:56,026
ACTUALLY INTERVENE WITH

8336
04:40:56,026 --> 04:40:56,293
BEHAVIORS.

8337
04:40:56,293 --> 04:40:57,795
AND SO THIS IS ABOUT NOVEL

8338
04:40:57,795 --> 04:41:03,934
METHODS TO INTUITIVELY INTEL

8339
04:41:03,934 --> 04:41:05,469
INTELLIGENTLY CONNECT, ANALYZE

8340
04:41:05,469 --> 04:41:06,904
AND DETERMINE DATA IN REALTIME.

8341
04:41:06,904 --> 04:41:10,841
WE ALSO HAVE SUPPORT FOR WOMEN'S

8342
04:41:10,841 --> 04:41:12,209
HEALTH IN ENGINEERING RESEARCH

8343
04:41:12,209 --> 04:41:13,310
AND I'M JUST HIGHLIGHTING A

8344
04:41:13,310 --> 04:41:13,644
COUPLE.

8345
04:41:13,644 --> 04:41:16,413
MOST OF WHAT WE FUND AT THE

8346
04:41:16,413 --> 04:41:17,548
NATIONAL SCIENCE FOUNDATION IS

8347
04:41:17,548 --> 04:41:17,882
UNSOLICITED.

8348
04:41:17,882 --> 04:41:19,183
THERE IS NO SPECIAL

8349
04:41:19,183 --> 04:41:20,017
SOLICITATION.

8350
04:41:20,017 --> 04:41:21,919
THAT DEAR COLLEAGUE LETTER IN

8351
04:41:21,919 --> 04:41:23,554
WOMEN'S HEALTH IS JUST TO POINT

8352
04:41:23,554 --> 04:41:24,588
TO THE MANY PROGRAMS THAT ARE

8353
04:41:24,588 --> 04:41:25,923
WAITING FOR YOUR APPLICATION.

8354
04:41:25,923 --> 04:41:28,859
RATHER THAN A LIMITED CALL.

8355
04:41:28,859 --> 04:41:31,462
AND WHAT HAS RESULTED JUST

8356
04:41:31,462 --> 04:41:33,197
WITHOUT THAT DCL, THE ONE ON THE

8357
04:41:33,197 --> 04:41:34,865
LEFT IS AN AWARD THAT WAS MADE

8358
04:41:34,865 --> 04:41:36,467
IN 2020 AND THE ONE ON THE RIGHT

8359
04:41:36,467 --> 04:41:38,936
IS ONE IN 2018, I HAVE THIS OLD

8360
04:41:38,936 --> 04:41:40,738
ONE ON THERE FOR A REASON,

8361
04:41:40,738 --> 04:41:45,943
BECAUSE IT'S STILL QUITE ACTIVE,

8362
04:41:45,943 --> 04:41:47,011
CHARACTERIZING THE INTERPLAY

8363
04:41:47,011 --> 04:41:49,980
BETWEEN THE UTERUS, CERVIX,

8364
04:41:49,980 --> 04:41:51,415
VAGINA, IN VIVO AND EX VIVO

8365
04:41:51,415 --> 04:41:52,783
BECAUSE AS SOMEONE SAID, IT'S A

8366
04:41:52,783 --> 04:41:54,285
COMPLEX STRUCTURE, AND THEY

8367
04:41:54,285 --> 04:41:55,553
ACTUALLY INFLUENCE EACH OTHER IN

8368
04:41:55,553 --> 04:41:56,687
THE BIOMECHANICS.

8369
04:41:56,687 --> 04:41:57,988
AND THAT WAS SO IMPORTANT TO

8370
04:41:57,988 --> 04:41:59,823
FUND THAT.

8371
04:41:59,823 --> 04:42:03,227
THE ONE ON THE RIGHT IS VERY

8372
04:42:03,227 --> 04:42:03,427
COOL.

8373
04:42:03,427 --> 04:42:05,262
I GOT A CHANCE TO SEE AT ROCKET

8374
04:42:05,262 --> 04:42:11,602
LAUNCH WITH PAYLOAD GOING UP TO

8375
04:42:11,602 --> 04:42:12,269
THE INTERNATIONAL SPACE STATION.

8376
04:42:12,269 --> 04:42:13,671
THIS PARTICULAR ONE IS ONE OF

8377
04:42:13,671 --> 04:42:14,738
THE ONES THAT WENT UP.

8378
04:42:14,738 --> 04:42:20,644
THIS IS COFUNDED BETWEEN NSF AND

8379
04:42:20,644 --> 04:42:23,347
NASA AND CAS IS WHICH ACTUALLY

8380
04:42:23,347 --> 04:42:24,215
PREPARES THE EXPERIMENTS TO BE

8381
04:42:24,215 --> 04:42:25,649
DONE NOT BY THE INVESTIGATORS

8382
04:42:25,649 --> 04:42:28,319
BUT BY THE ASTRONAUTS IN SPACE.

8383
04:42:28,319 --> 04:42:30,187
SO THERE ARE TWO TOPICAL AREAS

8384
04:42:30,187 --> 04:42:30,955
THAT WE FUND.

8385
04:42:30,955 --> 04:42:33,791
ONE IS ABOUT TRANSPORT MEDIATED

8386
04:42:33,791 --> 04:42:34,024
EVENTS.

8387
04:42:34,024 --> 04:42:35,626
VERY INTERESTING THINGS RELATED

8388
04:42:35,626 --> 04:42:39,363
TO WILDFIRES, SEDIMENTATION, AND

8389
04:42:39,363 --> 04:42:40,831
ALSO ADVANCED MANUFACTURING THAT

8390
04:42:40,831 --> 04:42:45,102
WE COULD BE DOING IN SPACE.

8391
04:42:45,102 --> 04:42:46,770
IN ADDITION WE DO TISSUE

8392
04:42:46,770 --> 04:42:47,404
ENGINEER.

8393
04:42:47,404 --> 04:42:48,806
THIS ONE ON SARCOMERES IS REALLY

8394
04:42:48,806 --> 04:42:50,074
ASKING THREE TYPES OF QUESTIONS.

8395
04:42:50,074 --> 04:42:53,577
THE BASIC QUESTION IS, IS THE

8396
04:42:53,577 --> 04:42:55,446
MUSCLE LOSS, THE SARCOMERE LOSS

8397
04:42:55,446 --> 04:42:56,914
THAT HAPPENS IN SPACE THE SAME

8398
04:42:56,914 --> 04:42:59,650
AS WHAT HAPPENS IN AGING?

8399
04:42:59,650 --> 04:43:01,952
AND IF SO, CAN WE USE SPACE AS

8400
04:43:01,952 --> 04:43:03,687
THE LABORATORY TO TEST NEW DRUG

8401
04:43:03,687 --> 04:43:09,927
INTERVENTIONS AND TREATMENTS?

8402
04:43:09,927 --> 04:43:11,328
NOW JUST MONDAY I MET WITH SPACE

8403
04:43:11,328 --> 04:43:12,463
FORCE.

8404
04:43:12,463 --> 04:43:13,464
THEY ACTUALLY CARE ABOUT THEIR

8405
04:43:13,464 --> 04:43:14,465
SPACE FORCE IN SPACE TO THEY

8406
04:43:14,465 --> 04:43:15,332
ACTUALLY CARE ABOUT IMPROVING

8407
04:43:15,332 --> 04:43:17,067
LIFE IN SPACE AS WELL, SO THAT'S

8408
04:43:17,067 --> 04:43:18,569
WHY I INCLUDED IT HERE.

8409
04:43:18,569 --> 04:43:20,537
WE GO TO ALL ENDS OF THE WORLD

8410
04:43:20,537 --> 04:43:22,406
AND BEYOND TO REALLY THINK ABOUT

8411
04:43:22,406 --> 04:43:23,674
WOMEN'S HEALTH.

8412
04:43:23,674 --> 04:43:25,542
THIS IS THE LAST PROJECT THAT

8413
04:43:25,542 --> 04:43:29,747
I'M GOING TO PRESENT, WHICH IS

8414
04:43:29,747 --> 04:43:31,649
ONE BY AN INVESTIGATOR AT

8415
04:43:31,649 --> 04:43:34,018
HOPKINS, AND HER WORK IS RELATED

8416
04:43:34,018 --> 04:43:37,087
TO THE FACT THAT ULTRASOUND

8417
04:43:37,087 --> 04:43:38,389
NEEDS INNOVATION TO BE ABLE TO

8418
04:43:38,389 --> 04:43:41,425
BE USED IN PEOPLE OF COLOR.

8419
04:43:41,425 --> 04:43:46,230
THE SKIN PENETRATION SHE'S

8420
04:43:46,230 --> 04:43:47,665
INNOVATING IN THIS AREA HAS

8421
04:43:47,665 --> 04:43:48,699
MULTIPLE PATENTS AND SEVERAL

8422
04:43:48,699 --> 04:43:50,034
STARTUPS TO REALLY CHANGE THE

8423
04:43:50,034 --> 04:43:51,535
ULTRASOUND TO BE ABLE TO HAVE

8424
04:43:51,535 --> 04:43:54,038
ITS ACCURACY AND SKIN OF ALL

8425
04:43:54,038 --> 04:43:55,239
COLORS.

8426
04:43:55,239 --> 04:43:57,107
SO I'D LIKE TO JUST TALK A

8427
04:43:57,107 --> 04:43:58,976
LITTLE BIT BECAUSE IT'S NOT ONLY

8428
04:43:58,976 --> 04:44:00,244
RESEARCH, WE'VE ALREADY

8429
04:44:00,244 --> 04:44:01,445
HIGHLIGHTED HOW CAN WE GET MORE

8430
04:44:01,445 --> 04:44:03,414
PEOPLE ENGAGED IN THIS AREA.

8431
04:44:03,414 --> 04:44:07,318
SO IN THE AREA OF WORKFORCE

8432
04:44:07,318 --> 04:44:07,885
DEVELOPMENT AND ENGINEERING

8433
04:44:07,885 --> 04:44:12,122
EDUCATION, WE HAVE ONE THAT IS

8434
04:44:12,122 --> 04:44:15,826
WITH THE LIMELSON FOUNDATION.

8435
04:44:15,826 --> 04:44:17,027
IT'S NOT ON THIS SLIDE.

8436
04:44:17,027 --> 04:44:20,431
THEY REALLY WANTED TO FUND

8437
04:44:20,431 --> 04:44:21,498
EDUCATION IN CURRICULUM TO

8438
04:44:21,498 --> 04:44:24,435
INCLUDE SUSTAINABILITY AND

8439
04:44:24,435 --> 04:44:25,602
RESILIENCE IN ENGINEERING

8440
04:44:25,602 --> 04:44:26,070
CURRICULUM.

8441
04:44:26,070 --> 04:44:29,106
IF YOU HAVE THE IDEA OF WHO WE

8442
04:44:29,106 --> 04:44:33,877
MIGHT APPROACH, PHILANTHROPIC

8443
04:44:33,877 --> 04:44:34,478
ORGANIZATION WHO THIPTION WE

8444
04:44:34,478 --> 04:44:37,047
NEED TO INFUSE IN ENGINEERING

8445
04:44:37,047 --> 04:44:42,586
EDUCATION THE OPPORTUNITIES --

8446
04:44:42,586 --> 04:44:44,421
BEYOND THE WOMEN WHO WANT TO BE

8447
04:44:44,421 --> 04:44:45,155
GRADUATE STUDENTS IN YOUR LAB,

8448
04:44:45,155 --> 04:44:46,890
MICHELLE, BUT TO BE ABLE TO

8449
04:44:46,890 --> 04:44:48,092
INFUSE EARLY ON THE EXCITEMENT

8450
04:44:48,092 --> 04:44:52,763
IN WOMEN'S HEALTH IN AN

8451
04:44:52,763 --> 04:44:54,932
UNDERGRADUATE CURRICULA, WE STAY

8452
04:44:54,932 --> 04:44:56,367
READY WITH A MECHANISM THAT

8453
04:44:56,367 --> 04:44:58,102
WOULD MIMIC WHAT WE'RE ALREADY

8454
04:44:58,102 --> 04:44:59,069
DOING WITH THE FOUNDATION.

8455
04:44:59,069 --> 04:45:01,505
SO I WOULD LOVE TO KNOW WHAT

8456
04:45:01,505 --> 04:45:04,308
THOSE POTENTIAL NON-PROFITS

8457
04:45:04,308 --> 04:45:04,641
MIGHT BE.

8458
04:45:04,641 --> 04:45:09,780
BUT WE ALSO ARE REVOLUTIONIZING

8459
04:45:09,780 --> 04:45:11,181
DEPARTMENTS, AND KREA ATING

8460
04:45:11,181 --> 04:45:13,517
THOSE EXCITING SPIRITS FOR

8461
04:45:13,517 --> 04:45:14,051
UNDERGRADUATES.

8462
04:45:14,051 --> 04:45:16,754
I DON'T KNOW ABOUT YOU BUT I GOT

8463
04:45:16,754 --> 04:45:19,390
HOOKED GOING INTO ACADEMIA THE

8464
04:45:19,390 --> 04:45:20,657
SUMMER OF MY FRESHMAN YEAR.

8465
04:45:20,657 --> 04:45:22,493
LET'S TALK ABOUT HOW WE

8466
04:45:22,493 --> 04:45:23,594
CULTIVATE PARTNERSHIPS.

8467
04:45:23,594 --> 04:45:28,265
WE COMBED 10 YEARS OF

8468
04:45:28,265 --> 04:45:30,701
PUBLICATIONS, PUBLIC -- ACCESS

8469
04:45:30,701 --> 04:45:32,870
PUPUBLICATIONS FOR ALL OF THE

8470
04:45:32,870 --> 04:45:34,671
PAPERS THAT CITED NIH AND NSF.

8471
04:45:34,671 --> 04:45:36,540
IN PARTICULAR, THE ENGINEERING

8472
04:45:36,540 --> 04:45:36,840
DIRECTORATE.

8473
04:45:36,840 --> 04:45:41,678
AND WE WANTED TO KNOW, THESE ARE

8474
04:45:41,678 --> 04:45:42,413
PEOPLE WHO ARE BRIDGING THAT

8475
04:45:42,413 --> 04:45:43,414
CHASM THEMSELVES.

8476
04:45:43,414 --> 04:45:45,582
THEY'RE CITING NIH GRANTS AND

8477
04:45:45,582 --> 04:45:47,518
NSF ENGINEERING AWARDS.

8478
04:45:47,518 --> 04:45:48,152
HOW MANY ARE THERE?

8479
04:45:48,152 --> 04:45:50,053
AND HOW CAN WE -- AND WHERE ARE

8480
04:45:50,053 --> 04:45:51,255
THEY SEEKING FUNDING AND GAINING

8481
04:45:51,255 --> 04:45:54,825
THAT FUNDING AT NIH, AND HOW CAN

8482
04:45:54,825 --> 04:45:57,861
WE AT NSF CREATE THOSE BRIDGES

8483
04:45:57,861 --> 04:46:00,230
OF EFFICIENCY SO THAT YOU DON'T

8484
04:46:00,230 --> 04:46:01,799
HAVE TO HAVE NECESSARILY TWO

8485
04:46:01,799 --> 04:46:02,666
SEPARATE GRANTS.

8486
04:46:02,666 --> 04:46:04,935
SO WHAT YOU SEE ON THE LEFT IS

8487
04:46:04,935 --> 04:46:06,904
THE NUMBER OF PUBLICATIONS WHERE

8488
04:46:06,904 --> 04:46:11,675
PEOPLE ARE CITING BOTH NIH AND

8489
04:46:11,675 --> 04:46:13,844
NSF IS INCREASING, A LOT.

8490
04:46:13,844 --> 04:46:15,145
WHAT YOU SEE AT THE BOTTOM IS

8491
04:46:15,145 --> 04:46:17,114
THE DATA THAT I PRESENTED TO

8492
04:46:17,114 --> 04:46:18,549
BEUS IN A ONE-ON-ONE.

8493
04:46:18,549 --> 04:46:21,018
LOOK, IT'S NOT GOING UP AND DOWN

8494
04:46:21,018 --> 04:46:22,986
SO THE FRACTION OF FUNDING THAT

8495
04:46:22,986 --> 04:46:27,191
IS COMING FROM NIBIB IN THESE

8496
04:46:27,191 --> 04:46:28,759
AREAS OF SYNERGY, THE FRACTION

8497
04:46:28,759 --> 04:46:30,060
IS DECREASING BECAUSE THE NUMBER

8498
04:46:30,060 --> 04:46:30,828
IS GOING UP.

8499
04:46:30,828 --> 04:46:33,497
BUT IF YOU LOOK AT -- YOU SEE

8500
04:46:33,497 --> 04:46:35,065
ALL THE DIFFERENT ICs AND SEE

8501
04:46:35,065 --> 04:46:37,267
THAT NIBIB IS SECOND.

8502
04:46:37,267 --> 04:46:40,270
SO NIGMS, SO MY QUESTION TO YOU

8503
04:46:40,270 --> 04:46:43,106
IS, HOW CAN WE SYNERGIZE EVEN

8504
04:46:43,106 --> 04:46:45,409
MORE, PARTICULARLY IN THE AREA

8505
04:46:45,409 --> 04:46:48,245
OF WOMEN'S HEALTH?

8506
04:46:48,245 --> 04:46:49,680
SO I'M GOING TO SHARE WITH YOU

8507
04:46:49,680 --> 04:46:50,814
THREE MECHANISMS THAT WE'VE

8508
04:46:50,814 --> 04:46:53,484
CREATED IN PARTNERSHIP BETWEEN

8509
04:46:53,484 --> 04:46:55,319
NIBIB AND THE ENGINEERING

8510
04:46:55,319 --> 04:46:55,919
DIRECTORATE, BUT ON OUR SIDE,

8511
04:46:55,919 --> 04:46:59,890
IT'S ALL OF NSF.

8512
04:46:59,890 --> 04:47:05,195
THIS ONE IS IN SIN THEY TECH SYC

8513
04:47:05,195 --> 04:47:05,863
BIOLOGY.

8514
04:47:05,863 --> 04:47:08,599
I BRING THIS UP THAT -- I PUT AT

8515
04:47:08,599 --> 04:47:10,701
THE BOTTOM, ONE PROJECT, TWO

8516
04:47:10,701 --> 04:47:12,269
PHASES, TWO AGENCY, ONE PROPOSAL

8517
04:47:12,269 --> 04:47:13,804
SUBMISSION.

8518
04:47:13,804 --> 04:47:15,439
YOU TAKE THOSE PEOPLE WHO HAVE

8519
04:47:15,439 --> 04:47:16,840
BEEN PUBLISHING, THEY KNOW HOW

8520
04:47:16,840 --> 04:47:18,475
TO WRITE AN NSF GRANT

8521
04:47:18,475 --> 04:47:19,776
SUCCESSFULLY, AND THEY KNOW HOW

8522
04:47:19,776 --> 04:47:21,478
TO WRITE A SUCCESSFUL NIH GRANT.

8523
04:47:21,478 --> 04:47:23,146
WHY DON'T WE COMBINE IT.

8524
04:47:23,146 --> 04:47:26,617
SO WE HAVE THIS MECHANISM, WHICH

8525
04:47:26,617 --> 04:47:28,652
IS IN SYNTHETIC BIOLOGY.

8526
04:47:28,652 --> 04:47:31,188
THE PROPOSALS ARE DELIBERATELY

8527
04:47:31,188 --> 04:47:32,489
DUE DECEMBER 4TH BECAUSE WE KNOW

8528
04:47:32,489 --> 04:47:35,592
THAT THE MECHANISMS ARE CHANGING

8529
04:47:35,592 --> 04:47:36,627
OVER SECTIONS AND REVIEW

8530
04:47:36,627 --> 04:47:37,160
CRITERIA.

8531
04:47:37,160 --> 04:47:39,029
SO IT HAS TO MEET THE NEW

8532
04:47:39,029 --> 04:47:39,496
CRITERIA.

8533
04:47:39,496 --> 04:47:40,831
THEY'LL GO INTO EFFECT IN

8534
04:47:40,831 --> 04:47:42,165
JANUARY, BUT WE THOUGHT THIS WAS

8535
04:47:42,165 --> 04:47:42,733
FINE.

8536
04:47:42,733 --> 04:47:45,369
ONE PROJECT HAS AN NSF PHASE,

8537
04:47:45,369 --> 04:47:48,372
TWO YEARS, MILESTONES, AND THEN

8538
04:47:48,372 --> 04:47:49,473
AN NIH PHASE.

8539
04:47:49,473 --> 04:47:50,908
AND THE BUDGET GOES UP TO THE

8540
04:47:50,908 --> 04:47:51,441
NIH PHASE.

8541
04:47:51,441 --> 04:47:53,944
IT WILL BE NIBIB.

8542
04:47:53,944 --> 04:47:57,214
THAT ONE PROJECT IS DESCRIBING

8543
04:47:57,214 --> 04:47:59,516
THE FULL FOUR YEARS.

8544
04:47:59,516 --> 04:48:02,352
THE BUDGET, ALL FOUR YEARS.

8545
04:48:02,352 --> 04:48:04,521
IT SUBMITTED, IT HAS TO HAVE ALL

8546
04:48:04,521 --> 04:48:07,257
THE FORM OF AN NIH GRANT AND IT

8547
04:48:07,257 --> 04:48:09,726
HAS TO HAVE ALL THE FORM OF AN

8548
04:48:09,726 --> 04:48:11,261
NSF GRANT.

8549
04:48:11,261 --> 04:48:12,796
WHEN I SAY THAT WITHIN MY

8550
04:48:12,796 --> 04:48:13,664
AGENCY, PEOPLE SAY WHO WOULD

8551
04:48:13,664 --> 04:48:14,865
WANT TO WRITE ONE LIKE THAT?

8552
04:48:14,865 --> 04:48:16,500
AND I SAID THE PEOPLE ARE

8553
04:48:16,500 --> 04:48:17,167
ALREADY WRITING THEM LAKE THAT

8554
04:48:17,167 --> 04:48:18,368
AND THEY WOULD LOVE TO BE ABLE

8555
04:48:18,368 --> 04:48:19,269
TO SHARE ALL OF IT AT THE SAME

8556
04:48:19,269 --> 04:48:20,938
TIME.

8557
04:48:20,938 --> 04:48:24,875
THE REVIEWERS ARE AT NSF, WITH

8558
04:48:24,875 --> 04:48:26,510
NIH THERE, ALL OF THE SAME

8559
04:48:26,510 --> 04:48:28,612
CRITERIA THAT ARE USED AT NIH

8560
04:48:28,612 --> 04:48:29,880
WILL BE USED, AS WELL AS ALL OF

8561
04:48:29,880 --> 04:48:31,648
THOSE FOR NSF.

8562
04:48:31,648 --> 04:48:33,183
WHO WOULD SERVE ON A PANEL AND

8563
04:48:33,183 --> 04:48:34,985
WRITE A REVIEW LIKE THAT?

8564
04:48:34,985 --> 04:48:36,753
ALL THE PEOPLE WHO ARE ALREADY

8565
04:48:36,753 --> 04:48:38,822
SERVING ON PANELS FOR BOTH OF

8566
04:48:38,822 --> 04:48:40,023
OUR AGENCIES.

8567
04:48:40,023 --> 04:48:41,558
SO I SEE THIS AS SUCH A WIN FOR

8568
04:48:41,558 --> 04:48:42,759
OUR AGENCIES.

8569
04:48:42,759 --> 04:48:47,764
IT'S FINALLY SOLVING THAT DESERT

8570
04:48:47,764 --> 04:48:48,298
OF FUNDING.

8571
04:48:48,298 --> 04:48:49,700
BECAUSE IF YOU ACCOMPLISH THOSE

8572
04:48:49,700 --> 04:48:51,868
HIGH RISK GOALS, IT THEN

8573
04:48:51,868 --> 04:48:54,304
TRANSLATES DIRECTLY TO NIH.

8574
04:48:54,304 --> 04:48:56,373
AND GUESS WHAT?

8575
04:48:56,373 --> 04:48:58,575
NO MONEY FROM NIH COMES TO NSF.

8576
04:48:58,575 --> 04:49:01,244
INSTEAD, THE FIRST TWO YEARS,

8577
04:49:01,244 --> 04:49:01,812
NIH WILL PUT IN A DOLLAR.

8578
04:49:01,812 --> 04:49:02,479
WHY?

8579
04:49:02,479 --> 04:49:05,515
THEY GET ANNUAL REPORTS FOR

8580
04:49:05,515 --> 04:49:07,351
THOSE FIRST TWO YEARS WHERE

8581
04:49:07,351 --> 04:49:08,018
THEY'RE NOT FUNDING THE BULK OF

8582
04:49:08,018 --> 04:49:10,654
IT, AND THE LAST TWO YEARS NSF

8583
04:49:10,654 --> 04:49:12,923
IS PUTTING IN JUST A DOLLAR.

8584
04:49:12,923 --> 04:49:13,557
SO WE'RE EXCITED ABOUT THIS AND

8585
04:49:13,557 --> 04:49:14,691
WE SEE THE POTENTIAL

8586
04:49:14,691 --> 04:49:16,059
APPLICATION.

8587
04:49:16,059 --> 04:49:18,362
THIS IS ONE THAT ALSO HAS AN

8588
04:49:18,362 --> 04:49:18,962
APPLICATION IN PUBLIC HEALTH.

8589
04:49:18,962 --> 04:49:20,998
REMEMBER I TALKED ABOUT THE

8590
04:49:20,998 --> 04:49:22,966
INDUSTRY UNIVERSITY COOPERATIVE

8591
04:49:22,966 --> 04:49:24,167
RESEARCH CENTERS?

8592
04:49:24,167 --> 04:49:28,505
THIS IS ONE THAT WE ARE GOING TO

8593
04:49:28,505 --> 04:49:33,110
DO BETWEEN NIBIB AND NSF AND THE

8594
04:49:33,110 --> 04:49:33,777
FDA.

8595
04:49:33,777 --> 04:49:38,548
THE TOPIC, PHANTOMS, STANDARDIZE

8596
04:49:38,548 --> 04:49:39,650
THEM, TOWARDS UNIFORM ADOPTION.

8597
04:49:39,650 --> 04:49:40,617
LET'S DO THIS FOR WOMEN'S

8598
04:49:40,617 --> 04:49:40,951
HEALTH.

8599
04:49:40,951 --> 04:49:42,786
WE COULD BE DOING THIS AS WELL.

8600
04:49:42,786 --> 04:49:45,522
THIS IS AN NSF MECHANISM THAT'S

8601
04:49:45,522 --> 04:49:48,825
NOW WHERE NIH IS COMING IN, AND

8602
04:49:48,825 --> 04:49:52,629
THE NIH MONEY WILL FLOW TO NSF

8603
04:49:52,629 --> 04:49:53,830
BECAUSE IT'S A MECHANISM THAT WE

8604
04:49:53,830 --> 04:49:54,164
HAVE.

8605
04:49:54,164 --> 04:49:56,566
SO IN CLOSING, THERE'S SO MANY

8606
04:49:56,566 --> 04:49:57,668
URGENT ISSUES THAT ARE AFFECTING

8607
04:49:57,668 --> 04:49:58,435
PUBLIC HEALTH AND WOMEN'S HEALTH

8608
04:49:58,435 --> 04:49:59,636
IN PARTICULAR.

8609
04:49:59,636 --> 04:50:02,339
AND I REALLY LOOK FORWARD TO

8610
04:50:02,339 --> 04:50:03,340
THOSE OPPORTUNITIES TO REALLY

8611
04:50:03,340 --> 04:50:04,641
MAKE A DIFFERENCE.

8612
04:50:04,641 --> 04:50:06,510
THE LAST ONE I'LL SHOW AT THE

8613
04:50:06,510 --> 04:50:08,812
TOP, IN THE ENGINEERING

8614
04:50:08,812 --> 04:50:11,314
DIRECTORATE, WE HAVE DISASTER

8615
04:50:11,314 --> 04:50:11,848
RESILIENCE RESEARCH.

8616
04:50:11,848 --> 04:50:14,685
WE HAVE TEST BEDS WITH SHAKE

8617
04:50:14,685 --> 04:50:16,853
TABLES, WHERE 10 STORY BUILDINGS

8618
04:50:16,853 --> 04:50:18,055
CAN GO ON IT.

8619
04:50:18,055 --> 04:50:19,256
WE ALSO HAVE PEOPLE THAT ARE

8620
04:50:19,256 --> 04:50:21,558
PREPARED TO GO LITERALLY

8621
04:50:21,558 --> 04:50:23,260
TOMORROW TO DISASTER SITE, AND

8622
04:50:23,260 --> 04:50:26,663
OUR RELATIONSHIP WITH NIH HAS

8623
04:50:26,663 --> 04:50:30,901
ALLOWED US TO, THROUGH NIH

8624
04:50:30,901 --> 04:50:32,135
FUNDING, TO FUND PEOPLE TO BE

8625
04:50:32,135 --> 04:50:35,839
TRAINED TO GET THE HUMAN -- THE

8626
04:50:35,839 --> 04:50:38,108
EPHEMERAL HUMAN DATA AND

8627
04:50:38,108 --> 04:50:39,109
DISASTER SITE SO THAT NIH CAN

8628
04:50:39,109 --> 04:50:41,478
HAVE THAT IMPORTANT DATA.

8629
04:50:41,478 --> 04:50:44,114
OH SO OUR PEOPLE ARE NOT

8630
04:50:44,114 --> 04:50:45,315
PREPARED TO GATHER THAT DATA

8631
04:50:45,315 --> 04:50:45,649
NORMALLY.

8632
04:50:45,649 --> 04:50:47,184
THEY'RE LOOKING AT OTHER

8633
04:50:47,184 --> 04:50:47,484
ASPECTS.

8634
04:50:47,484 --> 04:50:50,220
IT COULD BE NATURAL DISASTERS,

8635
04:50:50,220 --> 04:50:51,188
BUT WE NEED THE PEOPLE DATA TOO.

8636
04:50:51,188 --> 04:50:52,756
AND IF WE FOCUS ON THE PEOPLE

8637
04:50:52,756 --> 04:50:54,791
DATA FROM WOMEN AND MEN AND MAKE

8638
04:50:54,791 --> 04:50:57,094
IT A SEX-BASED DISTINCTION, WE

8639
04:50:57,094 --> 04:51:01,264
MAY GET SOME VERY INTERESTING

8640
04:51:01,264 --> 04:51:02,165
INFORMATION ABOUT WOMEN'S HEALTH

8641
04:51:02,165 --> 04:51:04,334
IN THE FACE OF DISASTERS.

8642
04:51:04,334 --> 04:51:05,502
SO I LOOK FORWARD TO OUR

8643
04:51:05,502 --> 04:51:07,704
COLLABORATION.

8644
04:51:07,704 --> 04:51:11,208
>> THANK YOU SO VERY MUCH.

8645
04:51:11,208 --> 04:51:13,210
WE HAVE TIME FOR ONE OR TWO

8646
04:51:13,210 --> 04:51:16,646
QUESTIONS.

8647
04:51:16,646 --> 04:51:26,423
 FROM MEMBERS.

8648
04:51:26,423 --> 04:51:28,892
>> THAT WAS SUCH AN
INCREDIBLE

8649
04:51:28,892 --> 04:51:29,326
PRESENTATION, SUSAN.

8650
04:51:29,326 --> 04:51:30,293
YOU HIGHLIGHTED SO MANY CRITICAL

8651
04:51:30,293 --> 04:51:31,595
ISSUES NOT JUST FOR OUR NATION,

8652
04:51:31,595 --> 04:51:33,130
FOR OUR WORLD.

8653
04:51:33,130 --> 04:51:35,632
YOU HIGHLIGHTED, FOR EXAMPLE,

8654
04:51:35,632 --> 04:51:36,833
THE MUSCLE CHANGES THAT ARE SEEN

8655
04:51:36,833 --> 04:51:39,002
IN SPACE, THERE ARE KNOWN SEX

8656
04:51:39,002 --> 04:51:44,474
DIFFERENCES IN SPACE TRAVEL'S IT

8657
04:51:44,474 --> 04:51:45,442
EFFECT ON MEN AND WOMEN, THERE

8658
04:51:45,442 --> 04:51:47,077
ARE OCULAR EFFECTS AS WELL, THAT

8659
04:51:47,077 --> 04:51:48,945
ARE REALLY UNIQUE, NOT SEEN

8660
04:51:48,945 --> 04:51:50,247
ANYWHERE ELSE SO THAT'S

8661
04:51:50,247 --> 04:51:50,814
FASCINATING SCIENCE.

8662
04:51:50,814 --> 04:51:56,920
BUT I THINK WHAT YOU CA CHALLEND

8663
04:51:56,920 --> 04:52:00,323
US TO DO WAS TO BE CREATIVE.

8664
04:52:00,323 --> 04:52:02,659
YOUR AND NSF'S VISION FOR

8665
04:52:02,659 --> 04:52:07,964
PARTNERSHIP.

8666
04:52:07,964 --> 04:52:10,033
WE TALK ABOUT INTERDISCIPLINARY

8667
04:52:10,033 --> 04:52:13,270
RESEARCH, WE KNOW THE HO  POWERF

8668
04:52:13,270 --> 04:52:14,371
BRINGING DISCIPLINES TOGETHER.

8669
04:52:14,371 --> 04:52:16,673
BUT I WONDER IF YOU MIGHT

8670
04:52:16,673 --> 04:52:19,176
COMMENT ON OVERCOMING THOSE

8671
04:52:19,176 --> 04:52:22,512
BARRIERS TO US WORKING TOGETHER,

8672
04:52:22,512 --> 04:52:23,747
HOW YOU SEE.

8673
04:52:23,747 --> 04:52:27,117
CLEARLY, YOU'VE DESIGNED THESE

8674
04:52:27,117 --> 04:52:27,884
MECHANISMS, BUT WE DO APPROACH

8675
04:52:27,884 --> 04:52:30,854
THINGS DIFFERENTLY.

8676
04:52:30,854 --> 04:52:31,822
SIMPLIFY REVIEW FRAMEWORK IS

8677
04:52:31,822 --> 04:52:33,023
GOING INTO EFFECT IN JANUARY.

8678
04:52:33,023 --> 04:52:34,324
HOPEFULLY THAT WILL MAKE THINGS

8679
04:52:34,324 --> 04:52:35,959
MORE STREAMLINED AND EASIER FOR

8680
04:52:35,959 --> 04:52:36,827
EVERYONE, BUT WHAT ARE YOUR

8681
04:52:36,827 --> 04:52:39,029
THOUGHTS FROM YOUR VANTAGE POINT

8682
04:52:39,029 --> 04:52:40,096
FROM THE NSF SIDE?

8683
04:52:40,096 --> 04:52:42,966
>> SO WE'VE HAD MANY YEARS
OF

8684
04:52:42,966 --> 04:52:43,333
COLLABORATIONS.

8685
04:52:43,333 --> 04:52:46,770
THEY TEND TO BE ONE PROGRAM

8686
04:52:46,770 --> 04:52:47,270
DIRECTOR AND ONE PROGRAM

8687
04:52:47,270 --> 04:52:49,506
DIRECTOR WHO FOUND EACH OTHER AT

8688
04:52:49,506 --> 04:52:51,141
A NATIONAL MEETING OR KNEW EACH

8689
04:52:51,141 --> 04:52:52,509
OTHER AND THEY DEVELOPED

8690
04:52:52,509 --> 04:52:53,343
SOMETHING ON A PARTICULAR TOPIC,

8691
04:52:53,343 --> 04:52:56,179
AND IT HAS A LIFE OF MAYBE JUST

8692
04:52:56,179 --> 04:52:58,915
A COUPLE YEARS.

8693
04:52:58,915 --> 04:53:00,684
IT'S IMPRESSIVE WHEN IT'S LONGER

8694
04:53:00,684 --> 04:53:02,385
THAN A COUPLE YEARS BUT IT'S

8695
04:53:02,385 --> 04:53:06,423
NOT -- THAT WOULD BE THE TAIL.

8696
04:53:06,423 --> 04:53:08,892
SO THESE MECHANISMS THAT ARE NOW

8697
04:53:08,892 --> 04:53:09,926
AT THE LEVEL OF LIKE IC

8698
04:53:09,926 --> 04:53:12,395
DIRECTOR.

8699
04:53:12,395 --> 04:53:14,764
AND I'M CONTENT WITH THE FACT

8700
04:53:14,764 --> 04:53:17,901
THAT AT NIH, IT'S IC BY IC.

8701
04:53:17,901 --> 04:53:19,436
SO BRUCE AND I HAVE TALKED ABOUT

8702
04:53:19,436 --> 04:53:21,304
SHOULD THERE BE A PRESENTATION

8703
04:53:21,304 --> 04:53:23,240
AT ONE OF THE GATHERINGS WHERE

8704
04:53:23,240 --> 04:53:25,342
YOU ALL GET TOGETHER AND THIS IS

8705
04:53:25,342 --> 04:53:29,613
POTENTIAL, AND THERE CAN BE AN

8706
04:53:29,613 --> 04:53:31,915
OPPORTUNITY TO THINK ABOUT A

8707
04:53:31,915 --> 04:53:34,150
TOPIC THAT SUITS OTHERS.

8708
04:53:34,150 --> 04:53:36,553
WHEN YOU TALK ABOUT THE ONE

8709
04:53:36,553 --> 04:53:37,320
PROPOSAL, ONE SUBMISSION, WE

8710
04:53:37,320 --> 04:53:38,288
EVEN HAVE TO TALK ABOUT IF

8711
04:53:38,288 --> 04:53:41,758
THERE'S A FREEDOM OF INFORMATION

8712
04:53:41,758 --> 04:53:43,493
REQUEST, SO IT GOT DOWN TO THE

8713
04:53:43,493 --> 04:53:44,628
OFFICE OF GENERAL COUNCIL IN

8714
04:53:44,628 --> 04:53:45,962
EACH OF OUR AGENCIES.

8715
04:53:45,962 --> 04:53:47,797
WE REALLY WORKED THINGS OUT ON

8716
04:53:47,797 --> 04:53:49,132
HOW THIS WOULD LOOK.

8717
04:53:49,132 --> 04:53:51,201
FOR AS MANY DIFFERENT DETAILS AS

8718
04:53:51,201 --> 04:53:51,801
POSSIBLE.

8719
04:53:51,801 --> 04:53:54,704
SO I VIEW THESE AS BLOCKS ON

8720
04:53:54,704 --> 04:53:58,975
WHICH WE CAN BUILD, RATHER THAN

8721
04:53:58,975 --> 04:54:00,510
A TENUOUS STRAIN THAT CONNECTS

8722
04:54:00,510 --> 04:54:02,913
OUR TWO AGENCIES TOGETHER.

8723
04:54:02,913 --> 04:54:03,546
SO OPPORTUNITIES TO GET IN FRONT

8724
04:54:03,546 --> 04:54:04,981
OF THOSE WHO ARE THE DECISION

8725
04:54:04,981 --> 04:54:07,617
MAKERS, WHO SAY WE'VE GOT TO USE

8726
04:54:07,617 --> 04:54:09,119
THIS BECAUSE THIS ALLOWS US TO

8727
04:54:09,119 --> 04:54:11,421
MEET THE NEEDS OF OUR

8728
04:54:11,421 --> 04:54:13,189
CONSTITUENCIES MORE THAN WE ARE

8729
04:54:13,189 --> 04:54:16,126
ABLE TO DO NOW, THAT'S WHAT I

8730
04:54:16,126 --> 04:54:17,961
LOOK TO AS AN OPPORTUNITY.

8731
04:54:17,961 --> 04:54:21,031
YOU KNOW YOUR AGENCY, AND I

8732
04:54:21,031 --> 04:54:25,435
WOULD BE DELIGHTED TO USE

8733
04:54:25,435 --> 04:54:26,536
WHATEVER MODALITIES YOU THINK

8734
04:54:26,536 --> 04:54:28,772
WOULD BE MOST CONVINCING TO HAVE

8735
04:54:28,772 --> 04:54:30,640
LOWERED THE BARRIERS AND NOW

8736
04:54:30,640 --> 04:54:33,710
WE'RE AT ADOPTION.

8737
04:54:33,710 --> 04:54:35,011
SO I WOULD LOOK FORWARD TO

8738
04:54:35,011 --> 04:54:38,715
HEARING, SO WHICH ARE THE ICs

8739
04:54:38,715 --> 04:54:40,684
WITH THE MOST WOMEN'S HEALTH

8740
04:54:40,684 --> 04:54:41,318
RESEARCH, BECAUSE THAT WOULD BE

8741
04:54:41,318 --> 04:54:42,319
THE ONES THAT WE WOULD GO TO

8742
04:54:42,319 --> 04:54:42,886
FIRST, RIGHT?

8743
04:54:42,886 --> 04:54:44,854
YEAH.

8744
04:54:44,854 --> 04:54:46,823
>> THAT WAS A MUCH LONGER
ANSWER

8745
04:54:46,823 --> 04:54:47,424
THAN I'M GOING TO GIVE YOU IN

8746
04:54:47,424 --> 04:54:49,659
TIME TODAY.

8747
04:54:49,659 --> 04:54:50,961
SO ANYWAY, BUT WE WILL FOLLOW UP

8748
04:54:50,961 --> 04:54:52,562
WITH YOU BECAUSE I THINK IT'S

8749
04:54:52,562 --> 04:54:53,463
JUST AN EXCITING OPPORTUNITY.

8750
04:54:53,463 --> 04:54:56,533
I'M GOING TO GIVE ALL OF YOU A

8751
04:54:56,533 --> 04:54:57,834
COUPLE, THREE MINUTES TO STAND

8752
04:54:57,834 --> 04:55:04,240
UP AND STRETCH, AND THEN -- SO

8753
04:55:04,240 --> 04:55:05,742
THANK YOU VERY MUCH ONCE AGAIN,

8754
04:55:05,742 --> 04:55:06,042
SUSAN.

8755
04:55:06,042 --> 04:55:08,044
IT WAS REALLY TERRIFIC HAVING

8756
04:55:08,044 --> 04:55:11,848
YOU HERE.

8757
04:55:11,848 --> 04:55:14,918
SO WE HAVE A 2 TO 3-MINUTE BREAK

8758
04:55:14,918 --> 04:55:16,465
AND WE'RE GOING TO START AGAIN.

8759
04:55:20,078 --> 04:55:22,180
IT'S MY DISTINCT PLEASURE TO

8760
04:55:22,180 --> 04:55:24,282
INTRODUCE DR. EVE HIGGINBOTHAM.

8761
04:55:24,282 --> 04:55:26,685
DR. HI HIGGINBOTHAM IS THE FORMR

8762
04:55:26,685 --> 04:55:28,620
VICE DEAN FOR DIVERSITY,

8763
04:55:28,620 --> 04:55:30,956
INCLUSION AND EQUITY AT THE

8764
04:55:30,956 --> 04:55:32,457
UNIVERSITY OF PENNSYLVANIA.

8765
04:55:32,457 --> 04:55:34,225
SHE'S ALSO A SENIOR FELLOW AT

8766
04:55:34,225 --> 04:55:35,660
THE LEONARD DAVIS INSTITUTE FOR

8767
04:55:35,660 --> 04:55:37,495
HEALTH ECONOMICS AND PROFESSOR

8768
04:55:37,495 --> 04:55:40,432
OF OPHTHALMOLOGY AT THE SHEA EYE

8769
04:55:40,432 --> 04:55:41,099
INSTITUTE.

8770
04:55:41,099 --> 04:55:43,068
SHE'S A GLAUCOMA SPECIALIST AND

8771
04:55:43,068 --> 04:55:45,770
IS ACTIVE IN SCHOLARSHIP RELATED

8772
04:55:45,770 --> 04:55:47,539
TO GLAUCOMA, OCULAR

8773
04:55:47,539 --> 04:55:48,640
PHARMACOLOGY, HEALTH POLICY,

8774
04:55:48,640 --> 04:55:50,141
HEALTH EQUITY AND ORGANIZATIONAL

8775
04:55:50,141 --> 04:55:52,110
CULTURE.

8776
04:55:52,110 --> 04:55:53,311
DR. HIGGINBOTHAM HAS SERVED AS

8777
04:55:53,311 --> 04:55:57,582
PRESIDENT OF THE ALPHA OMEGA

8778
04:55:57,582 --> 04:55:58,183
ALPHA HONOR SOCIETY AND WAS A

8779
04:55:58,183 --> 04:55:59,184
PAST MEMBER OF THE HARVARD BOARD

8780
04:55:59,184 --> 04:56:00,952
OF OVERSEERS AND THE MIT

8781
04:56:00,952 --> 04:56:02,921
CORPORATION.

8782
04:56:02,921 --> 04:56:05,156
SHE CURRENTLY SERVES ON THE TWO

8783
04:56:05,156 --> 04:56:09,461
VISITING COMMITTEES AT MIT, THE

8784
04:56:09,461 --> 04:56:10,328
INSTITUTE OF MEDICAL ENGINEERING

8785
04:56:10,328 --> 04:56:12,197
AND SCIENCE AND UNDERGRADUATE

8786
04:56:12,197 --> 04:56:15,133
AND GRADUATE STUDENT LIFE, AND

8787
04:56:15,133 --> 04:56:15,734
SERVES AS A BOARD OF DIRECTORS

8788
04:56:15,734 --> 04:56:18,870
ON SEVERAL OTHER ORGANIZATIONS.

8789
04:56:18,870 --> 04:56:20,872
IN ADDITION, SHE CURRENTLY

8790
04:56:20,872 --> 04:56:22,273
SERVES AS ASSOCIATE EDITOR ON

8791
04:56:22,273 --> 04:56:23,675
THE EDITORIAL BOARD OF THE

8792
04:56:23,675 --> 04:56:25,443
AMERICAN JOURNAL OF

8793
04:56:25,443 --> 04:56:26,344
OPHTHALMOLOGY.

8794
04:56:26,344 --> 04:56:28,747
IT IS ENGINEER DAY, AND

8795
04:56:28,747 --> 04:56:30,715
DR. HIGGINBOTHAM RECEIVED HER SB

8796
04:56:30,715 --> 04:56:32,250
AND SM DEGREES IN CHEMICAL

8797
04:56:32,250 --> 04:56:34,786
ENGINEERING AT MIT, AND HER

8798
04:56:34,786 --> 04:56:37,589
MEDICAL DEGREE AT HARVARD

8799
04:56:37,589 --> 04:56:38,923
UNIVERSITY, COMPLETING

8800
04:56:38,923 --> 04:56:42,961
OPHTHALMOLOGY RESIDENCY AT

8801
04:56:42,961 --> 04:56:43,862
LOUISIANA EYE CENTER.

8802
04:56:43,862 --> 04:56:45,597
SHE ALSO RECEIVED A MASTER'S OF

8803
04:56:45,597 --> 04:56:49,134
LAW DI GR DEGREE FROM THE

8804
04:56:49,134 --> 04:56:50,702
UNIVERSITY OF PENNSYLVANIA,

8805
04:56:50,702 --> 04:56:51,102
KERRY LAW SCHOOL.

8806
04:56:51,102 --> 04:56:53,071
SHE HAS BEEN A MEMBER OF THE

8807
04:56:53,071 --> 04:56:53,772
NATIONAL ACADEMY OF MEDICINE

8808
04:56:53,772 --> 04:56:55,006
SINCE 2000 AND SHE HAS CHAIRED

8809
04:56:55,006 --> 04:56:57,542
MANY GROUPS RELATED TO HER

8810
04:56:57,542 --> 04:57:00,145
NATIONAL ACADEMY WORK, MOST

8811
04:57:00,145 --> 04:57:01,279
RECENTLY THE IMPACT OF COVID-19

8812
04:57:01,279 --> 04:57:02,647
ON THE CAREERS OF WOMEN IN

8813
04:57:02,647 --> 04:57:05,583
ACADEMIC SCIENCES, ENGINEERING

8814
04:57:05,583 --> 04:57:06,084
AN MEDICINE.

8815
04:57:06,084 --> 04:57:11,189
IT IS MY HONOR TO INTRODUCE

8816
04:57:11,189 --> 04:57:13,591
SOMEONE WHO I'VE LOOKED UP TO IN

8817
04:57:13,591 --> 04:57:17,195
HER LEAD ARE SHIP POSITIONS IN

8818
04:57:17,195 --> 04:57:18,063
OPHTHALMOLOGY FOR MANY, MANY

8819
04:57:18,063 --> 04:57:19,497
YEARS, A PERSON WHO BRINGS

8820
04:57:19,497 --> 04:57:20,965
SCHOLARSHIP TO EVERYTHING SHE

8821
04:57:20,965 --> 04:57:22,667
DOES, AN EQUITABLE APPROACH AND

8822
04:57:22,667 --> 04:57:27,372
INCREDIBLY ALWAYS COMMITTED TO

8823
04:57:27,372 --> 04:57:29,207
EVIDENCE, EVIDENCE, WHERE'S THE

8824
04:57:29,207 --> 04:57:30,442
DATA, DR. EVE HIGGINBOTHAM.

8825
04:57:30,442 --> 04:57:33,711
>> THANK YOU, DR. CLAYTON.

8826
04:57:33,711 --> 04:57:35,847
I AM SO HAPPY TO BE HERE, AND

8827
04:57:35,847 --> 04:57:39,084
NOW THAT YOU RECEIVED THE COPIES

8828
04:57:39,084 --> 04:57:40,819
OF THE REPORT, YOU KNOW HOW

8829
04:57:40,819 --> 04:57:42,554
IMPOSSIBLE IT'S GOING TO BE FOR

8830
04:57:42,554 --> 04:57:44,322
ME TO DO THIS IN 20 TO 25

8831
04:57:44,322 --> 04:57:46,057
MINUTES, BUT I'LL DO MY BEST.

8832
04:57:46,057 --> 04:57:48,026
IT'S NEARLY 600 PAGES.

8833
04:57:48,026 --> 04:57:50,962
AND SO WITH THAT, I'LL JUST

8834
04:57:50,962 --> 04:57:53,131
START AND REALLY RECOGNIZE THAT

8835
04:57:53,131 --> 04:57:54,999
IT WAS A COMMITTEE THAT PULLED

8836
04:57:54,999 --> 04:57:59,270
THIS TOGETHER, NA SEMI

8837
04:57:59,270 --> 04:58:00,805
COMMITTEE, AND OUR TITLE WAS

8838
04:58:00,805 --> 04:58:02,373
FRAMEWORK FOR THE CONSIDERATION

8839
04:58:02,373 --> 04:58:03,541
OF CHRONIC DEBILITATING

8840
04:58:03,541 --> 04:58:04,976
CONDITIONS IN WOMEN.

8841
04:58:04,976 --> 04:58:07,078
CERTAINLY I'D LIKE TO THANK DRS.

8842
04:58:07,078 --> 04:58:10,014
CLAYTON AND WANG FOR THE

8843
04:58:10,014 --> 04:58:11,116
OPPORTUNITY TO PRESENT A SUMMARY

8844
04:58:11,116 --> 04:58:14,619
OF OUR WORK, WHICH COVERED A

8845
04:58:14,619 --> 04:58:17,889
YEAR AND A HALF OF EFFORT.

8846
04:58:17,889 --> 04:58:19,657
I WILL HIGHLIGHT THE STUDY'S

8847
04:58:19,657 --> 04:58:21,659
MAIN FINDINGS, CONFUSIONS, AND

8848
04:58:21,659 --> 04:58:28,133
RECOMMENDCONCLUSIONS ANDRECOMMEE

8849
04:58:28,133 --> 04:58:29,000
RESEARCH AGENDA WITH THE HOPE

8850
04:58:29,000 --> 04:58:31,069
THIS WILL INDEED HELP TO ADVANCE

8851
04:58:31,069 --> 04:58:31,936
RESEARCH ON CHRONIC CONDITIONS

8852
04:58:31,936 --> 04:58:33,271
IN WOMEN WITH THE OVERARCHING

8853
04:58:33,271 --> 04:58:35,340
GOAL OF IMPROVING THE HEALTH AND

8854
04:58:35,340 --> 04:58:38,743
QUALITY OF LIFE OF ALL WOMEN.

8855
04:58:38,743 --> 04:58:43,982
I WOULD LIKE TO FIRST THANK OUR

8856
04:58:43,982 --> 04:58:45,183
SPONSOR, IF WE CAN GET TO THE

8857
04:58:45,183 --> 04:58:45,617
NEXT SLIDE.

8858
04:58:45,617 --> 04:58:55,960
IT'S NOT ADVANCING.

8859
04:58:57,328 --> 04:59:06,337
I'D LIKE TO THANK OUR SPONSOR,

8860
04:59:06,337 --> 04:59:06,871
THE NATIONAL INSTITUTES OF

8861
04:59:06,871 --> 04:59:09,174
HEALTH, THE OFFICE OF RESEARCH

8862
04:59:09,174 --> 04:59:11,042
ON WOMEN'S HEALTH FOR THEIR

8863
04:59:11,042 --> 04:59:13,545
FINANCIAL SUPPORT FOR THIS

8864
04:59:13,545 --> 04:59:14,546
PROJECT, PARTICULARLY

8865
04:59:14,546 --> 04:59:16,381
DR. CLAYTON AND HER COLLEAGUES.

8866
04:59:16,381 --> 04:59:18,416
I ALSO WOULD LIKE TO ACKNOWLEDGE

8867
04:59:18,416 --> 04:59:20,285
THE MEMBERS OF OUR COMMITTEE,

8868
04:59:20,285 --> 04:59:22,287
ONE OF WHOM IS SITTING RIGHT

8869
04:59:22,287 --> 04:59:25,590
HERE AMONG YOU AS A MEMBER OF

8870
04:59:25,590 --> 04:59:27,458
THE ADVISORY COMMITTEE,

8871
04:59:27,458 --> 04:59:29,394
DR. ARNOLD.

8872
04:59:29,394 --> 04:59:32,463
THE COMMITTEE WAS CO CONVENED BY

8873
04:59:32,463 --> 04:59:33,698
THE NATIONAL ACADEMIES OF

8874
04:59:33,698 --> 04:59:34,332
SCIENCE, ENGINEERING AND

8875
04:59:34,332 --> 04:59:35,733
MEDICINE AND REPRESENT A RICH

8876
04:59:35,733 --> 04:59:37,602
DIVERSITY OF DISCIPLINES,

8877
04:59:37,602 --> 04:59:40,104
INCLUDING CLINICIANS, BASIC

8878
04:59:40,104 --> 04:59:40,738
SCIENTISTS,

8879
04:59:40,738 --> 04:59:42,607
CLINICIAN-SCIENTISTS, AND

8880
04:59:42,607 --> 04:59:44,142
EPIDEMIOLOGISTS, AND THE

8881
04:59:44,142 --> 04:59:45,577
BIOSKETCHES NOT ONLY DO WE HAVE

8882
04:59:45,577 --> 04:59:47,845
THE HARD COPY AVAILABLE, BUT YOU

8883
04:59:47,845 --> 04:59:51,249
CAN ACTUALLY ACCESS THE ENTIRE

8884
04:59:51,249 --> 04:59:54,018
REPORT ONLINE AS WELL.

8885
04:59:54,018 --> 04:59:56,087
AND THAT'S WHERE YOU'LL FIND ALL

8886
04:59:56,087 --> 04:59:57,055
THE BIOSKETCHES.

8887
04:59:57,055 --> 04:59:58,723
SO THE STATEMENT OF TASK IS

8888
04:59:58,723 --> 05:00:01,759
ALWAYS THE NORTH STAR FOR EVERY

8889
05:00:01,759 --> 05:00:02,727
NA SEMI REPORT.

8890
05:00:02,727 --> 05:00:04,929
AND OUR STATEMENT OF TASK ASKS

8891
05:00:04,929 --> 05:00:06,998
US TO DESCRIBE THE CURRENT

8892
05:00:06,998 --> 05:00:09,067
EVIDENCE AND GAPS IN THE SCIENCE

8893
05:00:09,067 --> 05:00:10,935
ON CHRONIC CONDITIONS IN WOMEN,

8894
05:00:10,935 --> 05:00:14,439
INCLUDING A REVIEW OF THE

8895
05:00:14,439 --> 05:00:15,173
LITERATURE, THE EPIDEMIOLOGY OF

8896
05:00:15,173 --> 05:00:16,708
CHRONIC CONDITIONS, DESCRIBE HOW

8897
05:00:16,708 --> 05:00:18,810
CHRONIC CONDITIONS IN WOMEN ARE

8898
05:00:18,810 --> 05:00:23,381
INFLUENCED BY FACTORS SUCH AS

8899
05:00:23,381 --> 05:00:24,916
MENOPAUSE, AGE-RELATED SKELETAL

8900
05:00:24,916 --> 05:00:26,150
DYSFUNCTION AND FRAILTY,

8901
05:00:26,150 --> 05:00:27,785
PREVENTION, DIAGNOSIS AND

8902
05:00:27,785 --> 05:00:29,520
TREATMENT TO FEMALE-SPECIFIC

8903
05:00:29,520 --> 05:00:30,521
GYNECOLOGIC CONDITIONS, AND WE

8904
05:00:30,521 --> 05:00:32,590
WERE ASKED TO DESCRIBE HOW THE

8905
05:00:32,590 --> 05:00:34,993
SOCIAL DETERMINANTS OF HEALTH

8906
05:00:34,993 --> 05:00:36,160
INFLUENCE THESE CONDITIONS.

8907
05:00:36,160 --> 05:00:38,896
WE WERE ALSO ASKED TO PROPOSE A

8908
05:00:38,896 --> 05:00:41,833
RESEARCH AGENDA, WHICH IS

8909
05:00:41,833 --> 05:00:43,167
PRESENTED IN THE SUMMARY AND

8910
05:00:43,167 --> 05:00:44,369
LAST CHAPTER OF THE REPORT.

8911
05:00:44,369 --> 05:00:47,305
SO I'M ALSO GOING TO BE GIVING

8912
05:00:47,305 --> 05:00:51,075
YOU IDEAS OF WHERE YOU CAN FIND

8913
05:00:51,075 --> 05:00:52,844
SOME OF THIS CONTENT.

8914
05:00:52,844 --> 05:00:54,479
THIS STATEMENT OF TASK SET THE

8915
05:00:54,479 --> 05:00:57,415
STAGE FOR OUR DISCUSSION.

8916
05:00:57,415 --> 05:00:59,984
WE CONSIDER THE NIH'S OFFICE OF

8917
05:00:59,984 --> 05:01:02,253
RESEARCH ON WOMEN'S HEALTH

8918
05:01:02,253 --> 05:01:03,388
FRAMEWORK, WHICH INCLUDES

8919
05:01:03,388 --> 05:01:04,656
44 CHRONIC CONDITIONS.

8920
05:01:04,656 --> 05:01:07,091
WE ALSO TOOK INTO ACCOUNT LIVED

8921
05:01:07,091 --> 05:01:08,826
EXPERIENCES OF WOMEN WITH

8922
05:01:08,826 --> 05:01:11,663
CHRONIC CONDITIONS.

8923
05:01:11,663 --> 05:01:14,365
WE ALSO CONSIDERED CONDITIONS

8924
05:01:14,365 --> 05:01:15,933
SUCH AS SUBSTANCE USE DISORDER

8925
05:01:15,933 --> 05:01:19,203
AND HIV, WHICH WERE ALSO

8926
05:01:19,203 --> 05:01:21,606
INCLUDED BECAUSE THEY IMPACT

8927
05:01:21,606 --> 05:01:22,907
WOMEN DIFFERENTLY.

8928
05:01:22,907 --> 05:01:25,009
AS A RESULT OF THIS PROCESS, WE

8929
05:01:25,009 --> 05:01:29,380
SELECTED THE FOLLOWING

8930
05:01:29,380 --> 05:01:31,149
CONDITIONS TO REVIEW IN THIS

8931
05:01:31,149 --> 05:01:31,382
REPORT.

8932
05:01:31,382 --> 05:01:33,584
THIS CREATED A BASIS FOR

8933
05:01:33,584 --> 05:01:37,388
IDENTIFYING RESEARCH GAPS AND

8934
05:01:37,388 --> 05:01:38,790
ULTIMATELY A RESEARCH PLAN.

8935
05:01:38,790 --> 05:01:39,590
THE CONDITIONS THAT YOU SEE

8936
05:01:39,590 --> 05:01:44,629
LISTED IN YELLOW ARE THOSE THAT

8937
05:01:44,629 --> 05:01:46,998
WERE ASH TICK LATED EXPLICITLY

8938
05:01:46,998 --> 05:01:48,566
IN THE STATEMENT OF TASK.

8939
05:01:48,566 --> 05:01:51,169
OF COURSE WE ADDED ADDITIONAL

8940
05:01:51,169 --> 05:01:52,170
CONDITIONS, MANY OF WHICH WE

8941
05:01:52,170 --> 05:01:54,939
HAVE ALREADY TALKED ABOUT TODAY.

8942
05:01:54,939 --> 05:01:57,342
THE COMMITTEE WAS GUIDED BY

8943
05:01:57,342 --> 05:01:59,544
CONCEPTUAL FRAMEWORK AS SHOWN IN

8944
05:01:59,544 --> 05:02:00,078
THIS FIGURE.

8945
05:02:00,078 --> 05:02:02,313
AS MENTIONED, THERE ARE THREE

8946
05:02:02,313 --> 05:02:03,581
MAJOR BUCKETS THAT WERE

8947
05:02:03,581 --> 05:02:06,317
CONSIDERED FOR CHRONIC

8948
05:02:06,317 --> 05:02:07,518
CONDITIONS.

8949
05:02:07,518 --> 05:02:09,220
FEMALE-SPECIFIC AND GYNECOLOGIC

8950
05:02:09,220 --> 05:02:09,721
CONDITIONS THAT LEAD TO

8951
05:02:09,721 --> 05:02:11,789
SIGNIFICANT MORBIDITY, CHRONIC

8952
05:02:11,789 --> 05:02:13,524
CONDITIONS THAT PREDOMINANTLY

8953
05:02:13,524 --> 05:02:16,160
IMPACT OR AFFECT WOMEN

8954
05:02:16,160 --> 05:02:18,663
DIFFERENTLY, AND A THIRD

8955
05:02:18,663 --> 05:02:20,098
CATEGORY, THE ACCUMULATION OF

8956
05:02:20,098 --> 05:02:22,500
MULTIPLE CHRONIC CONDITIONS,

8957
05:02:22,500 --> 05:02:24,135
SPECIFIC RESEARCH AREAS WHICH

8958
05:02:24,135 --> 05:02:25,903
WERE IDENTIFIED.

8959
05:02:25,903 --> 05:02:27,538
THE RESEARCH AREAS THAT WE

8960
05:02:27,538 --> 05:02:31,142
ACTUALLY FOCUSED ON AS YOU CAN

8961
05:02:31,142 --> 05:02:33,111
SEE HERE INCLUDED IMPACT OR

8962
05:02:33,111 --> 05:02:34,345
BURDEN, PATHOPHYSIOLOGY,

8963
05:02:34,345 --> 05:02:36,280
PREVENTION, DIAGNOSIS, AND

8964
05:02:36,280 --> 05:02:42,086
TREATMENT AND MANAGEMENT.

8965
05:02:42,086 --> 05:02:42,854
THE COMMITTEE CONSIDERED AREAS

8966
05:02:42,854 --> 05:02:45,390
ON THE TRANSLATIONAL RESEARCH

8967
05:02:45,390 --> 05:02:46,691
SPECTRUM FROM BASIC SCIENCE TO

8968
05:02:46,691 --> 05:02:48,059
OP LAITION HEALTH.

8969
05:02:48,059 --> 05:02:51,963
AND HOW THESE FINDINGS MAY TRANS

8970
05:02:51,963 --> 05:02:57,969
LALATE INTO INTERVENTIONS IN THE

8971
05:02:57,969 --> 05:02:59,270
HEALTHCARE SYSTEM ULTIMATELY.

8972
05:02:59,270 --> 05:03:00,371
WE ALSO TOOK INTO ACCOUNT THE

8973
05:03:00,371 --> 05:03:01,806
LIFECOURSE AND INFLUENCE OF

8974
05:03:01,806 --> 05:03:02,573
STRUCTURAL AND SOCIAL

8975
05:03:02,573 --> 05:03:07,078
DETERMINANTS OF HEALTH RELATED

8976
05:03:07,078 --> 05:03:08,212
TO SEX AND GENDER AS INTEGRAL

8977
05:03:08,212 --> 05:03:08,613
COMPONENTS.

8978
05:03:08,613 --> 05:03:11,916
THIS FRAMEWORK INFORMED THE

8979
05:03:11,916 --> 05:03:13,351
COMMITTEE'S COMPREHENSIVE

8980
05:03:13,351 --> 05:03:15,787
RESEARCH AGENDA.

8981
05:03:15,787 --> 05:03:17,855
IN CHAPTER 2, THE COMMITTEE

8982
05:03:17,855 --> 05:03:21,025
INTRODUCED THE ESSENTIAL FACTORS

8983
05:03:21,025 --> 05:03:22,894
NECESSARY FOR UNDERSTANDING

8984
05:03:22,894 --> 05:03:24,529
CHRONIC CONDITIONS IN WOMEN

8985
05:03:24,529 --> 05:03:26,297
THROUGHOUT THEIR LIVES.

8986
05:03:26,297 --> 05:03:29,801
THESE INCLUDE STAGES ACROSS THE

8987
05:03:29,801 --> 05:03:32,170
LIFECOURSE, STARTING IN UTERO,

8988
05:03:32,170 --> 05:03:35,006
EXTENDING TO OLDER ADULTHOOD,

8989
05:03:35,006 --> 05:03:38,743
AND ALSO MARKING REPRODUCTIVE

8990
05:03:38,743 --> 05:03:41,245
MILESTONES AS WE'VE HEARD TODAY

8991
05:03:41,245 --> 05:03:42,980
IN MANY OF THE TALKS.

8992
05:03:42,980 --> 05:03:44,515
REPRODUCTIVE MILESTONES AND

8993
05:03:44,515 --> 05:03:45,183
TRANSITIONS.

8994
05:03:45,183 --> 05:03:48,453
WE ALSO TOOK INTO ACCOUNT THE

8995
05:03:48,453 --> 05:03:50,054
INFLUENCING FACTORS YOU SEE AT

8996
05:03:50,054 --> 05:03:52,790
THE BOTTOM THERE, INCLUDING SEX

8997
05:03:52,790 --> 05:03:55,293
AND GENDER, BIOLOGY,

8998
05:03:55,293 --> 05:03:56,561
ENVIRONMENT, DIET, STRESS, AND

8999
05:03:56,561 --> 05:04:00,264
SOCIAL DETERMINANTS OF HEALTH.

9000
05:04:00,264 --> 05:04:02,133
THE COMMITTEE CHOSE TO CLARIFY

9001
05:04:02,133 --> 05:04:05,169
SEVERAL KEY TERMS RELEVANT TO

9002
05:04:05,169 --> 05:04:06,404
THIS REPORT THAT WERE IMPORTANT

9003
05:04:06,404 --> 05:04:08,139
IN INFORMING THE WORK, AND I

9004
05:04:08,139 --> 05:04:09,340
THINK IT'S IMPORTANT FOR ME TO

9005
05:04:09,340 --> 05:04:13,978
REVIEW A FEW OF THOSE WITH YOU

9006
05:04:13,978 --> 05:04:14,312
TODAY.

9007
05:04:14,312 --> 05:04:16,581
THE COMMITTEE ADOPTED THE U.S.

9008
05:04:16,581 --> 05:04:17,248
DEPARTMENT OF HEALTH AND HUMAN

9009
05:04:17,248 --> 05:04:21,319
SERVICES DEFINITION OF CHRONIC

9010
05:04:21,319 --> 05:04:22,086
CONDITIONS.

9011
05:04:22,086 --> 05:04:23,154
WHICH DESCRIBES THIS TERM AS

9012
05:04:23,154 --> 05:04:27,225
CONDITIONS THAT LAST ONE YEAR OR

9013
05:04:27,225 --> 05:04:29,327
MORE AND REQUIRE ONGOING MEDICAL

9014
05:04:29,327 --> 05:04:32,296
ATTENTION OR LIMIT SELF-CARE AND

9015
05:04:32,296 --> 05:04:35,399
INDEPENDENT LIVING, SOCIAL

9016
05:04:35,399 --> 05:04:39,270
INTERACTIONS, O.A.R. QUALITY OFF

9017
05:04:39,270 --> 05:04:41,772
LIFEMENT WE WERE INITIALLY

9018
05:04:41,772 --> 05:04:43,508
ENTITLED DEBILITATING CONDITIONS

9019
05:04:43,508 --> 05:04:46,477
IN OUR TITLE FOR OUR COMMITTEE.

9020
05:04:46,477 --> 05:04:48,112
BUT WE REMOVED THE TERM ALMOST

9021
05:04:48,112 --> 05:04:49,714
IMMEDIATELY.

9022
05:04:49,714 --> 05:04:53,384
WE AS A COMMITTEE AGREED THAT

9023
05:04:53,384 --> 05:04:55,353
THIS TERM NEGATED THE

9024
05:04:55,353 --> 05:04:57,321
EXPERIENCES OF SO MANY WOMEN WHO

9025
05:04:57,321 --> 05:05:00,491
LIVE WITH CHRONIC CONDITIONS AND

9026
05:05:00,491 --> 05:05:02,193
HAVE DEVELOPED COPING MECHANISMS

9027
05:05:02,193 --> 05:05:05,963
THAT HELP THEM FUNCTION MORE

9028
05:05:05,963 --> 05:05:06,864
FULLY.

9029
05:05:06,864 --> 05:05:08,266
THE COMMITTEE ALSO DEFINED

9030
05:05:08,266 --> 05:05:09,567
MULTIPLE CHRONIC CONDITIONS,

9031
05:05:09,567 --> 05:05:10,701
WHICH ARE TWO OR MORE CHRONIC

9032
05:05:10,701 --> 05:05:15,973
PHYSICAL OR MENTAL HEALTH

9033
05:05:15,973 --> 05:05:17,842
COMPANIES THAT CO-OCCUR BUT MAY

9034
05:05:17,842 --> 05:05:20,011
OR MAY NOT DIRECTLY INTERACT.

9035
05:05:20,011 --> 05:05:22,213
IN THIS REPORT, THE COMMITTEE

9036
05:05:22,213 --> 05:05:24,148
DEFINES WOMAN TO INCLUDE ANY

9037
05:05:24,148 --> 05:05:25,883
INDIVIDUAL WHO CONSIDERS

9038
05:05:25,883 --> 05:05:28,452
THEMSELVES TO BE A WOMAN OR WAS

9039
05:05:28,452 --> 05:05:31,856
ASSIGNED FEMALE SEX AT BIRTH.

9040
05:05:31,856 --> 05:05:34,058
RELATED TO SEX AND GENDER, THE

9041
05:05:34,058 --> 05:05:36,561
COMMITTEE REGARD BIOLOGIC

9042
05:05:36,561 --> 05:05:37,762
REGARDED BIOLOGICAL DIFFERENCES

9043
05:05:37,762 --> 05:05:40,831
AS SEX DIFFERENCES WHEREAS THOSE

9044
05:05:40,831 --> 05:05:43,134
ASSOCIATED WITH THE SOCIAL

9045
05:05:43,134 --> 05:05:43,701
ENVIRONMENT AS GENDER

9046
05:05:43,701 --> 05:05:50,708
DIFFERENCES.

9047
05:05:50,708 --> 05:05:52,343
THESE INCLUSIVE CONDITIONS WERE

9048
05:05:52,343 --> 05:05:53,945
INTENDED TO RECOGNIZE

9049
05:05:53,945 --> 05:05:54,478
INDIVIDUALS WHO HAVE BEEN

9050
05:05:54,478 --> 05:05:55,413
AFFECTED BY A SET OF BIOLOGICAL

9051
05:05:55,413 --> 05:05:57,615
AND SOCIAL FACTORS THAT

9052
05:05:57,615 --> 05:05:59,383
INFLUENCE WOMEN DIFFERENTLY THAN

9053
05:05:59,383 --> 05:06:03,554
MEN.

9054
05:06:03,554 --> 05:06:05,323
WE STRESSED THE IMPORTANCE OF

9055
05:06:05,323 --> 05:06:06,290
DISTINGUISHING BETWEEN SOCIAL

9056
05:06:06,290 --> 05:06:13,164
AND STRUCTURAL DETERMINANTS OF

9057
05:06:13,164 --> 05:06:14,865
HEALTH SMED STRUCTURAL FACTORS

9058
05:06:14,865 --> 05:06:16,367
WERE DEFINED AS THE MACRO

9059
05:06:16,367 --> 05:06:18,703
FECTORS SUCH AS LAWS, POLICIES

9060
05:06:18,703 --> 05:06:20,838
AND NORMS THAT SHAPED THE

9061
05:06:20,838 --> 05:06:21,305
DISTRIBUTION OF SOCIAL

9062
05:06:21,305 --> 05:06:24,575
DETERMINANT OF HEALTH ACROSS AND

9063
05:06:24,575 --> 05:06:26,444
WITHIN SOCIAL GROUPS.

9064
05:06:26,444 --> 05:06:28,879
THE COMMITTEE EXPLICITLY CALLS

9065
05:06:28,879 --> 05:06:34,218
SUCH FACTORS OUT AS SEXISM,

9066
05:06:34,218 --> 05:06:35,720
HOMOPHOBIA, HETEROSEXISM, RACISM

9067
05:06:35,720 --> 05:06:37,722
AND AGEISM.

9068
05:06:37,722 --> 05:06:39,256
THE COMMITTEE REVIEWED

9069
05:06:39,256 --> 05:06:41,425
DETERMINANTS SUCH AS ACCESS TO

9070
05:06:41,425 --> 05:06:43,728
EDUCATION QUALITY, HEALTH,

9071
05:06:43,728 --> 05:06:45,329
ECONOMIC STABILITY AND BUILT

9072
05:06:45,329 --> 05:06:45,930
ENVIRONMENT AND SOCIAL AND

9073
05:06:45,930 --> 05:06:48,666
COMMUNITY CONTEXT.

9074
05:06:48,666 --> 05:06:53,471
THIS NEW CONSENSUS REPORT REALLY

9075
05:06:53,471 --> 05:06:56,974
DOES A GREAT JOB IN SUMMARIZING

9076
05:06:56,974 --> 05:06:58,309
THE COMPLEXITIES OF EVERYTHING I

9077
05:06:58,309 --> 05:07:02,780
JUST MENTIONED IN 10 OVERARCHING

9078
05:07:02,780 --> 05:07:04,215
CONCLUSIONS AND 18

9079
05:07:04,215 --> 05:07:05,216
RECOMMENDATIONS.

9080
05:07:05,216 --> 05:07:06,484
AND CALLS ON THE NATIONAL

9081
05:07:06,484 --> 05:07:08,285
INSTITUTE OF HEALTH AND OTHER

9082
05:07:08,285 --> 05:07:12,890
FEDERAL AGENCIES TO SUPPORT

9083
05:07:12,890 --> 05:07:14,825
RESEARCH WHERE SIGNIFICANT

9084
05:07:14,825 --> 05:07:16,527
KNOWLEDGE GAPS EXIST AROUND

9085
05:07:16,527 --> 05:07:18,596
FEMALE SPECIFIC AND GYNECOLOGIC

9086
05:07:18,596 --> 05:07:19,897
CONDITIONS AS WELL AS CONDITIONS

9087
05:07:19,897 --> 05:07:22,166
THAT PREDOMINANTLY IMPACT OR

9088
05:07:22,166 --> 05:07:24,168
AFFECT WOMEN DIFFERENTLY.

9089
05:07:24,168 --> 05:07:27,438
THIS SET OF RECOMMENDATIONS

9090
05:07:27,438 --> 05:07:30,741
SERVE AS A RESEARCH AGENDA.

9091
05:07:30,741 --> 05:07:34,345
NOW, WITHIN ITS 10 CHAPTERS, THE

9092
05:07:34,345 --> 05:07:38,416
REPORT OUTLINES THESE SEVEN KEY

9093
05:07:38,416 --> 05:07:42,453
AREAS WHERE RESEARCH GAPS OR

9094
05:07:42,453 --> 05:07:43,120
RESEARCH DESERT AS WE HEARD FROM

9095
05:07:43,120 --> 05:07:46,824
OUR LAST SPEAKER, RESIDE, AND

9096
05:07:46,824 --> 05:07:48,392
THAT ARE ACTIONABLE TOWARDS

9097
05:07:48,392 --> 05:07:50,695
INCREASING FUNDING FOR RESEARCH

9098
05:07:50,695 --> 05:07:52,530
BY NIH AND OTHER RELEVANT

9099
05:07:52,530 --> 05:07:55,166
AGENCIES.

9100
05:07:55,166 --> 05:07:58,469
THESE AREAS AS I MENTIONED ARE

9101
05:07:58,469 --> 05:08:00,337
LISTED HERE, AND THEY CREATE THE

9102
05:08:00,337 --> 05:08:02,139
SCAFFOLD FOR THE RECOMMENDATIONS

9103
05:08:02,139 --> 05:08:03,941
LAID OUT IN THIS REPORT, AND

9104
05:08:03,941 --> 05:08:05,876
WE'LL WALK THROUGH THIS FOR THE

9105
05:08:05,876 --> 05:08:06,677
REMAINING PART OF THIS

9106
05:08:06,677 --> 05:08:10,514
PRESENTATION.

9107
05:08:10,514 --> 05:08:11,716
BEGINNING WITH RECOMMENDATION

9108
05:08:11,716 --> 05:08:12,583
ONE, IMPACT OF CHRONIC

9109
05:08:12,583 --> 05:08:16,654
CONDITIONS IN WOMEN.

9110
05:08:16,654 --> 05:08:19,590
CHAPTERS THREE AND FOUR

9111
05:08:19,590 --> 05:08:20,891
HIGHLIGHTED FINDINGS

9112
05:08:20,891 --> 05:08:21,425
UNDERSCORING THAT CHRONIC

9113
05:08:21,425 --> 05:08:24,462
CONDITIONS WITH UNKNOWN ETIOLOGY

9114
05:08:24,462 --> 05:08:27,031
LACK A STANDARD CRITERIA FOR

9115
05:08:27,031 --> 05:08:27,932
DIAGNOSIS AND SYMPTOMS THAT

9116
05:08:27,932 --> 05:08:30,534
OVERLAP WITH OTHER CONDITIONS,

9117
05:08:30,534 --> 05:08:32,436
HINDER THE ABILITY TO OBTAIN AN

9118
05:08:32,436 --> 05:08:35,706
ACCURATE MEASURE OF IMPACT.

9119
05:08:35,706 --> 05:08:37,241
CONSEQUENTLY, THERE'S A PAUCITY

9120
05:08:37,241 --> 05:08:43,514
OF DATA MEASURING THE IMPACT OF

9121
05:08:43,514 --> 05:08:44,715
CHRONIC CONDITIONS INCLUDING

9122
05:08:44,715 --> 05:08:46,917
PREVALENCE, QUALITY OF LIFE AND

9123
05:08:46,917 --> 05:08:47,551
ECONOMIC IMPACT.

9124
05:08:47,551 --> 05:08:51,288
FOR MANY OF THESE CONDITIONS

9125
05:08:51,288 --> 05:08:52,389
THAT WERE REVIEWED IN THIS

9126
05:08:52,389 --> 05:08:52,823
REPORT.

9127
05:08:52,823 --> 05:08:54,692
THEREFORE, WE RECOMMENDED THAT

9128
05:08:54,692 --> 05:08:57,561
RESEARCH IS NEEDED TO IMPROVE

9129
05:08:57,561 --> 05:09:01,799
ESTIMATE OS OF THE IMPACT OF

9130
05:09:01,799 --> 05:09:03,033
CHRONIC CONDITIONS IN WOMEN.

9131
05:09:03,033 --> 05:09:04,201
SPECIFICALLY, RESEARCH IS NEEDED

9132
05:09:04,201 --> 05:09:06,303
FOR IMPROVED DIAGNOSTIC ACCURACY

9133
05:09:06,303 --> 05:09:08,372
AS WE'D HEARD IN PREVIOUS

9134
05:09:08,372 --> 05:09:12,243
PRESENTATIONS FOR CHRONIC

9135
05:09:12,243 --> 05:09:12,543
CONDITIONS.

9136
05:09:12,543 --> 05:09:16,614
SPECIFIC TO OUR -- EXPERIENCED

9137
05:09:16,614 --> 05:09:17,314
DIFFERENTLY BY WOMEN.

9138
05:09:17,314 --> 05:09:20,017
IN SUMMARY OF THESE SPECIFICS,

9139
05:09:20,017 --> 05:09:21,685
BETTER CHARACTERIZATION OF THESE

9140
05:09:21,685 --> 05:09:26,524
DIFFERENCES IS NEEDED.

9141
05:09:26,524 --> 05:09:27,491
CURRENT CHRONIC CONDITION

9142
05:09:27,491 --> 05:09:29,160
SURVEILLANCE SYSTEMS FAIL TO

9143
05:09:29,160 --> 05:09:30,928
COLLECT DATA ON A NUMBER OF

9144
05:09:30,928 --> 05:09:34,098
FEMALE-SPECIFIC AND GYNECOLOGIC

9145
05:09:34,098 --> 05:09:36,066
CONDITIONS OR FAIL TO PUBLISH

9146
05:09:36,066 --> 05:09:37,434
DISAGGREGATED DATA.

9147
05:09:37,434 --> 05:09:39,403
ON CHRONIC CONDITIONS THAT

9148
05:09:39,403 --> 05:09:40,604
PREDOMINANTLY IMPACT OUR AFFECT

9149
05:09:40,604 --> 05:09:43,874
WOMEN DIFFERENTLY.

9150
05:09:43,874 --> 05:09:46,744
THEREFORE, WE ASK THAT THOSE WHO

9151
05:09:46,744 --> 05:09:49,647
CONDUCT NATIONAL SURVEILLANCE

9152
05:09:49,647 --> 05:09:50,915
AND POPULATION-BASED STUDIES

9153
05:09:50,915 --> 05:09:53,450
SHOULD BE ENCOURAGED TO EXPAND

9154
05:09:53,450 --> 05:09:55,719
DATA COLLECTION ACTIVITIES.

9155
05:09:55,719 --> 05:09:58,255
MOVING ON TO RECOMMENDATION TWO,

9156
05:09:58,255 --> 05:10:02,960
UNDER THE THEME OF BIOLOGY AND

9157
05:10:02,960 --> 05:10:03,727
PATHOPHYSIOLOGY OF CHRONIC

9158
05:10:03,727 --> 05:10:04,829
CONDITIONS IN WOMEN.

9159
05:10:04,829 --> 05:10:09,333
AND I MUST SAY, DR. ARNOLD WAS

9160
05:10:09,333 --> 05:10:11,535
PARTICULARLY HELPFUL IN GUIDING

9161
05:10:11,535 --> 05:10:14,371
US THROUGH THIS PART OF OUR

9162
05:10:14,371 --> 05:10:17,741
DISCUSSION IN THE REPORT.

9163
05:10:17,741 --> 05:10:20,911
THIS IS COVERED IN CHAPTERS 2,

9164
05:10:20,911 --> 05:10:24,448
5, 6 AND 9 OF THE REPORT, WHICH

9165
05:10:24,448 --> 05:10:27,151
HIGHLIGHTED EVIDENCE ON THE

9166
05:10:27,151 --> 05:10:27,818
BIOLOGICAL MECHANISMS THAT

9167
05:10:27,818 --> 05:10:29,019
CONTRIBUTE TO CHRONIC CONDITIONS

9168
05:10:29,019 --> 05:10:30,621
IN WOMEN.

9169
05:10:30,621 --> 05:10:32,456
WHICH THIS KNOWLEDGE IS CRUCIAL

9170
05:10:32,456 --> 05:10:34,892
FOR DEVELOPING APPROACHES TO

9171
05:10:34,892 --> 05:10:38,596
DIAGNOSE, TREAT AND PREVENT

9172
05:10:38,596 --> 05:10:39,230
FEMALE-SPECIFIC AND GYNECOLOGIC

9173
05:10:39,230 --> 05:10:39,697
CONDITIONS.

9174
05:10:39,697 --> 05:10:42,199
AND THOSE THAT PREDOMINANTLY

9175
05:10:42,199 --> 05:10:44,201
IMPACT OR AFFECT WOMEN

9176
05:10:44,201 --> 05:10:44,768
DIFFERENTLY.

9177
05:10:44,768 --> 05:10:47,271
HOW ESTROGENS AFFECT CHRONIC

9178
05:10:47,271 --> 05:10:49,673
CONDITIONS IN WOMEN ARE NOT

9179
05:10:49,673 --> 05:10:51,208
WELL-KNOWN ACROSS ALL CHRONIC

9180
05:10:51,208 --> 05:10:54,044
CONDITIONS AND THE INTERACTION

9181
05:10:54,044 --> 05:10:58,115
OF SEX HORMONES AND

9182
05:10:58,115 --> 05:10:59,650
GONADOHORMONES IS POORLY

9183
05:10:59,650 --> 05:11:00,317
UNDERSTOOD.

9184
05:11:00,317 --> 05:11:05,489
THEREFORE, THE REPORT RECOMMENDS

9185
05:11:05,489 --> 05:11:07,124
THAT NIH AND OTHER RELEVANT

9186
05:11:07,124 --> 05:11:08,993
RESEARCH AGENCIES SHOULD SUPPORT

9187
05:11:08,993 --> 05:11:10,961
RESEARCH TO UNDERSTAND THE

9188
05:11:10,961 --> 05:11:14,365
INDEPENDENT AND INTERACTING

9189
05:11:14,365 --> 05:11:17,334
ROLES OF GONADAL HORMONES AND

9190
05:11:17,334 --> 05:11:19,637
SEX CHROMOSOME GENES, CAUSING

9191
05:11:19,637 --> 05:11:20,304
SEX DIFFERENCES.

9192
05:11:20,304 --> 05:11:22,907
IN ADDITION, WE NEED TO DEVELOP

9193
05:11:22,907 --> 05:11:28,412
A BETTER UNDERSTANDING OF HOW

9194
05:11:28,412 --> 05:11:31,248
INFLAMMATORY AN IMMUNE PATHWAY

9195
05:11:31,248 --> 05:11:32,383
AFFECT CHRONIC CONDITIONS IN

9196
05:11:32,383 --> 05:11:34,351
WOMEN AND SUPPORT RESEARCH IN

9197
05:11:34,351 --> 05:11:36,854
SPECIFIC AREAS AS LISTED BELOW

9198
05:11:36,854 --> 05:11:42,192
ON THIS SLIDE.

9199
05:11:42,192 --> 05:11:44,728
RESEARCH HAS NOT YET DISCOVERED

9200
05:11:44,728 --> 05:11:47,698
THE GENETIC DRIVERS OF VERY

9201
05:11:47,698 --> 05:11:49,099
EXPERIENCES OF CHRONIC

9202
05:11:49,099 --> 05:11:50,868
CONDITIONS EITHER.

9203
05:11:50,868 --> 05:11:53,103
AND EFFORTS, THEREFORE, ARE

9204
05:11:53,103 --> 05:11:56,040
NEEDED TO FURTHER DISENTANGLE

9205
05:11:56,040 --> 05:11:57,908
THE VARIOUS SUBTYPES AND

9206
05:11:57,908 --> 05:11:59,243
HETEROGENEITY OF CHRONIC

9207
05:11:59,243 --> 05:12:00,210
CONDITIONS THAT AFFECT WOMEN TO

9208
05:12:00,210 --> 05:12:03,948
INFORM NOVEL TREATMENTS.

9209
05:12:03,948 --> 05:12:07,551
THEREFORE, THE REPORT RECOMMENDS

9210
05:12:07,551 --> 05:12:09,186
THAT GREATER SUPPORT OF RESEARCH

9211
05:12:09,186 --> 05:12:10,554
IS NEEDED TO BETTER UNDERSTAND

9212
05:12:10,554 --> 05:12:13,724
THE GENETIC DRIVERS OF SUBTYPES

9213
05:12:13,724 --> 05:12:16,260
AND SYMPTOM HETEROGENEITY OF

9214
05:12:16,260 --> 05:12:17,127
FEMALE-SPECIFIC AND GYNECOLOGIC

9215
05:12:17,127 --> 05:12:18,329
CONDITIONS.

9216
05:12:18,329 --> 05:12:20,965
AND ENSURE THE DATABASES USED IN

9217
05:12:20,965 --> 05:12:24,068
SUCH STUDIES ARE DIVERSE, GIVEN

9218
05:12:24,068 --> 05:12:26,136
THE OBSERVATION OF SUBPOPULATION

9219
05:12:26,136 --> 05:12:30,074
DIFFERENCES.

9220
05:12:30,074 --> 05:12:32,710
THE LACK OF SUITABLE ANIMAL

9221
05:12:32,710 --> 05:12:34,912
MODELS AND OTHER PRE-CLINICAL

9222
05:12:34,912 --> 05:12:36,313
SYSTEMS FOR EXPLORING THE

9223
05:12:36,313 --> 05:12:37,982
BIOLOGICAL MECHANISMS UNDERLYING

9224
05:12:37,982 --> 05:12:41,785
CHRONIC CONDITIONS IN WOMEN MUST

9225
05:12:41,785 --> 05:12:44,521
ALSO BE ADDRESSED, SO I WAS VERY

9226
05:12:44,521 --> 05:12:47,491
DELIGHTED TO HEAR SOME OF THAT

9227
05:12:47,491 --> 05:12:49,259
PROGRESS MADE IN THIS SPACE IN

9228
05:12:49,259 --> 05:12:51,028
THE LAST PANEL.

9229
05:12:51,028 --> 05:12:53,263
MOVING ON TO RECOMMENDATION

9230
05:12:53,263 --> 05:12:56,200
THREE, UNDER THE THEME OF

9231
05:12:56,200 --> 05:12:58,035
FEMALE-SPECIFIC FACTORS AND

9232
05:12:58,035 --> 05:12:58,469
CHRONIC CONDITIONS.

9233
05:12:58,469 --> 05:13:00,571
AS DISCUSSED IN CHAPTERS 5 AND

9234
05:13:00,571 --> 05:13:02,873
6, WITH EACH CHRONIC CONDITION,

9235
05:13:02,873 --> 05:13:05,576
REA PRODUCTIVE MILESTONES ARE

9236
05:13:05,576 --> 05:13:07,478
KEY FACTORS INFLUENCING THE

9237
05:13:07,478 --> 05:13:08,679
DEVELOPMENT OF CHRONIC

9238
05:13:08,679 --> 05:13:10,647
CONDITIONS IN WOMEN.

9239
05:13:10,647 --> 05:13:12,783
THE REPORT HIGHLIGHT THAT

9240
05:13:12,783 --> 05:13:14,084
VARIATION IN THESE MILESTONES

9241
05:13:14,084 --> 05:13:17,354
SUCH AS EARLY MENARCHE, A

9242
05:13:17,354 --> 05:13:19,490
SHORTER REPRODUCTIVE WINDOW,

9243
05:13:19,490 --> 05:13:23,427
INCLUDING EARLY MENOPAUSE AND

9244
05:13:23,427 --> 05:13:24,495
HORMONAL FLUCTUATIONS PLAY A

9245
05:13:24,495 --> 05:13:27,998
ROLE IN CONDITIONS SUCH AS

9246
05:13:27,998 --> 05:13:29,666
ENDOMETRIOSIS, WHICH HAS BEEN

9247
05:13:29,666 --> 05:13:32,736
DISCUSSED TODAY, DEPRESSION,

9248
05:13:32,736 --> 05:13:36,640
CARDIOVASCULAR DISEASE, STROKE,

9249
05:13:36,640 --> 05:13:38,509
AND HIV, BUT THEIR ROLE IS LESS

9250
05:13:38,509 --> 05:13:39,810
UNDERSTAND FOR OTHER CHRONIC

9251
05:13:39,810 --> 05:13:40,110
CONDITIONS.

9252
05:13:40,110 --> 05:13:43,480
THEREFORE, THE REPORT RECOMMENDS

9253
05:13:43,480 --> 05:13:46,417
THAT NIH AND OTHER RELEVANT

9254
05:13:46,417 --> 05:13:49,486
RESEARCH AGENCIES SHOULD SUPPORT

9255
05:13:49,486 --> 05:13:52,456
RESEARCH TO BETTER UNDERSTAND

9256
05:13:52,456 --> 05:13:54,525
EXACT MECHANISMS, HORMONAL

9257
05:13:54,525 --> 05:13:55,426
FLUCTUATIONS PLAY IN THE

9258
05:13:55,426 --> 05:13:56,293
DEVELOPMENT OF CHRONIC

9259
05:13:56,293 --> 05:13:59,930
CONDITIONS IN WOMEN.

9260
05:13:59,930 --> 05:14:01,932
THIS INCLUDES THE FOLLOWING AREA

9261
05:14:01,932 --> 05:14:03,233
SUCH AS CHRONIC CONDITIONS SUCH

9262
05:14:03,233 --> 05:14:06,270
AS THE AGE OF MENARCHE, WHETHER

9263
05:14:06,270 --> 05:14:09,206
OR NOT THE AGE OF THE START OF

9264
05:14:09,206 --> 05:14:12,042
PERIODS ACTUALLY MAKES A

9265
05:14:12,042 --> 05:14:13,677
DIFFERENCE IN THE SEVERITY OF

9266
05:14:13,677 --> 05:14:16,313
THESE CHRONIC CONDITIONS,

9267
05:14:16,313 --> 05:14:18,916
MENSTRUAL CYCLE REGULARITY OR

9268
05:14:18,916 --> 05:14:21,318
IRREGULARITY.

9269
05:14:21,318 --> 05:14:23,053
LENGTH AND MENSTRUAL CYCLE

9270
05:14:23,053 --> 05:14:23,720
PHASES.

9271
05:14:23,720 --> 05:14:26,890
AS WELL AS THE EFFECTS OF EARLY

9272
05:14:26,890 --> 05:14:29,293
AND PREMATURE MENOPAUSE AS

9273
05:14:29,293 --> 05:14:31,161
ANOTHER EXAMPLE, AND

9274
05:14:31,161 --> 05:14:35,232
CHARACTERIZING THESE MILESTONES

9275
05:14:35,232 --> 05:14:36,567
BASED ON ANCESTRAL AND ETHNIC

9276
05:14:36,567 --> 05:14:40,938
GROUPS OF WOMEN AS WELL AS

9277
05:14:40,938 --> 05:14:41,805
LGBTQIA+ WOMEN.

9278
05:14:41,805 --> 05:14:44,108
THIS REPORT ALSO HIGHLIGHTS THAT

9279
05:14:44,108 --> 05:14:47,544
A DECLINE AND CHANGE OF HORMONE

9280
05:14:47,544 --> 05:14:50,914
LEVELS DURING MENOPAUSE AND

9281
05:14:50,914 --> 05:14:52,583
PERIMENOPAUSE HAS SIGNIFICANT

9282
05:14:52,583 --> 05:14:54,718
EFFECT, SUCH AS THE SYMPTOM THAT

9283
05:14:54,718 --> 05:14:59,756
MANY WOMEN EXPERIENCE, AND

9284
05:14:59,756 --> 05:15:01,158
RESEARCH HAS YET TO IDENTIFY THE

9285
05:15:01,158 --> 05:15:03,360
EXACT BIOLOGICAL PATHWAYS THAT

9286
05:15:03,360 --> 05:15:03,927
CAUSE THESE EFFECTS.

9287
05:15:03,927 --> 05:15:06,130
RESEARCH HAS IDENTIFIED THE

9288
05:15:06,130 --> 05:15:09,566
REDUCTION IN ESTROGEN LEVELS IN

9289
05:15:09,566 --> 05:15:11,935
POST MENOPAUSE -- THAT POST

9290
05:15:11,935 --> 05:15:13,237
MENOPAUSE PERIOD AS AN IMPORTANT

9291
05:15:13,237 --> 05:15:16,540
CONTRIBUTOR TO DEVELOPING

9292
05:15:16,540 --> 05:15:17,975
SPECIFIC CHRONIC CONDITIONS,

9293
05:15:17,975 --> 05:15:21,512
MOST NOTABLY CARDIOVASCULAR

9294
05:15:21,512 --> 05:15:22,513
DISEASE AND STROKE.

9295
05:15:22,513 --> 05:15:23,814
HOWEVER, ITS INFLUENCE ON OTHER

9296
05:15:23,814 --> 05:15:25,782
CHRONIC CONDITIONS SUCH AS

9297
05:15:25,782 --> 05:15:29,953
SARCOPENIA IS POORLY UNDERSTOOD.

9298
05:15:29,953 --> 05:15:31,421
THEREFORE, THE REPORT RECOMMENDS

9299
05:15:31,421 --> 05:15:34,124
THAT THERE SHOULD BE GREATER

9300
05:15:34,124 --> 05:15:36,660
FOCUS ON RESEARCH THAT AIMS TO

9301
05:15:36,660 --> 05:15:40,497
DEVELOP NEW AND BETTER

9302
05:15:40,497 --> 05:15:41,398
APPROACHES FOR ADDRESSING THE

9303
05:15:41,398 --> 05:15:43,000
SYMPTOMS THAT AFFECT WOMEN

9304
05:15:43,000 --> 05:15:46,336
DURING PERIMENOPAUSE, MENOPAUSE,

9305
05:15:46,336 --> 05:15:49,506
AND POST MENOPAUSE.

9306
05:15:49,506 --> 05:15:53,210
MOVING ON TO RECOMMENDATIONS

9307
05:15:53,210 --> 05:15:55,712
4 THROUGH 6 AND THE THEME HERE,

9308
05:15:55,712 --> 05:15:59,683
DISPARITIES AND LIFE

9309
05:15:59,683 --> 05:16:00,284
EXPERIENCES.

9310
05:16:00,284 --> 05:16:04,521
CHAPTERS 2, 5, 6, AND

9311
05:16:04,521 --> 05:16:05,622
7 INTRODUCE THE BACKGROUND ON

9312
05:16:05,622 --> 05:16:07,724
HOW STRUCTURAL AND SOCIAL

9313
05:16:07,724 --> 05:16:08,525
DETERMINANTS OF HEALTH ARE KEY

9314
05:16:08,525 --> 05:16:10,928
FACTORS THAT CONTRIBUTE TO THE

9315
05:16:10,928 --> 05:16:12,462
DEVELOPMENT, DIAGNOSIS,

9316
05:16:12,462 --> 05:16:13,864
TREATMENT AND PROGRESSION OF

9317
05:16:13,864 --> 05:16:15,832
CHRONIC CONDITIONS IN WOMEN, AND

9318
05:16:15,832 --> 05:16:18,702
THAT EXISTING RESEARCH PRIMARILY

9319
05:16:18,702 --> 05:16:20,237
EXAMINES DIFFERENCES IN CHRONIC

9320
05:16:20,237 --> 05:16:22,806
CONDITIONS IN WOMEN BY SOCIAL

9321
05:16:22,806 --> 05:16:25,542
GROUP IDENTITY, BUT NOT HOW

9322
05:16:25,542 --> 05:16:26,743
STRUCTURAL AND SOCIAL

9323
05:16:26,743 --> 05:16:29,780
DETERMINANTS OF HEALTH INTERSECT

9324
05:16:29,780 --> 05:16:33,984
TO CONTRIBUTE TO DISPARITIES.

9325
05:16:33,984 --> 05:16:37,054
RESEARCH IS NEEDED TO BETTER

9326
05:16:37,054 --> 05:16:38,989
UNDERSTAND MULTIPLE SOCIAL

9327
05:16:38,989 --> 05:16:41,091
IDENTITIES AND HOW THEY INTERACT

9328
05:16:41,091 --> 05:16:44,194
WITH STRUCTURAL AND SOCIAL

9329
05:16:44,194 --> 05:16:48,565
DETERMINANTS OF HEALTH, TO

9330
05:16:48,565 --> 05:16:49,433
INFLUENCE CHRONIC CONDITIONS IN

9331
05:16:49,433 --> 05:16:50,667
WOMEN ACROSS THE ENTIRE

9332
05:16:50,667 --> 05:16:51,635
LIFECOURSE.

9333
05:16:51,635 --> 05:16:55,105
IT'S ALSO DISCUSSED IN CHAPTER W

9334
05:16:55,105 --> 05:16:58,909
OF VARIOUS CHRONIC CONDITIONS

9335
05:16:58,909 --> 05:17:01,645
THROUGHOUT THE REPORT THAT

9336
05:17:01,645 --> 05:17:03,680
ADVERSE AND/OR TRAUMATIC

9337
05:17:03,680 --> 05:17:06,416
CHILDHOOD EXPERIENCES AND

9338
05:17:06,416 --> 05:17:11,521
SOCIETAL GENDER EXPECTATIONS MAY

9339
05:17:11,521 --> 05:17:13,390
EXPOSE WOMEN TO TRAUMATIC EVENTS

9340
05:17:13,390 --> 05:17:14,625
THROUGHOUT THEIR LIVES THAT CAN

9341
05:17:14,625 --> 05:17:16,927
ADVERSELY AFFECT THEIR HEALTH.

9342
05:17:16,927 --> 05:17:20,097
THEREFORE, THE REPORT RECOMMENDS

9343
05:17:20,097 --> 05:17:21,431
SUPPORT FOR RESEARCH THAT WILL

9344
05:17:21,431 --> 05:17:24,401
EXPLORES THE ROLE OF TRAUMATIC

9345
05:17:24,401 --> 05:17:27,170
EXPERIENCES AS RISK FACTORS IN

9346
05:17:27,170 --> 05:17:27,638
DEVELOPMENT OF CHRONIC

9347
05:17:27,638 --> 05:17:29,373
CONDITIONS THROUGHOUT THE

9348
05:17:29,373 --> 05:17:30,674
LIFECOURSE.

9349
05:17:30,674 --> 05:17:34,044
LASTLY, THERE IS A LOT OF

9350
05:17:34,044 --> 05:17:36,213
EVIDENCE THAT HEALTH PROMOTING

9351
05:17:36,213 --> 05:17:39,116
BEHAVIORS ARE ASSOCIATED WITH

9352
05:17:39,116 --> 05:17:40,017
DECREASED RISK FOR CHRONIC

9353
05:17:40,017 --> 05:17:43,620
CONDITIONS.

9354
05:17:43,620 --> 05:17:48,125
THEREFORE, WE NEED GREATER FOCUS

9355
05:17:48,125 --> 05:17:49,226
ON RESEARCH TO DEEPEN OUR

9356
05:17:49,226 --> 05:17:50,761
UNDERSTANDING REGARDING THE ROLE

9357
05:17:50,761 --> 05:17:52,863
OF THESE LIFESTYLE BEHAVIORS ON

9358
05:17:52,863 --> 05:17:54,464
THE DEVELOPMENT OF CHRONIC

9359
05:17:54,464 --> 05:17:58,135
CONDITIONS IN WOMEN.

9360
05:17:58,135 --> 05:18:00,871
MOVING ON TO RECOMMENDATION 7,

9361
05:18:00,871 --> 05:18:03,940
IN CHAPTERS 6 AND 8, IT WAS

9362
05:18:03,940 --> 05:18:05,042
NOTED THAT WOMEN MAY EXHIBIT

9363
05:18:05,042 --> 05:18:07,144
DIFFERENCES IN PRE-CLINICAL AND

9364
05:18:07,144 --> 05:18:08,679
CLINICAL PRESENTATION OF

9365
05:18:08,679 --> 05:18:11,114
FEMALE-SPECIFIC AND

9366
05:18:11,114 --> 05:18:11,648
FEMALE-DOMINANT CHRONIC

9367
05:18:11,648 --> 05:18:14,951
CONDITIONS, AND THE FAILURE TO

9368
05:18:14,951 --> 05:18:16,586
DIFFERENTIATE CONDITION DISEASE

9369
05:18:16,586 --> 05:18:17,921
PRESENTATION BY SEX AND GENDER

9370
05:18:17,921 --> 05:18:20,223
HAS CONTRIBUTED TO SIGNIFICANT

9371
05:18:20,223 --> 05:18:22,659
MORBIDITY AND MORTALITY FROM

9372
05:18:22,659 --> 05:18:24,828
MANY CHRONIC CONDITIONS.

9373
05:18:24,828 --> 05:18:29,566
IN ADDITION, DIAGNOSTIC TOOLS

9374
05:18:29,566 --> 05:18:33,270
AND SEX-SPECIFIC BIOMARKERS ARE

9375
05:18:33,270 --> 05:18:34,237
LACKING FOR CERTAIN CHRONIC

9376
05:18:34,237 --> 05:18:36,440
CONDITIONS.

9377
05:18:36,440 --> 05:18:38,308
HINDERING THE ABILITY TO

9378
05:18:38,308 --> 05:18:39,976
ACCURATELY MAKE THE CORRECT

9379
05:18:39,976 --> 05:18:42,612
DIAGNOSIS.

9380
05:18:42,612 --> 05:18:44,247
THEREFORE, TO IMPROVE EARLY AND

9381
05:18:44,247 --> 05:18:47,451
ACCURATE DETECTION AND DIAGNOSIS

9382
05:18:47,451 --> 05:18:50,087
OF CHRONIC CONDITIONS IN WOMEN,

9383
05:18:50,087 --> 05:18:51,922
RESEARCH IS NEEDED TO DEVELOP

9384
05:18:51,922 --> 05:18:54,224
SEX AND GENDER-SPECIFIC

9385
05:18:54,224 --> 05:18:55,525
DIAGNOSTIC TOOLS FOR CONDITIONS

9386
05:18:55,525 --> 05:18:57,527
IN WHICH THERE ARE CLEAR

9387
05:18:57,527 --> 05:18:59,596
DIFFERENCES IN THE CLINICAL

9388
05:18:59,596 --> 05:19:02,466
PRESENTATION OF DISEASES IN

9389
05:19:02,466 --> 05:19:08,171
WOMEN SUCH AS CARDIOVASCULAR

9390
05:19:08,171 --> 05:19:08,405
DISEASE.

9391
05:19:08,405 --> 05:19:09,072
NACHHD, DIAGNOSTIC TOOLS NEED TO

9392
05:19:09,072 --> 05:19:10,707
BE DEVELOPED THAT CAN MORE

9393
05:19:10,707 --> 05:19:11,775
ACCURATELY BE DISTINGUISHED

9394
05:19:11,775 --> 05:19:13,977
BETWEEN CHRONIC CONDITIONS BUT

9395
05:19:13,977 --> 05:19:17,481
SHARE SIMILAR SYMPTOMS SUCH AS

9396
05:19:17,481 --> 05:19:18,715
FATIGUE AS A COMMON SYMPTOM

9397
05:19:18,715 --> 05:19:20,450
ACROSS MANY CHRONIC CONDITIONS,

9398
05:19:20,450 --> 05:19:23,987
AND EXPLORE A MULTILEVEL

9399
05:19:23,987 --> 05:19:25,522
APPROACH TO DIAGNOSIS THAT

9400
05:19:25,522 --> 05:19:27,157
ENCOMPASSES IDENTIFYING

9401
05:19:27,157 --> 05:19:29,359
BIOLOGICAL MARKERS, DEVELOPING

9402
05:19:29,359 --> 05:19:33,063
TOOLS THAT CAPTURE VARIATION IN

9403
05:19:33,063 --> 05:19:34,498
HOW SYMPTOM MANIFEST, AND

9404
05:19:34,498 --> 05:19:37,367
INCORPORATING THE LIVED

9405
05:19:37,367 --> 05:19:38,802
EXPERIENCE AND ENGAGING WITH

9406
05:19:38,802 --> 05:19:44,608
HEALTH SYSTEMS.

9407
05:19:44,608 --> 05:19:46,042
MAKING PROGRESS.

9408
05:19:46,042 --> 05:19:47,144
RECOMMENDATION EIGHT.

9409
05:19:47,144 --> 05:19:49,012
THE FOCUS HERE, MULTIPLE CHRONIC

9410
05:19:49,012 --> 05:19:52,616
CONDITIONS IN WOMEN.

9411
05:19:52,616 --> 05:19:54,618
IN CHAPTER 8, IT WAS HIGHLIGHTED

9412
05:19:54,618 --> 05:19:55,485
THAT MULTIPLE CHRONIC CONDITIONS

9413
05:19:55,485 --> 05:19:58,355
HAVE A SIGNIFICANT EFFECT ON

9414
05:19:58,355 --> 05:20:02,659
WOMEN, WITH EVIDENT GENDER

9415
05:20:02,659 --> 05:20:03,760
DIFFERENCES AND PRESENTATION OF

9416
05:20:03,760 --> 05:20:06,029
CLUSTERS OF CHRONIC CONDITIONS.

9417
05:20:06,029 --> 05:20:09,599
HOWEVER, RESEARCH HAS ACTIVELY

9418
05:20:09,599 --> 05:20:11,668
PRIORITIZED THE STUDY OF SINGLE

9419
05:20:11,668 --> 05:20:12,769
DISEASES AND SINGLE-DISEASE

9420
05:20:12,769 --> 05:20:16,406
MODELS.

9421
05:20:16,406 --> 05:20:16,973
TO UNDERSTAND THE CELLULAR

9422
05:20:16,973 --> 05:20:18,508
PROCESSES THAT HAVE BEEN PASS

9423
05:20:18,508 --> 05:20:21,478
TEU LATED TO BE POSSIBLE TARGETS

9424
05:20:21,478 --> 05:20:23,480
THAT COULD PLAY A ROLE IN

9425
05:20:23,480 --> 05:20:24,681
PREVENTING OR AMEAL YOUR AGENT

9426
05:20:24,681 --> 05:20:29,653
MULTIPLAMELIORATINGCHRONIC COND,

9427
05:20:29,653 --> 05:20:32,656
RESEARCH IS NEEDED TO BETTER

9428
05:20:32,656 --> 05:20:33,957
UNDERSTAND THE BIOLOGICAL

9429
05:20:33,957 --> 05:20:35,258
MECHANISMS INVOLVED IN THE

9430
05:20:35,258 --> 05:20:36,393
DEVELOPMENT OF MULTIPLE CHRONIC

9431
05:20:36,393 --> 05:20:38,929
CONDITIONS IN WOMEN, INCLUDING

9432
05:20:38,929 --> 05:20:40,864
AGE-RELATED MECHANISMS AND

9433
05:20:40,864 --> 05:20:42,699
INFLAMMATION.

9434
05:20:42,699 --> 05:20:45,535
WE MUST FURTHER INVESTIGATE THE

9435
05:20:45,535 --> 05:20:47,270
ROLE OF CELLULAR SENESCENCE IN

9436
05:20:47,270 --> 05:20:48,738
THE DEVELOPMENT OF MULTIPLE

9437
05:20:48,738 --> 05:20:52,909
CHRONIC CONDITIONS AND HOW ITS

9438
05:20:52,909 --> 05:20:54,978
REVERSAL OR PREVENTION CAN

9439
05:20:54,978 --> 05:20:56,413
POTENTIALLY DELAY DEVELOPMENT.

9440
05:20:56,413 --> 05:20:59,649
IT WOULD BE HELPFUL TO DEVELOP

9441
05:20:59,649 --> 05:21:02,919
AN ANIMAL MODEL THAT EXAMINED

9442
05:21:02,919 --> 05:21:05,388
COOCCURRENCE OF MORBIDITIES.

9443
05:21:05,388 --> 05:21:08,425
OF THESE CONDITIONS.

9444
05:21:08,425 --> 05:21:10,093
ALSO, IN CLINICAL RESEARCH,

9445
05:21:10,093 --> 05:21:12,162
STUDIES OF CHRONIC CONDITIONS

9446
05:21:12,162 --> 05:21:14,931
HAVE BEEN HAMPERED BY A LACK OF

9447
05:21:14,931 --> 05:21:16,233
STANDARDIZED DEFINITIONS, AS

9448
05:21:16,233 --> 05:21:19,669
WELL AS DIAGNOSTIC APPROACHES.

9449
05:21:19,669 --> 05:21:21,071
AND THAT HAS RESULTED IN

9450
05:21:21,071 --> 05:21:22,372
CHALLENGES AS RELATE TO

9451
05:21:22,372 --> 05:21:25,342
PREVENTION AND TREATMENT.

9452
05:21:25,342 --> 05:21:27,577
TO IMPROVE THE DIAGNOSIS OF

9453
05:21:27,577 --> 05:21:30,113
MULTIPLE CHRONIC CONDITIONS IN

9454
05:21:30,113 --> 05:21:32,282
WOMEN, NEW MEASUREMENT ACTUALS

9455
05:21:32,282 --> 05:21:34,484
NEED TO BE DEVELOPED FOR

9456
05:21:34,484 --> 05:21:37,521
MULTIPLE CHRONIC CONDITIONS THAT

9457
05:21:37,521 --> 05:21:39,756
INCLUDE FEMALE-SPECIFIC AND

9458
05:21:39,756 --> 05:21:41,057
GYNECOLOGIC CONDITIONS TO MORE

9459
05:21:41,057 --> 05:21:44,928
FULLY UNDERSTAND THE IMPACT AND

9460
05:21:44,928 --> 05:21:47,797
REVIEW AND VALIDATE DIAGNOSTIC

9461
05:21:47,797 --> 05:21:49,299
OR MEASUREMENT TOOLS FROM

9462
05:21:49,299 --> 05:21:50,200
MULTIPLE CHRONIC CONDITIONS TO

9463
05:21:50,200 --> 05:21:53,303
AID IN THE DEVELOPMENT OF A

9464
05:21:53,303 --> 05:21:57,807
STANDARDIZED DEFINITION.

9465
05:21:57,807 --> 05:22:01,978
IT WAS ALSO HIGHLIGHTED IN

9466
05:22:01,978 --> 05:22:03,513
CHAPTER 8 THAT EVIDENCE-BASED

9467
05:22:03,513 --> 05:22:06,182
GUIDELINES ARE LACKING, FOR

9468
05:22:06,182 --> 05:22:08,585
TREATING AND MANAGING THE

9469
05:22:08,585 --> 05:22:11,855
COMPLEX INTERACTIONS BETWEEN

9470
05:22:11,855 --> 05:22:12,722
CONDITIONS.

9471
05:22:12,722 --> 05:22:14,858
INTERACTIONS OF SPECIFIC

9472
05:22:14,858 --> 05:22:17,594
TREATMENTS, RESULTING IN

9473
05:22:17,594 --> 05:22:18,695
POLYPHARMACY CAN CONTRIBUTE TO

9474
05:22:18,695 --> 05:22:20,230
DEVELOPING OR EXACERBATING OTHER

9475
05:22:20,230 --> 05:22:24,000
CHRONIC CONDITIONS.

9476
05:22:24,000 --> 05:22:26,169
THE DESIGN OF TREATMENT AND

9477
05:22:26,169 --> 05:22:28,371
MANAGEMENT APPROACHES SHOULD BE

9478
05:22:28,371 --> 05:22:30,674
INFORMED BY THE EXPERIENCES OF

9479
05:22:30,674 --> 05:22:32,542
WOMEN LIVING WITH THESE MULTIPLE

9480
05:22:32,542 --> 05:22:36,079
CHRONIC CONDITIONS.

9481
05:22:36,079 --> 05:22:37,714
THEREFORE, THE REPORT RECOMMENDS

9482
05:22:37,714 --> 05:22:41,451
THAT RESEARCH APPROACHES THAT

9483
05:22:41,451 --> 05:22:42,953
APPROPRIATELY STUDY MULTIPLE

9484
05:22:42,953 --> 05:22:44,120
CHRONIC CONDITIONS IN WOMEN AND

9485
05:22:44,120 --> 05:22:45,655
ENSURE THE REPRESENTATION OF

9486
05:22:45,655 --> 05:22:50,594
WOMEN WITH MULTIPLE CHRONIC

9487
05:22:50,594 --> 05:22:52,362
CONDITIONS IN RESEARCH DESIGNS

9488
05:22:52,362 --> 05:22:55,432
IS REALLY SIGNIFICANTLY NEEDED.

9489
05:22:55,432 --> 05:22:57,500
WE MUST DO THIS TO IMPROVE THE

9490
05:22:57,500 --> 05:22:59,336
TREATMENT AND CARE OF WOMEN WITH

9491
05:22:59,336 --> 05:23:03,373
MULTIPLE CHRONIC CONDITIONS, AND

9492
05:23:03,373 --> 05:23:05,008
CERTAINLY RESEARCH IS NEEDED TO

9493
05:23:05,008 --> 05:23:08,678
DEVELOP EVIDENCE-BASED --

9494
05:23:08,678 --> 05:23:10,113
EVIDENCE-BASED TREATMENT AND

9495
05:23:10,113 --> 05:23:11,848
MANAGEMENT GUIDELINES FOR WOMEN

9496
05:23:11,848 --> 05:23:12,515
WITH MULTIPLE CHRONIC

9497
05:23:12,515 --> 05:23:18,855
CONDITIONS.

9498
05:23:18,855 --> 05:23:20,490
INEQUITIES AND WOMEN-CENTERED

9499
05:23:20,490 --> 05:23:22,826
RESEARCH WAS CERTAINLY AN

9500
05:23:22,826 --> 05:23:23,693
IMPORTANT COMPONENT OF THIS

9501
05:23:23,693 --> 05:23:26,196
REPORT.

9502
05:23:26,196 --> 05:23:28,898
 AS WELL.

9503
05:23:28,898 --> 05:23:31,935
INEQUITIES IN WOMEN'S HEALTHCARE

9504
05:23:31,935 --> 05:23:33,370
STEM FROM BIAS, DISCRIMINATION

9505
05:23:33,370 --> 05:23:37,040
AND STIGMA IN MEDICAL TREATMENT.

9506
05:23:37,040 --> 05:23:38,975
STRUCTURAL SEXISM ALSO CAN

9507
05:23:38,975 --> 05:23:42,278
SIGNIFICANTLY INFLUENCE HEALTH

9508
05:23:42,278 --> 05:23:43,480
POLICIES, INCLUDING ACCESS TO

9509
05:23:43,480 --> 05:23:45,315
CARE AND RESEARCH FUNDING.

9510
05:23:45,315 --> 05:23:49,753
AND I'M SURE WE'RE ALL AWARE,

9511
05:23:49,753 --> 05:23:51,287
FOR EXAMPLE, THAT THE PAIN THAT

9512
05:23:51,287 --> 05:23:53,189
WOMEN EXPRESS CLINICALLY IN

9513
05:23:53,189 --> 05:23:55,492
THE -- IN PRACTICE, IN MANY

9514
05:23:55,492 --> 05:23:59,229
PRACTICES, IS MORE OFTEN

9515
05:23:59,229 --> 05:24:01,264
UNDERESTIMATED BY CLINICIANS

9516
05:24:01,264 --> 05:24:03,066
WHEN COMPARED TO MEN.

9517
05:24:03,066 --> 05:24:04,634
AND SO A HEALTH EQUITY LENS IS

9518
05:24:04,634 --> 05:24:07,370
IMPORTANT FOR IMPROVING

9519
05:24:07,370 --> 05:24:09,239
HEALTHCARE ACCESS, TREATMENT

9520
05:24:09,239 --> 05:24:10,907
PARADIGMS AND PATIENT-CENTERED

9521
05:24:10,907 --> 05:24:14,310
OUTCOMES IN WOMEN.

9522
05:24:14,310 --> 05:24:16,179
THEREFORE, THE REPORT RECOMMENDS

9523
05:24:16,179 --> 05:24:18,381
THAT RESEARCH IS NEEDED TO

9524
05:24:18,381 --> 05:24:19,115
ADDRESS INEQUITIES THAT CONTINUE

9525
05:24:19,115 --> 05:24:20,917
TO EXIST FOR WOMEN IN THE

9526
05:24:20,917 --> 05:24:24,087
HEALTHCARE SETTING.

9527
05:24:24,087 --> 05:24:25,855
SPECIFICALLY CONSIDERING THE

9528
05:24:25,855 --> 05:24:28,425
ACTION ITEMS LISTED BELOW.

9529
05:24:28,425 --> 05:24:32,195
AND THEN FINALLY, RECOMMENDATION

9530
05:24:32,195 --> 05:24:36,032
10.

9531
05:24:36,032 --> 05:24:37,133
INEQUITIES AND WOMEN CENTER

9532
05:24:37,133 --> 05:24:41,137
RESEARCH.

9533
05:24:41,137 --> 05:24:42,639
DESPITE PROGRESS REGARDING THE

9534
05:24:42,639 --> 05:24:43,740
INCLUSION AND REPRESENTATION OF

9535
05:24:43,740 --> 05:24:45,175
WOMEN IN VARIOUS FIELDS OF

9536
05:24:45,175 --> 05:24:47,510
RESEARCH, THE EVIDENCE ON

9537
05:24:47,510 --> 05:24:48,178
CHRONIC CONDITIONS POINTS TO A

9538
05:24:48,178 --> 05:24:50,146
LACK OF ACTIVE INCLUSION OF

9539
05:24:50,146 --> 05:24:53,049
WOMEN FROM DIFFERENT ANCESTRIES,

9540
05:24:53,049 --> 05:24:54,684
ETHNIC, GENDER, IDENTITY AND

9541
05:24:54,684 --> 05:24:58,088
SEXUAL ORIENTATION GROUPS OF

9542
05:24:58,088 --> 05:25:00,890
RESEARCH, THE REPORT CONCLUDED

9543
05:25:00,890 --> 05:25:02,726
THAT WOMEN CENTRIC AND COMMUNITY

9544
05:25:02,726 --> 05:25:03,927
INCLUSIVE RESEARCH STRATEGIES

9545
05:25:03,927 --> 05:25:06,629
CAN HELP ENSURE THAT RESEARCH

9546
05:25:06,629 --> 05:25:08,231
ACTIVITIES ADDRESS THE UNIQUE

9547
05:25:08,231 --> 05:25:09,766
HEALTH NEEDS OF WOMEN, LEADING

9548
05:25:09,766 --> 05:25:12,368
TO MORE EFFECTIVE AND EQUITABLE

9549
05:25:12,368 --> 05:25:15,772
HEALTH OUTCOMES.

9550
05:25:15,772 --> 05:25:20,744
AND SO WE MUST ACTUALLY SUPPORT

9551
05:25:20,744 --> 05:25:22,846
AND ADVOCATE FOR RESEARCH THAT

9552
05:25:22,846 --> 05:25:24,814
IS WOMEN-CENTRIC.

9553
05:25:24,814 --> 05:25:26,950
WE MUST RECRUIT WOMEN FROM

9554
05:25:26,950 --> 05:25:29,819
DIFFERENT ANCESTRAL ETHNIC

9555
05:25:29,819 --> 05:25:32,922
GENDER IDENTITY, AGE AND SEXUAL

9556
05:25:32,922 --> 05:25:33,690
ORIENTATION BACKGROUNDS, AND

9557
05:25:33,690 --> 05:25:35,558
UNDERSERVED RURAL POPULATIONS TO

9558
05:25:35,558 --> 05:25:38,995
BETTER DEFINE THE FULL SPECTRUM

9559
05:25:38,995 --> 05:25:40,663
OF PRE-CLINICAL AND CLINICAL

9560
05:25:40,663 --> 05:25:41,531
DISEASE PRESENTATION.

9561
05:25:41,531 --> 05:25:43,633
WE MUST INVOLVE WOMEN WITH

9562
05:25:43,633 --> 05:25:45,702
CHRONIC CONDITIONS, INCLUDING

9563
05:25:45,702 --> 05:25:48,371
THEIR COMMUNITIES, IN DESIGN,

9564
05:25:48,371 --> 05:25:50,340
IMPLEMENTATION AND DISSEMINATION

9565
05:25:50,340 --> 05:25:52,876
OF RESEARCH FINDINGS.

9566
05:25:52,876 --> 05:25:55,578
WE MUST USE NOVEL TECHNIQUES FOR

9567
05:25:55,578 --> 05:25:56,412
ENGAGING AND INCORPORATING WOMEN

9568
05:25:56,412 --> 05:26:00,350
WHO HAVE YET TO SEEK CARE DUE TO

9569
05:26:00,350 --> 05:26:02,619
OBSTACLES IN ACCESSING

9570
05:26:02,619 --> 05:26:03,486
HEALTHCARE SERVICES, OR BECAUSE

9571
05:26:03,486 --> 05:26:05,989
THEIR CONDITIONS ARE IN A

9572
05:26:05,989 --> 05:26:06,956
PRE-CLINICAL STAGE.

9573
05:26:06,956 --> 05:26:09,793
WE MUST USE COMMUNITY-BASED

9574
05:26:09,793 --> 05:26:11,861
RESEARCH APPROACHES, AND WE MUST

9575
05:26:11,861 --> 05:26:14,497
ACCOUNT FOR SEX AND GENDER IN

9576
05:26:14,497 --> 05:26:17,500
STUDIES WHERE APPROPRIATE AND

9577
05:26:17,500 --> 05:26:18,568
STANDARDIZED MEASURES FOR

9578
05:26:18,568 --> 05:26:19,803
CAPTURING THESE VARIABLES

9579
05:26:19,803 --> 05:26:21,871
ACCURATELY.

9580
05:26:21,871 --> 05:26:24,140
SO IN SUMMARY, MUCH OF WHAT I'VE

9581
05:26:24,140 --> 05:26:26,509
HEARD TODAY IS REALLY IN THIS

9582
05:26:26,509 --> 05:26:29,045
RESEARCH AGENDA.

9583
05:26:29,045 --> 05:26:33,449
WE JUST REALLY NEED TO PUT A

9584
05:26:33,449 --> 05:26:34,884
BRIGHTER SPOTLIGHT ON IT, AND

9585
05:26:34,884 --> 05:26:37,287
HOPEFULLY THIS REPORT WILL

9586
05:26:37,287 --> 05:26:39,689
CONTRIBUTE TO THAT PURPOSE, IF

9587
05:26:39,689 --> 05:26:42,525
YOU WILL, THAT CAUSE.

9588
05:26:42,525 --> 05:26:46,429
AND WE MADE AN ATTEMPT TO

9589
05:26:46,429 --> 05:26:49,799
IDENTIFY THE KEY RESEARCH GAPS

9590
05:26:49,799 --> 05:26:53,436
AND WE HOPE THAT THIS WILL HELP

9591
05:26:53,436 --> 05:26:56,873
TO BRIDGE THOSE GAPS WITH

9592
05:26:56,873 --> 05:26:58,608
GREATER UNDERSTANDING OF HOW

9593
05:26:58,608 --> 05:27:01,878
BIOLOGICAL AND SOCIAL FACTORS

9594
05:27:01,878 --> 05:27:04,714
CAN INFLUENCE THE TRAJECTORY OF

9595
05:27:04,714 --> 05:27:06,850
CHRONIC CONDITIONS DURING THE --

9596
05:27:06,850 --> 05:27:09,485
OVER THE ENTIRE LIFECOURSE OF A

9597
05:27:09,485 --> 05:27:10,787
WOMAN.

9598
05:27:10,787 --> 05:27:13,256
ULTIMATELY, RESEARCH OUTCOMES

9599
05:27:13,256 --> 05:27:15,892
WOULD LEAD TO GREATER DIAGNOSTIC

9600
05:27:15,892 --> 05:27:17,527
RIGOR, BERT DATA ON THE IMPACT

9601
05:27:17,527 --> 05:27:20,330
OF THESE CONDITIONS, AND MORE

9602
05:27:20,330 --> 05:27:21,297
EFFECTIVE THERAPEUTIC

9603
05:27:21,297 --> 05:27:23,366
INTERVENTIONS.

9604
05:27:23,366 --> 05:27:26,436
AND WOMEN-CENTERED CARE.

9605
05:27:26,436 --> 05:27:30,073
SO THE REPORT YOU HAVE IN YOUR

9606
05:27:30,073 --> 05:27:34,577
POSSESSION, BUT IT CAN ALSO BE

9607
05:27:34,577 --> 05:27:35,678
DOWNLOADED AT THIS WEBSITE,

9608
05:27:35,678 --> 05:27:38,848
AND CERTAINLY I KNOW I'M AT

9609
05:27:38,848 --> 05:27:41,351
MINUS 3 MINUTES, BUT HAPPY TO

9610
05:27:41,351 --> 05:27:43,086
ENTERTAIN ANY QUESTIONS AND I

9611
05:27:43,086 --> 05:27:45,355
WOULD INVITE DR. ARNOLD AS WELL

9612
05:27:45,355 --> 05:27:47,357
TO MAKE ANY COMMENTS HE WOULD

9613
05:27:47,357 --> 05:27:49,859
LIKE TO MAKE AS WELL.

9614
05:27:49,859 --> 05:27:53,463
>> THANK YOU, DR.
HIGGINBOTHAM.

9615
05:27:53,463 --> 05:27:55,598
AND BEFORE WE GO FURTHER, I WANT

9616
05:27:55,598 --> 05:27:57,000
TO ACKNOWLEDGE THE LEADERSHIP OF

9617
05:27:57,000 --> 05:27:59,202
DR. SARAH TEMKIN HERE, WHO'S THE

9618
05:27:59,202 --> 05:28:02,338
LEAD FOR THIS EFFORT AND

9619
05:28:02,338 --> 05:28:02,772
ENGAGEMENT AT ORWH.

9620
05:28:02,772 --> 05:28:03,439
THANK YOU VERY MUCH.

9621
05:28:03,439 --> 05:28:07,377
[APPLAUSE]

9622
05:28:07,377 --> 05:28:08,478
SO ART AND EVE ARE AVAILABLE

9623
05:28:08,478 --> 05:28:10,647
FROM QUESTIONS FROM THE ADVISORY

9624
05:28:10,647 --> 05:28:11,047
COMMITTEE.

9625
05:28:11,047 --> 05:28:18,388
DR. HIGGINS.

9626
05:28:18,388 --> 05:28:21,424
>> SO WONDERFUL LECTURE,
AND

9627
05:28:21,424 --> 05:28:22,725
WONDERFUL DOCUMENT.

9628
05:28:22,725 --> 05:28:26,095
AND I WAS JUST -- DID THE

9629
05:28:26,095 --> 05:28:28,398
COMMITTEE GIVE ANY THOUGHT TO

9630
05:28:28,398 --> 05:28:29,933
CLINICALLY HOW WE MANAGE

9631
05:28:29,933 --> 05:28:31,000
PATIENTS THAT HAVE THESE

9632
05:28:31,000 --> 05:28:32,702
MULTIPLE CONDITIONS?

9633
05:28:32,702 --> 05:28:35,939
I WAS ON A PANEL DISCUSSING THIS

9634
05:28:35,939 --> 05:28:38,441
AROUND -- THIS PAST WEEKEND

9635
05:28:38,441 --> 05:28:39,976
AROUND CIGARETTE SMOKING AND

9636
05:28:39,976 --> 05:28:45,415
POPULATION OF PTSD, HIV, AND --

9637
05:28:45,415 --> 05:28:47,050
WHAT WAS THE OTHER ONE?

9638
05:28:47,050 --> 05:28:48,151
WELL, THAT'S ENOUGH.

9639
05:28:48,151 --> 05:28:50,887
AND WE WERE TRYING TO THINK ON

9640
05:28:50,887 --> 05:28:53,456
THE COMMITTEE, LIKE, TEAM

9641
05:28:53,456 --> 05:28:55,825
SCIENCE OR WHAT -- YEAH, SO --

9642
05:28:55,825 --> 05:29:00,330
>> AND YOU MIGHT ACTUALLY
FOCUS

9643
05:29:00,330 --> 05:29:05,401
ON CHAPTERS 8 AND 9, MULTIPLE

9644
05:29:05,401 --> 05:29:07,870
CHRONIC CONDITIONS, AS WELL AS

9645
05:29:07,870 --> 05:29:10,340
OUR CHAPTER WHERE WE REALLY

9646
05:29:10,340 --> 05:29:12,508
FOCUS ON THE CHALLENGES WITH

9647
05:29:12,508 --> 05:29:14,177
TRANSLATION INTO CLINICAL

9648
05:29:14,177 --> 05:29:14,944
PRACTICE.

9649
05:29:14,944 --> 05:29:17,580
AND WITHIN CHAPTER 9, WE TALK,

9650
05:29:17,580 --> 05:29:19,382
FOR INSTANCE, ABOUT THE LEARNING

9651
05:29:19,382 --> 05:29:20,817
HEALTH SYSTEM, AND THE

9652
05:29:20,817 --> 05:29:24,087
IMPORTANCE OF HAVING

9653
05:29:24,087 --> 05:29:26,055
INTERDISCIPLINARY ENGAGEMENT.

9654
05:29:26,055 --> 05:29:30,259
I THINK IT'S A MATTER OF REALLY

9655
05:29:30,259 --> 05:29:33,129
OPENING UP THE DOOR BETWEEN

9656
05:29:33,129 --> 05:29:34,330
SPECIALTIES, AND ONE OF THE

9657
05:29:34,330 --> 05:29:36,599
BOOKS I'LL JUST MENTION, I'VE

9658
05:29:36,599 --> 05:29:37,567
MENTIONED TO A COUPLE OF OTHER

9659
05:29:37,567 --> 05:29:45,942
PEOPLE, I'M READING ELDERHOOD BY

9660
05:29:45,942 --> 05:29:46,843
THE GERIATRICIAN FROM UCSF AND

9661
05:29:46,843 --> 05:29:48,478
SHE TALKS ABOUT THE IMPORTANCE

9662
05:29:48,478 --> 05:29:52,648
OF INTERDISCIPLINARY ENGAGEMENT,

9663
05:29:52,648 --> 05:29:54,283
PARTICULARLY FOR OUR OLDER

9664
05:29:54,283 --> 05:29:54,984
PATIENTS.

9665
05:29:54,984 --> 05:29:56,452
AND THAT'S WHAT WE NEED TO DO.

9666
05:29:56,452 --> 05:29:57,687
BUT THERE'S GOT TO BE THE

9667
05:29:57,687 --> 05:29:59,822
CULTURE OF A LEARNING HEALTH

9668
05:29:59,822 --> 05:30:02,558
SYSTEM AS A BASIC PLATFORM.

9669
05:30:02,558 --> 05:30:06,596
>> IN THE BILLING SYSTEM,
YEAH,

9670
05:30:06,596 --> 05:30:06,929
THANK YOU.

9671
05:30:06,929 --> 05:30:08,731
>> SO THE BILLING SYSTEM
--

9672
05:30:08,731 --> 05:30:11,401
WELL, I MEAN, IN MANY STATES OR

9673
05:30:11,401 --> 05:30:13,669
AT LEAST -- I'M ON THE BOARD OF

9674
05:30:13,669 --> 05:30:15,905
MASS EYE AND EAR AND I KNOW AT

9675
05:30:15,905 --> 05:30:17,006
LEAST IN MASSACHUSETTS, MEDICAID

9676
05:30:17,006 --> 05:30:20,743
IS MOVING MORE TOWARDS

9677
05:30:20,743 --> 05:30:23,780
VALUE-BASED CARE, SO AS WE GET

9678
05:30:23,780 --> 05:30:25,214
INTO THAT CONVERSATION OF

9679
05:30:25,214 --> 05:30:27,483
VALUE-BASED CARE, WE'RE GOING TO

9680
05:30:27,483 --> 05:30:31,754
BE REIMBURSED FOR OUR OUTCOMES.

9681
05:30:31,754 --> 05:30:33,222
BUT IT'S NOT GOING AS QUICKLY AS

9682
05:30:33,222 --> 05:30:40,730
IT SHOULD.

9683
05:30:40,730 --> 05:30:41,631
>> DR. NOEL.

9684
05:30:41,631 --> 05:30:43,299
>> VERY NICE PRESENTATION.

9685
05:30:43,299 --> 05:30:43,833
A LOT OF WORK DEFINITELY.

9686
05:30:43,833 --> 05:30:46,069
I WAS JUST WONDERING IF THERE

9687
05:30:46,069 --> 05:30:48,237
WAS ANY THOUGHTS THAT WERE PUT

9688
05:30:48,237 --> 05:30:50,406
INTO HOW DO WE PRIORITIZE IN THE

9689
05:30:50,406 --> 05:30:52,608
SENSE THAT WHEN YOU LOOK,

9690
05:30:52,608 --> 05:30:53,576
THERE'S A LOT OF CHRONIC

9691
05:30:53,576 --> 05:30:55,611
CONDITIONS, DO WE LOOK AT

9692
05:30:55,611 --> 05:30:56,279
PREVALENCE, DO WE LOOK AT IMPACT

9693
05:30:56,279 --> 05:30:57,713
THAT IT COULD HAVE ON THE WOMAN,

9694
05:30:57,713 --> 05:31:00,650
DO WE LOOK AT MORTALITY, YOU

9695
05:31:00,650 --> 05:31:02,118
KNOW, WHICH DISEASE WOULD LEAD

9696
05:31:02,118 --> 05:31:04,253
MORE TO MORTALITY, SO BECAUSE

9697
05:31:04,253 --> 05:31:06,422
THERE'S SO MANY DIFFERENT

9698
05:31:06,422 --> 05:31:08,057
FACTORS AND DIFFERENT CONDITIONS

9699
05:31:08,057 --> 05:31:10,126
THAT GOES INTO THAT, AND

9700
05:31:10,126 --> 05:31:11,194
RESEARCH IS DEFINITELY NEEDED,

9701
05:31:11,194 --> 05:31:13,396
YOU HAVE IDENTIFIED A LOT OF

9702
05:31:13,396 --> 05:31:15,965
GAP, BUT HOW DO WE PRIORITIZE?

9703
05:31:15,965 --> 05:31:16,899
>> YOU KNOW, THAT'S A
GREAT

9704
05:31:16,899 --> 05:31:18,968
QUESTION, AND I REALLY WOULD

9705
05:31:18,968 --> 05:31:23,506
LIKE, ART, IF YOU WOULD CHIME IN

9706
05:31:23,506 --> 05:31:24,240
HERE BECAUSE I DO THINK IT

9707
05:31:24,240 --> 05:31:27,510
STARTS IN THE BASIC SCIENCE.

9708
05:31:27,510 --> 05:31:29,579
WE COULD HAVE BIOMARKERS, THAT

9709
05:31:29,579 --> 05:31:32,081
WOULD HELP US WITH PREVENTION

9710
05:31:32,081 --> 05:31:35,418
AND DIAGNOSIS BUT ART, DO YOU

9711
05:31:35,418 --> 05:31:36,686
HAVE ANY THOUGHTS ON THAT

9712
05:31:36,686 --> 05:31:37,653
QUESTION?

9713
05:31:37,653 --> 05:31:40,423
>> SO I CAN'T ADDRESS
ANYTHING

9714
05:31:40,423 --> 05:31:44,627
CLINICALLY BECAUSE I'M A BASIC

9715
05:31:44,627 --> 05:31:47,363
SCIENTIST, BUT I SAW IT -- JUST

9716
05:31:47,363 --> 05:31:49,499
MORE GENERALLY, I SAW THIS

9717
05:31:49,499 --> 05:31:51,601
REPORT AS KIND OF A FOLLOW-UP TO

9718
05:31:51,601 --> 05:31:54,103
THE -- WAS IT 2001 REPORT, DOES

9719
05:31:54,103 --> 05:31:56,272
SEX MATTER, OKAY?

9720
05:31:56,272 --> 05:31:56,839
AND THERE HAVE BEEN OTHER

9721
05:31:56,839 --> 05:31:58,241
REPORTS, BUT IT WAS PART OF MY

9722
05:31:58,241 --> 05:31:59,976
OWN MOTIVATION TO SEE IT BECAUSE

9723
05:31:59,976 --> 05:32:01,644
I THOUGHT THAT 2001 REPORT WAS

9724
05:32:01,644 --> 05:32:03,146
REALLY A TURNING POINT, AND THIS

9725
05:32:03,146 --> 05:32:04,380
WAS A FOLLOW-UP.

9726
05:32:04,380 --> 05:32:05,982
AND THE SCIENCE -- THE BASIC

9727
05:32:05,982 --> 05:32:09,152
BIOLOGY HAS CHANGED IN THOSE

9728
05:32:09,152 --> 05:32:10,586
20-PLUS YEARS.

9729
05:32:10,586 --> 05:32:13,422
SO THAT THERE ARE NEW WAYS IN

9730
05:32:13,422 --> 05:32:15,291
WHICH WE IMAGINE HOW SEX

9731
05:32:15,291 --> 05:32:17,093
DIFFERENCES AND, THEREFORE,

9732
05:32:17,093 --> 05:32:18,961
DISEASES THAT AFFECT WOMEN MORE

9733
05:32:18,961 --> 05:32:23,666
THAN MEN, OCCUR AT THE BASIC --

9734
05:32:23,666 --> 05:32:27,603
NEW FACTORS THAT ARE SEX BIASING

9735
05:32:27,603 --> 05:32:29,105
THAT BE WE DON'T EVEN UNDERSTAND

9736
05:32:29,105 --> 05:32:32,275
IN ANIMAL RESEARCH YET, AND SO

9737
05:32:32,275 --> 05:32:35,077
THERE ARE REPORT COMING OUT

9738
05:32:35,077 --> 05:32:37,146
ABOUT A MOLECULE LIKE EXISTS

9739
05:32:37,146 --> 05:32:39,448
WHICH IS THOUGHT TO BALL PANS

9740
05:32:39,448 --> 05:32:40,983
MALES AND FEMALES BUT IT

9741
05:32:40,983 --> 05:32:43,586
ACTUALLY THEN HAS SPECIFIC

9742
05:32:43,586 --> 05:32:44,654
EFFECTS IN WOMEN.

9743
05:32:44,654 --> 05:32:48,491
AND THAT'S A NEW CONCEPT THAT A

9744
05:32:48,491 --> 05:32:50,026
BALANCING MOLECULE ON THE X

9745
05:32:50,026 --> 05:32:51,694
CHROMOSOME THAT MAKES WOMEN MORE

9746
05:32:51,694 --> 05:32:52,528
LIKE MEN ACTUALLY MAKES WOMEN

9747
05:32:52,528 --> 05:32:56,232
DIFFERENT FROM MEN AND CAUSES

9748
05:32:56,232 --> 05:33:00,403
DISEASES OR CONTRIBUTES TO

9749
05:33:00,403 --> 05:33:01,837
DISEASES MORE IN WOMEN.

9750
05:33:01,837 --> 05:33:02,705
SO I THINK THERE'S SOME BASIC

9751
05:33:02,705 --> 05:33:07,076
BIOLOGY THAT NEEDS TO DO SOME

9752
05:33:07,076 --> 05:33:10,580
CATCHUP NOW, AND I THINK THE

9753
05:33:10,580 --> 05:33:12,081
TOOLS ARE THERE AND THAT WILL

9754
05:33:12,081 --> 05:33:12,315
HAPPEN.

9755
05:33:12,315 --> 05:33:14,717
AT THE SAME TIME THAT THE

9756
05:33:14,717 --> 05:33:18,221
CLINICAL SIDE IS -- THIS IS A

9757
05:33:18,221 --> 05:33:21,624
VERY COMPLEX BOOK ACTUALLY, AND

9758
05:33:21,624 --> 05:33:22,992
I'VE LEARNED A WHOLE LOT.

9759
05:33:22,992 --> 05:33:26,495
I WAS REALLY DELIGHTED TO SERVE

9760
05:33:26,495 --> 05:33:27,930
WITH THE MEMBERS OF THIS

9761
05:33:27,930 --> 05:33:30,733
COMMITTEE WHO KNEW SO MANY

9762
05:33:30,733 --> 05:33:33,803
THINGS THAT I CERTAINLY DIDN'T.

9763
05:33:33,803 --> 05:33:35,438
SO IT WAS A HUMBLE AND

9764
05:33:35,438 --> 05:33:38,174
GRATIFYING EXPERIENCE.

9765
05:33:38,174 --> 05:33:40,476
BUT -- SO I REALLY CAN ONLY

9766
05:33:40,476 --> 05:33:41,811
COMMENT ABOUT THE BASIC BIOLOGY.

9767
05:33:41,811 --> 05:33:43,279
>> BUT I DO THINK THAT'S

9768
05:33:43,279 --> 05:33:45,848
IMPORTANT, BUT ALSO ON THE OTHER

9769
05:33:45,848 --> 05:33:46,949
END, CLINICAL GUIDELINES, YOU

9770
05:33:46,949 --> 05:33:50,786
KNOW, PRACTICE GUIDELINES THAT

9771
05:33:50,786 --> 05:33:51,687
AS LONG AS WE UNDERSTAND THEY'RE

9772
05:33:51,687 --> 05:33:54,323
GOING TO HAVE TO BE CONSTANTLY

9773
05:33:54,323 --> 05:33:56,659
TESTED AND EVALUATED AS WE LEARN

9774
05:33:56,659 --> 05:33:58,761
MORE ABOUT THE PATHOPHYSIOLOGY

9775
05:33:58,761 --> 05:34:01,297
OF THESE DISEASES, SO WE CAN DO

9776
05:34:01,297 --> 05:34:03,933
A LOT BY STANDARDIZING THE WAY

9777
05:34:03,933 --> 05:34:06,269
WE CARE FOR THESE PATIENTS, BUT

9778
05:34:06,269 --> 05:34:09,639
ALSO MAKING IT EASIER FOR OUR

9779
05:34:09,639 --> 05:34:10,740
VARIOUS DISCIPLINES TO WORK

9780
05:34:10,740 --> 05:34:12,908
TOGETHER TO CARE FOR THE PATIENT

9781
05:34:12,908 --> 05:34:15,745
AND BE MORE PATIENT-CENTERED.

9782
05:34:15,745 --> 05:34:18,814
SO I COULD SEE BOTH OF THOSE

9783
05:34:18,814 --> 05:34:20,349
PILLARS BEING IMPORTANT.

9784
05:34:20,349 --> 05:34:22,118
BUT MY HOPE IS IN THE BASIC

9785
05:34:22,118 --> 05:34:26,255
SCIENCE REALM.

9786
05:34:26,255 --> 05:34:28,758
>> WE NEED TO MOVE ON
BECAUSE

9787
05:34:28,758 --> 05:34:31,627
WE'RE REALLY LATE.

9788
05:34:31,627 --> 05:34:33,329
AND I KNOW SOME OF YOU ARE

9789
05:34:33,329 --> 05:34:34,096
NEEDING TO MEET SOME OTHER

9790
05:34:34,096 --> 05:34:35,064
TRAVEL DEADLINES.

9791
05:34:35,064 --> 05:34:36,165
BUT FOR THOSE OF YOU WHO HAVE

9792
05:34:36,165 --> 05:34:37,366
OTHER QUESTIONS, I WOULD

9793
05:34:37,366 --> 05:34:38,734
ENCOURAGE YOU TO EITHER REACH

9794
05:34:38,734 --> 05:34:40,603
OUT TO US OR DR. HIGGINBOTHAM

9795
05:34:40,603 --> 05:34:42,405
AND WE CAN ACTUALLY ADDRESS

9796
05:34:42,405 --> 05:34:42,838
THOSE.

9797
05:34:42,838 --> 05:34:44,874
WE'LL BE HAPPY TO DO SO.

9798
05:34:44,874 --> 05:34:45,441
OKAY.

9799
05:34:45,441 --> 05:34:46,642
LET'S TAKE A DEEP BREATH AND

9800
05:34:46,642 --> 05:34:48,177
WE'RE GOING TO CHANGE OUR

9801
05:34:48,177 --> 05:34:49,912
DIRECTION A LITTLE BIT AND NOW

9802
05:34:49,912 --> 05:34:52,081
TURN TO OUR CONCEPT CLEARANCES.

9803
05:34:52,081 --> 05:34:53,282
SO WE'RE GOING TO PUT YOU TO

9804
05:34:53,282 --> 05:34:58,988
WORK.

9805
05:34:58,988 --> 05:35:01,624
SO WHAT I WOULD LIKE TO DO IS TO

9806
05:35:01,624 --> 05:35:03,526
NOW INTRODUCE OUR NEXT SPEAKER,

9807
05:35:03,526 --> 05:35:06,262
DR. SARAH TEMKIN, WHO IS THE

9808
05:35:06,262 --> 05:35:08,864
ASSOCIATE DIRECTOR FOR CLINICAL

9809
05:35:08,864 --> 05:35:09,865
RESEARCH AT ORWH, WHO WILL BE

9810
05:35:09,865 --> 05:35:10,966
PRESENTING A CONCEPT CLEARANCE

9811
05:35:10,966 --> 05:35:12,401
ON FEMALE-SPECIFIC CHRONIC

9812
05:35:12,401 --> 05:35:17,039
CONDITIONS.

9813
05:35:17,039 --> 05:35:17,606
DR. TEMKIN PROVIDES CLINICAL

9814
05:35:17,606 --> 05:35:18,474
EXPERIENCE ON ISSUES RELATED TO

9815
05:35:18,474 --> 05:35:20,109
THE HEALTH OF WOMEN.

9816
05:35:20,109 --> 05:35:22,044
HER CLINICAL RESEARCH TEAM

9817
05:35:22,044 --> 05:35:24,347
OVERSEES THE UNDERREPRESENTED,

9818
05:35:24,347 --> 05:35:29,685
UNDERSERVED AND UNDERREPORTED OR

9819
05:35:29,685 --> 05:35:30,986
YOUTH-RESEARCH RELATED TO

9820
05:35:30,986 --> 05:35:32,755
CHRONIC CONDITIONS AND

9821
05:35:32,755 --> 05:35:35,257
MULTI-MORBIDITY AMONG WOMEN AND

9822
05:35:35,257 --> 05:35:36,125
RESEARCH ON THE MULTIPLE

9823
05:35:36,125 --> 05:35:37,626
BIOLOGIC, SOCIAL AND BEHAVIORAL

9824
05:35:37,626 --> 05:35:39,061
FACTORS THAT INFLUENCE DISEASE

9825
05:35:39,061 --> 05:35:40,830
AND RISK AS WELL AS HEALTH

9826
05:35:40,830 --> 05:35:42,431
OUTCOMES OF WOMEN.

9827
05:35:42,431 --> 05:35:44,233
DR. TEMKIN IS A GYNECOLOGIC

9828
05:35:44,233 --> 05:35:46,969
ONCOLOGIST WHO EARNED HER

9829
05:35:46,969 --> 05:35:53,309
MEDICAL DEGREE FROM -- AND

9830
05:35:53,309 --> 05:35:55,511
COMPLETED A FELLOWSHIP IN

9831
05:35:55,511 --> 05:35:58,280
GYNECOLOGIC ONCOLOGY AT THE SUNY

9832
05:35:58,280 --> 05:35:59,382
DOWN STATE MEDICAL CENTER.

9833
05:35:59,382 --> 05:36:01,150
SHE'S BEEN VERY ACTIVE IN

9834
05:36:01,150 --> 05:36:03,986
CLINICAL RESEARCH THROUGHOUT HER

9835
05:36:03,986 --> 05:36:05,354
CAREER, HAVING SERVED AS

9836
05:36:05,354 --> 05:36:06,255
INVESTIGATOR FOR CLINICAL TRAILS

9837
05:36:06,255 --> 05:36:08,858
FOR FEMALE-SPECIFIC

9838
05:36:08,858 --> 05:36:10,459
MALIGNANCIES, CANCER CONTROL,

9839
05:36:10,459 --> 05:36:11,894
AND SUPPORTIVE CARE FOR CANCER

9840
05:36:11,894 --> 05:36:12,161
PATIENTS.

9841
05:36:12,161 --> 05:36:14,730
IN ADDITION, DR. TEMKIN HAS BEEN

9842
05:36:14,730 --> 05:36:17,566
RECOGNIZED FOR EXCELLENCE IN

9843
05:36:17,566 --> 05:36:24,106
CLINICAL CARE AS WELL AS

9844
05:36:24,106 --> 05:36:25,441
EXPERTISE -- DR. TEMKIN HAS

9845
05:36:25,441 --> 05:36:26,942
SERVED AS THE NATIONAL CANCER

9846
05:36:26,942 --> 05:36:28,978
INSTITUTE AS A PROGRAM OFFICER

9847
05:36:28,978 --> 05:36:31,080
FOR THE COMMUNITY ONCOLOGY

9848
05:36:31,080 --> 05:36:32,047
RESEARCH PROGRAM AND IS A

9849
05:36:32,047 --> 05:36:33,416
SPECIAL VOLUNTEER FOR THE

9850
05:36:33,416 --> 05:36:35,651
DIVISION OF CANCER PREVENTION.

9851
05:36:35,651 --> 05:36:36,852
WELCOME, DR. TEMKIN.

9852
05:36:36,852 --> 05:36:40,122
>> THANKS SO MUCH FOR
HAVING ME.

9853
05:36:40,122 --> 05:36:42,491
I DIDN'T REALIZE I WAS GOING TO

9854
05:36:42,491 --> 05:36:44,794
GET MY WHOLE BIO READ.

9855
05:36:44,794 --> 05:36:47,997
I'M GOING TO TALK A LITTLE ABOUT

9856
05:36:47,997 --> 05:36:49,365
FEMALE CHRONIC CONDITIONS TODAY

9857
05:36:49,365 --> 05:36:50,766
FOR THIS CONCEPT CLEARANCE BY

9858
05:36:50,766 --> 05:36:52,401
THE SAME NAME, ADVANCING OUR

9859
05:36:52,401 --> 05:36:53,736
UNDERSTANDING OF FEMALE SPECIFIC

9860
05:36:53,736 --> 05:36:55,337
AND GYNECOLOGIC CHRONIC

9861
05:36:55,337 --> 05:36:55,638
CONDITIONS.

9862
05:36:55,638 --> 05:36:56,539
THE PURPOSE OF WHICH IS TO

9863
05:36:56,539 --> 05:36:58,808
INVITE RESEARCH PROJECTS TO

9864
05:36:58,808 --> 05:36:59,809
IMPROVE PREVENTION, DIAGNOSIS,

9865
05:36:59,809 --> 05:37:03,612
EARLY DETECTION AND TREATMENT

9866
05:37:03,612 --> 05:37:05,147
INTERVENTIONS FOR

9867
05:37:05,147 --> 05:37:06,315
FEMALE-SPECIFIC AND GYNECOLOGIC

9868
05:37:06,315 --> 05:37:10,052
CHRONIC CONDITIONS.

9869
05:37:10,052 --> 05:37:12,555
THE FUNDS AVAILABLE ARE

9870
05:37:12,555 --> 05:37:14,523
CONTINGENT UPON NIH

9871
05:37:14,523 --> 05:37:15,491
APPROPRIATIONS FOR MERITORIOUS

9872
05:37:15,491 --> 05:37:16,625
AWARDS.

9873
05:37:16,625 --> 05:37:20,196
WOUWE WOULD ANTICIPATE A FIVE-YR

9874
05:37:20,196 --> 05:37:21,397
PERIOD AND AT THE END OF THIS

9875
05:37:21,397 --> 05:37:22,264
PRESENTATION, WE WOULD ASK YOU

9876
05:37:22,264 --> 05:37:23,999
TO VOTE TO APPROVE THIS CONCEPT.

9877
05:37:23,999 --> 05:37:29,338
I'M GOING TO START BY GIVING A

9878
05:37:29,338 --> 05:37:32,274
SHORT -- THAT WE JUST HAD ON THE

9879
05:37:32,274 --> 05:37:33,676
NASEM ACTIVITY ON CHRONIC

9880
05:37:33,676 --> 05:37:33,976
CONDITIONS.

9881
05:37:33,976 --> 05:37:34,944
THE REASON THAT DEBILITATING WAS

9882
05:37:34,944 --> 05:37:38,280
IN THE TITLE IS BECAUSE THIS

9883
05:37:38,280 --> 05:37:40,883
ACTIVITY CAME OUT OF

9884
05:37:40,883 --> 05:37:44,153
CONGRESSIONAL REQUESTS IN FISCAL

9885
05:37:44,153 --> 05:37:46,322
YEAR 21 THAT THE NIH REVIEW ITS

9886
05:37:46,322 --> 05:37:50,326
PORTFOLIOS ON WOMEN'S HEALTH AND

9887
05:37:50,326 --> 05:37:51,093
SPECIFICALLY REVIEW THE

9888
05:37:51,093 --> 05:37:54,063
ACTIVITIES IN THE NIH SPECIFIC

9889
05:37:54,063 --> 05:37:58,968
TO MATERNAL MORBIDITY AND

9890
05:37:58,968 --> 05:38:02,238
MORTALITY, STAG NAT CERVICAL

9891
05:38:02,238 --> 05:38:05,140
CANCER SER VIEFL AND CHRONIC

9892
05:38:05,140 --> 05:38:05,708
DEBILITATING CONDITIONS IN

9893
05:38:05,708 --> 05:38:06,175
WOMEN.

9894
05:38:06,175 --> 05:38:07,843
SO THIS HAS BEEN A PRIORITY IN

9895
05:38:07,843 --> 05:38:09,211
ORWH FOR SEVERAL YEARS AND AS

9896
05:38:09,211 --> 05:38:10,412
LONG AS I'VE BEEN IN THE OFFICE.

9897
05:38:10,412 --> 05:38:12,414
WE DO KNOW THAT WOMEN HAVE

9898
05:38:12,414 --> 05:38:19,388
HIGHER RATES OF CHRONIC

9899
05:38:19,388 --> 05:38:20,589
CONDITIONS THAN MEN AND HIGHER

9900
05:38:20,589 --> 05:38:22,191
RATES OF MULTI-MORBIDITY.

9901
05:38:22,191 --> 05:38:25,327
SO AS PART OF THIS ACTIVITY,

9902
05:38:25,327 --> 05:38:26,795
MANY PEOPLE IN THIS ROOM ARE

9903
05:38:26,795 --> 05:38:29,431
FAMILIAR WITH WHAT WE CALLED THE

9904
05:38:29,431 --> 05:38:30,733
RAINBOW TABLE, BUT IN ORDER TO

9905
05:38:30,733 --> 05:38:35,738
TRY TO BE INCLUSIVE OF ALL OF

9906
05:38:35,738 --> 05:38:40,109
THE NIH CENTERS AND IN ORDER TO

9907
05:38:40,109 --> 05:38:40,743
GIVE EVERYBODY A SMALL PIECE OF

9908
05:38:40,743 --> 05:38:42,278
THIS AND MAKE EVERYONE FEEL AS

9909
05:38:42,278 --> 05:38:50,452
THIS IF THEY COULD CONTRIBUTE, E

9910
05:38:50,452 --> 05:38:51,820
DIVIDED THIS INTO FOUR CATEGORYS

9911
05:38:51,820 --> 05:38:53,255
THAT INCLUDED FEMALE-SPECIFIC,

9912
05:38:53,255 --> 05:38:54,823
THOSE CONDITIONS MORE COMMON IN

9913
05:38:54,823 --> 05:38:55,791
WOMEN, THOSE CONDITIONS THAT

9914
05:38:55,791 --> 05:38:57,760
OCCUR IN BOTH SEXES BUT ARE

9915
05:38:57,760 --> 05:38:59,628
POTENTIALLY UNDERSTUDIED IN

9916
05:38:59,628 --> 05:39:00,563
WOMEN, AND THEN LASTLY THOSE

9917
05:39:00,563 --> 05:39:02,665
CONDITIONS THAT HAVE HIGH

9918
05:39:02,665 --> 05:39:03,732
MORBIDITY FOR WOMEN.

9919
05:39:03,732 --> 05:39:06,669
AND JUST TO MAKE THIS VERY

9920
05:39:06,669 --> 05:39:09,204
COMPLICATED BUSY TABLE VERY

9921
05:39:09,204 --> 05:39:11,040
STRAIGHTFORWARD AS POSSIBLE, WE

9922
05:39:11,040 --> 05:39:14,510
COMPARED THE SPENDING IN FY 20

9923
05:39:14,510 --> 05:39:16,812
FROM THE NIH TO THE DISABILITY

9924
05:39:16,812 --> 05:39:18,213
ADJUSTED LIFE YEARS EXPERIENCED

9925
05:39:18,213 --> 05:39:23,686
BY WOMEN IN 2019, AND FROM THESE

9926
05:39:23,686 --> 05:39:27,923
FEW EXAMPLES, YOU CAN SEE THAT

9927
05:39:27,923 --> 05:39:29,558
THERE WAS A VERY WIDE RANGE,

9928
05:39:29,558 --> 05:39:31,427
THESE CONDITIONS, THE DISABILITY

9929
05:39:31,427 --> 05:39:35,030
ADJUSTED LIFE YEARS ARE HIGHER

9930
05:39:35,030 --> 05:39:35,998
ON THE RIGHT SIDE OF THE SCREEN

9931
05:39:35,998 --> 05:39:37,766
AND GO DOWN AS YOU MOVE LEFT,

9932
05:39:37,766 --> 05:39:41,203
BUT THE RATIO OF SPENDING TO

9933
05:39:41,203 --> 05:39:41,870
DISABILITY ADJUSTED LIFE YEARS

9934
05:39:41,870 --> 05:39:44,740
WAS SORT OF ALL OVER THE MAP,

9935
05:39:44,740 --> 05:39:47,142
REALLY DEMONSTRATING THAT NIH

9936
05:39:47,142 --> 05:39:49,111
SPENDING IS NOT ALIGNED WELL

9937
05:39:49,111 --> 05:39:50,512
WITH THE BURDENS OF DISEASE

9938
05:39:50,512 --> 05:39:53,482
AMONGST WOMEN.

9939
05:39:53,482 --> 05:39:54,683
WE SUMMARIZE THESE ACTIVITY FOR

9940
05:39:54,683 --> 05:39:56,385
ANYONE WHO'S INTERESTED IN GOING

9941
05:39:56,385 --> 05:40:00,723
BACK AND LOOKING AT THIS IN A

9942
05:40:00,723 --> 05:40:02,658
PUBLICATION IN 2023, WHERE WE

9943
05:40:02,658 --> 05:40:03,425
DEFINE MULTIPLE OPPORTUNITIES TO

9944
05:40:03,425 --> 05:40:04,860
ALIGN THE NIH RESEARCH AGENDA

9945
05:40:04,860 --> 05:40:08,330
WITH THE HEALTH NEEDS OF WOMEN,

9946
05:40:08,330 --> 05:40:09,932
INCLUDING THE INTEGRATION OF SEX

9947
05:40:09,932 --> 05:40:12,134
AS A BIOLOGIC VARIABLE ACROSS

9948
05:40:12,134 --> 05:40:13,902
THE LIFECOURSE OF WOMEN, AND

9949
05:40:13,902 --> 05:40:16,238
IMPROVING OUR UNDERSTANDING OF

9950
05:40:16,238 --> 05:40:17,172
HOW SOCIAL DETERMINANTS OF

9951
05:40:17,172 --> 05:40:19,041
HEALTH INFLUENCE THE HEALTH OF

9952
05:40:19,041 --> 05:40:21,543
WOMEN DIFFERENTLY THAN MEN.

9953
05:40:21,543 --> 05:40:25,214
ONE OF THE KEY OUTPUTS OF THIS

9954
05:40:25,214 --> 05:40:27,016
CONVENING WAS THE NATIONAL ACAD

9955
05:40:27,016 --> 05:40:29,585
PEES REPORT WHICH WE JUST HEARD

9956
05:40:29,585 --> 05:40:32,021
ABOUT WITH ITS MANY

9957
05:40:32,021 --> 05:40:34,056
RECOMMENDATIONS, AND I'M SO GLAD

9958
05:40:34,056 --> 05:40:35,958
I DON'T HAVE TO GO THROUGH ALL

9959
05:40:35,958 --> 05:40:37,826
OF THOSE WITH YOU, BUT I DID

9960
05:40:37,826 --> 05:40:40,329
WANT TO POINT OUT SPECIFICALLY

9961
05:40:40,329 --> 05:40:42,197
HOW THIS FRAMEWORK WAS CHANGED

9962
05:40:42,197 --> 05:40:44,700
BY THE COMMITTEE OR WERE

9963
05:40:44,700 --> 05:40:46,769
MODIFIED OR THEIR FRAMEWORK IS

9964
05:40:46,769 --> 05:40:50,572
DIFFERENT THAN HOURS -- OURS,

9965
05:40:50,572 --> 05:40:51,573
WHICH ACTUALLY I WAS DELIGHTED

9966
05:40:51,573 --> 05:40:52,875
BY THAT, FEMALE-SPECIFIC

9967
05:40:52,875 --> 05:40:54,510
CONDITIONS WERE ONE OF THREE

9968
05:40:54,510 --> 05:40:57,479
BOXES AT THE TOP OF THIS

9969
05:40:57,479 --> 05:40:59,415
FRAMEWORK, WHERE YOU CAN SEE,

9970
05:40:59,415 --> 05:41:01,417
AND I JUST WANT TO BE CLEAR,

9971
05:41:01,417 --> 05:41:03,886
LIKE ONE OF THE MAIN ISSUES WITH

9972
05:41:03,886 --> 05:41:04,887
THE UNDERSTUDYING AND OUR LACK

9973
05:41:04,887 --> 05:41:09,925
OF KNOWLEDGE ABOUT THE BASIC

9974
05:41:09,925 --> 05:41:11,126
PHYSIOLOGY AND LACK OF

9975
05:41:11,126 --> 05:41:12,628
DIAGNOSTICS TREATMENT FOR

9976
05:41:12,628 --> 05:41:13,395
FEMALE-SPECIFIC AND GYNECOLOGIC

9977
05:41:13,395 --> 05:41:15,164
CONDITIONS IS HOW IT INFLUENCES

9978
05:41:15,164 --> 05:41:16,465
THE ACCUMULATION OF DISEASE

9979
05:41:16,465 --> 05:41:18,534
ACROSS THE LIFESPAN OF WOMEN,

9980
05:41:18,534 --> 05:41:21,370
AND HOW THAT LEADS TO

9981
05:41:21,370 --> 05:41:22,671
MULTI-MORBIDITY WHICH MAY BE

9982
05:41:22,671 --> 05:41:24,440
LESS WELL UNDERSTOOD THAN IN

9983
05:41:24,440 --> 05:41:27,810
MEN.

9984
05:41:27,810 --> 05:41:31,747
WE KNOW THAT FEMALE SPECIFIC AND

9985
05:41:31,747 --> 05:41:33,048
CHRONOLOGIC CONDITIONS ARE VERY

9986
05:41:33,048 --> 05:41:35,217
COMMON AND CAUSE SPECIFIC

9987
05:41:35,217 --> 05:41:35,984
MORBIDITY PARTICULARLY AMONGST

9988
05:41:35,984 --> 05:41:36,552
YOUNGER PATIENTS.

9989
05:41:36,552 --> 05:41:39,121
THIS IS COMPOUNDED BY THE FACT

9990
05:41:39,121 --> 05:41:40,456
THAT THERE'S SIGNIFICANT STIGMA,

9991
05:41:40,456 --> 05:41:41,890
PATIENTS ARE OFTEN RELUCTANT AS

9992
05:41:41,890 --> 05:41:43,625
WE HEARD FROM MANY OF OUR

9993
05:41:43,625 --> 05:41:45,194
SPEAKERS TODAY TO DISCUSS THEIR

9994
05:41:45,194 --> 05:41:46,895
SYMPTOMS RELATED TO THE FEMALE

9995
05:41:46,895 --> 05:41:49,965
GENITAL TRACT, AND DELAYS IN

9996
05:41:49,965 --> 05:41:52,801
DIAGNOSIS ARE COMMON.

9997
05:41:52,801 --> 05:41:54,002
THE CONTRIBUTION OF THESE

9998
05:41:54,002 --> 05:41:56,538
DISORDERS TO MULTI-MORBIDITY IS

9999
05:41:56,538 --> 05:41:58,941
RARELY CONSIDERED MUCH LESS

10000
05:41:58,941 --> 05:42:00,509
MEASURED, AND WE KNOW THAT THERE

10001
05:42:00,509 --> 05:42:03,512
ARE SIGNIFICANT HEALTH

10002
05:42:03,512 --> 05:42:04,947
DISPARITIES IN MANY OF THESE

10003
05:42:04,947 --> 05:42:05,748
CONDITIONS.

10004
05:42:05,748 --> 05:42:07,549
WE ALSO KNOW THAT

10005
05:42:07,549 --> 05:42:10,486
MULTI-MORBIDITY IN WOMEN IS

10006
05:42:10,486 --> 05:42:11,253
COMPLICATED.

10007
05:42:11,253 --> 05:42:12,454
MULTI-MORBIDITY IS MORE LIKELY

10008
05:42:12,454 --> 05:42:14,757
TO CROSS ORGAN SYSTEMS THAN

10009
05:42:14,757 --> 05:42:18,460
NETWORKS OF MORBIDITY IN WOMEN

10010
05:42:18,460 --> 05:42:19,895
ARE ACROSS MORE ORGAN SYSTEMS

10011
05:42:19,895 --> 05:42:23,031
THAN THOSE IN MEN.

10012
05:42:23,031 --> 05:42:24,967
AND ALSO THAT WOMEN ARE MORE

10013
05:42:24,967 --> 05:42:27,169
LIKELY TO HAVE DISCORDANT

10014
05:42:27,169 --> 05:42:30,873
CHRONIC MEDICAL CONDITIONS AND

10015
05:42:30,873 --> 05:42:32,207
THOSE DISCORDANT CONDITIONS ARE

10016
05:42:32,207 --> 05:42:34,443
MORE LIKELY TO CROSS SOMATIC AS

10017
05:42:34,443 --> 05:42:37,212
WELL AS PSYCHIATRIC CONDITIONS.

10018
05:42:37,212 --> 05:42:39,515
WHEN YOU INCLUDE FACTORS THAT

10019
05:42:39,515 --> 05:42:46,889
ARE SOCIAL FACTORS SUCH AS FAITS

10020
05:42:46,889 --> 05:42:48,056
BECOMES MORE COMPLICATED.

10021
05:42:48,056 --> 05:42:48,824
THIS TABLE IS THE ONLY ONE WE'VE

10022
05:42:48,824 --> 05:42:50,459
BEEN ABLE TO FIND IN THE

10023
05:42:50,459 --> 05:42:51,960
LITERATURE THAT SHOWS WHAT THE

10024
05:42:51,960 --> 05:42:53,262
VARIABILITY IS OR HETEROGENEITY

10025
05:42:53,262 --> 05:42:56,431
IS OF THE DIAGNOSIS OF

10026
05:42:56,431 --> 05:42:58,367
MULTI-MORBIDITY ACROSS MEN AND

10027
05:42:58,367 --> 05:42:59,802
WOMEN OF DIFFERENT RACIAL AND

10028
05:42:59,802 --> 05:43:04,072
ETHNIC GROUPS.

10029
05:43:04,072 --> 05:43:05,474
AND SO THE SECOND OUTPUT FROM

10030
05:43:05,474 --> 05:43:07,142
THE ADVANCING RESEARCH ON

10031
05:43:07,142 --> 05:43:07,976
WOMEN'S HEALTH CONVENING THAT I

10032
05:43:07,976 --> 05:43:12,014
WANTED TO JUST TALK ABOUT TODAY

10033
05:43:12,014 --> 05:43:19,321
IN LEAD UP TO THE VOTE ON THE --

10034
05:43:19,321 --> 05:43:21,623
I LOST THE WORD.

10035
05:43:21,623 --> 05:43:25,994
CONCEPT CLEARANCE.

10036
05:43:25,994 --> 05:43:26,695
IS TWO FUNDING OPPORTUNITIES

10037
05:43:26,695 --> 05:43:28,730
THAT CAME OUT OF THE OFFICE.

10038
05:43:28,730 --> 05:43:35,904
THESE WERE RFA-OD-23-013 AND

10039
05:43:35,904 --> 05:43:38,106
014, UNDERSTANDING CHRONIC

10040
05:43:38,106 --> 05:43:39,775
CONDITIONING USING THE FRAMEWORK

10041
05:43:39,775 --> 05:43:41,143
WE HAD DEVELOPED IN THE

10042
05:43:41,143 --> 05:43:42,010
ADVANCING WOMEN'S HEALTH

10043
05:43:42,010 --> 05:43:45,647
CONFERENCE IN 2021.

10044
05:43:45,647 --> 05:43:47,916
WE HAD TWO RECEIPT DATES, BOTH

10045
05:43:47,916 --> 05:43:49,852
OF WHICH WERE PASSED.

10046
05:43:49,852 --> 05:43:51,053
THE FIRST ONE WAS AT THE END OF

10047
05:43:51,053 --> 05:43:51,820
TWEP 23.

10048
05:43:51,820 --> 05:43:53,589
WE HAD SEVERAL PARTNER ICOs

10049
05:43:53,589 --> 05:43:54,756
MENTIONED HERE AT THE BOTTOM, SO

10050
05:43:54,756 --> 05:43:58,193
I'M VERY PLEASED TO ANNOUNCE

10051
05:43:58,193 --> 05:44:00,329
THAT WE WERE ABLE TO FUND 21

10052
05:44:00,329 --> 05:44:03,899
AWARDS THROUGH THESE MECHANISMS

10053
05:44:03,899 --> 05:44:08,203
THAT CROSSED MULTIPLE DIFFERENT

10054
05:44:08,203 --> 05:44:15,811
ICs, SIX TO NHLBI, SIX TO

10055
05:44:15,811 --> 05:44:20,249
NICHD, ONE TO NIA, TWO TO NCI,

10056
05:44:20,249 --> 05:44:22,451
ONE TO NIAMS AND ONE TO NIDDK.

10057
05:44:22,451 --> 05:44:27,022
THEY WENT TO NICHD BUT ALSO TO

10058
05:44:27,022 --> 05:44:32,928
NHLBI, NIA AND THE NCI.

10059
05:44:32,928 --> 05:44:34,263
I JUST INCLUDED A FULL LIST

10060
05:44:34,263 --> 05:44:36,231
HERE, I KNOW IT'S TOO SMALL TO

10061
05:44:36,231 --> 05:44:36,932
READ, BUT TO SHOW YOU THE VERY

10062
05:44:36,932 --> 05:44:40,769
BROAD AND DIVERSE TOPICS THAT WE

10063
05:44:40,769 --> 05:44:42,204
WERE ABLE TO FUND THROUGH THIS

10064
05:44:42,204 --> 05:44:46,775
MECHANISM, BUT ALSO HERE

10065
05:44:46,775 --> 05:44:47,876
HIGHLIGHTED THE AWARDS THAT WERE

10066
05:44:47,876 --> 05:44:49,411
REALLY FOCUSED ON

10067
05:44:49,411 --> 05:44:50,646
FEMALE-SPECIFIC CONDITIONS SO

10068
05:44:50,646 --> 05:44:54,316
THAT YOU CAN SEE THE BREADTH OF

10069
05:44:54,316 --> 05:44:56,184
RESEARCH THAT THIS FUNDING

10070
05:44:56,184 --> 05:44:58,487
OPPORTUNITY BROUGHT IN.

10071
05:44:58,487 --> 05:45:00,589
THINGS LIKE MENOPAUSE, MEN TREUL

10072
05:45:00,589 --> 05:45:01,957
BLEEDING THAT ACTUALLY WENT TO

10073
05:45:01,957 --> 05:45:03,592
NHLBI BECAUSE OF THE ASSOCIATION

10074
05:45:03,592 --> 05:45:06,228
WITH ANEMIA, VAGINAL TOXICITY OF

10075
05:45:06,228 --> 05:45:08,397
RADIATION, POLYCYSTIC OVARIAN

10076
05:45:08,397 --> 05:45:10,666
SYNDROME, ENDOMETRIOSIS,

10077
05:45:10,666 --> 05:45:11,967
ADENOMYOSIS, CERVICAL DYSPLASIA,

10078
05:45:11,967 --> 05:45:13,502
AND PELVIC FLOOR DISORDERS.

10079
05:45:13,502 --> 05:45:16,672
AND THESE WENT TO A VARIETY OF

10080
05:45:16,672 --> 05:45:17,172
INVESTIGATORS ACROSS THE

10081
05:45:17,172 --> 05:45:19,508
COUNTRY.

10082
05:45:19,508 --> 05:45:27,049
HAASLY, I JUSTLASTLY I JUST WANO

10083
05:45:27,049 --> 05:45:28,917
CONTEXT THE OVERALL SPENDING, I

10084
05:45:28,917 --> 05:45:30,452
THINK EVERYONE IN THE ROOM KNOWS

10085
05:45:30,452 --> 05:45:34,122
THAT WOMEN'S HEALTH SPENDING IS

10086
05:45:34,122 --> 05:45:36,558
APPROXIMATELY 10% OF THE TOTAL

10087
05:45:36,558 --> 05:45:38,327
NIH BUDGET THAT'S BEEN PRETTY

10088
05:45:38,327 --> 05:45:43,432
CONSTANT FOR THE LAST NUMBER OF

10089
05:45:43,432 --> 05:45:43,632
YEARS.

10090
05:45:43,632 --> 05:45:45,067
SO IT'S HARD TO GET AN EXACT

10091
05:45:45,067 --> 05:45:46,702
NUMBER BUT I THINK

10092
05:45:46,702 --> 05:45:48,236
FEMALE-SPECIFIC CONDITIONS MAKE

10093
05:45:48,236 --> 05:45:52,140
UP ABOUT 12% OF THAT WHOLE

10094
05:45:52,140 --> 05:45:55,544
BUDGET OR ABOUT 1% EVIDENT WHOLE

10095
05:45:55,544 --> 05:45:57,212
NIH BUDGET SO I JUST PROVIDED A

10096
05:45:57,212 --> 05:46:00,349
FEW NUMBERS OF WHAT THE RCDC

10097
05:46:00,349 --> 05:46:03,085
PUBLIC SPENDING LOOKS LIKE FOR

10098
05:46:03,085 --> 05:46:03,852
SOME OF THESE CONDITIONS.

10099
05:46:03,852 --> 05:46:05,620
THE LARGEST AMOUNTS GO TO

10100
05:46:05,620 --> 05:46:06,822
OVARIAN AND CERVICAL CANCER.

10101
05:46:06,822 --> 05:46:08,023
LAST YEAR WAS THE FIRST YEAR WE

10102
05:46:08,023 --> 05:46:13,895
HAD A MENOPAUSE RCDC CODE, WHICH

10103
05:46:13,895 --> 05:46:16,631
WAS $56 MILLION, THEN OTHER

10104
05:46:16,631 --> 05:46:17,833
CANCERS, THEN THESE BENIGN

10105
05:46:17,833 --> 05:46:19,468
DISEASES START TO FALL TOWARDS

10106
05:46:19,468 --> 05:46:23,739
THE BOTTOM OF THE LIST.

10107
05:46:23,739 --> 05:46:27,476
SO JUST TO SUMMARIZE THIS WHOLE

10108
05:46:27,476 --> 05:46:29,778
CONCEPT, THE FEMALE-SPECIFIC

10109
05:46:29,778 --> 05:46:31,613
CHRONIC CONDITIONS ARE HIGHLY

10110
05:46:31,613 --> 05:46:32,914
PREVALENT, HAVE BEEN

10111
05:46:32,914 --> 05:46:37,185
HISTORICALLY UNDERSTUDIED ACROSS

10112
05:46:37,185 --> 05:46:38,820
MULTIPLE IC PRIORITIES, AND I

10113
05:46:38,820 --> 05:46:40,222
JUST SORT OF PUT THIS TOGETHER.

10114
05:46:40,222 --> 05:46:44,126
I DID NOT KNOW THAT NEXTGEN JANE

10115
05:46:44,126 --> 05:46:45,227
WAS GOING TO TALK AHEAD OF ME

10116
05:46:45,227 --> 05:46:47,429
AND PERFECTLY PREPARING ME FOR

10117
05:46:47,429 --> 05:46:48,196
THIS BUT SHE DID.

10118
05:46:48,196 --> 05:46:50,032
YOU KNOW, WHEN YOU THINK ABOUT

10119
05:46:50,032 --> 05:46:51,133
MENSTRUAL DISORDERS, IT DOESN'T

10120
05:46:51,133 --> 05:46:52,334
JUST FALL INTO THE PURVIEW OR

10121
05:46:52,334 --> 05:46:54,403
ALIGN WITH THE MISSION OF ONE

10122
05:46:54,403 --> 05:46:56,371
IC, BUT THERE ARE MULTIPLE

10123
05:46:56,371 --> 05:46:57,139
INSTITUTES AND CENTERS WHERE

10124
05:46:57,139 --> 05:47:00,742
THIS IS POTENTIALLY IMPORTANT.

10125
05:47:00,742 --> 05:47:05,414
WE'VE MENTIONED NHLBI THAT

10126
05:47:05,414 --> 05:47:09,251
FUNDED AN R01 ON ANEMIA BUT ALSO

10127
05:47:09,251 --> 05:47:10,619
MENSTRUAL MIGRAINES ARE A

10128
05:47:10,619 --> 05:47:12,287
SIGNIFICANT SOURCE OF MORBIDITY

10129
05:47:12,287 --> 05:47:14,689
AND ALIGNED WITH NINDS, OBESITY

10130
05:47:14,689 --> 05:47:16,892
CHANGES MENSTRUAL DISORDERS, THE

10131
05:47:16,892 --> 05:47:18,060
DIAGNOSIS AS WELL AS THE

10132
05:47:18,060 --> 05:47:21,296
TREATMENT FOR MANY WOMEN.

10133
05:47:21,296 --> 05:47:23,832
AND THAT IS ALIGNED WITH THE

10134
05:47:23,832 --> 05:47:24,466
NIDDK MISSION.

10135
05:47:24,466 --> 05:47:26,034
WE ALSO KNOW THERE ARE

10136
05:47:26,034 --> 05:47:27,836
SIGNIFICANT LET-RELATED

10137
05:47:27,836 --> 05:47:29,271
DISPARITIES FOR CONDITIONS LIKE

10138
05:47:29,271 --> 05:47:32,074
FIBROIDS AND ENDOMETRIOSIS, AND

10139
05:47:32,074 --> 05:47:34,376
WE KNOW THAT THESE INTERACTIONS

10140
05:47:34,376 --> 05:47:37,312
WITH OTHER CHRONIC DISEASES IS

10141
05:47:37,312 --> 05:47:37,646
UNKNOWN.

10142
05:47:37,646 --> 05:47:41,049
SO IN SUMMARY, I HOPE THAT I

10143
05:47:41,049 --> 05:47:44,319
HAVE CONVINCED YOU THAT THIS IS

10144
05:47:44,319 --> 05:47:49,024
A VALUABLE FUNDING OPPORTUNITY

10145
05:47:49,024 --> 05:47:51,326
TO ENHANCE OUR UNDERSTANDING OF

10146
05:47:51,326 --> 05:47:54,396
FEMALE-SPECIFIC CONDITIONS, AND

10147
05:47:54,396 --> 05:47:57,232
I WILL STOP THERE.

10148
05:47:57,232 --> 05:47:59,501
>> THANK YOU, DR. TIM KIN.

10149
05:47:59,501 --> 05:48:02,904
I'D LIKE NOW TO CALL ON THE TWO

10150
05:48:02,904 --> 05:48:08,243
DISCUSSANTS FOR THIS CONCEPT, WE

10151
05:48:08,243 --> 05:48:12,814
HAVE DR. MIELENZ AND DR. SHARPS.

10152
05:48:12,814 --> 05:48:14,516
I'LL HAVE DR. SHARPS GO FIRST.

10153
05:48:14,516 --> 05:48:14,950
>> GOOD AFTERNOON.

10154
05:48:14,950 --> 05:48:16,017
I REALLY DON'T HAVE ANY

10155
05:48:16,017 --> 05:48:18,420
QUESTIONS ABOUT THE CONCEPT, BUT

10156
05:48:18,420 --> 05:48:20,055
I DO HAVE JUST A FEW COMMENTS AS

10157
05:48:20,055 --> 05:48:21,256
WE THINK ABOUT MOVING FORWARD

10158
05:48:21,256 --> 05:48:25,861
WITH IT, WITH YOU I'M IN FAVOR.

10159
05:48:25,861 --> 05:48:28,797
AS HAS BEEN MENTIONED, I THINK

10160
05:48:28,797 --> 05:48:30,765
THE RESEARCH, THIS FOCUS IS

10161
05:48:30,765 --> 05:48:35,036
HIGHLY RELEVANT AND TIMELY, AND

10162
05:48:35,036 --> 05:48:39,841
WE HAVE WOMEN WHO HAVE CHRONIC

10163
05:48:39,841 --> 05:48:42,210
CONDITIONS AND MULTIPLE CHRONIC

10164
05:48:42,210 --> 05:48:43,445
CONDITIONS CERTAINLY IN THE

10165
05:48:43,445 --> 05:48:44,746
POPULATIONS I'VE WORKED WITH

10166
05:48:44,746 --> 05:48:49,784
THAT ARE LIVING LONGER, AND WE

10167
05:48:49,784 --> 05:48:51,987
DON'T UNDERSTAND ALL OF THE

10168
05:48:51,987 --> 05:48:53,388
MECHANISMS OF JUST NATURALLY

10169
05:48:53,388 --> 05:48:56,525
OCCURRING BIOLOGY, AND I CALL

10170
05:48:56,525 --> 05:48:59,294
THEM THE HORMONE MILESTONES,

10171
05:48:59,294 --> 05:49:01,830
PREGNANCY, MENOPAUSE, AND WE

10172
05:49:01,830 --> 05:49:03,932
DON'T EVEN KNOW THE LONG-TERM

10173
05:49:03,932 --> 05:49:10,772
EFFECTS AS WOMEN MOVE INTO OLDER

10174
05:49:10,772 --> 05:49:12,507
ADULTS, AND IN FACT, PEOPLE WHO

10175
05:49:12,507 --> 05:49:14,609
STUDY OLDER AGE NOW HAVE THREE

10176
05:49:14,609 --> 05:49:15,677
DIVISIONS LIKE WE DO WITH

10177
05:49:15,677 --> 05:49:17,012
ADOLESCENTS, EARLY, MIDDLE AND

10178
05:49:17,012 --> 05:49:21,383
LATE, SO WE DON'T UNDERSTAND ALL

10179
05:49:21,383 --> 05:49:24,019
OF THOSE MECHANISMS AND WHAT

10180
05:49:24,019 --> 05:49:26,955
HAPPENS IF WOMEN MAY HAVE HAD

10181
05:49:26,955 --> 05:49:28,623
STABLE OR THAT THEIR DISEASE WAS

10182
05:49:28,623 --> 05:49:30,492
MANAGED FAIRLY WELL, BUT THEN WE

10183
05:49:30,492 --> 05:49:34,462
HAVE THESE SHIFTS IN HORMONES OR

10184
05:49:34,462 --> 05:49:35,630
THINGS BIOLOGICALLY THAT OCCUR

10185
05:49:35,630 --> 05:49:36,731
WITH THE DIFFERENT MILESTONES OF

10186
05:49:36,731 --> 05:49:40,502
LIFE.

10187
05:49:40,502 --> 05:49:42,137
CERTAINLY WE KNOW IN VULNERABLE

10188
05:49:42,137 --> 05:49:44,773
PATIENTS POPULATIONS OF WOMEN,

10189
05:49:44,773 --> 05:49:47,142
THERE ARE HEAVIER BURDENS FOR

10190
05:49:47,142 --> 05:49:50,378
THESE DISEASES, SOME BIOLOGIC

10191
05:49:50,378 --> 05:49:52,847
AND SOME WITH ENVIRONMENTAL AND

10192
05:49:52,847 --> 05:49:55,050
OTHER CONDITIONS, AND SO I THINK

10193
05:49:55,050 --> 05:49:59,721
THE OPPORTUNITY TO LOOK AT THAT

10194
05:49:59,721 --> 05:50:03,058
INTERACTION OF BOTH LIFESTYLE

10195
05:50:03,058 --> 05:50:05,794
AND OTHER OPPORTUNITIES, IT ALSO

10196
05:50:05,794 --> 05:50:08,430
GIVES US A CHANCE TO LOOK AT THE

10197
05:50:08,430 --> 05:50:10,799
DIVERSITY OF WOMEN WHICH WE'VE

10198
05:50:10,799 --> 05:50:11,766
HEARD IN SEVERAL PRESENTATIONS,

10199
05:50:11,766 --> 05:50:14,669
WE ARE NOT A HOMOGENEOUS GROUP,

10200
05:50:14,669 --> 05:50:18,840
AND THERE ARE MANY CONDITIONS

10201
05:50:18,840 --> 05:50:25,180
THAT WOMEN -- AND I THINK ALSO,

10202
05:50:25,180 --> 05:50:26,514
JUST THINK ABOUT THE QUALITY OF

10203
05:50:26,514 --> 05:50:29,117
LIFE, I DID LIKE THAT

10204
05:50:29,117 --> 05:50:30,518
DR. HIGGINBOTHAM SAID THAT, THE

10205
05:50:30,518 --> 05:50:33,755
RATIONALE FOR LEAVING

10206
05:50:33,755 --> 05:50:34,522
DEBILITATING BECAUSE THERE ARE

10207
05:50:34,522 --> 05:50:38,226
WOMEN WHO DO COPE OR LEARN TO

10208
05:50:38,226 --> 05:50:41,329
COPE, AND THEY ARE -- THEIR

10209
05:50:41,329 --> 05:50:44,366
QUALITY OF LIFE, THEIR WORKING

10210
05:50:44,366 --> 05:50:46,434
CONDITIONS ARE ALL IMPACTED BY

10211
05:50:46,434 --> 05:50:50,372
THESE DISEASES THAT I THINK IT'S

10212
05:50:50,372 --> 05:50:52,474
IMPORTANT TO LOOK AT THE LIVED

10213
05:50:52,474 --> 05:50:53,708
EXPERIENCE, AND SO WE NEED A

10214
05:50:53,708 --> 05:50:57,646
VARIETY OF RESEARCH DESIGNS,

10215
05:50:57,646 --> 05:50:58,580
BOTH QUALITATIVE AND

10216
05:50:58,580 --> 05:51:00,582
QUANTITATIVE, AND TRUE MIXED

10217
05:51:00,582 --> 05:51:02,784
METHODS RESEARCH, I THINK WILL

10218
05:51:02,784 --> 05:51:04,419
BE REALLY IMPORTANT.

10219
05:51:04,419 --> 05:51:08,023
AS WELL AS AS THINK THAT MY

10220
05:51:08,023 --> 05:51:09,357
COLLEAGUE DR. NOEL WAS GETTING

10221
05:51:09,357 --> 05:51:11,293
AT, IS THERE IS -- PERHAPS SOME

10222
05:51:11,293 --> 05:51:14,229
OF THE RESEARCH WILL CARVE OUT

10223
05:51:14,229 --> 05:51:16,364
LOOKING -- HOW DO WE BRING

10224
05:51:16,364 --> 05:51:17,899
CLINICIANS ALONG WITH WHAT WE

10225
05:51:17,899 --> 05:51:20,335
KNOW BOTH NURSING MEDICINE

10226
05:51:20,335 --> 05:51:22,937
PUBLIC HEALTH, SOCIAL SERVICES,

10227
05:51:22,937 --> 05:51:24,906
TO HELP WOMEN AT LEAST -- YOU

10228
05:51:24,906 --> 05:51:27,075
KNOW, WE KNOW A LOT NOW, WE'RE

10229
05:51:27,075 --> 05:51:29,711
GOING TO KNOW MORE WHEN THIS

10230
05:51:29,711 --> 05:51:32,247
CONCEPT IS PASSED, BUT BRINGING

10231
05:51:32,247 --> 05:51:34,316
PEOPLE ALONG, THERE'S AN

10232
05:51:34,316 --> 05:51:36,718
OPPORTUNITY FOR EDUCATION BOTH

10233
05:51:36,718 --> 05:51:38,320
OF CLINICIANS SO THAT WOMEN

10234
05:51:38,320 --> 05:51:39,888
DON'T COME IN TO CLINICAL

10235
05:51:39,888 --> 05:51:44,693
SETTINGS AND THEY GET IGNORED,

10236
05:51:44,693 --> 05:51:47,095
REAL LIFE DISEASES AND

10237
05:51:47,095 --> 05:51:47,395
CONDITIONS.

10238
05:51:47,395 --> 05:51:47,962
I'M GOING TO STOP TALKING.

10239
05:51:47,962 --> 05:51:49,331
>> THANK YOU VERY MUCH,

10240
05:51:49,331 --> 05:51:51,299
DR. SHARPS.

10241
05:51:51,299 --> 05:51:51,599
DR. MIELENZ.

10242
05:51:51,599 --> 05:51:52,634
>> SURE.

10243
05:51:52,634 --> 05:51:54,269
THELMA MIELENZ.

10244
05:51:54,269 --> 05:51:55,403
I'LL BE QUICK WITH JUST ONE

10245
05:51:55,403 --> 05:51:55,804
QUESTION HERE.

10246
05:51:55,804 --> 05:51:57,605
THANK YOU VERY MUCH, DR. TIM

10247
05:51:57,605 --> 05:51:59,007
KIN, FOR A GREAT PRESENTATION

10248
05:51:59,007 --> 05:52:00,475
OVERVIEW.

10249
05:52:00,475 --> 05:52:03,144
AND REALLY JUST HAD ONE

10250
05:52:03,144 --> 05:52:06,548
QUESTION, SO YOU HAD THE SLIDE

10251
05:52:06,548 --> 05:52:08,516
WITH THE CONCEPTUAL FRAMEWORKS

10252
05:52:08,516 --> 05:52:11,152
FROM THE NATIONAL ACADEMIES

10253
05:52:11,152 --> 05:52:13,555
REPORT, SORT OF THE THREE

10254
05:52:13,555 --> 05:52:15,824
BUCKETS THAT DR. HIGGINBOTHAM

10255
05:52:15,824 --> 05:52:18,159
ALSO DISCUSSED.

10256
05:52:18,159 --> 05:52:20,261
AND THE FIRST BUCKET IS THE

10257
05:52:20,261 --> 05:52:22,097
FEMALE-SPECIFIC AND GYNECOLOGIC

10258
05:52:22,097 --> 05:52:23,732
CONDITIONS, AND THEN WE HAVE THE

10259
05:52:23,732 --> 05:52:26,701
MIDDLE BUCKET, CHRONIC

10260
05:52:26,701 --> 05:52:28,770
CONDITIONS, PREDOMINANTLY IMPACT

10261
05:52:28,770 --> 05:52:30,238
OR AFFECT WOMEN DIFFERENTLY AND

10262
05:52:30,238 --> 05:52:31,306
OUR LAST BUCKET, ACCUMULATION OF

10263
05:52:31,306 --> 05:52:32,040
MULTIPLE CHRONIC CONDITIONS.

10264
05:52:32,040 --> 05:52:35,343
SO MY QUESTION IS THAT IF

10265
05:52:35,343 --> 05:52:39,280
SOMEONE -- YOU KNOW, SO IF YOU

10266
05:52:39,280 --> 05:52:41,583
THINK ABOUT SOMEONE WITH CHRONIC

10267
05:52:41,583 --> 05:52:42,784
LOW BACK PAIN WHEN YOU WERE

10268
05:52:42,784 --> 05:52:44,552
LOOKING AT THE RAINBOW CHART,

10269
05:52:44,552 --> 05:52:46,654
YOU KNOW, AND WE KNOW THAT

10270
05:52:46,654 --> 05:52:48,823
THERE'S ONLY $17 SPENT ON

10271
05:52:48,823 --> 05:52:53,094
CHRONIC LOW BACK PAIN, SO IF

10272
05:52:53,094 --> 05:52:55,397
SOMEONE -- IT WOULD -- SOMEONE

10273
05:52:55,397 --> 05:52:58,333
COULD HAVE A CONDITION THAT A

10274
05:52:58,333 --> 05:52:59,567
FEMALE-SPECIFIC CONDITION AND

10275
05:52:59,567 --> 05:53:01,069
LOW BACK PAIN, BUT IT WOULDN'T

10276
05:53:01,069 --> 05:53:03,505
BE RESPONSIVE IF IT WAS JUST

10277
05:53:03,505 --> 05:53:05,106
FOCUSED ON LOW BACK PAIN AND

10278
05:53:05,106 --> 05:53:07,008
THEN MAYBE SOMETHING IN THE

10279
05:53:07,008 --> 05:53:07,342
THIRD BUCKET.

10280
05:53:07,342 --> 05:53:08,710
SO THAT'S MY QUESTION.

10281
05:53:08,710 --> 05:53:10,945
>> THANKS SO MUCH FOR THAT

10282
05:53:10,945 --> 05:53:11,212
QUESTION.

10283
05:53:11,212 --> 05:53:14,482
SO I THINK ONE OF THE REASONS TO

10284
05:53:14,482 --> 05:53:15,884
FOCUS -- THERE'S TWO REAL

10285
05:53:15,884 --> 05:53:17,352
REASONS TO FOCUS ON

10286
05:53:17,352 --> 05:53:18,887
FEMALE-SPECIFIC AND GYNECOLOGIC

10287
05:53:18,887 --> 05:53:19,287
CONDITIONS.

10288
05:53:19,287 --> 05:53:20,522
ONE IS THAT THEY HAVE JUST BEEN

10289
05:53:20,522 --> 05:53:22,924
SO UNDERSTUDIED ACROSS THE

10290
05:53:22,924 --> 05:53:26,728
BOARD, BUT ALSO IN THE LAST YEAR

10291
05:53:26,728 --> 05:53:28,163
AND TWO YEARS, I CAN THINK THERE

10292
05:53:28,163 --> 05:53:33,101
ARE JUST SO MANY VALUABLE NEW

10293
05:53:33,101 --> 05:53:35,270
WAYS FOR PEOPLE TO BRING WOMEN'S

10294
05:53:35,270 --> 05:53:36,704
HEALTH RESEARCH INTO THE NIH.

10295
05:53:36,704 --> 05:53:38,039
DR. CLAYTON TALKED ABOUT THE NEW

10296
05:53:38,039 --> 05:53:39,541
FRONT DOOR, THE EXECUTIVE ORDER,

10297
05:53:39,541 --> 05:53:42,710
AND I THINK THIS IS ONE AREA

10298
05:53:42,710 --> 05:53:46,815
THAT EVEN WITH THOSE NEW FUNDING

10299
05:53:46,815 --> 05:53:47,882
OPPORTUNITIES, IT'S SOMETIMES

10300
05:53:47,882 --> 05:53:50,518
LEFT BEHIND, AND SO THAT WAS

10301
05:53:50,518 --> 05:53:53,488
REALLY THE THINKING TO BE ABLE

10302
05:53:53,488 --> 05:53:56,491
TO STIMULATE THIS SPECIFIC

10303
05:53:56,491 --> 05:53:59,627
RESEARCH AGENDA.

10304
05:53:59,627 --> 05:54:00,728
>> GREAT.

10305
05:54:00,728 --> 05:54:05,867
THANK YOU, DR. MIELENZ AND

10306
05:54:05,867 --> 05:54:06,501
DR. SHARPS FOR YOUR INSIGHTFUL

10307
05:54:06,501 --> 05:54:07,302
COMMENTS AND QUESTIONS.

10308
05:54:07,302 --> 05:54:08,937
WE'D NOW LIKE TO OPEN UP THE

10309
05:54:08,937 --> 05:54:10,772
FLOOR FOR THE REST OF THE

10310
05:54:10,772 --> 05:54:11,306
COMMITTEE FOR QUESTIONS OR

10311
05:54:11,306 --> 05:54:13,007
COMMENTS.

10312
05:54:13,007 --> 05:54:16,177
>> I JUST HAD A QUICK
QUESTION.

10313
05:54:16,177 --> 05:54:20,415
SO WHEN YOU SAY FEMALE-SPECIFIC

10314
05:54:20,415 --> 05:54:21,316
CONDITIONS, GYNECOLOGIC

10315
05:54:21,316 --> 05:54:22,851
CONDITIONS, DOES THAT INCLUDE

10316
05:54:22,851 --> 05:54:24,819
PREGNANCY-RELATED CONDITIONS AS

10317
05:54:24,819 --> 05:54:25,153
WELL OR NOT?

10318
05:54:25,153 --> 05:54:27,555
>> SO THIS WAS NOT REALLY

10319
05:54:27,555 --> 05:54:29,190
DESIGNED TO BE INCLUSIVE OF

10320
05:54:29,190 --> 05:54:31,659
PREGNANCY CONDITIONS.

10321
05:54:31,659 --> 05:54:32,760
AGAIN, BECAUSE THERE ARE THESE

10322
05:54:32,760 --> 05:54:35,363
NEW OPPORTUNITY FOR PEOPLE TO

10323
05:54:35,363 --> 05:54:36,898
SUBMIT PREGNANCY-RELATED

10324
05:54:36,898 --> 05:54:38,867
RESEARCH.

10325
05:54:38,867 --> 05:54:40,502
IN THE INITIAL DEFINING OF

10326
05:54:40,502 --> 05:54:43,705
CHRONIC CONDITIONS FROM HHS,

10327
05:54:43,705 --> 05:54:46,274
FROM OUR ACTIVITY, FROM THE

10328
05:54:46,274 --> 05:54:49,043
NATIONAL ACADEMIES' ACTIVITY ARE

10329
05:54:49,043 --> 05:54:51,579
ALL CONDITIONS THAT LAST FOR

10330
05:54:51,579 --> 05:54:53,114
OVER ONE YEAR, AFFECT ACTIVITIES

10331
05:54:53,114 --> 05:54:56,184
OF DAILY LIVING AND THEN I LIKE

10332
05:54:56,184 --> 05:54:57,519
WHAT THE NATIONAL ACADEMIES HAD

10333
05:54:57,519 --> 05:54:59,787
ADDED AT THE END THERE TOO, BUT

10334
05:54:59,787 --> 05:55:01,656
I'M NOT GOING TO BE ABLE TO DO

10335
05:55:01,656 --> 05:55:03,525
IT OFF THE TOP OF MY HEAD,

10336
05:55:03,525 --> 05:55:06,060
BUT -- SO I THINK TO ME, AT

10337
05:55:06,060 --> 05:55:09,464
LEAST, PREGNANCY DOESN'T FALL

10338
05:55:09,464 --> 05:55:09,931
INTO THAT DEFINITION.

10339
05:55:09,931 --> 05:55:11,332
>> I THINK FOR ME, JUST
THE

10340
05:55:11,332 --> 05:55:17,572
CONCERN WAS IS THAT CLEAR OR NOT

10341
05:55:17,572 --> 05:55:19,240
IN THE --

10342
05:55:19,240 --> 05:55:21,142
>> I WILL SAY THERE IS AT
LEAST

10343
05:55:21,142 --> 05:55:22,176
ONE AWARD THAT WE MADE THAT'S

10344
05:55:22,176 --> 05:55:23,945
AROUND HOW PREGNANCY CHANGES THE

10345
05:55:23,945 --> 05:55:26,147
LIFECOURSE FOR CARDIOVASCULAR

10346
05:55:26,147 --> 05:55:30,952
DISEASE, AND SO THAT IS --

10347
05:55:30,952 --> 05:55:31,753
CARDIOVASCULAR DISEASE, TO ME

10348
05:55:31,753 --> 05:55:35,657
THERE IS THE CHRONIC CONDITION

10349
05:55:35,657 --> 05:55:41,162
AND PREGNANCY IS THE

10350
05:55:41,162 --> 05:55:41,829
FEMALE-SPECIFIC VARIABLE THAT'S

10351
05:55:41,829 --> 05:55:43,464
CHANGING THAT OUT COME.

10352
05:55:43,464 --> 05:55:45,767
SO THERE IS -- IT'S NOT LIKE WE

10353
05:55:45,767 --> 05:55:49,971
WOULD NOT BE OPEN TO HAVING

10354
05:55:49,971 --> 05:55:52,674
INCLUSION OF PREGNANCY IN ANY

10355
05:55:52,674 --> 05:55:53,575
GREAT APPLICATION, BUT I THINK

10356
05:55:53,575 --> 05:55:55,543
WE WERE REALLY LOOKING AT THINGS

10357
05:55:55,543 --> 05:55:58,079
THAT AFFECT WOMEN'S LIVES ON A

10358
05:55:58,079 --> 05:55:59,747
LONGER TERM.

10359
05:55:59,747 --> 05:56:01,449
>> YES.

10360
05:56:01,449 --> 05:56:03,451
>> THANK YOU.

10361
05:56:03,451 --> 05:56:08,256
I JUST HAVE SOME CLARIFICATION.

10362
05:56:08,256 --> 05:56:11,225
FROM MY EXPERIENCE OF STUDYING

10363
05:56:11,225 --> 05:56:14,829
THESE ISSUES IS THAT SOME OF

10364
05:56:14,829 --> 05:56:16,698
THESE CHRONIC CONDITIONS DON'T

10365
05:56:16,698 --> 05:56:19,767
EXIST BY THEMSELVES, THERE'S

10366
05:56:19,767 --> 05:56:20,635
COOCCURRENCE OF CHRONIC

10367
05:56:20,635 --> 05:56:22,270
CONDITION.

10368
05:56:22,270 --> 05:56:25,239
AND SOMETIMES ONCE YOU HAVE ONE,

10369
05:56:25,239 --> 05:56:26,040
OVER TIME, YOU DEVELOP THE NEXT

10370
05:56:26,040 --> 05:56:28,109
AND YOU DEVELOP THE NEXT.

10371
05:56:28,109 --> 05:56:33,481
AND CAN YOU CLARIFY HOW THIS

10372
05:56:33,481 --> 05:56:37,318
CONCEPT WILL ADDRESS THE

10373
05:56:37,318 --> 05:56:40,488
OCCURRENCE OF MULTIPLE CHRONIC

10374
05:56:40,488 --> 05:56:45,627
CONDITIONS, GIVEN THE WAY NIH

10375
05:56:45,627 --> 05:56:46,728
SUPPORTS OR FUNDS DIFFERENT

10376
05:56:46,728 --> 05:56:48,563
CONDITIONS?

10377
05:56:48,563 --> 05:56:51,666
HOW DOES THIS CONCEPT REALLY

10378
05:56:51,666 --> 05:56:52,967
TAKE INTO CONSIDERATION THIS

10379
05:56:52,967 --> 05:56:55,837
PHENOMENON OF CO-OCCURRENCE OF

10380
05:56:55,837 --> 05:56:56,137
CONDITIONS?

10381
05:56:56,137 --> 05:56:58,039
>> SO I MEAN, WE DON'T
OBVIOUSLY

10382
05:56:58,039 --> 05:57:00,241
HAVE THE LANGUAGE EXACTLY YET,

10383
05:57:00,241 --> 05:57:03,411
BUT I WAS HOPEFUL TO BE

10384
05:57:03,411 --> 05:57:05,513
INCLUSIVE OF HAVING -- OF

10385
05:57:05,513 --> 05:57:11,519
INVITING APPLICATIONS THAT

10386
05:57:11,519 --> 05:57:12,153
ARE -- INTERAK WITH OTHER

10387
05:57:12,153 --> 05:57:14,288
CONDITIONS AS WELL, AND THAT

10388
05:57:14,288 --> 05:57:16,691
REALLY BROADENS I THINK HOW THIS

10389
05:57:16,691 --> 05:57:19,427
MAY FIT INTO DIFFERENT IC

10390
05:57:19,427 --> 05:57:19,727
PRIORITIES.

10391
05:57:19,727 --> 05:57:21,195
WHICH IS I THINK ONE OF THE

10392
05:57:21,195 --> 05:57:23,064
GOALS OF THIS.

10393
05:57:23,064 --> 05:57:26,534
FOR EXAMPLE, ENDOMETRIOSIS AND

10394
05:57:26,534 --> 05:57:29,570
AUTOIMMUNE DISEASE OFTEN

10395
05:57:29,570 --> 05:57:34,108
CO-OCCUR IN PATIENTS, AND SO

10396
05:57:34,108 --> 05:57:35,410
UNDERSTANDING HOW ENDOMETRIOSIS

10397
05:57:35,410 --> 05:57:37,412
AND AUTOIMMUNE DISEASES INTERACT

10398
05:57:37,412 --> 05:57:40,148
MAY BE OF INTEREST TO MULTIPLE

10399
05:57:40,148 --> 05:57:42,116
ICs, I THINK, AND I HOPE THAT

10400
05:57:42,116 --> 05:57:44,986
ANSWERS YOUR QUESTION.

10401
05:57:44,986 --> 05:57:46,788
>> YES.

10402
05:57:46,788 --> 05:57:48,289
>> JUST A QUICK QUESTION.

10403
05:57:48,289 --> 05:57:50,625
I REALLY APPRECIATE THIS

10404
05:57:50,625 --> 05:57:51,092
CONCEPT.

10405
05:57:51,092 --> 05:57:52,627
IS BEING IN THE CLINICAL

10406
05:57:52,627 --> 05:57:55,663
RESEARCH SECTOR, WILL THIS ALSO

10407
05:57:55,663 --> 05:57:56,764
SPAN THROUGH BASIC RESEARCH AS

10408
05:57:56,764 --> 05:57:57,765
WELL?

10409
05:57:57,765 --> 05:57:58,766
THIS OPPORTUNITY?

10410
05:57:58,766 --> 05:58:01,502
>> I CERTAINLY HOPE SO.

10411
05:58:01,502 --> 05:58:03,838
I DON'T THINK WE WOULD -- WE

10412
05:58:03,838 --> 05:58:04,572
WERE PLANNING TO PUT

10413
05:58:04,572 --> 05:58:07,308
RESTRICTIONS ON THAT.

10414
05:58:07,308 --> 05:58:08,276
>> OKAY.

10415
05:58:08,276 --> 05:58:17,585
DO WE HAVE ANY QUESTIONS ONLINE?

10416
05:58:17,585 --> 05:58:20,221
OKAY, THANK YOU, EVERYBODY.

10417
05:58:20,221 --> 05:58:21,856
I DIDN'T MISS ANYTHING, RIGHT?

10418
05:58:21,856 --> 05:58:22,090
OKAY.

10419
05:58:22,090 --> 05:58:24,659
THANK YOU, EVERYONE.

10420
05:58:24,659 --> 05:58:26,461
SO AT THIS TIME, WE'LL VOTE TO

10421
05:58:26,461 --> 05:58:26,894
APPROVE THE FUNDING

10422
05:58:26,894 --> 05:58:28,329
OPPORTUNITIES FOR RESEARCH ON

10423
05:58:28,329 --> 05:58:31,199
CHRONIC FEMALE-SPECIFIC AND

10424
05:58:31,199 --> 05:58:33,501
GYNECOLOGIC CONDITIONS ON THE

10425
05:58:33,501 --> 05:58:34,602
CONCEPT CLEARANCE.

10426
05:58:34,602 --> 05:58:37,238
PLEASE NOTE THAT ONLY FULL

10427
05:58:37,238 --> 05:58:38,940
MEMBERS OF THE ADVISORY

10428
05:58:38,940 --> 05:58:39,574
COMMITTEE MAY VOTE, AND IF

10429
05:58:39,574 --> 05:58:41,409
YOU'RE AN AD HOC MEMBER OR

10430
05:58:41,409 --> 05:58:45,213
OTHERWISE NOT A MEMBER OF ACRWH,

10431
05:58:45,213 --> 05:58:47,281
PLEASE REFRAIN FROM VOTING.

10432
05:58:47,281 --> 05:58:48,850
SO IS THERE A MOTION ON THE

10433
05:58:48,850 --> 05:58:50,318
TABLE TO APPROVE THE FUNDING

10434
05:58:50,318 --> 05:58:52,019
OPPORTUNITY TO SUPPORT RESEARCH

10435
05:58:52,019 --> 05:58:58,359
ON CHRONIC FEMALE-SPECIFIC AND

10436
05:58:58,359 --> 05:58:59,694
GYNECOLOGIC --

10437
05:58:59,694 --> 05:59:00,561
>> I WOULD MAKE A MOTION.

10438
05:59:00,561 --> 05:59:02,330
>> THANK YOU VERY MUCH.

10439
05:59:02,330 --> 05:59:02,830
AND DO WE HAVE A SECOND?

10440
05:59:02,830 --> 05:59:04,232
>> I SECOND THE EMOTION.

10441
05:59:04,232 --> 05:59:14,709
>> DR. OYEN HAS THE
SECOND.

10442
05:59:17,178 --> 05:59:18,179
ALL THOSE IN FAVOR, KEEP YOUR

10443
05:59:18,179 --> 05:59:20,281
HANDS UP SO THEY CAN BE CLEARLY

10444
05:59:20,281 --> 05:59:21,482
VOTED.

10445
05:59:21,482 --> 05:59:24,385
THANK YOU, DR. TEMPLETON.

10446
05:59:24,385 --> 05:59:26,320
OKAY.

10447
05:59:26,320 --> 05:59:30,458
AND THOSE -- DR. JAGSI, THANK

10448
05:59:30,458 --> 05:59:31,025
YOU VERY MUCH.

10449
05:59:31,025 --> 05:59:37,598
THOSE OF YOU -- ALL OF THOSE

10450
05:59:37,598 --> 05:59:38,199
OPPOSED TO THE MOTION, PLEASE

10451
05:59:38,199 --> 05:59:43,971
RAISE YOUR HAND NOW.

10452
05:59:43,971 --> 05:59:48,609
AND ALL THOSE AB STAIPING FROM M

10453
05:59:48,609 --> 05:59:49,577
THE MOTION, PLEASE RAISE YOUR

10454
05:59:49,577 --> 05:59:50,978
HANDS.

10455
05:59:50,978 --> 06:00:01,489
HAVE THE VOTES BEEN RECORDED?

10456
06:00:04,292 --> 06:00:05,593
IF YOU COULD RAISE YOUR HANDS

10457
06:00:05,593 --> 06:00:07,495
ONE MORE TIME FOR THOSE WHO ARE

10458
06:00:07,495 --> 06:00:10,698
IN FAVOR OF APPROVING THE

10459
06:00:10,698 --> 06:00:12,900
CONCEPT CLEARANCE.

10460
06:00:12,900 --> 06:00:14,969
AND I BELIEVE WE HAD TWO WHO

10461
06:00:14,969 --> 06:00:23,077
WERE VIRTUAL AS WELL.

10462
06:00:23,077 --> 06:00:23,277
GREAT.

10463
06:00:23,277 --> 06:00:27,148
THANK YOU VERY MUCH, AND THE

10464
06:00:27,148 --> 06:00:27,682
CONCEPT CLEARANCE HAS BEEN

10465
06:00:27,682 --> 06:00:28,249
ACCEPTED WITH 11 IN FAVOR.

10466
06:00:28,249 --> 06:00:33,487
THANK YOU VERY MUCH.

10467
06:00:33,487 --> 06:00:35,323
OKAY, LET'S MOVE ON TO OUR NEXT

10468
06:00:35,323 --> 06:00:36,624
CONCEPT CLEARANCE.

10469
06:00:36,624 --> 06:00:46,534
I WOULD LIKE NOW TO WELCOME OUR

10470
06:00:46,534 --> 06:00:53,307
NEXT SPEAKER.

10471
06:00:53,307 --> 06:00:55,276
>> GOOD AFTERNOON,
EVERYONE.

10472
06:00:55,276 --> 06:00:58,112
I WOULD LIKE TO HAPPILY

10473
06:00:58,112 --> 06:01:00,448
INTRODUCE TO YOU DR. CAROLYN BON

10474
06:01:00,448 --> 06:01:00,882
DAR.

10475
06:01:00,882 --> 06:01:02,416
IT'S MY HONOR TO PRESENT TO YOU

10476
06:01:02,416 --> 06:01:04,652
A NEW PROGRAM OFFICER OF THE

10477
06:01:04,652 --> 06:01:06,587
CAREER SECTION WHO JOINED US

10478
06:01:06,587 --> 06:01:09,557
EARLIER THIS YEAR AND LEADS THE

10479
06:01:09,557 --> 06:01:10,391
CONTINUITY AND RETENTION

10480
06:01:10,391 --> 06:01:11,726
SUPPLEMENT AS WELL AS THE

10481
06:01:11,726 --> 06:01:16,030
RE-ENTRY SUPPLEMENTS FOR OUR

10482
06:01:16,030 --> 06:01:16,264
SECTION.

10483
06:01:16,264 --> 06:01:18,232
IN ADDITION TO SERVING AS

10484
06:01:18,232 --> 06:01:19,433
EXECUTIVE SECRETARY FOR THE NIH

10485
06:01:19,433 --> 06:01:21,269
WORKING GROUP ON WOMEN IN

10486
06:01:21,269 --> 06:01:22,737
BIOMEDICAL CAREERS.

10487
06:01:22,737 --> 06:01:24,038
DR. BONDAR IS A NEUROSCIENTIST

10488
06:01:24,038 --> 06:01:33,881
BY TRAINING, AND AFTERWARDS HER

10489
06:01:33,881 --> 06:01:38,486
POSTDOC TRAINING AT THE DUNCAN

10490
06:01:38,486 --> 06:01:39,453
NEUROLOGICAL RESEARCH INSTITUTE

10491
06:01:39,453 --> 06:01:40,922
AT THE TEXAS CHILDREN'S

10492
06:01:40,922 --> 06:01:42,456
HOSPITAL.

10493
06:01:42,456 --> 06:01:45,426
SHE JOINS US FROM THE NATIONAL

10494
06:01:45,426 --> 06:01:46,694
INSTITUTE OF NEUROLOGICAL

10495
06:01:46,694 --> 06:01:48,229
DISORDERS AND STROKE, WHERE SHE

10496
06:01:48,229 --> 06:01:51,232
USED TO WORK, AND SHE IS GOING

10497
06:01:51,232 --> 06:01:52,967
TO PRESENT A CONCEPT WHICH WE

10498
06:01:52,967 --> 06:01:55,469
HOPE WILL BENEFIT AND STRENGTHEN

10499
06:01:55,469 --> 06:01:57,738
THE FEMALE BIOMEDICAL WORKFORCE,

10500
06:01:57,738 --> 06:01:58,839
WHICH HAS BEEN MENTIONED SEVERAL

10501
06:01:58,839 --> 06:02:00,474
TIMES TODAY.

10502
06:02:00,474 --> 06:02:02,877
SO PLEASE WELCOME DR. CAROLYN

10503
06:02:02,877 --> 06:02:11,619
BONDAR.

10504
06:02:11,619 --> 06:02:15,489
>> THANK YOU SO MUCH FOR
ALL

10505
06:02:15,489 --> 06:02:19,527
YOUR SUPPORT LEADING UP TO

10506
06:02:19,527 --> 06:02:26,334
TODAY, AND ORWH LEADERSHIP AS

10507
06:02:26,334 --> 06:02:26,867
WELL.

10508
06:02:26,867 --> 06:02:29,704
SO THIS IS A NEW TITLE, NIH

10509
06:02:29,704 --> 06:02:32,206
EXCEPTIONAL RESEARCH SCIENTIST

10510
06:02:32,206 --> 06:02:32,406
AWARD.

10511
06:02:32,406 --> 06:02:33,040
THE OBJECTIVE IS TO ENCOURAGE

10512
06:02:33,040 --> 06:02:35,776
DEVELOPMENT OF STABLE RESEARCH

10513
06:02:35,776 --> 06:02:37,178
CAREER OPPORTUNITIES FOR

10514
06:02:37,178 --> 06:02:39,180
EXCEPTIONAL NON-TENURED

10515
06:02:39,180 --> 06:02:41,048
SCIENTISTS POSITIONED TO MAKE

10516
06:02:41,048 --> 06:02:44,085
OUTSTANDING CONTRIBUTIONS TO NIH

10517
06:02:44,085 --> 06:02:45,853
FUNDED RESEARCH PROGRAMS.

10518
06:02:45,853 --> 06:02:48,289
THE NUMBER OF AWARDS IS

10519
06:02:48,289 --> 06:02:49,724
CONTINGENT UPON NIH

10520
06:02:49,724 --> 06:02:51,025
APPROPRIATIONS.

10521
06:02:51,025 --> 06:02:52,893
WE ENVISION A FIVE-YEAR PROJECT

10522
06:02:52,893 --> 06:02:55,096
PERIOD AT MOST AND WE'RE LOOKING

10523
06:02:55,096 --> 06:02:56,297
FOR VOTE FOR APPROVAL OF THIS

10524
06:02:56,297 --> 06:02:59,033
CONCEPT.

10525
06:02:59,033 --> 06:03:01,002
SO EFFECTIVELY ADDRESSING AM

10526
06:03:01,002 --> 06:03:07,008
ADDRESSINGAMBITIOUS RESEARCH QUS

10527
06:03:07,008 --> 06:03:10,945
BECOME INCREASINGLY DEPENDENT ON

10528
06:03:10,945 --> 06:03:12,580
COLLABORATIVE APPROACHES THAT

10529
06:03:12,580 --> 06:03:13,381
LEVERAGE EXPERTISE AND

10530
06:03:13,381 --> 06:03:14,348
INNOVATION FROM MULTIPLE

10531
06:03:14,348 --> 06:03:15,349
DISCIPLINES AND TECHNOLOGIES,

10532
06:03:15,349 --> 06:03:17,351
AND I THINK IT'S SAFE TO SAY WE

10533
06:03:17,351 --> 06:03:18,886
SAW A LOT OF THAT DEMONSTRATED

10534
06:03:18,886 --> 06:03:22,490
TODAY.

10535
06:03:22,490 --> 06:03:23,924
TEAM SCIENCE IS GREAT.

10536
06:03:23,924 --> 06:03:26,227
IT HAS SEVERAL WELL DOCUMENTED

10537
06:03:26,227 --> 06:03:29,630
BENEFITS, INCLUDING INCREASED

10538
06:03:29,630 --> 06:03:31,832
IMPACT AND INNOVATION, OFTEN

10539
06:03:31,832 --> 06:03:34,402
EXTENDING APPLICABILITY TO

10540
06:03:34,402 --> 06:03:36,003
DIFFERENT FIELDS AND

10541
06:03:36,003 --> 06:03:37,304
DISCIPLINES.

10542
06:03:37,304 --> 06:03:38,839
INCREASED PRODUCTIVITY.

10543
06:03:38,839 --> 06:03:40,708
MORE PUBLICATIONS AND FASTER

10544
06:03:40,708 --> 06:03:43,144
PROGRESS.

10545
06:03:43,144 --> 06:03:45,746
IMPROVED PROBLEM SOLVING.

10546
06:03:45,746 --> 06:03:46,647
THE COLLECTIVE KNOWLEDGE AND

10547
06:03:46,647 --> 06:03:49,483
SKILLS OF A TEAM ENABLES THEM TO

10548
06:03:49,483 --> 06:03:52,987
TACKLE PROBLEMS THAT MATE BE TOO

10549
06:03:52,987 --> 06:03:54,955
CHALLENGING FOR YOU INDIVIDUAL

10550
06:03:54,955 --> 06:03:58,459
RESEARCHERS, BUT THE REALITY OF

10551
06:03:58,459 --> 06:04:00,227
TEAM SCIENCE IS THAT NOT

10552
06:04:00,227 --> 06:04:02,763
EVERYONE GET TO BE THE P.I.

10553
06:04:02,763 --> 06:04:05,066
AND INCREASING RELIANCE ON TEAM

10554
06:04:05,066 --> 06:04:07,802
SCIENCE, CORES AND OTHER

10555
06:04:07,802 --> 06:04:09,737
SCIENTIFIC SUPPORT FACILITIES

10556
06:04:09,737 --> 06:04:12,173
HAS BEEN ACCOMPANIED BY AN

10557
06:04:12,173 --> 06:04:14,909
UPTICK IN NON-TENURED RESEARCH

10558
06:04:14,909 --> 06:04:17,645
SCIENTIST POSITIONS.

10559
06:04:17,645 --> 06:04:19,647
DEMONSTRATING A GROWING NEED FOR

10560
06:04:19,647 --> 06:04:22,349
RESEARCH SCIENTISTS WITH

10561
06:04:22,349 --> 06:04:23,684
EXTENSIVE RESEARCH EXPERIENCE

10562
06:04:23,684 --> 06:04:26,654
THAT CAN PROVIDE CONTINUITY,

10563
06:04:26,654 --> 06:04:29,390
STABILITY, AND DETAILED

10564
06:04:29,390 --> 06:04:30,291
SCIENTIFIC KNOWLEDGE BEYOND THAT

10565
06:04:30,291 --> 06:04:33,828
OF A TRAINEE OR A TECHNICIAN.

10566
06:04:33,828 --> 06:04:36,230
SUPPORT FOR NON-TENURED,

10567
06:04:36,230 --> 06:04:38,199
NON-TRADITIONAL PI ROLES IS

10568
06:04:38,199 --> 06:04:41,102
NEEDED TO BOTH ATTRACT AND

10569
06:04:41,102 --> 06:04:44,905
RETAIN EXCEPTIONAL RESEARCH

10570
06:04:44,905 --> 06:04:46,207
SCIENTISTS WHO ARE AN

10571
06:04:46,207 --> 06:04:47,308
INCREASINGLY VITAL PART OF THE

10572
06:04:47,308 --> 06:04:53,881
NIH RESEARCH ENTERPRISE.

10573
06:04:53,881 --> 06:04:56,717
THIS CONCEPT AIMS TO FOSTER

10574
06:04:56,717 --> 06:04:57,251
WOMEN'S SCIENTIFIC CAREER

10575
06:04:57,251 --> 06:04:59,887
DEVELOPMENT AND IS ALIGNED WITH

10576
06:04:59,887 --> 06:05:03,557
GOAL 3 OF THE NIH STRATEGIC PLAN

10577
06:05:03,557 --> 06:05:06,727
FOCUS ON TRAINING AND EDUCATION.

10578
06:05:06,727 --> 06:05:08,696
OUR HOPE IS THAT THIS PROGRAM

10579
06:05:08,696 --> 06:05:10,898
WILL HELP RECRUIT, SUPPORT,

10580
06:05:10,898 --> 06:05:12,633
RETAIN, AND ADVANCE WOMEN

10581
06:05:12,633 --> 06:05:15,669
RESEARCH SCIENTISTS FROM EARLY

10582
06:05:15,669 --> 06:05:17,271
CAREERS ON, AND THAT INCLUDES

10583
06:05:17,271 --> 06:05:21,075
MID CAREER SCIENTISTS.

10584
06:05:21,075 --> 06:05:23,277
BECAUSE WOMEN AND GROUPS

10585
06:05:23,277 --> 06:05:24,912
UNDERREPRESENTED IN THE U.S.

10586
06:05:24,912 --> 06:05:27,248
SCIENTIFIC RESEARCH ENTERPRISE

10587
06:05:27,248 --> 06:05:30,518
ARE OFTEN OVERREPRESENTED IN

10588
06:05:30,518 --> 06:05:32,720
NON-TENURE RESEARCH POSITIONS

10589
06:05:32,720 --> 06:05:35,089
SUPPORTING THIS CAREER PATH IS

10590
06:05:35,089 --> 06:05:37,091
INTEGRAL TO THE NIH STRATEGIC

10591
06:05:37,091 --> 06:05:40,494
GOAL OF SUPPORTING A DIVERSE

10592
06:05:40,494 --> 06:05:41,795
SCIENTIFIC WORKFORCE, AS WELL AS

10593
06:05:41,795 --> 06:05:44,031
THE NIH STRATEGIC PLAN FOR

10594
06:05:44,031 --> 06:05:47,401
RESEARCH ON THE HEALTH OF WOMEN.

10595
06:05:47,401 --> 06:05:50,171
IT IS ALSO ALIGNED WITH THE NIH

10596
06:05:50,171 --> 06:05:51,438
ADVISORY COMMITTEE TO THE

10597
06:05:51,438 --> 06:05:54,241
DIRECTOR WORKING GROUP ON

10598
06:05:54,241 --> 06:05:56,110
REENVISIONING NIH SUPPORTED

10599
06:05:56,110 --> 06:05:58,379
POSTDOCTORAL TRAINING.

10600
06:05:58,379 --> 06:06:00,381
IT'S ALIGNED WITH RECOMMENDATION

10601
06:06:00,381 --> 06:06:02,349
3.1 IN THIS RECENT RAPPORT WHICH

10602
06:06:02,349 --> 06:06:04,952
CALLED FOR NIH-WIDE SUPPORT FOR

10603
06:06:04,952 --> 06:06:07,188
A RESEARCH PROFESSIONAL CAREER

10604
06:06:07,188 --> 06:06:07,821
TRACK.

10605
06:06:07,821 --> 06:06:09,490
THIS REPORT ARGUED THAT

10606
06:06:09,490 --> 06:06:12,226
FOSTERING A ROBUST RESEARCH

10607
06:06:12,226 --> 06:06:14,295
PROFESSIONAL CAREER TRACK WOULD

10608
06:06:14,295 --> 06:06:16,497
IMPROVE THE SUSTAINABILITY AND

10609
06:06:16,497 --> 06:06:19,366
HEALTH OF THE BIOMEDICAL SYSTEM

10610
06:06:19,366 --> 06:06:24,205
BY EXPANDING THE ACADEMIC JOB

10611
06:06:24,205 --> 06:06:26,173
POOL, RETAINING TALENTED

10612
06:06:26,173 --> 06:06:28,475
SCIENTIST IN ACADEMIC RESEARCH,

10613
06:06:28,475 --> 06:06:30,110
MAINTAINING INSTITUTIONAL

10614
06:06:30,110 --> 06:06:32,112
KNOWLEDGE LONG TERM, AND IT

10615
06:06:32,112 --> 06:06:33,981
REDUCES BURDENS ON PIs BECAUSE

10616
06:06:33,981 --> 06:06:37,918
WE KNOW THESE ROLES ALSO PROVIDE

10617
06:06:37,918 --> 06:06:39,253
MENTORSHIP AND TRAINING.

10618
06:06:39,253 --> 06:06:41,989
AND IT ALSO HELPS WITH BUILDING

10619
06:06:41,989 --> 06:06:44,058
RESEARCH ENTERPRISES AND

10620
06:06:44,058 --> 06:06:44,725
CAPACITY.

10621
06:06:44,725 --> 06:06:48,896
BUT THIS REPORT ALSO POINTED OUT

10622
06:06:48,896 --> 06:06:49,697
THAT THESE POSITIONS DO NOT

10623
06:06:49,697 --> 06:06:54,702
CURRENTLY PROVIDE INDIVIDUALS

10624
06:06:54,702 --> 06:06:56,036
WITH EITHER THE RECOGNITION NOR

10625
06:06:56,036 --> 06:06:58,505
INDEPENDENT FUNDING NEEDED TO

10626
06:06:58,505 --> 06:06:59,073
ATTRACT AND RETAIN THE BEST

10627
06:06:59,073 --> 06:07:02,109
SCIENTISTS.

10628
06:07:02,109 --> 06:07:03,944
THE PURPOSE OF THIS CONCEPT IS

10629
06:07:03,944 --> 06:07:07,381
TO IMPROVE SUSTAINABILITY AND

10630
06:07:07,381 --> 06:07:10,317
HELP OF THE BIOMEDICAL SYSTEM BY

10631
06:07:10,317 --> 06:07:12,286
SUPPORTING EXCEPTIONAL

10632
06:07:12,286 --> 06:07:14,955
NON-TENURED, NON-TRADITIONAL

10633
06:07:14,955 --> 06:07:16,924
P.I. RESEARCH SCIENTISTS SUCH AS

10634
06:07:16,924 --> 06:07:18,993
LABORATORY SCIENTISTS, CORE

10635
06:07:18,993 --> 06:07:21,895
SCIENTISTS, AND/OR

10636
06:07:21,895 --> 06:07:22,563
CLINICIAN-SCIENTISTS.

10637
06:07:22,563 --> 06:07:25,165
THIS SUPPORT IS INTENDED TO

10638
06:07:25,165 --> 06:07:27,368
ATTRACT AND RETAIN EXCEPTIONAL

10639
06:07:27,368 --> 06:07:29,370
RESEARCH SCIENTISTS BY ENHANCING

10640
06:07:29,370 --> 06:07:33,307
THEIR PROFESSIONAL STANDING AND

10641
06:07:33,307 --> 06:07:34,408
RECOGNITION.

10642
06:07:34,408 --> 06:07:35,809
IMPORTANTLY, THIS WILL PROVIDE

10643
06:07:35,809 --> 06:07:39,013
INDIVIDUALS WITH SUFFICIENT

10644
06:07:39,013 --> 06:07:40,648
AUTONOMY SO THEY ARE NOT SOLELY

10645
06:07:40,648 --> 06:07:43,384
DEPENDENT ON FUNDING BY OTHERS

10646
06:07:43,384 --> 06:07:44,918
FOR THEIR CAREER CONTINUITY.

10647
06:07:44,918 --> 06:07:46,987
AND BY PROVIDING SALARY AND

10648
06:07:46,987 --> 06:07:49,256
TRAVEL SUPPORT, THE INDIVIDUAL

10649
06:07:49,256 --> 06:07:53,060
WILL HAVE PROTECTED TIME TO MAKE

10650
06:07:53,060 --> 06:07:55,329
A TRANSFORMATIVE IMPACT IN

10651
06:07:55,329 --> 06:07:56,830
ADVANCING NIH FUNDED RESEARCH

10652
06:07:56,830 --> 06:08:00,668
PROGRAMS.

10653
06:08:00,668 --> 06:08:02,503
THIS APPLICATION WILL NOT

10654
06:08:02,503 --> 06:08:06,707
PROPOSE NEW RESEARCH, BUT WILL

10655
06:08:06,707 --> 06:08:07,241
INSTEAD DESCRIBE RESEARCH

10656
06:08:07,241 --> 06:08:10,277
PROGRAMS THAT THE APPLICANT

10657
06:08:10,277 --> 06:08:12,713
SUPPORT OR IS LIKELY TO SUPPORT

10658
06:08:12,713 --> 06:08:13,280
IN THE FUTURE AND HOW THEIR

10659
06:08:13,280 --> 06:08:15,249
PARTICIPATION WILL ENSURE

10660
06:08:15,249 --> 06:08:18,419
SUCCESS OF THE PROJECT.

10661
06:08:18,419 --> 06:08:20,154
APPLICANTS MUST DEMONSTRATE

10662
06:08:20,154 --> 06:08:23,257
RELEVANT SCIENTIFIC SKILLS,

10663
06:08:23,257 --> 06:08:24,992
EXPERTISE AND SUCCESS AS

10664
06:08:24,992 --> 06:08:27,194
MEASURED AND DOCUMENTED BY

10665
06:08:27,194 --> 06:08:30,164
RELEVANT PUBLICATIONS,

10666
06:08:30,164 --> 06:08:30,698
CONFERENCE PROCEEDINGS AND

10667
06:08:30,698 --> 06:08:32,833
AWARDS.

10668
06:08:32,833 --> 06:08:34,468
THE APPLICANT MUST BE A FULL

10669
06:08:34,468 --> 06:08:36,103
TIME NON-TENURED RESEARCH

10670
06:08:36,103 --> 06:08:40,307
SCIENTIST THAT IS NOT A

10671
06:08:40,307 --> 06:08:41,709
TRADITIONAL P.I., AND THE

10672
06:08:41,709 --> 06:08:42,609
APPLICATION SHOULD INCLUDE A

10673
06:08:42,609 --> 06:08:46,280
CAREER DEVELOPMENT PLAN WITH AN

10674
06:08:46,280 --> 06:08:46,780
INSTITUTIONAL LETTER OF

10675
06:08:46,780 --> 06:08:48,082
COMMITMENT AND SUPPORTING

10676
06:08:48,082 --> 06:08:49,516
LETTERS OF RECOMMENDATION THAT

10677
06:08:49,516 --> 06:08:52,486
DEMONSTRATE THE INDIVIDUALS'

10678
06:08:52,486 --> 06:08:53,053
LEADERSHIP IN THE FIELD AND

10679
06:08:53,053 --> 06:08:55,689
COLLEGIALITY.

10680
06:08:55,689 --> 06:08:58,325
THERE ARE A FEW OTHER PROGRAMS

10681
06:08:58,325 --> 06:08:59,727
THAT I'D LIKE TO HIGHLIGHT THAT

10682
06:08:59,727 --> 06:09:01,929
EXIST FOR SUPPORTING THE

10683
06:09:01,929 --> 06:09:04,231
SPECIFIC CAREER TRACK, AND THESE

10684
06:09:04,231 --> 06:09:05,666
PROGRAMS HAVE BEEN SUCCESSFUL.

10685
06:09:05,666 --> 06:09:08,035
WE CAN LEARN FROM THEM, WE CAN

10686
06:09:08,035 --> 06:09:09,303
BUILD ON THEM, AND WE CAN EXPAND

10687
06:09:09,303 --> 06:09:10,404
ON THEM.

10688
06:09:10,404 --> 06:09:13,574
SO THE FIRST IS THE NATIONAL

10689
06:09:13,574 --> 06:09:15,409
CANCER INSTITUTE RESEARCH

10690
06:09:15,409 --> 06:09:16,777
SPECIALIST AWARD, WHICH IS AN

10691
06:09:16,777 --> 06:09:17,644
R50.

10692
06:09:17,644 --> 06:09:21,582
THIS PROVIDES SALARY AND TRAVEL

10693
06:09:21,582 --> 06:09:24,885
SUPPORT FOR LABORATORY

10694
06:09:24,885 --> 06:09:26,053
SCIENTISTS AND CORE SCIENTISTS

10695
06:09:26,053 --> 06:09:28,055
WHICH WAS CREATED IN 2016, AND

10696
06:09:28,055 --> 06:09:31,825
THEN IN 2021, THEY ADDED

10697
06:09:31,825 --> 06:09:32,326
CLINICIAN-SCIENTISTS.

10698
06:09:32,326 --> 06:09:35,095
IT HAS A 19% AWARD RATE, WHICH

10699
06:09:35,095 --> 06:09:37,765
IS SIMILAR TO THAT OF YOUR

10700
06:09:37,765 --> 06:09:40,701
TYPICAL R01, AND THEY HAVE MADE

10701
06:09:40,701 --> 06:09:43,537
OVER 150 AWARDS.

10702
06:09:43,537 --> 06:09:46,407
ELIZABETH BARTMAN WAS A RESIP

10703
06:09:46,407 --> 06:09:47,241
YANT AT THIS AWARD AT

10704
06:09:47,241 --> 06:09:48,075
NORTHWESTERN UNIVERSITY AND I

10705
06:09:48,075 --> 06:09:50,711
THINK SHE DEMONSTRATES THE

10706
06:09:50,711 --> 06:09:52,913
POTENTIAL SUCCESS OF A PROGRAM

10707
06:09:52,913 --> 06:09:55,983
LIKE THIS BETTER THAN I EVER

10708
06:09:55,983 --> 06:09:56,517
COULD.

10709
06:09:56,517 --> 06:09:57,851
SHE SAYS, FREQUENTLY RESEARCHERS

10710
06:09:57,851 --> 06:10:00,053
WANT TO QUICKLY GET THE ANSWER

10711
06:10:00,053 --> 06:10:02,856
TO A SPECIFIC QUESTION.

10712
06:10:02,856 --> 06:10:04,057
AND ARE LESS INTERESTED IN

10713
06:10:04,057 --> 06:10:05,058
INVESTING IN MORE GENERAL

10714
06:10:05,058 --> 06:10:08,529
SOLUTIONS.

10715
06:10:08,529 --> 06:10:10,664
HAVING THE R50 SPECIALIST AWARD

10716
06:10:10,664 --> 06:10:13,500
GAVE ME MORE INDEPENDENCE TO SAY

10717
06:10:13,500 --> 06:10:14,802
LET'S DESPOAT SOME TIME TO

10718
06:10:14,802 --> 06:10:18,205
SETTING UP A COMPUTATIONAL

10719
06:10:18,205 --> 06:10:19,239
INFRASTRUCTURE THAT WE CAN USE

10720
06:10:19,239 --> 06:10:21,742
TO ANSWER ANY QUESTION, NOT JUST

10721
06:10:21,742 --> 06:10:22,943
THE QUESTION YOU STARTED OUT

10722
06:10:22,943 --> 06:10:25,345
WITH.

10723
06:10:25,345 --> 06:10:27,481
THAT EMPOWERED ME TO CREATE A

10724
06:10:27,481 --> 06:10:31,285
CUE TAITIONAL SYSTEM THAT MANY

10725
06:10:31,285 --> 06:10:32,186
SCIENTISTS ACROSS MY UNIVERSITY

10726
06:10:32,186 --> 06:10:36,590
ARE NOW USING FOR THEIR STUDIES.

10727
06:10:36,590 --> 06:10:38,025
AND LASTLY, I'D LIKE TO

10728
06:10:38,025 --> 06:10:40,627
HIGHLIGHT THE MOST RECENT

10729
06:10:40,627 --> 06:10:42,863
RESEARCH SOFTWARE ENGINEER

10730
06:10:42,863 --> 06:10:45,165
AWARD, WHICH IS ALSO AN R50 THAT

10731
06:10:45,165 --> 06:10:47,468
PROVIDES SALARY AND TRAVEL

10732
06:10:47,468 --> 06:10:48,802
SUPPORT, SPECIFICALLY FOR

10733
06:10:48,802 --> 06:10:50,804
RESEARCH SOFTWARE ENGINEERS, AND

10734
06:10:50,804 --> 06:10:53,106
VIRTUALLY ALL OF THE INSTITUTES

10735
06:10:53,106 --> 06:10:55,275
AND CENTERS HAVE SIGNED ON TO

10736
06:10:55,275 --> 06:10:56,977
THIS ANNOUNCEMENT THAT WAS

10737
06:10:56,977 --> 06:10:58,378
PUBLISHED BY THE OFFICE OF DATA

10738
06:10:58,378 --> 06:10:59,813
SCIENCE STRATEGY.

10739
06:10:59,813 --> 06:11:02,316
AND WITH THAT, I'LL TAKE ANY

10740
06:11:02,316 --> 06:11:03,450
QUESTIONS.

10741
06:11:03,450 --> 06:11:03,951
THANKS SO MUCH FOR YOUR

10742
06:11:03,951 --> 06:11:07,221
ATTENTION.

10743
06:11:07,221 --> 06:11:09,256
>> THANK YOU VERY MUCH,

10744
06:11:09,256 --> 06:11:09,556
DR. BONDAR.

10745
06:11:09,556 --> 06:11:12,025
I WOULD NOW LIKE TO CALL ON TWO

10746
06:11:12,025 --> 06:11:15,295
DISCUSSANTS TO DISCUSS THE

10747
06:11:15,295 --> 06:11:16,296
CONCEPT.

10748
06:11:16,296 --> 06:11:19,266
DRS. IRENE ANINYE AND

10749
06:11:19,266 --> 06:11:22,903
DR. KIMBERLY TEMPLETON.

10750
06:11:22,903 --> 06:11:23,937
DR. ANINYE, YOU CAN GO FIRST.

10751
06:11:23,937 --> 06:11:24,338
>> THANK YOU.

10752
06:11:24,338 --> 06:11:32,679
I THINK THIS PARTICULAR

10753
06:11:32,679 --> 06:11:33,247
CONCEPT -- I THINK SOMETIMES

10754
06:11:33,247 --> 06:11:34,648
THEY FEEL IS LIMITED WHEN

10755
06:11:34,648 --> 06:11:37,718
THEY'RE NOT A P.I.

10756
06:11:37,718 --> 06:11:41,722
AND THIS IS KIND OF A QUESTION,

10757
06:11:41,722 --> 06:11:42,389
KIND OF A COMMENT IF YOU CAN

10758
06:11:42,389 --> 06:11:42,923
SPEAK TO IT.

10759
06:11:42,923 --> 06:11:44,658
YOUR PLANS FOR OUTREACH TO

10760
06:11:44,658 --> 06:11:46,560
ENSURE THAT LIKE THE NON-PROFIT

10761
06:11:46,560 --> 06:11:51,498
OR THE SMALL BUSINESSES, AND FOR

10762
06:11:51,498 --> 06:11:53,600
PROFIT APPLICANTS ARE REACHED

10763
06:11:53,600 --> 06:11:55,569
BECAUSE I THINK THIS IS --

10764
06:11:55,569 --> 06:11:56,236
THERE'S A GREAT OPPORTUNITY HERE

10765
06:11:56,236 --> 06:11:58,672
FOR RE-ENTRY PARTICULARLY INTO

10766
06:11:58,672 --> 06:12:00,173
ACADEMIA AND BEING ABLE TO GROW

10767
06:12:00,173 --> 06:12:01,875
THEIR RESEARCH CAREER IN THAT

10768
06:12:01,875 --> 06:12:03,443
WAY.

10769
06:12:03,443 --> 06:12:05,279
>> WE BELIEVE IT'S A GREAT

10770
06:12:05,279 --> 06:12:06,813
OPPORTUNITY FOR RE-ENTRY AS

10771
06:12:06,813 --> 06:12:09,049
WELL, AND THE GREAT THING IS,

10772
06:12:09,049 --> 06:12:10,484
WE'RE DOING OUTREACH ON OUR

10773
06:12:10,484 --> 06:12:11,785
CONTINUITY AND RE-ENTRY

10774
06:12:11,785 --> 06:12:13,654
SUPPLEMENTS, AND I THINK WE CAN

10775
06:12:13,654 --> 06:12:16,223
DO MORE AND WE CAN INCLUDE THIS

10776
06:12:16,223 --> 06:12:18,525
IN THAT OUTREACH THAT WE -- AND

10777
06:12:18,525 --> 06:12:21,695
I AGREE WITH YOU, IT NEEDS TO

10778
06:12:21,695 --> 06:12:23,297
SPECIFICALLY TARGET NOT JUST THE

10779
06:12:23,297 --> 06:12:24,798
BIG UNIVERSITIES, WE NEED TO GO

10780
06:12:24,798 --> 06:12:28,769
OUT AND GET PEOPLE ON THE GROUND

10781
06:12:28,769 --> 06:12:30,871
FROM ALL -- THE GOAL WOULD BE

10782
06:12:30,871 --> 06:12:33,840
THAT WE HAVE PEOPLE ALL OVER THE

10783
06:12:33,840 --> 06:12:36,009
U.S. REPRESENTED IN THESE

10784
06:12:36,009 --> 06:12:37,210
AWARDS, AND THANK YOU FOR THAT

10785
06:12:37,210 --> 06:12:40,013
POINT, AND I AGREE, IT'S REALLY

10786
06:12:40,013 --> 06:12:50,390
AN IMPORTANT STRATEGY.

10787
06:12:52,793 --> 06:12:55,228
>> I WOULD AGREE, I THINK
THIS

10788
06:12:55,228 --> 06:12:57,197
IS AN INCREDIBLY IMPORTANT

10789
06:12:57,197 --> 06:12:58,999
PROJECT ESPECIALLY FOR WOMEN

10790
06:12:58,999 --> 06:13:00,300
RESEARCHERS AS YOU MENTIONED

10791
06:13:00,300 --> 06:13:02,536
THEY'RE LESS LIKELY TO BE

10792
06:13:02,536 --> 06:13:03,203
TENURED SO THIS IS A WAY TO HELP

10793
06:13:03,203 --> 06:13:03,870
SUPPORT THEM IN THEIR CAREERS.

10794
06:13:03,870 --> 06:13:05,572
JUST A QUESTION, YOU MENTIONED

10795
06:13:05,572 --> 06:13:07,174
IN THE APPLICATION THERE NEEDS

10796
06:13:07,174 --> 06:13:07,841
TO BE A CAREER DEVELOPMENT PLAN

10797
06:13:07,841 --> 06:13:09,409
AND THERE HAS TO BE A STATEMENT

10798
06:13:09,409 --> 06:13:12,112
OF SUPPORT FROM THE INSTITUTION

10799
06:13:12,112 --> 06:13:13,614
AND PROTECTED TIME.

10800
06:13:13,614 --> 06:13:16,750
WILL THERE BE A WAY TO HELP OR

10801
06:13:16,750 --> 06:13:17,351
MECHANISMS RECOMMENDED TO HELP

10802
06:13:17,351 --> 06:13:18,952
ENFORCE THAT OR KEEP TRACK OF

10803
06:13:18,952 --> 06:13:19,653
THAT?

10804
06:13:19,653 --> 06:13:22,389
AS WE KNOW WOMEN, ESPECIALLY

10805
06:13:22,389 --> 06:13:23,023
UNDERREPRESENTED MINORITY WOMEN

10806
06:13:23,023 --> 06:13:24,358
ARE OFTEN SUBJECT TO A MINORITY

10807
06:13:24,358 --> 06:13:25,926
TAX IN WHICH WE'RE ASKED TO DO A

10808
06:13:25,926 --> 06:13:28,061
LOT OF OTHER TASKS THAT OTHERS

10809
06:13:28,061 --> 06:13:29,563
DON'T THAT DON'T REALLY HELP US

10810
06:13:29,563 --> 06:13:31,198
PROGRESS OUR CAREERS MORE FOR

10811
06:13:31,198 --> 06:13:33,333
THE GOOD OF THE TEAM OR THE GOOD

10812
06:13:33,333 --> 06:13:34,801
OF THE INSTITUTION, IT DOESN'T

10813
06:13:34,801 --> 06:13:35,869
NECESSARILY HELP US PLOA SEED IN

10814
06:13:35,869 --> 06:13:38,505
OUR CAREERS.

10815
06:13:38,505 --> 06:13:40,841
SO MAYBE SOMETHING SUCH AS A

10816
06:13:40,841 --> 06:13:41,375
LOCAL MENTOR THAT CAN HELP

10817
06:13:41,375 --> 06:13:43,043
SUPPORT THE SCIENTISTS AND HELP

10818
06:13:43,043 --> 06:13:45,112
MAYBE INTERVENE IF THEY'RE BEING

10819
06:13:45,112 --> 06:13:47,114
ASKED TO DO TOO MANY OTHER

10820
06:13:47,114 --> 06:13:48,882
UNRELATED TASKS AND HELP THEM

10821
06:13:48,882 --> 06:13:49,783
NAVIGATE THOSE SOMETIMES

10822
06:13:49,783 --> 06:13:53,654
CHALLENGING POLITICAL WATERS OR

10823
06:13:53,654 --> 06:13:54,187
EVEN SPECIFIC -- SOMETHING

10824
06:13:54,187 --> 06:13:54,988
SPECIFICALLY OUTLINED IN TERMS

10825
06:13:54,988 --> 06:13:56,723
OF WHAT THAT PROTECTED TIME

10826
06:13:56,723 --> 06:13:59,493
MEANS AND THE LIMITATIONS THAT

10827
06:13:59,493 --> 06:14:01,595
THEY HAVE ON TRYING TO CRAM

10828
06:14:01,595 --> 06:14:04,564
OTHER -- PUT OTHER TASKS INTO AN

10829
06:14:04,564 --> 06:14:05,098
ALREADY BUSY SCHEDULE.

10830
06:14:05,098 --> 06:14:06,266
THANK YOU.

10831
06:14:06,266 --> 06:14:07,801
>> I THINK THAT'S A REALLY

10832
06:14:07,801 --> 06:14:09,102
IMPORTANT POINT AND A RECENT

10833
06:14:09,102 --> 06:14:11,304
PAPER EVEN DEMONSTRATED THEY HAD

10834
06:14:11,304 --> 06:14:13,240
DATA THAT SHOWED WOMEN IN THESE

10835
06:14:13,240 --> 06:14:16,743
POSITIONS NOT ONLY ARE THEY

10836
06:14:16,743 --> 06:14:18,045
OVERREPRESENTED, BUT THEY TEND

10837
06:14:18,045 --> 06:14:21,782
TO MENTOR TWICE AS MANY

10838
06:14:21,782 --> 06:14:22,382
INDIVIDUALS AS MEN IN THESE

10839
06:14:22,382 --> 06:14:23,016
ROLES.

10840
06:14:23,016 --> 06:14:25,085
SO I THINK THAT IS SOMETHING WE

10841
06:14:25,085 --> 06:14:26,186
WILL DEFINITELY TAKE INTO

10842
06:14:26,186 --> 06:14:28,722
ACCOUNT WHEN WE'RE WRITING THIS,

10843
06:14:28,722 --> 06:14:29,322
AND THANK YOU FOR THAT REALLY

10844
06:14:29,322 --> 06:14:35,996
IMPORTANT POINT.

10845
06:14:35,996 --> 06:14:40,467
>> THANK YOU VERY MUCH,

10846
06:14:40,467 --> 06:14:42,436
DR. ANINYE AND DR. TEMPLETON.

10847
06:14:42,436 --> 06:14:43,603
I'D NOW LIKE TO OPEN IT UP TO

10848
06:14:43,603 --> 06:14:44,805
THE FLOOR TO THE REST OF THE

10849
06:14:44,805 --> 06:14:46,606
MEMBERS FOR OTHER QUESTIONS OR

10850
06:14:46,606 --> 06:14:46,873
COMMENTS.

10851
06:14:46,873 --> 06:14:47,174
DR. ARNOLD?

10852
06:14:47,174 --> 06:14:51,912
>> SO MAJOR INTENT HERE IS
TO

10853
06:14:51,912 --> 06:14:52,979
DIVERSIFY THE WORKFORCE AND

10854
06:14:52,979 --> 06:14:55,015
INCLUDE MORE WOMEN.

10855
06:14:55,015 --> 06:14:59,286
ARE THERE ANY GENDER

10856
06:14:59,286 --> 06:15:01,054
QUALIFICATIONS HERE?

10857
06:15:01,054 --> 06:15:04,658
AND DO YOU HAVE DATA FROM THE

10858
06:15:04,658 --> 06:15:10,530
OTHER R50 AWARDING AGENCIES ON

10859
06:15:10,530 --> 06:15:11,932
WHAT PERCENTAGE OF THE AWARDEES

10860
06:15:11,932 --> 06:15:15,335
ARE WOMEN AND MINORITIES?

10861
06:15:15,335 --> 06:15:17,838
>> I DON'T HAVE DATA FROM
THE

10862
06:15:17,838 --> 06:15:19,005
OTHER R50s, BUT WE WILL NOT

10863
06:15:19,005 --> 06:15:20,307
RESTRICT THIS TO ONLY WOMEN.

10864
06:15:20,307 --> 06:15:22,476
IT'S JUST ALIGNED WITH OUR

10865
06:15:22,476 --> 06:15:24,511
STRATEGIC PLAN BECAUSE WE KNOW

10866
06:15:24,511 --> 06:15:30,550
THE DATA SUGGESTS THAT WOMEN

10867
06:15:30,550 --> 06:15:32,185
RRNT OVER REPRESENTED IN THESE

10868
06:15:32,185 --> 06:15:32,385
ROLES.

10869
06:15:32,385 --> 06:15:33,954
>> IS THERE ANY CORRECTIVE

10870
06:15:33,954 --> 06:15:35,122
MEASURE IF IT DOESN'T ACTUALLY

10871
06:15:35,122 --> 06:15:36,189
INCREASE THE NUMBER OF WOMEN?

10872
06:15:36,189 --> 06:15:40,994
>> I THINK IT'S -- IT --
IT MORE

10873
06:15:40,994 --> 06:15:42,796
ABOUT SUPPORTING THEM IN THESE

10874
06:15:42,796 --> 06:15:46,733
ROLES THAN HAVING THEM -- THAT

10875
06:15:46,733 --> 06:15:48,368
THIS WOULD BE TARGETED DIRECTLY

10876
06:15:48,368 --> 06:15:51,204
TOWARD WOMEN.

10877
06:15:51,204 --> 06:15:52,572
>> WOULD IT BE RENEWABLE?

10878
06:15:52,572 --> 06:15:55,008
>> YES.

10879
06:15:55,008 --> 06:15:57,611
WE HAVE TO DISCUSS THAT, BUT THE

10880
06:15:57,611 --> 06:15:59,980
ONE FROM NCI IS RENEWABLE, AND

10881
06:15:59,980 --> 06:16:03,283
THEY ACTUALLY FIND THAT PEOPLE

10882
06:16:03,283 --> 06:16:04,918
STAY ON THESE AWARDS, THEY SEE

10883
06:16:04,918 --> 06:16:07,154
THAT THEY ARE PROGRESSING IN

10884
06:16:07,154 --> 06:16:08,388
THEIR CAREERS AND THEY EVEN SEE

10885
06:16:08,388 --> 06:16:10,323
AN INCREASE IN THEIR SALARY AS

10886
06:16:10,323 --> 06:16:13,627
THEY PROGRESS.

10887
06:16:13,627 --> 06:16:16,029
>> DR. JONES AND THEN DR.
NOEL.

10888
06:16:16,029 --> 06:16:16,530
>> THANK YOU.

10889
06:16:16,530 --> 06:16:17,297
I LOVE THE CONCEPT.

10890
06:16:17,297 --> 06:16:18,165
I THINK IT GREAT.

10891
06:16:18,165 --> 06:16:20,734
I JUST HAVE A COUPLE QUESTIONS.

10892
06:16:20,734 --> 06:16:21,701
WHAT IS THE INSTITUTIONAL

10893
06:16:21,701 --> 06:16:23,336
COMMITMENT THAT'S GOING TO BE

10894
06:16:23,336 --> 06:16:24,304
REQUIRED, IF YOU COULD JUST

10895
06:16:24,304 --> 06:16:26,239
EXPAND A LITTLE BIT MORE ABOUT

10896
06:16:26,239 --> 06:16:26,840
WHAT THAT LOOKS LIKE AND WHAT

10897
06:16:26,840 --> 06:16:29,342
THOSE FUNDING SOURCES NEED TO,

10898
06:16:29,342 --> 06:16:31,311
BECAUSE THAT HE COULD BE A

10899
06:16:31,311 --> 06:16:32,946
LIMITING FACTOR.

10900
06:16:32,946 --> 06:16:33,513
AND THEN WHAT'S THE PERCENT

10901
06:16:33,513 --> 06:16:34,514
EFFORT ALLOWED ON THE AWARD?

10902
06:16:34,514 --> 06:16:35,015
THANK YOU.

10903
06:16:35,015 --> 06:16:38,385
>> SO I THINK PART OF
HAVING AN

10904
06:16:38,385 --> 06:16:41,354
INSTITUTIONAL LETTER OF

10905
06:16:41,354 --> 06:16:42,055
COMMITMENT JUST GOES HAND IN

10906
06:16:42,055 --> 06:16:43,657
HAPPENED WITH THE CAREER

10907
06:16:43,657 --> 06:16:45,692
DEVELOPMENT PLAN, WITH THE IDP

10908
06:16:45,692 --> 06:16:47,527
SAYING NOT ONLY DO I HAVE THIS

10909
06:16:47,527 --> 06:16:51,131
CAREER DEVELOPMENT PLAN, BUT MY

10910
06:16:51,131 --> 06:16:51,898
INSTITUTION KNOWS ABOUT IT AND

10911
06:16:51,898 --> 06:16:53,500
THEY'RE GOING TO SUPPORT ME IN

10912
06:16:53,500 --> 06:16:56,670
THIS PLAN, AND I THINK SOMETIMES

10913
06:16:56,670 --> 06:16:59,940
NON-TENURED SCIENTISTS GET LOST

10914
06:16:59,940 --> 06:17:01,942
IN THE INSTITUTION, AND THEIR

10915
06:17:01,942 --> 06:17:05,745
CAREER PATHS AND SUPPORT FOR

10916
06:17:05,745 --> 06:17:07,247
WHATEVER IT IS THAT THEIR CAREER

10917
06:17:07,247 --> 06:17:08,348
DEVELOPMENT PLAN LOOKS LIKE

10918
06:17:08,348 --> 06:17:10,851
ISN'T NECESSARILY A PRIORITY.

10919
06:17:10,851 --> 06:17:12,619
SO THIS IS ABOUT BRINGING THAT

10920
06:17:12,619 --> 06:17:14,454
AWARENESS TO THE INSTITUTION,

10921
06:17:14,454 --> 06:17:18,825
AND HAVING THEM SUPPORT.

10922
06:17:18,825 --> 06:17:19,459
>> SO IT'S A PLAN AND NOT
LIKE

10923
06:17:19,459 --> 06:17:21,094
YOU HAVE TO HAVE 25% OF YOUR

10924
06:17:21,094 --> 06:17:23,430
SALARY COVERED FROM NON-FEDERAL

10925
06:17:23,430 --> 06:17:23,630
FUNDS?

10926
06:17:23,630 --> 06:17:23,997
>> RIGHT, RIGHT.

10927
06:17:23,997 --> 06:17:24,231
>> OKAY.

10928
06:17:24,231 --> 06:17:24,531
THANK YOU.

10929
06:17:24,531 --> 06:17:25,866
AND THEN COULD YOU TALK ABOUT

10930
06:17:25,866 --> 06:17:29,102
PERCENT EFFORT OF --

10931
06:17:29,102 --> 06:17:29,803
>> SO LOOKING AT -- THAT'S

10932
06:17:29,803 --> 06:17:30,871
SOMETHING WE STILL NEED TO

10933
06:17:30,871 --> 06:17:34,674
DISCUSS, BUT I WILL SAY THAT THE

10934
06:17:34,674 --> 06:17:37,210
NCI AWARD, I BELIEVE, REQUIRES

10935
06:17:37,210 --> 06:17:38,545
50% EFFORT.

10936
06:17:38,545 --> 06:17:39,412
SO IT'S QUITE A BIT.

10937
06:17:39,412 --> 06:17:42,349
AND A LOT OF TIMES -- IT DOESN'T

10938
06:17:42,349 --> 06:17:44,484
MEAN THAT THEIR EFFORT IS NOT ON

10939
06:17:44,484 --> 06:17:45,252
OTHER GRANTS.

10940
06:17:45,252 --> 06:17:48,221
IT JUST MEANS THAT THAT EFFORT,

10941
06:17:48,221 --> 06:17:50,724
THAT MAYBE THEY'RE COVERED FOR

10942
06:17:50,724 --> 06:17:53,660
ANOTHER GRANT CAN BE SHIFTED TO

10943
06:17:53,660 --> 06:17:56,263
THIS AWART, AND THAT THAT COULD

10944
06:17:56,263 --> 06:17:57,697
MAYBE BE THE MOVE TO COVER

10945
06:17:57,697 --> 06:17:59,566
SUPPLIES OR MATERIALS, BUT IT

10946
06:17:59,566 --> 06:18:05,205
SHOULDN'T BE USED TO -- FOR THAT

10947
06:18:05,205 --> 06:18:05,438
PERSON.

10948
06:18:05,438 --> 06:18:06,873
>> THANK YOU, DR. NOEL.

10949
06:18:06,873 --> 06:18:08,608
>> YES, GREAT CONCEPT.

10950
06:18:08,608 --> 06:18:09,442
I JUST HAD A FEW QUESTIONS.

10951
06:18:09,442 --> 06:18:11,177
WE KNOW THAT THE ACADEMIC WORLD

10952
06:18:11,177 --> 06:18:15,916
COULD BE COMPLEX SOMETIMES.

10953
06:18:15,916 --> 06:18:17,217
SINCE YOU'RE TARGETING

10954
06:18:17,217 --> 06:18:17,851
NON-TENURED SCIENTISTS, IN THE

10955
06:18:17,851 --> 06:18:20,620
CAREER PLAN TO FOLLOW UP, WOULD

10956
06:18:20,620 --> 06:18:22,889
THAT INCLUDE GOING TO TENURE

10957
06:18:22,889 --> 06:18:23,089
TRACK?

10958
06:18:23,089 --> 06:18:23,790
BECAUSE SOMETIMES SOME

10959
06:18:23,790 --> 06:18:25,525
INSTITUTIONS COULD GO FROM

10960
06:18:25,525 --> 06:18:26,626
NON-TENURE TO TENURE TRACK AND

10961
06:18:26,626 --> 06:18:29,396
ALSO WITH THE OTHER R50s, LIKE

10962
06:18:29,396 --> 06:18:32,165
YOU SHOWED WITH THE CANCER

10963
06:18:32,165 --> 06:18:33,366
AGENCY, HAS THERE BEEN SOME

10964
06:18:33,366 --> 06:18:35,769
CHANGES WHERE SOMEBODY WENT WITH

10965
06:18:35,769 --> 06:18:38,305
THAT AWARD FROM NON-TENURED TO,

10966
06:18:38,305 --> 06:18:39,806
FOR EXAMPLE, TENURED TRACK?

10967
06:18:39,806 --> 06:18:42,242
>> SO WE WANT TO PROHIBIT
THEM

10968
06:18:42,242 --> 06:18:43,677
FROM DOING THAT, BUT IT ALSO

10969
06:18:43,677 --> 06:18:44,878
COULD BE A CAREER DEVELOPMENT

10970
06:18:44,878 --> 06:18:47,047
PLAN, LIKE I WANT TO BECOME THE

10971
06:18:47,047 --> 06:18:48,114
LEADER OF THE CORE FACILITY, I

10972
06:18:48,114 --> 06:18:50,216
WANT TO BE A SUPERVISOR, RIGHT?

10973
06:18:50,216 --> 06:18:54,020
BUT IF SOMEBODY DOES DECIDE TO

10974
06:18:54,020 --> 06:18:57,090
BECOME TENURE TRACK, THEN THEY

10975
06:18:57,090 --> 06:18:58,458
WOULD HAVE OTHER NIH RESOURCES

10976
06:18:58,458 --> 06:19:00,260
OPEN TO THEM, BECAUSE THIS,

10977
06:19:00,260 --> 06:19:01,628
THERE AREN'T A LOT.

10978
06:19:01,628 --> 06:19:03,697
THIS IS PRETTY MUCH IT FOR

10979
06:19:03,697 --> 06:19:07,000
RESEARCH PROFESSIONALS.

10980
06:19:07,000 --> 06:19:09,636
AND SO IF THEY DO MOVE TO THE

10981
06:19:09,636 --> 06:19:10,670
TENURE CAREER TRACK, THEN THEY

10982
06:19:10,670 --> 06:19:16,609
WOULD HAVE OTHER OPPORTUNITIES.

10983
06:19:16,609 --> 06:19:18,878
>> QUICK QUESTION ABOUT
WOULD

10984
06:19:18,878 --> 06:19:24,684
THERE BE A LIMITATION TO CAREER

10985
06:19:24,684 --> 06:19:24,884
STAGE?

10986
06:19:24,884 --> 06:19:26,052
IS THAT JUST MEANT FOR EARLY

10987
06:19:26,052 --> 06:19:27,287
CAREER RESEARCH SCIENTISTS OR IS

10988
06:19:27,287 --> 06:19:31,925
IT OPEN TO ALL RESEARCH

10989
06:19:31,925 --> 06:19:32,525
SCIENTISTS, REGARDLESS OF HOW

10990
06:19:32,525 --> 06:19:33,226
LONG THEY HAVE BEEN IN THAT

10991
06:19:33,226 --> 06:19:36,096
POSITION?

10992
06:19:36,096 --> 06:19:38,665
>> I'M SORRY, I DIDN'T GET
THE

10993
06:19:38,665 --> 06:19:38,932
QUESTION.

10994
06:19:38,932 --> 06:19:39,566
>> I WAS WONDERING IF THIS
IS

10995
06:19:39,566 --> 06:19:44,304
GOING TO BE LIMITED TO RESEARCH

10996
06:19:44,304 --> 06:19:46,773
SANE TISES DURING THE EARLY

10997
06:19:46,773 --> 06:19:47,741
STAGE OF THEIR CAREER OR IT'S

10998
06:19:47,741 --> 06:19:48,942
OPEN TO EVERYBODY REGARDLESS OF

10999
06:19:48,942 --> 06:19:50,810
HOW LONG THEY HAVE OCCUPIED THAT

11000
06:19:50,810 --> 06:19:51,911
POSITION.

11001
06:19:51,911 --> 06:19:53,813
>> EVERYBODY.

11002
06:19:53,813 --> 06:19:55,115
SO IT NOT GOING TO BE RESTRICTED

11003
06:19:55,115 --> 06:19:58,451
JUST TO EARLY STAGE.

11004
06:19:58,451 --> 06:19:58,752
>> GREAT.

11005
06:19:58,752 --> 06:19:59,285
THANK YOU.

11006
06:19:59,285 --> 06:20:04,624
DO WE HAVE ANY QUESTIONS --

11007
06:20:04,624 --> 06:20:04,858
PLEASE.

11008
06:20:04,858 --> 06:20:06,793
>> IF I HEARD CORRECTLY,
YOU

11009
06:20:06,793 --> 06:20:09,529
MENTIONED THAT IT CANNOT BE NEW

11010
06:20:09,529 --> 06:20:09,796
RESEARCH.

11011
06:20:09,796 --> 06:20:13,433
IT'S JUST EXISTING SUPPORT, OR

11012
06:20:13,433 --> 06:20:14,200
SUPPORTING SOMETHING IN THE

11013
06:20:14,200 --> 06:20:14,734
FUTURE.

11014
06:20:14,734 --> 06:20:18,004
HAVE YOU CONSIDERED, IN ORDER TO

11015
06:20:18,004 --> 06:20:20,507
STRENGTHEN THEIR BUFFER INTO

11016
06:20:20,507 --> 06:20:22,575
BECOMING -- FOR THAT CAREER

11017
06:20:22,575 --> 06:20:25,011
ADVANCEMENT, THE OPPORTUNITY TO

11018
06:20:25,011 --> 06:20:29,149
SUGGEST A NEW PROJECT EVEN --

11019
06:20:29,149 --> 06:20:31,751
THIS SMALL ONE, BECAUSE SOMEBODY

11020
06:20:31,751 --> 06:20:34,888
IN THESE ROLE, THEY TONIGHT GET

11021
06:20:34,888 --> 06:20:37,223
OPPORTUNITY TO DEVELOP THEIR OWN

11022
06:20:37,223 --> 06:20:38,425
IDEAS, THAT WOULD ALLOW THEM TO

11023
06:20:38,425 --> 06:20:40,360
MOVE TO THE NEXT POSITION.

11024
06:20:40,360 --> 06:20:41,561
>> THAT'S AN INTERESTING
POINT.

11025
06:20:41,561 --> 06:20:44,731
SO THEY DO DO THAT IN R35s

11026
06:20:44,731 --> 06:20:46,800
WHERE THEY DON'T HAVE A SPECIFIC

11027
06:20:46,800 --> 06:20:47,434
AIMS PAGE, BUT THEY CAN PROPOSE

11028
06:20:47,434 --> 06:20:48,868
NEW -- AND THAT'S SOMETHING THAT

11029
06:20:48,868 --> 06:20:50,703
WE CAN DISCUSS AND TAKE INTO

11030
06:20:50,703 --> 06:20:51,604
CONSIDERATION.

11031
06:20:51,604 --> 06:20:55,542
THANK YOU.

11032
06:20:55,542 --> 06:20:56,276
>> GREAT, THANK YOU.

11033
06:20:56,276 --> 06:20:57,911
DO WE HAVE ANY QUESTIONS OR

11034
06:20:57,911 --> 06:21:08,188
COMMENTS ONLINE?

11035
06:21:09,589 --> 06:21:11,458
BASED ON EVERYONE'S FEEDBACK,

11036
06:21:11,458 --> 06:21:11,825
LET'S CONTINUE.

11037
06:21:11,825 --> 06:21:12,358
SO THANK YOU, EVERYBODY.

11038
06:21:12,358 --> 06:21:14,727
AT THIS TIME, WE'LL VOTE ON THE

11039
06:21:14,727 --> 06:21:17,597
APPROVAL OF THE NIH EXCEPTIONAL

11040
06:21:17,597 --> 06:21:19,165
RESEARCH SCIENTIST AWARD CONCEPT

11041
06:21:19,165 --> 06:21:20,467
CLEARANCE.

11042
06:21:20,467 --> 06:21:22,135
PLEASE NOTE THAT ONLY FULL

11043
06:21:22,135 --> 06:21:24,037
MEMBERS OF THE ADVISORY

11044
06:21:24,037 --> 06:21:25,238
COMMITTEE MAY VOTE.

11045
06:21:25,238 --> 06:21:27,107
AND IF YOU'RE AN AD HOC MEMBER,

11046
06:21:27,107 --> 06:21:30,477
OTHERWISE NOT A MEMBER OF ACRWH,

11047
06:21:30,477 --> 06:21:30,910
PLEASE DO NOT VOTE.

11048
06:21:30,910 --> 06:21:32,011
IS THERE A MOTION ON THE TABLE

11049
06:21:32,011 --> 06:21:35,281
TO APPROVE THE NIH EXCEPTIONAL

11050
06:21:35,281 --> 06:21:37,016
RESEARCH SCIENTIST AWARD CONCEPT

11051
06:21:37,016 --> 06:21:40,753
CLEARANCE?

11052
06:21:40,753 --> 06:21:41,988
>> MOTION TO APPROVE.

11053
06:21:41,988 --> 06:21:43,957
>> AND DO I HEAR A SECOND?

11054
06:21:43,957 --> 06:21:44,724
>> I SECOND.

11055
06:21:44,724 --> 06:21:47,160
>> THANK YOU.

11056
06:21:47,160 --> 06:21:48,128
ALL THOSE IN FAVOR OF ACCEPTING

11057
06:21:48,128 --> 06:21:49,662
THE MOTION, CAN YOU PLEASE RAISE

11058
06:21:49,662 --> 06:21:55,568
YOUR HANDS NOW AND LEAVE THEM UP

11059
06:21:55,568 --> 06:21:59,539
WHILE THEY'RE -- IS THAT LONG

11060
06:21:59,539 --> 06:22:00,039
ENOUGH OVER THERE?

11061
06:22:00,039 --> 06:22:00,240
OKAY.

11062
06:22:00,240 --> 06:22:01,674
THANK YOU.

11063
06:22:01,674 --> 06:22:05,512
ALL THOSE OPPOSED TO THE

11064
06:22:05,512 --> 06:22:09,182
MOTION -- ONLINE?

11065
06:22:09,182 --> 06:22:11,618
ALL THOSE OPPOSED TO THE MOTION,

11066
06:22:11,618 --> 06:22:16,623
PLEASE RAISE YOUR HANDS NOW.

11067
06:22:16,623 --> 06:22:17,891
AND ALL THOSE ABSTAINING FROM

11068
06:22:17,891 --> 06:22:19,325
THE MOTION, PLEASE RAISE YOUR

11069
06:22:19,325 --> 06:22:24,664
HANDS NOW.

11070
06:22:24,664 --> 06:22:25,965
AND HAVE THE VOTES BEEN

11071
06:22:25,965 --> 06:22:32,205
RECORDED?

11072
06:22:32,205 --> 06:22:32,972
GREAT, THANK YOU.

11073
06:22:32,972 --> 06:22:34,974
THE NIH EXCEPTIONAL RESEARCH

11074
06:22:34,974 --> 06:22:35,775
SCIENTIST AWARD CONCEPT HAS BEEN

11075
06:22:35,775 --> 06:22:37,644
ACCEPTED WITH 11 VOTES IN FAVOR.

11076
06:22:37,644 --> 06:22:41,581
SO THANK YOU VERY MUCH.

11077
06:22:41,581 --> 06:22:44,517
[APPLAUSE]

11078
06:22:44,517 --> 06:22:46,152
SO WE'VE NOW REACHED THE OPEN

11079
06:22:46,152 --> 06:22:47,453
DISCUSSION SECTION OF OUR

11080
06:22:47,453 --> 06:22:48,354
AFTERNOON.

11081
06:22:48,354 --> 06:22:51,157
FIRST OF ALL, THANK YOU ALL FOR

11082
06:22:51,157 --> 06:22:51,591
YOUR CONTRIBUTIONS.

11083
06:22:51,591 --> 06:22:53,226
THEY'VE BEEN VERY -- THEY'VE

11084
06:22:53,226 --> 06:22:54,227
BEEN INVALUABLE.

11085
06:22:54,227 --> 06:22:57,197
IF ANY QUESTIONS -- AND IF

11086
06:22:57,197 --> 06:22:59,132
ANYONE HAS QUESTIONS THEY WOULD

11087
06:22:59,132 --> 06:23:01,267
LIKE TO DISCUSS, PLEASE LET US

11088
06:23:01,267 --> 06:23:09,042
KNOW BY RAISING YOUR HANDS.

11089
06:23:09,042 --> 06:23:09,209
YES.

11090
06:23:09,209 --> 06:23:12,178
>> I JUST WANTED TO MAKE A

11091
06:23:12,178 --> 06:23:13,580
COMMENT ABOUT THE AUTOIMMUNE --

11092
06:23:13,580 --> 06:23:15,782
I'M SORRY, NOT THE AUTOIMMUNE.

11093
06:23:15,782 --> 06:23:18,251
THAT'S ALWAYS IN MY MIND.

11094
06:23:18,251 --> 06:23:21,020
THE CHRONIC CONDITIONS, AND I

11095
06:23:21,020 --> 06:23:25,391
THINK IT'S A REALLY GREAT

11096
06:23:25,391 --> 06:23:26,793
OPPORTUNITY IN ADDRESSING THIS

11097
06:23:26,793 --> 06:23:29,295
FOR WOMEN LONG TERM.

11098
06:23:29,295 --> 06:23:30,496
ONE OF THE THINGS THAT I WANTED

11099
06:23:30,496 --> 06:23:32,565
TO NOTE IS, OF COURSE, WE

11100
06:23:32,565 --> 06:23:34,767
RECOGNIZE THAT SOME CONDITIONS

11101
06:23:34,767 --> 06:23:36,502
CAN ELEVATE AND BE A LITTLE BIT

11102
06:23:36,502 --> 06:23:38,504
MORE POPULAR THAN OTHERS, BUT I

11103
06:23:38,504 --> 06:23:41,274
LIKE THE FACT THAT THE APPROACH

11104
06:23:41,274 --> 06:23:42,375
WAS VERY INCLUSIVE AND IT

11105
06:23:42,375 --> 06:23:44,344
COVERED A LOT OF AREAS, AND SO

11106
06:23:44,344 --> 06:23:47,947
JUST TO ENCOURAGE KEEPING THAT

11107
06:23:47,947 --> 06:23:50,383
DOOR OPEN SO THAT AS CERTAIN

11108
06:23:50,383 --> 06:23:55,688
CONDITIONS MAY RISE TO THE

11109
06:23:55,688 --> 06:23:57,023
FOREFRONT, THERE'S -- TO ADDRESS

11110
06:23:57,023 --> 06:23:59,092
OTHER CONDITIONS AND MAKE SURE

11111
06:23:59,092 --> 06:23:59,659
THEY STILL GET THE ATTENTION

11112
06:23:59,659 --> 06:24:01,027
THEY NEED WHEN IT COMES TO

11113
06:24:01,027 --> 06:24:03,429
RESEARCH CONDITIONS YOU AND

11114
06:24:03,429 --> 06:24:04,230
FUNDING SUPPORT.

11115
06:24:04,230 --> 06:24:05,565
>> GREAT, THANK YOU.

11116
06:24:05,565 --> 06:24:09,636
THANK YOU VERY MUCH.

11117
06:24:09,636 --> 06:24:10,136
YES, DR. NOEL.

11118
06:24:10,136 --> 06:24:11,404
>> I HAVE A QUICK QUESTION

11119
06:24:11,404 --> 06:24:13,673
REGARDING TO DR. CLAYTON'S

11120
06:24:13,673 --> 06:24:14,207
PRESENTATION THIS MORNING.

11121
06:24:14,207 --> 06:24:15,642
I THINK IT WAS GREAT YOU

11122
06:24:15,642 --> 06:24:17,143
MENTIONED THAT FOR CLINICAL

11123
06:24:17,143 --> 06:24:20,647
TRIALS, THERE IS NOW

11124
06:24:20,647 --> 06:24:22,315
DISAGGREGATION OF DATA BY SEX

11125
06:24:22,315 --> 06:24:24,917
AND IT HAS TO BE PRESENTED AND

11126
06:24:24,917 --> 06:24:26,219
BOTH ANALYZED.

11127
06:24:26,219 --> 06:24:28,454
MY QUESTION WOULD BE, CAN

11128
06:24:28,454 --> 06:24:29,255
SIMILAR REQUIREMENTS BE

11129
06:24:29,255 --> 06:24:31,257
IMPLEMENTED WHEN IT COMES TO

11130
06:24:31,257 --> 06:24:34,093
PRE-CLINICAL MODELS AND RESEARCH

11131
06:24:34,093 --> 06:24:38,765
FUNDING BY NIH THROUGH, FOR

11132
06:24:38,765 --> 06:24:39,832
EXAMPLE, THE DATA MANAGEMENT AND

11133
06:24:39,832 --> 06:24:40,600
SHARING PLAN THAT THE

11134
06:24:40,600 --> 06:24:41,501
INVESTIGATORS HAVE TO SUBMIT AT

11135
06:24:41,501 --> 06:24:46,939
THE TIME OF SUBMISSION, IF THAT

11136
06:24:46,939 --> 06:24:51,778
COULD BE A REQUIREMENT, THEY

11137
06:24:51,778 --> 06:24:53,446
PRESENT THE DATA AS DEAGO DATED.

11138
06:24:53,446 --> 06:24:55,982
>> THANKS FOR THAT
QUESTION AND

11139
06:24:55,982 --> 06:25:02,588
COMMENT, ALEXANDRA.

11140
06:25:02,588 --> 06:25:05,091
SO AM CAL PHASE THREE TRIALS,

11141
06:25:05,091 --> 06:25:07,026
THE 21ST CENTURY CURES ACT

11142
06:25:07,026 --> 06:25:08,127
REQUIRES THAT THE RESULTS BE

11143
06:25:08,127 --> 06:25:09,996
DISAGGREGATED BY SEX, GENDER,

11144
06:25:09,996 --> 06:25:12,899
RACE -- SEX OR GENDER, RACE AND

11145
06:25:12,899 --> 06:25:14,434
ETHNICITY, PUT INTO

11146
06:25:14,434 --> 06:25:17,270
CLINICALTRIALS.GOV.

11147
06:25:17,270 --> 06:25:18,604
FOR PRE-CLINICAL RESEARCH, THE

11148
06:25:18,604 --> 06:25:20,640
SEX AS A BIOLOGICAL VARIABLE

11149
06:25:20,640 --> 06:25:21,541
POLICY APPLIES FOR BOTH

11150
06:25:21,541 --> 06:25:23,176
PRE-CLINICAL AND CLINICAL

11151
06:25:23,176 --> 06:25:24,377
RESEARCH, AND OUR CURRENT

11152
06:25:24,377 --> 06:25:26,479
REQUIREMENT IS THAT SEX BE

11153
06:25:26,479 --> 06:25:28,748
ACCOUNTED FOR AS A BIOLOGICAL

11154
06:25:28,748 --> 06:25:30,817
VARIABLE IN THE RESEARCH DESIGN,

11155
06:25:30,817 --> 06:25:35,955
ANALYSIS AND REPORTING.

11156
06:25:35,955 --> 06:25:37,590
SO DISAGGREGATING RESULTS BY SEX

11157
06:25:37,590 --> 06:25:39,792
IS SOMETHING THAT COULD HAPPEN

11158
06:25:39,792 --> 06:25:41,527
IN THE PROGRESS REPORTS BUT

11159
06:25:41,527 --> 06:25:43,596
YOU'RE ALSO ASKING ABOUT THE

11160
06:25:43,596 --> 06:25:45,198
DATA MANAGEMENT AND SHARING

11161
06:25:45,198 --> 06:25:48,234
PLANS AS ANOTHER PATHWAY TO

11162
06:25:48,234 --> 06:25:49,969
POTENTIALLY INCLUDE

11163
06:25:49,969 --> 06:25:50,837
DISAGGREGATION OF RESULTS

11164
06:25:50,837 --> 06:25:53,005
SPECIFICALLY FOR PRE-CLINICAL

11165
06:25:53,005 --> 06:25:54,340
STUDIES, AND YOU'RE ASKING

11166
06:25:54,340 --> 06:25:55,108
WHETHER THERE'S AN OPPORTUNITY

11167
06:25:55,108 --> 06:25:57,176
TO MAKE THAT A REQUIREMENT.

11168
06:25:57,176 --> 06:25:59,512
SO THAT'S SOMETHING I'M HAPPY TO

11169
06:25:59,512 --> 06:26:01,414
TAKE BACK TO MY COLLEAGUES AT

11170
06:26:01,414 --> 06:26:03,716
NIH AND DISCUSS FURTHER.

11171
06:26:03,716 --> 06:26:05,251
JUST TO MAKE SURE I

11172
06:26:05,251 --> 06:26:12,258
UNDERSTOOD -- THANK YOU.

11173
06:26:12,258 --> 06:26:14,293
SO WE GOT A LITTLE OVERSCHEDULED

11174
06:26:14,293 --> 06:26:17,063
TODAY, BUT SOMEHOW WE GOT BACK

11175
06:26:17,063 --> 06:26:18,464
ALMOST ON TRACK, BUT I KNOW THAT

11176
06:26:18,464 --> 06:26:20,166
THERE ARE TRAVEL ARRANGEMENTS

11177
06:26:20,166 --> 06:26:20,967
THAT EVERYONE NEEDS, SO I JUST

11178
06:26:20,967 --> 06:26:22,068
WANT TO MAKE SURE THAT THERE'S

11179
06:26:22,068 --> 06:26:23,369
AN OPPORTUNITY IF THERE'S

11180
06:26:23,369 --> 06:26:25,171
ANYTHING ELSE, ANY BURNING

11181
06:26:25,171 --> 06:26:27,607
COMMENTS OR QUESTIONS ANYONE

11182
06:26:27,607 --> 06:26:28,274
HAS, ON

11183
06:26:28,274 --> 06:26:30,143
, IN THE ROOM?

11184
06:26:30,143 --> 06:26:31,811
WE USUALLY HAVE A LITTLE BIT

11185
06:26:31,811 --> 06:26:32,445
MORE TIME TO TALK AND I USUALLY

11186
06:26:32,445 --> 06:26:35,448
GET TO ASK YOU ALL QUESTIONS.

11187
06:26:35,448 --> 06:26:38,384
DR. JAGSI PUT HER CAMERA ON.

11188
06:26:38,384 --> 06:26:39,118
>> THANK YOU.

11189
06:26:39,118 --> 06:26:40,853
>> JUST WANT TO SAY HI?

11190
06:26:40,853 --> 06:26:44,824
>> GREAT TO SEE YOU GUYS,
THANK

11191
06:26:44,824 --> 06:26:44,991
YOU.

11192
06:26:44,991 --> 06:26:46,659
>> THANK YOU, RESHMA AND
THANK

11193
06:26:46,659 --> 06:26:47,860
YOU, KIM, FOR PUTTING YOUR

11194
06:26:47,860 --> 06:26:50,430
CAMERA ON AS WELLMENT I DO WANT

11195
06:26:50,430 --> 06:26:50,930
TO JUST THANK ALL OF THE

11196
06:26:50,930 --> 06:26:51,230
PRESENTERS.

11197
06:26:51,230 --> 06:26:52,465
THIS WAS AN INCREDIBLE MEETING.

11198
06:26:52,465 --> 06:26:55,435
I WANT TO ECK PRESS MY

11199
06:26:55,435 --> 06:26:56,269
APPRECIATION FOR EVERYONE'S

11200
06:26:56,269 --> 06:26:56,702
PRESENTATIONS.

11201
06:26:56,702 --> 06:26:58,337
I ALSO WANT TO EXPRESS MY

11202
06:26:58,337 --> 06:27:00,540
APPRECIATION TO THE ADVISORY

11203
06:27:00,540 --> 06:27:00,940
COMMITTEE MEMBERS.

11204
06:27:00,940 --> 06:27:01,707
WE DEEPLY APPRECIATE THE WORK

11205
06:27:01,707 --> 06:27:02,809
THAT UM DO.

11206
06:27:02,809 --> 06:27:06,479
YOU DO.IT DOES COME SPORADICALLD

11207
06:27:06,479 --> 06:27:08,181
THERE WILL BE WORK COMING, AND I

11208
06:27:08,181 --> 06:27:10,450
WANT TO THANK THOSE MEMBERS WHO

11209
06:27:10,450 --> 06:27:10,883
ARE ROTATING OFF.

11210
06:27:10,883 --> 06:27:11,451
WE REALLY APPRECIATE YOUR

11211
06:27:11,451 --> 06:27:12,018
SERVICE.

11212
06:27:12,018 --> 06:27:13,619
IT'S VERY IMPORTANT TO HEAR YOUR

11213
06:27:13,619 --> 06:27:14,320
PERSPECTIVES.

11214
06:27:14,320 --> 06:27:16,923
AND I'D LIKE TO ALSO ACKNOWLEDGE

11215
06:27:16,923 --> 06:27:20,293
THE STAFF OF ORWH AND OUR

11216
06:27:20,293 --> 06:27:20,960
CONTRACT SUPPORT AND

11217
06:27:20,960 --> 06:27:21,861
COMMUNICATIONS COLLEAGUES,

11218
06:27:21,861 --> 06:27:23,596
BECAUSE THEY MAKE THE MEETING

11219
06:27:23,596 --> 06:27:23,863
POSSIBLE.

11220
06:27:23,863 --> 06:27:25,298
THANK YOU VERY, VERY MUCHMENT

11221
06:27:25,298 --> 06:27:27,800
AND SO ON BEHALF OF ORWH, THANK

11222
06:27:27,800 --> 06:27:29,869
YOU, EVERYONE, AND WE LOOK

11223
06:27:29,869 --> 06:27:32,405
FORWARD TO SEEING YOU AT THE

11224
06:27:32,405 --> 06:27:35,575
62ND MEETING OF THE ADVISORY

11225
06:27:35,575 --> 06:27:36,876
COMMITTEE ON RESEARCH ON WOMEN'S

11226
06:27:36,876 --> 06:27:39,479
HEALTH ON APRIL 8TH, 2025, WHICH

11227
06:27:39,479 --> 06:27:41,247
WILL BE A HYBRID MEETING.

11228
06:27:41,247 --> 06:27:42,448
SAFE TRAVELS TO EVERYONE HOME.

11229
06:27:42,448 --> 06:27:44,617
OUR MEETING IS NOW ADJOURNED.

11230
06:27:44,617 --> 06:27:54,927
THANKS, EVERYONE.